<SEC-DOCUMENT>0001213900-20-029638.txt : 20201001
<SEC-HEADER>0001213900-20-029638.hdr.sgml : 20201001
<ACCEPTANCE-DATETIME>20201001172750
ACCESSION NUMBER:		0001213900-20-029638
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		12
FILED AS OF DATE:		20201001
DATE AS OF CHANGE:		20201001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aptorum Group Ltd
		CENTRAL INDEX KEY:			0001734005
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-248743
		FILM NUMBER:		201217226

	BUSINESS ADDRESS:	
		STREET 1:		17 HANOVER SQUARE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1S 1BN
		BUSINESS PHONE:		852 3953 7700

	MAIL ADDRESS:	
		STREET 1:		17 HANOVER SQUARE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1S 1BN
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>ea127698-424b4_aptorumgroup.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 52%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed pursuant to Rule 424(b)(4)</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-248743</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration No. 333-249140</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APTORUM GROUP LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,769,231 Class A Ordinary Shares and
Warrants to Purchase up to 2,769,231 Class A Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>or</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,769,231 Pre-Funded Warrants to Purchase
Class A Ordinary Shares and Warrants to Purchase up to 2,769,231 Class A Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>(5,538,462
Class A Ordinary Shares Issuable Upon Exercise of the Pre-Funded Warrants and Warrants)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are offering in
a best-efforts offering up to 2,769,231 Class A Ordinary Shares and warrants to purchase up to 2,769,231 Class A Ordinary Shares,
or up to 2,769,231 pre-funded warrants to purchase up to 2,769,231 Class A Ordinary Shares and warrants to purchase up to 2,769,231
Class A Ordinary Shares, (the &ldquo;Offering&rdquo;) of Aptorum Group Limited (referred to herein as &ldquo;we&rdquo;, &ldquo;us&rdquo;,
&ldquo;our&rdquo;, &ldquo;Registrant&rdquo;, or the &ldquo;Company&rdquo;), at a combined public offering price of $3.25 per share
and related warrant. Each Class A Ordinary Share is being sold together with one warrant to purchase one Class A Ordinary Share.
Each warrant will have an exercise price per share equal to 100% of the of the combined public offering price per Class A Ordinary
Share and related warrant in this offering, will be immediately exercisable and will expire on the fifth anniversary of the original
issuance date. The Class A Ordinary Shares and warrants are immediately separable and will be issued separately, but will be purchased
together in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also offering
to certain purchasers whose purchase of Class A Ordinary Shares in this offering would otherwise result in the purchaser, together
with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%)
of our outstanding Class A Ordinary Shares immediately following the consummation of this offering, the opportunity to purchase,
if such purchasers so choose, pre-funded warrants in lieu of Class A Ordinary Shares that would otherwise result in any such purchaser&rsquo;s
beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Class A Ordinary Shares.
Each pre-funded warrant will be exercisable for one Class A Ordinary Share and related warrant and will be exercisable at any
time after its original issuance until exercised in full. The purchase price of each pre-funded warrant will be equal to the price
at which a Class A Ordinary Share is sold to the public in this offering, minus $0.01, and the exercise price of each pre-funded
warrant will be $0.01 per share. The pre-funded warrant and warrants will be issued separately, but will be purchased together
in this offering. This offering also relates to the Class A Ordinary Shares issuable upon exercise of any pre-funded warrants
sold in this offering. For each pre-funded warrant we sell, the number of Class A Ordinary Shares we are offering will be decreased
on a one-for-one basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the above, we may sell an additional 2,769,231 Class A Ordinary Shares and warrants to purchase up to 2,769,231 Class
A Ordinary Shares, or up to 2,769,231 pre-funded warrants to purchase up to 2,769,231 Class A Ordinary Shares and warrants to purchase
up to 2,769,231 Class A Ordinary Shares (collectively, the &ldquo;Participation Shares&rdquo;), to certain investors who participated
in the Registered Direct Offering (as hereinafter defined), all of which Participation Shares were previously registered in the
registration statements of which this prospectus forms a part. As further explained in the &ldquo;Transactions with Related Persons&rdquo;
section below, due to the right of participation granted to the investors of the Registered Direct Offering (the &ldquo;RDO Investors&rdquo;),
they are entitled to participate, in the aggregate, in this Offering up to $9,000,000 (&ldquo;Participation Maximum&rdquo;) on
the same terms, conditions and at the same price as investors in this Offering, on a pro-rata basis determined by their participation
in the Registered Direct Offering. Accordingly, three of the RDO Investors can purchase up to $1,800,000 of the Participation Shares
and the other RDO Investor can purchase up to $3,600,000 of the Participation Shares. If none of the investors of the Registered
Direct Offering purchase any of the Participation Shares, the Company may, but need not, sell the Participation Shares to the investors
of this Offering. There is no guarantee that any of the Participation Shares will be sold. (See, &ldquo;Transactions with Related
Persons - Registered Direct Offering&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
Class A Ordinary Shares are traded on The NASDAQ Global Market under the symbol &ldquo;APM&rdquo; and the Professional Compartment
of Euronext in Paris under the Euronext ticker symbol &ldquo;APM.&rdquo; On September 29, 2020, the last reported sale price of
our Class A Ordinary Shares as reported on The NASDAQ Global Market was $4.76 per share. There is no established public trading
market for the warrants or pre-funded warrants, and we do not expect a market to develop. We do not intend to apply for listing
of the warrants or pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active
trading market, the liquidity of the warrants and pre-funded warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging
growth company, as defined in the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, have elected
to comply with certain reduced public company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our
securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page  16 of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per <BR> Class A <BR> Ordinary <BR> Share and related Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per <BR> Pre-Funded <BR> Warrant and related Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Placement Agent&rsquo;s fees(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.2275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.2275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">630,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.0225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.0125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,370,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We have agreed to reimburse </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C. Wainwright &amp; Co., LLC <FONT STYLE="background-color: white">(the &ldquo;Placement Agent&rdquo;) for certain of its offering-related expenses, including a cash fee of 7.0% and a management fee of 0.75% of the gross proceeds raised in this offering. In addition, we have agreed to issue to the Placement Agent warrants to purchase up to a number of Class A Ordinary Shares </FONT>equal to 7.0% of the number of <FONT STYLE="background-color: white">Class A Ordinary Shares</FONT> and pre-funded warrants being offered at an exercise price equal to 125% of the public offering price of Class A Ordinary Shares (the &ldquo;Placement Agent&rsquo;s Warrants&rdquo;)<FONT STYLE="background-color: white">. See &ldquo;Plan of Distribution&rdquo; for additional information and a description of the compensation payable to the Placement Agent.</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the total expenses of this offering payable by us, excluding the Placement Agent&rsquo;s fees, will be approximately $209,600.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
engaged H.C. Wainwright &amp; Co., LLC (&ldquo;Wainwright&rdquo; or the &ldquo;Placement Agent&rdquo;) as our exclusive placement
agent to use its reasonable best efforts to solicit offers to purchase our securities in this offering. The Placement Agent has
no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount
of the securities. We have agreed to pay the placement agent the placement agent fees set forth in the table above and to provide
certain other compensation to the placement agent. See &ldquo;Plan of Distribution&rdquo; beginning on page</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">143 of this prospectus for more information regarding these arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that delivery
of the ordinary shares and warrants being offered pursuant to this prospectus supplement and the accompanying prospectus will be
made on or about October 2, 2020.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>H.C.
Wainwright&nbsp;&amp; Co.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement
is September 29, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 91%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%; padding: 0.25pt 0.25pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B>&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">Commonly Used Defined Terms</FONT></A></TD>
    <TD STYLE="text-align: center; padding: 0.25pt">ii</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">Industry and Market Data</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center"><FONT STYLE="font-size: 10pt">v</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">Prospectus Summary</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_030"><FONT STYLE="font-size: 10pt">Offering Summary</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">16</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">Special Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">63</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">Trademarks, Service Marks and Tradenames</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">64</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">Use of Proceeds</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">65</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">Dividend Policy</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">66</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">Capitalization</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">67</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">Dilution</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">68</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">68</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">Quantitative And Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">71</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">Our Business</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">72</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">Management</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">109</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">Transactions With Related Persons</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">121</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">Security Ownership Of Certain Beneficial Owners And Management</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">128</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">Shares Eligible for Future Sale</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">131</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_018">Description Of Share Capital</A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">132</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="#a_019">Plan of Distribution</A></P></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">143</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">Taxation</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">146</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_021"><FONT STYLE="font-size: 10pt">Expenses Of This Offering</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">151</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_022"><FONT STYLE="font-size: 10pt">Legal Matters</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">151</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_023"><FONT STYLE="font-size: 10pt">Experts</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">152</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_024"><FONT STYLE="font-size: 10pt">Enforcement Of Civil Liabilities</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">152</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_025"><FONT STYLE="font-size: 10pt">Where You Can Find More Information</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">153</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt"><A HREF="#a_026"><FONT STYLE="font-size: 10pt">Incorporation Of Certain Information By Reference</FONT></A></TD>
    <TD STYLE="padding: 0.25pt; text-align: center">154</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>We have not authorized
any person to provide you with information different from that contained in this prospectus or any related free-writing prospectus
that we authorize to be distributed to you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities
in any jurisdiction where the offer or sale is not permitted. The information in this prospectus speaks only as of the date of
this prospectus unless the information specifically indicates that another date applies, regardless of the time of delivery of
this prospectus or of any sale of the securities offered hereby.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For investors outside
of the United States: We have not done anything that would permit this Offering or possession or distribution of this prospectus
in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States
who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the Offering
and the distribution of this prospectus outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus includes
statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted
by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information
has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.
While we believe these industry publications and third-party research, surveys and studies are reliable, you are cautioned not
to give undue weight to this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this
prospectus to &#8220;$,&#8221; &#8220;U.S.$,&#8221; &#8220;U.S. dollars,&#8221; &#8220;dollars,&#8221; &#8220;US$,&#8221; and &#8220;USD&#8221;
mean United States dollars unless otherwise noted. All references to the &#8220;UK&#8221; in this prospectus refer to the United
Kingdom. All references to the &#8220;PRC&#8221; or &#8220;China&#8221; in this prospectus refer to the People&#8217;s Republic
of China. All references to &#8220;Hong Kong&#8221; or &#8220;H.K.&#8221; in this prospectus refer to Hong Kong Special Administrative
Region of the People&#8217;s Republic of China. All references to the &#8220;United States,&#8221; &#8220;U.S.&#8221; or &#8220;US&#8221;
refer to the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>COMMONLY USED DEFINED TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;505(b)(2) Application&#8221; refers to an application for which one or more of the investigations relied upon by the applicant for approval &#8220;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted&#8221; (21 U.S.C. 355(b)(2)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Acticule&#8221; refers to Acticule Life Sciences Limited, an 80% owned subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Aeneas&#8221; refers to AENEAS CAPITAL LIMITED, a wholly-owned subsidiary of Aeneas Group Limited, which is an indirect wholly-owned subsidiary of Jurchen Investment Corporation through Aeneas Limited. Because Mr. Huen, our CEO, holds 100% equity interest in Jurchen Investment Corporation, we refer to Aeneas as a fellow subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;AGL&#8221; refers to Aeneas Group Limited, a wholly-owned subsidiary of Aeneas Limited and we refer to AGL as a fellow subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;AL&#8221; refers to Aeneas Limited, an entity 76.8% owned by Jurchen Investment Corporation and we refer to AL as a fellow subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;AML&#8221; refers to Aptorum Medical Limited, a 93% owned-subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;AML Clinic&#8221; refers to an outpatient medical clinic operated by AML under the name of Talem Medical.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Annual Reports&#8221; refer collectively, to our annual report on Form 20-F and Form 20-F/A for the year ended December 31, 2018, filed with the SEC on April 15, 2019 and April 22, 2019, respectively, and our annual report on Form 20-F for the year ended December 31, 2019, filed with the SEC on April 29, 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Aptorum Group,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;Group&#8221; and &#8220;us&#8221; refer to Aptorum Group Limited, a Cayman Islands exempted company with limited liability whose principal place of business is in the United Kingdom.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Aptorum Non-Therapeutics Group&#8221; refers to the Company&#8217;s non-therapeutics segment that encompasses: (i) the development of surgical robotics and medical devices, which is operated through Signate Life Sciences Limited, (ii) AML Clinic and (iii) the sales of natural supplements through Nativus Life Sciences Limited.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Aptorum Therapeutics Group&#8221; refers to the Company&#8217;s therapeutics segment that is operated through its wholly-owned subsidiary, Aptorum Therapeutics Limited, a Cayman Islands exempted company with limited liability, whose principal place of business is in Hong Kong and its indirect subsidiary companies, whose principal places of business are in the United Kingdom, Singapore and Hong Kong.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Bond&#8221; refers to the $15,000,000 convertible bond
the Company originally issued to Peace Range (as hereinafter defined) in the Bond Offering, but which has since been repurchased
by one of the Company&rsquo;s wholly-owned subsidiaries, Aptorum Investment Holding Limited, pursuant to that certain Bond Repurchase
Agreement dated April 24, 2019 between the Company, Peace Range and Aptorum Investment Holding Limited, and which has matured
and been redeemed on October 25, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Bond Offering&#8221; refers to the Company&#8217;s private offering of the Bond that closed on April 25, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;cGCP&#8221; refers to Current Good Clinical Practice as adopted by the applicable regulatory authority.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;cGLP&#8221; refers to Current Good Laboratory Practice as adopted by the applicable regulatory authority.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;cGMP&#8221; refers to Current Good Manufacturing Practice as adopted by the applicable regulatory authority.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Class A Ordinary Shares&#8221; refers to the Company&#8217;s Class A Ordinary Shares, par value $1.00 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Class B Ordinary Shares&#8221; refers to the Company&#8217;s Class B Ordinary Shares, par value $1.00 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;CMC&#8221; refers to chemical, manufacturing and control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Covar&#8221; refers to Covar Pharmaceuticals Incorporated, a contract research organization engaged by the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;CROs&#8221; refers to contract research organizations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;CTA&rdquo;
                                         refers to Clinical Trial Application.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;EEA&#8221; refers to the European Economic Area.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;EMA&#8221; refers to the European Medicines Agency.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;EMEA&#8221; refers to Europe, the Middle East and Africa.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;EPO&#8221; refers to the European Patent Organization or the European Patent Office operated by it.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;European Patent&#8221; refers to patents issuable by the EPO.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;EU&#8221; refers to the European Union. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Exchange Act&#8221; refers to the U.S. Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;FDA&#8221; refers to U.S. Food and Drug Administration.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;FDCA&#8221; refers to the U.S. Federal Food, Drug and Cosmetic Act.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Fiscal year&#8221; refers to the period from January 31 of each calendar year to December 31 of the following calendar year.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;HC Wainwright&#8221; refers to H.C Wainwright &amp; Co., LLC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;HKD&#8221; refers to Hong Kong Dollars.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Hong Kong&#8221; or &#8220;H.K.&#8221; refers to Hong Kong Special Administrative Region of the People&#8217;s Republic of China.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Hong Kong Doctors&#8221; refers to the doctors in Hong Kong under the employment of AML Clinic.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;IND&#8221; refers to Investigational New Drugs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;IP&#8221; refers to intellectual property.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&#8220;IPO&#8221; means the initial public offering by the Company of 761,419 Class A Ordinary Shares consummated on December 17, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Jurchen&#8221; refers to Jurchen Investment Corporation, a company wholly-owned by our CEO, Ian Huen, and a holding company of Aptorum Group.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Lead Projects&#8221; refers to two of the Company&#8217;s therapeutic projects ALS-4 and SACT-1.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Major Patent Jurisdictions&#8221; refers to the United States, member states of the European Patent Organization and the People&#8217;s Republic of China.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Nativus&#8221; refers to Nativus Life Sciences Limited, a wholly-owned subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;NMPA&#8221; refers to China&#8217;s National Medical Products Administration and its predecessor, the China Food and Drug Administration.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;NDA&#8221; refers to a New Drug Application issued by the FDA.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Ordinary Shares&#8221; refers to the Class A Ordinary Shares and Class B Ordinary Shares collectively.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;PRC&#8221; and &#8220;China&#8221; refer to the People&#8217;s Republic of China.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Registered Direct Offering&#8221; means the registered direct offering by the Company of 1,351,350 Class A Ordinary Shares and warrants to purchase up to 1,351,350 Class A Ordinary Share consummated on February 28, 2020.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Restructure&#8221; refers to the Company&#8217;s change from an investment fund with management shares and non-voting participating redeemable preference shares to a holding company with operating subsidiaries, effective as of March 1, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;R&amp;D&#8221; refers to research and development.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;R&amp;D Center&#8221; refers to a pharmaceutical development center located at Hong Kong Science and Technology Park.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Securities Exchange Commission,&#8221;
    &#8220;SEC,&#8221; &#8220;Commission&#8221; or similar terms refer to the United States Securities and Exchange
    Commission.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Sarbanes-Oxley Act&#8221; refers to the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Securities Act&#8221; refers to the U.S. Securities Act of 1933, as amended.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Series A Notes&#8221; refers to Series A convertible notes, at a purchase price of $10,000 per note, sold in the Series A Note Offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Series A Note Investors&#8221; refers to the investors who purchased Series A Notes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Series A Note Offering&#8221; refers to the private offering of Series A Notes, pursuant to Regulation S or Regulation D, as promulgated under the Securities Act that closed on May 15, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Signate&#8221; refers to Signate Life Sciences Limited, a wholly-owned subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;UK&#8221; refers to the United Kingdom.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;United States,&#8221; &#8220;U.S.&#8221; and &#8220;US&#8221; refer to the United States of America.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;Videns&#8221; refers to Videns Incorporation Limited, a wholly-owned subsidiary of Aptorum Group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#8220;$,&#8221; &#8220;U.S. $,&#8221; &#8220;U.S. dollars,&#8221; &#8220;dollars,&#8221; &#8220;US$&#8221; and &#8220;USD&#8221; refer to the United States dollars.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>
</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>INDUSTRY AND MARKET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus includes information with respect to market and industry conditions and market share from third-party sources or based
upon estimates using such sources when available. We have not, directly or indirectly, sponsored or participated in the publication
of any of such materials. We believe that such information and estimates are reasonable and reliable. We also assume the information
extracted from publications of third-party sources has been accurately reproduced.&nbsp; We understand that the Company would
be liable for the information included in this prospectus if any part of the information was incorrect, misleading or imprecise
to a material extent.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><B><A NAME="a_003"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights
information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making
your investment decision. Before investing in our securities, you should carefully read the entire prospectus, including our financial
statements and the related notes and management&rsquo;s discussion and analysis incorporated herein by reference. You should also
consider, among other things, the matters described under &ldquo;Risk Factors&rdquo; in each case appearing elsewhere in this
prospectus. Unless otherwise stated, all references to &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Aptorum,&rdquo; &ldquo;we,&rdquo;
the &ldquo;Company,&rdquo; the &ldquo;group&rdquo; and similar designations refer to Aptorum Group Limited, a Cayman Islands exempted
company with limited liability.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a pharmaceutical
company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical
needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched
through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic
screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
above main focus, we are also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders,
women&#8217;s health and other disease areas. We also have projects focused on surgical robotics and natural supplement for women
undergoing menopause and experiencing related symptoms. Also, we opened a medical clinic, AML Clinic, in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although none of our
drug or device candidates have yet been approved for testing in humans, our goal is to develop a broad range of early stage novel
therapeutics and diagnostics across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this
goal include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Developing therapeutic
and diagnostic innovations across a wide range of disease/therapeutic areas;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Selectively expanding our
portfolio with potential products from our drug discovery platforms that may be able to attain orphan drug designation and/or
satisfy current unmet medical needs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Collaborating with leading
academic institutions and CROs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expanding our pharmaceutical
development capabilities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Leveraging our management&#8217;s
expertise, experience and commercial networks;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Obtaining and leveraging
government grants to fund project development.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have begun to devote
a significant percentage of our resources, which will include a substantial portion of the proceeds from this Offering, to the
development of two drug candidates (&#8220;Lead Projects&#8221;). The drug candidates being advanced as the Lead Projects are ALS-4
and SACT-1, described in further detail below. If the results of the remaining preclinical studies of these drug candidates are
positive, we expect to be able to submit in the fourth quarter of 2020, subject to regulatory review, an Investigational New Drug
Application (&#8220;IND&#8221;) for at least one of these candidates to the U.S. Food and Drug Administration (&#8220;FDA&#8221;)
or an equivalent application to the regulatory authorities in one or more other jurisdictions such as the China&#8217;s National
Medical Products Administration (&#8220;NMPA&#8221;), the European Medicines Agency (&#8220;EMA&#8221;) and/or Health Canada. Acceptance
of these applications by the relevant regulatory authority would enable the Company to begin testing that drug candidate in humans
in that jurisdiction. Our ability to obtain any approval of such applications is entirely dependent upon the results of our preclinical
studies, none of which have yet been completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our evaluation
of preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies,
potential market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our
rationale for selecting Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on
a combination of the factors and individual attributes of the Lead Projects themselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current business
consists of &#8220;therapeutics&#8221; and &#8220;non-therapeutics&#8221; segments. However, our focus is on the therapeutics segments.
Because of the risks, costs and extended development time required for successful drug development, we have determined to pursue
projects within our non-therapeutics segments, such as AML Clinic, to provide some interim revenue, as well as medical robots and
natural supplements that may be brought to market and generate revenue more quickly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Therapeutics
Segment</U></I>. In our therapeutics segment (&#8220;Aptorum Therapeutics Group&#8221;), we are currently seeking to develop various
drug molecules and certain technologies for the treatment (&#8220;therapeutics&#8221;) and diagnosis (&#8220;diagnostics&#8221;)
of human disease conditions to tackle unmet needs, in particular, our Lead Projects target infectious disease and cancer (including
orphan oncology indications). In addition to our main areas of focus above, we are also pursuing therapeutic projects in neurology,
gastroenterology, metabolic disorders, women&#8217;s health and other disease areas, as well as the development of natural supplements
for women undergoing menopause and experiencing related symptoms. Aptorum Therapeutics Group is operated through Aptorum&#8217;s
wholly-owned subsidiary, Aptorum Therapeutics Limited, a Cayman Islands exempted company with limited liability, whose principal
place of business is in Hong Kong whose subsidiaries (who we sometimes refer to herein as project companies) are based in the United
Kingdom, Singapore and Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><I><U>Non-Therapeutics
Segment</U></I>. The non-therapeutics segment (&#8220;Aptorum Non-Therapeutics Group&#8221;) encompasses three businesses: (i)
the development of surgical robotics and medical devices, (ii) AML Clinic and (iii) sales of natural supplements. The development
of surgical robotics and medical devices business is operated through Signate Life Sciences Limited, a subsidiary of Aptorum Therapeutics
Limited. The outpatient clinic is operated through our subsidiary, Aptorum Medical Limited. Effective as of March 2018, we leased
office space in Central, Hong Kong as the home to AML Clinic. AML Clinic commenced operations under the name of Talem Medical in
June 2018. The clinic is currently generating revenue. The sale of natural supplements is operated through Nativus Life Sciences
Limited (&#8220;Nativus&#8221;), a subsidiary of Aptorum Therapeutics Limited. As part of the commercialization, the Group, through
Nativus, entered into a regional distribution and marketing agreement with Multipak Limited, a Hong Kong based group that operates
household brands, including the Luk Yu&reg; tea bag and other health related products. Through Multipak, the Group will be able
to increase the accessibility of the product to a large consumer base regionally. The production of Aptorum Group&#8217;s dioscorea
opposita bioactive nutraceutical tablets has commenced production in Canada and will be marketed under the brand name NativusWell</FONT><SUP>&reg;</SUP><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to March 2017,
the Company had pursued passive healthcare related investments in early stage companies primarily in the United States. However,
we have since ceased pursuing further passive investment operations and intend to exit all such portfolio investments over an appropriate
timeframe to focus resources on our current business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24, 2019, the Company signed an agreement with AENEAS
CAPITAL LIMITED, and A*ccelerate Technologies Pte. Ltd, the enterprise office of the Agency for Science, Technology and Research
(&ldquo;A*STAR&rdquo;), (collectively, the &ldquo;Parties&rdquo;) to co-create local deep tech startups. This agreement, which
is part of A*ccelerate&rsquo;s venture co-creation (&ldquo;VCC&rdquo;) initiative, commits all parties to the co-creation of local
startups in the healthcare and life science sector (the &ldquo;Master Collaboration Agreement&rdquo;). Through this agreement,
we partnered with A*Star to explore suitable opportunities, if identified, to set up tech ventures in Singapore over the next 5
years. A*STAR shall contribute a total of up to $30,000,000 to any suitable startups, at their discretion. The Company and AENEAS
CAPITAL LIMITED will contribute a total of up to $30,000,000 to any suitable startups at their discretion with a focus on (i) securing
pilot customers; (ii) incorporation of the startups as companies and financial commitments of such customers; (iii) capital raising
and capital market plans; (iv) recruiting and building of the startup teams; (v) equipment and infrastructure; and (vi) licensing
of IP to the startups under the Technology License Agreements. The Master Collaboration Agreement shall continue for a period of
5 years, unless otherwise terminated or extended by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Aptorum&#8217;s Lead Projects</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our evaluation of preliminary
data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential
market size, competition in market, the Company have decided to prioritize our resources in developing our two Lead Projects, namely,
ALS-4 and SACT-1, among all our projects under development. Overall, our rationale for selecting Lead Projects was not based on
any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors and individual attributes
of the Lead Projects themselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 800px; height: 177px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For the definition of different
stages of development, such as Target Identification &amp; Selection, Lead Discovery, Lead Optimization, etc., please refer to
page 75.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ALS-4: Small molecule for the treatment
of bacterial infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bacteria such as&nbsp;<I>Staphylococcus
aureus</I>,&nbsp;<I>Mycobacterium tuberculosis</I>&nbsp;and&nbsp;<I>Pseudomonas aeruginosa&nbsp;</I>have become &#8220;superbugs&#8221;,
having developed resistance to many, if not all, of the existing drugs available to treat them, rendering those treatments ineffective
in many instances. MRSA is one such bacterium, a gram-positive bacterium that is genetically different from other strains of Staphylococcus
aureus. Staphylococcus aureus and MRSA can cause a variety of problems ranging from skin infections and sepsis to pneumonia and
bloodstream infections. It is estimated that about one out of every three people (33%) carry Staphylococcus aureus in their nose,
usually without any illness; about two in a hundred (2%) carry MRSA (source: https://www.cdc.gov/mrsa/tracking/index.html). Both
adults and children may carry MRSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most MRSA infections
occur in people who have been in hospital or other health care settings, such as nursing homes and dialysis centers (source: https://www.mayoclinic.org/diseases-conditions/mrsa/symptoms-causes/syc-20375336),
which is known as Healthcare-Associated MRSA (&#8220;HA-MRSA&#8221;). HA-MRSA infections are typically associated with invasive
procedures or devices, such as surgeries, intravenous tubing or artificial joints. Another type of MRSA infection, known as Community-Associated
MRSA (&#8220;CA-MRSA&#8221;), has occurred in wider community among healthy people. It often begins as a painful skin boil and
spreads by skin-to-skin contact. About 85% of serious, invasive MRSA infections are healthcare associated infections (https://www.cdc.gov/media/pressrel/2007/r071016.htm).
The incidence of CA-MRSA varies according to population and geographic location. In the U.S., more than 94,000 people develop serious
MRSA infection and about 19,000 patients die as a result each year (https://www.cdc.gov/media/pressrel/2007/r071016.htm). According
to the US Centers for Disease Control and Prevention (&#8220;CDC&#8221;), Staphylococcus aureus, including MRSA, caused about 11%
of healthcare-associated infections in 2011 (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml). Each year
in the U.S., around one out of every twenty-five hospitalized patients contracts at least one infection in the hospital (N Engl
J Med. 2014, 27;370(13):1198-208). In the U.S., there were over 80,000 invasive MRSA infections and 11,285 related deaths in 2011
(source: https://edition.cnn.com/2013/06/28/us/mrsa-fast-facts/index.html). Indeed, severe MRSA infections most commonly occur
during or soon after inpatient medical care. More than 290,000 hospitalized patients are infected with Staphylococcus aureus and
of these staphylococcal infections, approximately 126,000 are related to MRSA (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-4 is a small drug
molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival
of the bacterium in the body or that cause damage to the body&#8217;s systems. These products of bacterial genes are referred to
as &#8220;virulence expression.&#8221; Targeting bacterial virulence is an alternative approach to antimicrobial therapy that offers
promising opportunities to overcome the emergence and increasing prevalence of antibiotic-resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Richard
Kao from The University of Hong Kong (who is also the Founder and Principal Investigator of Acticule and Inventor of ALS-2, ALS-3
and ALS-4) initiated a high throughput approach for screening compounds which are active against virulence expression, which resulted
in the discovery of ALS-2, ALS-3 and ALS-4.&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-4 targets an enzyme
essential for Staphylococcus aureus (including MRSA) survival in vivo. This enzyme is involved in the production of Staphyloxanthin,
a carotenoid pigment produced by Staphylococcus aureus including MRSA, and is responsible for the characteristic golden color.
This pigment has proven to be an important factor in promoting bacterial invasion as well as rendering the bacteria resistant to
attack from reactive oxygen species (ROS) and neutrophils. In other words, pigmented bacteria have increased resistance to the
host&#8217;s immune defenses. ALS-4 may have particular value if it can be shown to be an effective therapy in situations where
a Staphylococcus aureus infection is resistant to available antibiotics (i.e., where the pathogen is MRSA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a recent study by
the inventor, Prof. Richard Kao, ALS-4 demonstrates potent activity against Staphylococcus aureus pigment formation in vitro, as
indicated in Figure 1, with an IC<SUB>50</SUB>&nbsp;(IC<SUB>50</SUB>&nbsp;is defined as the concentration of a drug which inhibits
half of the maximal response of a biochemical process. In this case, inhibition of the formation of the golden pigment is the response)
equal to 20 nM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Figure 1&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 600px; width: 527px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Figure 1: In vitro pigment inhibition
by compound ALS-4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(A) Inhibition of wild-type (WT)
Staphylococcus aureus pigmentation in the presence of increasing concentrations of ALS-4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(B) Pigment inhibition by ALS-4;
the IC<SUB>50</SUB>&nbsp;for pigment formation is roughly 300 nM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All data represent mean values
&plusmn; SD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">NP16 = ALS-4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This assay was conducted in triplicate
and repeated twice for confirmation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(Adapted from mBio (8(5): e01224,
2017))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By employing a systemic
Staphylococcus aureus rat infection model, the treatment (10mg/kg of ALS-4 twice daily) and control groups (vehicle) were compared.
In the lethal dose model, all the animals died by day 4 in the control group. On the contrary, the ALS-4 treated group showed &gt;50%
survival until the end of the study (Day 7), which is determined to be statistically significant compared with the control (p =
0.0102 by a Log-rank (Mantel-Cox) test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(Mantel-Cox) test</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the delayed treatment
model, ALS-4 brought a statistically significant reduction in bacterial count (99.5%) compared with the control (p = 0.0126 by
an unpaired student&#8217;s t-test).&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 278px; width: 525px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_005.jpg" ALT="" STYLE="height: 341px; width: 199px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 2: ALS-4 is observed to
reduce bacterial load in mice&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">CFU = Colony Forming Unit, a
unit used to estimate the number of viable bacteria in a sample</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ALS-4 is currently undergoing
CTA enabling stage to prepare for regulatory submission in Canada for a Phase 1 clinical trial. The development of ALS-4 candidate
has been progressing well and the first series of GLP toxicology studies have been completed through an appointed contract research
organization (CRO) based in Canada. In particular, ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4
development is on our proposed track and we target the related regulatory submission for a Phase 1 clinical trial in the second
half year of 2020 in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patent License</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2017,
the Company&#8217;s subsidiary, Acticule, entered into an exclusive license agreement with Versitech Limited, the licensing entity
of HKU, for ALS-4. Subsequently on June 7, 2018, the parties entered into a first amendment to the exclusive license agreement,&nbsp;and
on July 10, 2019, the parties entered into a second amendment to the license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2019,
Acticule and Versitech Limited entered into a second license agreement for ALS-4, where Acticule exclusively licensed the intellectual
property rights on certain HKU-owned improvements to the original licensed invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the exclusive
license agreements, we were granted an exclusive, royalty-bearing, sublicensable licenses to develop, make, have made, use, sell,
offer for sale and import products that are covered by the licensed patents (as described below). The territory of the licenses
is worldwide and the field of the licenses is for treatment or prevention of bacterial infections caused by Staphylococcus aureus
including MRSA and bacterial virulence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We paid an upfront
fee upon entering into the license agreements. We are required to pay less than 10% of the net sales of the licensed products sold
by us or our affiliates as royalties, as well as a low teens percentage of sublicense royalties that we receive from our sublicensees,
if any. In addition, we agreed to pay to the licensor aggregate regulatory milestones of up to US$1 million subject to the following
achievements: submission of investigational new drug application; completion of phase 1, 2 and 3 clinical trials; and submission
of new drug application; grant of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones of up to
US$7.8 million subject to the following achievement: first commercial sale; and annual net sales exceeding US$100 million in one
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the license
agreements, Acticule became the exclusive licensee of 2 pending U.S. non-provisional patent applications and 2 PCT applications
(now expired). Prior to the expiration of the PCT applications, we filed national phase applications in member states of the EPO,
in PRC and 11 other jurisdictions. The claimed inventions are described as: &#8220;Compounds Affecting Pigment Production and Methods
for Treatment of Bacterial Diseases.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acticule has the right
to grant sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign
the agreements to any successor to the business related to the licenses. In the event that Acticule makes an improvement to the
licensed technologies, so long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such
improvement, subject to a non-exclusive royalty-free license being granted back to Versitech Limited for academic and research
purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exclusive license
agreements shall be in effect until the expiration of all licensed patents (please refer to the patent expiration dates under &#8220;Item
4. Information on the Company &#8211; B. Business Overview &#8211; Intellectual Property&#8221;). Acticule may terminate the licenses
at any time with 6-month written notice in advance. Either party may terminate the agreements upon a material breach by other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SACT-1: A Repurposed Drug for the Treatment of Neuroblastoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug repurposing is
a strategy for identifying new indications for approved or investigational drugs that are outside the scope of the original medical
uses. It is often viewed as a lower-cost method for drug commercialization, as it is based on already-approved drugs (which has
been proven to be safe for human use by the respective governing regulatory agency) and explores new target indications. (Ashburn,
T. T. &amp; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673&#8211;683,
2004).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the advantages
of drug repurposing is a lower development risk due to safety and toxicity, as well as other properties related to water solubility,
absorption, distribution and metabolism, as the safety and CMC profiles of marketed drugs are usually well-established. Due to
the same reason, the development time is also shortened because there is no need to repeat the whole spectrum of the safety assessment.
As a result, the drug repurposing approach appears to be attractive due to its superior risk management, smaller capital investment
and quicker financial return. (Sudeep Pushpakom, et. al. Drug repurposing: progress, challenges and recommendations. Nat. Rev.
Drug Discov. 18, 41-58, 2019)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of bringing
a repurposed drug is estimated to be around US$300 million, which is only one-tenth of the development cost for a new drug. (Nosengo,
N. Can you teach old drugs new tricks? Nature. 534, 314-316, 2016).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In summary, drug repurposing
offers the following advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Well-established safety
profiles: The development risk for new indications can be substantially reduced by applying existing drugs that are approved or
have been shown to be safe in large scale late-stage trials. Since safety accounts for approximately 30% of drug failures in clinical
trials, this is a key advantage that repositioned drugs can harness to great effect. (Key benefits of drug repositioning. (n.d.).
Retrieved from http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Time-saving: As repositioned
drugs can rely on existing data, including efficacy and toxicity studies, the process is usually faster than de novo development.
Developing a new chemical entity (NCE) can take 10 to 17 years, depending on indications. (Roin, B. N. Solving the Problem of
New Uses, 2013). For a drug repositioning company, the development process from compound identification to launch can be around
3 to 8 years. (Walker, N. (2017, December 07). Accelerating Drug Development Through Repurposing, Repositioning and Rescue. Retrieved
from https://www.pharmoutsourcing.com/Featured-Articles/345076-Accelerating-Drug-Development-Through-Repurposing-Repositioning-and-Rescue/)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cost-saving: Along with time-saving, money-saving is also a key benefit. With a single compound to enter clinical trials costing around US$10 to $20 million, the cost of identifying a repositioning candidate that already has phase 1 data could be as low as US$2 to $3 million. (http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Potential for out-licensing: Pharmaceutical companies are said to be exploring new models to out-license some of their clinical drug candidates that may have been shelved for pure business reasons unrelated to safety or efficacy, even though they have met their endpoints and have proven themselves to be safe. If such drugs were to be repositioned, the pharmaceutical company increases the attractiveness of these drugs and gives itself more options to find interested buyers. (http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Lower failure rate: According to BCC Research, approval rates for repurposed drugs are close to 30%, which is greater than the approval rate for new drug applications. ( Front Oncol. 2017; 7: 273)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the major limitations
of the current drug repurposing and repositioning practice is that there is a lack of a systematic way to identify and reinvestigate
drugs that are approved and/or have failed approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SACT-1 is the first
repurposed drug candidate to be developed under the Smart-ACT<SUP>&reg; </SUP>drug discovery platform. SACT-1 is one of the Company&rsquo;s
proprietary technologies. Our first targeted indication is neuroblastoma. Neuroblastoma is a rare form of cancer, and classified
as an orphan disease, that forms in certain types of nerve tissue and most frequently in the adrenal glands as well as spine,
chest, abdomen or neck, predominantly in children, especially for those aged 5 years and below. For the high-risk group, which
is close to 20% (Annu Rev Med. 2015; 66: 49&ndash;63.) of total new patient population per year, the 5-year survival rate of this
condition is around 40-50% as observed by the American Cancer Society (https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html).
The current high drug treatment cost for high risk patients can average USD200,000 per regimen (all 6 cycles) (https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf
). In addition, most pediatric patients often do not tolerate or survive the relevant chemotherapy stage which, subject to further
clinical studies, may be positively addressed by the SACT-1 candidate due to the potential synergistic effects when applied with
standard chemotherapy.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our recent studies,
SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent
the high-risk neuroblastoma patient group. In addition, by using a bliss score as a quantitative measure of the extent of drug
interaction, Aptorum Group has seen a high and robust synergism between SACT-1 and traditional chemotherapy in vitro (Figure 3),
indicating a potential efficacy enhancement/dose reduction of the chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_006.jpg" ALT="" STYLE="height: 301px; width: 540px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 3 synergism
between SACT-1 and traditional chemotherapy in vitro</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in our
recent study, the maximum tolerable dose of SACT-1 in a rodent model was determined to be higher than 400mg/kg. Compared with the
MTD of standard chemotherapy such as paclitaxel (20-30mg/kg) (Clin Cancer Res. 5(11):3632-8) and cisplatin (6mg/kg) (BMC Cancer
17: 684 (2017)), the safety profile of SACT-1 appears to be very impressive. Based on our internal observations of pre-existing
information from approved products, (subject to FDA&#8217;s approval and on a case-by-case basis, a 505(b)(2) Application can rely
in part on existing information from approved products (such as the FDA&#8217;s previous findings on safety and efficacy) or products
in literature (such as data available). However, typically speaking, the applicant is nonetheless required to carry out a Phase
1 bridging study to compare the Reference Listed Drug and reference the established safety and efficacy information), SACT-1 also
exhibits a well-established safety profile: at 150mg/day, the death rate was 0% in prior clinical studies with no dosage related
adverse events (Table 1). In addition, the pharmacokinetic profile of SACT-1 has also been reported (Table 2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Table 1:
Safety Profiles of SACT-1 in Human Clinical Trials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_007.jpg" ALT="" STYLE="height: 182px; width: 613px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Table 2:
The pharmacokinetic Profile of SACT-1 in Humans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_008.jpg" ALT="" STYLE="width: 660px; height: 223px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing
a pediatric formulation of SACT-1 to better address the needs of neuroblastoma patients who are exclusively children younger than
5. SACT-1 is undergoing preparation for IND submission and is on track for regulatory application to target to commence phase 1b/2a
clinical trials under the US FDA&#8217;s 505(b)(2) pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Statistical Significance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term statistical
significance is to define the probability that a measured difference between two groups (e.g. two treatment groups, treatment versus
control groups) is the result of a real difference in the tested variations and not the result of chance. It means that the result
of a test does not appear randomly or by chance, but because of a specific change that is tested, so it can be attributed to a
specific cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The confidence level
indicates to what percentage the test results will not commit a type 1 error, the false positive. A false positive occurs when
a change in the result is due to randomness (or other noise) and not the change in variations. At a 95% confidence level (p = 0.05),
there is a 5% chance that the test results are due to a type 1 error. 95% has become the standard and usually be the minimum confidence
level for the tests. To make the test more stringent, a 99% confidence level (p = 0.01) is also commonly employed, which means
that there is a 1% chance that the test results are due to a type 1 error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In other words, a p
value represents the confidence level. For example, if the p-value for a test is &lt; 0.05, it means that there is less than 5%
chance the difference between two groups is due to random error or by chance. If the p-value is &lt; 0.01, it means that there
is less than 1% chance the difference between two groups is due to random error or by chance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employed statistical
testing to compare different treatment groups in animal studies simply for proof of concept and to aid internal decision making
for further development. We do not intend to use this standard for any regulatory submission. The US FDA or other regulatory agencies
may not necessarily employ the same statistical standard to assess the efficacy in clinical trials, the results of which would
be submitted for regulatory approval.&nbsp;Although a p-value of 0.05 has become the standard,&nbsp;the US FDA or other regulatory
agencies may also individualize their efficacy standard for different clinical programs based on the indications, the purpose of
a clinical trial, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>FDA Application Status</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
prospectus, we have not submitted any applications for investigational new drugs (&#8220;IND&#8221;) to the US Food and Drug Administration
(&#8220;FDA&#8221;). In the fourth quarter of 2020, subject to regulatory review, we expect to be in a position to submit at least
one application for one of our drug candidates to commence trials in humans (INDs to the FDA or an equivalent application to the
regulatory authorities in another jurisdiction such as the China&#8217;s National Medical Products Administration (the &#8220;NMPA&#8221;)
or the European Medicines Agency (&#8220;EMA&#8221;)). However, there can be no assurance we will be able to make any such application
by such time. Should we be delayed in making such filing or should such filing not be approved, our business will be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B><I>Our
Structure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The following
diagram illustrates our corporate structure as of the date of this prospectus. For more details regarding our corporate history
and current structure, please refer to &#8220;Corporate History and Background&#8221; appearing on page<B> </B>87 of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_010.jpg" ALT="" STYLE="width: 650px; height: 417px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><B><I>Controlled
Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">As
long as our officers and directors, either individually or in the </FONT>aggregate, own at least 50% of the voting power of our
Company, we will be a &#8220;controlled company&#8221; as defined under NASDAQ Marketplace Rules. However, even if we qualify as
a &#8220;controlled company,&#8221; we do not intend to rely on the controlled company exemptions provided under NASDAQ Marketplace
Rules. To that extent, we have set up the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance
Committee, all of which consist solely of independent directors and adopted a charter for each committee. For so long as we are
a controlled company under that definition, we are permitted however to elect to rely, and may rely, on certain exemptions from
corporate governance rules, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exemption from the rule that a majority of our board of directors must be independent directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exemption from the rule that the compensation of our chief executive officer must be determined or recommended solely by independent directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exemption from the rule that our director nominees must be selected or recommended solely by independent directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">As a result,
you will not have the same protection afforded to shareholders of companies that are subject to these corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Although
we do not intend to rely on the &#8220;controlled company&#8221; exemption under the Nasdaq listing rules, we could elect to rely
on this exemption in the future. If we elect to rely on the &#8220;controlled company&#8221; exemption, a majority of the members
of our board of directors might not be independent directors and our nominating and corporate governance and compensation committees
might not consist entirely of independent directors. (See &#8220;Risk Factors &#8211; Risks Related to Our Corporate Structure
&#8211; <B><I>As a &#8220;controlled company&#8221; under the rules of the NASDAQ Global Market, we may choose to exempt our company
from certain corporate governance requirements that could have an adverse effect on our public shareholders.&#8221;</I></B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>Risks Associated with Our Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Investing
in our securities involves risks. You should carefully consider the risks described in &#8220;Risk Factors&#8221; beginning
on page 16 of this prospectus before making a decision to purchase our securities. If any of these risks actually
occurs, our business, financial condition or results of operations would likely be materially adversely affected. In such
case, the trading price of our Class A Ordinary Shares would likely decline, and you may lose all or part of your
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B><I>Recent Events</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 27,
2020, we entered into certain warrant exchange agreements (the &ldquo;Purchaser Exchange Agreements&rdquo;) with two
non-affiliated purchasers to purchase our Class A Ordinary Shares (the &ldquo;Purchaser Warrant Exchange&rdquo;); the
purchasers were two of the purchasers in the Registered Direct Offering. Pursuant to the Purchaser Exchange Agreements, the
Company and the purchasers agreed that in consideration for exchanging in full all of the Purchaser Exchange Warrants held by
the purchasers, the Company will exchange one (1) Class A Ordinary Share for each one (1) Purchaser Exchange Warrant
(&ldquo;Purchaser Exchange Share&rdquo;). To the extent a purchaser would otherwise beneficially own in excess of any
beneficial ownership limitation applicable to such holder after giving effect to the Purchaser Warrant Exchange, the Company
shall only issue such number of Class A Ordinary Shares to the purchaser that would not cause such purchaser to exceed the
beneficial ownership limitation with the balance to be held in abeyance until written notice from the purchaser that the
balance (or portion thereof) may be issued in compliance with the beneficial ownership limitation, which abeyance shall be
evidenced through the existing warrant from the Registered Direct Offering, which shall be deemed prepaid thereafter, and
exercised pursuant to a notice of exercise in the February 2020 Warrants (as defined below).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">On July 24,
2020, our Class A Ordinary Shares began to trade on the Professional Compartment of the regulated market of Euronext Paris under
the symbol &#8220;APM&#8221; and will be denominated in Euros on Euronext Paris.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 25,
2020, we entered into certain securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) to effect the Registered Direct
Offering, with certain non-affiliated institutional investors and Jurchen Investment Corporation, the ultimate parent of the Group,
pursuant to which we agreed to sell total 1,351,350 Class A Ordinary Shares (the &ldquo;Shares&rdquo;) and warrants (&ldquo;February
2020 Warrants&rdquo;) to purchase 1,351,350 of the Shares, for gross proceeds of approximately $10 million. The February 2020
Warrants are exercisable immediately following the date of issuance for a period of seven years at an initial exercise price of
$7.40. The purchase price for each Share and the corresponding Warrant was $7.40. The Shares and February 2020 Warrants were issued
on February 28, 2020. Additionally, we issued 43,243 warrants to the placement agent on terms substantially the same as the February
2020 Warrants except that the exercise price of the warrants issued to the Placement Agent was initially $8.88. As a result of
the Purchaser Warrant Exchange, the exercise prices of the February 2020 Warrants, including those issued to the Placement Agent,
were reduced to a nominal amount pursuant to the anti-dilution provisions in such warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">On January
30, 2020, the World Health Organization declared the coronavirus outbreak a &#8220;Public Health Emergency of International Concern&#8221;
and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus
include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses.
The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies
and financial markets of many countries, including the geographical area in which the Company operates. While the closures and
limitations on movement, domestically and internationally, are expected to be temporary, if the outbreak continues on its current
trajectory the duration of the supply chain disruption could reduce the availability, or result in delays, of materials or supplies
to and from the Group, which in turn could materially interrupt the Group&#8217;s business operations. Given the speed and frequency
of the continuously evolving developments with respect to this pandemic, the Group cannot reasonably estimate the magnitude of
the impact to its consolidated results of operations. Additionally, it is reasonably possible that estimates made in the financial
statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including
losses on investments; impairment losses related to long-lived assets and current obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On
January 14, 2020, we entered into a regional distribution agreement with Multipak Limited for the commercialization of our natural
supplements for women undergoing menopause and experiencing related symptoms. The dioscorea opposita bioactive nutraceutical tablets
has commenced production in Canada and will be marketed under the brand name NativusWell</FONT><SUP>&reg;</SUP><FONT STYLE="font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>Our Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Our authorized
share capital is divided into Class A Ordinary Shares and Class B Ordinary Shares. Holders of Class A Ordinary Shares and Class
B Ordinary Shares have the same rights except for voting and conversion rights. In respect of matters requiring a shareholder vote,
each Class A Ordinary Share will be entitled to one vote and each Class B Ordinary Share will be entitled to ten votes. Due to
the Class B Ordinary Share&#8217;s voting power, the holders of Class B Ordinary shares currently and may continue to have a concentration
of voting power, which limits the holders of Class A Ordinary Shares&#8217; ability to influence corporate matters. <FONT STYLE="background-color: white">(See
&#8220;Risk Factors </FONT>&#8211; <FONT STYLE="background-color: white">Risks Related to our securities &#8211;</FONT> <B><I>Our
Class B Ordinary Shares have greater voting power than our Class A Ordinary Shares and certain existing shareholders have substantial
influence over our Company and their interests may not be aligned with the interests of our other shareholders.&#8221;) </I></B>Each
Class B Ordinary Share is convertible into one Class A Ordinary Share at any time by the holder thereof. Class A Ordinary Shares
are not convertible into Class B Ordinary Shares under any circumstances. (See &#8220;Description of Share Capital&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B><I>Corporate Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 34pt">Our principal
executive office is located at 17 Hanover Square, London W1S 1BN, United Kingdom. Our telephone number is +44 20 80929299.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 34pt">Our website
is www.aptorumgroup.com. <B>The information on our website is not part of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>&nbsp;</I></B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I></I></B></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>Implications of Being an Emerging Growth Company
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;), and we are eligible
to take advantage of certain exemptions from various reporting and financial disclosure requirements that are applicable to other
public companies, that are not emerging growth companies, including, but not limited to, (1) not being required to comply with
the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (2) reduced disclosure obligations regarding executive
compensation in our periodic reports and proxy statements, and (3) exemptions from the requirements of holding a non-binding advisory
vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We intend to
take advantage of these exemptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Section
107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided
in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. As a result, an emerging growth
company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could remain an
emerging growth company for up to five years, or until the earliest of (1) the last day of the first fiscal year in which our annual
gross revenues exceed $1.07 billion, (2) the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2
under the Exchange Act, which would occur if the market value of our Ordinary Shares that is held by non-affiliates exceeds $700
million as of the last business day of our most recently completed second fiscal quarter and we have been publicly reporting for
at least 12 months, or (3) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year
period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Implications of Being a Foreign Private Issuer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">We are also
considered a &#8220;foreign private issuer.&#8221; In our capacity as a foreign private issuer, we are exempted from certain rules
under the U.S. Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), that impose certain disclosure obligations
and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors
and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16
of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Class A Ordinary Shares.
Moreover, we are not required to file periodic reports and financial statements with the U.S. Securities and Exchange Commission
(&#8220;SEC&#8221;), as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. In
addition, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">We may take
advantage of these exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private
issuer at such time when more than 50% of our outstanding voting securities are held by U.S. residents and any of the following
three circumstances applies: (1) the majority of our executive officers or directors are U.S. citizens or residents; (2) more than
50% of our assets are located in the United States; or (3) our business is administered principally in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">We have taken
advantage of certain reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein
may be different than the information you receive from other public companies in which you hold equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B><I>Notes on Prospectus Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Numerical
figures included in this prospectus have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in
various tables may not be arithmetic aggregations of the figures that precede them. Certain market data and other statistical information
contained in this prospectus is based on information from independent industry organizations, publications, surveys and forecasts.
Some market data and statistical information contained in this prospectus are also based on management&#8217;s estimates and calculations,
which are derived from our review and interpretation of the independent sources listed above, our internal research and our knowledge
of pharmaceutical industry. While we believe such information is reliable, we have not independently verified any third-party information
and our internal data has not been verified by any independent source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Accordingly,
actual events or circumstances may differ materially from events and circumstances that are assumed in this information and you
are cautioned not to give undue weight to such data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_030"></A>The Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer: </FONT></TD>
    <TD STYLE="width: 1%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 64%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aptorum Group Limited</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A Ordinary Shares &nbsp;being offered by us</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 2,769,231 Class A Ordinary Shares and related warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Combined public price per share and related warrant</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.25.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants offered by us</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase up to 2,769,231 Class A Ordinary Shares. Each Class A Ordinary Share is being sold together with one warrant to purchase one Class A Ordinary Share. Each warrant will have an exercise price per share equal to 100% of the of the combined public offering price per Class A Ordinary Share and related warrant in this offering, will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The Class A Ordinary Shares and warrants are immediately separable and will be issued separately, but will be purchased together in this offering. This prospectus also relates to the offering of the Class A Ordinary Shares issuable upon exercise of the warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-funded Warrants being offered by us</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are also offering to certain purchasers whose purchase of Class A Ordinary Shares in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Class A Ordinary Shares immediately following the consummation of this offering, the opportunity to purchase, if such purchasers so choose,&nbsp;pre-funded&nbsp;warrants in lieu of Class A Ordinary Shares that would otherwise result in any such purchaser&rsquo;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Class A Ordinary Shares. The exercise price of each&nbsp;pre-funded&nbsp;warrant&nbsp;will equal $0.01 per share. Each&nbsp;pre-funded&nbsp;warrant&nbsp;will be exercisable upon issuance and will not expire prior to exercise. For each&nbsp;pre-funded&nbsp;warrant&nbsp;we sell, the number of Class A Ordinary Shares we are offering will be decreased on a&nbsp;one-for-one&nbsp;basis. This prospectus also relates to the offering of the Class A Ordinary Shares issuable upon exercise of the&nbsp;pre-funded&nbsp;warrants.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Securities we are Offering</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We may sell an
        additional 2,769,231 Class A Ordinary Shares and warrants to purchase up to 2,769,231 Class A Ordinary Shares, or up to 2,769,231
        pre-funded warrants to purchase up to 2,769,231 Class A Ordinary Shares and warrants to purchase up to 2,769,231 Class A Ordinary
        Shares (collectively, the &ldquo;Participation Shares&rdquo;), to certain investors who participated in the Registered Direct Offering
        (as hereinafter defined), all of which Participation Shares were previously registered in the registration statements of which
        this prospectus forms a part. As further explained in the Transactions with Related Persons section below, due to the right of
        participation granted to the investors of the Registered Direct Offering (the &ldquo;RDO Investors&rdquo;), they are entitled to
        participate, in the aggregate, in this Offering up to $9,000,000 (&ldquo;Participation Maximum&rdquo;) on the same terms, conditions
        and at the same price as investors in this Offering, on a pro-rata basis determined by their participation in the Registered Direct
        Offering. Accordingly, three of the RDO Investors can purchase up to $1,800,000 of the Participation Shares and the other RDO Investor
        can purchase up to $3,600,000 of the Participation Shares. If none of the investors of the Registered Direct Offering purchase
        any of the Participation Shares, the Company may, but need not, sell the Participation Shares to the investors of this Offering.
        There is no guarantee that any of the Participation Shares will be sold.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A Ordinary Shares outstanding prior to this Offering (1)</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,491,526</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A Ordinary Shares outstanding immediately following the consummation of this Offering</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,260,757</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Class A Ordinary Shares trade on the NASDAQ Global Market under the symbol APM. There is no established public trading market for the warrants or pre-funded warrants, and we do not expect a market to develop. We do not intend to apply for listing of the warrants or the pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the warrants and the pre-funded warrants will be limited.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="padding: 5; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Agent</FONT></TD>
    <TD STYLE="width: 1%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 64%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continental Stock Transfer &amp; Trust Company</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities involves a high degree of risk and purchasers of our securities may lose part or all of their investment. See &ldquo;Risk Factors&rdquo; for a discussion of factors you should carefully consider before deciding to invest in our securities beginning on Page 16.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 7.7pt; padding-left: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming all of the Class A Ordinary Shares and Pre-Funded Warrants are sold but no Participation Shares are sold, we estimate that we will receive net proceeds from this Offering of approximately $8.05 million, based on a public offering price of $3.25, after deducting placement agent commissions and estimated offering expenses. We currently intend to use the net proceeds we receive from this Offering for general corporate purposes. See &ldquo;Use of Proceeds&rdquo; for additional information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    number of shares to be outstanding before this offering is based on 8,491,526 Class A Ordinary Shares and 22,437,754 Class
    B Ordinary Shares outstanding as of September 29, 2020 and excludes:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">926,840 Class A Ordinary Shares issuable upon the exercise of share options outstanding; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">854,053 Class A Ordinary Shares underlying outstanding warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated, all information
in this prospectus assumes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that no Participation Shares are sold; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of 854,053 outstanding warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the warrants issuable pursuant to this offering;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the Pre-Funded Warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the Placement Agent&rsquo;s Warrants;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the 926,840 Class A Ordinary Shares issuable upon the exercise of share options outstanding.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

</DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><I>Investing in our securities involves
a high degree of risk. You should carefully consider the following risks and all other information contained in this prospectus,
including our financial statements, consolidated financial statements and the related notes, before making an investment decision
regarding our securities. The risks and uncertainties described below are those significant risk factors, currently known and specific
to us that we believe are relevant to an investment in our securities. If any of these risks materialize, our business, financial
condition or results of operations could suffer, the price of our Class A Ordinary Shares could decline and you could lose part
or all of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Preclinical and
Clinical Development of Our Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We currently do not generate revenue
from product sales and may never become profitable; unless we can raise more capital through additional financings, of which there
can be no guarantee, our principal source of revenue will be from AML Clinic, which may not be substantial.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to generate
revenue and become profitable depends upon our ability to successfully complete the development of, and obtain the necessary regulatory
approvals for, the drug candidates in our Lead Projects and any future drug candidates we may develop, as we do not currently have
any drugs that are available for commercial sale. We expect to continue to incur losses before commercialization of our drug candidates
and any future drug candidates. None of our drug candidates has been approved for marketing in the U.S., Europe, the PRC or any
other jurisdictions and may never receive such approval. Our ability to generate revenue and achieve profitability is dependent
on our ability to complete the development of our drug candidates and any future drug candidates we develop in our portfolio, obtain
necessary regulatory approvals, and have our drugs products under development manufactured and successfully marketed, of which
there can be no guarantee. Although AML Clinic commenced operations in June 2018 and we have received some revenue from such operations,
even at full capacity, AML Clinic may not bring enough revenue to support our operation and R&amp;D. Thus, we may not be able to
generate a profit until our drug candidates become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive
regulatory approval and marketing authorization for one or more of our drug candidates or one or more of any future drug candidates
for commercial sale, a potential product may not generate revenue at all unless we are successful in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developing a sustainable and scalable manufacturing process for our drug candidates and any approved products, including establishing and maintaining commercially viable supply relationships with third parties;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">launching and commercializing drug candidates following regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtaining market acceptance of our drug candidates as viable treatment options;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">addressing any competing technological and market developments;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">negotiating and maintaining favorable terms in any collaboration, licensing or other arrangement into which we may enter to commercialize drug candidates for which we have obtained required approvals and marketing authorizations; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">maintaining, protecting and expanding our portfolio of IP rights, including patents, trade secrets and know-how.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our ability
to achieve and maintain profitability depends on timing and the amount of expenses we will incur. Our expenses could increase materially
if we are required by the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities to perform studies in addition
to those that we currently have anticipated. Even if our drug candidates are approved for commercial sale, we anticipate incurring
significant costs associated with the commercial launch of these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to become
and remain profitable depends on our ability to generate revenue. Even if we are able to generate revenues from AML Clinic or the
sale or sublicense of any products we may develop or license, we may not become profitable on a sustainable basis or at all. Our
failure to become and remain profitable would decrease the value of our Company and adversely affect the market price of our Class
A Ordinary Shares, which could impair our ability to raise capital, expand our business or continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AML Clinic&#8217;s operations may
be our principal source of revenue for the foreseeable future and most likely, without additional financing, such revenue will
not be sufficient for us to carry out all of our plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As stated above, we
have not generated any revenue and do not foresee generating any revenue from our drug candidates in the near future. Effective
as of March 2018, we leased the property in Central, Hong Kong that is the home to AML Clinic, which commenced operations in June
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until our therapeutic
candidates produce revenue, our principal source of revenue is from AML Clinic, but we it is not sufficient by itself to fund our
other operations. We believe that available cash, together with the efforts from management plans and actions described elsewhere
in this prospectus, should enable the Company to meet presently anticipated cash needs for at least the next 12 months after the
date that the financial statements are issued and the Company has prepared the consolidated financial statements on a going concern
basis. However, the Company continues to have ongoing obligations and it expects that it will require additional capital in order
to execute its longer-term development plan. If the Company encounters unforeseen circumstances that place constraints on its capital
resources, management will be required to take various measures to conserve liquidity, which could include, but not necessarily
be limited to, deferring some of its research and seeking to dispose of marketable securities. Management cannot provide any assurance
that the Company will raise additional capital if needed.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend substantially on the
success of the drug candidates being researched as our current Lead Projects, which are in the preclinical stage of development.
The preclinical development, IND-enabling, CTA-enabling, and clinical trials of our drug candidates may not be successful. If
we are unable to license or sublicense, sell or otherwise commercialize our drug candidates, or experience significant delays
in doing so, our business will be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and the
ability to generate revenue related to product sales, if ever achieved, will depend on the successful development, regulatory approval
and licensing or sublicensing or other commercialization of our drug candidates or any other drug candidates we may develop. We
have invested a significant amount of financial resources in the development of our drug candidates and we may invest in other
drug candidates. The success of our drug candidates and any other potential drug candidates will depend on many factors, including
but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">successful enrollment in, and completion of, studies in animals and clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">other parties&#8217; ability in conducting our clinical trials safely, efficiently and according to the agreed protocol;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">receipt of regulatory approvals from the FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities for our drug candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to establish commercial manufacturing capabilities by making arrangements with third-party manufacturers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reliance on other parties to conduct our clinical trials swiftly and effectively;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">launch of commercial sales of our drug candidates, if and when approved;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">obtaining and maintaining patents, trade secrets and other IP protection and regulatory exclusivity, as well as protecting our rights in our own IP;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">ensuring that we do not infringe, misappropriate or otherwise violate patents, trade secrets or other IP rights of other parties;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">obtaining acceptance of our drug candidates by doctors and patients;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">obtaining reimbursement from third-party payors for our drug candidates, if and when approved;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to compete with other drug candidates and drugs; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">maintenance of an acceptable safety profile for our drug candidates following regulatory approval, if and when received.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not achieve
regulatory approval and commercialization in a timely manner or at all. Significant delays in obtaining approval for and/or to
successfully commercialize our drug candidates would materially harm our business and we may not be able to generate sufficient
revenues and cash flows to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Preclinical
development is a long, expensive and uncertain process, and we may terminate one or more of our current preclinical development
programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Traditionally,
drug discovery and development is a time-consuming, costly and high-risk business. On average, the cost of launching a new drug
is estimated to approach US$2.6 billion and can take around 12 years to make it to the market (4 key benefits of drug repositioning.
(n.d.). Retrieved from http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/). Despite the huge expenditures,
only approximately 1 in 1,000 potential drugs is graduated to human clinical trials after pre-clinical testing in the United States,
(Norman, G. A. Drugs, Devices, and the FDA: Part 1. JACC: Basic to Translational Science, 1(3), 170-179, 2016) and nearly 86.2%
of drug candidates entering phase 1 trials fails to achieve drug approval. (Wong C. H., Siah K. W. &amp; Lo A. W. (2019, April),
&#8220;Estimation of clinical trial success rates and related parameters,&#8221; retrieved from https://academic.oup.com/biostatistics/article/20/2/273/4817524).
Even after a drug is commercialized, there are just too many factors affecting the sales of pharmaceutical products, including
unmet need/burden of disease (68.2%), clinical efficacy (47.3%), comparator choice (36.4%), safety profile (36.4%), and price (35.5%)
(Sendyona, S., Odeyemi, I., &amp; Maman, K. &#8220;Perceptions and factors affecting pharmaceutical market access: Results from
a literature review and survey of stakeholders in different settings&#8221; Journal of Market Access &amp; Health Policy, 4(1),
31660, 2016). In the end, on average, only 20% of approved new drugs generate revenues that exceed the average R&amp;D investment.
(Rosenblatt, M. (2014, December 19) &#8220;The Real Cost of &#8220;High-Priced&#8221; Drugs,&#8221; retrieved from https://hbr.org/2014/11/the-real-cost-of-high-priced-drugs).
We may determine that certain preclinical product candidates or programs do not have sufficient potential to warrant the allocation
of resources toward them. Accordingly, we may elect to terminate our programs for and, in certain cases, our licenses to, such
product candidates or programs. If we terminate a preclinical program in which we have invested significant resources, we will
have expended resources on a program that will not provide a full return on our investment and missed the opportunity to have allocated
those resources to potentially more productive uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Management has discretion to terminate the development
of any of our projects at any time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the costs,
both in time and expense, as well as the preclinical results and general business considerations, management may decide not to
continue developing a particular preclinical program without announcement. Management will always base its decision on what it
believes to be the most efficient use of the Company&#8217;s resources to provide the most value to its shareholders. As a result,
investors may not always be aware of the termination of a previously announced study or trial. The Company will continue to provide
update on its active preclinical projects in its SEC filings and/or press releases, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be successful in our efforts
to identify or discover additional drug candidates. Due to our limited resources and access to capital, we must continue to prioritize
development of certain drug candidates; such decisions may prove to be wrong and may adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we intend
to explore other therapeutic opportunities in addition to the drug candidates that we are currently developing, we may fail to
identify other drug candidates for a number of reasons. For example, our research methodology may be unsuccessful in identifying
potential drug candidates or those we identify may be shown to have harmful side effects or other undesirable characteristics that
make them unmarketable or unlikely to receive regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research programs to
pursue the development of our drug candidates for additional indications and to identify new drug candidates and disease targets
require substantial technical, financial and human resources whether or not we ultimately are successful. Our research programs
may initially show promise in identifying potential indications and/or drug candidates, yet fail to yield results for clinical
development for a number of reasons, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the research methodology used may not be successful in identifying potential indications and/or drug candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">potential drug candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs than we will possess, thereby limiting our ability to diversify and expand our drug portfolio.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have limited
financial and managerial resources, we have chosen to focus at present on our two Lead Projects, which may ultimately prove to
be unsuccessful. As a result of this focus, we may forego or delay pursuit of opportunities with other drug candidates, or for
other indications that later prove to have greater commercial potential or a greater likelihood of success. Even if we determine
to pursue alternative therapeutic or diagnostic drug candidates, these other drug candidates or other potential programs may ultimately
prove to be unsuccessful. In short, our resource allocation decisions may cause us to fail to capitalize on viable commercial products
or profitable market opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, there
can be no assurance that we will ever be able to develop suitable potential drug candidates through internal research programs.
This could materially adversely affect our future growth and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have not commenced
any clinical trials, assuming we obtain approval to do so from at least one regulatory authority, of which there can be no assurance,
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a
sufficient number of patients who meet the trial criteria and remain in the trial until its conclusion. We may experience difficulties
enrolling and retaining appropriate patients in our clinical trials for a variety of reasons, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the size and nature of the patient population;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">patient eligibility criteria defined in the clinical protocol;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the size of study population required for statistical analysis of the trial&#8217;s primary endpoints;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the proximity of patients to trial sites;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the design of the trial and changes to the design of the trial;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">competing clinical trials for similar therapies or other new therapeutics exist and will reduce the number and types of patients available to us;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and side effects of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain and maintain patient consents;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">patients enrolled in clinical trials may not complete a clinical trial; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the availability of approved therapies that are similar to our drug candidates. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we are able
to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or
may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect
our ability to advance the development of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical drug development involves
a lengthy and expensive process and could fail at any stage of the process. We have limited experience in conducting clinical trials
and results of earlier studies and trials may not be reproduced in future clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For our drug candidates,
clinical testing is expensive and can take many years to complete, while failure can occur at any time during the clinical trial
process. The results of studies in animals and early clinical trials of our drug candidates may not predict the results of later-stage
clinical trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through studies in animals and initial clinical trials. In some instances, there can be significant variability
in safety and/or efficacy results between different trials of the same drug candidate due to numerous factors, including changes
in trial procedures set forth in protocols, differences in the size and type of the patient populations (including genetic differences),
patient adherence to the dosing regimen and the patient dropout rate. Results in later trials may also differ from earlier trials
due to a larger number of clinical trial sites and additional countries and languages involved in such trials. In addition, the
design of a clinical trial can determine whether its results will support approval of a drug candidate, and flaws in the design
of a clinical trial may not become apparent until the clinical trial is well advanced and significant expense has been incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of companies
in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of
demonstrated efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Clinical trials of potential
products often reveal that it is not practical or feasible to continue development efforts. Furthermore, if the trials we conduct
fail to meet their primary statistical and clinical endpoints, they will not support the approval from the FDA, NMPA, EMA, Health
Canada or other comparable regulatory authorities for our drug candidates. If this occurs, we would need to replace the failed
study with new trials, which would require significant additional expense, cause substantial delays in commercialization and materially
adversely affect our business, financial condition, cash flows and results of operations. (See &#8220;We are subject to risks related
to the carrying out and outcome of clinical trials of medical devices&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If clinical trials of our drug candidates
fail to demonstrate safety and efficacy to the satisfaction of the FDA, NMPA, EMA, Health Canada or other comparable regulatory
authorities, or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or
ultimately be unable to complete, the development and commercialization of our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before applying for
and obtaining regulatory approval for the sale of any of our drug candidates, we must conduct extensive clinical trials to demonstrate
the safety and efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement, can
take many years to complete and may fail. A failure of one or more of our clinical trials can occur at any stage of testing and
successful interim results of a clinical trial do not necessarily predict successful final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our CROs are
required to comply with current Good Clinical Practices (&#8220;cGCP&#8221;) requirements, which are regulations and guidelines
enforced by the FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities for all drugs in clinical development.
Regulatory authorities enforce these cGCP through periodic inspections of trial sponsors, principal investigators and trial sites.
Compliance with cGCP can be costly and if we or any of our CROs fail to comply with applicable cGCP, the clinical data generated
in our clinical trials may be deemed unreliable and the FDA, NMPA, EMA, Health Canada or comparable regulatory authorities may
require us to perform additional clinical trials before approving our marketing applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience numerous
unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval
or commercialize our drug candidates, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">regulators, institutional review boards (&#8220;IRBs&#8221;) or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our contractors and investigators may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a lack of clinical response or a determination that participants are being exposed to unacceptable health risks;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including non-compliance with regulatory requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the cost of clinical trials of our drug candidates may be greater than we anticipate;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our drug candidates may cause adverse events, have undesirable side effects or other unexpected characteristics, causing us, our investigators, or regulators to suspend or terminate the trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are required
to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we
are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or
tests are not positive or are only modestly positive or if they raise safety concerns, we may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">be delayed in obtaining regulatory approval for our drug candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">not obtain regulatory approval at all;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">obtain approval for indications that are not as broad as intended;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">have a drug removed from the market after obtaining regulatory approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">be subject to additional post-marketing testing requirements;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">be subject to restrictions on how a drug is distributed or used; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">be unable to obtain reimbursement for use of a drug.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in testing or
approvals may result in increases in our drug development costs. We do not know whether any clinical trials will begin as planned,
will need to be restructured, or will be completed on schedule, or at all. Clinical trials may produce negative or inconclusive
results. Moreover, these trials may be delayed or proceed less quickly than intended. Delays in completing our clinical trials
will increase our costs, slow down our drug candidate development and approval process, and jeopardize our ability to commence
product sales and generate revenues and we may not have sufficient funding to complete the testing and approval process. Any of
these events may significantly harm our business, financial condition and prospects, lead to the denial of regulatory approval
of our drug candidates or allow our competitors to bring drugs to market before we do, impairing our ability to commercialize our
drugs if and when approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant clinical
trial delays also could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow
our competitors to bring products to market before we do, impair our ability to commercialize our drug candidates and may harm
our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may in the future conduct clinical
trials for our drug candidates in sites outside the U.S. and the FDA may not accept data from trials conducted in such locations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the future
conduct certain of our clinical trials outside the U.S. Although the FDA may accept data from clinical trials conducted outside
the U.S. for our New Drug Application (&#8220;NDA&#8221;), acceptance of this data is subject to certain conditions imposed by
the FDA. There can be no assurance the FDA will accept data from any of the clinical trials we conduct outside the U.S. If the
FDA does not accept the data from any of our clinical trials conducted outside the U.S., it would likely result in the need for
additional clinical trials in the U.S., which would be costly and time-consuming and could delay or prevent the commercialization
of any of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Obtaining Regulatory
Approval for Our Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The regulatory approval processes
of the FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable,
and if we are ultimately unable to obtain regulatory approval for our current drug candidates or any future drug candidates we
may develop, our business will be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot commercialize
drug candidates without first obtaining regulatory approval to market each drug from the FDA, NMPA, EMA, Health Canada or comparable
regulatory authorities. Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication,
we must demonstrate in studies in animals and well-controlled clinical trials, and, with respect to approval in the United States
and other regulatory agencies, to the satisfaction of the FDA, NMPA, EMA, Health Canada or comparable regulatory authorities, that
the drug candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and
controls are adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to
obtain approval from the FDA, NMPA, EMA, Health Canada and other comparable regulatory authorities is unpredictable but typically
takes many years following the commencement of studies in animals and clinical trials and depends upon numerous factors, including
the substantial discretion of the regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, approval
policies, regulations or the type and amount of clinical data necessary to gain approval can differ among regulatory authorities
and may change during the course of the development of a drug candidate. We have not obtained regulatory approval for any drug
candidate. It is possible that neither our existing drug candidates nor any drug candidates we may discover or acquire for development
in the future will ever obtain regulatory approval. Even if we obtain regulatory approval in one jurisdiction, we may not obtain
it in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates
could fail to receive regulatory approval from any of the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities
for many reasons, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">disagreement with regulators regarding the design or implementation of our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">failure to demonstrate that a drug candidate is safe and effective or safe, pure and potent for its proposed indication;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">failure of clinical trial results to meet the level of statistical significance required for approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">failure to demonstrate that a drug candidate&#8217;s clinical and other benefits outweigh its safety risks;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">disagreement with regulators regarding our interpretation of data from studies in animals or clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">insufficiency of data collected from clinical trials of our drug candidates to support the submission and filing of a New Drug Application (&#8220;NDA&#8221;), or other submission or to obtain marketing approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the FDA, NMPA, EMA, Health Canada or a comparable regulatory authority&#8217;s finding of deficiencies related to the manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">changes in approval policies or regulations that render our preclinical studies and clinical data insufficient for approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of the FDA, NMPA,
EMA, Health Canada or other comparable regulatory authorities may require more information, including additional preclinical studies
or clinical data, to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to
abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our drug candidates for
fewer or more limited indications than we request. Regulatory authorities also may grant approval contingent on the performance
of costly post-marketing clinical trials, or may approve a drug candidate with a label that is not desirable for the successful
commercialization of that drug candidate. In addition, if our drug candidate produces undesirable side effects or involves other
safety issues, the FDA may require the establishment of a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;), or NMPA, EMA,
Health Canada or other comparable regulatory authorities may require the establishment of a similar strategy. Such a strategy may,
for instance, restrict distribution of our drug candidates, require patient or physician education, or impose other burdensome
implementation requirements on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory approval may be substantially
delayed or may not be obtained for one or all of our drug candidates if regulatory authorities require additional time or studies
to assess the safety or efficacy of our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not
have any drug candidates that have gained approval for sale by the FDA, NMPA or EMA, Health Canada or other regulatory authorities
in any other country, and we cannot guarantee that we will ever have marketable drugs. Our business is substantially dependent
on our ability to complete the development of, obtain marketing approval for and successfully commercialize drug candidates in
a timely manner. We cannot commercialize drug candidates without first obtaining marketing approval from the FDA, NMPA, EMA, Health
Canada and comparable regulatory authorities. In the U.S., we hope to file INDs for the drug candidates from our Lead Projects
and, subject to the approval of IND, Phase 1 clinical trials in humans. Even if we are permitted to commence such clinical trials,
they may not be successful and regulators may not agree with our conclusions regarding the data generated by our clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to
complete development of our drug candidates or initiate or complete development of any future drug candidates we may develop on
our projected schedule. While we believe that our existing cash will likely enable us to complete the preclinical development of
at least one of our current Lead Projects, the full clinical development, manufacturing and launch of that drug candidate, will
take significant additional time and likely require funding beyond the existing cash. In addition, if regulatory authorities require
additional time or studies to assess the safety or efficacy of our drug candidates, we may not have or be able to obtain adequate
funding to complete the necessary steps for approval for our drug candidates or any future drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies
in animals and clinical trials in humans to demonstrate the safety and efficacy of our drug candidates are time-consuming, expensive
and take several years or more to complete. Delays in preclinical or clinical trials, regulatory approvals or rejections of applications
for regulatory approval in the U.S., Europe, the PRC or other markets may result from many factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our inability to obtain sufficient funds required to conduct or continue a trial, including lack of funding due to unforeseen costs or other business decisions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">regulatory reports for additional analysts, reports, data, preclinical studies and clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">failure to reach agreement with, or inability to comply with conditions imposed by the FDA, NMPA, EMA, Health Canada or other regulators regarding the scope or design of our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">regulatory questions regarding interpretations of data and results and the emergence of new information regarding our drug candidates or other products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">delay or failure in obtaining authorization to commence a clinical trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to participate in our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">unfavorable or inconclusive results of clinical trials and supportive non-clinical studies, including unfavorable results regarding effectiveness of drug candidates during clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">difficulty in maintaining contact with patients during or after treatment, resulting in incomplete data;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our inability to obtain approval from IRBs or ethics committees to conduct clinical trials at their respective sites;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our inability to enroll and retain a sufficient number of patients who meet the inclusion and exclusion criteria in a clinical trial;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our inability to conduct a clinical trial in accordance with regulatory requirements or our clinical protocols;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, withdrawing from or dropping out of a trial, or becoming ineligible to participate in a trial;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">failure of our clinical trial managers to satisfy their contractual duties or meet expected deadlines;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">manufacturing issues, including problems with manufacturing or timely obtaining from third parties sufficient quantities of a drug candidate for use in a clinical trial;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">ambiguous or negative interim results, or results that are inconsistent with earlier results;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">feedback from the FDA, NMPA, EMA, Health Canada, an IRB, data safety monitoring boards, or comparable entities, or results from earlier stage or concurrent studies in animals and clinical trials, regarding our drug candidates, including which might require modification of a trial protocol;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">unacceptable risk-benefit profile or unforeseen safety issues or adverse side effects; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">a decision by the FDA, NMPA, EMA, Health Canada, an IRB, comparable entities, or the Company, or recommendation by a data safety monitoring board or comparable regulatory entity, to suspend or terminate clinical trials at any time for safety issues or for any other reason.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in regulatory
requirements and guidance may also occur, and we may need to amend clinical trial protocols submitted to applicable regulatory
authorities to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs or ethics committees
for re-examination, which may increase the costs or time required to complete a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays
in the completion of, or the termination of, a clinical trial, of any of our drug candidates, the commercial prospects of our drug
candidates will be harmed, and our ability to generate product sales revenues from any of those drug candidates will be delayed.
In addition, any delay in completing our clinical trials will increase our costs, slow down our drug candidate development and
approval process, and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm
our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay
in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are required
to conduct additional clinical trials or other studies with respect to any of our drug candidates beyond those that we initially
contemplated, if we are unable to successfully complete our clinical trials or other studies or if the results of these studies
are not positive or are only modestly positive, we may be delayed in obtaining regulatory approval for that drug candidate, we
may not be able to obtain regulatory approval at all or we may obtain approval for indications that are not as broad as intended.
Our product development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient
funding to complete the testing and approval process. Significant clinical trial delays could allow our competitors to bring their
products to market before we do and impair our ability to commercialize our drugs, if and when approved. If any of this occurs,
our business will be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our drug candidates may cause undesirable
adverse events or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of
an approved label, or result in significant negative consequences following any regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable adverse
events caused by our drug candidates or any future drug candidates we may develop could cause us or regulatory authorities to interrupt,
delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the
FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities. Results of our potential clinical trials could reveal
a high and unacceptable severity or prevalence of adverse effects. In such event, our trials could be suspended or terminated and
the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities could order us to cease further development of, or
deny approval of, our drug candidates for any or all target indications. Drug-related adverse events could also affect patient
recruitment or the ability of enrolled subjects to complete the trial, could result in potential product liability claims and may
harm our reputation, business, financial condition and business prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, if any
of our current or future drug candidates receives regulatory approval, and we or others later identify undesirable side effects
caused by such drugs, a number of potentially significant negative consequences could result, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">suspending the marketing of the drug;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">having regulatory authorities withdraw approvals of the drug;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">adding warnings on the label;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">developing a REMS for the drug or, if a REMS is already in place, incorporating additional requirements under the REMS, or to develop a similar strategy as required by a comparable regulatory authority;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">conducting post-market studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">being sued and held liable for harm caused to subjects or patients; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">damage to our reputation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events
could prevent us from achieving or maintaining market acceptance of the particular drug candidate, if approved, and could significantly
harm our business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we receive regulatory approval
for our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result
in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience
unanticipated problems with our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our drug candidates
or any future drug candidates we develop are approved, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission
of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and
requirements of comparable regulatory authorities outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers and manufacturers&#8217;
facilities are required to comply with extensive requirements from the FDA, NMPA, EMA, Health Canada and comparable regulatory
authorities, including, in the United States, ensuring that quality control and manufacturing procedures conform to cGMP regulations.
As such, our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence
to commitments made in any NDA, other marketing application, and previous responses to inspection observations. Accordingly, we
and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing,
production and quality control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals
that we receive for our drug candidates may be subject to limitations on the approved indicated uses for which the drug may be
marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase
4 clinical trials and surveillance to monitor the safety and efficacy of the drug candidate. The regulatory authorities may also
require risk management plans or programs as a condition of approval of our drug candidates (such as REMS of the FDA and risk-management
plan of the EMA), which could entail requirements for long-term patient follow-up, a medication guide, physician communication
plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. In addition, if the FDA, NMPA, EMA, Health Canada or a comparable regulatory authority approves our drug candidates, we
will have to comply with requirements including, for example, submissions of safety and other post-marketing information and reports,
registration, as well as continued compliance with cGCP and cGMP, for any clinical trials that we conduct post-approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may impose
consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems
occur after the drug reaches the market. Later discovery of previously unknown problems with our drug candidates, including adverse
events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to
comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition
of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions
under a REMS program. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on the marketing or manufacturing of our drug candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">fines, untitled or warning letters, or holds on clinical trials;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">product seizure or detention, or refusal to permit the import or export of our drug candidates; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Companies may promote drugs only for
the approved indications and in accordance with the provisions of the approved label and may not promote drugs for any off-label
use, such as uses that are not described in the product&#8217;s labeling and that differ from those approved by the regulatory
authorities. However, physicians may prescribe drug products for off-label uses and such off-label uses are common across some
medical specialties. Thus, they may, unbeknownst to us, use our product for an &#8220;off label&#8221; indication for a specific
treatment recipient. The FDA, NMPA, EMA, Health Canada and other regulatory authorities actively enforce the laws and regulations
prohibiting the promotion of off-label uses, and if we are found to be out of compliance with the requirements and restrictions
imposed on us under those laws and restrictions, we may be subject to significant liability, including civil and administrative
remedies as well as criminal sanctions, and the off-label use of our products may increase the risk of product liability claims.
In addition, management&#8217;s attention could be diverted from our business operations and our reputation could be damaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The policies of the
FDA, NMPA, EMA, Health Canada and other regulatory authorities may change and we cannot predict the likelihood, nature or extent
of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we
are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve
or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may be unable to successfully pursue the 505(b)(2)
pathway for the pediatric formulation of SACT-1 to treat neuroblastoma as planned, which would materially impact our likelihood
of obtaining FDA approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A 505(b)(2) application
that relies for approval on the FDA&rsquo;s finding of safety and/or effectiveness for one or more listed drugs must establish
that such reliance is scientifically appropriate, and must submit data necessary to support any aspects of the proposed drug product
that represent modifications to the listed drug(s). We must establish a bridge between our proposed drug product and each listed
drug upon which we propose to rely, to demonstrate that such reliance is scientifically justified. Determining and reaching agreement
with the FDA regarding exactly what additional or &ldquo;bridging&rdquo; data will be needed to support the proposed modification
to the listed drug can present challenges and is a fact-specific determination that must be made on a case-by-case basis. If we
are unable to establish to the FDA&rsquo;s satisfaction that our reliance on the listed drug is scientifically appropriate, and
that we have sufficiently addressed the safety and effectiveness implications of our proposed modifications, we may be unable
to utilize this regulatory pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA does
not allow us to pursue the 505(b)(2) regulatory pathway for our product candidates as anticipated, we may need to conduct additional
clinical trials, provide additional data and information and meet additional standards for regulatory approval. If this were to
occur, the time and financial resources required to obtain FDA approval for our product candidates would likely substantially
increase. Moreover, the inability to pursue the 505(b)(2) regulatory pathway could result in new competitive products reaching
the market faster than our product candidates, which could materially adversely impact our competitive position and prospects.
Even if we are allowed to pursue the 505(b)(2) regulatory pathway for a product candidate, we cannot assure you that we will receive
the requisite or timely approvals for commercialization of such product candidate. Any failure to obtain regulatory approval of
our product candidates would significantly limit our ability to generate revenues, and any failure to obtain such approval for
all of the indications and labeling claims we deem desirable could reduce our potential revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we or our third-party suppliers
fail to comply with the FDA&rsquo;s good manufacturing practice regulations or fail to adequately, timely, or sufficiently respond
to an FDA Form 483 or subsequent Warning Letter, this could impair our ability to market our products in a cost-effective and
timely manner and could result in FDA enforcement action.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our third-party
suppliers are required to comply with the FDA&rsquo;s Current Good Manufacturing Practices (cGMP) which covers the methods and
documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and
shipping of our products. The FDA audits compliance with the cGMP and related regulations through periodic announced and unannounced
inspections of manufacturing and other facilities. The FDA may conduct these inspections or audits at any time. If, during the
inspection, FDA identifies issues which, in FDA&rsquo;s judgment, may constitute violations of the Federal Food, Drug, and Cosmetic
Act or FDA&rsquo;s regulations, the FDA inspector may issue an FDA Form 483 listing these observations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Note that if an
entity does not address observations found in an FDA Form 483 to FDA&rsquo;s satisfaction, the FDA could take enforcement action,
including any of the following sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
                                         letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
                                         notifications or recall, detention or seizure of our product;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                         restrictions or partial suspension or total shutdown of production;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing
                                         or delaying our requests for pre-market approval of new products;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing
                                         pre-market approvals that have already been granted;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                         to grant export approval for our product; or</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
                                         prosecution.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Any of the foregoing
actions could have a material adverse effect on our reputation, business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks Related to Commercialization
of Our Drug Candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if any of our drug candidates
receive regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors
and others in the medical community necessary for commercial success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After we complete clinical
trials and receive regulatory approval for any of our drug candidates, which may not happen for some time, we recognize that such
candidate(s) may ultimately fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in
the medical community. We may not be able to achieve or maintain market acceptance of our products over time if new products or
technology are introduced that are more favorably received than our products, are more cost effective or render our drug obsolete.
We will face competition with respect to our drug candidates from other pharmaceutical companies developing products in the same
disease/therapeutic area and specialty pharmaceutical and biotechnology companies worldwide. Many of the companies against which
we may be competing have significantly greater financial resources and expertise in research and development, manufacturing, animal
testing, conducting clinical trials, obtaining regulatory approvals and marketing approval for drugs than we do. Physicians, patients
and third-party payors may prefer other novel products to ours, which means that we may not generate significant sales revenues
for that product and that product may not become profitable. The degree of market acceptance of our drug candidates, if approved
for commercial sale, will depend on a number of factors, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">clinical indications for which our drug candidates are approved;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">physicians, hospitals, and patients considering our drug candidates as a safe and effective treatment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the potential and perceived advantages of our drug candidates over alternative treatments;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the prevalence and severity of any side effects;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">product labeling or product insert requirements of the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">limitations or warnings contained in the labeling approved by the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the timing of market introduction of our drug candidates as well as competitive drugs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the cost of treatment in relation to alternative treatments and their relative benefits;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">lack of experience and financial and other limitations on our ability to create and sustain effective sales and marketing efforts or ineffectiveness of our sales and marketing partners; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">changes in legislative and regulatory requirements that could prevent or delay regulatory approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any drug candidates for which we obtain regulatory approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our IP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A significant portion of our IP portfolio
currently includes pending patent applications that have not yet been issued as granted patents and if the pending patent applications
covering our product candidates fail to be issued, our business will be adversely affected. If we or our licensors are unable to
obtain and maintain patent protection for our technology and drugs, our competitors could develop and commercialize technology
and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
largely on our ability to obtain and maintain patent protection and other forms of IP rights for the composition of matter, method
of use and/or method of manufacture for each of our drug candidates. Failure to obtain, maintain protection, enforce or extend
adequate patent and other IP rights could materially adversely affect our ability to develop and market one or more of our drug
candidates. We also rely on trade secrets and know-how to develop and maintain our proprietary and IP position for each of our
drug candidates. Any failure to protect our trade secrets and know-how with respect to any specific drug and device candidate could
adversely affect the market potential of that potential product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
the Company has, through its licenses, obtained rights to patents and patent applications covering some or all its drug and device
candidates that have been filed in major jurisdictions such as the United States, member states of the European Patent Organization
(the &#8220;EPO&#8221;) and the PRC (collectively, &#8220;Major Patent Jurisdictions&#8221;), as well as in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
report, the Company has, through its licenses, obtained rights to patents and patent applications covering some or all its drug
and device candidates that have been filed in major jurisdictions such as the United States, member states of the European Patent
Organization (the &#8220;EPO&#8221;) and the PRC (collectively, &#8220;Major Patent Jurisdictions&#8221;), as well as in other
countries. We have also filed a number of provisional applications to establish earlier filing dates for certain of our other ongoing
researches, the specifics of which are currently proprietary and confidential. To the extent we do not seek or obtain patent protection
in a particular jurisdiction, we may not have commercial incentive to seek marketing authorization in such jurisdiction. Nonetheless,
other parties might enter those markets with generic versions or copies of our products and received regulatory approval without
having significantly invested in their own research and development costs compared to the Company&#8217;s investment. For more
information about our IP portfolio, please refer to the Intellectual Property section below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to issued
patents in certain jurisdictions, for example in the U.S. and under the EPO, we may be entitled to obtain a patent term extension
to extend the patent expiration date provided we meet the applicable requirements for obtaining such patent term extensions. We
have sought to support our proprietary position by working with our licensors in filing patent applications in the names of the
licensors in the United States and through the PCT, related to the Lead Projects and certain other drug candidates. In the future,
we intend to file patent applications on supplemental or improvement IP derived from the licensed technologies, where those IP
would be solely or jointly owned by the Company pursuant to the terms of respective license agreements. Filing patents covering
multiple technologies in multiple countries is time-consuming and expensive, and we may not have the resources file and prosecute
all necessary or desirable patent applications in a timely manner. It is also possible that we will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain
that patents will be issued or granted with respect to patent applications that are currently pending, or that issued or granted
patents will not later be found to be invalid or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position
of biotechnology and pharmaceutical companies is generally uncertain because it involves complex legal and factual considerations.
The standards applied by the EPO, the U.S. Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents
are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject
matter or the scope of claims allowable in biotechnology and pharmaceutical patents. Consequently, patents may not issue from our
pending patent applications and even if they do issue, such patents may not issue in a form that effectively prevents others from
commercializing competing products. As such, we do not know the degree of future protection that we will have on our proprietary
products and technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the issuance
of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the
courts or patent offices in the United States and abroad. Even if patents do successfully issue and even if such patents cover
our drug candidates, other parties may initiate, for patents filed before March 16, 2013 (i.e., the enactment of the America Invents
Act), interference or re-examination proceedings, for patents filed on or after March 16, 2013, post-grant review, <I>inter partes</I>
review, nullification or derivation proceedings, in court or before patent offices, or similar proceedings challenging the validity,
enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Successful defense
of its patents can constitute a material factor in a company&#8217;s expenses. According to an August 2017 article published by
Bloomberg News (https://www.bna.com/cost-patent-infringement-n73014463011/), depending on the value at stake, the American Intellectual
Property Law Association&#8217;s &#8220;2017 Report of the Economic Survey&#8221; reported the average cost of a patent litigation
in 2017 to be $1.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the fact
that the Company has exclusive rights to prevent others from using a patented invention does not necessarily mean that the Company
itself will have the unrestricted right to use that invention. Other parties may obtain ownership or licenses to patents or other
IP rights that cover the manufacture, use or sale of our current or future products (or elements thereof). This may enable such
other parties to enforce their patents or IP rights against us, and may, as a result, affect the commercialization of our products
or exploitation of our own technology. We endeavor to identify early patents and patent applications which may block development
of a product or technology and minimize this risk by conducting prior art searches before and during the projects. However, relevant
documents may be overlooked, yet-to-be published or missed, which may in turn impact on the freedom to commercialize the relevant
asset. In such cases, we may not be in a position to develop or commercialize products or drug candidates unless we successfully
pursue litigation to nullify or invalidate the other IP rights concerned, or enter into a license agreement with the IP right holder,
if available on commercially reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to obtain and maintain
the appropriate scope for our patents, our competitors could develop and commercialize technology and drugs similar or identical
to ours, and our ability to successfully commercialize our technology and drugs may be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not obtain sufficient
claim scope in those patents to prevent another party from competing successfully with our drug and device candidates. Even if
our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent
our patents by developing similar or alternative technology or drug and device candidates in a non-infringing manner. The issuance
of a patent is not conclusive as to its scope, validity or enforceability, and our patents may be challenged in the courts or patent
offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable,
which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology
and drug and device candidates, or limit the duration of the patent protection of our technology and drug and device candidates.
Given the amount of time required for the development, testing and regulatory review of new drug and device candidates, patents
protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio
may not provide us with sufficient rights to exclude others from commercializing drug and device candidates similar or identical
to ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, the issuance,
scope, validity, enforceability and commercial value of our and our current or future licensors&#8217; or collaboration partners&#8217;
patent rights are highly uncertain. Our and our licensors&#8217; pending and future patent applications may not result in patents
being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect and
enforce our IP rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
will depend, in part, on our ability to maintain IP protection for our drug candidates in which we seek to develop and commercialize.
While we rely primarily upon a combination of patents, trademarks, trade secrets and other contractual obligations to protect the
IP related to our brands, products and other proprietary technologies, these legal means may afford only limited protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing and prosecuting
patents on drug candidates and defending the validity of the same (if challenged) in all countries throughout the world could be
prohibitively expensive for us, and our IP rights in countries outside the Major Patent Jurisdictions can be less extensive than
those in the Major Patent Jurisdictions. In addition, the laws of some countries in the rest of the world such as India do not
protect IP rights to the same extent as laws in the Major Patent Jurisdictions. Consequently, we may not be able to prevent other
parties from practicing our inventions in the rest of the world. Competitors may use our technology in jurisdictions where we have
not or not yet obtained patent protection to develop their own drugs and further, may export otherwise infringing drugs to non-U.S.
jurisdictions where we have patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our, our licensors&#8217;
or collaboration partners&#8217; patent applications cannot be enforced against other parties practicing the technology claimed
in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover
the technology. In addition, patents and other IP rights also will not protect our technology, drug candidates if another party,
including our competitors, design around our protected technology, drug candidates without infringing, misappropriating or otherwise
violating our patents or other IP rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, currently
and as our R&amp;D continues to progress, some of our patents and patent applications are or may be co-owned with another party.
Some of our licenses already provide that future-developed technologies (and any resulting patents) will be co-owned with the licensors
and other patents for technologies we may acquire or develop with other parties may also be jointly owned. If we are unable to
obtain an exclusive license to any such co-owners&#8217; interest in such patents or patent applications, such co-owners may be
able to license their rights to other persons, including our competitors, and our competitors could market competing products and
technology, and we will be unable to transfer or grant exclusive rights to potential purchasers or development partners of such
co-owned technologies. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents
against other parties, and such cooperation may not be provided to us. Any of the foregoing could limit the revenue we might generate
from our patents or patent applications and thus have a material adverse effect on our competitive position, business, financial
conditions, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because patent applications
are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors
or collaborators were or will be the first to file any patent application related to a drug or device candidate. Furthermore, in
the United States, if patent applications of other parties have an effective filing date before March 16, 2013, an interference
proceeding can be initiated by such other party to determine who was the first to invent any of the subject matter covered by the
patent claims of our applications. If patent applications of other parties have an effective filing date on or after March 16,
2013, in the United States a derivation proceeding can be initiated by such other parties to determine whether our invention was
derived from theirs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even where we have
a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show
that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. In addition,
we may be subject to other challenges regarding our exclusive ownership of our IP. If another party were successful in challenging
our exclusive ownership of any of our IP, we may lose our right to use such IP, such other party may be able to license such IP
to other parties, including our competitors, and our competitors could market competing products and technology. Any of the foregoing
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have
encountered significant problems in protecting and defending IP rights in jurisdictions outside Major Patent Jurisdictions. The
legal systems of some countries do not favor the enforcement of patents, trade secrets and other IP, which could make it difficult
in those jurisdictions for us to stop the infringement or misappropriation of our patents or other IP rights, or the marketing
of competing drugs in violation of our proprietary rights generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not
sought to enforce any issued patents in any jurisdictions. Proceedings to enforce our patent and other IP rights in any jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, such proceedings
could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications
at risk of not issuing, and could provoke other parties to assert claims of infringement or misappropriation against us. We may
not prevail in any lawsuits that we initiate in jurisdictions where opposition proceedings are available and the damages or other
remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries,
particularly developing countries. Certain countries in Europe, the PRC, and developing countries including India, have compulsory
licensing laws under which a patent owner may be compelled to grant licenses to other parties. In those countries, we and our licensors
may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to another party,
which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly,
our efforts to enforce our IP rights around the world may be inadequate to obtain a significant commercial advantage from the IP
that we develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may become involved in lawsuits
to protect or enforce our IP, which could be expensive, time-consuming and unsuccessful. Our patent rights relating to our drug
and device candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable non-U.S.
authority.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe
our patent rights or misappropriate or otherwise violate our IP rights. To counter infringement or unauthorized use, litigation
may be necessary in the future to enforce or defend our IP rights, to protect our trade secrets or determine the validity and scope
of our own IP rights or the proprietary rights of others. This can be expensive and time-consuming. Any claim that we assert against
perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their IP rights.
Many of our current and potential competitors have the ability to dedicate substantially greater resources to enforce and/or defend
their IP rights than we can. Accordingly, despite our efforts, we may not be able to prevent other parties from infringing upon
or misappropriating our IP. Litigation could result in substantial costs and diversion of management resources, which could harm
our business and financial results. In addition, in an infringement proceeding, a court may decide that patent rights or other
IP rights owned by us are invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on
the grounds that our patent rights or other IP rights do not cover the technology in question. An adverse result in any litigation
proceeding could put our patent, as well as any patents that may issue in the future from our pending patent applications, at risk
of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required
in connection with IP litigation, there is risk that some of our confidential information could be compromised by disclosure during
this type of litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we initiate legal
proceedings against another party to enforce our patent, or any patents that may be issued in the future from our patent applications,
that relates to one of our drug and device candidates, the defendant could counterclaim that such patent rights are invalid or
unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace,
and there are numerous grounds upon which another party can assert invalidity or unenforceability of a patent. Parties may also
raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such
mechanisms include ex parte re-examination, <I>inter partes</I> review, post-grant review, derivation and equivalent proceedings
in non-U.S. jurisdictions, such as opposition proceedings. Such proceedings could result in revocation or amendment to our patents
in such a way that they no longer cover and protect our drug and device candidates. With respect to the validity of our patents,
for example, there may be invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution.
If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps
all, of the patent protection on our drug and device candidates. Such a loss of patent protection could have a material adverse
impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able
to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not
protect those rights as fully as in the United States. Furthermore, because of the substantial amount of discovery required in
connection with IP litigation, there is a risk that some of our confidential information could be compromised by disclosure during
this type of litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims challenging
the inventorship of our patents and other IP.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we are not
currently experiencing any claims challenging the inventorship of our patents or ownership of our IP, we may in the future be subject
to claims that former employees, collaborators or other parties have an interest in our patents or other IP as inventors or co-inventors.
For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in
developing our drug and device candidates and who have not clearly contracted to transfer or assign any rights they may have to
the Company. In addition, for our licensed patents, although a majority of our licensors have procured assignment forms and records
from inventors to affirm their ownership in the licensed IP, another party or former employee or collaborator of our licensors
not named in the patents may challenge the inventorship of claim an ownership interest in one or more of our or our licensors&#8217;
patents. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose rights such as exclusive ownership of, or right to use, our
patent rights or other IP. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are sued for infringing IP
rights of other parties, such litigation could be costly and time-consuming and could prevent or delay us from developing or commercializing
our drug candidates, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
depends in part on our avoiding infringement of the patents and other IP rights of other parties. There is a substantial amount
of litigation involving patent and other IP rights in the biotechnology and pharmaceutical industries. Numerous issued patents,
provisional patents and pending patent applications, which are owned by other parties, exist in the fields in which we are developing
drug candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that
our drug candidates may give rise to claims of infringement of the patent rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other parties may assert
that we are employing their proprietary technology without authorization. There may be other patents of which we are currently
unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture
of our drug candidates. Because patent applications can take many years to issue, there may be currently pending patent applications
or provisional patents which may later result in issued patents that our drug candidates may infringe. In addition, other parties
may obtain patents in the future and claim that use of our technology infringes upon these patents. If any other patents were held
by a court of competent jurisdiction to cover the manufacturing process of any of our drug candidates, any molecules formed during
the manufacturing process or any final drug itself, the holders of any such patents may be able to prevent us from commercializing
such drug candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined
to be held invalid or unenforceable. Similarly, if any other patent were held by a court of competent jurisdiction to cover aspects
of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the
holders of any such patent may be able to block our ability to develop and commercialize the applicable drug candidate unless we
obtain a license, limit our uses, or until such patent expires, or is finally determined to be held invalid or unenforceable. In
either case, such a license may not be available on commercially reasonable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other parties who bring
successful claims against us for infringement of their IP rights may obtain injunctive or other equitable relief, which could prevent
us from developing and commercializing one or more of our drug candidates. Defense of these claims, regardless of their merits,
would involve substantial litigation expense and be a substantial diversion of employee resources from our business. In the event
of a successful claim of infringement or misappropriation against us, we may have to pay substantial damages, including treble
damages and attorneys&#8217; fees in the case of willful infringement, obtain one or more licenses from other parties, pay royalties
or redesign our infringing drug candidates, which may be impossible or require substantial time and monetary expenditure. In the
event of an adverse result in any such litigation, or even in the absence of litigation, we may need to obtain licenses from other
parties to advance our research or allow commercialization of our drug candidates. Any required license may not be available at
all, or may not be available on commercially reasonable terms. In the event that we are unable to obtain such a license, we would
be unable to further develop and commercialize one or more of our drug candidates, which could harm our business significantly.
We may also elect to enter into license agreements in order to settle patent infringement claims or resolve disputes prior to litigation,
and any such license agreements may require us to pay royalties and other fees that could significantly reduce our profitability
for any product related to that patent and thus harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if resolved in
our favor, litigation or other legal proceedings relating to IP claims may cause us to incur significant expenses, and could distract
our technical personnel, management personnel, or both from their normal responsibilities. In addition, there could be public announcements
of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the market price of our Class A Ordinary Shares. Such
litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to
adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation
or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation
and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the
marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be patent applications
pending of which we are not aware, but which cover similar products to the ones we are attempting to license or develop, which
may result in lost time and money, as well as litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is possible that
we have failed to identify relevant outstanding patents or applications. For example, U.S. applications filed before November 29,
2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until
patents are issued. Patent applications filed in the United States after November 29, 2000 and generally filed elsewhere are published
approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly
referred to as the priority date. Therefore, patent applications covering our products could have been filed by others without
our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later
amended in a manner that could cover our products or the use of our products. Holders of any such unanticipated patents or patent
applications may actively bring infringement claims against us, with the same potential litigation consequences as alluded to elsewhere
in this prospectus. Any of these events could require us to divert substantial financial and management resources that we would
otherwise be able to devote to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining our patent
protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance
fees on any issued patent are due to be paid to the USPTO and other patent agencies in several stages over the lifetime of the
patent. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary,
fee payment, and other similar provisions during the patent application process. Although an inadvertent lapse can in many cases
be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights
in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application
include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly submit
documents requesting an extension of time. In any such event, our competitors might be able to enter the market, which would have
a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The terms of our patents may not
be sufficient to effectively protect our drug and device candidates and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In most countries in
which we file, including the United States, the term of an issued patent is generally 20 years from the earliest claimed filing
date of a non-provisional patent application in the applicable country. Although various extensions may be available, the life
of a patent and the protection it affords is limited. For example, depending upon the timing, duration and specifics of the FDA
regulatory approval for our drug candidates, one or more of our U.S. patents, if issued, might be eligible for limited patent term
restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments.
The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for patent term lost during drug
development and the FDA regulatory review process. Patent term extensions, however, cannot extend the remaining term of a patent
beyond a total of 14 years from the date of drug approval by the FDA, and only one patent can be extended for a particular drug.
The application for patent term extension is subject to approval by the USPTO, in conjunction with the FDA. We may not be granted
an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant
patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection
afforded could be less than we request. If we are unable to obtain a patent term extension for a given patent or the term of any
such extension is less than we request, the period during which we will have the right to exclusively market our drug will be that
of the originally issued patents themselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if patents covering
one of our drug candidates are obtained, thereby giving us a period of exclusivity for manufacturing and marketing that drug, we
will not be able to assert such patent rights upon the expiration of the issued patents against potential competitors who may begin
marketing generic copies of our medications, and our business and results of operations may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in patent law in the United
States could diminish the value of patents in general, thereby impairing our ability to protect our drug and device candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States has
recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed
the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents once obtained, if any. Depending on decisions by the U.S. Congress, the
federal courts and the USPTO, the laws and regulations governing patents in the United States could change in unpredictable ways
that would weaken our ability to obtain new patents, or to enforce our existing patents and patents that we might obtain in the
future. For example, in a recent case, <I>Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</I>, the U.S. Supreme Court held
that certain claims to naturally-occurring substances are not patentable. Although we do not believe that any of the patents owned
or licensed by us will be found invalid based on this decision, future decisions by the courts, the U.S. Congress or the USPTO
may impact the value of our patent rights. There could be similar changes in the laws of foreign jurisdictions that may impact
the value of our patent rights or our other IP rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, recent
patent reform legislation in the U.S., including the Leahy-Smith America Invents Act, or the America Invents Act, could increase
those uncertainties and costs. The America Invents Act was signed into law on September 16, 2011, and many of the substantive changes
became effective on March 16, 2013. The America Invents Act reforms U.S. patent law in part by changing the U.S. patent system
from a &#8220;first to invent&#8221; system to a &#8220;first inventor to file&#8221; system, expanding the definition of prior
art, and developing a post-grant review system, thus changing the U.S. patent law in a way that may weaken our ability to obtain
patent protection in the U.S. for those applications filed after March 16, 2013. Further, the America Invents Act created new procedures
to challenge the validity of issued patents in the U.S., including post-grant review and <I>inter </I>partes review proceedings,
which some other parties have been using to cause the cancellation of selected or all claims of issued patents of competitors.
For a patent with an effective filing date of March 16, 2013 or later, a petition for post-grant review can be filed by another
party in a nine-month window from issuance of the patent. A petition for <I>inter partes</I> review can be filed immediately following
the issuance of a patent if the patent has an effective filing date prior to March 16, 2013. A petition for <I>inter partes</I>
review can be filed after the nine-month-period for filing a post-grant review petition has expired for a patent with an effective
filing date of March 16, 2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas <I>inter
partes</I> review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial
actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal
courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier
for a competitor or other party to have a U.S. patent invalidated in a USPTO post-grant review or <I>inter partes</I> review proceeding
than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by another party in such a USPTO
proceeding, there is no guarantee that we or our licensors or collaborators will be successful in defending the patent, which would
result in our loss of the challenged patent right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our
issued patents, provisional patent, and pending patent applications, we expect to rely on trade secrets, including unpatented know-how,
technology and other proprietary information, to maintain our competitive position and protect our drug and device candidates.
We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties that
have access to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract
manufacturers, consultants, advisors and other parties. We also enter into confidentiality and invention or patent assignment agreements
with our employees and consultants. However, any of these parties may breach such agreements and disclose our proprietary information,
and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. If trade secrets which are material
to our business were to be obtained by a competitor, our competitive position would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims that
our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we try to
ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that we or these employees have used or disclosed IP, including trade secrets or other proprietary information, of any
such employee&#8217;s former employer. In addition, while we typically require our employees, consultants and contractors who may
be involved in the development of IP to execute agreements assigning such IP to us, we may be unsuccessful in executing such an
agreement with each party who in fact develops IP that we regard as our own, which may result in claims by or against us related
to the ownership of such IP. We are not aware of any threatened or pending claims that any of our projects involve misappropriated
IP or other proprietary information, but in the future litigation may be necessary to defend against such claims. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to execute on the
optimal development plan for one or more of our existing product candidates if we are unable to obtain or maintain necessary rights
for some aspect of the developing technology through acquisitions or licenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing programs
currently use or may in the future use additional technologies subject to proprietary rights held by others, such as particular
compositions or methods of manufacture, treatment or use. The licensing and acquisition of IP rights is a competitive area, and
more established companies may pursue strategies to license or acquire such IP rights that we may consider necessary or useful.
These established companies may have a competitive advantage over us due to their size, cash resources and greater capabilities
in clinical development and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, companies
that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire
IP rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain
or maintain licenses or other rights from other parties to use IP of those parties, our business, financial condition and prospects
for growth could suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
in the agreements under which we license IP rights from other parties or otherwise experience disruptions to our business relationships
with our licensors, we could be required to pay monetary damages or could lose license rights that are important to our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our projects
(including our Lead Projects) are based on IP which we have licensed from other parties. (See &#8220;Our Business &#8211; Intellectual
Property&#8221;) Certain of these license agreements impose diligence, development or commercialization obligations on us, such
as obligations to pay royalties on net product sales of our drug and device candidates once commercialized by us, to pay a percentage
of sublicensing revenues if the licensed product is sublicensed, to make other specified milestone and/or annual payments relating
to our drug candidates or to pay license maintenance and other fees, as well as obligations to pursue commercialization with due
diligence. Specifically, a number of our license agreements also require us to meet development timelines in order to maintain
the related license(s). In spite of our efforts, our licensors might conclude that we have materially breached our obligations
under such license agreements and might therefore seek to terminate the license agreements. If one of our licensors, despite our
efforts, were to be successful in terminating its agreement with us, we would not be able to continue to develop, manufacture or
market any drug candidate under that license agreements, and we could face claims for monetary damages or other penalties under
that agreement. Such an occurrence would diminish or eliminate the value of that project to our Company, even if we are able to
negotiate new or reinstated agreements, which may have less favorable terms. Depending on the importance of the IP and the related
project, any such development could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, disputes
may arise regarding intellectual property subject to a licensing agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the priority of invention of patented technology. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we currently license intellectual property or technology from other parties are complex, and certain provisions in
such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that
may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
what we believe to be our financial or other obligations under the relevant agreement, either of which (depending on the importance
of the IP and the related project) could have a material adverse effect on our business, financial condition, results of operations,
and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain
our current licensing arrangement for a project on commercially acceptable terms, we may be unable to successfully develop and
commercialize the affected drug or device candidates, which could have a material adverse effect on our business, financial conditions,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not have complete control
of the preparation, filing and prosecution of patent applications, or to maintain patents, licensed by us from other parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has in-licensed,
and may in the future in-license patents owned or controlled by others for our use as part of our development plans. We also may
out-license or sublicense patents which we own or control in collaborations with others for development and commercialization of
our products. In either case, the continuing right to control the preparation, filing and prosecution of patent applications, or
to maintain the patents, covering technology under development is a matter for negotiation and we may not always be the party that
obtains such control, in which case we will be reliant on our licensors, collaboration partners or sublicensees for determining
strategies with respect to those patents. For our existing licenses, while we have an understanding with most of the licensors
who maintain control over patent prosecution and we have jointly appointed and engaged patent agents nominated by us under one
or more of our licenses, we cannot guarantee that such licensors or collaborators will always accept prosecution strategies proposed
by us and/or our patent agents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent
with the best interests of our business. If our current or future licensors or collaboration partners fail to establish, maintain
or protect such patents and other IP rights, such rights may be reduced or eliminated. If our licensors or joint development partners
are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent
rights could be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Reliance on Unrelated
Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on unrelated parties to conduct
discovery and further improvement of our innovations and licensed technologies, as well as our preclinical studies and clinical
trials. If these unrelated parties do not successfully carry out their contractual duties or meet expected deadlines, we may not
be able to obtain regulatory approval for or commercialize our drug candidates, and our business could be substantially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon
and plan to continue to rely upon CROs and collaborating institutions to monitor and manage data for our ongoing preclinical studies
and programs. We rely on these parties for execution of preclinical studies and clinical trials, and control only certain aspects
of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the
applicable protocol, legal, and regulatory requirements and scientific standards, and our reliance on the CROs and collaborating
institutions does not relieve us of our regulatory responsibilities. If CROs, collaborating institutions or clinical investigators
do not successfully carry out their contractual duties or obligations or meet expected deadlines, development of our product candidates
could be delayed and our business could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our CROs
and collaborating institutions, are subject to numerous environmental, health and safety laws and regulations, including those
governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and waste. In the
event of contamination or injury resulting from our use of hazardous materials, we might be held liable for any resulting damages,
and any liability could exceed our resources. We could also be subject to civil or criminal fines and penalties, and significant
associated costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the Company obtains approval of
an IND for one of our drug candidates and moves into human clinical trials requiring significantly larger quantities of the candidate
to be tested, we expect to rely on unrelated parties to manufacture supplies of that candidate. If those unrelated parties fail
to provide us with sufficient quantities of clinical supply on that candidate or fail to do so at acceptable quality levels or
prices, or fail to maintain required cGMP licenses, we may not be able to manufacture that candidate in sufficient quantities to
conduct the necessary human trials. Should the failure by the CRO occur in anticipation of or after marketing approval of that
candidate, we may be unable to generate as much revenue as rapidly (and such revenue may not be as profitable) as we had anticipated.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of
many drug products, particularly in commercial quantities, can be complex and may require significant expertise and capital investment,
particularly if the development of advanced manufacturing techniques and process controls are required. If we obtain approval of
an IND for any of our drug candidates, of which there can be no assurance, we intend to contract with outside contractors to manufacture
clinical supplies and process our drug candidates. We have not yet had our drug candidates to be manufactured or processed on a
commercial scale and may not be able to do so for any of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we expect to engage
contract manufacturers, the Company will be exposed to the following risks:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">we might be unable to identify manufacturers on acceptable terms or at all because the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities must approve any manufacturers we determine to use and any potential manufacturer may be unable to satisfy federal, state or international regulatory standards;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">although we would be choosing manufacturers with the type of experience most suitable for our drug candidates, it is possible that our contract manufacturers may not be able to execute unique manufacturing procedures and other logistical support requirements we have developed and they might require a significant amount of support from us to implement and maintain the infrastructure and processes required to manufacture our particular drug candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our contract manufacturers might be unable to reproduce the quantity and quality of the drugs we need to meet our clinical and commercial needs within the time frames when we require those drugs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our contract manufacturers may breach their contracts with us, including by not performing as agreed or not devoting sufficient resources to our drug candidates, or they may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">even if initially accepted by regulatory authorities, a manufacturer remains subject to ongoing periodic unannounced inspection by regulatory authorities to ensure strict compliance with cGMP and other government regulations, and our contract manufacturers may fail to comply with these regulations and requirements, resulting in rescission of cGMP licenses and our inability to continue using their services, requiring us to find a replacement manufacturer;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">depending on the terms of our agreement with a manufacturer, we may not own, or may have to share, the IP rights to any improvements made by the manufacturer in the manufacturing process for our drug candidates; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of these risks
could delay or prevent the completion of our clinical trials or the approval of any of our drug candidates by the FDA, NMPA, EMA,
Health Canada or other comparable regulatory authorities, result in higher costs or adversely impact commercialization of our drug
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also responsible
for quality control by our manufacturers. We intend to rely on those unrelated-party manufactures to perform certain quality assurance
tests on our drug candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable,
patients could be put at risk of serious harm and the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities
could place significant restrictions on our Company until deficiencies are remedied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers of drug
products often encounter difficulties in production, particularly in scaling up or out, validating the production process, and
assuring high reliability of the manufacturing process (including the absence of contamination). These problems include logistics
and shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing,
operator error, availability of qualified personnel, as well as compliance with strictly enforced federal, state and non-U.S. regulations.
Furthermore, if contaminants are discovered in our supply of our drug candidates or in the manufacturing facilities, such manufacturing
facilities may need to be closed for an extended period of time to investigate and remedy the contamination. It is possible that
stability failures or other issues relating to the manufacture of our drug candidates may occur in the future. Additionally, our
manufacturers may experience manufacturing difficulties due to resource constraints, or as a result of labor disputes or unstable
political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their
contractual obligations, our ability to provide our drug candidate to patients in clinical trials would be jeopardized. Any delay
or interruption in the manufacturing of clinical trial supplies could delay the completion of clinical trials, increase the costs
associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials
with additional costs or terminate clinical trials completely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Review of changes in the manufacturing
process of our drug candidates could cause delays resulting from the need for additional regulatory approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in a process
or procedure for manufacturing one of our drug candidates, including a change in the location where the drug candidate is manufactured
or a change of a contract manufacturer, could require prior review by the FDA, NMPA, EMA, Health Canada or other comparable regulatory
authorities and approval of the manufacturing process and procedures in accordance with the FDA, NMPA EMA, or Health Canada&#8217;s
regulations, or comparable requirements. This review may be costly and time-consuming and could delay or prevent the launch of
a product. The new facility will also be subject to pre-approval inspection. In addition, we would have to demonstrate that the
product made at the new facility is equivalent to the product made at the former facility by physical and chemical methods, which
are costly and time-consuming. It is also possible that the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities
may require clinical testing as a way to prove equivalency, which would result in additional costs and delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to AML Clinic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with all laws and
regulations applicable to the business of AML Clinic could have a material, adverse impact on the Company&#8217;s business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Operation of AML Clinic
subjects the Company to a variety of Hong Kong laws and regulations specific to companies and professionals in the business of
delivering medical care. We and our employees will be subject to licensing and professional qualifications that do not apply to
our other businesses. Breach of any of these laws, regulations or licensing requirements could subject the Company to significant
fines and other penalties and possibly damage the Company&#8217;s reputation, which could have a material adverse effect on the
Company&#8217;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Natural Supplements</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to government regulations
for natural supplements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From a regulatory perspective,
some of the Company&#8217;s non-drug candidates (including those developed under the project company Nativus), may be regulated
as dietary supplements, including NativusWell<SUP>&reg;</SUP> (NLS-2). For those non-drug candidates that the Company plans to
develop, they are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers
for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, state and local
governments and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics and drugs under different
regulatory schemes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, the FDA
regulates the processing, formulation, safety, manufacturing, packaging, labeling, advertising and distribution of dietary supplements
and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development,
pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval,
advertising, promotion, sale, distribution, import and export of pharmaceutical products under various regulatory provisions. If
any drug products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments,
whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding
than corresponding U.S. regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government regulation
substantially increases the cost and risk of researching, developing, manufacturing and selling products. Our failure to comply
with these regulations could result in, by way of example, significant fines, criminal and civil liability, product seizures, recalls,
withdrawals, withdrawals of approvals and exclusion and debarment from government programs. Any of these actions, including the
inability of our hormone therapy drug candidates to obtain and maintain regulatory approval, would have a materially adverse effect
on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA&#8217;s
policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval
of our drug candidates, or impose more stringent product labeling and post-marketing testing and other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to first
launch and market NativusWell<SUP>&reg;</SUP> (NLS-2) in Hong Kong. In Hong Kong, natural supplements are defined as &#8220;health
food&#8221; products. &#8220;Health food&#8221; containing medicines are subject to the Pharmacy and Poisons Ordinance (Cap 138)
and such &#8220;health food&#8221; containing Chinese medicines are regulated by the Chinese Medicine Ordinance (Cap 549), where
they must meet the requirements in respect of safety, quality and efficacy before they can be registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other &#8220;health
food&#8221; products which cannot be classified as Chinese medicine or western medicine are regulated under the Public Health and
Municipal Services Ordinance (Cap 132) as general food products. The Public Health and Municipal Services Ordinance requires the
manufacturers and sellers of food to ensure that their products are fit for human consumption and comply with the requirements
in respect of food safety, food standards and labelling. In addition, all prepackaged food should bear labels which correctly list
out the ingredients of the food under the Food and Drugs (Composition and Labelling) Regulations (Cap 132W) under the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The&nbsp;NativusWell<SUP>&reg;</SUP>
(NLS-2) is made with the bioactive ingredient extracted Chinese yam powder and does not contain any western or Chinese medicine;
therefore, registration is not required under the local laws for marketing in Hong Kong. We will, however, ensure the compliance
of the Food and Drugs (Composition and Labelling) Regulations (Cap 132W) with by proper labelling in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Device Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to risks related to
obtaining regulatory approval for device candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#8217;s
device candidates (including those being developed under SLS-1), are likely to be regulated as medical devices. Medical devices
are subject to extensive regulations, supervised by regulatory authorities around the world, including the FDA, NMPA and applicable
national authorities in relevant European countries. The regulatory framework related to medical devices covers research, development,
design, manufacturing, safety, reporting, testing, labeling, packaging, storage, installation, servicing, marketing, sales and
distribution. The Company is and may also be, in addition to these industry-specific regulations, subject to numerous other ongoing
regulatory obligations, such as data protection, environmental, health and safety laws and restrictions. The costs of compliance
with applicable regulations, requirements or guidelines could be substantial. Furthermore, the regulatory environment has generally
become more stringent and extensive over time. Failure to comply with these regulations could result in sanctions including fines,
injunctions, civil penalties, denial of applications for marketing approval of the Company&#8217;s products, delays, suspension
or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, partial suspension or
total shutdown of production and criminal prosecutions, any of which could significantly increase the Company&#8217;s costs, delay
the development and commercialization of its device candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are subject to risks related to the carrying out and
outcome of clinical trials of medical devices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may sponsor
studies on human participants in clinical studies of its device candidates. Such clinical studies are performed to support regulatory
approvals for market access or to generate evidence relating to clinical benefits and cost benefits of using such device candidates.
Clinical studies are costly and time consuming and associated with risks such as finding trial sites, recruitment of suitable patients,
the actual cost per patient exceeding budget and inadequacies in the execution of the trials. There is also a risk of delays in
the performance of clinical studies, which can occur for a variety of reasons. For example, delays in obtaining regulatory approval
to commence a trial, reaching agreements on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;)
and clinical investigational sites, obtaining institutional review board approval at each site, difficulties in patient enrolment,
patients failing to complete a trial or return for follow-up, adding new sites or obtaining sufficient supplies of products or
clinical sites dropping out of a trial. If delays persist, there is a risk that studies eventually are suspended or terminated
if the delays occur due to circumstances that a sponsor of a clinical trial has difficulties controlling, or is unable to control,
or if the measures required for conducting the studies further are deemed too costly or extensive in relation to the scopes and
goals of the studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are many factors
which may affect patient enrollment. Amongst these are the size and nature of the patient population, the proximity of patients
to clinical sites, the eligibility criteria for the trial, the design of the clinical study and competing clinical studies. Furthermore,
clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product being studied in relation to other
available therapies, including any new products that may be approved for the indications the company is investigating. Clinical
studies may also be suspended or terminated if participating subjects are exposed to unacceptable health risks or undesired side-effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, there
is a risk that clinical studies may not demonstrate the required clinical benefit for the prospective indication the trial is aimed
at. Failure in premarketing clinical studies could lead to market clearance or approvals not being obtained which could delay or
jeopardize the Company&#8217;s ability to develop, market and sell the device candidates being studied. At any stage of the development,
the Company may discontinue device candidate based on review of available preclinical and clinical data, the estimated costs of
continued development, market considerations and other factors. Furthermore, with respect to the clinical studies of device candidates
conducted by CROs and others, the Company may have less control over their timing or outcome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Industry, Business
and Operation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not comply with laws regulating
the protection of the environment and health and human safety, our business could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and clinic operations involve the use of hazardous materials, chemicals and various radioactive compounds/radiation and AML Clinic
may create medical waste and radiation. Our R&amp;D Center may maintain quantities of various flammable and toxic chemicals in
our facilities that are required for our research, development and manufacturing activities. We are subject to local laws and regulations
governing the use, manufacture, storage, handling and disposal of these hazardous materials and of medical waste at the jurisdictions
where we operate our clinic and research facilities, which are currently limited to Hong Kong. We believe our procedures for storing,
handling and disposing of these materials comply with the relevant guidelines and laws of the jurisdictions in which our facilities
are located. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards
mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If
an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous
environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne
pathogens and the handling of biohazardous materials and medical waste.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain
workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting
from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain
insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal
of biological, hazardous or radioactive materials. Additional federal, state and local laws and regulations affecting our operations
may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties, if we violate
any of these laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future success depends on our
ability to retain our Chief Executive Officer, our scientific and clinical advisors, and other key executives and to attract, retain
and motivate qualified personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent
on Ian Huen, our Chief Executive Officer, as well as, other principal members of our management teams, scientific teams as well
as scientific and clinical advisors. Although we have formal employment agreements, which we refer to as appointment letters, with
all of our executive officers, these agreements do not prevent our executives from terminating their employment with us at any
time, subject to applicable notice periods. Nevertheless, the loss of the services of any of these persons could impede the achievement
of our research, development and commercialization objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To induce valuable
employees to remain at our Company, in addition to salary and cash incentives, we plan to provide share incentive grants that vest
over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in the
price of our Class A Ordinary Shares that are beyond our control, and may at any time be insufficient to counteract more lucrative
offers from other companies. Although we have appointment letters with our key employees, any of our employees could resign at
any time, with 1-month to 3-months prior written notice or with payment in lieu of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recruiting and retaining
qualified officers, scientific, clinical, sales and marketing personnel or consultants will also be critical to our success. In
addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery
and preclinical studies development and commercialization strategy. The loss of the services of our executive officers or other
key employees and consultants could impede the achievement of our research, development and commercialization objectives and seriously
harm our ability to successfully implement our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, replacing
executive officers and key employees or consultants may be difficult and may take an extended period of time, because of the limited
number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory
approval of and commercialize drug and device candidates. Competition to hire from this limited pool is intense, and we may be
unable to hire, train, retain or motivate these key personnel or consultants on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also experience
competition for the hiring of scientific and clinical personnel from universities and research institutions. Our consultants and
advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our
ability to pursue our growth strategy will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to increase the size
and capabilities of our organization, and we may experience difficulties in managing our growth.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
we have 38 employees, including 35 full-time employees and 3 part-time employees. Of these, 11 are engaged in full-time research
and development and laboratory operations, 20 are engaged in full-time general and administrative functions, 4 are full-time employees
engaged in the clinic operation and 3 part-time employees are engaged in sponsored research and development, clinic operations,
finance, and legal clerical support. As of the date of hereof, 37 of our employees are located in Asia and 1 of our employees is
located in Europe. In addition, we have engaged and may continue to engage 48 independent contracted consultants and advisors to
assist us with our operations. As our development and commercialization plans and strategies develop, and as we have transitioned
into operating as a public company, we will need to establish and maintain effective disclosure and financial controls and make
changes in our corporate governance practices. We will need to add a significant number of additional managerial, operational,
sales, marketing, financial and other personnel with the appropriate public company experience and technical knowledge and we may
not successfully recruit and maintain such personnel. Future growth will impose significant added responsibilities on members of
management, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">managing our internal development efforts effectively, including clinical, the FDA or other comparable regulatory authority review process for our drug and device candidates, while complying with our contractual obligations to contractors and others; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">improving our operational, financial and management controls, reporting systems and procedures.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future financial
performance and our ability to commercialize our drug candidates will depend, in part, on our ability to effectively manage our
future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely,
and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants
for significant input in selecting and evaluating new products to pursue. These independent organizations, advisors and consultants
may not continue to be available to us on a timely basis when needed, and in such case, we may not have the ability to find qualified
replacements. In addition, if we are unable to effectively manage our outsourced activities, or if the quality or accuracy of the
services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and
we may not be able to obtain regulatory approval of our drug candidates or otherwise advance our business. Furthermore, we may
not be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable
terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are not able
to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may
not be able to successfully implement the tasks necessary to further develop and commercialize our drug and device candidates and,
accordingly, may not achieve our research, development and commercialization goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We intend to seek additional collaborations,
strategic alliances or acquisitions or enter into royalty-seeking or sublicensing arrangements in the future, but we may not realize
the benefits of these arrangements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to form or
seek strategic alliances, create joint ventures or collaborations, acquire complimentary products, IP rights, technology or businesses
or enter into additional licensing arrangements with unrelated parties that we determine may complement or augment our development
and commercialization efforts with respect to our drug and device candidates. Any of these relationships may require us to incur
non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders,
or disrupt our management and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will face significant
competition in seeking appropriate strategic partners and the negotiation process is likely to be time-consuming, costly and complex.
Moreover, we may not be successful in our efforts to establish a strategic partnership or another alternative arrangement for any
of our drug and device candidates because their state of development may be deemed to be too early for collaborative effort and
others may not view our drug and device candidates as having the requisite potential to demonstrate safety and efficacy. If and
when we enter into an agreement with a collaboration partner or sublicensee for development and commercialization of a drug or
device candidate, we can expect to relinquish some or all of the control over the future success of that drug and device candidate
to the unrelated-party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, even if we
enter into a collaboration involving any of our drug and device candidates, the arrangement will be subject to numerous risks,
which may include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborators will likely have significant discretion in determining the efforts and resources that they will apply to a collaboration; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborator may ultimately choose not pursue development and commercialization of our drug candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborator may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug or device candidate, repeat or conduct new clinical trials, or require a new formulation of a drug or device candidate for clinical testing; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborator could independently develop, or develop with unrelated parties, drugs that compete directly or indirectly with our drugs or drug and device candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to their marketing and distribution; </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborator may not properly maintain or defend our IP rights or may use our IP or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our IP or proprietary information or expose us to potential liability; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">disputes may arise between us and the collaborator that cause the delay or termination of the research, development or commercialization of our drug and device candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaboration may be terminated and, if terminated, may result the Company needing additional capital to pursue further development or commercialization of the applicable drug and device candidates; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaborator may own or co-own IP covering our drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such IP; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaboration may result in increased operating expenses or the assumption of indebtedness or contingent liabilities; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the collaboration arrangement may result in the loss of key personnel and uncertainties in our ability to maintain key business relationships.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, if we
enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit
of such transactions, which could delay our timelines or otherwise adversely affect our business. Following a strategic transaction
or license, we may not achieve the revenue or specific net income that justifies such transaction. If we are unable to reach agreements
with a suitable collaborator on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug
or device candidate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development
or commercialization activities at our own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to enter
into collaborations, we may seek to fund and undertake development or commercialization activities on our own, but we may not have
sufficient funds or expertise to undertake the necessary development and commercialization activities. In such a case, we may not
be able to further develop our drug and device candidates or bring them to market and generate product sales revenue, which would
harm our business prospects, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees, independent contractors,
consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with
regulatory standards and requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the
risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, commercial partners
and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the
laws of the FDA and other similar non-U.S. regulatory authorities; provide true, complete and accurate information to the FDA and
other similar non-U.S. regulatory authorities; comply with manufacturing standards we have established; comply with healthcare
fraud and abuse laws in the United States and similar non-U.S. fraudulent misconduct laws; or report financial information or data
accurately or to disclose unauthorized activities to us. If we obtain the FDA approval for any of our drug and device candidates
and begin commercializing those drugs in the United States, our potential exposure under U.S. laws will increase significantly
and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things,
our current activities with principal investigators of our sponsored researches and research patients and our use of information
obtained in the course of patient recruitment for clinical trials, as well as proposed and future sales, marketing and education
programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements
in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring
and commission(s), certain customer incentive programs and other business arrangements generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is not always possible
to identify and deter misconduct by employees and other parties, and the precautions we take to detect and prevent this activity
may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact
on our business, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our disclosure controls and procedures may not prevent
or detect all errors or acts of fraud.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our disclosure controls
and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under
the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time
periods specified in the rules and forms of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that any
disclosure controls and procedures, or internal controls and procedures, no matter how well conceived and operated, can provide
only reasonable, not absolute, assurance that the objectives of the control system are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or
mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people
or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements
due to error or fraud may occur and not be detected, which would likely cause investors to lose confidence in our reported financial
information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the
trading price of our Class A Ordinary Shares. Additionally, ineffective internal control over financial reporting could expose
us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which
we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial statements
from prior periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish and maintain
proper internal financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations
could be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section
404 of the Sarbanes-Oxley Act, we are required to file a report by our management on our internal control over financial reporting,
including an attestation report on internal control over financial reporting issued by our independent registered public accounting
firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal
control over financial reporting issued by our independent registered public accounting firm. The presence of material weaknesses
in internal control over financial reporting could result in financial statement errors which, in turn, could lead to errors in
our financial reports and/or delays in our financial reporting, which could require us to restate our operating results. In connection
with the audit of our financial statements for the year ended December 31, 2018 and the period March 1, 2017 through December 31,
2017, we and our independent registered public accounting firm identified one material weakness in our internal control over financial
reporting, as defined in the standards established by the Public Company Accounting Oversight Board of the United States. The material
weakness identified was the lack of dedicated resources to take responsibility for the finance and accounting functions and the
preparation of financial statements in compliance with generally accepted accounting principles in the United States, or U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, we took actions
to remediate the abovementioned material weakness, and we believe we have remediated the material weakness by implementing the
following measures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">provide trainings to staff regarding to the preparation of financial statements in compliance with generally accepted accounting principles in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">change to a new and well-established accounting system to enhance effectiveness and financial and system control;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">establish clear roles and responsibilities for accounting and financial reporting staff to address finance and accounting issues; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">continue to monitor the improvement on internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, we determined that the aforementioned measures have remediated the material weakness.&nbsp;However, since we are still in
the process of replenishing and building up a qualified finance and accounting team with sufficient dedicated resources, our management
assessed that the deficiency related to the lack of dedicated resources to take responsibility for the finance and accounting functions
and the preparation of financial statements in compliance with generally accepted accounting principles in the United States, or
U.S. GAAP, still existed as of December 31, 2019. Therefore, based on the definition of &#8220;material weakness&#8221; and &#8220;significant
deficiency&#8221; in the standards established by the Public Company Accounting Oversight Board of the United States, our management
concluded that the deficiency now only rises to the level of a significant deficiency. However, we cannot assure you that we will
not identify additional material weaknesses or significant deficiencies in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management concluded
that our internal controls over financial reporting were effective as of December 31, 2019. However, if we fail to maintain effective
internal controls over financial reporting in the future, our management and our independent registered public accounting firm
may conclude that our internal control over financial reporting is not effective. Investors may lose confidence in our operating
results, the price of the Class A Ordinary Shares could decline and we may be subject to litigation or regulatory enforcement actions.
In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, the Class A Ordinary Shares may
not be able to remain listed on the NASDAQ Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may market our products, if approved,
globally; if we do, we will be subject to the risk of doing business internationally.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate and expect
to operate in various countries, and we may not be able to market our products in, or develop new products successfully for, these
markets. We may also encounter other risks of doing business internationally including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">unexpected changes in, or impositions of, legislative or regulatory requirements; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">efforts to develop an international sales, marketing and distribution organization may increase our expenses, divert our management&#8217;s attention from the acquisition or development of drug candidates or cause us to forgo profitable licensing opportunities in these geographies; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the occurrence of economic weakness, including inflation or political instability; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the effects of applicable non-U.S. tax structures and potentially adverse tax consequences; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">differences in protection of our IP rights including patent rights of other parties; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the burden of complying with a variety of foreign laws including difficulties in effective enforcement of contractual provisions; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">delays resulting from difficulty in obtaining export licenses, tariffs and other barriers and restrictions, potentially longer payment cycles, greater difficulty in accounts receivable collection and potentially adverse tax treatment; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are
subject to general geopolitical risks in foreign countries where we operate, such as political and economic instability and changes
in diplomatic and trade relationships, which could affect, among other things, customers&#8217; inventory levels and consumer purchasing,
which could cause our results to fluctuate and our net sales to decline. The occurrence of any one or more of these risks of doing
business internationally, individually or in the aggregate, could materially and adversely affect our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we engage in future acquisitions
or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume
contingent liabilities, and subject us to other risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may evaluate various
acquisitions and strategic partnerships, including licensing or acquiring complementary products, IP rights, technology or businesses.
Any potential acquisition or strategic partnership may entail numerous risks, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">increase in operating expenses and cash requirements; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the assumption of additional indebtedness or contingent liabilities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the issuance of our equity securities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">assimilation of operations, IP and products of an acquired company, including difficulties associated with integrating new personnel; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug and device candidates and regulatory approvals; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we
undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire
intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable
acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may
be important to the development of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with the U.S.
Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), or other anti-bribery laws, including the Bribery Act 2010 of the United Kingdom
(UK Bribery Act&#8221;), our reputation may be harmed and we could be subject to penalties and significant expenses that have a
material adverse effect on our business, financial condition and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the
FCPA. The FCPA and UK Bribery Act generally prohibits us from making improper payments to non-U.S. officials for the purpose of
obtaining or retaining business or other benefits. We are also subject to the anti-bribery laws of other jurisdictions, particularly
the PRC. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our
procedures and controls to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our
employees or agents. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable
anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant
expenses, which could have a material adverse effect on our business, including our financial condition, results of operations,
cash flows and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business and results of operations
may be negatively impacted by the UK&#8217;s withdrawal from the EU.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 23, 2016, the
UK held a referendum in which a majority of voters approved an exit from the EU, or&nbsp;Brexit. After nearly three years of negotiation
and political and economic uncertainty, the UK&#8217;s withdrawal from the EU became effective on January 31, 2020. Under the terms
of the withdrawal agreement, the UK and the EU will continue to negotiate the terms of trade and other matters during a transition
period that will end on December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the&nbsp;Brexit&nbsp;transition
period, the UK will continue to be subject to the laws and obligations applicable to all EU members, including laws related to
trade and data privacy and the EU&#8217;s pharmaceutical laws. However, future regulations that will apply in the UK following
the transition period (including financial laws and regulations, tax and free trade agreements, intellectual property rights, data
protection laws, supply chain logistics, environmental, health and safety laws and regulations medicine licensing and regulations,
immigration laws and employment laws), have yet to be addressed. This lack of clarity on future UK laws and regulations and their
interaction with the EU laws and regulations may negatively impact foreign direct investment in the UK, increase costs, depress
economic activity and restrict access to capital.&nbsp;Brexit, including developments that occur during the&nbsp;Brexit&nbsp;transition
period, may affect our results of operations in a number of ways, including increasing currency exchange risk, generating instability
in the global financial markets or negatively impacting the economies of the UK and Europe. In addition, as we are headquartered
in the UK, it is possible that&nbsp;Brexit&nbsp;may impact some or all of our current operations. For example, following the transition
period,&nbsp;Brexit&nbsp;may impact our ability to freely move employees from our headquarters in the UK to other locations in
Europe. If the UK and the EU are unable to negotiate acceptable agreements or if other EU member states pursue withdrawal, barrier-free
access between the UK and other EU member states or among the EEA overall could be diminished or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The long-term effects
of&nbsp;Brexit&nbsp;will depend in part on any agreements the UK makes during the&nbsp;Brexit&nbsp;transition period to retain
access to markets in the EU. Such a withdrawal from the EU is unprecedented, and it is unclear how the UK&#8217;s access to the
European single market for goods, capital, services and labor within the EU, or single market, and the wider commercial, legal
and regulatory environment, will impact our current and future operations (including business activities conducted by third parties
and contract manufacturers on our behalf).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also face new
regulatory costs and challenges that could have an adverse effect on our operations as a result of&nbsp;Brexit. Depending on the
terms of the UK&#8217;s withdrawal from the EU, the UK could lose the benefits of global trade agreements negotiated by the EU
on behalf of its member states, which may result in increased trade barriers that could make our doing business in the EU and the
EEA more difficult. Since the regulatory framework in the UK covering quality, safety and efficacy of therapeutic substances, clinical
trials, marketing authorization, commercial sales and distribution of therapeutic substances is derived from EU directives and
regulations,&nbsp;Brexit&nbsp;could materially impact the future regulatory regime with respect to the approval of our drug candidates
or any future therapeutic candidates, should we decide to seek marketing approvals for such candidates in the UK or to carry out
any clinical trials in the UK for our drug candidates in support of marketing approvals by EMA in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that following
the transition period,&nbsp;Brexit&nbsp;could lead to legal uncertainty and potentially divergent national laws and regulations
as the UK determines which EU laws to replicate or replace, including those related to data privacy and the regulation of medicinal
products, as described above. Any of these effects of&nbsp;Brexit, and others we cannot anticipate, could negatively impact our
business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we commence clinical trials of
one of our drug or device candidates, and product liability lawsuits are brought against us, we may incur substantial liabilities
and the commercialization of such drug or device candidates may be affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our drug
or device candidates enter clinical trials, we will face an inherent risk of product liability suits and will face an even greater
risk if we obtain approval to commercialize any drugs. For example, we may be sued if our drug candidates cause or are perceived
to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the drug, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit commercialization of our drug candidates. Even successful defense would require significant financial and management resources.
Regardless of the merits or eventual outcome, liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">decreased demand for our drugs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">injury to our reputation;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">withdrawal of clinical trial participants and inability to continue clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">initiation of investigations by regulators;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">costs to defend the related litigation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">a diversion of management&#8217;s time and our resources;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">substantial monetary awards to trial participants or patients;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">loss of revenue;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">exhaustion of any available insurance and our capital resources;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the inability to commercialize any drug candidate; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">a decline in the price of our Class A Ordinary Shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We shall seek to obtain
the appropriate insurance once our candidates are ready for clinical trial. However, our inability to obtain sufficient product
liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization
of drugs we develop, alone or with collaborators. We currently do not have in place product liability insurance and although we
plan to have in place such insurance as and when the products are ready for commercialization, as well as insurance covering clinical
trials, the amount of such insurance coverage may not be adequate, we may be unable to maintain such insurance, or we may not be
able to obtain additional or replacement insurance at a reasonable cost, if at all. Our insurance policies may also have various
exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded
by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we
may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators
entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, we may
be sued if the products that we commercialize, market or sell cause or are perceived to cause injury or are found to be otherwise
unsuitable, and may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">decreased demand for those products;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">damage to our reputation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">costs incurred related to product recalls;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">limiting our opportunities to enter into future commercial partnership; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">a decline in the price of our Class A Ordinary Shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our insurance coverage may be inadequate
to protect us against losses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently maintain
property insurance for our office premises (including one unit of server and accessories). We hold employer&#8217;s liability insurance
generally covering death or work-related injury of employees; we maintain &#8220;Office Care Plan Insurance&#8221; for those persons
working in our offices and &#8220;Medical Plan&#8221; for our employee. We hold public liability insurance covering certain incidents
involving unrelated parties that occur on or in the premises of the Company. We do have directors and officers liability insurance.
We do not have key-man life insurance on any of our senior management or key personnel, or business interruption insurance. Our
insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries.
If any claims for damage are brought against us, or if we experience any business disruption, litigation or natural disaster, we
might incur substantial costs and diversion of resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fluctuations in exchange rates could
result in foreign currency exchange losses </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations and
equity are funded in U.S. dollars and we currently incur the majority of our expenses in U.S. dollars or in H.K. dollars. H.K.
dollar is currently pegged to the U.S. dollar; however, we cannot guarantee that such peg will continue to be in place in the future.
Our exposure to foreign exchange risk primarily relates to the limited cash denominated in currencies other than the functional
currencies of each entity and limited revenue contracts dominated in H.K. dollars in certain Hong Kong operating entities. We do
not believe that we currently have any significant direct foreign exchange risk and have not hedged exposures denominated in foreign
currencies or any other derivative financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are exposed to
foreign currency exchange risk as our results of operations, cash flows maybe subject to fluctuations in foreign currency exchange
rates. For example, if a significant portion of our clinical trial activities may be conducted outside of the United States, and
associated costs may be incurred in the local currency of the country in which the trial is being conducted, which costs could
be subject to fluctuations in currency exchange rates. We currently do not engage in hedging transactions to protect against uncertainty
in future exchange rates between particular foreign currencies and the U.S. dollar. A decline in the value of the U.S. dollar against
currencies in countries in which we conduct clinical trials could have a negative impact on our research and development costs.
Foreign currency fluctuations are unpredictable and may adversely affect our financial condition, results of operations and cash
flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our investments are subject to risks
that could result in losses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We had unrestricted
cash of $4.02 million, $5.19 million and $12.01 million as of June 30, 2020, December 31, 2019 and December 31, 2018, respectively.
We may invest our cash in a variety of financial instruments. All of these investments are subject to credit, liquidity, market
and interest rate risk. Such risks, including the failure or severe financial distress of the financial institutions that hold
our cash, cash equivalents and investments, may result in a loss of liquidity, impairment to our investments, realization of substantial
future losses, or a complete loss of the investments in the long-term, which may have a material adverse effect on our business,
results of operations, liquidity and financial condition. While we believe our cash position does not expose us to excessive risk,
future investments may be subject to adverse changes in market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are exposed to risks associated
with our computer hardware, network security and data storage.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to all other
computer network users, our computer network system is vulnerable to attack of computer virus, worms, trojan horses, hackers or
other similar computer network disruptive problems. Any failure in safeguarding our computer network system from these disruptive
problems may cause breakdown of our computer network system and leakage of confidential information of the Company. Any failure
in the protection of our computer network system from external threat may disrupt our operation and may damage our reputation for
any breach of confidentiality to our customers, which in turn may adversely affect our business operation and performance. In the
event that our confidential information is stolen and misused, we may become exposed to potential risks of losses from litigation
and possible liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are
highly dependent on our IT infrastructure to store research data and information and manage our business operations. We do not
backup all data on a real-time basis and the effectiveness of our business operations may be materially affected by any failure
in our IT infrastructure. If our communications and IT systems do not function properly, or if there is any partial or complete
failure of our systems, we could suffer financial losses, business disruption or damage to our reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Business disruptions could seriously
harm our future revenue and financial condition and increase our costs and expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations, and
those of our research institution collaborators, CROs, suppliers and other contractors and consultants, could be subject to earthquakes,
power shortages, telecommunications failures, damage from computer viruses, material computer system failures, water shortages,
floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business
interruptions. In addition, we partially rely on our research institution collaborators for conducting research and development
of our drug candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business
disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on contract
manufacturers to produce and process our drug candidates. Our ability to obtain clinical supplies of our drug candidates could
be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.
A large portion of our contract manufacturer&#8217;s operations is located in a single facility. Damage or extended periods of
interruption to our corporate or our contract manufacturer&#8217;s development or research facilities due to fire, natural disaster,
power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or
all of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Although we do not currently conduct
any business in the PRC, we may in the future; in doing so we would be exposed to various risks related to doing business in the
PRC.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we currently
do not conduct any business in the PRC, we are the exclusive licensee to certain PRC patents directed to our drug candidates, and
we intend to file application for certain products in the PRC. The pharmaceutical industry in the PRC is subject to comprehensive
government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing
of new drugs. (See &#8220;Our Business &#8211;Regulation &#8211; PRC Regulations&#8221;). In recent years, the regulatory framework
in the PRC regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo
significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in
or prevent the successful development or commercialization of our drug candidates in the PRC and reduce the current benefits that
we believe are available to us from developing and manufacturing drugs in the PRC. Chinese authorities have become increasingly
vigilant in enforcing laws in the pharmaceutical industry and any failure by us or our partners to maintain compliance with applicable
laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business
activities in the PRC. We believe our strategy and approach is aligned with the PRC government&#8217;s policies, but we cannot
ensure that our strategy and approach will continue to be aligned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If in the future, we
commence business or operation in the PRC, changes in the political and economic policies of the PRC government may materially
and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our
growth and expansion strategies. Once we start doing business in the PRC, our financial condition and results of operation in the
PRC could be materially and adversely affected by government control over capital investments or changes in tax regulations that
are applicable to us, and consequently have a material adverse effect on our businesses, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The SEC could take the position that
we are an &#8220;investment company&#8221; subject to the extensive requirements of the Investment Company Act of 1940. Such a
characterization and the associated compliance requirements could have a material adverse effect on our business, financial condition,
and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business had historically
included passive healthcare related investments in early stage companies primarily in the United States. Although we are in the
process of liquidating those securities that remain in our portfolio, we still hold some such investments and these are included
as assets of our Company on a consolidated basis. As part of the Restructure, we resolved to exit such portfolio investments over
an appropriate timeframe and focus our resources on our current business. Since the date of the Restructure, we have not held ourselves
out as an investment company and we do not believe we are an &#8220;investment company&#8221; under the Investment Company Act
of 1940. If the SEC or a court, however, were to disagree with us, we could be required to register as an investment company. This
would subject us to disclosure and accounting rules geared toward investment companies, rather than operating companies, which
may limit our ability to borrow money, issue options, issue multiple classes of stock and debt, and engage in transactions with
affiliates, and may require us to undertake significant costs and expenses to meet the disclosure and regulatory requirements to
which we would be subject as a registered investment company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are classified as a passive
foreign investment company for U.S. federal income tax purposes, United States holders of our Class A Ordinary Shares may be subject
to adverse United States federal income tax consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. corporation
will be a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, for such year, if either</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">At least 75% of its gross income for such year is passive income; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The average percentage of our assets (determined at the end of each quarter) during such year which produce passive income or which are held for the production of passive income is at least 50%.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Passive income generally
includes dividends, interests, rents and royalties (other than rents or royalties derived from the active conduct of a trade or
business) and gains from the disposition of passive assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A separate determination
must be made after the close of each taxable year as to whether a non-U.S. corporation is a PFIC for that year. For purposes of
the PFIC analysis, in general, a non-U.S. corporation is deemed to own its pro rata share of the gross income and assets of any
entity in which it is considered to own at least 25% of the equity by value. Based on the current and anticipated value of our
assets, we believe we were a PFIC for U.S. federal income tax purposes for our taxable year ending December 31, 2018, and we may
be a PFIC for U.S. federal income tax purposes for our current taxable year ending December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In determining whether
we are a PFIC, cash and investment are considered by the U.S. Internal Revenue Service (&#8220;IRS&#8221;) to be a passive asset.
During our taxable year ending December 31, 2019, we believe that the amount of restricted and unrestricted cash we had on hand
and investments were greater than 50% of our total assets. The composition of our assets during the current taxable year may cause
us to continue to be classified as a PFIC. The determination of whether we will be a PFIC for our current taxable year or a future
year may depend in part upon how quickly we spend our liquid assets, and on the value of our goodwill and other unbooked intangibles
not reflected on our balance sheet, which may depend upon the market value of our Class A Ordinary Shares from time to time. Further,
while we will endeavor to use a classification methodology and valuation approach that is reasonable, the IRS may challenge our
classification or valuation of our goodwill and other unbooked intangibles for purposes of determining whether we are a PFIC in
the current or one or more future taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are a PFIC
for any taxable year during which a U.S. Holder owns our Class A Ordinary Shares, warrants or pre-funded warrants, certain adverse
U.S. federal income tax consequences could apply to such U.S. Holder. As discussed under &ldquo;Taxation &ndash; Material U.S.
Federal Income Tax Considerations for U.S. Holders &ndash; Passive Foreign Investment Company Rules&rdquo;, a U.S. Holder may
be able to make certain tax elections that would lessen the adverse impact of PFIC status; however, in order to make such elections
the U.S. holder will usually have to have been provided information about the company by us, and there is no assurance that the
company will provide such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a more detailed
discussion of the application of the PFIC rules to us and the consequences to U.S. holders if we were determined to be a PFIC.
(See &#8220;Taxation &#8211; Material U.S. Federal Income Tax Considerations for U.S. Holders &#8211; Passive Foreign Investment
Company Rules&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Political risks associated with conducting
business in Hong Kong.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we operate our
business globally, part of our business operations is based in Hong Kong. Accordingly, our business operation and financial conditions
will be affected by the political and legal developments in Hong Kong. During the period covered by the financial information incorporated
by reference into and included in this prospectus, we derive substantially all of our revenue from operations in Hong Kong and,
specifically, from the AML Clinic in Hong Kong operating under the name of Talem Medical. Any adverse economic, social and/or political
conditions, material social unrest, strike, riot, civil disturbance or disobedience, as well as significant natural disasters,
may affect the market may adversely affect the business operations of the AML Clinic. Hong Kong is a special administrative region
of the PRC and the basic policies of the PRC regarding Hong Kong are reflected in the Basic Law, namely, Hong Kong&#8217;s constitutional
document, which provides Hong Kong with a high degree of autonomy and executive, legislative and independent judicial powers, including
that of final adjudication under the principle of &#8220;one country, two systems&#8221;. However, there is no assurance that there
will not be any changes in the economic, political and legal environment in Hong Kong in the future. Since a substantial part of
our operations is based in Hong Kong, any change of such political arrangements may pose immediate threat to the stability of the
economy in Hong Kong, thereby directly and adversely affecting our results of operations and financial positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Hong Kong protests
that begun in 2019 are ongoing protests in Hong Kong (the &#8220;Hong Kong Protests&#8221;) triggered by the introduction of the
Fugitive Offenders amendment bill by the Hong Kong government. If enacted, the bill would have allowed the extradition of criminal
fugitives who are wanted in territories with which Hong Kong does not currently have extradition agreements, including mainland
China. This led to concerns that the bill would subject Hong Kong residents and visitors to the jurisdiction and legal system of
mainland China, thereby undermining the region&#8217;s autonomy and people&#8217;s civil liberties. Various sectors of the Hong
Kong economy have been adversely affected as the protests turned increasingly violent. Most notably, the airline, retail, and real
estate sectors have seen their sales decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Basic Law
of the Hong Kong Special Administrative Region of the People&#8217;s Republic of China, Hong Kong is exclusively in charge of its
internal affairs and external relations, while the government of the PRC is responsible for its foreign affairs and defense. As
a separate customs territory, Hong Kong maintains and develops relations with foreign states and regions. We cannot assure that
the Hong Kong Protests will not affect Hong Kong&#8217;s status as a Special Administrative Region of the People&#8217;s Republic
of China and thereby affecting its current relations with foreign states and regions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenue is susceptible
to the ongoing Hong Kong Protests as well as any other incidents or factors which affect the stability of the social, economic
and political conditions in Hong Kong. Any drastic events may adversely affect our business operations. Such adverse events may
include changes in economic conditions and regulatory environment, social and/or political conditions, civil disturbance or disobedience,
as well as significant natural disasters. Given the relatively small geographical size of Hong Kong, any of such incidents may
have a widespread effect on our business operations, which could in turn adversely and materially affect our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure that
the Hong Kong Protests will end in the near future and that there will be no other political or social unrest in the near future
or that there will not be other events that could lead to the disruption of the economic, political and social conditions in Hong
Kong. If such events persist for a prolonged period of time or that the economic, political and social conditions in Hong Kong
are to be disrupted, our overall business and results of operations may be adversely affected.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Furthermore,
on June 30, 2020, the Standing Committee of the National People&#8217;s Congress of the People&#8217;s Republic of China passed
the Law of the People&#8217;s Republic of China on Safeguarding National Security in the Hong Kong Special Administrative Region
(the &#8220;National Security Law&#8221;). In response to the implementation of the National Security Law, President Trump of the
U.S. signed an executive order on Hong Kong Normalization on July 14, 2020 to end the preferential trading status of Hong Kong
and, going forward, Hong Kong will receive the same treatment from the U.S. as China. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">At
the same time, the U.S. has imposed sanctions on and suspended collaborations with a number of Chinese companies and universities
by including these entities in the Entity List and the Unverified List of the Bureau of Industry and Security of the U.S. Department
of Commerce. Our Company has working relationships with universities in Hong Kong on R&amp;D of some projects. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">While
none of our collaboration partners is currently under sanction by the U.S., it may cause significant disruptions if the universities&#8217;
ability to conduct R&amp;D is adversely affected due to difficulty in acquiring essential equipment and materials, as well as our
business operations due to possible suspension of dealings with sanctioned entities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">To
this date, the U.S. government has not imposed or threatened to impose any sanctions on the universities in Hong Kong. However,
as U.S.-China relations continue to deteriorate, there is a possibility that sanctions could be imposed on the universities in
Hong Kong in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to the risks of doing
business globally.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject
to risks associated with doing business globally. Accordingly, our business and financial results in the future could be adversely
affected due to a variety of factors, including: changes in a specific country&#8217;s or region&#8217;s political and cultural
climate or economic condition; unexpected changes in laws and regulatory requirements in local jurisdictions; difficulty of effective
enforcement of contractual provisions in local jurisdictions; inadequate intellectual property protection in certain countries;
enforcement of anti-corruption and anti-bribery laws; trade-protection measures, import or export licensing requirements and fines,
penalties or suspension or revocation of export privileges; the effects of applicable local tax regimes and potentially adverse
tax consequences; and significant adverse changes in local currency exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our results of operation may be negatively
affected should the 2019-nCov virus (Coronavirus) continue to spread on a wider scale.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could
be adversely affected by the effects of a widespread outbreak of contagious disease, including the recent outbreak of respiratory
illness caused by a novel coronavirus. Any outbreak of contagious diseases, and other adverse public health developments, particularly
in China, could have a material and adverse effect on our business operations. These could include disruptions or restrictions
on our ability to travel or to distribute our products, as well as temporary closures of our facilities or the facilities of our
suppliers or customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The&nbsp;COVID-19&nbsp;pandemic
continues to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies and clinical trials will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic
spread of the disease, the duration of the pandemic, travel restrictions and social distancing in various countries, business closures
or business disruptions and the effectiveness of actions taken to contain and treat the disease. If we or any of the third parties
with whom we engage were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner
and on the timelines presently planned could be materially and negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the trading
prices for our Class A Ordinary Shares and other biopharmaceutical companies have been highly volatile as a result of the&nbsp;COVID-19&nbsp;pandemic.
As a result, we may face difficulties raising capital through sales of our securities or such sales may be on unfavorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The outbreak of the novel coronavirus
disease,&nbsp;COVID-19,&nbsp;or other pandemic, epidemic or outbreak of an infectious disease may materially and adversely impact
our preclinical studies and clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the&nbsp;COVID-19&nbsp;outbreak,
or similar pandemics, we have and may in the future experience disruptions that could materially and adversely impact our manufacturing,
preclinical development activities, preclinical studies and planned clinical trial. Potential disruptions include but are not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays or difficulties in
enrolling patients in our clinical trials, should the relevant clinical trials be approved;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays or difficulties in
initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical
site investigators and clinical site staff;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increased rates of patients
withdrawing from our clinical trials following enrollment as a result of contracting&nbsp;COVID-19&nbsp;or other health conditions
or being forced to quarantine;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">diversion of healthcare
resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and
hospital staff supporting the conduct of our clinical trials;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">interruption of key clinical
trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by governments,
employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of
subject data and clinical study endpoints;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">interruption or delays in
the operations of the FDA or other regulatory authorities, which may impact review and approval timelines for regulatory submission
and trial initiation;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">interruption or delays in
our CROs and collaborators meeting expected deadlines or complying with regulatory requirements related to preclinical development
activities, preclinical studies and planned clinical trials;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays
                                         or disruptions in preclinical experiments and investigational new drug application-enabling
                                         or clinical trial application-enabling studies due to restrictions of&nbsp;on-site&nbsp;staff
                                         and unforeseen circumstances at contract research organizations and vendors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">interruption of, or delays
in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production
slowdowns or stoppages and disruptions in delivery systems;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limitations on our ability
to recruit and hire key personnel due to our inability to meet with candidates because of travel restrictions and &#8220;shelter
in place&#8221; orders;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limitations on employee
resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of
sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">interruption or delays to
our sourced discovery and clinical activities.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our CEO has control over key decision
making as a result of his control of a majority of our voting shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Founder, CEO, and
our Executive Director, Mr. Ian Huen, and his affiliates, over which he is deemed to have control and/or have substantial influence,
has voting rights with respect to an aggregate of 18,927,211 ordinary shares, on an as converted basis (2,865,742 Class A Ordinary
Shares and 16,061,469 Class B Ordinary Shares), representing approximately 70% of the voting power of our outstanding ordinary
shares as of the date hereof. As a result, Mr. Huen has the ability to control the outcome of matters submitted to our shareholders
for approval, including the election of directors and any merger, consolidation, or sale of all or substantially all of our assets.
In addition, Mr. Huen has the ability to control the management and affairs of our company as a result of his position as our CEO
and his ability to control the election of our directors. Additionally, in the event that Mr. Huen controls our company at the
time of his death, control may be transferred to a person or entity that he designates as his successor. As a board member and
officer, Mr. Huen owes a fiduciary duty to our shareholders and must act in good faith in a manner he reasonably believes to be
in the best interests of our shareholders. As a shareholder, even a controlling shareholder, Mr. Huen is entitled to vote his shares,
and shares over which he has voting control as a result of voting agreements, in his own interests, which may not always be in
the interests of our shareholders generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The dual class structure of our ordinary
shares has the effect of concentrating voting control with our CEO, directors and their affiliates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Class B Ordinary
Share has ten votes per share and each Class A Ordinary Share has one vote per share. Shareholders who hold shares of Class B Ordinary
Shares, including our executive officers and their affiliates who hold such shares, hold approximately 96% of the voting power
of our outstanding ordinary shares as of the date hereof. Because of the ten-to-one voting ratio between our Class B and Class
A Ordinary Shares, the holders of our Class B Ordinary Shares collectively will continue to control a majority of the combined
voting power of our ordinary share and therefore be able to control all matters submitted to our shareholders for approval so long
as the shares of Class B Ordinary Shares represent at least 9.1% of all outstanding shares of our Class A Ordinary Shares and Class
B Ordinary Shares. This concentrated control will limit your ability to influence corporate matters for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future transfers by
holders of Class B Ordinary Shares will generally result in those shares converting to Class A Ordinary Shares, subject to limited
exceptions, such as certain transfers effected for estate planning purposes. The conversion of Class B Ordinary Shares to Class
A Ordinary Shares will have the effect, over time, of increasing the relative voting power of those holders of Class B Ordinary
Shares who retain their shares in the long term. If, for example, Mr. Huen retains a significant portion of his holdings of Class
B Ordinary Share for an extended period of time, he could, in the future, continue to control a majority of the combined voting
power of our Class A Ordinary Shares and Class B Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a &#8220;controlled company&#8221;
under the rules of the NASDAQ Global Market, we may choose to exempt our company from certain corporate governance requirements
that could have an adverse effect on our public shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors and officers
beneficially own a majority of the voting power of our outstanding Class A Ordinary Shares. Under the Rule 4350(c) of the NASDAQ
Global Market, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled
company&#8221; and may elect <B><I>not</I></B> to comply with certain corporate governance requirements, including the requirement
that a majority of our directors be independent, as defined in the NASDAQ Global Market Rules, and the requirement that our compensation
and nominating and corporate governance committees consist entirely of independent directors. Although we do not intend to rely
on the &#8220;controlled company&#8221; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the
future. If we elect to rely on the &#8220;controlled company&#8221; exemption, a majority of the members of our board of directors
might not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely
of independent directors. Accordingly, during any time while we remain a controlled company relying on the exemption and during
any transition period following a time when we are no longer a controlled company, you would not have the same protections afforded
to shareholders of companies that are subject to all of the NASDAQ Global Market corporate governance requirements. Our status
as a controlled company could cause our Class A Ordinary Share to look less attractive to certain investors or otherwise harm our
trading price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Shares eligible for future sale may
adversely affect the market price of our Class A Ordinary Shares if the shares are successfully listed on NASDAQ or other stock
markets, as the future sale of a substantial amount of outstanding Class A Ordinary Shares in the public marketplace could reduce
the price of our Class A Ordinary Shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of
our Class A Ordinary Shares could decline as a result of sales of substantial amounts of our Class A Ordinary Shares in the public
market, or the perception that these sales could occur. In addition, these factors could make it more difficult for us to raise
funds through future offerings of our Class A Ordinary Shares. An aggregate of 8,491,526 Class A Ordinary Shares are outstanding
as of the date of this prospectus. 4,139,712 of the Class A Ordinary Shares are freely transferable without restriction or further
registration under the Securities Act. The remaining Class A Ordinary Shares will be &#8220;restricted securities&#8221; as defined
in Rule 144. These Class A Ordinary Shares may be sold without registration under the Securities Act to the extent permitted by
Rule 144 or other exemptions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A sale or perceived sale of a substantial
number of our Ordinary Shares may cause the price of our Class A Ordinary Shares to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our shareholders
sell substantial amounts of our Class A Ordinary Shares in the public market, the market price of our Class A Ordinary Shares could
fall. Moreover, the perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors
to short our Class A Ordinary Shares. These sales also may make it more difficult for us to sell equity or equity-related securities
in the future at a time and price that we deem reasonable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Issuances by us of additional securities,
could affect ownership and voting rights over us. In addition, the issuance of preferred shares, or options or warrants to purchase
those preferred shares, could negatively impact the value of the Ordinary Shares as the result of preferential dividend rights,
conversion rights, redemption rights and liquidation provisions granted to the stockholders of such preferred shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time,
we may issue in public or private sales additional securities to third party investors. Such securities may provide holders with
ownership and voting rights that could provide the holders thereof with substantial influence over our business. Any preferred
shares that may be issued shall have such rights, preferences, privileges and restrictions as may be designated from time-to-time
by our board, including preferential dividend rights, voting rights, conversion rights, redemption rights and liquidation provisions.
There cannot be any assurance that we will not issue preferred securities with rights and preferences that are more beneficial
than those provided to our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have not paid dividends in the
past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid
any cash dividends on our Class A Ordinary Shares and do not anticipate paying any cash dividends on our Class A Ordinary Shares
in the foreseeable future, and any return on investment may be limited to the value of our Class A Ordinary Shares. We plan to
retain any future earnings to finance growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our dividend policy
is subject to the discretion of our Board of Directors and will depend on, among other things, our earnings, financial condition,
capital requirements and other factors. There is no assurance that our Board of Directors will declare dividends even if we are
profitable. Under Cayman Islands law, dividends may be declared and paid only out of funds legally available therefor, namely out
of either profit or our share premium account, and provided further that a dividend may not be paid if this would result in our
Company being unable to pay its debts as they fall due in the ordinary course of business and the realizable value of assets of
our Company will not be less than the sum of our total liabilities, other than deferred taxes as shown on our books of account,
and our capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our Class B Ordinary Shares have
greater voting power than our Class A Ordinary Shares and certain existing shareholders have substantial influence over our Company
and their interests may not be aligned with the interests of our other shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a dual-class
voting structure consisting of Class A Ordinary Shares and Class B Ordinary Shares. Under this structure, holders of Class A Ordinary
Shares are entitled to one vote per share, and holders of Class B Ordinary Shares are entitled to ten votes per share, which can
cause the holders of Class B Ordinary Shares to have an unbalanced, higher concentration of voting power. Our management team as
a group beneficially owns over 18 million Class B Ordinary Shares representing 80% voting power. As a result, until such time as
their collective voting power is below 50%, our management team as a group of controlling shareholders have substantial influence
over our business, including decisions regarding mergers, consolidations and the sale of all or substantially all of our assets,
election of directors and other significant corporate actions. They may take actions that are not in the best interests of us or
our other shareholders. These corporate actions may be taken even if they are opposed by our other shareholders. <FONT STYLE="background-color: white">Further,
concentration of ownership of our Class B Ordinary Shares may discourage, prevent or delay the consummation of change of control
transactions that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium
for their shares. Future issuances of Class B Ordinary Shares may also be dilutive to the holders of Class A Ordinary Shares. As
a result, the market price of our Class A Ordinary Shares could be adversely affected. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders who hold
shares of Class B Ordinary Shares, including our executive officers and their affiliates, hold approximately 96% of the voting
power of our outstanding ordinary shares. Because of the ten-to-one voting ratio between our Class B and Class A Ordinary Shares,
the holders of our Class B Ordinary Shares will collectively continue to control a majority of the combined voting power of our
Ordinary Shares and therefore be able to control all matters submitted to our shareholders for approval, so long as the Class B
Ordinary Shares represent at least 9.1% of all outstanding shares of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Raising additional capital may cause
dilution to our shareholders, restrict our operations or require us to relinquish rights to our technology or drug and device candidates.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional
funding through a combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances
and marketing or distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely
affect your rights as a holder of our Class A Ordinary Shares. The incurrence of additional indebtedness or the issuance of certain
equity securities could result in increased fixed payment obligations, and could also result in certain additional restrictive
covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to
acquire or license IP rights and other operating restrictions that could adversely impact our ability to conduct our business.
In addition, issuance of additional equity securities, or the possibility of such issuance, may cause the market price of our Class
A Ordinary Shares to decline. In the event that we enter into collaborations or licensing arrangements to raise capital, we may
be required to accept unfavorable terms, including relinquishing or licensing to another party on unfavorable terms our rights
to technology or drug and device candidates that we otherwise would seek to develop or commercialize ourselves or potentially reserve
for future potential arrangements when we might be able to achieve more favorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Since we are a Cayman Islands exempted
company, the rights of our shareholders may be more limited than those of shareholders of a company organized in the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate affairs
are governed by our Second Amended and Restated Memorandum and Articles of Association (as may be amended from time to time) (&#8220;Memorandum
and Articles&#8221;), the Companies Law (2018 Revision) of the Cayman Islands (the &#8220;Companies Law&#8221;) and the common
law of the Cayman Islands. <FONT STYLE="background-color: white">The rights of shareholders to take action against the directors,
actions by minority shareholders and the fiduciary responsibilities of our directors are to a large extent governed by the common
law of the Cayman Islands. This common law is derived in part from comparatively limited judicial precedent in the Cayman Islands
as well as from English common law, which has persuasive, but not binding, authority on a court in the Cayman Islands. </FONT>Under
the laws of some jurisdictions in the United States, majority and controlling shareholders generally have certain fiduciary responsibilities
to the minority shareholders. Shareholder action must be taken in good faith, and actions by controlling shareholders which are
obviously unreasonable may be declared null and void. Cayman Islands law protecting the interests of minority shareholders may
not be as protective in all circumstances as the law protecting minority shareholders in some U.S. jurisdictions. In addition,
the circumstances in which a shareholder of a Cayman Islands company may sue the company derivatively, and the procedures and defenses
that may be available to the company, may result in the rights of shareholders of a Cayman Islands company being more limited than
those of shareholders of a company organized in the United States. Accordingly, shareholders may have fewer alternatives available
to them if they believe that corporate wrongdoing has occurred. The Cayman Islands courts are also unlikely to recognize or enforce
judgments from U.S. courts based on certain liability provisions of U.S. securities laws that are penal in nature. There is no
statutory recognition in the Cayman Islands of judgments obtained in the United States, although the courts of the Cayman Islands
will generally recognize and enforce non-penal judgment of a foreign court of competent jurisdiction for a liquidated sum without
retrial on its merits which is not obtained in a manner contrary to public policy in the Cayman Islands and in respect of which
there are no concurrent proceedings in the Cayman Islands. This means, even if shareholders were to sue us successfully, they may
not be able to recover anything to make up for the losses suffered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, our directors
have the power to take certain actions without shareholder approval which would require shareholder approval under the laws of
most U.S. jurisdictions. For example, the directors of a Cayman Islands company, without shareholder approval, may implement a
sale of any assets, property, part of the business, or securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While Cayman Islands
law allows a dissenting shareholder to express the shareholder&#8217;s view that a court sanctioned reorganization of a Cayman
Islands company would not provide fair value for the shareholder&#8217;s shares, Cayman Islands statutory law does not specifically
provide for shareholder appraisal rights on a merger or consolidation of a company. This may make it more difficult for you to
assess the value of any consideration you may receive in a merger or consolidation or to require that the acquirer gives you additional
consideration if you believe the consideration offered is insufficient. However, Cayman Islands&#8217; statutory law does provide
a mechanism for a dissenting shareholder in a merger or consolidation to apply to the Grand Court for a determination of the fair
value of the dissenter&#8217;s shares, if it is not possible for the Company and the dissenter to agree a fair price within the
time limits prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders of Cayman
Islands exempted companies, such as our Company, have no general rights under Cayman Islands&#8217; law to inspect corporate records
and accounts or to obtain copies of lists of shareholders. Our directors have discretion under our Memorandum and Articles to determine
whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make
them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts
necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lastly, under the law
of the Cayman Islands, there is little statutory law for the protection of minority shareholders. The principal protection under
statutory law is that shareholders may bring an action to enforce the constituent documents of the corporation, our Memorandum
and Articles. Shareholders are entitled to have the affairs of the company conducted in accordance with the general law and the
memorandum and articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are common law
rights for the protection of shareholders that may be invoked, largely dependent on English company law, since the common law of
the Cayman Islands for business companies is limited. Under the general rule pursuant to English company law known as the rule
in Foss v. Harbottle, a court will generally refuse to interfere with the management of a company at the insistence of a minority
of its shareholders who express dissatisfaction with the conduct of the company&#8217;s affairs by the majority or the board of
directors. However, every shareholder is entitled to have the affairs of the company conducted properly according to law and the
constituent documents of the company. As such, if those who control the company have persistently disregarded the requirements
of company law or the provisions of the company&#8217;s memorandum and articles of association, then the courts will grant relief.
Generally, the areas in which the courts will intervene are the following: (1) an act complained of which is outside the scope
of the authorized business or is illegal or not capable of ratification by the majority; (2) acts that constitute fraud on the
minority where the wrongdoers control the company; (3) acts that infringe on the personal rights of the shareholders, such as the
right to vote; and (4) where the company has not complied with provisions requiring approval of a special or extraordinary majority
of shareholders, which are more limited than the rights afforded minority shareholders under the laws of many states in the United
States subject to limited exceptions, under Cayman Islands Law a minority shareholder may not bring a derivative action against
directors. Our Cayman Islands&#8217; counsel has advised us that they are aware of one recent as yet unreported derivative action
having been brought in a Cayman Islands&#8217; court. Class actions are not recognized in the Cayman Islands, but groups of shareholders
with identical interests may bring representative proceedings, which are similar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, you may
be limited in your ability to protect your interests if you are harmed in a manner that would otherwise enable you to sue in a
United States federal court. In addition, shareholders of Cayman Islands companies may not have standing to initiate a shareholder
derivative action in U.S. federal courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of all
of the above, shareholders of our Company may have more difficulty in protecting their interests in the face of actions taken by
management, members of the board of directors or controlling shareholders than they would have as shareholders of a public U.S.
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>You may
face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be
limited because we are incorporated under Cayman Islands law, we currently conduct substantially all of our operations outside
the United States and some of our directors and executive officers reside outside the United States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are incorporated in the Cayman Islands and currently conduct substantially all of our operations outside the United States through
our subsidiaries. Some of our directors and executive officers reside outside the United States and a substantial portion of their
assets are located outside of the United States. As a result, it may be difficult or impossible for you to bring an action against
us or against these individuals in the Cayman Islands or in Hong Kong or the United Kingdom, in the event that you believe that
your rights have been infringed under the securities laws of the United States or otherwise. Even if you are successful in bringing
an action of this kind, the laws of the Cayman Islands, the United Kingdom and Hong Kong may render you unable to enforce a judgment
against our assets or the assets of our directors and officers. There is no statutory recognition in the Cayman Islands of judgments
obtained in the United States, the United Kingdom or Hong Kong, although the courts of the Cayman Islands will generally recognize
and enforce a non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits if such judgment is
final, for a liquidated sum, not in the nature of taxes, a fine or penalty, is not inconsistent with a Cayman Islands&#8217; judgment
in respect of the same matters, and was not obtained in a manner which is contrary to public policy. In addition, a Cayman Islands
court may stay proceedings if concurrent proceedings are being brought elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a foreign private issuer, we are
permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the
NASDAQ Global Market corporate governance listing standards. These practices may afford less protection to shareholders than they
would enjoy if we complied fully with corporate governance listing standards.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private
issuer, we are permitted to take advantage of certain provisions in the NASDAQ Global Market listing rules that allow us to follow
Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly
from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman Islands law has
no corporate governance regime which prescribes specific corporate governance standards. We may follow Cayman Islands corporate
governance practices in lieu of the corporate governance requirements of the Nasdaq Global Market in respect of the following.
For instance, Cayman law does not require that we obtain shareholder approval to issue 20% or more of our outstanding Ordinary
Shares in a private offering and we are not required to make our interim results available to shareholders, although as a NASDAQ
listed company we do publicly file interim results for the first six months of our fiscal year. Therefore, our shareholders may
be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic
issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an emerging growth company
within the meaning of the Securities Act and will take advantage of certain reduced reporting requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in the JOBS Act and take advantage of certain exemptions from various requirements applicable
to other public companies that are not emerging growth companies including, most significantly, not being required to comply with
the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act for so long as we are an emerging growth company.
As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to certain
information they may deem important.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The JOBS Act also provides
that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date
that a private company is otherwise required to comply with such new or revised accounting standards. The Company has elected to
use the extended transition period for complying with new or revised accounting standard under Section 102(b)(2) of the Jobs Act,
that allows the Company to delay the adoption of new or revised accounting standards that have different effective dates for public
and private companies until those standards apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will have broad discretion in how we use the proceeds,
and we may use the proceeds in ways in which you and other shareholders may disagree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will use its discretion to direct the use of
the net proceeds from this offering. We intend to use the net proceeds from this offering to fund research and development of our
lead product candidates, including clinical trial activities, as well as for working capital. Our management&rsquo;s judgments
may not result in positive returns on your investment and you will not have the opportunity to evaluate the economic, financial
or other information upon which our management bases its decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and
substantial dilution in the net tangible book value per share of the Class A Ordinary Shares you purchase.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the combined
public price per Class A Ordinary Share and related warrant being offered is substantially higher than the net tangible book value
per share of our Class A Ordinary Shares, you will suffer substantial dilution in the net tangible book value of the Class A Ordinary
Shares you purchase in this offering. With a combined public offering price of $3.25 per Class A Ordinary Share, if you purchase
Class A Ordinary Shares in this offering, you will suffer immediate and substantial dilution of approximately $2.52 per Class A
Ordinary Share and related warrant in the net tangible book value of the Class A Ordinary Shares and related warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Assuming the Participation
Maximum is sold at a combined public offering price of $3.25 per Class A Ordinary Share, if you purchase Class A Ordinary Shares
in this offering, you will suffer immediate and substantial dilution of approximately $2.35 per Class A Ordinary Share and related
warrant in the net tangible book value of the Class A Ordinary Shares and related warrants. (See &ldquo;Dilution&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>This is a best efforts offering,
no minimum number or dollar amount of securities is required to be sold, and we may not raise the amount of capital we believe
is required for our business plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent has agreed to use its reasonable best efforts
to solicit offers to purchase the securities in this offering. The Placement Agent has no obligation to buy any of the securities
from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required
minimum number of securities that must be sold as a condition to completion of this offering. We may sell fewer than all of the
securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering
will not receive a refund in the event that we do not sell an amount of securities sufficient to fund research and development
of our lead product candidates, including clinical trial activities. &nbsp;Thus, we may not raise the amount of capital we believe
is required for our operations in the short-term and may need to raise additional funds, which may not be available or available
on terms acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because there is no minimum required
for the offering to close, investors in this offering will not receive a refund in the event that we do not sell an amount of
securities sufficient to pursue the business goals outlined in this prospectus.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not specified
a minimum offering amount nor have or will we establish an escrow account in connection with this offering. Because there is&nbsp;no
escrow account and no minimum offering amount, investors could be in a position where they have invested in our company, but we
are unable to fulfill our objectives due to a lack of interest in this offering. Further, because there is&nbsp;no escrow account
in operation and no minimum investment amount, any proceeds from the sale of securities offered by us will be available for our
immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan.
Investor funds will not be returned under any circumstances whether during or after the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for
the warrants or pre-funded warrants.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no established
public trading market for the warrants or pre-funded warrants, and we do not expect a market to develop. In addition, we do not
intend to apply to list the warrants or pre-funded warrants on any national securities exchange or other nationally recognized
trading system, including the Nasdaq Capital Market. Without an active market, the liquidity of the warrants and pre-funded warrants
will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants and pre-funded warrants
in this offering are speculative in nature.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants and
pre-funded warrants in this offering do not confer any rights of Class A Ordinary Shares ownership on their holders, but rather
merely represent the right to acquire Class A Ordinary Shares at a fixed price. In addition, following this offering, the market
value of the warrants and pre-funded warrants, if any, is uncertain and there can be no assurance that the market value of the
warrants or pre-funded warrants will equal or exceed their imputed offering price. The warrants and pre-funded warrants will be
not listed or quoted for trading on any market or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Holders of the warrants and pre-funded
warrants will not have rights of holders of our Class A Ordinary Shares until such warrants or pre-funded warrants are exercised.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until holders of
warrants or pre-funded warrants acquire Class A Ordinary Shares upon exercise of the warrants or pre-funded warrants, holders
of warrants or pre-funded warrants will have no rights with respect to the Class A Ordinary Shares underlying such securities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, including the sections titled &ldquo;Prospectus
Summary,&rdquo; &ldquo;Risk Factors,&rdquo; and &ldquo;Our Business,&rdquo; as well as information we incorporated herein by reference,
contains forward-looking statements that are based on our management&rsquo;s belief and assumptions and on information currently
available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable,
these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different
from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Forward-looking statements in this prospectus and the documents incorporated herein by reference include, but are not limited to,
statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the initiation, timing, progress and results of our preclinical and clinical trials, and our research and development programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to advance our drug candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to identify and develop new drug and device candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our reliance on the success of our drug candidates currently undergoing preclinical development; in particular, our Lead Project candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the timing or likelihood of regulatory filings and approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the commercialization of our drug and device candidates, if approved;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to develop sales and marketing capabilities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the pricing and reimbursement of our drug candidates, if approved;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the implementation of our business model, strategic plans for our business and technology;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the scope of protection we are able to establish and maintain for IP rights covering our drug and device candidates and technology;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to operate our business without infringing the IP rights and proprietary technology of other parties;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">costs associated with defending IP infringement, product liability and other claims;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">regulatory development in the U.S., Europe and PRC and other jurisdictions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to maintain and establish collaborations or obtain additional grant funding; the rate and degree of market acceptance of our drug and device candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">developments relating to our competitors and industry, including competing therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to effectively manage our anticipated growth;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to attract and retain qualified employees and key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the future trading price of our Class A Ordinary Shares and impact of securities analysts&#8217; reports on these prices; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some cases, you
can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221;
&#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221;
&#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminologies. These statements
are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown
risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.
Factors that may cause actual results to differ materially from current expectations include, among other things, those listed
under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. If one or more of these risks or uncertainties occur, or if
our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected
by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this prospectus
and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement, of
which this prospectus is a part, completely and with the understanding that our actual future results may be materially different
from any future results expressed or implied by these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking
statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future,
we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these
forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains
market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and
limitations, and you are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity
and market size information included in this prospectus is generally reliable, such information is inherently imprecise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>TRADEMARKS, SERVICE MARKS AND TRADENAMES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains
trademarks, service marks and trade names of others, which are the property of their respective owners. Solely for convenience,
the trademarks, service marks, logos and trade names referred to in this prospectus are included without the &reg; and &#8482;
symbols. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their
respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks, copyrights or trade
names to imply a relationship with, or endorsement or sponsorship of us by, any other companies or unrelated parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Assuming all of the
Class A Ordinary Shares and related warrants and/or pre-funded warrants offered in this offering are sold, we estimate that
our net proceeds from this offering will be approximately $8.05 million based on a combined public offering price of $3.25
per Class A Ordinary Share and related warrant from current securities sold. We will receive additional proceeds of
approximately $9.0 million if the warrants are exercised in full for cash, if any. Additionally, if the Maximum Participation
is sold, we estimate that we will receive additional net proceeds of $8.0 million and approximately $9.0 million if the
warrants issued as part of the Participation Shares are exercised in full for cash. However, because there is no minimum
offering amount required as a condition to the closing of this offering and we do not know how many Participation Shares, if
any, will be sold, the actual offering amount, Placement Agent fees and proceeds to us are not presently determinable and may
be substantially less than the maximum amounts set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><B>&nbsp;</B></TD><TD STYLE="background-color: White"><B>&nbsp;</B></TD>
    <TD STYLE="background-color: White; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; background-color: White; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Use
                                         of net proceeds</FONT></TD><TD STYLE="background-color: White; text-align: left"><B>&nbsp;</B></TD><TD STYLE="background-color: White"><B>&nbsp;</B></TD>
    <TD STYLE="background-color: White; text-align: left"><B>&nbsp;</B></TD><TD STYLE="background-color: White; text-align: right"><B>&nbsp;</B></TD><TD STYLE="background-color: White; text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From Current Securities Sold</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From the Maximum Participation</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Continued clinical development of our programs in particular for SACT1 and ALS-4</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$5.6 million</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$11.2 million</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Further discovery and R&amp;D collaborations with our proprietary platforms and third party institutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$2.4 million</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$4.8 million</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date
of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds from this offering. The amounts
and timing of our actual expenditures may vary significantly from our expectations depending upon numerous factors, including
the progress of our research, development and commercialization efforts, the progress of our preclinical trials, and our operating
costs and capital expenditures. Drug discovery and development in the pharmaceutical industry is characterized by significant
risks and uncertainties inherent in the research, clinical development and regulatory approval process. These uncertainties make
it difficult for us to estimate the costs to conduct our research and development and complete our preclinical trials. Accordingly,
we will retain broad discretion in the allocation of the net proceeds of this Offering, and we reserve the right to change the
allocation of use of these proceeds as a result of contingencies such as the progress and results of our preclinical trials and
our research and development activities, the results of our commercialization efforts, competitive developments and our manufacturing
requirements. In addition, when and if the opportunity arises, we may use a portion of the proceeds to license, acquire or invest
in complementary businesses, products, or technologies. In order to license, acquire or invest in complementary businesses, products
or technologies, we may need to curtail our development of our other projects under development, or enter into agreements allowing
others to obtain rights for further development of one or more of our drug and device candidates earlier than anticipated. We
currently have no commitments or agreements to acquire any such businesses, products or technologies, and we cannot determine
with certainty which, if any, of the programs above might be affected should we enter into any such commitments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds from
this offering, together with our cash and marketable securities, may not be sufficient for us to fund any of our product candidates
through regulatory approval, and we may need to raise additional capital to complete the development of our product candidates.
We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate
collaborations or license agreements, grant funding, through interest income earned on cash balances or a combination of one or
more of these sources. This expected use of net proceeds from this offering represents our intentions based upon our current plans
and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and timing of
our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, the status
of and results from different preclinical and clinical trials, as well as any collaborations that we may enter into with third
parties for our programs, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation
of the net proceeds. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing
of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared
or paid cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future. We intend to
reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy will be
at the discretion of our Board of Directors and will depend on a number of factors, including future earnings, our financial condition,
operating results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand
our business, applicable law and other factors that our Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands
law, dividends may be declared and paid only out of funds legally available therefor, namely out of either profit or our share
premium account, and provided further that a dividend may not be paid if this would result in our Company being unable to pay its
debts as they fall due in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(See &#8220;Risk Factors
&#8211; We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may
be limited to the value of our shares&#8221; and &#8220;Description of Share Capital &#8211; Dividends&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets
forth our capitalization and indebtedness as of June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">on an actual basis; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma basis, to give effect to the issuance of 22,437,754 Class A Ordinary Shares issuable upon conversion of the Class B Ordinary Shares; and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">on a pro forma as adjusted basis, to give effect to the issuance
of 2,769,231 Class A Ordinary Shares in this Offering, each at a price to the public of $3.25, after deducting placement agent
commissions and estimated offering expenses, assuming that no warrants are exercised and that no pre-funded warrants or Participation
Shares are sold (See &ldquo;Description of Share Capital&rdquo;).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The table does not include any shares underlying the outstanding share options and warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This table should be read in conjunction with management&rsquo;s
discussion and analysis of financial condition and results of operations and our financial statements, consolidated financial statements
and related notes incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information
discussed in the table below is illustrative only and will be adjust based on the actual combined public offering price, the actual
number of Class A Ordinary Shares sold in this offering and other terms of this offering determined at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Pro Forma</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">As Adjusted</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Equity</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Class A Ordinary Shares</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,950,986</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">30,388,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">33,157,971</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Class B Ordinary Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,437,754</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,184,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,184,104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,394,876</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,618</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,618</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,618</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,760,545</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,760,545</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,760,545</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Non-controlling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,315,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,315,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,315,532</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,522,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,522,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,502,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total capitalization</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,522,385</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,522,385</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,502,388</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you purchase
Class A Ordinary Shares and related warrants in this offering, assuming no value is attributed to the Placement Agent&rsquo;s
Warrants and warrants, your interest will be diluted to the extent of the difference between the combined public price per
share you pay in this offering and the net tangible book value per share of our Class A Ordinary Shares immediately after
this offering. The net tangible book value of our Class A Ordinary Shares on June 30, 2020 was $16.3 million, or $0.54 per
share. Net tangible book value per share is equal to the amount of consolidated total assets, less intangible assets,
goodwill and consolidated total liabilities, divided by number of Ordinary Shares outstanding. Such calculation does not
reflect any dilution associated with the exercise of the share options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect
to the sale by us of an aggregate of 2,769,231 Class A Ordinary Shares and warrants to purchase up to 2,769,231 Class A Ordinary
Shares in this offering at a combined public offering price of $3.25 per share and related warrant, after deducting the placement
agent commissions and estimated offering expenses payable by us and assuming no exercise of the warrants, no value is attributed
to the warrant or Placement Agent&rsquo;s Warrants and no Pre-Funded Warrants and no Participation Shares are sold, our as adjusted
net tangible book value as of June 30, 2020 would have been $24.3 million, or $0.73 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This represents an
immediate increase in net tangible book value of $0.20 per share to existing shareholders and an immediate dilution of $2.52 per
share to new investors purchasing Class A Ordinary Shares and related warrants in this offering. The following table illustrates
this per share dilution assuming no value is attributed to the Placement Agent&rsquo;s Warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Combined public offering price per share and related warrant</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Increase in pro forma net tangible book value per share after giving effect to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.20</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">As adjusted net tangible book value per share as of June 30, 2020 after giving effect to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.73</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Dilution per share to investors participating in this offering</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.52</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table illustrates this per
share dilution assuming the Maximum Participation amount is purchased and no value is attributed to the Placement Agent&rsquo;s
Warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Combined public offering price per share and related warrant</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3.25</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net tangible book value per share as of June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Increase in pro forma net tangible book value per share after giving effect to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.36</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">As adjusted net tangible book value per share as of June 30, 2020 after giving effect to this offering and the Participation Maximum being sold</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.90</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Dilution per share to investors participating in this offering</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.35</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of Class
A Ordinary Shares reflected in the discussion and table above is based on 7,950,986 Class A Ordinary Shares and 22,437,754 Class
B Ordinary Shares issued and outstanding as of June 30, 2020 and excludes outstanding share options and warrants (See &#8220;Capitalization&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>SELECTED FINANCIAL DATA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary
consolidated balance sheets (successor basis) as of December 31, 2019 and 2018, consolidated statements of operations and comprehensive
loss (successor basis) for the year ended December 31, 2019, 2018 and the period March 1, 2017 through December 31, 2017, as well
as the statement of operations (predecessor basis) for the period January 1, 2017 through February 28, 2017, have been derived
from our audited financial statements included in our Annual Reports, which are incorporated herein by reference. The related consolidated
balance sheet as of June 30, 2020, consolidated statements of operations and comprehensive loss for the six months ended June 30,
2020 and 2019 have been derived from our unaudited financial statements that are incorporated herein by reference. The following
summary consolidated balance sheet (successor basis) as of December 31, 2017 has been derived from our audited consolidated financial
statements which is not included in this prospectus. You should read this data together with <FONT STYLE="background-color: white">&ldquo;Item
4. Information on the Company&rdquo; and &ldquo;Item 5. Operating and Financial Review and Prospects&rdquo; and the consolidated
financial statements, related notes and other financial information included in our Annual Reports, and </FONT>&ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; included in our Report on Form 6-K furnished with
the Commission on September 2, 2020, <FONT STYLE="background-color: white">which are incorporated herein by reference </FONT>and
the information under the captions &ldquo;Capitalization.&rdquo; Our historical results are not necessarily indicative of our future
results. Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in
the United States, or U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not view
our historical results as an indicator of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
presents our summary consolidated statements of operations and comprehensive loss (successor basis) for the six months ended June
30, 2020 and 2019, the year ended December 31, 2019 and 2018, and the period March 1, 2017 through December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Selected Consolidated Statements of Operations
and Comprehensive Loss (Successor Basis)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In U.S. Dollars, except number of shares)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months<BR> ended<BR> June 30,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six months ended <BR> June 30,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December 31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 1,<BR> 2017<BR> through <BR> December 31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-indent: -0.125in">Revenue</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; width: 40%; text-align: left; padding-left: 0.125in">Healthcare services income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">327,273</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">239,792</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">535,166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">383,450</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Cost of healthcare services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(436,171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(371,218</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(794,545</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(318,011</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,315,033</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,714,217</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,939,051</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,101,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,560,323</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">General and administrative fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,076,634</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,232,916</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,373,425</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,919,626</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,480,093</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Legal and professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,540,304</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,008,774</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,405,705</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,811,770</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,395,490</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Other operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(641,457</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(120,788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(220,891</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(560,709</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(257,177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,009,599</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,447,913</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,733,617</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,711,548</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,693,083</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Other income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Gain (loss) on investments in marketable securities, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81,839</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">501,522</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,912,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Gain on non-marketable investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,635,939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">(Loss) gain on investments in derivatives, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(101,233</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">310,195</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(974,444</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(827,501</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Gain on use of digital currencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,717</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Changes in fair value of warrant liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(866,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(866,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Gain on extinguishment of convertible debts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,198,490</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,198,490</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Interest (expense) income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(144,226</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,678,566</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,699,672</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,458,191</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,269</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Sundry income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">111,398</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">128,444</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">249,328</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Total other income (loss), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,694,012</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,432,227</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,918,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,806,387</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,131,576</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,988,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,640,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,116,938</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15,134,485</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,561,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Less: net loss attributable to non-controlling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(783,749</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(551,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,430,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(302,762</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(14,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Net loss attributable to Aptorum Group Limited</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,204,565</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(9,088,471</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,686,762</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(14,831,723</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,547,462</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Net loss per share &ndash; basic and diluted*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.21</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.31</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.64</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.53</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.09</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Weighted-average shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">29,956,393</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,978,151</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">29,008,445</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">27,909,788</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26,963,435</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,988,314</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(9,640,348</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(20,116,938</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(15,134,485</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,561,507</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in">Other comprehensive income (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Unrealized loss on investments in available-for-sale securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,122,251</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(367,782</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Exchange differences on translation of foreign operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,170</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,345</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Other comprehensive income (loss)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,170</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,116,906</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(367,782</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Comprehensive loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,957,144</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,638,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,127,835</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,251,391</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,929,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Less: comprehensive loss attributable to non-controlling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(783,751</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(551,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,430,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(302,762</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(14,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Comprehensive loss attributable to the shareholders of Aptorum Group Limited</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6,173,393</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(9,086,471</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,697,659</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(15,948,629</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,915,244</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 97%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">The shares and per share data are presented at a weighted average basis to reflect the nominal share issuance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
presents our summary statements of operations (predecessor basis) for the period January 1, 2017 through February 28, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">Selected Statement of
Operations (Predecessor Basis)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In U.S. Dollars)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">January 1,<BR> 2017<BR> through<BR> February 28,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Investment income:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; border-bottom: Black 1.5pt solid">$3,011</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25pt">Total investment income</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">3,011</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25pt">Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">General and administrative fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,516</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Management fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Legal and professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,646</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25pt">Other operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,907</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25pt">Total expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">227,027</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.25pt">Net investment loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(224,016</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Realized and unrealized losses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Net realized losses on investments in unaffiliated issuers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(15,327</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25pt">Net change in unrealized depreciation on investments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(386,741</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25pt">Net realized and unrealized losses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(402,068</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0.25pt">Net decrease in net assets resulting from operations</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(626,084</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
presents our summary consolidated balance sheets (successor basis) as of June 30, 2020, December 31, 2019, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of<BR> June 30,<BR> 2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of<BR> December 31,<BR> 2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of <BR> December 31,<BR> 2018</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">As of <BR> December 31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0.25pt">Cash, restricted cash and marketable securities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,426,543</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,356,284</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">27,121,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">18,698,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,128,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,032,881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,722,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,283,399</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,309,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,954,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,074,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,559,982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,080,408</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,674,675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,184,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,330,734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,786,690</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,102,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,328,738</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,330,734</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total equity attributable to the shareholders of Aptorum Group Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,837,917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,361,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,114,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,243,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Non-controlling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,315,532</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,509,456</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(368,533</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,045</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,522,385</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,851,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,745,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,229,248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25pt">Total liabilities and equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,309,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,954,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45,074,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">31,559,982</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><I>For purposes of this section, reference to the &#8220;Group&#8221;
means Aptorum Group Limited and all of its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Foreign Exchange Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currency risk is the
risk that the value of financial assets or liabilities will fluctuate due to changes in foreign exchange rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Currency risk sensitivity analysis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At June 30, 2020, December
31, 2019, 2018 and 2017, the Group has no significant foreign currency risk because most of the transactions are denominated in
the United States dollars and Hong Kong dollar. Since the Hong Kong dollar is pegged to the United States dollar, the Group&#8217;s
exposure to foreign currency risk in respect of the balances denominated in Hong Kong dollars is considered to be minimal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial assets which
potentially subject the Group to concentrations of credit risk consist principally of bank deposits and balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group takes on
exposure to credit risk on cash and restricted cash balances held with HSBC, DBS Bank Ltd, Hong Kong Branch, Industrial and Commercial
Bank of China (Macao) Limited, Bank of China (Hong Kong) Limited, and Silicon Valley Bank for the purposes of payments of Group
expenses.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All transactions in
listed securities are settled or paid for upon delivery using approved and reputable brokers. The risk of default is considered
minimal, as delivery of securities sold is only made when the broker has received payment. Payment is made on a purchase when the
securities have been received by the broker. The trade will fail if either party fails to meet its obligation. The Group limits
its exposure to credit risk by transacting all of its securities and contractual commitment activities with broker-dealers, banks
and regulated exchanges with high credit ratings and that the Group considers to be well established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidity Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Liquidity risk is the
risk that the Group will encounter difficulty in raising funds to meet commitments associated with financial assets and liabilities.
Liquidity risk may result from an inability to sell a financial asset quickly at an amount close to its fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group invests in
private equities which are generally unquoted and not readily marketable. The Group manages its liquidity risk by setting investment
limits on unlisted securities that cannot be readily disposed of. Investment of the Group&#8217;s assets in unquoted securities
may restrict the ability of the Group to dispose of its investment at a price and time it wishes to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Interest Rate Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest rate risk
arises from the possibility that changes in interest rates will affect future cash flows or the fair values of financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Interest rate risk sensitivity analysis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Group&#8217;s cash
held with the Cash Custodian and the Custodian are exposed to interest rate risk. However, Management considers the risk to be
minimal as they are short-term with terms less than one month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Inflation Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In recent years, inflation
has not had a material impact on our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30pt"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Overview </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a pharmaceutical
company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical
needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched
through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic
screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
above main focus, we are also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders,
women&#8217;s health and other disease areas. We also have projects focused on surgical robotics and natural supplement for women
undergoing menopause and experiencing related symptoms. Also, we opened a medical clinic, AML Clinic, in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although none of our
drug or device candidates has yet been approved for testing in humans, our goal is to develop a broad range of novel therapeutics
and diagnostics across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include:
(for details of our strategy, See &#8220;Our Strategy&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Selectively expanding our portfolio with potential products from our drug discovery platforms that may be able to attain orphan drug designation and/or satisfy current unmet medical needs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Collaborating with leading academic institutions and CROs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Expanding our pharmaceutical development capabilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Leveraging our management&#8217;s expertise, experience and commercial networks;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Obtaining and leveraging government grants to fund project development.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have devoted a portion
of the proceeds from our IPO, to two therapeutic projects (&#8220;Lead Projects&#8221;). The drug candidates being advanced as
the Lead Projects are ALS-4 and SACT-1, described in further detail below. If the results of the remaining preclinical studies
of these drug candidates are positive, we expect to be able to submit by second half of 2020, subject to regulatory review, an
Investigational New Drug Application (&#8220;IND&#8221;) for at least one of these candidates to the U.S. Food and Drug Administration
(&#8220;FDA&#8221;) or an equivalent application to the regulatory authorities in one or more other jurisdictions such as the China&#8217;s
National Medical Products Administration (&#8220;NMPA&#8221;) and/or the European Medicines Agency (&#8220;EMA&#8221;). Acceptance
of these applications by the relevant regulatory authority would enable the Company to begin testing that drug candidate in humans
in that jurisdiction. Our ability to obtain any approval of such applications is entirely dependent upon the results of our preclinical
studies, none of which have yet been completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current business
consists of &#8220;therapeutics&#8221; and &#8220;non-therapeutics&#8221; segments. However, our focus is on the therapeutics segments.
Because of the risks, costs and extended development time required for successful drug development, we have determined to pursue
projects within our non-therapeutics segments, such as AML Clinic, to provide some interim revenue, as well as medical robots and
natural supplements that may be brought to market and generate revenue more quickly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Therapeutics
Segment</U></I>. In our therapeutics segment (&#8220;Aptorum Therapeutics Group&#8221;), we are currently seeking to develop various
drug molecules and certain technologies for the treatment (&#8220;therapeutics&#8221;) and diagnosis (&#8220;diagnostics&#8221;)
of human disease conditions to tackle unmet needs, in particular, our Lead Projects targeting infectious disease and cancer (including
orphan oncology indications). In addition to our main areas of focus above, we are also pursuing therapeutic projects in neurology,
gastroenterology, metabolic disorders, women&#8217;s health and other disease areas, as well as the development of natural supplements
for women undergoing menopause and experiencing related symptoms. Aptorum Therapeutics Group is operated through Aptorum&#8217;s
wholly-owned subsidiary, Aptorum Therapeutics Limited, a Cayman Islands exempted company with limited liability, whose principal
place of business is in Hong Kong whose subsidiaries (who we sometimes refer to herein as project companies) are based in the United
Kingdom, Singapore and Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I><U>Non-Therapeutics
Segment</U></I>. The non-therapeutics segment (&#8220;Aptorum Non-Therapeutics Group&#8221;) encompasses three businesses: (i)
the development of surgical robotics and medical devices, (ii) AML Clinic and (iii) sales of natural supplements. The development
of surgical robotics and medical devices business is operated through Signate Life Sciences Limited, a subsidiary of Aptorum Therapeutics
Limited. The outpatient clinic is operated through our subsidiary, Aptorum Medical Limited. Effective as of March 2018, we leased
office space in Central, Hong Kong as the home to AML Clinic. AML Clinic commenced operations under the name of Talem Medical in
June 2018. The clinic is currently generating revenue. The sale of natural supplements is operated through Nativus Life Sciences
Limited (&#8220;Nativus&#8221;), a subsidiary of Aptorum Therapeutics Limited. As part of the commercialization, the Group, through
Nativus, entered into a regional distribution and marketing agreement with Multipak Limited, a Hong Kong based group that operates
household brands, including the Luk Yu&reg; tea bag and other health related products. Through Multipak, the Group will be able
to increase the accessibility of the product to a large consumer base regionally. The production of Aptorum Group&#8217;s dioscorea
opposita bioactive nutraceutical tablets has commenced production in Canada and will be marketed under the brand name NativusWell<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to March 2017,
the Company had pursued passive healthcare related investments in early stage companies primarily in the United States. However,
we have since ceased pursuing further passive investment operations and intend to exit all such portfolio investments over an appropriate
timeframe to focus resources on our current business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24, 2019,
the Company signed an agreement with AENEAS CAPITAL LIMITED, and A*ccelerate Technologies Pte. Ltd, the enterprise office of the
Agency for Science, Technology and Research (&ldquo;A*STAR&rdquo;), (collectively, the &ldquo;Parties&rdquo;) to co-create local
deep tech startups. This agreement, which is part of A*ccelerate&rsquo;s venture co-creation (&ldquo;VCC&rdquo;) initiative, commits
all parties to the co-creation of local startups in the healthcare and life science sector (the &ldquo;Master Collaboration Agreement&rdquo;).
Through this agreement, we partnered with A*Star to explore suitable opportunities, if identified, to set up tech ventures in
Singapore over the next 5 years. A*STAR shall contribute a total of up to $30,000,000 to any suitable startups, at their discretion.
The Company and AENEAS CAPITAL LIMITED will contribute a total of up to $30,000,000 to any suitable startups at their discretion
with a focus on (i) securing pilot customers; (ii) incorporation of the startups as companies and financial commitments of such
customers; (iii) capital raising and capital market plans; (iv) recruiting and building of the startup teams; (v) equipment and
infrastructure; and (vi) licensing of IP to the startups under the Technology License Agreements. The Master Collaboration Agreement
shall continue for a period of 5 years, unless otherwise terminated or extended by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Strategy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we plan to
continue the development and improvement of a broad range of novel therapeutics and diagnostics across a wide range of disease/therapeutic
areas, over the next 24-36 months we plan to concentrate on development of our Lead Projects, while also allocating some resources
to develop SLS-1, maintaining our AML Clinic and sale of natural supplements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that execution
of this strategy will position the Company to catalyze the development and improvement of a broad range of early-staged novel therapeutics
and diagnostics across a wide range of disease/therapeutic areas. Failure to achieve positive results in at least one of the programs
for a Lead Project could have a material adverse effect on the Company&#8217;s prospects and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To achieve this goal,
we are implementing the following strategies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas. </B>We are currently developing drug and device candidates in several disease/therapeutic areas. We believe that by diversifying our research efforts, it would increase the likelihood that at least one of our projects will achieve clinical success and therefore add value to the Company. As of the date of this prospectus, the Company is developing 17 projects covering therapeutic assets, diagnostic assets, natural supplements and medical device projects, in broad range of areas across infectious diseases, cancers (including rare oncology indications), neurology, gastroenterology, metabolic disorders and women&#8217;s health. The 17 projects are comprised of 9 exclusively licensed projects (including Lead Project ALS-4 being exclusively licensed from the University of Hong Kong) and 8 proprietary projects developed by our scientists (including Lead Project SACT-1). Our initial focus will be on developing our Lead Projects, but intend to continue developing our other current projects and may seek new licensing opportunities where we determine that the market potential justifies the additional commitment of our limited resources.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Selectively expanding our portfolio with potential products from our drug discovery platforms that may be able to attain orphan drug designation and/or satisfy current unmet medical needs. </B>We have selected innovations for development which we believe are of superior scientific quality, whilst taking into account the potential market size and demand for same, for example, taking into consideration whether the relevant product can satisfy significant unmet medical needs, particularly from our drug development platforms. In particular, Aptorum Therapeutics Limited has established a Scientific Assessment Committee, which helped us to select our current projects and which we expect will provide input from a scientific perspective towards any future opportunities for acquiring or licensing life science innovations. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Collaborating with leading academic institutions and CROs. </B>In building and developing our product portfolio, we believe that accessing external innovation, expertise and technology through collaboration with leading academic institutions and CROs is a vital and cost-efficient strategy. We have established strong relationships with leading academic institutions around the world and expect to continue to strengthen our collaborations by, for example, seeking to provide their affiliated Principal Investigators resources through sponsorship to conduct further research in specialty fields of interest and association with personnel connected to our current project companies, in exchange for obtaining for the Company the first right to negotiate for an exclusive license to any resulting innovations. In addition, we have entered and will continue to actively source arrangements with pharmaceutical companies, in most cases in roles as CROs, to streamline the development of our projects. This may include outsourcing part of the preclinical, clinical studies and clinical supplies manufacturing to externally accredited cGLP, cGMP and cGCP standard CROs or laboratories in order to attain the required studies for submission to the regulatory authorities as part of the clinical development plan. (See &#8220;Arrangements with Other Parties&#8221;)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Expanding our pharmaceutical development capabilities. </B>We believe collaborations between the R&amp;D Center and the scientists engaged in work for our project companies will enhance clinical and commercial potential of the projects. In addition, we will assist the project companies by engaging external pharmaceutical companies and/or CROs to outsource any part of the preclinical or clinical development work that cannot be performed by the R&amp;D Center in order to obtain the resources necessary for our development process.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 7%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; width: 3%"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify; width: 90%"><FONT STYLE="font-size: 10pt"><B>Leveraging our management&#8217;s expertise, experience and commercial networks. </B>We believe the combination of our management&#8217;s expertise and experience, with their academic and commercial networks make us an effective platform for advancing healthcare innovations towards clinical studies and commercialization in key global markets. We have assembled a management team with global experience and an extensive record of accomplishments in medical research, consulting and financing, and identification and acquisition of pharmaceutical and biopharmaceutical drug and device candidates. Our Head of Research and Development also has extensive experiences in drug development. We also employ key management personnel with banking and financial experience, which enhances our capability to establish the most efficient financial structure for the development of our programs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Obtaining and leveraging government grants to fund project development. </B>Governments across the world pay close attention to the development of the biotechnology sector and provide support and funding. We intend to aggressively seek government support from the governments in the United States, the United Kingdom, Hong Kong, Singapore and elsewhere for our product development and to facilitate the development of some of our projects.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Arrangements with Other Parties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As mentioned above,
part of our business model includes collaborating with research entities such as academic institutions and CROs, as well as highly
regarded experts in their respective fields. We engage these entities and researchers either for purposes of exploring new innovations
or advancing preclinical studies of our existing licensed drug candidates. Although the financial cost of these arrangements does
not represent a material expense to the Company, the relationships we can access through, specifically, sponsored research arrangements
(&#8220;SRAs&#8221;) with academic institutions and organizations can provide significant value for our business; for example,
we may decide whether to continue development of certain early-staged projects and/or out-license a project based on the data and
results from research governed by SRAs. However, as of the date hereof, we do not consider the particulars of any of our SRAs to
be material to the success of our current business plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug discovery
programs are based upon licenses from universities and are mainly conducted in universities via SRAs. As for the development of
our drug candidates, our R&amp;D Center conducts part of the CMC work. However, since our current facilities are not cGMP, cGLP
or cGCP qualified, we will have to rely on CROs to conduct that type of work, if and when our drug candidates reach the level of
development that requires such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Lead Projects, Natural Supplement
and Other Projects under Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are actively operating
and managing the development of our drug and device candidates through various subsidiaries. Each candidate is being researched
in a subsidiary with a medical/scientific area of focus related to the drug and device candidate in development. We refer to these
as our &#8220;Project Companies&#8221; and their products or areas of focus as either our Lead Projects (i.e., ALS-4 and SACT-1),
our natural supplement (i.e., NativusWell<SUP>&reg;</SUP>) or Other Projects under Development (as defined below). The selection
of a drug and device candidate is based on our estimate of the market potential for that candidate, the scientific expertise required
to develop it, and our overall corporate strategy, including our ability to commit personnel and future investment to that candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To pursue a number
of our current projects, our Project Companies have entered into standard license agreements with various university and licensing
entities customized to the nature of each project. These license agreements largely contain the same terms, as is typically seen
in license agreements for an early-stage life science invention; such terms include a worldwide license with licensed field comprising
indications in the intended treatment areas, having upfront payments, certain royalty rates, sublicensing royalties, as well as
provisions for payments upon occurrence of development and/or regulatory milestones. Under the license agreements, the Project
Company must also adhere to certain diligence obligations and may or may not be required to obtain prior consent from the licensor
to sublicense the invention. The license terms of our Lead Projects are discussed in detail below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally speaking,
pharmaceutical development consists of preclinical and clinical phases. Our immediate efforts would be on the preclinical phase
which can further sub-divided into the following stages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify"><U>Target Identification &amp; Selection</U>:
The target is the naturally existing cellular or modular structure that appears to have an important role in a particular disease
pathway and will be targeted by the drug that will subsequently be developed. Target validation techniques for different disease
areas can be very different but typically include from in vitro and in silico methods through to the use of whole animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>Lead Discovery</U>: Following &#8220;Target
Identification &amp; Selection,&#8221; compound screening assays are developed as part of the Lead Discovery. &#8216;Lead&#8217;
molecules can mean slightly different things to different researches or companies, but in this prospectus, we refer to Lead Discovery
as the process of identifying one or more small molecules with the desired activity against the identified targets. Leads can be
identified through one or more approaches, which can depend on the target and what, if any, previous knowledge exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>Lead Optimization</U>: In this stage
of the drug discovery process, the aim is to produce a preclinical drug candidate by maintaining the desired and favorable properties
in the lead compounds, while repairing or reducing deficiencies in their structures. For example, to optimize the chemical structures
to improve, among others, efficacy, reduce toxicity, improve metabolism, absorption and pharmacokinetic properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>CTA-Enabling
Studies</U>: Includes all the essential studies such as GLP toxicology studies, pharmacology and efficacy, pharmacokinetics, in
vitro metabolism, CMC studies, and the data of which are used for CTA submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>IND-Enabling Studies</U>: Includes all
the essential studies such as GLP toxicology studies, pharmacology and efficacy, pharmacokinetics, in vitro metabolism, CMC studies,
and the data of which are used for IND submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>In vitro validation</U>: At this stage,
the efficacy and safety of a drug candidate are assessed at cellular levels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>In vivo validation</U>: At this stage,
the efficacy, safety and pharmacokinetic of a drug candidate are assessed in animal models.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><U>IND Preparation and Submission</U>:
Preparation of a package of documents for different sections such as CMC, clinical, nonclinical, etc. and getting them reviewed,
approved and final checked and followed by submission to regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_011.jpg" ALT="" STYLE="width: 650px; height: 557px">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Another subsidiary,
Aptorum Medical Limited (&#8220;AML&#8221;),<SUP>1</SUP>&nbsp;is our vehicle for developing our business of delivering medical
services in the form of AML Clinic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0; margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: left; width: 0.25in"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Clark Cheng, our Chief Medical Officer and an Executive
Director, owns 7% of Aptorum Medical Limited as of the date of this prospectus.</TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">We
anticipate allocating approximately 20% of our resources to develop projects other than our Lead Projects (such other projects
being referred to herein as &#8220;Other Projects under Development&#8221;), with a strong focus on NativusWell<SUP>&reg;</SUP>,
SLS-1 and AML Clinic. As part of the commercialization of NativusWell<SUP>&reg;</SUP> natural supplement NativusWell<SUP>&reg;</SUP>,
we entered into a regional distribution and marketing agreement with Multipak Limited, a Hong Kong based group that operates household
brands, including the Luk Yu&reg; tea bag and other health related products. Through Multipak, the Group will be able to increase
the accessibility of the product to a large consumer base regionally. The production of Aptorum Group&#8217;s dioscorea opposita
bioactive nutraceutical tablets has commenced production in Canada and will be marketed under the brand name NativusWell</FONT><SUP>&reg;</SUP><FONT STYLE="font-size: 10pt">.
As a device candidate, SLS-1 may not need to undergo the same regulatory approval process as a drug candidate and therefore we
may be able to bring it to market sooner. AML Clinic is expected to provide us with a modest amount of revenue. Even if NativusWell<SUP>&reg;</SUP>
and SLS-1 achieves commercial sales, of which there can be no assurance, revenue from these products alone will not be sufficient
for us to carry out all of our plans, but it will assist with name recognition and supplement our income while we develop our Lead
Projects.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Lead Projects </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_012.jpg" ALT="" STYLE="width: 800px; height: 177px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After consideration
of various factors, such as time and resources required for further development, potential success rate and market size, the Group
decided to focus the majority of its resources on ALS-4 and SACT-1 as the current Lead Projects. The Group will continue to invest
some of its resources to develop other projects, including those previously classified as Lead Projects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ALS-4: Small molecule for the treatment
of bacterial infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bacteria such as&nbsp;<I>Staphylococcus
aureus</I>,&nbsp;<I>Mycobacterium tuberculosis</I>&nbsp;and&nbsp;<I>Pseudomonas aeruginosa&nbsp;</I>have become &#8220;superbugs&#8221;,
having developed resistance to many, if not all, of the existing drugs available to treat them, rendering those treatments ineffective
in many instances. MRSA is one such bacterium, a gram-positive bacterium that is genetically different from other strains of Staphylococcus
aureus. Staphylococcus aureus and MRSA can cause a variety of problems ranging from skin infections and sepsis to pneumonia and
bloodstream infections. It is estimated that about one out of every three people (33%) carry Staphylococcus aureus in their nose,
usually without any illness; about two in a hundred (2%) carry MRSA (source: https://www.cdc.gov/mrsa/tracking/index.html). Both
adults and children may carry MRSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most MRSA infections
occur in people who have been in hospital or other health care settings, such as nursing homes and dialysis centers (source: https://www.mayoclinic.org/diseases-conditions/mrsa/symptoms-causes/syc-20375336),
which is known as Healthcare-Associated MRSA (&#8220;HA-MRSA&#8221;). HA-MRSA infections are typically associated with invasive
procedures or devices, such as surgeries, intravenous tubing or artificial joints. Another type of MRSA infection, known as Community-Associated
MRSA (&#8220;CA-MRSA&#8221;), has occurred in wider community among healthy people. It often begins as a painful skin boil and
spreads by skin-to-skin contact. About 85% of serious, invasive MRSA infections are healthcare associated infections (https://www.cdc.gov/media/pressrel/2007/r071016.htm).
The incidence of CA-MRSA varies according to population and geographic location. In the U.S., more than 94,000 people develop serious
MRSA infection and about 19,000 patients die as a result each year (https://www.cdc.gov/media/pressrel/2007/r071016.htm). According
to the US Centers for Disease Control and Prevention (&#8220;CDC&#8221;), Staphylococcus aureus, including MRSA, caused about 11%
of healthcare-associated infections in 2011 (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml). Each year
in the U.S., around one out of every twenty-five hospitalized patients contracts at least one infection in the hospital (N Engl
J Med. 2014, 27;370(13):1198-208). In the U.S., there were over 80,000 invasive MRSA infections and 11,285 related deaths in 2011
(source: https://edition.cnn.com/2013/06/28/us/mrsa-fast-facts/index.html). Indeed, severe MRSA infections most commonly occur
during or soon after inpatient medical care. More than 290,000 hospitalized patients are infected with Staphylococcus aureus and
of these staphylococcal infections, approximately 126,000 are related to MRSA (source: http://www.healthcommunities.com/mrsa-infection/incidence.shtml).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-4 is a small drug
molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival
of the bacterium in the body or that cause damage to the body&#8217;s systems. These products of bacterial genes are referred to
as &#8220;virulence expression.&#8221; Targeting bacterial virulence is an alternative approach to antimicrobial therapy that offers
promising opportunities to overcome the emergence and increasing prevalence of antibiotic-resistant bacteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Richard Kao
from The University of Hong Kong (who is also the Founder and Principal Investigator of Acticule and Inventor of ALS-2, ALS-3 and
ALS-4) initiated a high throughput approach for screening compounds which are active against virulence expression, which resulted
in the discovery of ALS-2, ALS-3 and ALS-4.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-4 targets an enzyme
essential for Staphylococcus aureus (including MRSA) survival in vivo. This enzyme is involved in the production of Staphyloxanthin,
a carotenoid pigment produced by Staphylococcus aureus including MRSA, and is responsible for the characteristic golden color.
This pigment has proven to be an important factor in promoting bacterial invasion as well as rendering the bacteria resistant to
attack from reactive oxygen species (ROS) and neutrophils. In other words, pigmented bacteria have increased resistance to the
host&#8217;s immune defenses. ALS-4 may have particular value if it can be shown to be an effective therapy in situations where
a Staphylococcus aureus infection is resistant to available antibiotics (i.e., where the pathogen is MRSA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a recent study by
the inventor, Prof. Richard Kao, ALS-4 demonstrates potent activity against Staphylococcus aureus pigment formation in vitro, as
indicated in Figure 1, with an IC<SUB>50</SUB>&nbsp;(IC<SUB>50</SUB>&nbsp;is defined as the concentration of a drug which inhibits
half of the maximal response of a biochemical process. In this case, inhibition of the formation of the golden pigment is the response)
equal to 20 nM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Figure 1&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1734005|000121390020010347|image_004.jpg" STYLE="height: 599px; width: 527px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Figure 1: In vitro pigment inhibition
by compound ALS-4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(A) Inhibition of wild-type (WT)
Staphylococcus aureus pigmentation in the presence of increasing concentrations of ALS-4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(B) Pigment inhibition by ALS-4;
the IC<SUB>50</SUB>&nbsp;for pigment formation is roughly 300 nM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All data represent mean values
&plusmn; SD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">NP16 = ALS-4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This assay was conducted in triplicate
and repeated twice for confirmation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(Adapted from mBio (8(5): e01224,
2017))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By employing a systemic
Staphylococcus aureus rat infection model, the treatment (10mg/kg of ALS-4 twice daily) and control groups (vehicle) were compared.
In the lethal dose model, all the animals died by day 4 in the control group. On the contrary, the ALS-4 treated group showed &gt;50%
survival until the end of the study (Day 7), which is determined to be statistically significant compared with the control (p =
0.0102 by a Log-rank (Mantel-Cox) test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(Mantel-Cox) test</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the delayed treatment
model, ALS-4 brought a statistically significant reduction in bacterial count (99.5%) compared with the control (p = 0.0126 by
an unpaired student&#8217;s t-test).&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 278px; width: 525px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_005.jpg" ALT="" STYLE="height: 341px; width: 199px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 2: ALS-4 is observed to
reduce bacterial load in mice&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">CFU = Colony Forming Unit, a
unit used to estimate the number of viable bacteria in a sample</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">ALS-4 is currently undergoing
CTA enabling stage to prepare for regulatory submission in Canada for a Phase 1 clinical trial. The development of ALS-4 candidate
has been progressing well and the first series of GLP toxicology studies have been completed through an appointed contract research
organization (CRO) based in Canada. In particular, ALS-4 candidate did not show any mutagenicity in the in vitro Ames tests. ALS-4
development is on our proposed track and we target the related regulatory submission for a Phase 1 clinical trial in the second
half year of 2020 in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Patent License</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2017,
the Company&#8217;s subsidiary, Acticule, entered into an exclusive license agreement with Versitech Limited, the licensing entity
of HKU, for ALS-4. Subsequently on June 7, 2018, the parties entered into a first amendment to the exclusive license agreement,&nbsp;and
on July 10, 2019, the parties entered into a second amendment to the license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 11, 2019,
Acticule and Versitech Limited entered into a second license agreement for ALS-4, where Acticule exclusively licensed the intellectual
property rights on certain HKU-owned improvements to the original licensed invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the exclusive
license agreements, we were granted an exclusive, royalty-bearing, sublicensable licenses to develop, make, have made, use, sell,
offer for sale and import products that are covered by the licensed patents (as described below). The territory of the licenses
is worldwide and the field of the licenses is for treatment or prevention of bacterial infections caused by Staphylococcus aureus
including MRSA and bacterial virulence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We paid an upfront
fee upon entering into the license agreements. We are required to pay less than 10% of the net sales of the licensed products sold
by us or our affiliates as royalties, as well as a low teens percentage of sublicense royalties that we receive from our sublicensees,
if any. In addition, we agreed to pay to the licensor aggregate regulatory milestones of up to US$1 million subject to the following
achievements: submission of investigational new drug application; completion of phase 1, 2 and 3 clinical trials; and submission
of new drug application; grant of regulatory approval. We also agreed to pay to the licensor aggregate sales milestones of up to
US$7.8 million subject to the following achievement: first commercial sale; and annual net sales exceeding US$100 million in one
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the license
agreements, Acticule became the exclusive licensee of 2 pending U.S. non-provisional patent applications and 2 PCT applications
(now expired). Prior to the expiration of the PCT applications, we filed national phase applications in member states of the EPO,
in PRC and 11 other jurisdictions. The claimed inventions are described as: &#8220;Compounds Affecting Pigment Production and Methods
for Treatment of Bacterial Diseases.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acticule has the right
to grant sublicenses to third parties under the license agreements without prior approval from Versitech Limited and to assign
the agreements to any successor to the business related to the licenses. In the event that Acticule makes an improvement to the
licensed technologies, so long as the improvement does not incorporate any licensed patents, Acticule will be the owner to such
improvement, subject to a non-exclusive royalty-free license being granted back to Versitech Limited for academic and research
purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exclusive license
agreements shall be in effect until the expiration of all licensed patents. Acticule may terminate the licenses at any time with
6-month written notice in advance. Either party may terminate the agreements upon a material breach by other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SACT-1: A Repurposed Drug for the Treatment of Neuroblastoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug repurposing is
a strategy for identifying new indications for approved or investigational drugs that are outside the scope of the original medical
uses. It is often viewed as a lower-cost method for drug commercialization, as it is based on already-approved drugs (which has
been proven to be safe for human use by the respective governing regulatory agency) and explores new target indications. (Ashburn,
T. T. &amp; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673&#8211;683,
2004).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the advantages
of drug repurposing is a lower development risk due to safety and toxicity, as well as other properties related to water solubility,
absorption, distribution and metabolism, as the safety and CMC profiles of marketed drugs are usually well-established. Due to
the same reason, the development time is also shortened because there is no need to repeat the whole spectrum of the safety assessment.
As a result, the drug repurposing approach appears to be attractive due to its superior risk management, smaller capital investment
and quicker financial return. (Sudeep Pushpakom, et. al. Drug repurposing: progress, challenges and recommendations. Nat. Rev.
Drug Discov. 18, 41-58, 2019)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of bringing
a repurposed drug is estimated to be around US$300 million, which is only one-tenth of the development cost for a new drug. (Nosengo,
N. Can you teach old drugs new tricks? Nature. 534, 314-316, 2016).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In summary, drug repurposing
offers the following advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Well-established safety profiles: The development risk for new indications can be substantially reduced by applying existing drugs that are approved or have been shown to be safe in large scale late-stage trials. Since safety accounts for approximately 30% of drug failures in clinical trials, this is a key advantage that repositioned drugs can harness to great effect. (Key benefits of drug repositioning. (n.d.). Retrieved from http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Time-saving: As repositioned drugs can rely on existing data, including efficacy and toxicity studies, the process is usually faster than de novo development. Developing a new chemical entity (NCE) can take 10 to 17 years, depending on indications. (Roin, B. N. Solving the Problem of New Uses, 2013). For a drug repositioning company, the development process from compound identification to launch can be around 3 to 8 years. (Walker, N. (2017, December 07). Accelerating Drug Development Through Repurposing, Repositioning and Rescue. Retrieved from https://www.pharmoutsourcing.com/Featured-Articles/345076-Accelerating-Drug-Development-Through-Repurposing-Repositioning-and-Rescue/)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Cost-saving: Along with time-saving, money-saving is also a key benefit. With a single compound to enter clinical trials costing around US$10 to $20 million, the cost of identifying a repositioning candidate that already has phase 1 data could be as low as US$2 to $3 million. (http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Potential for out-licensing: Pharmaceutical companies are said to be exploring new models to out-license some of their clinical drug candidates that may have been shelved for pure business reasons unrelated to safety or efficacy, even though they have met their endpoints and have proven themselves to be safe. If such drugs were to be repositioned, the pharmaceutical company increases the attractiveness of these drugs and gives itself more options to find interested buyers. (http://www.totalbiopharma.com/2012/07/04/4-key-benefits-drug-repositioning/)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Lower failure rate: According to BCC Research, approval rates for repurposed drugs are close to 30%, which is greater than the approval rate for new drug applications. ( Front Oncol. 2017; 7: 273)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the major limitations
of the current drug repurposing and repositioning practice is that there is a lack of a systematic way to identify and reinvestigate
drugs that are approved and/or have failed approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SACT-1 is the first
repurposed drug candidate to be developed under the Smart-ACT<I><SUP>&reg;</SUP></I>&nbsp;&nbsp;drug discovery platform. SACT-1
is one of the Company&#8217;s proprietary technologies. Our first targeted indication is neuroblastoma. Neuroblastoma is a rare
form of cancer, and classified as an orphan disease, that forms in certain types of nerve tissue and most frequently in the adrenal
glands as well as spine, chest, abdomen or neck, predominantly in children, especially for those aged 5 years and below. For the
high-risk group, which is close to 20% (Annu Rev Med. 2015; 66: 49&#8211;63.) of total new patient population per year, the 5-year
survival rate of this condition is around 40-50% as observed by the American Cancer Society (https://www.cancer.org/cancer/neuroblastoma/detection-diagnosis-staging/survival-rates.html).
The current high drug treatment cost for high risk patients can average USD200,000 per regimen (all 6 cycles) (https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf
). In addition, most pediatric patients often do not tolerate or survive the relevant chemotherapy stage which, subject to further
clinical studies, may be positively addressed by the SACT-1 candidate due to the potential synergistic effects when applied with
standard chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our recent studies,
SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent
the high-risk neuroblastoma patient group. In addition, by using a bliss score as a quantitative measure of the extent of drug
interaction, Aptorum Group has seen a high and robust synergism between SACT-1 and traditional chemotherapy in vitro (Figure 3),
indicating a potential efficacy enhancement/dose reduction of the chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_006.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1734005|000121390020010347|image_006.jpg" STYLE="height: 301px; width: 540px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Figure 3 synergism
between SACT-1 and traditional chemotherapy in vitro</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in
our recent study, the maximum tolerable dose of SACT-1 in a rodent model was determined to be higher than 400mg/kg. Compared with
the MTD of standard chemotherapy such as paclitaxel (20-30mg/kg) (Clin Cancer Res. 5(11):3632-8) and cisplatin (6mg/kg) (BMC Cancer
17: 684 (2017)), the safety profile of SACT-1 appears to be very impressive. Based on our internal observations of pre-existing
information from approved products, subject to FDA&#8217;s approval and on a case-by-case basis, a 505(b)(2) Application can rely
in part on existing information from approved products (such as the FDA&#8217;s previous findings on safety and efficacy) or products
in literature (such as data available). However, typically speaking, the applicant is nonetheless required to carry out a Phase
1 bridging study to compare the Reference Listed Drug and reference the established safety and efficacy information), SACT-1 also
exhibits a well-established safety profile: at 150mg/day, the death rate was 0% in prior clinical studies with no dosage related
adverse events (Table 1). In addition, the pharmacokinetic profile of SACT-1 has also been reported (Table 2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Table 1:
Safety Profiles of SACT-1 in Human Clinical Trials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_007.jpg" ALT="https:||www.sec.gov|Archives|edgar|data|1734005|000121390020010347|image_007.jpg" STYLE="height: 182px; width: 612px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Table 2:
The pharmacokinetic Profile of SACT-1 in Humans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_008.jpg" ALT="" STYLE="width: 660px; height: 223px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently developing
a pediatric formulation of SACT-1 to better address the needs of neuroblastoma patients who are exclusively children younger than
5. SACT-1 is undergoing preparation for IND submission and is on track for regulatory application to target to commence phase 1b/2a
clinical trials under the US FDA&#8217;s 505(b)(2) pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SACT-1 is a proprietary
technology not subject to any license agreement. As of the date of this prospectus, we have filed U.S. provisional application
for such proprietary technology and intend to submit a non-provisional application before the expiration of the U.S. provisional
application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Statistical Significance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term statistical
significance is to define the probability that a measured difference between two groups (e.g. two treatment groups, treatment versus
control groups) is the result of a real difference in the tested variations and not the result of chance. It means that the result
of a test does not appear randomly or by chance, but because of a specific change that is tested, so it can be attributed to a
specific cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The confidence level
indicates to what percentage the test results will not commit a type 1 error, the false positive. A false positive occurs when
a change in the result is due to randomness (or other noise) and not the change in variations. At a 95% confidence level (p = 0.05),
there is a 5% chance that the test results are due to a type 1 error. 95% has become the standard and usually be the minimum confidence
level for the tests. To make the test more stringent, a 99% confidence level (p = 0.01) is also commonly employed, which means
that there is a 1% chance that the test results are due to a type 1 error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In other words, a p
value represents the confidence level. For example, if the p-value for a test is &lt; 0.05, it means that there is less than 5%
chance the difference between two groups is due to random error or by chance. If the p-value is &lt; 0.01, it means that there
is less than 1% chance the difference between two groups is due to random error or by chance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employed statistical
testing to compare different treatment groups in animal studies simply for proof of concept and to aid internal decision making
for further development. We do not intend to use this standard for any regulatory submission. The US FDA or other regulatory agencies
may not necessarily employ the same statistical standard to assess the efficacy in clinical trials, the results of which would
be submitted for regulatory approval.&nbsp;Although a p-value of 0.05 has become the standard,&nbsp;the US FDA or other regulatory
agencies may also individualize their efficacy standard for different clinical programs based on the indications, the purpose of
a clinical trial, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>FDA Application Status</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
prospectus, we have not submitted any applications for investigational new drugs (&#8220;IND&#8221;) to the US Food and Drug Administration
(&#8220;FDA&#8221;). In the fourth quarter of 2020, subject to regulatory review, we expect to be in a position to submit at least
one application for one of our drug candidates to commence trials in humans (INDs to the FDA or an equivalent application to the
regulatory authorities in another jurisdiction such as the China&#8217;s National Medical Products Administration (the &#8220;NMPA&#8221;),
the European Medicines Agency (&#8220;EMA&#8221;), or Health Canada). However, there can be no assurance we will be able to make
any such application by such time. Should we be delayed in making such filing or should such filing not be approved, our business
will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Projects under Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following provides
additional detail regarding Other Projects under Development. As noted elsewhere in this prospectus, based on certain criteria,
we sometimes cease work on certain projects to focus on projects we believe are more promising. We typically discontinue the development
of a candidate because the expected result could not be generated, so we decided to focus our capital and efforts on our other
candidates. The patents and patent applications covering the Other Projects are either owned by the Company or have been in-licensed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SACT-COV19: Drug repurposing for the
treatment of infections caused by COVID-19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SACT-COV19 is a drug
repurposing program for the treatment of infections caused by COVID-19. We have completed initial screening under the Smart-ACT<I><SUP>&reg;</SUP></I>
platform to select, out of more than 2,600 small drug molecules that were previously approved for other indications, at least 3
potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. We are collaborating
with Toronto based Covar Pharmaceuticals and have also entered into agreement with the University of Hong Kong and University of
Oxford to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies
to initiate clinical trials on suitable candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug candidates from
the SACT-COV19 program are currently undergoing in vitro validation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ALS-1: Small molecule intended for the
treatment of viral infections caused by Influenza virus A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Richard Kao,
the Inventor of ALS-1, was the first to identify viral nucleoproteins (NP) as an effective drug target (Nature Biotechnology. 28:600-605)
We are exploring ALS-1 as a potential treatment for viral infections caused by Influenza virus A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is our hypothesis
that Influenza A NP is an essential protein for the proliferation of the influenza virus. ALS-1 targets NP and triggers the aggregation
of NP and this prevents the aggregated NP from entering the nucleus. In an animal study published by the inventor, Prof. Richard
Kao, in Nature Biotechnology (28 (6): 600, 2010), after treating with ALS-1, 50% of the mice receiving two doses of ALS-1 (100
&#956;l of 2.3 mg/ml ALS-1) per day for 7 days survived for more than 21 days compared with 100% mortality in the treatment-free
control group within 7 days. In addition, about a 10x reduction of viral load in the lungs of the ALS-1-treated mice was observed
compared to the untreated control group. The animal study results suggest that ALS-1 has the potential to be developed into a useful
anti-influenza therapeutic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-1 is designed to
target a broad range of NP variants, a novel therapeutic target. Compared with the currently marketed antiviral drugs for which
the viruses have acquired extensive resistance, ALS-1 acts on a completely different therapeutic target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-1 is currently
undergoing Lead Optimization to optimize its drug-like properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ALS-2: Small molecule for the treatment of bacterial infections
caused by Staphylococcus aureus including MRSA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-2 is a next generation
small molecule targeting bacterial virulence for the treatment of bacterial infections caused by Staphylococcus aureus including
MRSA. In a recent paper published by the inventor, Professor Richard Kao from The University of Hong Kong (also the Founder and
Principal Investigator of Acticule), in PNAS (115(310: 8003, 2018), ALS-2 suppresses the expression of multiple virulence factors
in Staphylococcus aureus simultaneously. In a lethal infection mouse model, compared with the vehicle group, ALS-2 protected against
Staphylococcus aureus for all the mice in the group, with significant differences between the treatment and control groups [P =
0.0057, by log-rank (Mantel-Cox) test].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-2 is currently
at the Lead Optimization stage to optimize its drug-like properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ALS-3: Small molecule acting synergistically with certain
existing antibiotics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALS-3 is a novel small
molecule that is at present under investigation to combine with certain classes of existing antibiotics to overcome drug resistance.
We are exploring ALS-3 for the treatment of bacterial infections including MRSA. ALS-3 is currently at the Lead Optimization stage
to optimize its drug-like properties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CLS-1: An orally administered macromolecule for the treatment
of obesity based on chemical signaling of gut microbiome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prevalence of obesity
continues to escalate globally; however, there is no current optimal therapy for this condition. For the majority of obese patients,
conventional medical therapies (i.e., diet, exercise, behavioral counseling) often have a high failure rate for the long term.
(Obes Surg. 2012:22(6):956-66). We believe current pharmacotherapy has limited efficacy and is associated with substantial safety
issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Chemical signaling
of gut microbiota is known to be one of the major causes of obesity. CLS-1 is an orally administered non-absorbable macromolecule
that we believe modulate the metabolite excreted by gut microbiota with high affinity and specificity. In this way, we believe
the absorption of this particular metabolite, which is linked to obesity, can be inhibited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CLS-1 is undergoing
Lead Optimization and is intended to be commercialized as a pharmaceutical drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NLS-1: A Derivative of Epigallocatechin-3-Gallate
(&#8220;Pro-EGCG&#8221;) for the treatment of Endometriosis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NLS-1, a drug molecule
derived from natural products (green tea), is currently under development for the treatment of endometriosis, a disease in which
the tissue that normally lines the uterus (endometrium) grows outside the uterus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NLS-1 acts as an anti-angiogenic
to offer a potential novel treatment of endometriosis. In a paper published by the inventors in Angiogenesis (16:59, 2013), NLS-1
brought a statistically significantly reduction in the lesion size and weight compared with EGCG and the control without any treatment
in an experimental endometriosis mouse model (Student t-test, p &lt; 0.05). In addition, the inhibition by NLS-1 in all of the
angiogenesis parameters was statistically significantly greater than that by EGCG (Student t-test, p &lt; 0.05). In addition, NLS-1
significantly (Student t-test, p &lt; 0.05) reduces the lesion size in both prevention and treatment group compared with both saline
and EGCG groups. Moreover, NLS-1 also had better bioavailability and greater antioxidation and anti-angiogenesis capacities compared
with EGCG. As a follow-up study in an animal model of endometriosis, orally administered NLS-1 reduced the lesion size significantly
better than oral EGCG (p&lt;0.05-0.001 at week 3- 8, ANOVA) and other hormone-based therapy such as intramuscular GnRH analog (p&lt;0.05
at week 4-8, ANOVA) and other synthetic anti-angiogenesis agents such as intraperitoneal PTK787 (p&lt;0.05-0.01 at week 4-8, ANOVA).
Regarding safety, there was no signs of stress to NLS-1 administration were observed during the treatment period. No significant
weight change was observed over the course of the experiment. Histological examination revealed no obvious reproductive effects
on ovarian follicles and endometrial glands under NLS-1 treatments. Also, vascularization of the ovaries and the uterus was not
affected in the NLS-1 treatment group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lead optimization
has been completed and it is currently undergoing a preparatory phase to enter CTA-enabling studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SPLS-1: A quinoline derivate for liver
cancer treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SPLS-1, a novel quinoline
derivative from Ephedra pachyclada, is at present under active investigation for the treatment of liver cancer. It is currently
at the Lead Discovery stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>VLS-2: mTOR-independent transcription
factor EB activator (&#8220;MITA&#8221;) as autophagy activator for treatment of neurodegenerative diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Autophagy is an endogenous
cellular mechanism for clearing multiple pathological protein aggregates including tau, the presence of which is believed to account
for neurodegeneration in AD and other neurodegenerative diseases. mTOR is part of a biological pathway that is a central regulator
of mammalian metabolism and physiology. Inhibition of mTOR activity is associated with various side effects, such as immunosuppression.
Many other molecules that activate autophagy also inhibit mTOR activity. VLS-2 is a small drug molecule that appears to activate
autophagy without inhibiting mTOR function. VLS-2 is currently at the Lead Discovery stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>VLS-4: Other contrast agents for MRI diagnostics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is actively
developing a new class of MRI contrast agents for diagnosis of neurodegenerative diseases. The design of these agents takes into
consideration the physicochemical properties that need to be optimized for best imaging performance, and the novel agents are currently
undergoing rigorous evaluation. VLS-4 is currently at the Lead Discovery stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SLS-1: Robotic Catheter Platform for Intra-operative MRI-guided
Cardiac Catheterization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SLS-1 is our robotic
catheter platform for MRI-guided cardiovascular intervention for the treatment of arrhythmia. The platform consists of a magnetic
resonance imaging-guided (&#8220;MRI-guided&#8221;) robotic electrophysiology (&#8220;EP&#8221;) catheter system, an MR-based positional
tracking unit, and a navigation interface. This platform has the potential to offer a major step toward achievement of several
clinical goals: (i) enhancing catheter manipulation and lesion ablation, which we believe will decrease the chance of arrhythmia
recurrence; (ii) improving the safety of catheter navigation, thereby decreasing the rates of undesired or inadvertent tissue damage;
and (iii) enhancing catheter control, thus facilitating shorter learning curves for surgeons and better treatment in more complex
patient cases. Should such goals be demonstrated, patient outcomes should be improved, compensating for the cost of using MRI and
reducing the overall expenditure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, a product
prototype has been developed. Lab-based experiments have been conducted to verify the performance of the robot towards an image-guided
pulmonary vein isolation (&#8220;PVI&#8221;) task. The MR-based tracking unit has also been developed and validated in MRI scanners.
The next step is to test the robotic catheterization using a dynamic heart phantom simulated with the pulsatile liquid flow. Preclinical
trials can then be conducted with all the components ready. Radiofrequency ablation will be conducted in a live porcine model,
prepared with arrhythmia. If all the results are positive, we will approach the US FDA or other regulatory agencies to apply for
conducting clinical trials on the equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SLS-1 is currently
in Lab-based Phantom Trial and it will follow the regulatory pathway for approval as indicated in the table in Page 76.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Aptorum Medical Limited - AML Clinic</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Incorporated in August
2017, Aptorum Medical Limited is a Hong Kong-based company incorporated in Cayman Islands focused on delivering premium healthcare
and clinic services. AML can draw on the expertise of many of the region&#8217;s most experienced medical practitioners, and is
committed to providing a comprehensive cross-functional facility for healthcare professionals to practice evidence-based medicine
and offer high-quality medical services to their patients. We also intend that AML will offer to conduct clinical trials of both
the Company&#8217;s and third parties&#8217; new drug and device products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective as of March
2018, we leased office space in Central, Hong Kong, the commercial and financial heart of Hong Kong, as the home to AML Clinic.
We operate the AML Clinic under the name of Talem Medical. AML Clinic commenced operation in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recently renovated
medical center is staffed by our group of medical professionals and offers state-of-the-art facilities. Initially we expect to
focus our expertise on treatment of chronic diseases resulting from modern sedentary lifestyles and an aging population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Natural supplement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NLS-2: DOI, a Bioactive Ingredient (DOI)
in Chinese Yam for the Relief of Menopausal Symptoms as a Natural Supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NativusWell<SUP>&reg;</SUP>
is a natural supplement made with the bioactive ingredient extracted Chinese yam powder containing &#8220;DOI&#8221;, which is
Aptorum Group&#8217;s non-hormonal approach intended to meet certain growing consumer nutritional trends and concerns. It is estimated
that 1.2 billion women worldwide will be menopausal or postmenopausal by the year 2030<SUP>1</SUP>. The global woman&#8217;s health
supplement market for menopausal symptoms is projected to reach over USD$50bn by 2025 with a CAGR rate of 16.4% (2016-2025)<SUP>2</SUP>.
Initially, the supplement will be commercialized and sold in Hong Kong; the Company is seeking regulatory clearance to market the
product in other major jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the commercialization,
Aptorum Group, through its wholly-owned subsidiary Nativus Life Sciences Limited, entered into a regional distribution and marketing
agreement with Multipak Limited, a Hong Kong based group that operates household brands, including the Luk Yu&reg; tea bag and
other health related products (the &#8220;Multipak Agreement&#8221;). Pursuant to the Multipak Agreement, Multipak is appointed
as a non-exclusive distributor for the distribution and release of NativusWell<I><SUP>&reg;</SUP></I>, yam powder tablets to be
formulated according to proprietary technologies of Nativus and the Group in Hong Kong and China, and such other territories as
agreed by both parties from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through Multipak and
other channels, Aptorum Group will be able to increase the accessibility of the product to a large consumer base regionally. The
production of Aptorum Group&#8217;s dioscorea opposita bioactive nutraceutical tablets has commenced production in Canada and will
be marketed under the brand name NativusWell<I><SUP>&reg;</SUP></I>. The Multipak Agreement has a term of one year, which shall
automatically renew for four additional one-year terms, unless terminated by either party with at least 30 days prior written notice.
Either party may also terminate the Multipak Agreement upon written notice to the other party if such other party commits a material
breach of the terms and conditions of the agreement and it is not remedied within 30 days&#8217; notice or if the other party cannot
pay its debts or becomes insolvent, or otherwise is involved in a bankruptcy or liquidation proceeding. Nativus also has the option
to terminate the agreement upon written notice to Multipak upon the occurrent of certain events, including: if Multipak is later
by more than 30 days in paying amounts due under the agreement, Multipak challenges the validity of any of Nativus&#8217; or the
Group&#8217;s intellectual property, Multipak does something that could reasonably be expected to have an adverse effect on the
reputation of Nativus or the Group, or Multipak has a change in control for which Nativus did not pre-approve. During the 3-month
period following any termination (the &#8220;Sell-Off Period&#8221;), Multipak may sell of it stock of products, but may not return
any, nor shall Nativus have any liability for breach of warranty for such product during the Sell-Off Period. At the end of Multipak
Agreement also provides for certain indemnitees of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NativusWell<I><SUP>&reg;</SUP></I>&nbsp;tablets
are natural, non-hormonal supplements containing DOI. The yam powder with DOI utilizes a non-hormonal approach that is intended
to boost the general wellness of women undergoing menopause. Third party scientific studies indicate that DOI, the naturally occurring
bioactive ingredient in Chinese yam, appears to stimulate estradiol biosynthesis, induce estradiol and progesterone secretion and
increase bone density, thereby potentially counteracting the progression of osteoporosis<SUP>3</SUP>, one of the common symptoms
associated with menopause<SUP>4</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Corporate History and Background</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aptorum was incorporated
under the laws of the Cayman Islands on September 13, 2010. Our share capital is $100,000,000.00 divided into 60,000,000 Class
A Ordinary Shares with a nominal or par value of $1.00 each and 40,000,000 Class B Ordinary Shares with a nominal or par value
of $1.00 each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0; margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: left">World Health Technical Report Series. Research on the
Menopause in the 1990&#8217;s. Geneva, Switzerland: World Health Organization; 1996.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP></TD><TD STYLE="text-align: left">https://www.grandviewresearch.com/press-release/global-isoflavones-market</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.ke.hku.hk/story/innovation/the-magic-of-chinese-yam-for-treatment-of-menopausal-syndrome;
see also, Scientific Reports, 5-10179.</FONT></TD>
</TR></TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.everydayhealth.com/menopause/osteoporosis-and-menopause.aspx</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">APTUS CAPITAL LIMITED,
which has since been renamed to AENEAS CAPITAL LIMITED and which we refer to herein as Aeneas, was always under the direct ownership
of Jurchen and not under the ownership chain of Aptorum Group. However, Aptus Asia Financial Holdings Limited (&#8220;AAFH&#8221;),
which has since been renamed to Aeneas Group Limited, was transferred out of the Aptorum Group on November 10, 2017 to be held
directly by Jurchen Investment Corporation and that subsequently, APTUS CAPITAL LIMITED was then transferred to be under AAFH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 4, 2017, Mr.
Huen transferred all of the ordinary shares in the Company he owned (in the amount of 22,307,596) to Jurchen, a company incorporated
in the British Virgin Islands and wholly-owned by Mr. Huen. On October 13, 2017, as part of the Conversions (as defined below)
the ordinary shares held by Jurchen were redesignated as 2,230,760 Class A Ordinary Shares and 20,076,836 Class B Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 21, 2017
the sole director of the Company and on March 1, 2017, the Company&#8217;s board of directors and shareholders respectively, resolved
to restructure the Company from an investment fund with management shares and non-voting participating redeemable preference shares
to a holding company with operating subsidiaries, respectively (the &#8220;Restructuring Plan&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Restructuring
Plan, the 256,571.12 issued participating shares with par value of $0.01 (&#8220;Participating Shares&#8221;) were redeemed and
4,743,418.88 unissued Participating Shares were cancelled; following such redemption and cancellation, we no longer have any Participating
Shares authorized or issued. Additionally, the Company authorized a class of shares consisting of 100,000,000 ordinary shares,
par value $1.00 per share (&#8220;Ordinary Shares&#8221;) and issued 25,657,110 Ordinary Shares to our original investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the period
March 1, 2017 through October 13, 2017, an aggregate of 2,207,025 Ordinary Shares were issued at a price of approximately $3.90
per share in a private placement we described as a &#8220;Series A&#8221; offering. Each investor of the Series A offering, in
addition to a subscription agreement, signed a shareholder agreement, which set forth the basic governance terms of the Company,
as well as our capital structure. The shareholders agreement was terminated in October 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2017,
ordinary resolutions were passed at an extraordinary general meeting of the Company approving (the &#8220;Conversions&#8221;):
(i) converting 72,135,865 of authorized but unissued Ordinary Shares into 54,573,620 authorized but unissued Class A Ordinary
Shares, par value of $1.00 per share and 17,562,245 authorized but unissued Class B Ordinary Shares, par value of $1.00 per share
(&#8220;Class B Ordinary Shares&#8221;), respectively; (ii) converting 24,930,839 Ordinary Shares held by three shareholders into
an aggregate of 2,493,085 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares; and (iii) converting 2,933,296 Ordinary
Shares held by 24 shareholders into an aggregate 2,933,296 Class A Ordinary Shares. Following these issuances, we had 27 shareholders
of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 19, 2017,
we changed our name from APTUS Holdings Limited to our current name, Aptorum Group Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2018,
Jurchen transferred 446,152 Class A Ordinary Shares and 4,015,367 Class B Ordinary Shares to CGY Investments Limited, a company
incorporated in Hong Kong and which we deem Mr. Darren Lui controls and/or of which he has substantial influence on the disposition
rights and voting rights of such shares. Following this transfer, Jurchen owns approximately 33% and 72% of our Class A Ordinary
Shares and Class B Ordinary Shares, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 17, 2018,
the Company consummated its IPO of 761,419 Class A Ordinary Shares. The Registration Statement was declared effective by the U.S.
Securities and Exchange Commission on December 3, 2018 (the &#8220;Effective Date&#8221;). The shares were sold at a price of $15.80
per share, generating gross proceeds to the Company of approximately $12,030,420. Immediately following the consummation of the
IPO and automatic conversion of the Notes and Bonds, there were an aggregate of 6,537,269 Class A Ordinary Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2020,
the Company consummated a Registered Direct Offering of 1,351,350 Class A Ordinary Shares and warrants to purchase up to 1,351,350
Class A Ordinary Shares. The shares were sold at a price of $7.40 per share, generating gross proceeds to the Company of approximately
$10 million. The warrants will be exercisable immediately following the date of issuance for a period of seven years at an initial
exercise price of $7.40. Immediately following the consummation of the Registered Direct Offering, there were an aggregate of 7,948,712
Class A Ordinary Shares issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over the past three
years, we have invested approximately $9.9 million towards our principal capital expenditures, which include laboratory equipment,
premises, leasehold improvements, and medical and other equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please see the chart
illustrating our current corporate structure, under the heading of &#8220;Our Structure&#8221; in the Prospectus Summary, included
earlier in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The technologies underlying
our various research and development projects are the subject of various patents and patent applications claiming, in certain
instances, composition of matter and, in other instances, methods of use. Prosecution, maintenance and enforcement of these patents,
as well as those on any future protectable technologies we may acquire, are and will continue to be an important part of our strategy
to develop and commercialize novel medicines and medical devices, as described in more detail below. Through entering into license
agreements with their owners, we have obtained exclusive rights to these patents, applications and related know-how in the U.S.
and certain other countries to develop, manufacture and commercialize the products using or incorporating the protected inventions
that are described in this prospectus and that are expected to contribute significant value to our business. The technologies
protected by these patents may also for the basis for the development of other products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to
licensed intellectual property, our scientists have been actively developing our own proprietary intellectual property. No non-provisional&nbsp;patent
application has yet been filed in the Company&rsquo;s own name for the Lead Projects. We have, however, filed a number of provisional
applications to establish earlier filing dates for certain of our other ongoing researches, the specifics of which are currently
proprietary and confidential.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. patent system
permits the filing of provisional and non-provisional patent applications (i.e., a regular patent application). A non-provisional
patent application is examined by the USPTO, and can mature into a patent once the USPTO determines that the claimed invention
meets the standards for patentability. On the other hand, a provisional patent application is not examined for patentability, and
automatically expires 12 months after its filing date. As a result, a provisional patent application cannot mature into a patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisional applications
are often used, among other things, to establish an earlier filing date for a subsequent non-provisional patent application. The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effective filing
date of a non-provisional patent application is used by the USPTO to determine what information is prior art when it considers
the patentability of a claimed invention. If certain requirements are satisfied, a non-provisional patent application can claim
the benefit of the filing date of an earlier filed provisional patent application. As a result, the filing date accorded by the
provisional patent application may supersede information that otherwise could preclude the patentability of an invention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A provisional patent
application is not eligible to become an issued patent unless, among other things, we file a non-provisional patent application
within 12 months of the filing date of the provisional patent application. If we do not timely file a non-provisional patent application
claiming priority to said provisional application, we may lose our priority date with respect to our provisional patent applications.
Further, if any (self or by others) publication of the invention is made after such priority date, and if we do not file a non-provisional
application claiming priority to said provisional application, our invention may become unpatentable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we cannot
predict whether such future patent applications will result in the issuance of patents that effectively protect any of our product
candidates or will effectively prevent others from commercializing competitive products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect to
incur material expenses in the prosecution of the provisional applications or other licensed patent applications. We expect to
fund the patent costs from our cash and restricted cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">The value of
our drug and device products will depend significantly on our ability to obtain and maintain patent and other proprietary protection
for those products, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable
patents and proprietary rights of other parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">As of the date
hereof, we are the patentee of a number of provisional and non-provisional patent applications, both on our proprietarily developed
projects and improvement to our in-licensed projects. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth a list of our patent rights under the exclusive licenses as of the date of this prospectus related to our Lead Project,
ALS-4; on the other hand, our other Lead Project, SACT-1 is a proprietary technology not subject to any license agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Project Company / Project name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>License Agreement</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Licensor(s)</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Licensee</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Licensed / IP Rights</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Patent Expiration Dates</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Acticule / ALS-4&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exclusive Patent License Agreement, dated October
        18, 2017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">First Amendment to Exclusive License Agreement,
        dated June 7, 2018</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Second Amendment to Exclusive License Agreement
        dated July 10, 2019</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exclusive Patent License Agreement dated January
        11, 2019</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Versitech Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Acticule Life Sciences Limited</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Exclusive licensee of: 1 U.S. patent (US10471045),
            4 pending U.S. applications (16/041,838, US 16/679,313, 16/867,540 and US 17/006,985), 2 pending European applications
            (EP18835480.7 and EP18835238.9), 2 pending PRC application (CN201880048665.6 and 201880048674.5), 17 pending applications
            in other foreign jurisdictions including Australia, Brazil, Canada, Chile, Eurasia, Israel, Japan, Korea, Malaysia,
            New Zealand, Singapore</P>

        </TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The licensed IP rights include the granted patent in
        the U.S. and pending patent applications in the U.S., Europe, PRC and other foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The U.S. patent will expire in 2038; any other patent based
on the pending application, if granted, will have a 20-year patent term from 2018.</P>.
</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">Because of
the extensive time required for clinical development and regulatory review of a drug we may develop, it is possible that, before
any of our drug and device candidates can be commercialized, any related patent may expire or remain in force for only a short
period following commercialization, thereby reducing any advantage of any such patent. If appropriate, the Company may seek to
extend the period during which it has exclusive rights to a product by pursuing patent term extensions and marketing exclusivity
periods that are available from the regulatory authorities of certain countries (including the United States) and the EPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though the Company
has certain patent rights, the ability to obtain and maintain protection of biotechnology and pharmaceutical products and processes
such as those we intend to develop and commercialize involves complex legal and factual questions. No consistent policy regarding
the breadth of claims allowed in such patents has emerged to date in the U.S. The scope of patent protection outside the United
States is even more uncertain. Changes in the patent laws or in interpretations of patent laws in the United States and other countries
have diminished (and may further diminish) our ability to protect our inventions and enforce our IP rights and, more generally,
could affect the value of IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have
already secured rights to a number of issued patents directed to our drug candidates, we cannot predict the breadth of claims
that may issue from the pending patent applications and provisional patents that we have licensed or that we have filed.
Substantial scientific and commercial research has been conducted for many years in the areas in which we have focused our
development efforts, which has resulted in other parties having a number of issued patents, provisional patents and pending
patent applications relating to such areas. The patent examiner in any particular jurisdiction may take the view that prior
issued patents and prior publications render our patent claims &#8220;obvious&#8221; and therefore unpatentable or require us
to reduce the scope of the claims for which we are seeking patent protection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, patent
applications in the United States and elsewhere generally are not available to the public until at least 18 months from the priority
date, and the publication of discoveries in the scientific or patent literature frequently occurs substantially later than the
date on which the underlying discoveries were made. Therefore, patent applications relating to drugs and devices similar to our
drug and device candidates may have already been filed, which (if they result in issued patents) could restrict or prohibit our
ability to commercialize our drug and device candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and
pharmaceutical industries are characterized by extensive litigation regarding patents and other IP rights. Our ability to prevent
competition for our drug and device candidates and technologies will depend on our success in obtaining patents containing substantial
and enforceable claims for those candidates and enforcing those claims once granted. With respect to any applications which have
not yet resulted in issued patents, there can be no assurance that meaningful claims will be obtained. Even issued patents may
be challenged or invalidated. If others have prepared and filed patent applications in the United States that also claim technology
to which we have filed patent applications or otherwise wish to challenge our patents, we may have to participate in interferences,
post-grant reviews, inter parties reviews, derivation or other proceedings in the USPTO and other patent offices to determine issues
such as priority of claimed invention or validity of such patent applications as well as our own patent applications and issued
patents. Patents may also be circumvented, and our competitors may be able to independently develop and commercialize similar drugs
or mimic our technology, business model or strategy without infringing our patents. The rights granted under any issued patents
may not provide us with proprietary protection or competitive advantages against competitors with similar technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely, in some
limited circumstances, on unpatented trade secrets and know-how to protect aspects of our technology. However, it is challenging
to monitor and prevent the disclosure of trade secrets. We seek to protect our proprietary trade secrets and know-how, in part,
by entering into confidentiality agreements with consultants, scientific advisors and contractors and invention assignment agreements
with our employees. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
security of our premises and physical and electronic security of our information technology systems. While we have confidence in
these individuals, organizations and systems, agreements or security measures may be breached, giving our competitors knowledge
of our trade secrets and know-how, and we may not have adequate remedies for any such breach, in which case our business could
be adversely affected. Our trade secrets will not prevent our competitors from independently discovering or developing the same
know-how. Although our agreements with our consultants, contractors or collaborators require them to provide us only original work
product and prohibit them from incorporating or using IP owned by others in their work for us, if they breach these obligations,
disputes may arise as to the rights in any know-how or inventions that arise from their work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
will also depend in part on not infringing the proprietary rights of other parties. Although we seek to review the patent landscape
relevant to our technologies on an ongoing basis, we may become aware of a new patent which has been issued to others with claims
covering or related to aspects of one of our drug or device candidate. The issuance of such a patent could require us to alter
our development plans for that candidate, redesign the candidate, obtain a license from the patent holder or cease development.
Our inability to obtain a license to proprietary rights that we may require to develop or commercialize any of our drug and device
candidates would have a material adverse impact on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trademarks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date
of this prospectus, we own trademark registrations covering the trade names and logos of Aptorum and our subsidiaries, including
but not limited to &ldquo;APTORUM&rdquo;, &ldquo;<FONT STYLE="text-transform: uppercase">APTORUM THERAPEUTICS</FONT>,&rdquo; &ldquo;<FONT STYLE="text-transform: uppercase">VIDENS
LIFE SCIENCES,</FONT>&rdquo; &ldquo;ACTICULE LIFE SCIENCES,&rdquo;, &ldquo;CLAVES LIFE SCIENCES&rdquo;, &ldquo;NATIVUS LIFE SCIENCES&rdquo;,
&ldquo;TALEM,&rdquo;, in one&nbsp;or more of Hong Kong, EU, the United Kingdom, and PRC. Furthermore, we are in the process of
applying for registration of trademarks in the U.S., EU, the United Kingdom, and PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own certain
unregistered trademark rights.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All other trade names,
trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders. Solely
for convenience, the trademarks and trade names in prospectus are referred to without the&nbsp;<SUP>&reg;</SUP>&nbsp;and&nbsp;<SUP>&#8482;&nbsp;</SUP>symbols,
but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks and trade
names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Advisors and Consultants to
the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to Company
management, the following individuals provide the Company with significant advice and insight in their respective fields:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Scientific Advisory Board </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We restructured the
Scientific Assessment Committee into a newly formed Scientific Advisory Board. The Scientific Advisory Board shall help the Company
sharpen its focus on innovation and technological advancements and address critical scientific challenges in our research and development;
it will provide overall advice on the scientific development of the company. As of the date hereof, we have 26 members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the Company&#8217;s
focus on developing treatment for infectious diseases, we have established a second scientific advisory board, i.e., the Infectious
Diseases Scientific Advisory Board in April 2020. As of the date hereof, the Infectious Diseases Scientific Advisory Board have
4 members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. KEITH CHAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The appointment of
Dr. Chan is through a Consultancy Agreement by and between the Company and GloboAsia LLC, a firm based in Rockville, Maryland (&#8220;GloboAsia&#8221;),
where Dr. Chan serves as Director of International Affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Chan is currently
a Senior Advisor of Cornerstone Intellectual Property Foundation in Taiwan. He is also serving as an adjunct professor at the Graduate
Institute of Intellectual Property, College of Commerce, National Chengchi University and adjunct professor and advisor at the
Research Center for Drug Discovery, National Yang Ming University in Taipei, Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Chan co-founded
GloboMax LLC, a drug development organization, in Hanover, Maryland, in July 1997, and served as a consultant for numerous multi-national
pharmaceutical and biotech firms in the U.S, Europe and Asia. GloboMax LLC was acquired by ICON, plc. in August 2003, and Dr. Chan
exited the operation. Prior to that, he joined the FDA in 1995 as a Director of Division of Bioequivalence, Office of Generic Drugs,
responsible for managing and approval of generic drugs in the States. Dr. Chan had worked for Ciba-Geigy Corporation in Ardsley,
New York, for 15 years, and held various senior and management positions. Dr. Chan also has extensive experience in new and generic
drug development in executing preclinical animal studies, bioassay development, Phases I to VI Pharmacokinetics, pharmacodynamics,
bioavailability, bioequivalence studies, outside contract, regulatory submission, advanced drug delivery systems, and all phases
of new drug development. In addition, he has served as Professor/adjunct Professor at the School of Pharmacy, University of Maryland
at Baltimore during 1996-2009 and also as Adjunct Professor and National Board of Advisor, College of Pharmacy, University of Minnesota
during 1984 - 2006. He has published more than 150 abstracts and research articles in peer-reviewed journals and delivered over
200 professional presentations. He was elected as Fellow of the American Association of Pharmaceutical Scientists (&#8220;AAPS&#8221;)
in 1995 for his scientific accomplishments on drug absorption in humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although much of his
career was based in the United States, Dr. Chan has been assisting Asian pharmaceutical and biotech companies for over 14 years.
He has organized numerous workshops and conferences in the PRC, Taiwan, Hong Kong, Singapore and Korea. He lectures frequently
in Asia and serves as a scientific advisor for many regulatory agencies in Asia. Over the last several years, he has successfully
assisted many Asian companies in their technology transfers and licensing deals to and from the U.S., as well as with numerous
regulatory submissions to the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Chan obtained his
Ph.D. degree in Pharmaceutics from the University of Minnesota in January 1980.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DR. ROBBIE MAJZNER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to serving
on the Scientific Advisory Board, Dr. Majzner will provide specific scientific advice and support for certain targeted clinical
development aspects of our repurposed drug candidate SACT-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Majzner is an Assistant
Professor of Pediatrics in the Division of Hematology and Oncology at the Stanford University Medical Center. Prior to joining
Stanford, he worked in the laboratory of Dr. Crystal Mackall at the National Cancer Institute. His research interests lie in the
optimization of chimeric antigen receptor (CAR) T cell therapies for sarcomas and other solid tumors. Dr. Majzner received his
M.D. from Harvard Medical School, and completed his pediatric residency at Columbia University and fellowship in pediatric hematology-oncology
at the joint program of Johns Hopkins University and the National Cancer Institute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Senior Medical Advisor and CEO of
Claves Life Sciences Limited</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DR. HERMAN WEISS, M.D.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Herman Weiss, M.D.,
has been appointed as our senior medical advisor and also the Chief Executive Officer and Executive Director of one of our wholly-owned
subsidiaries, Claves Life Sciences Limited (&ldquo;Claves&rdquo;). Claves is focused on microbiome-based approach to metabolic
diseases. Dr. Weiss will be leading the development of Claves&rsquo; business and drive Claves&rsquo; microbiome-based research
platform for treatments of metabolic diseases, and potentially other indications, to targeted clinical stages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Weiss has over
20 years of experience in the medical field. He is currently a Physician at Maccabi and Meuchedet Kuppot Health System and Chairman
of the Board of Directors of Todos Medical in Israel. Dr. Weiss previously held senior roles at both Juniper Pharmaceuticals, as
Head of Clinical Development and Medical Affairs, and at Teva Pharmaceuticals, as Global Medical Director. He has also consulted
for various medical device and biotech companies. He owns multiple patents and is the author of numerous publications in the area
of women&#8217;s health/gynecology. Dr. Weiss received his MBA from the George Washington University, his M.D. from the Ohio State
University College of Medicine and his B.A. from Ramapo College of New Jersey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Senior Strategic Consultant</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Dr.
Kira Sheinerman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Kira Sheinerman
is the co-founder, CEO and Executive Director of DiamiR Biosciences, a molecular diagnostics company focused on developing blood-based
tests for early detection and monitoring of brain health conditions. Dr. Sheinerman also serves as a Managing Director, Healthcare
Investment Banking at H.C. Wainwright &amp; Co. Previously, she was a Managing Director at Rodman &amp; Renshaw, where she worked
on financial and strategic transactions for growth biotech companies with a focus on CNS, oncology, and infectious diseases, as
well as molecular diagnostics. Prior to healthcare investment banking, Dr. Sheinerman worked at the Arcus group, a life sciences
strategic consulting firm. She is a board member of the Boyce Thompson Institute, an affiliate of Cornell University. Dr. Sheinerman
received her Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in New York for her work on molecular mechanisms
of Alzheimer's disease. She also holds an MBA from the Honors program at the Zicklin School of Business, Baruch College, City University
of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Senior Clinical Advisor of Aptorum
Therapeutics Limited </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. NISHANT AGRAWAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Agrawal, MD, has
been serving as the Director of Head and Neck Surgical Oncology, and Professor of Surgery at The University of Chicago School of
Medicine since October 2015. He is specialized in management of patients with benign and malignant tumors of the head and neck,
and has been practicing Otolaryngology - Head and Neck Surgery, at The University of Chicago Medicine, and Center for Advanced
Medicine, both in Chicago since 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Agrawal&#8217;s
work has achieved international recognition in the field of head and neck surgical oncology, as well as head and neck cancer genetics.
Under his leadership, a team of researchers completed a landmark study that examined the genome of head and neck squamous cell
carcinoma. His team has published extensively in the genomic landscapes of major head and neck cancers, including esophageal squamous
cell carcinoma, esophageal adenocarcinoma, medullary thyroid cancer, adenoid cystic carcinoma, and mucoepidermoid carcinoma. Dr.
Agrawal then applied these findings to identify tumor DNA as a biomarker that improves cancer diagnostics in the saliva and plasma
of patients with head and neck squamous cell carcinoma. His researches focus on the application of cancer genetics to design diagnostic
approaches to reduce morbidity and mortality from head and neck cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to his
clinical and research contributions, Dr. Agrawal is an accomplished educator-teaching medical students, residents, and fellows
about the management of patients with head and neck cancer. Prior to joining the University of Chicago, Dr. Agrawal was an associate
professor at Johns Hopkins University, where he completed his medical training in 2001, followed by internship and residency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Dr. Agrawal
was granted fellowships from the Memorial Sloan Kettering Cancer Center, New York (Head and Neck Surgical Oncology), and from Johns
Hopkins University School of Medicine, Baltimore (Molecular Genetics). He holds numerous Memberships from accredited American medical
associations and institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Specifically,
as a Senior Clinical Advisor, Dr. Agrawal supports our efforts to identify, develop and commercialize novel therapies for patients
and the healthcare industry. He provides a diverse collection of academic, industrial and regulatory expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly
competitive and subject to rapid and significant change. While we believe that our development and commercialization experience,
scientific knowledge and industry relationships provide us with competitive advantages, we face competition from pharmaceutical
and biotechnology companies, including specialty pharmaceutical companies, and generic drug companies, academic institutions, government
agencies and research institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are a number
of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drugs
and devices for the diagnosis and treatment of diseases for which we are developing products or technology. Moreover, a number
of additional drugs are currently in clinical trials and may become competitors if and when they receive regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors
have longer operating histories, better name recognition, stronger management capabilities, better supplier relationships, a larger
technical staff and sales force and greater financial, technical or marketing resources than we do. Mergers and acquisitions in
the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of
our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other
novel therapies that are more effective, safer or less costly than our current drug candidates, or any future drug candidates we
may develop, or obtain regulatory approval for their products more rapidly than we may obtain approval for our current drug candidates
or any such future drug candidates. Our success will be based in part on our ability to identify, develop and manage a portfolio
of drug and device candidates that are safer and more effective than competing products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities
in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the
research and clinical development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping,
promotion, advertising, distribution, post-approval monitoring and reporting, marketing, pricing, export and import of drug and
device products (&#8220;Regulated Products&#8221;), such as those we are developing. Generally, before a new Regulated Product
can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized to address the requirements
of and in the format specific to each regulatory authority, submitted for review and approved by the regulatory authority. This
process is very lengthy and expensive, and success is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulated Products
are also subject to other federal, state and local statutes and regulations in the United States and other countries, as applicable.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable
regulatory requirements at any time during the product development process, approval process or after approval, may subject an
applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the regulatory authority&#8217;s
refusal to approve pending applications, withdrawal of an approval, clinical holds, untitled or warning letters, voluntary product
recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions,
disbarment, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any such administrative
or judicial enforcement action could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As AML Clinic and part
of the Company&#8217;s operation are located in Hong Kong, the Company is subject to various Hong Kong laws and regulation covering
its business activities there, described in further detail below. Also, the Company anticipates that, if it obtains marketing approval
for any of its drug and device candidates, it intends to focus its marketing and sales efforts primarily in three regions: the
United States, Europe and PRC. The regulatory framework for each of these regions is described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>U.S. Drug Development Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining
regulatory approvals and maintaining compliance with appropriate federal, state and local statutes and regulations requires the
expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during
the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions
or lead to voluntary product recalls. Administrative or judicial sanctions could include the FDA&#8217;s refusal to approve pending
applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product seizures, total or partial suspension
of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal
penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">completion of non-clinical laboratory tests, preclinical studies according to cGLP and manufacturing of clinical supplies according to cGMP;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">approval by an independent IRB, at each clinical site before each trial may be initiated;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">performance of adequate and well-controlled human clinical trials according to cGCP, to establish the safety and efficacy of the proposed product for its intended use;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">preparation and submission to the FDA of an NDA, for a drug;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">satisfactory completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">payment of user fees and the FDA review and approval of the NDA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Devices are subject
to different forms of testing and approval, but (except for certain laboratory-developed diagnostic tests) still require satisfaction
of various FDA requirements in order to be brought to market. As of the date hereof, the device candidate currently under development
is SLS-1. We do not currently have a commercialization timeline for SLS-1 and cannot assure you that SLS-1 will ever be ready for
commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and approval
process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our drug candidates,
or any future drug candidates we may develop, will be granted on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a drug candidate
is identified for development, it enters the non-clinical testing stage. Non-clinical tests include laboratory evaluations of product
chemistry, toxicity, formulation and stability, as well as preclinical studies. An IND sponsor must submit the results of the non-clinical
tests, together with manufacturing information, analytical data and any available clinical data or literature, to the FDA as part
of the IND prior to commencing any testing in humans. An IND sponsor must also include a protocol detailing, among other things,
the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in
monitoring safety, and the effectiveness criteria to be evaluated if the initial clinical trial lends itself to an efficacy evaluation.
Some non-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt
by the FDA, unless the FDA raises concerns or questions related to a proposed clinical trial and places the trial on a clinical
hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the
clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety
concerns or non-compliance, and may be imposed on all products within a certain class of products. The FDA also can impose partial
clinical holds, for example, prohibiting the initiation of clinical trials for certain duration or for certain doses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All clinical trials
must be conducted under the supervision of one or more qualified investigators in accordance with cGCP regulations. These regulations
include the requirement that all research subjects provide informed consent in writing before their participation in any clinical
trial. Further, an IRB representing each institution participating in a clinical trial must review and approve the plan for any
clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least
annually. An IRB is responsible for protecting the rights of clinical trial subjects and considers, among other things, whether
the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits.
The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical
trial subject or his or her legal representative and must monitor the clinical trial until completed. Each new clinical protocol
and any amendments to the protocol must be submitted to the FDA for review, and to the IRBs for approval. Protocol detail, among
other things, includes the objectives of the clinical trial, testing procedures, sublease selection and exclusion criteria, and
the parameters to be used to monitor subject safety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials
are typically conducted in three sequential phases that may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Phase 1.</B> Phase 1 includes the initial introduction of an investigational new drug into humans. These studies are closely monitored and may be conducted in patients, but are usually conducted in healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug&#8217;s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. Phase 1 studies also evaluate drug metabolism, structure-activity relationships, and the mechanism of action in humans. These studies also determine which investigational drugs are used as research tools to explore biological phenomena or disease processes. The total number of subjects included in Phase 1 studies varies with the drug, but is generally in the range of twenty to eighty.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Phase 2.</B> Phase 2 includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular indication or indications in patients with the disease or condition. This phase of testing also helps determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well-controlled, closely monitored, and conducted in a relatively small number of patients, usually involving several hundred people.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Phase 3. </B>Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained in Phase 2, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug. Phase 3 studies are designed to provide an adequate basis for extrapolating the results to the general population and transmitting that information in the physician labeling. Phase 3 studies usually include several hundred to several thousand people.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Progress reports detailing
the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA
and clinical investigators within 15 calendar days for serious and unexpected suspected adverse events, any clinically important
increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure,
or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the drug
candidate. Additionally, a sponsor must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction no
later than 7 calendar days after the sponsor&#8217;s receipt of the information. There is no assurance that Phase 1, Phase 2 and
Phase 3 testing can be completed successfully within any specified period, or at all. The FDA or the sponsor may suspend or terminate
a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to
an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the
clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product has been associated with
unexpected serious harm to subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical
trials, companies usually complete additional preclinical studies and must also develop additional information about the chemistry
and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance
with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product drug
and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final
product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
that the product drug does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of product
development, non-clinical studies and clinical trials, together with other detailed information regarding the manufacturing process,
analytical tests conducted on the product, proposed labeling and other relevant information, are submitted to the FDA as part of
an NDA requesting approval to market the new drug. The FDA reviews all NDAs submitted within 60 days of submission to ensure that
they are sufficiently complete for substantive review before it accepts them for filing. If the submission is accepted for filing,
the FDA begins an in-depth substantive review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval process
is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may
require additional clinical data or other data and information. Even if such data and information are submitted, the FDA may ultimately
decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and
the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency
decides not to approve the NDA in its present form. The complete response letter usually describes all of the specific deficiencies
that the FDA identified in the NDA that must be satisfactorily addressed before it can be approved. The deficiencies identified
may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally,
the complete response letter may include recommended actions that the applicant might take to place the application in a condition
for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies
identified in the letter, or withdraw the application or request an opportunity for a hearing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If after such review
a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain
contraindications, warnings or precautions be included in the product labeling. Any products for which we receive the FDA approval
would be subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of
adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution
requirements, complying with certain electronic records and signature requirements and complying with the FDA promotion and advertising
requirements. In addition, the FDA may require post-approval studies, including Phase 4 clinical trials, to further assess a product&#8217;s
safety and effectiveness after NDA approval and may require testing and surveillance programs to monitor the safety of approved
products that have been commercialized. The FDA also may conclude that an NDA may only be approved with a Risk Evaluation and Mitigation
Strategy designed to mitigate risks through, for example, a medication guide, physician communication plan, or other elements to
assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any products for which
we receive the FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling
and distribution requirements, complying with certain electronic records and signature requirements and complying with the FDA
promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information
on products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the
provisions of the approved label. Further, manufacturers must continue to comply with cGMP requirements, which are extensive and
require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process
generally require prior the FDA approval before being implemented and other types of changes to the approved product, such as adding
new indications and additional labeling claims, are also subject to further the FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may withdraw
a product approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product may result in restrictions on the product&#8217;s marketing
or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements
may result in administrative or judicial actions, such as fines, untitled or warning letters, holds on clinical trials, product
seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements,
restrictions on marketing or manufacturing, injunctions or consent decrees, or civil or criminal penalties, or may lead to voluntary
product recalls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent Term Restoration and Marketing
Exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because drug approval
can take an extended period of time, there may be limited remaining life for the patents covering the approved drug, meaning that
the company has limited time to use the patents to protect the sponsor&#8217;s exclusive rights to make, use and sell that drug.
In such a case, U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term
Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of
up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However,
patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDCA
provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval
of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity
period, the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted
by another company for another version of such drug where the applicant does not own or have a legal right of reference to all
the data required for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, if appropriate,
we intend to apply for restorations of patent term and/or marketing exclusivity for some of our products; however, there can be
no assurance that any such extension or exclusivity will be granted to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disclosure of Clinical Trial Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sponsors of clinical
trials of the FDA-regulated products, including drugs are required to register and disclose certain clinical trial information,
which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation,
study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors
are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials
can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available
information to gain knowledge regarding the progress of development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pharmaceutical Coverage, Pricing
and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Much of the revenue
generated by new Regulated Products depends on the willingness of third-party payors to reimburse the price of the product. Significant
uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In
the United States, sales of any products for which we may receive regulatory approval for commercial sale will depend in part on
the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed
care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage
for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party
payors may limit coverage to specific products on an approved list, or formulary, which is not required to include all of the FDA-approved
products for a particular indication. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that
an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain
price levels sufficient to realize an appropriate return on our investment in product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-party payors
are increasingly challenging the price and examining the medical necessity and cost- effectiveness of medical products and services,
in addition to their safety and efficacy. To obtain coverage and reimbursement for any product that might be approved for sale,
we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness
of any products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered
medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available
therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may
not be sufficient to allow a company to sell its products at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. government
and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid
health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products
for branded prescription drugs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions
with existing controls and measures, could limit payments for pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if favorable coverage
and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future. Unfavorable coverage or reimbursement policies regarding any
of the Company&#8217;s products would have a material adverse impact on the value of that product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other Healthcare Laws and Compliance Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain regulatory
approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry.
These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject
to patient privacy regulation by both the federal government and the states in which we conduct our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patient Protection and the Affordable Care Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Affordable Care
Act, enacted in March 2010, includes measures that have or will significantly change the way health care is financed in the United
States by both governmental and private insurers. Among the provisions of the Affordable Care Act of greatest importance to the
pharmaceutical industry are the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. The Affordable Care Act increased pharmaceutical manufacturers&#8217; rebate liability on most branded prescription drugs from 15.1% of the average manufacturer price to 23.1% of the average manufacturer price, added a new rebate calculation for line extensions of solid oral dosage forms of branded products, and modified the statutory definition of average manufacturer price. The Affordable Care Act also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and expanding the population potentially eligible for Medicaid drug benefits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The Affordable Care Act expanded the types of entities eligible to receive discounted 340B pricing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Affordable Care Act imposed a requirement on manufacturers of branded drugs to provide a 50% discount off the negotiated price of branded drugs dispensed to Medicare Part D patients in the coverage gap (i.e., the &#8220;donut hole&#8221;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Affordable Care Act imposed an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, although this fee does not apply to sales of certain products approved exclusively for orphan indications.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to these
provisions, the Affordable Care Act established a number of bodies whose work may have a future impact on the market for certain
pharmaceutical products. These include the Patient-Centered Outcomes Research Institute, established to oversee, identify priorities
in, and conduct comparative clinical effectiveness research, the Independent Payment Advisory Board, which has authority to recommend
certain changes to the Medicare program to reduce expenditures by the program, and the Center for Medicare and Medicaid Innovation
within the Centers for Medicare and Medicaid Services, to test innovative payment and service delivery models to lower Medicare
and Medicaid spending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other laws
may result in additional reductions in healthcare funding, which could have a material adverse effect on customers for our product
candidates, if we gain approval for any of them. Although we cannot predict the full effect on our business of the implementation
of existing legislation or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe
that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect
how much or under what circumstances healthcare providers will use our product candidates if we gain approval for any of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Medical Device Regulatory Approval
Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Medical Devices are
subject to different forms of testing and approval, and require satisfaction of various FDA requirements including the Food, Drug
and Cosmetic Act (FDCA) in order to be brought to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The two primary types
of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket
approval. The type of marketing authorization is generally linked to the classification of the device. The FDA classifies medical
devices into one of three classes &#8212; Class I, Class II or Class III &#8212; based on the degree of risk the FDA determines
to be associated with a device and the level of regulatory control deemed necessary to ensure the device&#8217;s safety and effectiveness.
Devices requiring fewer controls because they are deemed to pose lower risk are placed in Class I or II. Class I devices are deemed
to pose the least risk and are subject only to general controls applicable to all devices, such as requirements for device labeling,
premarket notification, and adherence to the FDA&#8217;s Good Manufacturing Practices. Class II devices are intermediate risk devices
that are subject to general controls and may also be subject to special controls such as performance standards, product-specific
guidance documents, special labeling requirements, patient registries, or post-market surveillance. Class III devices are those
for which insufficient information exists to assure safety and effectiveness solely through general controls or if the device is
a life-sustaining, life-supporting or a device of substantial importance in preventing impairment of human health, or which presents
a potential, unreasonable risk of illness or injury and special controls are not adequate to assure safety and effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most Class I devices
and some Class II devices are exempted by regulation from the 510(k) clearance requirement and can be marketed without prior authorization
from the FDA. Most Class II devices (and certain Class I devices that are not exempt) are eligible for marketing through the 510(k)
clearance pathway. By contrast, devices placed in Class III generally require premarket approval or 510(k) de novo clearance prior
to commercial marketing. The premarket approval process is more stringent, time-consuming, and expensive than the 510(k) clearance
process. However, the 510(k) clearance process has also become increasingly stringent and expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">510(k) Clearance Pathway.
When a 510(k) clearance is required, a premarket notification must be submitted to the FDA demonstrating that a proposed device
is &#8220;substantially equivalent&#8221; to a previously cleared and legally marketed 510(k) device or a device that was in commercial
distribution before May 28, 1976 for which the FDA has not yet called for the submission of a premarket approval application, which
is commonly known as the &#8220;predicate device.&#8221; A device is substantially equivalent if, with respect to the predicate
device, it has the same intended use and has either (i) the same technological characteristics or (ii) different technological
characteristics and the information submitted demonstrates that the device is as safe and effective as a legally marked device
and does not raise different questions of safety or effectiveness. By law, the FDA is required to clear or deny a 510(k) premarket
notification within 90 days of submission of the application. As a practical matter, clearance often takes significantly longer.
The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence. If
the FDA determines that the device, or its intended use, is not substantially equivalent to a previously-cleared device or use,
the FDA will issue a not substantially equivalent decision. This means the device cannot be cleared through the 510k process and
will require marketing authorization through the premarket approval pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Premarket Approval
Pathway. A premarket approval application must be submitted to the FDA if the device cannot be cleared through the 510(k) process.
The premarket approval application process is much more demanding than the 510(k) premarket notification process and requires the
payment of significant user fees. A premarket approval application must be supported by valid scientific evidence, which typically
requires extensive data, including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate
to the FDA&#8217;s satisfaction reasonable evidence of safety and effectiveness of the device. The FDA has 45 days from its receipt
of a premarket approval application to determine whether the application will be accepted for filing based on the FDA&#8217;s threshold
determination that it is sufficiently complete to permit substantive review. After the FDA determines that the application is sufficiently
complete to permit a substantive review, the FDA will accept the application and begin its in-depth review. The FDA has 180 days
to review an &#8220;accepted&#8221; premarket approval application, although this process typically takes significantly longer
and may require several years to complete. During this review period, the FDA may request additional information or clarification
of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate
the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct
a preapproval inspection of the manufacturing facility to ensure compliance with quality system regulations. The FDA may delay,
limit or deny approval of a premarket approval application for many reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">failure of the applicant to demonstrate that there is reasonable assurance that the medical device is safe or effective under the conditions of use prescribed, recommended or suggested in the proposed labeling;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">insufficient data from the preclinical studies and clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the manufacturing processes, methods, controls or facilities used for the manufacture, processing, packing or installation of the device do not meet applicable requirements. If the FDA evaluations of both the premarket approval application and the manufacturing facilities are favorable, the FDA will either issue an approval order or an approvable letter, which usually contains a number of conditions that must be met in order to secure final approval of the premarket approval application. If the FDA&#8217;s evaluation of the premarket approval application or manufacturing facilities is not favorable, the FDA will deny approval of the premarket approval application or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the premarket approval application. The FDA may also determine that additional clinical trials are necessary, in which case the premarket approval application may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the premarket approval application. Once granted, a premarket approval application may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical Trials. Clinical
trials are almost always required to support premarket approval and are sometimes required for 510(k) clearance. In the United
States, these trials generally require submission of an application for an Investigational Device Exemption, or IDE, to the FDA.
The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing it is safe to
test the device in humans and that the testing protocol is scientifically sound. The FDA must approve the IDE in advance of trials
for a specific number of patients unless the product is deemed a non-significant risk device eligible for more abbreviated IDE
requirements or the clinical investigation is exempt from the IDE regulations. Clinical trials for significant risk devices may
not begin until the IDE application is approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinical
trial sites. The applicant, the FDA or the IRB at each site at which a clinical trial is being performed may suspend a clinical
trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits. Even if a trial
is completed, the results of clinical testing may not demonstrate the safety and efficacy of the device, may be equivocal or may
otherwise not be sufficient to obtain approval or clearance of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both the 510(k) and
premarket approval processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies.
The FDA&#8217;s 510(k) clearance process usually takes from approximately three to 12 months, but may take longer. The process
of obtaining a premarket approval is much more costly and uncertain than the 510(k) clearance process and generally takes from
approximately one to five years, or longer, from the time the application is submitted to the FDA until an approval is obtained.
The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and the
applicant may not be able to obtain these clearances or approvals on a timely basis, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
our sole device candidate currently under development is SLS-1, which is a platform for the dexterous manipulation of cardiovascular
robotic surgical catheter, conventionally classified as a cardiovascular steerable catheter, in the MRI environment. We do not
currently have a commercialization timeline for SLS-1 and cannot assure you that SLS-1 will ever be ready for commercialization.
If we are ready to seek regulatory approval for the SLS-1 device in the U.S., we expect that the FDA will classify it as a Class
II non-exempted device requiring premarket clearance under Section 510(k) of the FDCA. If our device cannot clear through the 510(k)
process, we will need to obtain marketing authorization through the premarket approval pathway, which will be more costly, lengthy
and uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Canadian Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Canada, our
pharmaceutical product candidates and our research and development activities are primarily regulated by the&nbsp;<I>Food and
Drugs Act&nbsp;</I>and the rules and regulations thereunder, which are enforced by Health Canada. Health Canada regulates, among
other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion,
distribution, post-approval monitoring, marketing and import and export of pharmaceutical products. Drug approval laws require
licensing of manufacturing facilities, carefully controlled research and testing of products, government review and approval of
experimental results prior to giving approval to sell drug products. Regulators also typically require that rigorous and specific
standards such as Good Manufacturing Practices, Good Laboratory Practices, or GLP, and Good Clinical Practices, or GCP, are followed
in the manufacture, testing and clinical development, respectively, of any drug product. The processes for obtaining regulatory
approvals in Canada, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial
time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The principal
steps required for drug approval in Canada is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Preclinical
Toxicology Studies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-clinical&nbsp;studies
are conducted&nbsp;<I>in vitro&nbsp;</I>and in animals to evaluate pharmacokinetics, metabolism and possible toxic effects to
provide evidence of the safety of the drug candidate prior to its administration to humans in clinical studies and throughout
development. Such studies are conducted in accordance with applicable laws and GLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Initiation
of Human Testing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Canada, the
process of conducting clinical trials with a new drug cannot begin until we have submitted a Clinical Trial Application, or CTA,
and the required number of days has lapsed without objection from Health Canada. Similar regulations apply in Canada to a CTA
as to an IND in the United States. Once approved, two key factors influencing the rate of progression of clinical trials are the
rate at which patients can be enrolled to participate in the research program and whether effective treatments are currently available
for the disease that the drug is intended to treat. Patient enrollment is largely dependent upon the incidence and severity of
the disease, the treatments available and the potential side effects of the drug to be tested and any restrictions for enrollment
that may be imposed by regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Clinical
Trials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar regulations
apply in Canada regarding clinical trials as in the United States. In Canada, Research Ethics Boards, or REBs, instead of IRBs,
are used to review and approve clinical trial plans. Clinical trials involve the administration of an investigational new drug
to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCP,
requirements, which include review and approval by REBs. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria
to be evaluated and a statistical analysis plan. Human clinical trials are typically conducted in three sequential phases, as
discussed above in the context of government regulation in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture
of investigational drugs for the conduct of human clinical trials is subject to current Good Manufacturing Practice, or cGMP,
requirements. Investigational drugs and active pharmaceutical ingredients imported into Canada are also subject to regulation
by Health Canada relating to their labeling and distribution. Progress reports detailing the results of the clinical trials must
be submitted at least annually to Health Canada and the applicable REBs, and more frequently if serious adverse events occur.
Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore,
in Canada, Health Canada or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a
finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an REB can suspend or terminate
approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the REB&rsquo;s
requirements or if the drug has been associated with unexpected serious harm to subjects. Additionally, some clinical trials are
overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring
board or committee. This group regularly reviews accumulated data and advises the study sponsor regarding the continuing safety
of trial subjects, potential trial subjects and the continuing validity and scientific merit of the clinical trial. We may also
suspend or terminate a clinical trial based on evolving business objectives or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>New
Drug Application</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon successful
completion of Phase 3 clinical trials, in Canada the company sponsoring a new drug then assembles all the preclinical and clinical
data and other testing relating to the product&rsquo;s pharmacology, chemistry, manufacture, and controls, and submits it to Health
Canada as part of a New Drug Submission, or NDS. The NDS is then reviewed by Health Canada for approval to market the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the
approval process, Health Canada will inspect the facility or the facilities at which the drug is manufactured. Health Canada will
not approve the product unless compliance with cGMP&mdash;a quality system regulating manufacturing&mdash;is satisfactory and
the NDS contains data that provide substantial evidence that the drug is safe and effective in the indication studied. In addition,
before approving an NDS, Health Canada will typically inspect one or more clinical sites to assure compliance with GCP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and
approval process for an NDS requires substantial time, effort and financial resources, and may take several years to complete.
Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations,
which could delay, limit or prevent regulatory approval. Health Canada may not grant approval of an NDS on a timely basis, or
at all. In Canada, NDSs are subject to user fees and these fees are typically increased annually to reflect inflation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if Health
Canada approves a product candidate, the relevant authority may limit the approved indications for use of the product candidate,
require that contraindications, warnings or precautions be included in the product labeling, including a black box warning, require
that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&rsquo;s safety after approval,
require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution restrictions or other risk management mechanisms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Health Canada may
prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional
labeling claims, are subject to further testing requirements, notification, and regulatory authority review and approval. Further,
should new safety information arise, additional testing, product labeling or regulatory notification may be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>European Union Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Regulation in the European Union</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process governing
approval of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory completion
of pharmaceutical development, non-clinical studies and adequate and well-controlled clinical trials to establish the safety and
efficacy of the medicinal product for each proposed indication. It also requires the submission to relevant competent authorities
for clinical trials authorization and to the European Medicines Authority, or EMA, for a marketing authorization application, or
MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinical Trial Approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the currently
applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on cGCP, a system for the approval of clinical trials
in the EU (the equivalent of the IND process in the United States) has been implemented through national legislation of the EU
member states. Under this system, an applicant must obtain approval from the competent national authority of an EU member state
in which the clinical trial is to be conducted or in multiple EU member states if the clinical trial is to be conducted in a number
of EU member states. Furthermore, the applicant may only start a clinical trial at a specific study site after the independent
ethics committee has issued a favorable opinion. The clinical trial application, or CTA, must be accompanied by an investigational
medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding
national laws of the EU member states and further detailed in applicable guidance documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2014, the
EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC.
It is expected that the new Clinical Trials Regulation will apply in 2019. It will overhaul the current system of approvals for
clinical trials in the EU. Specifically, the new regulation, which will be directly applicable in all EU member states, aims at
simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Clinical Trials Regulation provides
for a streamlined application procedure using a single entry point and strictly defined deadlines for the assessment of clinical
trial applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Marketing Authorization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To obtain a marketing
authorization for a product under the EU regulatory system (the equivalent of the NDA process in the United States), an applicant
must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent
authorities in EU member states (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization
may be granted only to an applicant established in the EU. Regulation (EC) No. 1901/2006 provides that prior to obtaining a marketing
authorization in the EU, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation
Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver,
or a deferral for one or more of the measures included in the PIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized procedure
provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states. Pursuant
to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced
by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products
with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For
products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for
which a centralized process is in the interest of patients, the centralized procedure may be optional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized
procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established by the EMA is responsible for conducting
the assessment of a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the
evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided
by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases,
when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of
therapeutic innovation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the CHMP accepts
such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard
time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Periods of Authorization and Renewals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization
is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk benefit
balance by the EMA or by the competent authority of the authorizing Member State. To that end, the marketing authorization holder
must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy,
including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization
ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission
or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year
renewal period. Any authorization that is not followed by the placement of the drug on the EU market (in the case of the centralized
procedure) or on the market of the authorizing Member State within three years after authorization ceases to be valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory Requirements after Marketing
Authorization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following approval,
the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing,
promotion and sale of the medicinal product. These include compliance with the EU&#8217;s stringent pharmacovigilance or safety
reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition,
the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted
in strict compliance with the EMA&#8217;s cGMP requirements and comparable requirements of other regulatory bodies in the EU, which
mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and
identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education
and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU under Directive
2001/83EC, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Orphan Drug Designation and Exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulation (EC) No.
141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission
if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening
or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made,
or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is
unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either
of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment
of the condition in question that has been authorized in the EU or, if such method exists, the drug has to be of significant benefit
compared to products available for the condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An orphan drug designation
provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU
marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this
market exclusivity period, neither the EMA nor the European Commission or the EU member states can accept an application or grant
a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as
a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product,
and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication
may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the
criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>European Medical Device Regulatory
Approval Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As in the United States,
there is a separate regulatory framework for approval of medical devices. If the Company determines to commercialize SLS-1 or another
medical device, it will become subject to all of the requirements for approval required by those regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PRC Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to protect
our potential market in the PRC, we have obtained an exclusive license of certain PRC patents directed to certain of the drug candidates
that we are developing and are currently seeking approval of additional patent and other IP filings in the PRC. We do not otherwise
conduct business in the PRC. Seeking IP approval in the PRC subjects us to some of the rules and practices of the PRC government.
Since the Company intends eventually to market its products in the PRC, at least some of our drug candidates may become subject
to regulatory approval and marketing authorization in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hong Kong Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The operations of AML
Clinic in Hong Kong are subject to certain general laws and regulations in relation to clinic medical professionals, trade description
and safety of consumer goods, medical advertisement and importation, exportation, dealing in and sale of pharmaceutical products
and drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Medical Clinics Ordinance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Medical Clinics
Ordinance provides for the registration, control and inspection of medical clinics. It requires a medical clinic to be registered,
with name and address and other prescribed particulars. &#8220;Medical clinic&#8221; means any premises used or intended to be
used for the medical diagnosis or treatment of persons suffering from, or believed to be suffering from, any disease, injury or
disability of mind or body, with specific exceptions, including private consulting rooms used exclusively by registered medical
practitioners in the course of their practice on their own account and not bearing any title or description which includes the
word &#8220;clinic&#8221; or &#8220;polyclinic&#8221; in the English language.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The application of registration may be refused
if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the income derived or to be derived from the establishment or operation of the clinic is not, or will not be, applied solely towards the promotion of the objects of the clinic; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any portion of such income, except payment of remuneration to employed registered medical practitioners, nurses and menial servants, will be paid by way of dividend, bonus or otherwise howsoever by way of profit to the applicant himself, or to any persons properly so employed, or to any other persons howsoever.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not believe that
the Medical Clinic Ordinance is applicable to the business of our Company and its subsidiaries, having considered, among others,
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the legislative intent behind the Medical Clinics Ordinance was to provide for registration of non-profit making clinics;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Food and Health Bureau of Hong Kong published a consultation document, &#8220;Regulation of Private Healthcare Facilities&#8221; in 2014 which specifically states that the Medical Clinics Ordinance and the Code of Practice For Clinics Registered Under The Medical Clinics Ordinance (Chapter 343 of the Laws of Hong Kong) set out the regulatory framework for non-profit-making medical clinics and that other private healthcare facilities, such as ambulatory medical centers and clinics operated by medical groups or individual medical practitioners, are not subject to direct statutory control beyond the regulation of an individual&#8217;s professional practice; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">our business is one which makes and intends to continue making profit as a listed entity. The payment of bonuses to some of our Hong Kong Doctors is clearly a reflection of the profit-making nature of our business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Hence, we do not believe
that AML Clinic is required to be registered under the Medical Clinics Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Waste Disposal Ordinance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Waste Disposal
Ordinance (Chapter 354 of the Laws of Hong Kong) (&#8220;WDO&#8221;) and the Waste Disposal (Clinical Waste) (General) Regulation
(Chapter 354O of the Laws of Hong Kong) (the &#8220;WDR&#8221;) provide for, among others, the control and regulation of the production,
storage, collection and disposal of clinical waste.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the WDO, clinical
waste means waste consisting of any substance, matter or thing generated in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">a dental, medical, nursing or veterinary practice;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any other practice, or establishment (howsoever described), that provides medical care and services for the sick, injured, infirm or those who require medical treatment;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">dental, medical, nursing, veterinary, pathological or pharmaceutical research; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">a dental, medical, veterinary or pathological laboratory practice,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">and which consists wholly or partly of
any of the materials specified in one or more of the groups listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">used or contaminated sharps;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">laboratory waste;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">human and animal tissues;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">infectious materials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">dressings; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">such other wastes as specified by the Director of the Environmental Protection Department (&#8220;EPD&#8221;) of Hong Kong.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the medical services
provided by AML Clinic and the research works in our R&amp;D Center may produce used or contaminated sharps such as syringes and
needles as well as dressings, we are subject to WDO, WDR and the Code of Practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Public Health and Municipal Services
Ordinance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to first
launch and market NativusWell<SUP>&reg;</SUP> (NLS-2) in Hong Kong. In Hong Kong, natural supplements are defined as &#8220;health
food&#8221; products. &#8220;Health food&#8221; containing medicines are subject to the Pharmacy and Poisons Ordinance (Cap 138)
and such &#8220;health food&#8221; containing Chinese medicines are regulated by the Chinese Medicine Ordinance (Cap 549), where
they must meet the requirements in respect of safety, quality and efficacy before they can be registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other &#8220;health
food&#8221; products which cannot be classified as Chinese medicine or western medicine are regulated under the Public Health and
Municipal Services Ordinance (Cap 132) as general food products. The Public Health and Municipal Services Ordinance requires the
manufacturers and sellers of food to ensure that their products are fit for human consumption and comply with the requirements
in respect of food safety, food standards and labelling. In addition, all prepackaged food should bear labels which correctly list
out the ingredients of the food under the Food and Drugs (Composition and Labelling) Regulations (Cap 132W) under the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NativusWell<SUP>&reg;</SUP>
(NLS-2) is made with the bioactive ingredient extracted Chinese yam powder and does not contain any western or Chinese medicine;
therefore, registration is not required under the local laws for marketing in Hong Kong. We will, however, ensure the compliance
of the Food and Drugs (Composition and Labelling) Regulations (Cap 132W) with by proper labelling in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rest of the World Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For other countries
in the world, the requirements governing the conduct of clinical trials, medical product licensing, pricing and reimbursement vary
from country to country. In all cases if clinical trials are required, they must be conducted in accordance with cGCP requirements
and the applicable regulatory requirements and the ethical principles having their origin in the Declaration of Helsinki.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply
with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory
approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
we have 38 employees, including 35 full-time employees and 3 part-time employees. Of these, 11 are engaged in full-time research
and development and laboratory operations, 20 are engaged in full-time general and administrative functions, 4 are full-time employees
engaged in the clinic operation and 3 part-time employees are engaged in sponsored research and development, clinic operations,
finance, and legal clerical support. As of the date of hereof, 37 of our employees are located in Asia and 1 of our employees is
located in Europe. In addition, we have engaged and may continue to engage 48 independent contracted consultants and advisors to
assist us with our operations. None of our employees are represented by a labor union or covered by a collective bargaining agreement.
We have never experienced any employment related work stoppages, and we consider our relations with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have several operating
leases for offices, laboratories and clinic. Our offices are located in London, New York and Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our office space in
London consists of approximately 172 square feet under a lease that commenced in August 2019, expires in March 2020 and has a rent
of $2,715 per month, and renewed in April 2020, expires in November 2020 and has a rent of $3,313 per month. Our office space in
New York consists of approximately 95 square feet under a lease that commenced in February 2020, which will automatically renew
until 1 month&#8217;s notice for termination, and has a rent of $1,844 per month. Our facilities in Hong Kong consists of: (i)
638 square feet lab space under a lease that commenced in December 2017 and expires in December 2020, that carries a monthly rent
of $2,127 and which is used for the center for R&amp;D (the &#8220;previous R&amp;D Center&#8221;); (ii) 851 square feet office
space under a lease that commenced in December 2017 and expires in December 2020 that carries a monthly rent of $2,509, (the &#8220;HKSTP
Office Space&#8221;); (iii) 2,021 square feet lab space that commenced in March 2020 and expires in March 2023, that carries a
monthly rent of $6,348 (the &#8220;new R&amp;D Center&#8221;); and (iv) 3,173 square feet space under a lease that commenced in
March 2018 and expires in March 2022 (the &#8220;AML Lease&#8221;, which is home to AML Clinic). The previous R&amp;D Center will
be expected to be terminated in the fourth quarter of 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payments under operating
leases are expensed on a straight-line basis over the periods of the respective leases, and the terms of the leases do not contain
rent escalation, contingent rent, and renewal or purchase options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our current
facilities are sufficient to meet our needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time we
may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently
a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse
effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have
an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Directors and Executive Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a list of
our directors and executive officers, as of the date of this prospectus, and a brief account of the business experience of each
of them. The business address for the directors and officers of Aptorum Group Limited is 17 Hanover Square, London W1S 1BN, United
Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 10, 2019,
Mr. Lui resigned from his position as Chief Business Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; padding: 0.25pt 3.25pt 0.75pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 3.25pt 0.75pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Executive Officers</I></FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Ian Huen</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Founder, Chief Executive Officer and Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Darren Lui</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">President and Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Clark Cheng</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">40</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Medical Officer and Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Sabrina Khan</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Thomas Lee</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Head of Research and Development</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Angel Ng</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">39</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Non-Management Directors</I></FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Charles Bathurst</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">65</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Independent Non-Executive Director and Chair of Audit Committee</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mirko Scherer</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">52</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Independent Non-Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Justin Wu</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">50</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Independent Non-Executive Director and Chair of Compensation Committee</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Douglas Arner</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">51</FONT></TD>
    <TD STYLE="padding: 0.25pt 3.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 3.25pt 0.25pt 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Independent Non-Executive Director and Chair of Nominating and Corporate Governance Committee</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Executive Officers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MR. IAN HUEN, Founder, Chief Executive
Officer and Executive Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Ian Huen is the
Founder, Chief Executive Officer and Executive Director of Aptorum Group Limited. Mr. Huen is also Co-Founder of a Hong Kong company,
AENEAS CAPITAL LIMITED, a licensed corporation regulated by the Hong Kong Securities &amp; Futures Commission as a Type 9 Asset
Manager, since 2005. He has over 17 years of global asset management experience and previously covered the U.S. healthcare sector
as an equity research analyst at Janus Henderson Group plc (formerly known as Janus Capital). Mr. Huen was the financial advisor
in the sale of Seng Heng Bank Limited (Macau) to Industrial and Commercial Bank of China in 2007 and was appointed as the vice
president of the Board of General Meeting in Industrial and Commercial Bank of China (Macau) Capital Limited in March 2007 for
a term of 12 years until March 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a trustee board
member of the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, access to research
resources across Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Huen graduated
from Princeton University with an A.B. degree in Economics in June 2001, earned a MA in Comparative and Public History from CUHK
in June 2016. Mr. Huen is also a Chartered Financial Analyst (&#8220;CFA&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MR. DARREN LUI</B>, <B>President and
Executive Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Darren Lui is the
President and an Executive Director of Aptorum Group Limited. Mr. Lui is also an Executive Director and Co-Founder of AENEAS CAPITAL
LIMITED, a licensed corporation regulated by the Hong Kong Securities &amp; Futures Commission as a Type 9 Asset Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Lui was previously
the founder, director and responsible officer of Varengold Capital Securities Limited and Varengold Capital Asset Management Limited
in Hong Kong, with subsidiaries operating brokerage, asset management, and investment businesses in Asia established since January
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this, he was
a Director within the Fixed Income Group of Barclays Capital, where he spent over nine years from September 2005 to February 2014
developing and establishing their London, Singapore and New York structuring teams. From September 2002 to August 2005 he was qualified
as a Chartered Accountant with Ernst &amp; Young LLP (London), specializing in capital markets advisory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Lui graduated with
First-Class Honors from Imperial College, London with a BSc degree in Biochemistry in June 2002. He is a Chartered Accountant (ICAS),
a CFA, and an Associate of Chartered Institute of Securities &amp; Investments (UK).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. CLARK CHENG, Chief Medical Officer
and Executive Director, Aptorum Group Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Director, Aptorum Medical
Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Clark Cheng is
the Chief Medical Officer and Executive Director of Aptorum Group Limited; he is also an executive director of AML; Dr. Cheng also
serves as a director of several other of our subsidiaries. Prior to this appointment, Dr. Cheng served as the Operations Director
since 2009 of Raffles Medical Group, and the company&#8217;s Deputy General Manager since 2011, representing an expanded role in
the region. During his employment with Raffles Medical Group, he practiced as a full-time medical administrator to overlook Raffles
Medical Hong Kong operations and supported its development in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Cheng received
his medical training at the University College London, UK, in 2005 and completed his foundation year training at The Royal Free
Hospital in 2007. Pursuing his career in surgery, he obtained his membership of the Royal College of Surgeons of Edinburgh in 2009
and commenced his training in Orthopaedics where he practiced as Specialist Registrar at the National University Hospital, Singapore,
with special interest in Traumatology of the lower limbs. In 2011, he also obtained his Master in Business &amp; Administration
with distinction from Tippie College of Business, University of Iowa, US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Cheng is an active
member of the Singapore Chamber of Commerce, and appears regularly as a guest speaker for The Open University of Hong Kong, The
Airport Authority Hong Kong and other corporate events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MISS SABRINA KHAN, Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Miss Sabrina Khan is
the Chief Financial Officer of Aptorum Group Limited. She leads the Company&#8217;s financial strategy and operations, as well
as Investor Relations. She has extensive experience working at KPMG (Hong Kong) and Ernst &amp; Young LLP (Hong Kong). She was
a regional financial controller in Asia for St. James&#8217;s Place Wealth Management (Hong Kong), which St. James&#8217;s Place
Wealth Management Group (LON: STJ) is a FTSE100 company. Prior to that, she served as the senior finance manager of Neo Derm Group,
a leading medical aesthetic group in Asia, in charge of its finance-related matters and expansion in the PRC. From August 2009
to May 2013, she served as the senior finance manager of Global Cord Blood Corporation (formerly known as China Cord Blood Corporation
(NYSE: CO)), which was previously a subsidiary of Golden Meditech Holdings Limited (HK: 801), where she played an important role
with the NYSE listing filings, investor relations and post IPO reporting. During her employment with Global Cord Blood Corporation,
she was actively involved in the issuance of convertible bonds to Kohlberg Kravis Roberts and various merger and acquisition projects,
facilitated and liaised with investment banks on due diligence, deal structuring, and also involved in commercial negotiation with
respect to major contract terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Miss Khan qualified
as certified public accountant and graduated with a BBA (Hons) in Accounting &amp; Finance at The University of Hong Kong in 2003.
She was qualified as an Advanced China Certified Taxation Consultant in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. THOMAS LEE, Head of Research and
Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Thomas Lee is the
Head of Research &amp; Development of Aptorum Group Limited. He served as Chief Executive Officer and Chief Scientific Officer
of Aptorum Therapeutics Limited, a wholly-owned therapeutics subsidiary of Aptorum Group Limited from January 2018 to March 2019.
Prior to that, Dr. Lee served as an Assistant Professor in the School of Pharmacy, Faculty of Medicine, The Chinese University
of Hong Kong from August 2013 to January 2018. Dr. Lee&#8217;s key area of research involves drug delivery with specialties including:
formulation development of poorly soluble compounds, oral delivery, Nanotechnology, and similar fields.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to academia,
Dr. Lee accumulated big-pharma experience from the decade he spent at two multinational pharmaceutical companies in the U.S. From
November 2008 to July 2013, Dr. Lee worked at Celgene Corporation as a Senior Scientist of the Formulations Research &amp; Development.
From June 2003 to November 2008, Dr. Lee worked at Novartis Pharmaceuticals Corporation, as a Principal Scientist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Lee graduated with
B.Pharm. (Hons) Degree from The Chinese University of Hong Kong in December 1995, and received his Ph.D. in Pharmaceutical Sciences
(Drug Delivery) from the University of Wisconsin-Madison in the U.S in May 2003.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. ANGEL NG, Chief Operating Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Angel Ng is the
Chief Operating Officer of Aptorum Group Limited. She served as the Chief Operating Officer (&#8220;COO&#8221;) of Aptorum Therapeutics
Limited, a wholly-owned therapeutics subsidiary of Aptorum Group Limited from September 2017 to March 2019. During this time, Dr.
Ng led Aptorum Therapeutics Limited and its subsidiaries&#8217; operations and business strategies. Dr. Ng has extensive experience
in project management with Innovation and Technology government funds and academic institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since September 2016,
Dr. Ng works as a Research Officer cum Project Manager at The University of Hong Kong (&#8220;HKU&#8221;) in project management
for various research projects including government funded project of novel medical device. During this time, Dr. Ng led the research
team towards cadaveric trial for a novel soft robotics medical device and coordinated all research related agreements. During December
2014 to September 2015, Dr. Ng served as Project Manager at Hong Kong Science &amp; Technology Parks Corporation (&#8220;HKSTP&#8221;),
where she worked on technology transfer and commercialization for research and development projects through partnerships between
local universities and the worldwide network and expertise of the Oxford University commercial arm. Dr. Ng also worked for The
Chinese University of Hong Kong (&#8220;CUHK&#8221;) as Project Manager from September 2007 to January 2009. She managed a HK$60M
government funded R &amp; D project with a team of specialists in CUHK where she kept close liaison with industry and government
authorities. Dr. Ng was in the precision chemical machining industry from 2003 to 2007, where she managed the manufacturing team
and business operations in PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Ng serves as a
Director of Tecford Trading &amp; Technology Company Limited since December 2017. Dr. Ng graduated with a B.Sc (Hons) from Department
of Chemistry at HKU in December 2002, received her M.Sc in Composite Materials from Imperial College London in November 2003 and
obtained her Ph.D. in Mechanical Engineering from HKU in December 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Independent Non-Executive Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MR. CHARLES BATHURST</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Bathurst is an
Independent Non-Executive Director of Aptorum Group Limited. He has over 41 years&#8217; experience of management and senior executive
roles primarily in financial services. In 2011, he set up his own independent consultancy service, Summerhill Advisors Limited,
advising on management structure, business development, financial reporting, internal audit controls and compliance to both emerging
and multinational companies. Today he holds Non-Executive and Advisory board positions on fast-growing companies in healthcare,
technology and financial services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to establishing
Summerhill, he served as a Director for J.O. Hambro Investment Management from September 2008 to August 2011, where he oversaw
the restructuring and commercialization a range of in-house investment funds. He was appointed to the management board and supervised
reporting teams including Business development, accounting teams, regulatory reporting teams and internal controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From April 2004 to
March 2008, Mr. Bathurst served in multiple roles at Old Mutual Asset Managers (UK), including being a member of the senior management
team and head of international sales. Duties included business development, launching new investment funds, recruitment, establishing
and supervision of regulatory and financial reporting teams, as well as ensuring compliance with funds&#8217; regulatory requirements
and corporate governance standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this, Mr.
Bathurst was an advisor to Lion Capital Advisors Limited from April 2003 to March 2004, and from June 2002 to March 2003 business
development reporting to the board of management of LCF Rothschild Asset Management Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From April 1995 to
March 2002, Mr. Bathurst joined a newly formed alternative investment management team at Credit Agricole Asset Management, establishing
the London Branch as the Managing Director in 1998. He was responsible for the recruitment and development strategy for marketing,
sales, investment, financial reporting, compliance and regulatory controls and investor relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Between the period
of September 1989 and December 1994, Mr. Bathurst worked for GNI, the largest futures and options execution and clearing broker
on the London International Financial Futures Exchange, where he focused on marketing to European and Middle East financial institutions.
In 1991, he joined a new management team to launch a series of specialist investment funds while serving as the Head of Sales and
Product Development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Bathurst graduated
from the Royal Military Academy Sandhurst in November 1974 and commissioned into the British Army serving in the UK and Germany.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. MIRKO SCHERER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Mirko Scherer is
an Independent Non-Executive Director of Aptorum Group Limited. Dr. Scherer has been serving as the Chief Executive Officer at
CoFeS China (formerly known as &#8220;TVM Capital China&#8221;) in Hong Kong since March 2015. CoFeS China focuses on cross-border
activities in the life science industry between China and the West. CoFeS China acts as a bridge between China and the West, assisting
Chinese investors and pharmaceutical companies accessing western innovations, while collaborating with innovative life science
companies from the West to enter the fast-growing China market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Mirko Scherer has
served on the Board of the Frankfurt Stock Exchange from 2005 to 2007 and has been a board member of the Stichting Preferente Aandelen
QIAGEN since 2004. From August 2016 through July 2018, Dr. Scherer served as a Non-Executive board member of Quantapore Inc. and
from April 2015 through September 2017, he was a director of China BioPharma Capital I, (GP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Scherer is an experienced
biotechnology executive and has led numerous financing M&amp;A and licensing transactions, in both public and private markets,
in Europe and the U.S. for over 20 years. He consulted MPM Capital for the period between July 2012 and December 2014. Dr. Scherer
was also a co-founder and partner of KI Kapital from November 2008 to February 2014, a company which was specialized in providing
consultation in life science industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to working in
the venture capital industry, Dr. Scherer co-founded GPC Biotech (Munich and Princeton, NJ) and served as the Chief Financial Officer
from October 1997 to December 2007. GPC Biotech engaged in numerous pharmaceutical alliances with companies such as Sanofi Aventis,
Boehringer Ingelheim, Altana (now part of Takeda), Yakult, and Pharmion (now part of Celgene). Over the past 20 years, Dr. Scherer
has established an extensive network in the U.S., European, and China&#8217;s biotechnology and venture capital industry. Prior
to his time at GPC Biotech, Dr. Scherer worked as a consultant from May 1993 to June 1994 at the Boston Consulting Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Scherer earned
a Doctorate in Finance from the European Business School in Oestrich-Winkel/Germany in 1998, a MBA from Harvard Business School
in June 1996, and a degree in Business Administration from the University of Mannheim/Germany in February 1993.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DR. JUSTIN WU</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Justin Wu is an
Independent Non-Executive Director of Aptorum Group Limited. He also has been serving as the Chief Operating Officer of CUHK Medical
Centre since August 2018. He served as the Associate Dean (Development) of the Faculty of Medicine at CUHK from July 2014 to June
2018 and the Associate Dean (Clinical) of the Faculty of Medicine at CUHK from December 2012 to July 2014, and has been serving
a Professor in the Department of Medicine and Therapeutics since 2009, also the Director of the S. H. Ho Center for Digestive Health,
a research center specializing in functional gastrointestinal diseases, reflux and motility disorders, and digestive endoscopy.
Active in research publications and assessments, Dr. Wu served as the International Associate Editor of American Journal of Gastroenterology
(&#8220;AJG&#8221;), and Managing Editor of Journal of Gastroenterology and Hepatology (&#8220;JGH&#8221;). He is also the Secretary
General of the Asian Neurogastroenterology and Motility Association (&#8220;ANMA&#8221;), and Secretary General of the Asia Pacific
Association of Gastroenterology (&#8220;APAGE&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Wu has won a number
of awards including the Emerging Leader in Gastroenterology Award by the JGH Foundation, and the Vice Chancellor&#8217;s Exemplary
Teaching Award at CUHK. Aside from his expertise in gastroenterology, Dr. Wu has an extensive interest in the development of Integrative
Medicine in Hong Kong. He is the Founding Director of the Hong Kong Institute of Integrative Medicine, working closely with the
School of Chinese Medicine to develop an integrative model at an international level. The institute aims at maximizing the strength
of Western and Chinese medicine to provide a safe and effective integrative treatment to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Wu served as a
consultant and an advisory board member for Takeda Pharmaceutical, AstraZeneca, Menarini, Reckitt Benckiser and Abbott Laboratory.
He earned his Bachelor of Medicine and Bachelor of Surgery Degree (1993), and his Doctor of Medicine Degree (2000) from CUHK. Additionally,
he attained Fellowships of the Royal College of Physicians of Edinburgh and London in 2007 and 2012 respectively, Fellowship of
the Hong Kong College of Physicians in 2002, Fellowship of the Hong Kong Academy of Medicine in 2002, and has been an American
Gastroenterological Association Fellow since 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROFESSOR DOUGLAS ARNER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Professor Douglas W.
Arner is an Independent Non-Executive Director of Aptorum Group Limited. He is the Kerry Holdings Professor in Law at the University
of Hong Kong and one of the world&#8217;s leading experts on financial regulation, particularly the intersection between law, finance
and technology. At HKU, he is Faculty Director of the Faculty of Law&#8217;s LLM in Compliance and Regulation, LLM in Corporate
and Financial Law and Law, Innovation, Technology and Entrepreneurship (LITE) Programmes. He is a Senior Visiting Fellow of Melbourne
Law School, University of Melbourne, and an Executive Committee Member of the Asia Pacific Structured Finance Association. He led
the development of the world&#8217;s largest massive open online course (MOOC): Introduction to FinTech, launched on edX in May
2018, now with over 35,000 learners spanning every country in the world. From 2006 to 2011, he was the Director of HKU&#8217;s
Asian Institute of International Financial Law, which he co-founded in 1999, and from 2012 to 2018, he led a major research project
on Hong Kong&#8217;s future as a leading international financial center. He was an inaugural member of the Hong Kong Financial
Services Development Council, of which he was a member from 2013-2019. Douglas served as Head of the HKU Department of Law from
2011 to 2014 and as Co-Director of the Duke University-HKU Asia-America Institute in Transnational Law from 2005 to 2016. He has
published fifteen books and more than 150 articles, chapters and reports on international financial law and regulation, including
most recently Reconceptualising Global Finance and its Regulation (Cambridge 2016) (with Ross Buckley and Emilios Avgouleas). The
RegTech Book (forthcoming 2019, with Janos Barberis and Ross Buckley). His recent papers are available on SSRN at https://papers.ssrn.com/sol3/cf_dev/AbsByAuth.cfm?per_id=524849,
where he is among the top 150 authors in the world by total downloads.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Douglas has served
as a consultant with, among others, the World Bank, Asian Development Bank, APEC, Alliance for Financial Inclusion, and European
Bank for Reconstruction and Development, and has lectured, co-organized conferences and seminars and been involved with financial
sector reform projects around the world. He has been a visiting professor or fellow at Duke, Harvard, the Hong Kong Institute for
Monetary Research, IDC Herzliya, McGill, Melbourne, National University of Singapore, University of New South Wales, Shanghai University
of Finance and Economics, and Zurich, among others. Since March 1, 2018, Professor Arner is the Senior Regulatory &amp; Strategic
Advisor of AENEAS CAPITAL LIMITED, a licensed corporation regulated by the Hong Kong Securities &amp; Futures Commission as a Type
9 Asset Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">He holds a BA from
Drury College (where he studied literature, economics and political science) in 1992, a JD (cum laude) from Southern Methodist
University in 1995, an LLM (with distinction) in banking and finance law from the University of London (Queen Mary College) in
1996, and a PhD from the University of London in 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Governance </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt"><FONT STYLE="background-color: white">As
long as our officers and directors, either individually or in the </FONT>aggregate, own at least 50% of the voting power of our
Company, we will be a &#8220;controlled company&#8221; as defined under NASDAQ Marketplace Rules (specifically, as defined in Rule
5615(c)). We have no current intention to rely on the controlled company exemptions afforded to a controlled company under the
NASDAQ Marketplace Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Composition of Our Board of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Our Board of
Directors currently consists of seven members, all of whom were elected pursuant to our current Memorandum and Articles. Our
nominating and corporate governance committee and board of directors will consider a broad range of factors relating to the
qualifications and background of nominees, which may include diversity and is not limited to race, gender or national origin.
We have no formal policy regarding board diversity. Our nominating and corporate governance committee&#8217;s and board of
directors&#8217; priority in selecting board members is identification of persons who will further the interests of our
shareholders through his or her established record of professional accomplishment, the ability to contribute positively to
the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape and
professional and personal experiences and expertise relevant to our growth strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">There is no Cayman Islands
law requirement that a director must hold office for a certain term and stand for re-election unless the resolutions appointing
the director impose a term on the appointment. The Memorandum and Articles provide that our directors will be elected annually
to serve a term of one year, or until his or her earlier resignation or removal. We do not have any age limit requirements relating
to our director&#8217;s term of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Our Memorandum and Articles
also provide that our directors may be removed by the directors or ordinary resolution of the shareholders, and that any vacancy
on our Board of Directors, including a vacancy resulting from an enlargement of our Board of Directors (which shall not exceed
any maximum number stated therein), may be filled by ordinary resolution or by vote of a majority of our directors then in office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Director Independence</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Our Board of Directors
has determined that Justin Wu, Mirko Scherer, Douglas Arner and Charles Bathurst are independent, as determined in accordance with
the rules of the NASDAQ Global Market. In making such independence determination, our Board of Directors considered the relationships
that each such non-employee director has with us and all other facts and circumstances that the board of directors deemed relevant
in determining their independence, including the beneficial ownership of our share capital by each non-employee director and the
transactions involving them described in the section titled &#8220;Transactions with Related Persons.&#8221; We believe that the
composition and functioning of our Board of Directors and each of our committees comply with all applicable requirements of the
NASDAQ Global Market and the rules and regulations of the SEC. There are no family relationships among any of our directors or
executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Board&#8217;s Role in Risk Oversight
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Our Board of Directors
oversees the management of risks inherent in the operation of our business and the implementation of our business strategies. Our
Board of Directors performs this oversight role by using several different levels of review. In connection with its reviews of
our operations and corporate functions, our Board of Directors addresses the primary risks associated with those operations and
corporate functions. In addition, our Board of Directors reviews the risks associated with our business strategies periodically
throughout the year as part of its consideration of undertaking any such business strategies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Each of our board committees
also oversees the management of our risk that falls within the committee&#8217;s areas of responsibility. In performing this function,
each committee has full access to management, as well as the ability to engage advisors. Our Chief Financial Officer reports to
the audit committee and is responsible for identifying, evaluating and implementing risk management controls and methodologies
to address any identified risks. In connection with its risk management role, our audit committee meets privately with representatives
from our independent registered public accounting firm and our Chief Financial Officer. The audit committee oversees the operation
of our risk management program, including the identification of the primary risks associated with our business and periodic updates
to such risks, and reports to our Board of Directors regarding these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Board Committees </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Our Board of Directors
has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which
operates pursuant to a separate charter adopted by our Board of Directors. The composition and functioning of all of our committees
will comply with all applicable requirements of the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act, the NASDAQ Global Market and SEC rules and regulations. Our Board of Directors may establish other committees from time to
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Charles Bathurst, Douglas
Arner and Justin Wu currently serve on the audit committee, which is chaired by Charles Bathurst. Our Board of Directors has determined
that each member of the audit committee is &#8220;independent&#8221; for audit committee purposes as that term is defined in the
rules of the SEC and the applicable rules of the NASDAQ Global Market. The audit committee&#8217;s responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">selecting and appointing our independent registered public accounting firm, and approving the audit and permitted non-audit services to be provided by our independent registered public accounting firm;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">evaluating the performance and independence of our independent registered public accounting firm;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements or accounting matters;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">establishing procedures for the receipt, retention and treatment of accounting-related complaints and concerns;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing and discussing with the independent registered public accounting firm the results of our year-end audit, and recommending to our Board of Directors, based upon such review and discussions, whether our financial statements shall be included in our Annual Report on Form 20-F;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing all related party transactions for potential conflict of interest situations and approving all such transactions; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing the type and presentation of information to be included in our earnings press releases, as well as financial information and earnings guidance provided by us to analysts and rating agencies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee Financial Expert</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">We have one financial
expert as of the date hereof. Our Board of Directors has determined that Mr. Charles Bathurst, Chair of our audit committee, qualifies
as an &#8220;audit committee financial expert&#8221; as defined in the SEC rules and satisfies the financial sophistication requirements
of The NASDAQ Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">Charles Bathurst, Douglas
Arner and Justin Wu currently serve on the compensation committee, which is chaired by Justin Wu. Our Board of Directors has determined
that each member of the compensation committee is &#8220;independent&#8221; as that term is defined in the applicable rules of
the NASDAQ Global Market. The compensation committee&#8217;s responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing the goals and objectives of our executive compensation plans, as well as our executive compensation plans in light of such goals and objectives;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">evaluating the performance of our executive officers in light of the goals and objectives of our executive compensation plans and recommending to our Board of Directors with respect to the compensation of our executive officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing the goals and objectives of our general compensation plans and other employee benefit plans as well as our general compensation plans and other employee benefit plans in light of such goals and objectives;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">retaining and approving the compensation of any compensation advisors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing all equity-compensation plans to be submitted for shareholder approval under the NASDAQ listing rules, and reviewing and approving all equity-compensation plans that are exempt from such shareholder approval requirement;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">evaluating the appropriate level of compensation for board and board committee service by non-employee directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">reviewing and approving description of executive compensation included in our Annual Report on Form 20-F.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Nominating and Corporate Governance
Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Charles Bathurst, Douglas
Arner and Justin Wu currently serve on the nominating and corporate governance committee, which is chaired by Professor Arner.
Our Board of Directors has determined that each member of the nominating and corporate governance committee is &#8220;independent&#8221;
as that term is defined in the applicable rules of the NASDAQ Global Market. The nominating and corporate governance committee&#8217;s
responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">assisting our Board of Directors in identifying prospective director nominees and recommending nominees for election by the shareholders or appointment by our Board of Directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">advising the board of directors periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our Board of Directors on all matters of corporate governance and on any corrective action to be taken;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">overseeing the evaluation of our Board of Directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">recommending members for each board committee of our Board of Directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Scientific Advisory Board</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We restructured the
Scientific Assessment Committee into a newly formed Scientific Advisory Board. The Scientific Advisory Board shall help the Company
sharpen its focus on innovation and technological advancements and address critical scientific challenges in our research and development;
it will provide overall advise on the scientific development of the company. As of the date hereof, we have 26 members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the Company&rsquo;s
focus on developing treatment for infectious diseases, we have established a second scientific advisory board, i.e., the Infectious
Diseases Scientific Advisory Board in April 2020. As of the date hereof, the Infectious Diseases Scientific Advisory Board have
4 members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Code of Business Conduct and Ethics</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board has adopted
a code of business conduct and ethics that applies to our directors, officers and employees. A copy of this code is available on
our website: www.aptorumgroup.com. We intend to disclose on our website or in a current report on Form 6-K, any amendments to the
Code of Business Conduct and Ethics and any waivers of the Code of Business Conduct and Ethics that apply to our principal executive
officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Duties of Directors </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands
law, our directors have a duty to act honestly, in good faith and with a view to our best interests. Our directors also have a
duty to exercise the care, diligence and skills that a reasonably prudent person would exercise in comparable circumstances. (See
&#8220;Description of Share Capital &#8211; Differences in Corporate Law&#8221;) In fulfilling their duty of care to us, our directors
must ensure compliance with our Memorandum and Articles. We have the right to seek damages if a duty owed by our directors is breached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The functions and powers
of our Board of Directors include, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">appointing officers and determining the term of office of the officers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">authorizing the payment of donations to religious, charitable, public or other bodies, clubs, funds or associations as deemed advisable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">exercising the borrowing powers of the company and mortgaging the property of the company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">executing checks, promissory notes and other negotiable instruments on behalf of the company; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">maintaining or registering a register of mortgages, charges or other encumbrances of the company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Interested Transactions </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So long as it does
not adversely affect such person&#8217;s performance of duties or responsibilities to the Company and so long as it is not in direct
competition with the Company and the Company&#8217;s business, no director or officer shall be disqualified by his office from
contracting and/or dealing with the Company as vendor, purchaser or otherwise; nor shall any such contract or any contract or arrangement
entered into by or on behalf of the Company in which any director or officer shall be in any way interested be or be liable to
be avoided; nor shall any director or officer so contracting or being so interested be liable to account to the Company for any
profit realized by any such contract or arrangement by reason of such director or officer holding that office or the fiduciary
relationship thereby established. However, any such transaction that would reasonably be likely to affect a director status as
an &#8220;Independent Director,&#8221; or that would constitute a &#8220;related party transaction&#8221; pursuant to the laws
or rules promulgated by the SEC or the stock exchange on which our shares are then listed, shall require the review and approval
of the Audit Committee. The nature of the director&#8217;s interest must be disclosed by him at the meeting of the directors at
which the contract or arrangement is considered if his interest then exists, or in any other case, at the first meeting of the
directors after the acquisition of his interest. A director, having disclosed his interest as aforesaid, shall not be counted in
the quorum and shall refrain from voting as a director in respect of any contract or arrangement in which he is as interested as
aforesaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director must promptly
disclose the interest to all other directors after becoming aware of the fact that he or she is interested in a transaction we
have entered into or are to enter into. A general notice or disclosure to the board or otherwise contained in the minutes of a
meeting or a written resolution of the board or any committee of the board that a director is a shareholder, director, officer
or trustee of any specified firm or company and is to be regarded as interested in any transaction with such firm or company will
be sufficient disclosure, and, after such general notice, it will not be necessary to give special notice relating to any particular
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Qualification </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shareholding qualification
for directors may be fixed by the Company in general meeting, and unless and until so fixed no qualification shall be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Compensation of Executive Officers and
Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth all cash compensation paid by us, as well as certain other compensation paid or accrued, in fiscal 2019 to each of the
following named executive officers. The total amount was $2.7 million in 2019. A total 91,477 options were awarded to directors
and executive officers in 2019. This amount does not include business travel, relocation, professional and business association
dues and expenses reimbursed to such persons, and other benefits commonly reimbursed or paid by companies in our industry. In addition
to the compensation included in the table below, which covers the fiscal year ended December 31, 2019, we issued an aggregate of
378,193 options to the persons included in the table below since January 1, 2020 through the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The base salary of
Mr. Huen and Dr. Cheng shall remain unchanged in 2020, and the base salary of Mr. Lui has been adjusted to US$6,667 per month with
effect from January 10, 2020 due to his resignation as Chief Business Officer. The Company entered into a consulting agreement
with CGY Investment Limited effective on January 10, 2020, with a monthly service fee of HK$104,000 (approximately US$13,333 per
month). CGY is 50% held by Seng Fun Yee (Mr. Lui&#8217;s spouse), 25% held by Mandy Lui (Mr. Lui&#8217;s sister) and 25% held by
Adrian Lui (Mr. Lui&#8217;s brother). Mr. Lui controls and/or has substantial influence on the disposition and voting rights of
the shares held by his spouse, but no such control over the shares held by his sister or brother. Hence, for the purposes of this
filing and disclosure, 50% of the consulting service fee and share options will be deemed as Mr. Lui&#8217;s compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name and Principal Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal<BR> Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Salary<BR> ($)<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Non-Equity<BR> Incentive<BR> Plan<BR> Compensation<BR> ($)<SUP>(10)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change in<BR> Pension<BR> Value&nbsp;and<BR> Nonqualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<BR> Compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: left"><P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Ian
Huen<SUP>(2)<BR>
 </SUP>(CEO)</B></P></TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: center">2019</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">288,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">24,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">148,275</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">129,791</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">2,308</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">592,374</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Darren
Lui<SUP>(3) </SUP><BR>
(CBO, President)</B></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">148,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">540,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><B>Clark
Cheng<SUP>(4) </SUP><BR>
(CMO)</B></P></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">279,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">148,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">583,056</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Sabrina Khan<SUP>(5)</SUP><BR> (CFO)</B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">196,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,310</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">394,991</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Thomas Lee&nbsp;<SUP>(7)</SUP><BR> (Head of R&amp;D)</B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,667</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">148,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,791</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">467,041</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Angel Ng&nbsp;<SUP>(8)</SUP><BR> (COO)</B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,440</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,760</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Dr. Keith Chan<SUP>(9)</SUP></B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">2019</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The Appointment Letters provide salaries in HKD; for purposes of this table, we used a conversion ratio of HKD7.80 to USD1.00 to determine the salary in USD.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Huen is the founder and was appointed as the Chief Executive Officer of Aptorum Group on October 1, 2017. Before that, he was a director of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Lui was appointed as the Chief Business Officer and President of Aptorum Group on October 1, 2017 and resigned as Chief Business Officer on October 10, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Cheng was appointed as the Chief Medical Officer of Aptorum Group on January 2, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Miss Khan was appointed as the Chief Financial Officer of Aptorum Group on October 16, 2017.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to Dr. Cheng&#8217;s appointment letter, Dr. Cheng received a share bonus of 526 ordinary shares of AML, representing 5% of AML&#8217;s issued and outstanding ordinary shares (the &#8220;Share Bonus&#8221;) in 2018. Based on the Company&#8217;s financial position and Dr. Cheng&#8217;s performance, on each anniversary of Dr. Cheng&#8217;s employment commencement date, the Share Bonus is eligible to increase by 1% of AML&#8217;s then issued and outstanding ordinary share count per year up to a maximum additional amount of 5% of AML&#8217;s then issued and outstanding ordinary share count by the 5th anniversary from his employment commencement date. As of the date of this prospectus, Dr. Cheng received a total of 753 ordinary shares of AML, representing 7% of AML&#8217;s issued and outstanding ordinary shares; during fiscal 2019, Dr. Cheng received 112 ordinary shares of AML, the cash value of which is USD112.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Lee was appointed as the Head of Research &amp; Development of Aptorum Group on April 1, 2019. Before that, he was the Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, a wholly-owned therapeutics subsidiary of Aptorum Group Limited from January 2018 to March 2019, for which he received an aggregate of $56,000 for the period from January 1, 2019 to March 31, 2019. This table only includes the compensation paid or payable to Dr. Lee for the period from April 1, 2019 to December 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Ng was appointed as the Chief Operating Officer of Aptorum Group on April 1, 2019. Before that, she was the Chief Operating Officer of Aptorum Therapeutics Limited, a wholly-owned therapeutics subsidiary of Aptorum Group Limited from September 2017 to March 2019, for which she received an aggregate of $24,000 for the period from January 1, 2019 to March 31, 2019. This table only includes the compensation paid or payable to Dr. Ng for the period from April 1, 2019 to December 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">As described elsewhere in this prospectus, we were party to a consulting agreement dated August 18, 2017 with GloboAsia, LLC, for which Dr. Chan serves as the Director of International Affairs. All fees payable to Dr. Chan for services provided to us as Chief Scientific Officer were paid to GloboAsia, LLC, pursuant to the consulting agreement and appointment letter with Dr. Chan. Following Dr. Chan&#8217;s resignation in March 2019, the consulting agreement was terminated effective as of March 31, 2019. No other compensation was paid or payable to Dr. Chan for the period from April 1, 2019 to December 31, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(10)&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Represents deferred bonuses provided to directors and executive officers, which will be vested after 1-2 year vesting period.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation of Non-executive Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information for the fiscal year ended December 31, 2019 regarding the compensation of our non-executive directors who
at December 31, 2019, were not also named executive officers. A total 8,044&nbsp;options were awarded to non-executive directors
in 2019. In addition to the compensation included in the table below, which covers the fiscal year ended December 31, 2019, we
issued an aggregate of 45,504 options to the persons included in the table below since January 1, 2020 through the date of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fees<BR> Earned&nbsp;or<BR> Paid in<BR> Cash<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<BR> Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<BR> Awards<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<BR> Incentive<BR> Plan<BR> Compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-qualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<BR> Compensation<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Charles Bathurst&nbsp;<SUP>(1)</SUP></B></FONT></TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">48,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">14,832</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">12,987</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">75,819</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Mirko Scherer&nbsp;<SUP>(3)</SUP></B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">30,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">14,832</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">12,987</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">57,819</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Justin Wu&nbsp;<SUP>(4)</SUP></B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">30,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">14,832</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">12,987</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">57,819</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt"><B>Douglas Arner&nbsp;<SUP>(5)</SUP></B></FONT></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">30,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">14,832</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">12,987</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">57,819</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Bathurst was appointed as one of our directors as of October 2017 and pursuant to his appointment letter, is entitled to receive $48,000 annually for his combined services as a director and a committee member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Bathurst&#8217;s appointment Letter provides his salary in GBP. For purposes of this table, we used a conversion ratio of GBP0.75 to USD1.00 to determine his salary in USD; however, the ultimate amount paid is based on the actual rate as of the relevant pay day at the end of each month.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Scherer was appointed as one of our directors as of October 2017 and pursuant to his appointment letter, is entitled to receive $30,000 annually for his services as a director.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Wu was appointed as one of our directors as of October 2017 and pursuant to his appointment letter, is entitled to receive $30,000 annually for his combined services as a director and a committee member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Professor Arner&#8217;s appointment as one of our directors became effective as of April 1, 2018. Pursuant to his appointment letter, Professor Arner is entitled to receive $30,000 annually for his combined services as a director and a committee member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>2017 Share Option Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2017,
we adopted the 2017 Share Option Plan (the &#8220;Option Plan&#8221;). Under the Option Plan, up to an aggregate of 5,500,000 Class
A Ordinary Shares (subject to subsequent adjustments described more fully below) may be issued pursuant to awards under the Option
Plan. Subsequent adjustments include that on each January 1, starting with January 1, 2020, an additional number of shares equal
to the lesser of (A) 2% of the outstanding number of Class A Ordinary Shares (on a fully diluted basis) on the immediate preceding
December 31, and (B) such lower number of Class A Ordinary Shares as may be determined by the board of directors, subject in all
cases to adjustments as provided in Section 10 of the Option Plan. Awards will be made pursuant to agreements and may be subject
to vesting and other restrictions as determined by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adopted the Option
Plan to provide additional incentives to selected directors, officers, employees and consultants, and enable our Company to obtain
and retain the services of these individuals. The Option Plan will enable us to grant options, restricted shares or other awards
to our directors, employees and consultants. Awards will be made pursuant to agreements and may be subject to vesting and other
restrictions as determined by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of
this prospectus, we have granted options that can be exercised for an aggregate of 931,264 Class A Ordinary Shares. Additionally,
pursuant to his appointment letter, on each anniversary of his appointment, Dr. Majzner shall be granted an option to purchase
that number of Class A Ordinary Shares with a value of no less than $20,000. 218,222 options were granted on March 15, 2019. One-half
of each option grant vests on January 1, 2020 and the other half vests on January 1, 2021. The exercise price is $12.91 per share,
which was based on the closing price of the shares traded on the NASDAQ stock exchange on the trading day preceding the grant
date. 536,777 options were granted on March 16, 2020. Nearly one-half of each option grant vests on January 1, 2021 and the remaining
vests on January 1, 2022. The exercise price is US$2.99 per share, which was based on the average closing price of the shares
traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant date. 148,792 options were granted
on June 1, 2020. Nearly one-half of each option grant vests on December 1, 2020 and the remaining vests on January 1, 2021. The
exercise price is US$3.11 per share, which was based on the average closing price of the shares traded on the NASDAQ stock exchange
for the five trading days immediately preceding the grant date. 27,473 options were granted on August 10, 2020 to Dr. Weiss, which
will be vested on August 10, 2021. The exercise price is $3.64 per share, which was based on the average closing price of the
shares traded on the NASDAQ stock exchange for the five trading days immediately preceding the grant date.<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Limitation on Liability and Other Indemnification Matters</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law does
not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers
and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy,
such as to provide indemnification against civil fraud or the consequences of committing a crime. Our Memorandum and Articles permit
indemnification of officers and directors for actions, proceedings, claims, losses, damages, costs, liabilities and expenses (&#8220;Indemnified
Losses&#8221;) incurred in their capacities as such unless such Indemnified Losses arise from dishonesty of such directors or officers.
This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the
foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>TRANSACTIONS WITH RELATED PERSONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion
is a brief summary of certain material arrangements, agreements and transactions we have with related parties since January 1,
2016, other than the compensation and shareholding arrangements we describe in &#8220;Management&#8221; and &#8220;Principal Shareholders.&#8221;
We also engage in other transactions with related parties that we do not perceive as material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Line of Credit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 13, 2019
(the &#8220;Effective Date&#8221;), Aptorum Therapeutics Limited (&#8220;ATL&#8221;), entered into two separate Promissory Notes
and Line of Credit Agreements (the &#8220;Agreements&#8221;) with AGL and Jurchen. The AGL Agreement and Jurchen Agreement provide
ATL with a line of credit up to twelve million dollars ($12,000,000) and three million dollars ($3,000,000), respectively (collectively,
the &#8220;Line of Credit&#8221;), representing the maximum aggregate amount of the advances of funds from the Line of Credit
that may be outstanding at any time under the Line of Credit (the &#8220;Principal Indebtedness&#8221;). ATL may draw down from
the Line of Credit at any time through the day immediately preceding the third anniversary of the Effective Date (the &#8220;Maturity
Date&#8221;). Interest will be payable on the outstanding Principal Indebtedness at the rate of eight percent (8%) per annum,
payable semi-annually in arrears on February 12 and August 12 in each year. ATL may pre-pay in whole or in part, the Principal
Indebtedness of the Line of Credit, and all interest accrued at any time prior to the Maturity Date, without penalty. Under the
Agreements, in addition to certain standard covenants, we are also not permitted, without the prior written consent of AGL and
Jurchen to (i) liquidate, dissolve or wind-up our business and affairs; (ii) effect any merger or consolidation transaction; (iii)
sell, lease, transfer, license or otherwise dispose, in a single transaction or series of related transactions, all or substantially
all of our assets; or (iv) consent to any of the foregoing. The Agreements are subject to standard events of default, which if
not cured within the agreed upon cure period, permits AGL or Jurchen, as applicable, to declare the outstanding Principal Indebtedness
immediately due and payable, to exercise any other remedy provided for in the Agreements or any other right available to AGL or
Jurchen as provided at law or in equity. Jurchen and AGL also maintain the right to set-off during the term of the Agreements.
As of the date hereof, the Company has drawn down approximately $3.0 million from the Line of Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sales and Purchases of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.25pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20.25pt"><B><I>Share Issuances</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the period of
March 2017 through December 2017, we issued an aggregate of 2,207,025 Ordinary Share at a purchase price of approximately $3.90
per share, in a private placement we described as a &#8220;Series A&#8221; offering. Each investor of the Series A offering, in
addition to a subscription agreement, signed a shareholder agreement, which set forth the basic governance terms of the Company,
as well as our capital structure. The shareholders agreement was terminated in October 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 13, 2017,
ordinary resolutions were passed at an extraordinary general meeting of the Company approving: (i) converting 72,135,865 of authorized
but unissued Ordinary Shares into 54,573,620 authorized but unissued Class A ordinary shares, par value of $1.00 per share (&#8220;Class
A Ordinary Shares&#8221;) and 17,562,245 authorized but unissued Class B ordinary shares, par value of $1.00 per share (&#8220;Class
B Ordinary Shares&#8221;), respectively; (ii) converting 24,930,839 Ordinary Shares held by three shareholders into an aggregate
of 2,493,085 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares; and (iii) converting 2,933,296 Ordinary Shares held
by 24 shareholders into an aggregate 2,933,296 Class A Ordinary Shares. Following these issuances, we had 27 shareholders of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KHE Holdings Limited,
which is owned by Dr. Kenny Yu&#8217;s family, purchased $200,000 Series A Notes in our private Note offering, which closed on
May 15, 2018; such notes automatically converted into 28,776 Class A Ordinary Shares upon the closing of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">A
total of 5,504 shares were purchased in the IPO by related persons.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Share Transfer: Change in direct substantial
shareholders of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 4, 2017, Mr.
Huen transferred all of the ordinary shares in the Company he owned (in the amount of 22,307,596) to Jurchen, a company incorporated
in the British Virgin Islands and wholly-owned by Mr. Huen. On October 13, 2017, the ordinary shares held by Jurchen were redesignated
as 2,230,760 Class A Ordinary Shares and 20,076,836 Class B Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 23, 2018,
Jurchen transferred 446,152 Class A Ordinary Shares and 4,015,367 Class B Ordinary Shares to CGY Investments Limited, a company
incorporated in Hong Kong and which we deem Mr. Darren Lui controls and/or of which he has substantial influence on the disposition
rights and voting rights of such shares.&nbsp;Following this transfer, Jurchen owned approximately 33% and 72% of our Class A Ordinary
Shares and Class B Ordinary Shares, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consulting Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>GloboAsia, LLC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a consulting
agreement with GloboAsia effective as of August 18, 2017 (the &#8220;2017 GA Agreement&#8221;); GloboAsia is not associated or
affiliated with any FINRA members. However, the 2017 GA Agreement was terminated when Dr. Chan resigned from his position as our
Chief Scientific Officer in March 2019. Dr. Chan serves as the Director of International Affairs of GloboAsia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective as of April
1, 2019, GloboAsia, through Dr. Chan, shall serve as a member on our Scientific Advisory Board. To formalize such service, we entered
into that certain consulting agreement with GloboAsia dated March 13, 2019 (the &#8220;2019 GA Agreement&#8221;). Pursuant to the
2019 GA Agreement, GloboAsia provides advisory and management services to us and as a member of the Scientific Advisory Board,
they provide advice to us regarding research and development, the scientific merit of licenses or products and other related scientific
issues. We agreed to pay GloboAsia an hourly rate of USD300 for work actually performed. The initial term of 2019 GA Agreement
is until December 31, 2020 and shall thereafter be automatically renewed for successive one-year terms, unless earlier terminated
by either party upon three months&#8217; notice prior to the end of the then applicable term; either party may also terminate the
agreement upon 2 months written notice and the Company may terminate the agreement if Dr. Chan is no longer with GloboAsia or if
GloboAsia commits any act of fraud or dishonesty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Aeneas Limited and its subsidiaries (&#8220;Aeneas
Group&#8221;)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a. In March 2017,
we entered into a new Management Agreement with AENEAS CAPITAL LIMITED (the &ldquo;2017 Agreement&rdquo;), pursuant to which AENEAS
CAPITAL LIMITED will provide certain management and administrative functions, as well as investment functions related to the Company,
IP acquisitions and other investor relations services (the &ldquo;Services&rdquo;). In consideration for the Services, we agreed
to pay Aeneas HK$500,000 per month (approximately US$64,103 per month), payable on the last day of each month. The 2017 Agreement
was terminated in July 2018. Prior to the termination, we paid Aeneas an aggregate of $1.1 million pursuant to the terms of the
2017 Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b. On April 24, 2019,
the Company signed an agreement with AENEAS CAPITAL LIMITED, and A*ccelerate Technologies Pte. Ltd, the enterprise office of the
Agency for Science, Technology and Research (&ldquo;A*STAR&rdquo;), (collectively, the &ldquo;Parties&rdquo;) to co-create local
deep tech startups. This agreement, which is part of A*ccelerate&rsquo;s venture co-creation (&ldquo;VCC&rdquo;) initiative, commits
all parties to the co-creation of local startups in the healthcare and life science sector (the &ldquo;Master Collaboration Agreement&rdquo;).
Through this agreement, we partnered with A*Star to explore suitable opportunities, if identified, to set up tech ventures in Singapore
over the next 5 years. A*STAR shall contribute a total of up to $30,000,000 to any suitable startups, at their discretion. The
Company and AENEAS CAPITAL LIMITED will contribute a total of up to $30,000,000 to any suitable startups at their discretion with
a focus on (i) securing pilot customers; (ii) incorporation of the startups as companies and financial commitments of such customers;
(iii) capital raising and capital market plans; (iv) recruiting and building of the startup teams; (v) equipment and infrastructure;
and (vi) licensing of IP to the startups under the Technology License Agreements. The Master Collaboration Agreement shall continue
for a period of 5 years, unless otherwise terminated or extended by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c. On January 1, 2019,
Aptus Management Limited (one of our wholly-owned subsidiaries) (&#8220;Aptus Management&#8221;) entered into an Administrative
consultant Services Agreement with Aeneas Management Limited (a subsidiary of Aeneas Limited). Pursuant to this agreement, Aeneas
shall provide certain business and financial services to Aptus Management Limited; Aeneas shall be paid a monthly service fee of
HK$452,000 per month (approximately US$57,949 per month), payable by the 25th day of each month during the term of the agreement,
which was until December 31, 2019. Either party was able to terminate the agreement by providing 3-months written notice to the
other party. On December 16, 2019, the parties agreed to renew the agreement under the same terms, but with an expiration date
of December 31, 2020. The agreement was terminated on April 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d. On January 1, 2019,
Aenco Limited (&ldquo;Aenco&rdquo;) (a subsidiary of AGL) and Aptus Management entered into a Secondment Agreement. Pursuant to
this agreement, Aenco shall assign certain of its employees to Aptus Management from time to time to assist Aptus Management with
information technology development and maintenance activities for Aptus Management&rsquo;s affiliates; such employees shall be
integrated into Aptus Management&rsquo;s organization only to the extent necessary to carry out such employees specific duties
for Aptus Management. Aptus Management shall pay all salary and benefits up to HK$540,000 per month (approximately US$69,231 per
month); Aenco shall be responsible for the costs associated with any employee relocation required as a result of this agreement.
The agreement was originally set to terminate on December 31, 2019, although either party may terminate the agreement upon giving
the other party 3-months written notice. On December 16, 2019 the parties agreed to renew the agreement under the same terms, but
with an expiration date of December 31, 2020. The agreement was terminated on April 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 1, 2020, the
agreement was replaced and superseded with a New Secondment Agreement. Pursuant to this New Secondment Agreement, Aenco shall assign
certain of its employees to Aptus Management from time to time to assist Aptus Management with information technology application
development and maintenance activities for Aptus Management&rsquo;s affiliates; such employees shall be integrated into Aptus Management&rsquo;s
organization only to the extent necessary to carry out such employees specific duties for Aptus Management. Aptus Management shall
pay all salary and benefits up to HK$700,000 per month (approximately US$89,744 per month); Aenco shall be responsible for the
costs associated with any employee relocation required as a result of this agreement. The agreement shall terminate on December
31, 2020, although either party may terminate the agreement upon giving the other party 3-months written notice. The agreement
was terminated on September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e. On 30 April 2020,
Aptorum Therapeutics Limited entered into a contract research agreement with Aeneas Technology (Hong Kong) Limited (&ldquo;Aeneas
Technology&rdquo;). Pursuant to this agreement, Aeneas Technology shall perform the research in accordance with the terms and conditions
of this agreement. Aptorum Therapeutics Limited shall pay a research fee of HK$963,760 per month (approximately US$123,559 per
month). The agreement shall terminate on 30 September 2021, although Aptorum Therapeutics Limited may terminate the agreement upon
giving 30 days prior written notice. The agreement was terminated on September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f. In July 2019, Smart
Pharmaceutical Limited Partnership, (&ldquo;SPLP&rdquo;), a wholly-owned subsidiary of the Group, transferred 100,000,000 Smart
Pharma Tokens (&ldquo;SMPT token&rdquo;) to Aenco Solutions Limited, a related party, in exchange of the service to deal with
the token creation, offering and 5-years consultancy service. The 100,000,000 SMPT tokens were equivalents to $300,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AENEAS CAPITAL LIMITED
is wholly-owned by Aeneas Group Limited (&ldquo;AGL&rdquo;), which in turn is wholly-owned by Aeneas Limited (&ldquo;AL&rdquo;).
AL is 76.8% owned by Jurchen, which is wholly-owned by Mr. Huen, our CEO. Professor Arner, one of our directors, is a Senior Regulatory
and Strategic Advisor for AGL. Under his agreement with AGL dated March 12, 2018, Professor Arner shall, among other services,
advise the board of AGL with its management, execution of business, and regulatory initiatives of AGL and AL, assist AGL with
access to expert networks as appropriate and required. Professor Arner&rsquo;s compensation thereunder is HK$234,000 per year
(approximately US$30,000 per year) and Professor Arner is entitled to participate in AGL&rsquo;s share option plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, AGL was
one of the selected dealers for our IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>CGY Investment Limited</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a consulting
agreement with CGY Investment Limited (&#8220;CGY&#8221;) effective on January 10, 2020. Pursuant to this agreement, CGY shall
provide certain consultancy, advisory, and management services to the Group on potential investment projects related to health
care or R&amp;D platform; CGY shall be paid a monthly service fee of HK$104,000 per month (approximately US$13,333 per month),
during the term of the agreement, which is remain in effect unless it is terminated. The agreement may be terminated by either
party providing 1-months written notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CGY is 50% held by
Seng Fun Yee (Mr. Lui&#8217;s spouse), 25% held by Mandy Lui (Mr. Lui&#8217;s sister) and 25% held by Adrian Lui (Mr. Lui&#8217;s
brother). Mr. Lui, President and Executive Director of the Group, controls and/or has substantial influence on the disposition
and voting rights of the shares held by his spouse, but no such control over the shares held by his sister or brother. Hence, 50%
of the consulting service fee will be deemed as Mr. Lui&#8217;s compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Appointment Letters </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into
Appointment Letters with each of our executive officers. The terms of the Appointment Letters for each of our executive officers
are consistent with each other, except with regard to the individual&#8217;s compensation, term of employment and duties and responsibilities,
the latter of which coincides with the standard functions normally associated with the given position. Below, we set forth the
specific compensation and term of employment terms of each of our executive officer&#8217;s appointment letter, as in effect as
of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Ian Huen - Chief Executive Officer and Executive Director- US$24,000 (HKD187,200) per month payable in an equivalent amount of thirteen (13) months per calendar year with no set term of employment. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Darren Lui - President and Executive Director- Mr. Lui&#8217;s base salary was adjusted from $US$20,000 (HKD156,000) per month to US$6,667 per month, effective as of January 10, 2020 due to his resignation as Chief Business Officer. The Company entered into a consulting agreement with CGY Investment Limited, which is 50% held by Seng Fun Yee (Mr. Lui&#8217;s spouse), effective on January 10, 2020, with a monthly service fee of HK$104,000 (approximately US$13,333 per month). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Clark Cheng - Chief Medical Officer and Executive Director- US$23,275 (HKD181,542) per month payable in twelve (12) instalments per calendar year with no set term of employment. Dr. Cheng is also entitled to receive a share bonus of 5% of Aptorum Medical Limited&#8217;s ordinary shares upon commencement of employment, which shall be increased by 1% annually up to a maximum additional amount of 5% of issued ordinary share capital of Aptorum Medial Limited. The Board also determined to issue Dr. Cheng a discretionary cash bonus equal to one-month of his base salary.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Sabrina Khan - Chief Financial Officer- US$16,333 (HKD127,400) per month payable in an equivalent amount of twelve (12) months per calendar year with no set term of employment. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Thomas Lee&ndash; Head of Research &amp; Development - US$18,667 (HKD145,600) per month payable in an equivalent amount of thirteen (13) months per calendar year with no set term of employment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Angel Ng &ndash; Chief Operating Officer &ndash; US$8,000 (HKD 62,400) per month payable in an equivalent amount of thirteen (13) months per calendar year with no set term of employment.</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Remaining
material terms of the appointment agreements are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may terminate employment for cause, at any time, without advance notice or remuneration, for certain acts of the executive officer,
such as conviction or plea of guilty to a felony or any crime involving moral turpitude, negligent or dishonest acts to our detriment,
or misconduct or a failure to perform agreed duties. We may also terminate an executive officer&#8217;s employment without cause
upon three-month advance written notice. In such case of termination by us, we will provide severance payments to the executive
officer as expressly required by applicable law of the jurisdiction where the executive officer is based. The executive officer
may resign at any time with three-month advance written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Each
executive officer has agreed to hold, both during and after the termination or expiration of his or her Appointment Letter, in
strict confidence and not to use, except as required in the performance of his or her duties in connection with the employment
or pursuant to applicable law, any of our confidential information or trade secrets, any confidential information or trade secrets
of our clients or prospective clients, or the confidential or proprietary information of any third-party received by us and for
which we have confidential obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, each executive officer has agreed to be bound by non-solicitation and non-compete restrictions during the term of his
or her employment and typically for one year following the last date of employment. Specifically, each executive officer has agreed
not to (i) solicit or entice away from the Company, any person, firm, company or organization that is or shall have been at any
time within 12 months prior to termination of employee a customer, client, identified prospective customer or client of the Company
or in the habit of dealing with the Company; (ii) employ, solicit or entice away from the Company any person who is or shall have
been on the date of or within 12 months prior to termination of employment an employee of the Company; or (iii) assume employment
with or provide services to, or otherwise engage in income generating activities with any of our competitors, or engage, whether
as principal, partner, licensor or otherwise, any of our competitors, without our express consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our Appointment
Letters also provide for the executive officer to participate in our mandatory provident fund, which is similar to a pension fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Leased Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Jurchen Investment
Corporation entered into a sub-tenancy agreement with a subsidiary of the Group for the rental arrangement of an office in Hong
Kong. For the period February 1, 2018 through January 31, 2021, Jurchen Investment Corporation was entitled to receive a fixed
amount of rental fee of HKD130,000 (approximately $16,667) per calendar month. In May 2020, Jurchen Investment Corporation and
the Group mutually agreed to early terminate the rental agreement and returned the office on May 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As stated elsewhere
in this prospectus, Dr. Cheng serves as our Chief Medical Officer and one of our Executive Directors, who is also an Executive
Director of Aptorum Medical. Dr. Cheng is also the guarantor on the AML Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Senior Strategic
Consultant, Dr. Kira Sheinerman is the Managing Director, Healthcare Investment Banking of HC Wainwright, the placement agent in
this Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Bond Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 6, 2018, we
entered into a subscription agreement (the &#8220;Bond Subscription Agreement&#8221;) with Peace Range Limited (&#8220;Peace Range&#8221;),
a company incorporated under the laws of the British Virgin Islands and wholly-owned special purpose vehicle of Adamas Ping An
Opportunities Fund L.P. Adamas Ping An Opportunities Fund L.P. is the third fund from Adamas Asset Management (HK) Limited (&#8220;Adamas&#8221;)
and the first fund from the joint venture between Adamas and Yun Sheng Capital Company Limited, a subsidiary of Ping An Insurance
(Group) Company of China, Limited and is advised by Ping An Capital Company Limited. Pursuant to the Bond Subscription Agreement,
we issued Peace Range a $15,000,000 convertible bond (the &#8220;Bond&#8221; and the &#8220;Bond Offering&#8221;), minus a structuring
fee equal to 2% of the principal amount of the Bond, on April 25, 2018. We also agreed to pay certain expenses, up to an aggregate
limit of $250,000, incurred by Peace Range in connection with the Bond Offering. The closing of the transaction contemplated by
the Bond Subscription Agreement and the issuance of the Bond are subject to standard closing conditions, which may be satisfied
or waived by the impacted party. The Bond earns interest at the rate of 8% per annum, payable semi-annually. The payment of the
Bond is guaranteed by our holding company, Jurchen Investment Corporation (&#8220;Jurchen&#8221;), a company wholly-owned by our
CEO, Ian Huen (See &#8220;Transactions with Related Persons&#8221;), pursuant to a deed of guarantee (the &#8220;Guarantee&#8221;).
In addition, the repayment of the principal of the Bond and interest payables is secured by a fund we set aside in a debt service
reserve account, with the funds in the debt service reserve account to be released in an amount pro rata to the principal amount
of the Bond being converted. The Bond shall mature on the twelfth calendar month following the issuance date, or with prior written
consent of the holders of the Bond, the business day falling six calendar months thereafter. 10% of the principal amount of the
Bond automatically converted into our Class A Ordinary Shares following the IPO; the rest of the Bond is convertible at the option
of the holder commencing on the closing of the IPO until the earlier of the date falling 12 calendar months after the maturity
of the Bond and the date falling 12 calendar months after the closing of the IPO. We closed the Bond Offering on April 25, 2018
and issued a Bond to Peace Range pursuant to the Bond Subscription Agreement. Pursuant to the aforementioned conversion rights,
we issued an aggregate of 119,217 shares of Class A Ordinary Shares to the Bond holder after the IPO closed. Following the IPO
and pursuant to the terms of the related agreements, the shares Jurchen previously submitted to be held in escrow to guarantee
the payment of the Bond were released to Jurchen and the related share charge agreement and escrow agreement were terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 24, 2019,
one of our wholly-owned subsidiaries, Aptorum Investment Holding Ltd., repurchased the Bonds from Peace Range. According to the
amended and restated terms and conditions of the Bonds, the Bondholder was granted certain rights to subscribe for additional
ordinary shares of the Company, in an amount up to the principal amount of the Bonds at a price of US$12.17 (subject to adjustment)
on or before 7 days prior to the maturity date (&ldquo;Subscription Right&rdquo;). The total consideration of the repurchase of
Bonds and the Subscription Rights was US$13.6 million in cash, excluding accrued interest. The Bond matured and was redeemed on
October 25, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the underwriters
in the IPO also served as a placement agent for the Bond Offering and received (i) a cash success fee of $600,000 and (ii) warrants
to purchase 67,790 Class A Ordinary Shares, at an exercise price of $12.17 per share, subject to adjustment (the &#8220;Bond PA
Warrants&#8221;). The Bond PA Warrants are exercisable on a cashless basis. China Renaissance Securities (HK) Limited (&#8220;China
Renaissance&#8221;) also served as a placement agent for the Bond Offering; for such services, China Renaissance received a cash
success fee of $150,000.&nbsp;Prior to the commencement the IPO, Boustead assigned all such securities to a non-affiliate; the
assignment is non-recourse. As of the date hereof, there are no outstanding Bond PA Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Series A Note Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 15, 2018, we
closed a private financing with certain investors (the &#8220;Series A Note Investors&#8221;) who purchased an aggregate of $1,600,400
Series A convertible notes, at a purchase price of $10,000 per note (the &#8220;Series A Notes&#8221;), pursuant to a note purchase
agreement. Some of the Series A Note Investors are either affiliates of the Company or &#8220;related persons,&#8221; as such term
is defined in Item 404 of Regulation S-K (See &#8220;Transactions with Related Persons&#8221;). We refer to this private placement
transaction as the &#8220;Series A Note Offering.&#8221; The Series A Note Investors entered into a lock-up agreement, pursuant
to which they agreed not to sell or otherwise transfer or dispose the Series A Notes or the Class A Ordinary Shares underlying
the Series A Notes during the six-month period commencing on the date our Class A Ordinary Shares commence trading on NASDAQ Global
Market, which has now expired. The Series A Notes automatically converted into 230,252 Class A Ordinary Shares at the closing of
the IPO and at the commencement of trading our Class A Ordinary Shares on NASDAQ Global Market at a conversion price equal to a
56% discount to the actual price per Class A Ordinary Share (&#8220;Conversion Price&#8221;). Accordingly, the Series A Notes converted
into, and we issued an aggregate of 230,252 shares of Class A Ordinary Shares after the IPO closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 15, 2018, we
closed a private financing with certain investors (the &#8220;Series A Note Investors&#8221;) who purchased an aggregate of approximately
$1,600,400 Series A convertible notes, at a purchase price of $10,000 per note (the &#8220;Series A Notes&#8221;), pursuant to
a note purchase agreement. Some of the Series A Note Investors are either affiliates of the Company or &#8220;related persons&#8221;
as such term is defined in Item 404 of Regulation S-K (See &#8220;Transactions with Related Persons&#8221;). We refer to this private
placement transaction as the &#8220;Series A Note Offering.&#8221; The Series A Note Investors entered into a lock-up agreement,
pursuant to which they agreed not to sell or otherwise transfer or dispose the Series A Notes or the Class A Ordinary Shares underlying
the Series A Notes during the six-month period commencing on the date our Class A Ordinary Shares commence trading on NASDAQ Global
Market. The Series A Notes automatically converted into Class A Ordinary Shares at the closing of the IPO at a conversion price
equal to a 56% discount to the actual price per Class A Ordinary Share (&#8220;Conversion Price&#8221;). Accordingly, the Series
A Notes converted into, and we issued an aggregate of 230,252 shares of Class A Ordinary Shares after the IPO closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the underwriters
in the IPO also served as a placement agent for the Series A Note Offering and received: (i) a cash success fee of $68,516 and
(ii) warrants to purchase 12,663 Class A Ordinary Shares, at an exercise price of $6.95 per share, subject to adjustment (the &#8220;Series
A Note PA Warrants&#8221;). The Series A Note PA Warrants are also exercisable on a cashless basis, at the holder&#8217;s discretion.
As of the date hereof, there are no outstanding Series A Note PA Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registered Direct Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 28, 2020,
we closed a Registered Direct Offering with certain non-affiliated institutional investors (the &ldquo;Non-affiliated Purchasers&rdquo;)
and Jurchen Investment Corporation, our largest shareholder and wholly-owned by Mr. Ian Huen, our Chief Executive Officer (the
&ldquo;Affiliated Purchaser&rdquo; collectively with the Non-affiliated Purchasers, the &ldquo;Purchasers&rdquo;). The Purchasers
purchased an aggregate of 1,351,350 Class A Ordinary Shares and warrants (&ldquo;February 2020 Warrants&rdquo;) to purchase 1,351,350
Class A Ordinary Shares (the &ldquo;Offering&rdquo;), for gross proceeds of approximately $10 million. The February 2020 Warrants
will be exercisable immediately following the date of issuance for a period of seven years at an initial exercise price of $7.40.
The purchase price for each Share and the corresponding Warrant is $7.40.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed that we would
not issue any Class A Ordinary Shares (or Class A Ordinary Share Equivalents (as defined in the purchase agreement entered on February
25, 2020)) for 45 days following the closing of the Registered Direct Offering subject to certain customary exceptions, including,
without limitation, issuances of restricted securities to consultants or employees of the Company, share option grants and issuances
pursuant to existing outstanding securities and issuance in connection with strategic acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed from the
date of the purchase agreement until the date that is the later of (i) the 12 month anniversary of the closing date or (ii) one
or more subsequent issuance by the Company or any of its subsidiaries of ordinary share equivalent having aggregate gross proceeds
of at least $20,000,000, the Purchasers shall have the right to participate in the subsequent financing up to an amount equal to
50% of the Subsequent Financing (the &#8220;Participation Maximum&#8221;) on the same terms, conditions and price provided for
in the Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also agreed certain
most favored nation treatment of the all the Purchasers pursuant to which each Purchaser will have the opportunity to automatically
have the same benefit if the terms and conditions with respect to this Purchase Agreement or any securities offered therein the
Company offered to the other Purchasers are more favorable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Purchaser Warrant Exchange, we paid the Placement Agent $212,500 in fees ($25,000 of which was for non-accountable expenses
and $50,000 of which was for legal and other fees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Appointment
Letters&#8221; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_016"></A>SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our
Ordinary Shares as of September 29, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">each of our directors and executive officers who beneficially own our Ordinary Shares; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">each person known to us to own beneficially more than 5.0% of our Ordinary Shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership
includes voting or investment power with respect to the securities. Except as indicated below, and subject to applicable community
property laws, the persons named in the table have sole voting and investment power with respect to all Ordinary Shares shown
as beneficially owned by them. Percentage of beneficial ownership owned before the Offering of each listed person is based on
8,491,526 Class A Ordinary Shares and 22,437,754 Class B Ordinary Shares outstanding as of the date of this prospectus. The percentage
of beneficial ownership owned after the Offering is based on 11,260,757 Class A Ordinary Shares and 22,437,754 Class B ordinary
Shares outstanding after we close on the current amount sold; the percentage of beneficial ownership owned after the Participation
Maximum is sold is based on 14,029,987 Class A Ordinary Shares and 22,437,754 Class B ordinary Shares outstanding if the Participation
Maximum is sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information with respect
to beneficial ownership has been furnished by each director, officer or beneficial owner of 5% or more of our Ordinary Shares.
Beneficial ownership is determined in accordance with the rules of the SEC and generally requires that such person have voting
or investment power with respect to securities. In computing the number of Ordinary Shares beneficially owned by a person listed
below and the percentage ownership of such person, Ordinary Shares underlying options, warrants or convertible securities held
by each such person that are exercisable or convertible within 60 days of the date of this prospectus are deemed outstanding, but
are not deemed outstanding for computing the percentage ownership of any other person. Except as otherwise indicated in the footnotes
to this table, or as required by applicable community property laws, all persons listed have sole voting and investment power for
all Ordinary Shares shown as beneficially owned by them. As of the date of the prospectus, we have 3 shareholders of record holding
beneficial ownership of 5% or more, none of which are located in the United States.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
the business address of each of the individuals is 17 Hanover Square, London W1S 1BN, United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name and Address of Beneficial Owner</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class A<BR>
Ordinary<BR>
Shares<BR>
Beneficially<BR>
Owned</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class B<BR>
Ordinary<BR>
Shares<BR>
Beneficially<BR>
Owned</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage<BR>
of Total<BR>
Class A and<BR>
Class B<BR>
Ordinary<BR>
Shares<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage<BR>
        of Total<BR>
        Voting<BR>
        Power </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Before </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offering<SUP>(2)</SUP></B></P></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Percentage<BR>
        of Total<BR>
        Voting<BR>
        Power </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>After </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>the Offering<SUP>(2)</SUP></B></P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Percentage<BR>
of Total<BR>
Voting<BR>
Power<BR>
After<BR>
 the <BR>
Participation<BR>
Maximum <SUP>(2)</SUP></B></P></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 31%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Huen<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,865,742</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,061,469</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.20</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70.20</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.38</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.57</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Darren Lui<SUP>(4)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">260,809</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,141,333</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.77</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.31</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.20</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.09</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clark Cheng<SUP>(5)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sabrina Khan<SUP>(6)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Lee Wai Yip<SUP>(7)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Angel Ng Siu Yan<SUP>(8)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Charles Bathurst<SUP>(9)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mirko Scherer<SUP>(10)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin Wu<SUP>(11)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">207,566</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.67</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.09</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Douglas Arner<SUP>(12)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 9pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All directors and executive officers as a group (10 persons)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,334,117</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,202,802</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.63</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79.60</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78.66</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77.25</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5% Beneficial Owner</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurchen Investment&nbsp;Corporation<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,855,688</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,061,469</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.16</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70.20</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.37</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68.57</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sui Fong Isabel Huen Ng<SUP>(13)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211,986</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,907,870</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.85</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.28</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.19</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.09</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CGY Investments Limited<SUP>(14)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">471,809</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,015,367</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.51</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.45</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.24</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.04</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Less than 1%.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">For each person and group included in this column, percentage ownership is calculated by dividing the number of Class A Ordinary Shares and Class B Ordinary Shares beneficially owned by such person or group, including shares that such person or group has the right to acquire within 60 days after </FONT><FONT STYLE="font-size: 10pt">the date of this prospectus<FONT STYLE="background-color: white">, by the sum of total Class A Ordinary Shares and Class B Ordinary Shares. </FONT>Following the IPO, each Class B Ordinary Share can be converted at any time on a one-for-one basis into Class A Ordinary Shares at the discretion of the holder.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">For each person and group included in this column, percentage of total voting power represents voting power based on both Class&nbsp;A Ordinary Shares and Class&nbsp;B Ordinary Shares beneficially owned by such person or group with respect to all of our outstanding Class&nbsp;A Ordinary Shares and Class&nbsp;B Ordinary Shares as one single class. Holders of Class&nbsp;A Ordinary Shares are entitled to one vote per share and holders of Class&nbsp;B Ordinary Shares are entitled to ten votes per share on all matters subject to a shareholders&#8217; vote.&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 2,315,148 Class A Ordinary Shares owned by Jurchen, warrants held by Jurchen to purchase 540,540 Class A Ordinary Shares, options granted to Mr. Huen to purchase 10,054 Class A Ordinary Shares, and 16,061,469 Class B Ordinary Shares owned by Jurchen. Jurchen Investment Corporation, is a company wholly-owned by Mr. Huen. Mr. Huen maintains sole voting control over the shares held by Jurchen, the principal office address of which is at 17th Floor, Guangdong Investment Tower, 148 Connaught Road Central, Hong Kong.&nbsp;&nbsp;Does not include 10,053 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 66,890 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 20,107 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Mr. Huen pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of the date of this prospectus.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes (i) 14,850 Class A Ordinary Shares and 133,649 Class B Ordinary Shares indirectly owned through DSF Investment Holdings Limited (&#8220;DSF&#8221;)<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT> DSF holds 50,339 Class A Ordinary Shares and 453,048 Class B Ordinary Shares of the Company and is 29.5% held by Mr. Lui; Eternal Clarity Holdings Limited, which is wholly-owned by Mr. Lui&#8217;s mother, Ms. Emily Woo, owns the remaining 70.5% of DSF. DSF is located at Flat A2, 11th Floor, Wing Hang Insurance Building, 11 Wing Kut Street, Hong Kong, (ii) 235,905 Class A Ordinary Shares and 2,007,684 Class B Ordinary Shares indirectly owned through CGY Investments Limited, which is 50% held by Seng Fun Yee (Mr. Lui&#8217;s spouse) and holds 471,809 Class A Ordinary Shares and 4,015,367 Class B Ordinary Shares of the Company.&nbsp;&nbsp;CGY Investments Limited is 50% held by Seng Fun Yee (Mr. Lui&#8217;s spouse), 25% held by Mandy Lui (Mr. Lui&#8217;s sister) and 25% held by Adrian Lui (Mr. Lui&#8217;s brother). The principal business address of CGY Investments are Unit A 3/F Cheong Sun Tower, 116-118 Wing Lok St, Sheung Wan, Hong Kong, and (iii) options granted to Mr. Lui to purchase 10,054 Class A Ordinary Shares. Mr. Lui only controls and/or has substantial influence on the disposition and voting rights of 29.5% of the Aptorum shares DSF owns; Mr. Lui controls and/or has substantial influence on the disposition and voting rights of the shares held by his spouse, but no such control over the shares held by his sister or brother regarding the CGY shares. Does not include 10,053 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 66,890 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 to CGY Investments Limited, of which 50% is deemed controlled by Mr. Lui, and 20,107 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to CGY Investments Limited, of which 50% is deemed controlled by Mr. Lui pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pursuant to his appointment letter, Dr. Cheng received a stock bonus of 7% of Aptorum Medical Limited&#8217;s ordinary shares as of the date of this prospectus.&nbsp;&nbsp;Does not include 10,053 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 66,890 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 20,107 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Dr. Cheng pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include 4,749 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 54,627 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 9,498 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Miss Khan pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include 10,053 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 66,890 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 20,107 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Dr. Lee pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include 775 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 8,027 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 1,551 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Dr. Ng pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include 1,005 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 9,365 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 2,011 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Mr. Bathurst pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include 1,005 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 9,365 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 2,011 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Mr. Scherer pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes (i) 129,589 Class A Ordinary Shares held by Chi Ling Lily Heung, the wife of Dr. Wu, (ii) 76,971 Class A Ordinary Shares held by Dr. Wu, and (iii) options granted to Dr. Wu to purchase 1,006 Class A Ordinary Shares.&nbsp;&nbsp;Does not include 1,005 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 9,365 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 2,011 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Dr. Wu pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Does not include 1,005 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 15, 2019, 9,365 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 2,011 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to Dr. Arner pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Sui Fong Isabel Huen Ng is the mother of Mr. Ian Huen. Mr. Ian Huen does not have control nor substantial influence on the disposition and voting rights of the shares held by his mother.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(14)&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">CGY Investments Limited is 50% held by Seng Fun Yee (Mr. Lui&#8217;s spouse), 25% held by Mandy Lui (Mr. Lui&#8217;s sister) and 25% held by Adrian Lui (Mr. Lui&#8217;s brother). The principal business address of CGY Investments are Unit A 3/F Cheong Sun Tower, 116-118 Wing Lok St, Sheung Wan, Hong Kong. Mr. Lui controls and/or has substantial influence on the disposition and voting rights of the shares held by his spouse, but no such control over the shares held by his sister or brother. Does not include 66,890 Class A Ordinary Shares issuable upon exercise of outstanding options issued on March 16, 2020 and 20,107 Class A Ordinary Shares issuable upon exercise of outstanding options issued on June 1, 2020 to CGY Investments Limited pursuant to the Option Plan, since such options have not vested and will not be exercisable within 60 days of&nbsp;the date of this prospectus .</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>SHARES ELIGIBLE FOR FUTURE SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of substantial
amounts of our Class A Ordinary Shares, including shares issued upon exercise of outstanding options and warrants, in the public
market after this Offering could adversely affect market prices prevailing from time to time and could impair our ability to raise
capital through the sale of our equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion
of this Offering, based on the number of shares outstanding as of September 29, 2020, we will have&nbsp;11,260,757&nbsp;Class A
Ordinary Shares outstanding. Of these outstanding shares, all of the 2,769,231 Class A Ordinary Shares sold in this Offering and
5,137,567 existing Class A Ordinary Shares will be freely tradable, except that any shares purchased by our affiliates, as that
term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below. If we
sell the Participation Maximum, we will have&nbsp;14,029,987&nbsp;Class A Ordinary Shares outstanding. Of these outstanding shares,
all of the 5,538,461 Class A Ordinary Shares sold in this Offering and 5,137,567 existing Class A Ordinary Shares will be freely
tradable, except that any shares purchased by our affiliates, as that term is defined in Rule 144 under the Securities Act, may
only be sold in compliance with the limitations described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remaining outstanding
shares will be deemed restricted securities as defined under Rule 144. Restricted securities may be sold in the public market only
if registered or if they qualify for an exemption from registration under Rule 144 or Rule 701 promulgated under the Securities
Act, which rules are summarized below. In addition, all of our shareholders have entered into market standoff agreements with us
or lock-up as further described in &#8220;&#8212; Lock-Up Agreements&#8221; below, under which they agreed not to sell their shares
until certain time or performance metrics have been met. Subject to the provisions of Rule 144 or Rule 701, shares are or will
be available for sale in the public market as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the date of this prospectus, 7,960,798&nbsp;Class A Ordinary Shares (including all shares sold in this Offering but assumed that no Participation Shares are sold), or 10,676,028 Class A Ordinary Shares (including all shares and Participation Shares are sold in this Offering), are available for sale in the public market, except for the shares purchased by affiliates which are subject to the volume and other restrictions of Rule 144 as well as the lock-up agreement restrictions described below;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the remainder of the shares will be eligible for sale in the public market from time to time thereafter, subject in some cases to the volume and other restrictions of Rule 144, as described below.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule
144 as currently in effect, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at
any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months,
including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with
the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements
of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding
period of any prior owner other than our affiliates, then that person is entitled to sell those shares without complying with any
of the requirements of Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule
144, as currently in effect, our affiliates are entitled to sell upon expiration of the lock-up agreements described above, within
any three-month period beginning 90 days after the date of this prospectus, a number of shares that does not exceed the greater
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of shares then outstanding, which will equal approximately&#8199;112,607&nbsp;or 140,299 shares immediately after this offering or immediately after the Participation Maximum is also sold, respectively; or</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The average weekly trading volume of the shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to that sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales under Rule 144
by our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current
public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule 701 generally
allows a shareholder who purchased ordinary shares pursuant to a written compensatory plan or contract and who is not deemed to
have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144,
but without being required to comply with the public information and holding period requirements of Rule 144. Rule 701 also permits
affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of
Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted registration rights and right to participate
to placement agent and certain of our shareholders. For a further description of these rights, see &ldquo;Description of Share
Capital &mdash; Registration Rights&rdquo; and &ldquo;Transactions with Related Persons &mdash; Registered Direct Offering.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_018"></A>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Cayman Islands
exempted company with limited liability and our affairs are governed by our Memorandum and Articles, the Companies Law, the common
law of the Cayman Islands, our corporate governance documents and rules and regulations of the stock exchange on which are shares
are traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof,
the authorized share capital of the Company is $100,000,000, consisting of 60,000,000 Class A Ordinary Shares, par value $1.00
each and 40,000,000 Class B Ordinary Shares, par value $1.00 each. As of the date hereof, 8,491,526 Class A Ordinary Shares and
22,437,754 Class B Ordinary Shares are issued and outstanding. All of our issued and outstanding Class A Ordinary Shares and Class
B Ordinary Shares are fully paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shares</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summaries
of material provisions of our Memorandum and Articles, corporate governance policies and the Companies Law insofar as they relate
to the material terms of our Class A Ordinary Shares and Class B Ordinary Shares (our class B Ordinary Shares are not registered
pursuant to Section 12(b), 12(g) or Section 15(d) of the Act, but we are voluntarily including information with respect to same
in this exhibit).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Objects of Our Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Memorandum
and Articles, the objects of our Company are unrestricted and we have the full power and authority to carry out any object not
prohibited by the law of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized share
capital is divided into Class A Ordinary Shares and Class B Ordinary Shares. Holders of our Class A Ordinary Shares and Class B
Ordinary Shares will have the same rights except for voting rights and conversion rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Class
A Ordinary Shares are entitled to one vote for each such share held and shall be entitled to notice of any shareholders&#8217;
meeting, and, subject to the terms of Memorandum and Articles, to vote thereat. The Class A Ordinary Shares are not redeemable
at the option of the holder and are not convertible into shares of any other class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Class
B Ordinary Shares shall have the right to ten votes for each such share held, and shall be entitled to notice of any shareholders&#8217;
meeting and, subject to the terms of the Memorandum and Articles, to vote thereat. The Class B Ordinary Shares are not redeemable
at the option of the holder but are convertible into Class A Ordinary Shares at any time after issue at the option of the holder
on a one to one basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our
Class A Ordinary Shares and Class B Ordinary Shares are entitled to such dividends as may be declared by our Board of Directors
subject to the Companies Law and to our Memorandum and Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In respect of all matters
subject to a shareholders&#8217; vote, each Class B Ordinary Share is entitled to ten votes, and each Class A Ordinary Share is
entitled to one vote, voting together as one class. Voting at any shareholders&#8217; meeting is by show of hands unless a poll
is demanded by the chairman or persons holding certain amounts of shares as set forth in the Memorandum and Articles. Actions that
may be taken at a general meeting also may be taken by a unanimous resolution of the shareholders in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No business shall be
transacted at any general meeting unless a quorum of members is present at the time when the meeting proceeds to business; two
members present in person or by proxy, one of whom shall be the holder of the majority of the shares in the Company, shall be a
quorum provided always that if the Company has one member of record the quorum shall be that one member present in person or by
proxy. An ordinary resolution to be passed at a general meeting requires the affirmative vote of a simple majority of the votes
cast, while a special resolution requires the affirmative vote of at least two-thirds of votes cast at a general meeting. A special
resolution will be required for important matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special resolution
of members is required to change the name of the Company, approve a merger, wind up the Company, amend the Memorandum and Articles
and reduce the share capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Conversion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Class A Ordinary Shares
are not convertible. Each Class B Ordinary Share shall be convertible, at the option of the holder thereof, into such number of
fully paid and non-assessable Class A Ordinary Shares on the basis that one Class B Ordinary Share shall be converted into one
Class A Ordinary Share (being a 1:1 ratio and hereafter referred to as the &#8220;<B>Conversion Rate</B>&#8221;), subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transfer of Shares</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the restrictions
set out below, any of our shareholders may transfer all or any of his, its or her Class A Ordinary Shares or Class B Ordinary Shares
by an instrument of transfer in the usual or common form or any other form approved by our Board of Directors or in a form prescribed
by the stock exchange on which our shares are then listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
may, in its sole discretion, decline to register any transfer of any Class A Ordinary Shares or Class B Ordinary Shares whether
or not it is fully paid up to the total consideration paid for such shares. Our directors may also decline to register any transfer
of any Class A Ordinary Shares or Class B Ordinary Shares if (a) the instrument of transfer is not accompanied by the certificate
covering the shares to which it relates or any other evidence as our Board of Directors may reasonably require to prove the title
of the transferor to, or his/her right to transfer the shares; or (b) the instrument of transfer is in respect of more than one
class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our directors refuse
to register a transfer, they shall, within two months after the date on which the instrument of transfer was lodged, send to the
transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration of
transfers may be suspended and the register closed at such times and for such periods as our Board of Directors may from time to
time determine, provided, however, that the registration of transfers shall not be suspended nor the register closed for more than
30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Winding-Up/Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On a return of capital
on winding up or otherwise (other than on conversion, redemption or purchase of shares), a liquidator may be appointed to determine
how to distribute the assets among the holders of the Class A Ordinary Shares and Class B Ordinary Shares. If our assets available
for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne
by our shareholders proportionately; a similar basis will be employed if the assets are more than sufficient to repay the whole
of the capital at the commencement of the winding up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Calls on Shares and Forfeiture of
Shares</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
may from time to time make calls upon shareholders for any amounts unpaid on their Class A Ordinary Shares or Class B Ordinary
Shares in a notice served to such shareholders at least 14 days prior to the specified time and place of payment. The shares that
have been called upon and remain unpaid on the specified time are subject to forfeiture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Redemption of Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue shares
on terms that are subject to redemption, at our option or at the option of the holders, on such terms and in such manner as may
be determined by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Variations of Rights of Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All or any of the special
rights attached to any class of shares may, be varied with the resolution of at least two thirds of the issued shares of that class
or a resolution passed at a general meeting of the holders of the shares of that class present in person or by proxy or with the
consent in writing of the holders of at least two-thirds of the issued shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Inspection of Books and Records</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors shall from
time to time determine whether and to what extent and at what times and places and under what conditions or regulations the accounts
and books of the Company or any of them shall be open to the inspection of members not being Directors and no member (not being
a Director) shall have any right of inspecting any account or book or document of the Company except as conferred by Companies
Law or authorized by the Directors or by the Company in a general meeting. However, the Directors shall from time to time cause
to be prepared and to be laid before the Company in a general meeting, profit and loss accounts, balance sheets, group accounts
(if any) and such other reports and accounts as may be required by Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Issuance of Additional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Memorandum and
Articles authorize our Board of Directors to issue additional Class A Ordinary Shares or Class B Ordinary Shares from time to time
as our Board of Directors shall determine, to the extent there are available authorized but unissued shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Memorandum and
Articles also authorizes our Board of Directors to establish from time to time one or more series of preferred shares and to determine,
subject to compliance with the variation of rights of shares provision in the Memorandum and Articles, with respect to any series
of preferred shares, the terms and rights of that series, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the designation of the series;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the number of shares of the series;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the dividend rights, dividend rates, conversion rights, voting rights; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the rights and terms of redemption and liquidation preferences.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
may, issue preferred shares without action by our shareholders to the extent there are authorized but unissued shares available.
Issuance of additional shares may dilute the voting power of holders of Class A Ordinary Shares and Class B Ordinary Shares. However,
our Memorandum of Association provides for authorized share capital comprising Class A Ordinary Shares and Class B Ordinary Shares
and to the extent the rights attached to any class may be varied, the Company must comply with the provisions in the Memorandum
and Articles relating to variations to rights of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Anti-Takeover Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of
our Memorandum and Articles may discourage, delay or prevent a change of control of our Company or management that shareholders
may consider favorable, including provisions that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">authorize our Board of Directors to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders (subject to variation of rights of shares provisions in our Memorandum and Articles); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limit the ability of shareholders to requisition and convene general meetings of shareholders. Our Memorandum and Articles allow our shareholders holding shares representing in aggregate not less than ten percent of our paid up share capital (as to the total consideration paid for such shares) in issue to requisition an extraordinary general meeting of our shareholders, in which case our directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under Cayman
Islands law, our directors may only exercise the rights and powers granted to them under our Memorandum and Articles for a proper
purpose and for what they believe in good faith to be in the best interests of our Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General Meetings of Shareholders and Shareholder Proposals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shareholders&#8217;
general meetings may be held in such place within or outside the Cayman Islands as our Board of Directors considers appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a Cayman Islands
exempted company, we are not obliged by the Companies Law to call shareholders&#8217; annual general meetings. However, our Memorandum
and Articles provide that we shall hold a general meeting in each year as our annual general meeting other than the year in which
the Memorandum and Articles were adopted at such time and place as determined by the directors. The directors may, whenever they
think fit, convene an extraordinary general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders&#8217;
annual general meetings and any other general meetings of our shareholders may be convened by a majority of our Board of Directors.
Our Board of Directors shall give not less than seven days&#8217; written notice of a shareholders&#8217; meeting to those persons
whose names appear as members in our register of members on the date the notice is given (or on any other date determined by our
directors to be the record date for such meeting) and who are entitled to vote at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cayman Islands law
provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right
to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association.
Our Memorandum and Articles allow our shareholders holding shares representing in aggregate not less than ten percent of our paid
up share capital (as to the total consideration paid for such shares) in issue to requisition an extraordinary general meeting
of our shareholders, in which case our directors are obliged to call such meeting and to put the resolutions so requisitioned to
a vote at such meeting; otherwise, our Memorandum and Articles do not provide our shareholders with any right to put any proposals
before annual general meetings or extraordinary general meetings not called by such shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exempted Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an exempted
company with limited liability under the Companies Law. The Companies Law distinguishes between ordinary resident companies and
exempted companies. A Cayman Islands exempted company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">is a company that conducts its business mainly outside of the Cayman Islands;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">is exempted from certain requirements of the Companies Law, including the filing an annual return of its shareholders with the Registrar of Companies or the Immigration Board;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">does not have to make its register of members open for inspection;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">does not have to hold an annual general meeting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may issue negotiable or bearer shares or shares with no par value (subject to the provisions of the Companies Law);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Limited liability&#8221;
means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except
in exceptional circumstances, such as involving fraud, the establishment of an agency relationship or an illegal or improper purpose
or other circumstances in which a court may be prepared to pierce or lift the corporate veil).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Register of Members</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands
law, we must keep a register of members and there should be entered therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the names and addresses of the members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of each member;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the date on which the name of any person was entered on the register as a member; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the date on which any person ceased to be a member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Cayman Islands
law, the register of members of our Company is prima facie evidence of the matters set out therein (i.e. the register of members
will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members
is deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members.
Once our register of members has been updated, the shareholders recorded in the register of members are deemed to have legal title
to the shares set against their name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the name of any
person is incorrectly entered in, or omitted from, our register of members, or if there is any default or unnecessary delay in
entering on the register the fact of any person having ceased to be a member of our Company, the person or member aggrieved (or
any member of our Company or our Company itself) may apply to the Cayman Islands Grand Court for an order that the register be
rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for
the rectification of the register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Indemnification of Directors and
Executive Officers and Limitation of Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cayman Islands law
does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of
officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public
policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our Memorandum and Articles
require us to indemnify our officers and directors for actions, proceedings, claims, losses, damages, costs, liabilities and expenses
(&#8220;Indemnified Losses&#8221;) incurred in their capacities as such unless such Indemnified Losses arise from dishonesty of
such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General Corporation
Law for a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Insofar
as indemnification for liabilities arising under the&nbsp;Securities Act&nbsp;may be permitted to our directors, officers or persons
controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against
public policy as expressed in the&nbsp;Securities Act&nbsp;and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following summary of certain terms and provisions of the warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the warrants, the form of which is filed as an exhibit to the registration
statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the
form of warrant for a complete description of the terms and conditions of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Exercise
Price and Duration.</I> The warrants will have an exercise price equal to 100% of the combined public offering price per Class
A Ordinary Share and related warrant. The warrants are exercisable immediately upon issuance, and at any time thereafter up to
the fifth anniversary of the issuance date. The exercise price is subject to appropriate adjustment in the event of certain stock
dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Class A Ordinary
Shares and also upon any distributions of assets, including cash, stock or other property to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Exercisability.
</I>The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise
notice and, at any time a registration statement registering the issuance of the Class A Ordinary Share underlying the warrants
under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the
Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number
of Class A Ordinary Shares purchased upon such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Cashless
Exercise</I>. If at the time of exercise there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Class A Ordinary Shares underlying the warrants, then the warrants may also be
exercised, in whole or in part, at such time by means of a cashless exercise, in which case the holder would receive upon such
exercise the net number of Class A Ordinary Shares determined according to the formula set forth in the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Exercise
Limitation.</I> A holder will not have the right to exercise any portion of the warrant if the holder (together with its affiliates)
would beneficially own in excess of 4.99% (or 9.99% upon the request of the holder) of the number of Class A Ordinary Shares outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the
warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until
the 61st day after such election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Transferability</I>.
Subject to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Fractional
Shares. </I>No fractional Class A Ordinary Shares will be issued upon the exercise of the warrants. Rather, the number of Class
A Ordinary Shares to be issued will be rounded to the nearest whole number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Trading
Market</I>. There is no established public trading market for the warrants being issued in this offering, and we do not expect
a market to develop. We do not intend to apply for listing of the warrants on any securities exchange or other nationally recognized
trading system. Without an active trading market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Fundamental
Transactions</I>. If a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and
may exercise every right and power that we may exercise and will assume all of our obligations under the warrants with the same
effect as if such successor entity had been named in the warrant itself. If holders of our Class A Ordinary Shares are given a
choice as to the securities, cash or property to be received in a fundamental transaction, then the holder shall be given the
same choice as to the consideration it receives upon any exercise of the warrant following such fundamental transaction. In addition,
in certain circumstances, upon a fundamental transaction, the holder will have the right to require us to repurchase its warrant
at its fair value using the Black Scholes option pricing formula; provided, however, that, if the fundamental transaction is not
within our control, including not approved by our board of directors, then the holder shall only be entitled to receive the same
type or form of consideration (and in the same proportion), at the Black Scholes value of the unexercised portion of the warrant,
that is being offered and paid to the holders of our Class A Ordinary Shares in connection with the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Rights
as a Shareholder</I>. Except as otherwise provided in the warrants or by virtue of such holder&rsquo;s ownership of our Class
A Ordinary Shares, the holder of a warrant does not have the rights or privileges of a holder of our Class A Ordinary Shares,
including any voting rights, until the holder exercises the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>Amendment
and Waiver</I>. The warrants may be modified or amended or the provisions thereof waived with the written consent of our company
on the one the hand and a holder on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-Funded Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary
of certain terms and provisions of the pre-funded warrants that are being offered hereby is not complete and is subject to, and
qualified in its entirety by, the provisions of pre-funded warrant, the form of which will be filed as an exhibit to the registration
statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the
form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each pre-funded warrant
offered hereby will have an initial exercise price per share equal to $0.01. The pre-funded warrants will be immediately exercisable
and will expire when exercised in full. Each pre-funded warrant is exercisable for one Class A Ordinary Share. The exercise price
and number of Class A Ordinary Shares issuable upon exercise is subject to appropriate adjustment in the event of stock dividends,
stock splits, reorganizations or similar events affecting our Class A Ordinary Shares and the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pre-funded warrants
will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied
by payment in full for the number of Class A Ordinary Shares purchased upon such exercise (except in the case of a cashless exercise
as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent
that the holder would own more than 4.99% of the outstanding Class A Ordinary Shares immediately after exercise, except that upon
at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of beneficial ownership of outstanding
Class A Ordinary Shares after exercising the holder&#8217;s pre-funded warrants up to 9.99% of the number of Class A Ordinary Shares
outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the
terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the
pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cashless Exercise</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at the time a holder
exercises its pre-funded warrants, a registration statement registering the issuance of the Class A Ordinary Shares underlying
the pre-funded warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu
of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price,
the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of Class A Ordinary Shares
determined according to a formula set forth in the pre-funded warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable
laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together
with the appropriate instruments of transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No fractional Class A Ordinary Shares will
be issued upon the exercise of the pre-funded warrants. Rather, the number of Class A Ordinary Shares to be issued will be rounded
to the nearest whole number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trading Market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no trading
market available for the pre-funded warrants on any securities exchange or nationally recognized trading system. The Class A Ordinary
Shares issuable upon exercise of the pre-funded warrants are currently listed on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Right as a Shareholder</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise
provided in the pre-funded warrants or by virtue of such holder&#8217;s ownership of Class A Ordinary Shares, the holders of the
pre-funded warrants do not have the rights or privileges of holders of our Class A Ordinary Shares, until they exercise their pre-funded
warrants. The pre-funded warrants will provide that holders have the right to participate in distributions or dividends paid on
our Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fundamental Transaction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a fundamental
transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification
of our ordinary shares, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation
or merger with or into another person, the acquisition of more than 50% of our outstanding Class A Ordinary Shares, or any person
or group becoming the beneficial owner of 50% of the voting power represented by our outstanding Class A Ordinary Shares, the holders
of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities,
cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such
fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Differences in Corporate Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law is
modeled after that of English law but does not follow many recent English law statutory enactments. In addition, the Companies
Law differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of some of
the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated
in the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt"><B><I>Mergers and
Similar Arrangements.&nbsp;</I></B>The Companies Law permits mergers and consolidations between Cayman Islands companies and between
Cayman Islands companies and non-Cayman Islands companies. For these purposes, a &#8220;merger&#8221; means the merging of two
or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving
company, and a &#8220;consolidation&#8221; means the combination of two or more constituent companies into a consolidated company
and the vesting of the undertaking, property and liabilities of such companies to the consolidated company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to effect
a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which
must then be authorized by a special resolution of the shareholders of each constituent company, and such other authorization,
if any, as may be specified in such constituent company&#8217;s articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The plan of merger
or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to: the solvency
of the consolidated or surviving company, the merger or consolidation being bona fide and not intended to defraud creditors, no
petition or other proceeding, order or resolution to wind up the Company, no receiver, administrator or similar having been appointed
over assets or property and no scheme or other arrangement having been entered into with creditors; a list of the assets and liabilities
of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members
and creditors of each constituent company; and that notification of the merger and consolidation will be published in the Cayman
Islands Gazette. The non-surviving constituent company must have resigned from any fiduciary office held or will do so and each
constituent company having complied with any applicable regulatory laws. Dissenting shareholders have the right to be paid the
fair value of their shares if they follow the required procedures under the Companies Law subject to certain exceptions. The fair
value of the shares will be determined by the Cayman Islands court if it cannot be agreed among the parties. Court approval is
not required for a merger or consolidation effected in compliance with these statutory procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, there
are statutory provisions that facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved
by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition
represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting
either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently
the arrangement must be sanctioned by the Grand Court of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While a dissenting
shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected
to approve the arrangement if it determines that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the statutory provisions as to the required majority vote have been met;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the shareholders have been fairly represented at the meeting in question;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the arrangement is such that an intelligent and honest man of that class acting in respect of his interest would reasonably approve; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Law or that would amount to a &#8220;fraud on the minority.&#8221;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When a take-over offer
is made and accepted by holders of not less than 90% of the shares within four months, the offer, or may, within a two-month period
commencing on the expiration of such four months period, require the holders of the remaining shares to transfer such shares on
the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed unless
there is evidence of fraud, bad faith or collusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the arrangement
and reconstruction is thus approved, the dissenting shareholder would have no rights comparable to appraisal rights, which would
otherwise ordinarily be available to dissenting shareholders of United States corporations, providing rights to receive payment
in cash for the judicially determined value of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Shareholders&#8217;
Suits.</I></B>&nbsp;In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company and as a
general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would
in all likelihood be of persuasive authority in the Cayman Islands, there are exceptions to the foregoing principle, including
when:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a company acts or proposes to act illegally or ultra vires and is therefore incapable of ratification by the shareholders;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the act complained of, although not ultra vires, could only be duly effected if authorized by more than a simple majority vote that has not been obtained; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Indemnification
of Directors and Executive Officers and Limitation of Liability.</I></B>&nbsp;The Companies Law does not limit the extent to which
a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the
extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against civil fraud or the consequences of committing a crime. As stated above, our Memorandum and Articles permit indemnification
of officers and directors for actions, proceedings, claims, losses, damages, costs, liabilities and expenses (&#8220;Indemnified
Losses&#8221;) incurred in their capacities as such unless such losses or damages arise from dishonesty of such directors or officers.
This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.
Insofar as indemnification for liabilities arising under the&nbsp;Securities Act&nbsp;may be permitted to our directors, officers
or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification
is against public policy as expressed in the&nbsp;Securities Act&nbsp;and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Directors&#8217;
Fiduciary Duties.</I></B>&nbsp;Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation
and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a
director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this
duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding
a significant transaction. The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best
interests of the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing
by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed
by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director
are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best
interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.
Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the
transaction, and that the transaction was of fair value to the corporation. As a matter of Cayman Islands law, a director of a
Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he or
she owes the following duties to the company: a duty to act bona fide in the best interests of the company, a duty not to make
a profit based on his or her position as director (unless the company permits him or her to do so) and a duty not to put himself
or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a
third-party. Our Memorandum and Articles do not disqualify a director from acting or from contacting with the Company as a vendor,
purchaser or otherwise provided that it does not adversely affect his or her performance of duties or responsibilities and the
nature of the interest is disclosed at the meeting at which the contract or arrangement is considered (if not previously disclosed),
and having disclosed such interest the director is not counted in the quorum and must refrain from voting on the contract or arrangement.
A director of a Cayman Islands company also owes to the company a duty to exercise the powers for the purpose for which they were
given and the duty to act with skill and care. It was previously considered that a director need not exhibit in the performance
of his or her duties a greater degree of skill than may reasonably be expected from a person of his or her knowledge and experience.
However, courts are moving towards an objective standard with regard to the required skill and care and these authorities are likely
to be followed in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Shareholder Action
by Written Consent.</I></B>&nbsp;Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders
to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our Memorandum and Articles
provide that shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each
shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Shareholder Proposals.</I></B>&nbsp;Under
the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders,
provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors
or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.
The Companies Law provides shareholders with only limited rights to requisition a general meeting and does not provide shareholders
with any right to put any proposal before a general meeting. However, these rights may be provided in articles of association.
Our Memorandum and Articles allow our shareholders holding not less than 1/10 of all voting power of our (paid up) share capital
in issue to requisition a shareholder&#8217;s meeting. Other than this right to requisition a shareholders&#8217; meeting, our
Memorandum and Articles do not provide our shareholders other rights to put proposal before a meeting. As an exempted Cayman Islands
company, we are not obliged by law to call shareholders&#8217; annual general meetings although our Memorandum and Articles provide
for same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Cumulative Voting.</I></B>&nbsp;Under
the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#8217;s
certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority
shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is
entitled on a single director, which increases the shareholder&#8217;s voting power with respect to electing such director. There
are no prohibitions in relation to cumulative voting under the Companies Law but our Memorandum and Articles do not provide for
cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Removal of Directors.</I></B>&nbsp;Under
the Delaware General Corporation Law, a director of a corporation with a may be removed with the approval of a majority of the
outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our Memorandum and Articles,
directors may be removed with or without cause, by the directors or by an ordinary resolution of our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Transactions
with Interested Shareholders.</I></B>&nbsp;The Delaware General Corporation Law contains a business combination statute applicable
to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment
to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#8220;interested
shareholder&#8221; for three years following the date that such person becomes an interested shareholder. An interested shareholder
generally is a person or a group who or which owns or owned 15% or more of the target&#8217;s outstanding voting share within the
past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in
which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which
such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction
which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation
to negotiate the terms of any acquisition transaction with the target&#8217;s board of directors. The Cayman Islands has no comparable
statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute.
However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does
provide that such transactions must be entered into bona fide in the best interests of the company and for a proper corporate purpose
and not with the effect of constituting a fraud on the minority shareholders. Our Memorandum and Articles, as well as our Code
of Business Conduct and Ethics that applies to our officers, directors and employees outlines how to handle these types of transactions
and other potential conflicts of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Dissolution;
Winding up.</I></B>&nbsp;Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve,
dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution
is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware
law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection
with dissolutions initiated by the board. Under the Companies Law, a company may be wound up by either an order of the courts of
the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by
an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including
where it is, in the opinion of the court, just and equitable to do so. Under the Companies Law a company may be dissolved, liquidated
or wound up by a special resolution of our shareholders; however, under our Memorandum and Articles, only our Directors have power
to present a winding up petition in the name of the Company and/or to apply for the appointment of provisional liquidators in respect
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Variation of
Rights of Shares.</I></B>&nbsp;Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares
with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.
Under the Companies Law and our Memorandum and Articles, if our share capital is divided into more than one class of shares, we
may vary the rights attached to any class with the written consent of the holders of two-thirds of the issued shares of that class
or with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Amendment of
Governing Documents.</I></B>&nbsp;Under the Delaware General Corporation Law, a corporation&#8217;s governing documents may be
amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides
otherwise. As permitted by the Companies Law, each of our Memorandum of Association and Articles of Association may only be amended
with a special resolution of our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Rights of Non-resident
or Foreign Shareholders.</I></B>&nbsp;There are no limitations imposed by our Memorandum and Articles on the rights of non-resident
or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our Memorandum
and Articles governing the ownership threshold above which shareholder ownership must be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rule 144</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.25pt"><B><I>Shares Held
for Six Months</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule
144 as currently in effect, and subject to the terms of any lock-up agreement, commencing 90 days after the closing of the IPO,
a person (or persons whose shares are aggregated), including an affiliate, who has beneficially owned our Class A Ordinary Shares
for six months or more, including the holding period of any prior owner other than one of our affiliates (i.e., commencing when
the shares were acquired from our Company or from an affiliate of our Company as restricted securities), is entitled to sell our
shares, subject to the availability of current public information about us. In the case of an affiliate shareholder, the right
to sell is also subject to the fulfillment of certain additional conditions, including manner of sale provisions and notice requirements,
and to a volume limitation that limits the number of shares to be sold thereby, within any three-month period, to the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1% of the number of Class A Ordinary Shares then outstanding; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the average weekly trading volume of our Class A Ordinary Shares on the NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The six-month holding
period of Rule 144 does not apply to sales of unrestricted securities. Accordingly, persons who hold unrestricted securities may
sell them under the requirements of Rule 144 described above without regard to the six-month holding period, even if they were
considered our affiliates at the time of the sale or at any time during the 90 days preceding such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.25pt"><B><I>Shares Held
by Non-Affiliates for One Year</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Rule 144 as currently
in effect, a person (or persons whose shares are aggregated) who is not considered to have been one of our affiliates at any time
during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least one year, including
the holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144
without complying with the provisions relating to the availability of current public information or with any other conditions under
Rule 144. Therefore, unless subject to a lock-up agreement or otherwise restricted, such shares may be sold immediately upon the
closing of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.25pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.25pt"><B><I>Registration
Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.25pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of their engagement, we agreed to register the Class A Ordinary Shares underlying the Placement Agent&rsquo;s Warrants in this
prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><A NAME="a_019"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a placement
agency agreement, dated September 29, 2020, we have engaged H.C. Wainwright &amp; Co., LLC (the &ldquo;Placement Agent&rdquo;)
to act as our exclusive placement agent in connection with this offering. The Placement Agent is not purchasing or selling any
such securities, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities,
other than to use its &ldquo;reasonable best efforts,&rdquo; to arrange for the sale of such securities by us. The terms of this
offering are subject to market conditions and negotiations between us, the Placement Agent, and prospective investors. The placement
agency agreement does not give rise to any commitment by the Placement Agent to purchase any of our securities, and the Placement
Agent will have no authority to bind us by virtue of the placement agency agreement. Further, the Placement Agent does not guarantee
that it will be able to raise new capital in any prospective offering. The Placement Agent may engage sub-agents or selected dealers
to assist with the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will enter into
a securities purchase agreement directly with institutional investors, at such investor&#8217;s option, which purchase our securities
in this offering, providing such investors with certain representations, warranties and covenants from us, which representations,
warranties and covenants will not be available to other investors which do not enter into a securities purchase agreement. Investors
which do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of
our securities in the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will deliver the
Class A Ordinary Shares being issued to the investors electronically and will mail such investors physical warrant certificates
for the warrants and pre-funded warrants, if any, sold in this offering, upon receipt of investor funds for the purchase of the
Class A Ordinary Shares, pre-funded warrants, if any, and warrants offered pursuant to this prospectus. We expect to deliver the
securities being offered pursuant to this prospectus on or about October 2, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fees and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
show the total placement agent fees we will pay in connection with the sale of the securities in this offering, assuming the purchase
of all of the securities we are offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Class A Ordinary Share and <BR> related Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Pre-Funded Warrant and <BR> related Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 76%; text-align: left">Placement Agent Fees</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.2275</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">0.2275</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">630,000.00</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to pay
to the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds raised in this offering and a management fee equal
to 0.75% of the aggregate gross proceeds raised in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">The cash fee paid to the Placement Agent was reduced to 5.19% with respect to certain investors
participating in this offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate the total
expenses payable by us for this offering to be approximately $942,000, which amount includes (i) a Placement Agent&rsquo;s cash
fee of $552,000; (ii) the management fee of $67,500 (equal to 0.75% of the aggregate gross proceeds raised in this offering); (iii)
reimbursement of the accountable expenses of the Placement Agent equal to $100,000, including the legal fees of the Placement Agent
being paid by us (none of which has been paid in advance); (iv) the Placement Agent&rsquo;s clearing expenses in the amount of
$12,900 in connection with this offering; and (v) other estimated expenses of approximately $209,598 which include legal, accounting,
printing costs and various fees associated with the registration and listing of our shares. In addition, we have agreed to issue
the Placement Agent&rsquo;s Warrants to the Placement Agent. See &ldquo;Placement Agent&rsquo;s Warrants&rdquo; below for additional
detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Placement Agent&#8217;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to issue
to the Placement warrants to purchase 147,538 Class A Ordinary Shares (including the Class A Ordinary Shares issuable upon exercise
of the pre-funded warrants) being sold in this offering. The Placement Agent&rsquo;s Warrants will have a term of five years from
the commencement of sales in this offering and an exercise price per Class A Ordinary Share equal to $4.0625 per share, which represents
125% of the combined public offering price for the Class A Ordinary Shares and related warrants sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tail Financing Payments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The Placement Agent
will be entitled to compensation as set forth above, with respect to any public or private offering or other financing or capital-raising
transaction of any kind (&ldquo;Tail Financing&rdquo;) to the extent that such financing or capital is received by the Company
from (i) in connection with a public offering, investors whom the Placement Agent had contacted during the term of our placement
agent agreement with the Placement Agent or introduced to the Company during such term, or (ii) in connection with a non-public
offering, investors whom the Placement Agent had brought over-the-wall during such term, if such Tail Financing is consummated
at any time within the 12-month period following the expiration or termination of our placement agent agreement with the Placement
Agent and a list of such investors is provided to the Company as promptly as practicable following the expiration or termination
of our placement agent agreement with the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed with
the Placement Agent to be subject to a lock-up period of 30 days following the date of closing of the offering pursuant to this
prospectus. This means that, during the applicable lock-up period, we may not issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any Class A Ordinary Shares or their equivalents, subject to certain exceptions. The placement
agent may waive the terms of these lock-up agreements in its sole discretion and without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our officers
and directors have also agreed with the Placement Agent to be subject to a lock-up period of 90 days following the date of closing
of the offering pursuant to this prospectus. This means that, during the lock-up period, such persons may not offer for sale, contract
to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly
or indirectly, any Class A Ordinary Shares or any securities convertible into, or exercisable or exchangeable for, our Class A
Ordinary Shares. Certain limited transfers are permitted during the lock-up period if the transferee agrees to these lock-up restrictions.
The placement agent may waive the terms of these lock-up agreements in its sole discretion and without notice.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">Our Class A Ordinary
Shares are listed on the Nasdaq Global Market under the symbol &ldquo;APM&rdquo;. There is no established public trading market
for the warrants or the pre-funded warrants and we do not plan to list the warrants or pre-funded warrants or the Placement Agent&rsquo;s
Warrants on the Nasdaq Global Market or any other securities exchange or trading market. Without an active trading market, the
liquidity of the warrants and the pre-funded warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have agreed to indemnify
the Placement Agent and specified other persons against some civil liabilities, including liabilities under the Securities Act,
and the Securities Exchange Act of 1934, as amended, or the Exchange Act, and to contribute to payments that the Placement Agent
may be required to make in respect of such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation M</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Placement Agent
may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act and any fees received by it and
any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts
or commissions under the Securities Act. The Placement Agent will be required to comply with the requirements of the Securities
Act and the Exchange Act including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations
may limit the timing of purchases and sales of our securities by the Placement Agent. Under these rules and regulations, the Placement
Agent may not (i) engage in any stabilization activity in connection with our securities; and (ii) bid for or purchase any of our
securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until
they have completed their participation in the distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Purchaser Warrant Exchange, we paid the Placement Agent $212,500 in fees ($25,000 of which was for non-accountable expenses
and $50,000 of which was for legal and other fees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time,
the Placement Agent has provided and may provide in the future, various advisory, investment and commercial banking and other services
to us in the ordinary course of business, for which it has and may receive customary fees and commissions. However, except as disclosed
in this prospectus, we have no present arrangements with the Placement Agent for any services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">Dr.
Kira Sheinerman serves as a senior strategic consultant to the company. Dr. Sheinerman also serves as a Managing Director, Healthcare
Investment Banking at H.C. Wainwright &amp; Co., the placement agent for this offering. Dr. Sheinerman did not participate in
this offering on behalf of the Company or H.C. Wainwright &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>TAXATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>The
following summary contains a description of certain Cayman Islands and U.S. federal income tax consequences of the acquisition,
ownership and disposition of Class A Ordinary Shares, warrants and pre-funded warrants. Please note that this summary should not
be considered a comprehensive description of all the tax considerations that may be relevant to the decision to purchase Class
A Ordinary Shares, warrants and pre-funded warrants. The summary is based upon the tax laws of the Cayman Islands and regulations
thereunder and on the tax laws of the United States and regulations thereunder as of the date hereof, which are subject to change</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Cayman Islands
Tax Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there
is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by
the government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought within,
the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties which are applicable to any
payments made by or to our Company. There are no exchange control regulations or currency restrictions in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Payments
of dividends and capital in respect of our Class A Ordinary Shares will not be subject to taxation in the Cayman Islands and no
withholding will be required on the payment of a dividend or capital to any holder of our Class A Ordinary Shares, nor will gains
derived from the disposal of our Class A Ordinary Shares be subject to Cayman Islands income or corporation tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
stamp duty is payable in respect of the issue of our Class A Ordinary Shares or on an instrument of transfer in respect of our
Class A Ordinary Shares except on instruments executed in, or brought within, the jurisdiction of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Material U.S.
Federal Income Tax Considerations for U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following is a description of the material U.S. federal income tax consequences to U.S. Holders (as defined below) of purchasing,
owning and disposing of Class A Ordinary Shares, warrants and pre-funded warrants. It is not a comprehensive description of all
U.S. federal income tax considerations that may be relevant to a particular person&rsquo;s decision to acquire Class A Ordinary
Shares, warrants and pre-funded warrants. This discussion applies only to a U.S. Holder that holds a Class A Ordinary Share, warrant
and pre-funded warrant as a capital asset for U.S. federal income tax purposes (generally, property held for investment). In addition,
it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&rsquo;s particular circumstances,
including state and local tax consequences, non-U.S. tax consequences, federal estate or gift tax consequences, alternative minimum
tax consequences, the potential application of the provisions of the Code known as the Medicare Contribution Tax, and tax consequences
applicable to U.S. Holders subject to special rules, such as:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">banks and other financial institutions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">insurance companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">dealers or traders in securities who use a mark-to-market method of tax accounting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">persons holding Class A Ordinary Shares as part of a hedging transaction, &#8220;straddle,&#8221; wash sale, conversion transaction or integrated transaction or persons entering into a constructive sale with respect to the Class A Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">tax exempt entities, including &#8220;individual retirement accounts&#8221; and &#8220;Roth IRAs&#8221;;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">former citizens or long-term residents of the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">entities or arrangements classified as partnerships for U.S. federal income tax purposes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">regulated investment companies or real estate investment trusts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">persons who acquired our Class A Ordinary Shares pursuant to the exercise of an employee share option or otherwise as compensation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">persons that own or are deemed to own ten percent or more of our shares; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">persons holding Class A Ordinary Shares in connection with a trade or business conducted outside the United States.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds Class A Ordinary Shares,
the U.S. federal income tax treatment of such partnership and each partner thereof will generally depend on the status of the partner
and the activities of the partnership. Partnerships holding Class A Ordinary Shares and partners in such partnerships are encouraged
to consult their tax advisors as to the particular U.S. federal income tax consequences of purchasing, holding and disposing of
Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
discussion is based on the Code, the Treasury Regulations issued thereunder, and administrative and judicial interpretations thereof,
all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect, or to different interpretation.
Such change could materially and adversely affect the tax consequences described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
purposes of this discussion, a &ldquo;U.S. Holder&rdquo; is a holder who, for U.S. federal income tax purposes, is a beneficial
owner of Class A Ordinary Shares, warrants or pre-funded warrants and that is:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 90%; padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">an individual citizen or resident of the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">a trust, (i) if a court within the United States is able to exercise primary supervision over its administration and one or more &#8220;U.S. persons&#8221; (within the meaning of the Code) have the authority to control all of its substantial decisions, or (ii) if a valid election is in effect for the trust to be treated as a U.S. person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">U.S.
Holders are encouraged to consult their tax advisors concerning the U.S. federal, state, local and foreign tax consequences of
purchasing, owning and disposing of Class A Ordinary Shares in their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white"><B><I>Taxation
of Distributions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subject
to the discussion below under &#8220;Passive Foreign Investment Company Rules,&#8221; a U.S. Holder will be required to include
in gross income as dividend income the gross amount of any distributions paid on Class A Ordinary Shares (including any amount
of taxes withheld), other than certain <I>pro rata </I>distributions of Class A Ordinary Shares, to the extent paid out of our
current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of
our current and accumulated earnings and profits would be treated as a non-taxable return of capital to the extent of the U.S.
Holder&#8217;s adjusted tax basis in the Class A Ordinary Shares and thereafter as a gain from the sale of the Class A Ordinary
Shares. However, because we do not calculate our earnings and profits under U.S. federal income tax principles, we expect that
distributions generally will be reported to U.S. Holders as dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
case of a U.S. Holder that is a corporation, dividends paid on the Class A Ordinary Shares will be subject to regular corporate
rates and will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders with
respect to dividends received from U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Dividends
received by an individual, trust or estate will be subject to taxation at standard tax rates. A reduced income tax rate applies
to dividends paid by a &#8220;qualified foreign corporations&#8221; (if certain holding period requirements and other conditions
are met). A non-U.S. corporation generally will be considered to be a qualified foreign corporation (i) if it is eligible for the
benefits of a comprehensive tax treaty with the United States which includes an exchange of information program or (ii) with respect
to any dividend it pays on stock which is readily tradable on an established securities market in the United States. US. Treasury
Department guidance indicates that our Class A Ordinary Shares, which will be listed on the NASDAQ Global Market will be readily
tradable on an established securities market in the United States. There can be no assurance, however, that our Class A Ordinary
Shares will be considered readily tradable on an established securities market in later years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Non-corporate
U.S. Holders will not be eligible for reduced rates of taxation on any dividends received from us if we are a PFIC in the taxable
year in which such dividends are paid or in the preceding taxable year (see &#8220;Passive Foreign Investment Company Rules&#8221;
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
U.S. Holder may be eligible, subject to a number of complex limitations, to claim a foreign tax credit in respect of any foreign
withholding taxes imposed on dividends received on the Class A Ordinary Shares. A U.S. Holder who does not elect to claim a foreign
tax credit for foreign income tax withheld may instead claim a deduction for U.S. federal income tax purposes in respect of such
withholding, but only for a year in which such investor elects to do so for all creditable foreign income taxes. For purposes of
calculating the foreign tax credit limitation, dividends paid by us will, depending on the circumstances of the U.S. Holder, be
either general or passive income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">While
we do not expect to pay dividends in the near future, in the event any dividends are paid and if a dividend is paid in non-U.S.
currency, it must be included in a U.S. Holder&#8217;s income as a U.S. dollar amount based on the exchange rate in effect on the
date such dividend is actually or constructively received, regardless of whether the dividend is in fact converted into U.S. dollars.
If the dividend is converted to U.S. dollars on the date of receipt, a U.S. Holder generally will not recognize a foreign currency
gain or loss. If the non-U.S. currency is converted into U.S. dollars on a later date, however, the U.S. Holder must include in
income any gain or loss resulting from any exchange rate fluctuations. Such gain or loss will generally be ordinary income or loss
and will be from sources within the United States for foreign tax credit limitation purposes. U.S. Holders should consult their
own tax advisors regarding the tax consequences to them if we pay dividends in non-U.S. currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white"><B><I>Sale
or Other Taxable Disposition of Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subject
to the discussion below under &ldquo;Passive Foreign Investment Company Rules,&rdquo; gain or loss realized on the sale or other
taxable disposition of Class A Ordinary Shares and warrants will be capital gain or loss, and will be long-term capital gain or
loss if the U.S. Holder held the Class A Ordinary Shares for more than one year. The amount of the gain or loss will equal the
difference between the U.S. Holder&rsquo;s tax basis in the Class A Ordinary Shares disposed of and the amount realized on the
disposition. Long-term capital gain of a non-corporate U.S. Holder is generally taxed at preferential rates. This gain or loss
will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to
limitations. U.S. Holders are urged to consult their tax advisors regarding the tax consequences if a foreign tax is imposed on
the disposition of Class A Ordinary Shares, including the availability of the foreign tax credit under an investor&rsquo;s own
particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
U.S. Holder that receives non-U.S. currency on the disposition of the Class A Ordinary Shares will realize an amount equal to the
U.S. dollar value of the foreign currency received on the date of disposition (or in the case of cash basis and electing accrual
basis taxpayers, the settlement date) whether or not converted into U.S. dollars at that time. Very generally, the U.S. Holder
will recognize currency gain or loss if the U.S. dollar value of the currency received on the settlement date differs from the
amount realized with respect to the Class A Ordinary Shares. Any currency gain or loss on the settlement date or on any subsequent
disposition of the foreign currency generally will be U.S.-source ordinary income or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I></I></B></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white"><B><I>Exercise of a&nbsp;Pre-funded&nbsp;Warrant</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder generally
will not recognize taxable gain or loss on the acquisition of Class A Ordinary Shares upon exercise of a&nbsp;pre-funded&nbsp;warrant.
The U.S. Holder&#8217;s aggregate tax basis in the share of our Class A Ordinary Shares received upon exercise of a&nbsp;pre-funded&nbsp;warrant&nbsp;generally
will be an amount equal to the sum of the U.S. Holder&#8217;s tax basis in the&nbsp;pre-funded&nbsp;warrant&nbsp;prior to exercise
and the warrant&#8217;s exercise price. Provided that a&nbsp;pre-funded&nbsp;warrant&nbsp;is treated as our Class A Ordinary Shares,
a U.S. Holder&#8217;s holding period for the Class A Ordinary Shares received upon exercise of a warrant will include the holding
period for the&nbsp;pre-funded&nbsp;warrant. On the other hand, if the&nbsp;pre-funded&nbsp;warrant&nbsp;is treated as an option
to purchase our stock, a U.S. Holder&#8217;s holding period for the Class A Ordinary Shares received upon exercise of a warrant
will begin on the date following the date of exercise of the warrant and will not include the period during which the U.S. Holder
held the warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may
be permitted to undertake a cashless exercise of pre-funded warrants into our Class A Ordinary Shares. The U.S. federal income
tax treatment of a cashless exercise is unclear, and the tax consequences of a cashless exercise could differ from the consequences
of an exercise described above. For example, the cashless exercise could be treated as a taxable disposition of a portion of the
Warrants or the common shares into which they are exercisable. U.S. Holders should consult their own tax advisors regarding the
U.S. federal income tax consequences of a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.5pt; text-align: justify; background-color: white"><B><I>Passive
Foreign Investment Company Rules</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Special
U.S. federal income tax rules apply to a U.S. Holder that holds stock in a foreign corporation classified as a PFIC for U.S. federal
income tax purposes. In general, a non-U.S. corporation will be classified as a PFIC for any taxable year in which, after applying
certain look-through rules, either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">at least 75% of its gross income for such taxable year is passive income (e.g., dividends, interest, capital gains and rents derived other than in the active conduct of a rental business); or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that produce passive income or are held for the production of passive income.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other
corporation in which we own, directly or indirectly, 25% or more (by value) of the equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result,
our PFIC status may change. In particular, the total value of our assets generally will be calculated using the market price of
our Class A Ordinary Shares, which may fluctuate considerably. Fluctuations in the market price of our Class A Ordinary Shares
may result in our being a PFIC for any taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Due
to the amount of restricted and unrestricted cash that we had on hand during our year ending December 31, 2018 and 2017, we believe
that we were classified as a PFIC for that tax year. Depending on the future composition and value of our assets, we may be classified
as a PFIC for future years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
we were to be classified as a PFIC, a U.S. Holder would be subject to different taxation rules depending on whether the U.S. Holder
(i) takes no action, (ii) makes an election to treat us as a &ldquo;Qualified Electing Fund&rdquo; (a &ldquo;QEF election&rdquo;)
or (iii) if permitted, makes a &ldquo;mark-to-market&rdquo; election with respect to our Class A Ordinary Shares (a Mark-to-Market
Election will be unavailable with respect to our warrants and is not expected to be available with respect to the pre-funded warrants,
which are not likely to be treated as regularly traded on a qualified exchange). A U.S. Holder of our Class A Ordinary Shares
will also be required under applicable Treasury Regulations to file an annual information return (Form 8621) containing information
regarding our company. Additional explanations of the PFIC rules are set forth below: this material is complex and may affect
different U.S. Holders differently. Accordingly, U.S. Holders should consult their own tax advisors about the consequences of
our company being classified as a PFIC and about what steps, if any, they might take to lessen the tax impact of our PFIC status
on them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
U.S. Holder who does not make a timely QEF or mark-to-market election (a &ldquo;Non-Electing Holder,&rdquo;), as discussed below,
will be subject to special tax rules with respect to any &ldquo;excess distribution&rdquo; that you receive and any gain you realize
from a sale or other disposition (including a pledge) of Class A Ordinary Shares. Distributions you receive in a taxable year
that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable
years or your holding period for the Class A Ordinary Shares, warrants or pre-funded warrants will be treated as an excess distribution.
Under these special tax rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    excess distribution or gain will be allocated ratably over your holding period for the Class A Ordinary Shares, warrants or
    pre-funded warrants;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
should be noted that, until such time as we make a distribution, there are no tax consequences to Non-Electing Holders. However,
if we ever did make a distribution it would in all likelihood be an excess distribution (because we would not have previously
made any distributions to holders of Class A Ordinary Shares). At that point, and for all subsequent distributions, the rules
described above would apply to Non-Electing Holders. The tax liability for amounts allocated to years prior to the year of disposition
or &ldquo;excess distribution&rdquo; cannot be offset by any net operating losses for such years, and gains (but not losses) realized
on the sale of the Class A Ordinary Shares, warrants or pre-funded warrants cannot be treated as capital, even if you hold the
Ordinary Shares as capital assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Certain
elections may be available that would result in alternative treatments. The adverse consequences of owning stock in a PFIC could
be mitigated if a U.S. Holder makes a valid QEF election (a U.S. Holder which we refer to as an &ldquo;Electing Holder&rdquo;)
which, among other things, would require the Electing Holder to include currently in income its pro rata share of the PFIC&rsquo;s
net capital gain and ordinary earnings, if any, for our taxable year that ends with or within the taxable year of the Electing
Holder, regardless of whether or not the Electing Holder actually received distributions from us. When an Electing Holder makes
a QEF election, its adjusted tax basis in our Class A Ordinary Shares, warrants or pre-funded warrants is increased to reflect
taxed but undistributed earnings and profits. Distributions of earnings and profits that had been previously taxed will result
in a corresponding reduction in the adjusted tax basis in our Class A Ordinary Shares and will not be taxed again once distributed.
An Electing Holder would generally recognize capital gain or loss on the sale, exchange or other disposition of our Class A Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
U.S. Holder can make a QEF election with respect to any year that we are a PFIC by filing IRS Form 8621 with its U.S. federal income
tax return. This election must be made by the deadline (including extensions) for filing the U.S. Holder&#8217;s federal tax return
for the year in question. U.S. Holders should discuss their election alternatives with their own tax advisors. Once an election
is made, the Electing Holder is subject to the QEF rules for as long as we are a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">It
should be noted that in order to make a QEF election a U.S. Holder needs information from us concerning our PFIC status and our
financial results for the year. We cannot assure our U.S. Holders that we will provide such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
an alternative to making a QEF election, a U.S. Holder may make a &#8220;mark-to-market&#8221; election with respect to our Class
A Ordinary Shares provided our Class A Ordinary Shares are treated as &#8220;marketable stock.&#8221; The Class A Ordinary Shares
generally will be treated as marketable stock if they are regularly traded on a &#8220;qualified exchange or other market&#8221;
(within the meaning of applicable Treasury Regulations) on at least 15 days during each calendar quarter (other than in de minimis
amounts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
a U.S. Holder makes an effective mark-to-market election, for each taxable year that we are a PFIC, the U.S. Holder will include
as ordinary income the excess of the fair market value of its Class A Ordinary Shares at the end of the year over its adjusted
tax basis in the Class A Ordinary Shares. You will be entitled to deduct as an ordinary loss in each such year the excess of your
adjusted tax basis in the Class A Ordinary Shares over their fair market value at the end of the year, but only to the extent of
the net amount previously included in income as a result of the mark-to-market election. A U.S. Holder&#8217;s adjusted tax basis
in the Class A Ordinary Shares will be increased by the amount of any income inclusion and decreased by the amount of any deductions
under the mark-to-market rules. In addition, upon the sale or other disposition of your Class A Ordinary Shares in a year that
we are PFIC, any gain will be treated as ordinary income and any loss will be treated as ordinary loss, but only to the extent
of the net amount of previously included income as a result of the mark-to-market election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
a U.S. Holder makes a mark-to-market election, it will be effective for the taxable year for which the election is made and all
subsequent taxable years unless the Class A Ordinary Shares are no longer regularly traded on a qualified exchange or other market,
or the IRS consents to the revocation of the election. You are urged to consult your tax advisor about the availability of the
mark-to-market election, and whether making the election would be advisable in your particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Information Reporting and Backup
Withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Payments
of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries
generally are subject to information reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation
or other exempt recipient or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification
number and certifies that it is not subject to backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Backup
withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a
credit against the holder&#8217;s U.S. federal income tax liability and may entitle it to a refund, provided that the required
information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Information with Respect to Foreign
Financial Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Certain
U.S. Holders may be required to report information relating to the Class A Ordinary Shares, warrants or pre-funded warrants, subject
to certain exceptions (including an exception for Class A Ordinary Shares held in accounts maintained by certain U.S. financial
institutions). U.S. Holders should consult their tax advisors regarding their reporting obligations with respect to their purchase,
ownership and disposition of the Class A Ordinary Shares, warrants and pre-funded warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_021"></A>EXPENSES OF THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is
an itemization of our total expenses, which are expected to be incurred in connection with the offer and sale of the Class A Ordinary
Shares by us. With the exception of the SEC registration fee, all amounts are estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Assume no Participation Shares are sold</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Assume all Participation Shares are sold</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 0.25pt">Securities and Exchange Commission registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,878</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,878</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.25pt">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">180,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.25pt">Other professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,720</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25pt">Placement agent&rsquo;s fee</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">810,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,822,920</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt; padding-left: 0.25pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,019,998</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,032,498</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_022"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of
the Class A Ordinary Shares, warrants and pre-funded warrants being offered by this prospectus and other legal matters relating
to Cayman Islands law will be passed upon for us by Campbells. Certain legal matters with respect to the United States federal
securities law and New York law will be passed upon for us by Hunter Taubman Fischer &amp; Li LLC, New York, New York. The placement
agent is being represented by Ellenoff Grossman &amp; Schole LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_023"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: justify">The consolidated balance sheets (successor
basis) as of December 31, 2019 and 2018, the related consolidated statements (successor basis) of operations and comprehensive
loss, equity and cash flows for each of the two years in the period ended December 31, 2019, and the period March 1, 2017 through
December 31, 2017, and the statements (predecessor basis) of operations, changes in net assets, and cash flows for the period January
1, 2017 through February 28, 2017 incorporated by reference in this prospectus have been audited by Marcum Bernstein &amp; Pinchuk
LLP, an independent registered public accounting firm (&#8220;Marcum&#8221;), as set forth in their report thereon, included therein,
and incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting
and auditing. The consolidated financial statements for the six months ended June 30, 2020 incorporated herein by reference are
not audited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_024"></A>ENFORCEMENT OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated
under the laws of the Cayman Islands as an exempted company with limited liability. We incorporated in the Cayman Islands because
of certain benefits associated with being a Cayman Islands corporation, such as political and economic stability, an effective
judicial system, a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability
of professional and support services. However, the Cayman Islands have a less developed body of securities laws that provide significantly
less protection to investors as compared to the securities laws of the United States. In addition, Cayman Islands companies may
not have standing to sue before the federal courts of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our assets are
located outside the United States. In addition, some of our directors and officers are residents of jurisdictions other than the
United States and all or a substantial portion of their assets are located outside the United States. As a result, it may be difficult
for investors to effect service of process within the United States upon us or our directors and officers, or to enforce against
us or them judgments obtained in United States courts, including judgments predicated upon the civil liability provisions of the
securities laws of the United States or any state in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to our local
Cayman Islands&#8217; counsel, there is uncertainty with regard to Cayman Islands law relating to whether a judgment obtained from
the United States, United Kingdom or Hong Kong courts under civil liability provisions of the securities laws will be determined
by the courts of the Cayman Islands as penal or punitive in nature. If such a determination is made, the courts of the Cayman Islands
will not recognize or enforce the judgment against a Cayman Islands&#8217; company. The courts of the Cayman Islands in the past
determined that disgorgement proceedings brought at the instance of the Securities and Exchange Commission are penal or punitive
in nature and such judgments would not be enforceable in the Cayman Islands. Other civil liability provisions of the securities
laws may be characterized as remedial, and therefore enforceable but the Cayman Islands&#8217; Courts have not yet ruled in this
regard. Our Cayman Islands&#8217; counsel has further advised us that a final and conclusive judgment in the federal or state courts
of the United States under which a sum of money is payable other than a sum payable in respect of taxes, fines, penalties or similar
charges, may be subject to enforcement proceedings as a debt in the courts of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
prospectus, no treaty or other form of reciprocity exists between the Cayman Islands and United Kingdom and/or Hong Kong governing
the recognition and enforcement of judgments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cayman Islands&#8217;
counsel further advised that although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United
States, United Kingdom or Hong Kong, a judgment obtained in such jurisdictions will be recognized and enforced in the courts of
the Cayman Islands at common law, without any re-examination of the merits of the underlying dispute, by an action commenced on
the foreign judgment debt in the Grand Court of the Cayman Islands, provided such judgment (1) is given by a foreign court of competent
jurisdiction, (2) imposes on the judgment debtor a liability to pay a liquidated sum for which the judgment has been given, (3)
is final, (4) is not in respect of taxes, a fine or a penalty, and (5) was not obtained in a manner and is of a kind the enforcement
of which is contrary to natural justice or the public policy of the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_025"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with
the SEC a registration statement on Form F-1 under the Securities Act relating to this Offering of our Class A Ordinary Shares.
This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the
SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in
this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information
about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents
as an exhibit to the registration statement, you may read the document itself for a complete description of its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may read and copy
the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge
at the SEC&#8217;s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of
the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington,
D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains
an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings
with the SEC are also available to the public through the SEC&#8217;s website at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the
information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements
file reports with the SEC. Those other reports or other information may be inspected without charge at the locations described
above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit
recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to
file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies
whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each
fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited
by an independent registered public accounting firm, and will submit to the SEC, on Form 6-K, unaudited interim financial information
for the first six months of each fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate
website at www.aptorumgroup.com. Information contained on, or that can be accessed through, our website does not constitute a part
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_026"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to
&#8220;incorporate by reference&#8221; information into this document. This means that we can disclose important information to
you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered
to be a part of this document, except for any information superseded by information that is included directly in this document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus incorporates
by reference the documents listed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in; padding: 0.25pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020024906/ea126270-6k_aptorumgroup.htm">Form 6-K</A> furnished with the Commission on September 2, 2020, which contains Management's Discussion and Analysis of Financial Condition and Results of Operations and the unaudited interim condensed consolidated financial statements and related notes thereto for the Company, as of and for the six months ended June 30, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020024657/ea126221-6k_aptorumgroup.htm">Form 6-K</A> furnished with the Commission on September 1, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020023942/ea125951-6k_aptorumgroup.htm">Form 6-K</A> furnished with the Commission on August 27, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020022976/ea125772-6k_aptorumgroup.htm">Form 6-K</A> furnished with the Commission on August 20, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020018438/ea124489-6k_aptorum.htm">Form 6-K</A> furnished with the Commission on July 24, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on<A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020017705/ea0124246-6k_aptorum.htm"> Form 6-K</A> furnished with the Commission on July 17, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020016025/ea123502-6k_aptorum.htm">Form 6-K</A> furnished with the Commission on June 29, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Report on<A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020011956/ea121754-6k_aptorumgroup.htm"> Form 6-K</A> furnished with the Commission on May 13, 2020;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390020010347/f20f2019_aptorumgroup.htm">Form 20-F</A> for the fiscal year ended December 31, 2019, filed with the SEC on April 29, 2020, <FONT STYLE="background-color: white">which contains our audited consolidated financial statements for the most recent fiscal year for which those statements have been filed</FONT>;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the description of our Ordinary Shares contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1734005/000121390018017387/f8a12b120318_aptorumgroup.htm">Form 8-A</A> filed with the SEC on December 14, 2018, including any amendments and reports filed for the purpose of updating such description.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will provide a copy
of the documents we incorporate by reference, at no cost, to any person who receives this prospectus. To request a copy of any
or all of these documents, you should write or telephone us at 17 Hanover Square, London W1S 1BN, United Kingdom, Attention: Sabrina
Khan, Chief Financial Officer, +44 20 80929299. Additionally, copies of the documents incorporated herein by reference may be
accessed at our website at www.aptorumgroup.com. The reference to our website address does not constitute incorporation by reference
of the information contained on or accessible through our website, and you should not consider the contents of our website in making
an investment decision with respect to our Class A Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_009.jpg" ALT="" STYLE="height: 132px; width: 468px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>Aptorum Group Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 2,769,231 Class A Ordinary Shares
and Warrants to purchase up to 2,769,231 Class A Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>or</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to 2,769,231 Pre-Funded Warrants
to Purchase Class A Ordinary Shares and Warrants to Purchase up to 2,769,231 Class A Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>(5,538,462
Class A Ordinary Shares Issuable Upon Exercise of the Pre-Funded Warrants and Warrants)&nbsp;</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="background-color: white"></FONT></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><FONT STYLE="font-size: 16pt"><B>H.C.
Wainwright &amp; Co.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B></B></P>


























































































































































































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 &5F:6QE+F5D
M9V%R   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  !E &8 :0!L &4 +@!E &0 9P!A '(   #_X0L>:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[
MOR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB
M83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(O/CQR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W
M-3$X,F8Q8B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(CX\>&UP.D-R96%T941A=&4^,C R,"TP.2TQ,50P-SHP,CHU,"XY.3D\
M+WAM<#I#<F5A=&5$871E/CPO<F1F.D1E<V-R:7!T:6]N/CQR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q
M+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E
M;&5M96YT<R\Q+C$O(CX\9&,Z8W)E871O<CX\<F1F.E-E<2!X;6QN<SIR9&8]
M(FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B
M/CQR9&8Z;&D^969I;&4N961G87(\+W)D9CIL:3X\+W)D9CI397$^#0H)"0D\
M+V1C.F-R96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO>#IX
M;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD
M/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7
M&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4
M*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ_\  $0@!106X P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
M       ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042
M(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V
M-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KA
MXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$
M!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3
M(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&
M1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CI
MZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***R;_ ,5:%IOGK=ZO8I- "7@-R@DR!G&TG.?:DY*.Y<*<ZCM!7-:BL_1M
M=TWQ!8B[TB[CN(OXMI^9#Z,.H/UIVE:O!K$5S);)(@MKJ6U?S !EHVVDC!/&
M1Q1=,4X2@^62LR]16=IGB+1-::X71M8L-0:VP)Q:722F+.<;MI.WH>OH:99^
M)M!U'3[F_P!/UO3KJSM<_:+F"[C>.' R=[ X7 YYIDFI16#HGBRP\0ZU?6FD
M36UY:VL$,R7MK<+*DOF-("HV\?*8_4]>V*I/X^M8M0FCN-(U.&P@OO[/DU1A
M";=9BP4 @2&0 LRKNV8R1G YHZV#I<ZNBLU?$FAO=SVJ:SI[7%M&\L\(ND+Q
M(C%79ESD!6!!)X!&#4 \5Z/<:%<ZOI.H6FK6ML=LCV5Y"RAN/E+EP@."#RPH
M V:*SKWQ#HNFZA;V&I:O86=[=$""VN+E$DER<#:I.6R>..]-O?$NA:9J"V&H
MZUI]I>/&95MY[I$D9 "2P4G./E//L?2@#3HKF]*^(/A;5O#[ZU%K=A!8Q2F*
M62>[B41-N*@,=Q"[L9&3R"#6_:W=O?6D5U93Q7-O,H>*:%PZ.IZ$,."/<4 2
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT?\ "^_'_P#T%(/_  #B_P#B:\WHH]A2_E#VL^YZ1_POOQ__ -!2#_P#B_\
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M , XO_B:/^%]^/\ _H*0?^ <7_Q->;T4>PI?RA[6?<](_P"%]^/_ /H*0?\
M@'%_\31_POOQ_P#]!2#_ , XO_B:\WHH]A2_E#VL^YZ1_P +[\?_ /04@_\
M .+_ .)J6Z^.WCZ"\FB3582L<C*";.+. <?W:\RJQJ'_ "$KK_KL_P#,U/L*
M?-L/VL[;GH'_  OOQ_\ ]!2#_P  XO\ XFC_ (7WX_\ ^@I!_P" <7_Q->;U
MH:;H&LZS'(^CZ3?7Z1?ZQK6V>4)]=H.*KV%)=!>UJ=SN/^%]^/\ _H*0?^ <
M7_Q-'_"^_'__ $%(/_ .+_XFO.&4HQ5@58'!!'(-)1["EV#VL^YZ1_POOQ__
M -!2#_P#B_\ B:/^%]^/_P#H*0?^ <7_ ,37F]%'L*7\H>UGW/2/^%]^/_\
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MYKMH-%TIR_CPV'[ZPBD"VY S$H92 OL.G;!I15*35H_T^7_,;YTG=[?IS?\
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M !-'_"^_'_\ T%(/_ .+_P")KS>BJ]A2_E%[6?<](_X7WX__ .@I!_X!Q?\
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M ,37F]%'L*7\H>UGW/2/^%]^/_\ H*0?^ <7_P 31_POOQ__ -!2#_P#B_\
MB:\WHH]A2_E#VL^YZ;=?';Q]!>31)JL)6.1E!-G%G ./[M1?\+[\?_\ 04@_
M\ XO_B:\_P!0_P"0E=?]=G_F:KU,:%-Q6@Y59WW/2/\ A??C_P#Z"D'_ (!Q
M?_$T?\+[\?\ _04@_P# .+_XFN'GT'6+;[7]ITJ^A^PA#=>9;.OV??\ =WY'
MRY[9QFI+;PUKMY/%!::+J,\LT N8HXK1V:2+./,  Y7/&X<4_8T>R%[2IW.T
M_P"%]^/_ /H*0?\ @'%_\31_POOQ_P#]!2#_ , XO_B:X+4M)U'1[H6VKV%U
M83E0PBNH6B;'KA@#BKECX2\1ZG8I>:;X?U2[M7SMGM[*21&P<'# 8.""*/8T
M;7L@]I4O:YV/_"^_'_\ T%(/_ .+_P")H_X7WX__ .@I!_X!Q?\ Q-><LK(Y
M5U*LIP01@@TVG["EV#VM3N>D?\+[\?\ _04@_P# .+_XFC_A??C_ /Z"D'_@
M'%_\37F]%'L*7\H>UGW/2/\ A??C_P#Z"D'_ (!Q?_$T?\+[\?\ _04@_P#
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M=+9PS6E[#<1F9B $9XW95)R/O$4W1HIV:0O:5'U.F_X7WX__ .@I!_X!Q?\
MQ-'_  OOQ_\ ]!2#_P  XO\ XFN&_L34/^$A_L/[/_Q,?M/V3R-Z_P"MW;=N
M[.WKQG./>K%]X6UC3=/N+Z]L_+MK:^;3Y7\U#MN%&2F <GCN./>E[*CV0^>K
M>QV/_"^_'_\ T%(/_ .+_P")H_X7WX__ .@I!_X!Q?\ Q-<U-X"\26[1B73@
MIDOH]/4?:(C_ *0ZAU3AN,JP.3P,X)!JG?>%M8TW3KB^O;/RK:VOFT^5_-0[
M9U&2F <GCN./>CV5#LOZ_P"'0<]7S_K_ (9G8_\ "^_'_P#T%(/_  #B_P#B
M:/\ A??C_P#Z"D'_ (!Q?_$UYO4UI:S7U[#:6B&2>>18XT! W,QP!S[FJ^KT
MOY2?;3[GH7_"^_'_ /T%(/\ P#B_^)H_X7WX_P#^@I!_X!Q?_$UQECX:U;4O
M$AT"RM1-J8DDC\D2IC<@)8;B=O 4]^W%0Z/HNH:_K,&E:3;_ &B]G8K'%O5=
MQ )/+$ < ]ZGV-'LNY3J5%NSN?\ A??C_P#Z"D'_ (!Q?_$T?\+[\?\ _04@
M_P# .+_XFO.&4HQ5A@@X-7=&T:_\0:O!I>D0?:+RX)$46]4W$ D\L0!P#U-/
MV%*U["]K46ESNO\ A??C_P#Z"D'_ (!Q?_$T?\+[\?\ _04@_P# .+_XFO/)
M+:>&-9)872-RRHY4[6*]0#T.,BHJ?L*78'4J+1L](_X7WX__ .@I!_X!Q?\
MQ->E?!+XD>)O&OBF_M/$%['/!!9F5$2!$^;>HSD#/0G\Z^?+K1-0L]%L=6N;
M?98W[2+;2[U/F%" W .1@D=0*]9_9G_Y';5O^P=_[42N>O2IQI-Q7]7-:4YN
M:39]+T445Y9W'S1^TQ_R.VD_]@[_ -J/7B]>T?M,?\CMI/\ V#O_ &H]>+U[
M6%_@K^NIYM?^(PHHK>\#?\E"\/?]A.V_]&K728-V5S!HKV+Q?XEMK:+QKIFM
M^)/[=DN[LQZ?IQ6>3["XE.6W2H%3:ORX0D'Z<U2U7X=^&K'Q5KMA')JWV/P]
M8?;+IVN(VDN2RH51 (P$Y8Y8[OH*YXUDU>2MU_#_ ()O*E9V3ZV_&QY517KF
MA>$[>Q6;5-"U"^M;'5O"U[=+%)Y3RKL.UXG8IM92?XE"M].]2\^&>B:?I$4=
M]JZ6VH2Z4M^MS-J=JD1D9=PA%N2)2". X.,]J;K13U_K?_(E4VTFNO\ P/\
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MNDWR7$L:I9PD1\!&'.$R#^>>*\ETN\M=#^)=K=Z<[&SL]55H68\F)9>,_P#
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M32'<\DC%F8^I)ZU<*<HM7?\ 5O\ /7\-B93B[Z?U_6A'1116YD%%%% %A/\
MD&S?]=H_Y/5>K"?\@V;_ *[1_P GJO4QW8WLAR(TCJD:EF8X55&23Z5HWGAK
M7=.EMXM0T74+62Z8+ D]JZ&8^B@CYCR.E=)\(_)_X6);;_\ CY^SW'V+./\
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MOZW*IRYJD?Z[GTO1117D'>?-'[3'_([:3_V#O_:CUXO7M'[3'_([:3_V#O\
MVH]>+U[6%_@K^NIYM?\ B,*L6-[<:;J-O?64GE7-M*LT3[0=KJ<@X/!Y'>J]
M%=!B6+Z^N-2U&XOKV3S;FYE:65]H&YV.2<#@<GM6N?&_B$^)+C7CJ).HW,?E
M3R>4FV5-H78T>W8RX4<$8.*P**7*K6L/F=[G=:+X_P#*;5[_ %^XNKN_N-)E
MTNSMX;:-((D<8_A90@'/RJASGM6*/'/B)=(&FC4/W"VQM _D1^<(#UB$VWS
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M)/()&>#4.F?$C6-)@TB&WM[%X])-SY:RQ,PF6X_UBO\ -R/3&#[T-5?Z^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O2/@A_R.UY_P!@Y_\ T9'7F]>D?!#_ )':\_[!
MS_\ HR.@#W:BBBD!6:&*:^D\V-'Q&F-R@XY:G_8[;_GVA_[]BA?^/Z7_ *YI
M_-JFH A^QVW_ #[0_P#?L4?8[;_GVA_[]BIJ* (?L=M_S[0_]^Q1]CMO^?:'
M_OV*FHH A^QVW_/M#_W[%'V.V_Y]H?\ OV*FHH A^QVW_/M#_P!^Q1]CMO\
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M6:7?\SK_ +"S#_GW^,?\SUC[';?\^T/_ '[%'V.V_P"?:'_OV*\G_P"%[_\
M4N?^3W_VNC_A>_\ U+G_ )/?_:Z/K-+O^8?V%F'_ #[_ !C_ )GK'V.V_P"?
M:'_OV*/L=M_S[0_]^Q7D_P#PO?\ ZES_ ,GO_M='_"]_^I<_\GO_ +71]9I=
M_P P_L+,/^??XQ_S/6/L=M_S[0_]^Q1]CMO^?:'_ +]BO)_^%[_]2Y_Y/?\
MVNC_ (7O_P!2Y_Y/?_:Z/K-+O^8?V%F'_/O\8_YGK'V.V_Y]H?\ OV*/L=M_
MS[0_]^Q7D_\ PO?_ *ES_P GO_M='_"]_P#J7/\ R>_^UT?6:7?\P_L+,/\
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M'UFEW_,/["S#_GW^,?\ ,]8^QVW_ #[0_P#?L4?8[;_GVA_[]BO)_P#A>_\
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M_,/["S#_ )]_C'_,]8^QVW_/M#_W[%'V.V_Y]H?^_8KR?_A>_P#U+G_D]_\
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M_8H^QVW_ #[0_P#?L5-10!#]CMO^?:'_ +]BC[';?\^T/_?L5-10!#]CMO\
MGVA_[]BC[';?\^T/_?L5-10!#]CMO^?:'_OV*8L,4-]'Y4:)F-\[5 SRM6:A
M;_C^B_ZYO_-: )J*** (5_X_I?\ KFG\VJ:H5_X_I?\ KFG\VJ:@ HHHH \*
M>\U[0OBJ\_CK7/$VEQSZL%TVX@82Z/-;LV$AD0#Y'(^7<>1]X],F#XA?$&>P
M^)%WJ-KXF^QV?A>XLX)-(6]"?V@)&S<'RLYDVJRCH<$'TKO1\'=";7%O;G5=
M>NK..Z^UQZ/<:BSV4<N[<"(\=CS@DCFK$7P@\'?V=J-O?Z5#J5QJ4L\T^H7L
M$4ET&E))*R; 5QGY<=*2;2CY?\#_ ((W9N7G_P ';\+'/^(KG4O'/Q9B\)67
MB2_T/1K;2%U-Y=*F$-Q=L[[5VR8)" $=/Q[8P_B!X-UCP_#X<D7XA>+IIM0U
MJVTN9DU'R5$+EAD*H_U@  W'.3DD<UVNH_!_1-0L=&C35-:L;_1K46EMJME>
M"&Z,(_@9PN"/^ C]36C)\.-)ET'1=)DN]1>+1]134HII+@22S3*S-F1F!W L
MY)QCVQ5*R:79_>K_ .6A.NK?;]/\]2#3_%'AGPAJVG> [SQ'?WNM.H\G^T1+
M//-O+$%I0FWU')' %8_@M]:M?C)XITO6-?N]6CBL;6=%E^2*)G+9"1CY5&,#
MN3CDFO3*\_T7X1V6B>,?^$EB\4^*;J\9LRQW6HJ\<ZC.U'&P%E&> 3Q25^=-
M^?Y#?PM+R/0**** "H6_X_HO^N;_ ,UJ:H6_X_HO^N;_ ,UH FKQG4=4D.NZ
M\EKJ>N1^(!KR6VEYN;E;$#;$?+;<?LW(\SY#\QS\H)*U[-7.W7@G3;S2M9L)
M9;D)J]W]LDD5EWPR@)M:,[<#:8U(R#S0M)7\OU7_  0>L;?ULSG_ !)\6;#P
M_KFI61_LO9I.S[6MYJR6US)E0Y%O"5/FD*1U9,M\H]:N:IX\O[2369M.T)+S
M3M$C2>[N7OA&SQ-$LI\I-AW,%)X8H.!AN2!J7/A$G5;G4-*U[5-(FO-C72V@
MMV2=U7:'(EB?#;0 =NT' R.*Q[GP)-K7B'Q&^HW^HV>G:D\*/#;31[+V(0JK
M*P*L4Y# E-C$'J0!A:V_K^K?B/2^NQ>U'QTEEHOB;48K'SX]"@695\[;]H#0
MB4?P_)]['?\ I4-QXWU!=1\01VNAPR6>@1^9<W,M]L:3-N)@J((VR><')4 8
M(+<@3:[\/;#76U%'U+4[*TU2W6"]M+22-8YMJE58DH74@8&%8 A0&##(,VJ>
M%UCT;Q4VF>;->ZW;-F-W4+Y@MQ$H7@8!"CJ>I/2E-M1;79V'!*\5+Y_A_P $
MS7^(DNECSO%&C?V;:S:;-J5JT%T+B1HX@I=)%"J$?#J0%9U//S<<S#QKJMC=
MFVU_PV89YM/FOK*+3KO[6\_E %XB"B;9/G3 &Y3DX;@973OAY8M: :]=W^J[
M]-;3Q;WLRLMM"X'F1JR*K-G:HWNS-\HPW7-NQ\%BSF^TS:_J]]>Q6IM+2\NF
M@:2S1L;B@$04L=JY9U<G:,GKFY))M+S_ %M^GE^L1>B;_K;_ (/G^F5#\2XT
M\%7OB2^&C2VUNT<<8TS6/M*^8Y"A)7:*,18++G.< DGIS7MOBQ:S6.IA8M,O
MM0LS;B"'2-56[@N&G?RXU\W8NQM_# KP"#SG%;!^']C<1ZB=7U'4-3N[^.*-
M[V<Q1RQ")B\6SRHT4%7)8$J3GKD<58G\(-?Z/=Z=K7B#5=3CG,;QR3BWC>V=
M&WJ\9BA09#!3\P8?*.,9!-+_ -?U?\!]#'\*SZC/\5/$QUBQALKE=-T]2EO<
M^?&PWW!#*Y5"1SCE0<@]1@EHT=?$?Q \46U_J6L0QVL-HMNMEJUQ;+"7C8LP
M6-PI.0#R#TK?T/PI#HFKWVJ/J6H:C?7\445Q/>NAW",N5PJ(JK_K",* . <9
M))KWW@QKG7+_ %.Q\1:QI<FH)&ES%9_9]K!%*J07A9E.">584I=+!]IO^MD<
M_HWCC7"FFZ,EA%K&J33ZA;&[FN1:QL+24)YC[4;&X-_"I^;L 25VYO&Q@T9K
MYM.!9=;323&)^,M<+#YF=O\ M;L8[8SWJ]9^#])TZ\TB?3TDMUTB":"WB5\J
M1*5+ERV69LH#G.222<YJC=_#ZQN[YY7U35$M&U"/4Q81RQB%;A'5]_W-Y!*Y
M*EBN6) !P0X_$K_/[U^EP>VG];_EI]QG_P#"P-3N-8MXK#0[.33[C6)-)6XF
MU,QS!XPV]S"(6X_=M@;\G@G:#Q)\54U&?PWI]GHVIW6F75YJMO;K<VLIC==Q
M/&1U&<9'>N:T;PCX@TKQ=_:%EHTEKJ$VI2/=7AAT\V<EL\I9\2?->%F3& 3]
M_'1!@>EZQHMOK2V0NGE3[%>1WD?ED#+QG(!R#QSS_.IM>,?5?I?]?R')VE*W
M9V_&WZ?F>8>-?%VI:_X!LWTB\NM,NH[%]1U)[24QO"T9\KR"P.1F;=D>D3 U
MUNJ^.;VR.L3Z9HJ7^G:!@:E.][Y,N1&LCB&/80Y6-@?F9 2< ]ZG/PWT/R?$
MD<9N8SXC??>.L@RG4XCR,*-S.W.>78T_4? 5EJ%]?RKJ6I6EIJFW^T;"WD00
MWA"A26W(77<@"MY;)D 9]:=[_P!=?\DM!))/R7Y?YG/R^*K/PWK_ (TUZ<>9
M (M-\L,XC#-(A5-S-PBY898]!D]JL6?Q7LY[34@R:;>7UH;<0Q:-JBWD-PT[
M^7&OF[$VMOX8%> 0><XK?O/!&DWK:J9O/4:FMN'$;A?(:#_5-'@94@X/.1D#
MC'%$WA$W^CWFFZUK^J:I'<[#').+>-[9T;<KQF*)/F#!3\VX94<=<FEWV_3_
M #_ 2ORJ^XT^(M5L381:YHT%M/>:@MFIMK[SH]K1L^\,8U8D;2"I5?8FN?\
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M#L,8%5-*^'-GI-SI<D6LZM-#H^\:?;2O#Y=NKHR%1MC!? ;@N6(P.>6RNO\
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M^V4?5JO8/[<R_P#Y^?A+_(\BHKUW_A1'_4Q_^2/_ -LH_P"%$?\ 4Q_^2/\
M]LH^K5>P?VYE_P#S\_"7^1Y%17KO_"B/^IC_ /)'_P"V4?\ "B/^IC_\D?\
M[91]6J]@_MS+_P#GY^$O\CR*BO7?^%$?]3'_ .2/_P!LH_X41_U,?_DC_P#;
M*/JU7L']N9?_ ,_/PE_D>145ZTGP,WO(O_"18\MMO_'CUX!_YZ>]/_X41_U,
M?_DC_P#;*/JU7L']N9?_ ,_/PE_D>145Z[_PHC_J8_\ R1_^V4?\*(_ZF/\
M\D?_ +91]6J]@_MS+_\ GY^$O\CR*BO7?^%$?]3'_P"2/_VRC_A1'_4Q_P#D
MC_\ ;*/JU7L']N9?_P _/PE_D>145Z[_ ,*(_P"IC_\ )'_[91_PHC_J8_\
MR1_^V4?5JO8/[<R__GY^$O\ (\BHKUW_ (41_P!3'_Y(_P#VRC_A1'_4Q_\
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M_8H^QVW_ #[0_P#?L4 345#]CMO^?:'_ +]BC[';?\^T/_?L4 345#]CMO\
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M#]CMO^?:'_OV*/L=M_S[0_\ ?L4 345#]CMO^?:'_OV*/L=M_P ^T/\ W[%
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M_OV* )J*A^QVW_/M#_W[%'V.V_Y]H?\ OV* )J*A^QVW_/M#_P!^Q1]CMO\
MGVA_[]B@":BH?L=M_P ^T/\ W[%'V.V_Y]H?^_8H FHJ'[';?\^T/_?L4?8[
M;_GVA_[]B@":BH?L=M_S[0_]^Q1]CMO^?:'_ +]B@ @_UUS_ -=!_P"@+4U0
M_8[;_GVA_P"_8H^QVW_/M#_W[% $U%0_8[;_ )]H?^_8H^QVW_/M#_W[% $U
M%0_8[;_GVA_[]BC[';?\^T/_ '[% $U%0_8[;_GVA_[]BC[';?\ /M#_ -^Q
M0!-14/V.V_Y]H?\ OV*/L=M_S[0_]^Q0!-14/V.V_P"?:'_OV*/L=M_S[0_]
M^Q0!-14/V.V_Y]H?^_8H^QVW_/M#_P!^Q0!F^&O#-AX6TE;+3TR3\TLS#YI6
M]3_AVK8J'[';?\^T/_?L4?8[;_GVA_[]BDDDK(NI4G4FYS=VPL_^/&#_ *YK
M_*IJA^QVW_/M#_W[%'V.V_Y]H?\ OV*9!-14/V.V_P"?:'_OV*/L=M_S[0_]
M^Q0!-14/V.V_Y]H?^_8H^QVW_/M#_P!^Q0!-14/V.V_Y]H?^_8H^QVW_ #[0
M_P#?L4 345#]CMO^?:'_ +]BC[';?\^T/_?L4 345#]CMO\ GVA_[]BC[';?
M\^T/_?L4 345#]CMO^?:'_OV*/L=M_S[0_\ ?L4 35#=?ZE?^ND?_H8H^QVW
M_/M#_P!^Q1]CMO\ GVA_[]B@":BH?L=M_P ^T/\ W[%'V.V_Y]H?^_8H FHJ
M'[';?\^T/_?L4?8[;_GVA_[]B@":BH?L=M_S[0_]^Q1]CMO^?:'_ +]B@":B
MH?L=M_S[0_\ ?L4?8[;_ )]H?^_8H FHJ'[';?\ /M#_ -^Q1]CMO^?:'_OV
M* )J*A^QVW_/M#_W[%'V.V_Y]H?^_8H FHJ'[';?\^T/_?L4?8[;_GVA_P"_
M8H FJ%O^/Z+_ *YO_-:/L=M_S[0_]^Q3H[>&)MT42(<8RJ@4 24444 %%>8?
M$OXR_P#"N_$EOI/]A?VCYUHMSYOVSRL9=UVXV-_<SG/>N/\ ^&HO^I0_\J?_
M -JK>.'JR5TC)UH)V;/?Z*\ _P"&HO\ J4/_ "I__:J/^&HO^I0_\J?_ -JJ
MOJM;M^0O;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]
M/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%
M> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H
M?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^
MU583]I??ID]W_P (GCRIHXMG]I==ZN<Y\KML_6E]6JKI^0>VI]SW>BO /^&H
MO^I0_P#*G_\ :J/^&HO^I0_\J?\ ]JI_5:W;\@]O3[GO]%> ?\-1?]2A_P"5
M/_[51_PU%_U*'_E3_P#M5'U6MV_(/;T^Y[_17@'_  U%_P!2A_Y4_P#[51_P
MU%_U*'_E3_\ M5'U6MV_(/;T^Y[_ $5X!_PU%_U*'_E3_P#M5'_#47_4H?\
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M4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\
M#47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y
M4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51
M]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;
MT^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17
M@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\
M4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\
M[51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_
M %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U58U#]I?[!J=U:?\
M(GYGV>9XM_\ :6-VUB,X\KCI2^K5;VM^0>VI]SW>BO /^&HO^I0_\J?_ -JH
M_P"&HO\ J4/_ "I__:J?U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_
M %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\
M[51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=
MOR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[
M_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#
M47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^
M5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_
MPU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'
M_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]
M5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V
M]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@
M'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4
MH?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\
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M7_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\
ME3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?
M\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_
M )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5
M'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]
M/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%
M> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H
M?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^
MU4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?
M]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4_
M_M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6M
MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_
MT5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\
M-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/
M_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\
M-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_
MY4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'
MU6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/
M;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!
M_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]
M2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U
M4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U5V'PT^,
MO_"Q/$EQI/\ 87]G>3:-<^;]L\W.'1=N-B_W\YSVJ98>K%7:&JT&[)GI]%%%
M8&I\P?M*_P#)2=/_ .P3'_Z.FKQ^O8/VE?\ DI.G_P#8)C_]'35X_7N4/X43
MS*OQL****V,@HHHH **** "BBB@ HHHH *T8?^19O?\ K\M__0)JSJT8?^19
MO?\ K\M__0)JF6PX[F=1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T?$'
M_(S:I_U^2_\ H9K.K1\0?\C-JG_7Y+_Z&:G[2'T,ZBBBJ$%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6CX@_P"1FU3_ *_)?_0S6=6CX@_Y&;5/^OR7_P!#-3]I#Z&=
M1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -KPWX:G\37%ZD%Y:V<=
MC9O>3S71?:L:$ \(K,3\PXQ2Z[X6NM#L;&_%U:ZAI^H!OL]Y9LYC9E.&4AU5
ME8<<$#K6U\-I8%D\2V\]W:VTEYH-Q;P&ZN4@5Y&9,+N<A<G![]J['PCJWA[P
MW;>%]#\0WEA<3QWEW>2R13QS0VCO'LAW2KN3.1G(R%X)Z5C4G*+T[;=]_P"O
M^'-(Q36O_#;'C-%>T7/C&RL-?\.C5I(+GS#<6FHW!UF/4)WM)OD*RR1Q*A4$
M[U&YB .0.*GL=?\ #>G^+Y]$M-1ADATC0C8Z5?I=) CW)(>5TF8,L;,2P#GC
MCWJ?;2M\/?\ "_\ P/O\A^S7?^G_ $W\O,\G\/\ AR[\237T=C)!&;&REO9/
M.8C*1C+ 8!^;GCH/>LBO:?\ A(-+;Q'J+W5S807)\)W-M-<?VHETUS,1\BO*
ML:(\N,#Y=V<#DD5+#KVDBWM7_M?3QX07P_Y$^C^>@D:Z\L@@P?>:3S,'S,>^
MZDZTEK;^O>_.RMZC]FM%?K_\C^5W]QXC17OMUJ?]G:=H;:OJMJF@-X.1+C3I
M+A ]Q*T9$>(3R[;MN& .W:>1W@3QK!;SM!!KUJMM%X)C$48N$V"]3&T8S@RC
M' ^\*;K-7LMO^#_E^*"--.VN]OQY?\_P/":*]TLO$FA3:QIUY>ZG!+K$WA)(
MDO?MT<<B7>XY#3L&$<NW@,XR.G>J\?B?3X?$&J7+7=C:WZ^$YH&NAJD=T]Q/
ME2@>41HCS8&/DW9P.210ZTDW[O?\+_Y?B"II]>WXV_S_  /'K#2K[4Q<FPMG
MG%I UQ.5'$<:]6)]*G\/Z%>^)M>M=(TP(;FY8A/,;:J@ DDGT !/X5[';>+(
M9) UMXBACU._\%K$]R=16(M>JQVB20L )0.[$&O*/!\]]9^,K.XTW5K/2KV*
M0M'=WLF(0V#D,P!&&Y&3QSR1UJXS;;7;_-K]"9122=_ZLG^H^?P=>-?65IHM
M[8:[+>JYC73I69EV9W!T=59.!G+  CD&N>KWRP\2Z!;^-?#NKW3Z1HVNW:7<
M>J'2KY&M2IC/EM(RL44L^#]XGH2>F'>!=5LM-M]'BUCQ#IUS'.]V=9-WK,2J
MLK%E :-"/M&[(/F.9% SC&!67MI16JO_ $_\OQ\S1TXWW_K3^OQV/ :*]]^&
M]_')>>"K30=4L[:U@>[75+ 7*"2:<[MKF/.9,KMVL 0H'453\-^(=%M/">B1
MV<]HL=N;D:O9W6KQ6D4S$MS-"T3O."N NP$C@8XXJ59IM)?UK_E^*)]EY_U_
MG_P3PZBI+AHWN96A39&7)1<YVC/ SWJ.NA;&35G8****!!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>P?LU?\E)U#_L$R?^CH:\?KV#]FK_DI.H?]@F3_ -'0
MUC7_ (4C2E\:/I^BBBO#/4/F#]I7_DI.G_\ 8)C_ /1TU>/U[!^TK_R4G3_^
MP3'_ .CIJ\?KW*'\*)YE7XV%%%%;&04444 %%%% !1110 4444 %:,/_ "+-
M[_U^6_\ Z!-6=6C#_P BS>_]?EO_ .@35,MAQW,ZBBBJ$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5H^(/^1FU3_K\E_]#-9U:/B#_D9M4_Z_)?\ T,U/VD/H
M9U%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#I2;O>W]/_-/Y ZD4K)?U>__  !GC+PW:^%VTBS22=M0FT^.YOTD(Q#(^2$
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MC)@C:2$2?ZP1R%2T8;N%(S5F/XC^*H['[(NI)Y9M/L3,UI"9'@P1Y;2%-S*
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M^9--_LI3Y,?%KC'E_=_\>^][U@UK&,E)MO\ J[_2Q$G%Q26__ 7ZW"BBBM"
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M1110 4444 %%%% !1110 5H^(/\ D9M4_P"OR7_T,UG5H^(/^1FU3_K\E_\
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M2-)$#U"L3D9]JC7Q+KJ:LVJ)K6H+J#KL:\%TXF9?0OG../6IE"<G=.VG^?\
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ML?V?>?\ /I/_ -^C_A1_9]Y_SZ3_ /?H_P"%'-'N'*^Q7HJQ_9]Y_P ^D_\
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M\*OZY9W,WB+49(K>5XWNI65E0D,"YP0>XJ>:/-N/E=MC(HJQ_9]Y_P ^D_\
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M5*_,FY:>OK_P/N)TY;6U_P"&_P"#]YCT58_L^\_Y])_^_1_PH_L^\_Y])_\
MOT?\*VYH]S/E?8LP_P#(LWO_ %^6_P#Z!-6=6O#9W(\.W<9MY1(UU RKL.2
MDN3CT&1^8JA_9]Y_SZ3_ /?H_P"%2I1N]1N+LM"O15C^S[S_ )])_P#OT?\
M"C^S[S_GTG_[]'_"JYH]Q<K[%>BK']GWG_/I/_WZ/^%']GWG_/I/_P!^C_A1
MS1[AROL5Z*L?V?>?\^D__?H_X4?V?>?\^D__ 'Z/^%'-'N'*^Q7HJQ_9]Y_S
MZ3_]^C_A1_9]Y_SZ3_\ ?H_X4<T>X<K[%>BK']GWG_/I/_WZ/^%']GWG_/I/
M_P!^C_A1S1[AROL5Z*L?V?>?\^D__?H_X4?V?>?\^D__ 'Z/^%'-'N'*^Q9\
M0?\ (S:I_P!?DO\ Z&:SJU]<L[F;Q%J,D5O*\;W4K*RH2&!<X(/<50_L^\_Y
M])_^_1_PJ8RCRK4<HN[T+5WXCUN_T]+"^UC4+FSCQLMIKIWC7'3"DX&*V/$7
MCS4M;TW3M/MI;JPLK738;&:VCNV,=R8\_.R@ <^ASC'6N=_L^\_Y])_^_1_P
MH_L^\_Y])_\ OT?\*'[-]@7.MBV/$NNK:1VJZUJ MXX6@2$73[$C;AD S@*<
M#(Z'%1G7=7+%CJE[N-M]D)^T/DP?\\NOW/\ 9Z>U0?V?>?\ /I/_ -^C_A1_
M9]Y_SZ3_ /?H_P"%.\/(5I$XUW5UV[=5O1MMC:+BX?B ]8AS]S_9Z>U6F\8>
M)GT\V+^(M6:S,?E&W-](8RF,;=N[&,<8Z5G?V?>?\^D__?H_X4?V?>?\^D__
M 'Z/^%%X/L/WD7KKQ5XAO;0VM[KVIW%NR>689;R1T*Y!V[2<8X''L*9=>)==
MO8'AO=:U"XBDC6)XY;IW5D4Y52">0#R!T!JI_9]Y_P ^D_\ WZ/^%']GWG_/
MI/\ ]^C_ (47AY![Q8N=>UB\TZ+3[O5;Z>RAQY5M+<NT:8Z84G _"DGUW5[D
MW9N=4O9C>A1=>9<.WGA?NA\GYL8&,YQ4']GWG_/I/_WZ/^%']GWG_/I/_P!^
MC_A1>'D*TBO6C#_R+-[_ -?EO_Z!-5;^S[S_ )])_P#OT?\ "K\-G<CP[=QF
MWE$C74#*NPY("2Y./09'YBE*4;;C47?8R**L?V?>?\^D_P#WZ/\ A1_9]Y_S
MZ3_]^C_A5<T>XN5]BO15C^S[S_GTG_[]'_"C^S[S_GTG_P"_1_PHYH]PY7V*
M]%6/[/O/^?2?_OT?\*/[/O/^?2?_ +]'_"CFCW#E?8KT58_L^\_Y])_^_1_P
MH_L^\_Y])_\ OT?\*.:/<.5]BO15C^S[S_GTG_[]'_"C^S[S_GTG_P"_1_PH
MYH]PY7V*]%6/[/O/^?2?_OT?\*/[/O/^?2?_ +]'_"CFCW#E?8KUH^(/^1FU
M3_K\E_\ 0S5;^S[S_GTG_P"_1_PJ_KEG<S>(M1DBMY7C>ZE965"0P+G!![BI
MYH\VX^5VV,BBK']GWG_/I/\ ]^C_ (4?V?>?\^D__?H_X57-'N+E?8KT58_L
M^\_Y])_^_1_PH_L^\_Y])_\ OT?\*.:/<.5]BO15C^S[S_GTG_[]'_"C^S[S
M_GTG_P"_1_PHYH]PY7V*]%6/[/O/^?2?_OT?\*/[/O/^?2?_ +]'_"CFCW#E
M?8KT58_L^\_Y])_^_1_PH_L^\_Y])_\ OT?\*.:/<.5]BO15C^S[S_GTG_[]
M'_"C^S[S_GTG_P"_1_PHYH]PY7V+,/\ R+-[_P!?EO\ ^@35G5KPV=R/#MW&
M;>42-=0,J[#D@)+DX]!D?F*H?V?>?\^D_P#WZ/\ A4J4;O4;B[+0KT58_L^\
M_P"?2?\ []'_  H_L^\_Y])_^_1_PJN:/<7*^Q7HJQ_9]Y_SZ3_]^C_A1_9]
MY_SZ3_\ ?H_X4<T>X<K[%>BK']GWG_/I/_WZ/^%']GWG_/I/_P!^C_A1S1[A
MROL5Z*L?V?>?\^D__?H_X4?V?>?\^D__ 'Z/^%'-'N'*^Q7HJQ_9]Y_SZ3_]
M^C_A1_9]Y_SZ3_\ ?H_X4<T>X<K[%>BK']GWG_/I/_WZ/^%']GWG_/I/_P!^
MC_A1S1[AROL6?$'_ ",VJ?\ 7Y+_ .AFLZM?7+.YF\1:C)%;RO&]U*RLJ$A@
M7."#W%4/[/O/^?2?_OT?\*F,H\JU'*+N]"O15C^S[S_GTG_[]'_"C^S[S_GT
MG_[]'_"JYH]Q<K[%>BK']GWG_/I/_P!^C_A1_9]Y_P ^D_\ WZ/^%'-'N'*^
MQ7HJQ_9]Y_SZ3_\ ?H_X4?V?>?\ /I/_ -^C_A1S1[AROL5Z*L?V?>?\^D__
M 'Z/^%']GWG_ #Z3_P#?H_X4<T>X<K[%>BK']GWG_/I/_P!^C_A1_9]Y_P ^
MD_\ WZ/^%'-'N'*^Q7KW']F/_D8M=_Z](_\ T,UXM_9]Y_SZ3_\ ?H_X5[9^
MS3#+;^)=;6>-XF>T0J'4@L _.,_4?G7/B9)TG9FM%/VB/HNBBBO'/1/"?C?_
M ,CM9_\ 8.3_ -&25YO7I'QO_P"1VL_^P<G_ *,DKS>F 59CT^]EL9+V*SG>
MTA.V2X6)C&AXX+8P.H_.J]>NZ1;66GV^E^$[S4;>W-_82+>6CK)YAGGPR'A"
MF5VJ.6'?\3H%]3R*M&#P_JMQ<W5NEC*DUI;FYGCE C9(P 2V&QV(/J<UUM_I
M=QHWA?3_ .S-+L[GRUG_ +4N)K5)#%,K8VL[#Y, #:N0&/9LX.[K5N=1\8:O
M->V,$MD=!DGLIVM$ =A#'\ROM^8@]#D[>V*&]';S&EK9_P!:K_,\CJ6VMY;R
MZBMK==\TSB-%R!EB< 9/O7HTEA;VNI>'U@TRPE\.O':M+?26Z$/(7&_,I&2V
M<@H20!GY>,BTN@)I=O))<Z;%;7 \4QB!C$JN(2WR[>X0XX[''%4EK9][?BE^
MI-]+KM^C?Z'F-Y:3Z??3V=VGESP2&.1,@[6!P1D<'FI/[-NSI)U/RO\ 0Q-Y
M'F;A]_;NQC.>G?&*]/;3[)YM<O+>S>^U :]*MPD.F1W\BQ DA?+=AM5CGYQS
MQBN/2]3_ (2T:7;V$YT?^U!.-*N L;[AQL.3P<?+M)]JB.MEWM^G^94M+^7_
M  3E:MW.E:C96L5S>6%U;P38,4LL+*LG&?E)&#QSQ72>-]/%EK%A/ L4)ND,
MJ6TEFEI) /,.U98U.W_@7&0.>E=-J=A9:VT.L>*+:ZT"XFU"W@N[>>8B"]4<
M&1,X(P#U!*@=#R336J^?ZV$]&>55<MM*O;S3;R_MH=]M8A#<2;U&S<<+P3DY
M/IFO2[S3K!?$%G:7F@W"9UF-()7T>.VM_*+$&(NK$2@@ @D9.#ZUDRQ65[:>
M,VEL;*!+&2&&W,-LBF!!<%200,DXZGJ:%K_7I_F'_ _,\^HKU'Q1IVE65M?P
MP:-<36'EP_8;J'38XX4^[AS=A\NK D'=W/;%9'Q TZ"*TM+^VM$TV.:9XTL)
M+)()HPJKD[D/[U"<X<\\]3FE<%J<+1113 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *](^"'_([7G_8.
M?_T9'7F]>D?!#_D=KS_L'/\ ^C(Z /=J***0'B?QETK4;[QC:RV5A=7,8L$4
MO#"S@'S).,@=>17G_P#PCNM_] >__P# 5_\ "OJ9?^/Z7_KFG\VJ:F!\I_\
M".ZW_P! >_\ _ 5_\*/^$=UO_H#W_P#X"O\ X5]644 ?*?\ PCNM_P#0'O\
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M ?*?_".ZW_T![_\ \!7_ ,*/^$=UO_H#W_\ X"O_ (5]644 ?*?_  CNM_\
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M ,*/^$=UO_H#W_\ X"O_ (5]644 ?*?_  CNM_\ 0'O_ /P%?_"C_A'=;_Z
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M7_PH_P"$=UO_ * ]_P#^ K_X5]644 ?*?_".ZW_T![__ ,!7_P */^$=UO\
MZ ]__P" K_X5]650M]7@N->O=)1)!/9PQ32,0-I$A<+@YSG]V<\>E 'S%_PC
MNM_] >__ / 5_P#"C_A'=;_Z ]__ . K_P"%?3VE:O!K$5S);)(HMKJ6U?S
M!EXVVDC!/&1Q5ZE?2X'RG_PCNM_] >__ / 5_P#"C_A'=;_Z ]__ . K_P"%
M?5E0V?\ QXP?]<U_E3 ^6?\ A'=;_P"@/?\ _@*_^%'_  CNM_\ 0'O_ /P%
M?_"OJRB@#Y3_ .$=UO\ Z ]__P" K_X4?\([K?\ T![_ /\  5_\*^K** /E
M/_A'=;_Z ]__ . K_P"%'_".ZW_T![__ ,!7_P *^K** /E/_A'=;_Z ]_\
M^ K_ .%'_".ZW_T![_\ \!7_ ,*^K** /E/_ (1W6_\ H#W_ /X"O_A1_P (
M[K?_ $![_P#\!7_PKZLHH ^4_P#A'=;_ .@/?_\ @*_^%'_".ZW_ - >_P#_
M  %?_"OJRB@#Y3_X1W6_^@/?_P#@*_\ A1_PCNM_] >__P# 5_\ "OJ9O^/Z
M+_KF_P#-:FH ^4_^$=UO_H#W_P#X"O\ X4?\([K?_0'O_P#P%?\ PKZLHH ^
M4_\ A'=;_P"@/?\ _@*_^%'_  CNM_\ 0'O_ /P%?_"OJRB@#Y3_ .$=UO\
MZ ]__P" K_X4?\([K?\ T![_ /\  5_\*^K** /E/_A'=;_Z ]__ . K_P"%
M'_".ZW_T![__ ,!7_P *^K** /E/_A'=;_Z ]_\ ^ K_ .%'_".ZW_T![_\
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MO_H#W_\ X"O_ (4?\([K?_0'O_\ P%?_  KZLHH ^4_^$=UO_H#W_P#X"O\
MX4?\([K?_0'O_P#P%?\ PKZLHH ^4_\ A'=;_P"@/?\ _@*_^%'_  CNM_\
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M?_0'O_\ P%?_  KZLHH ^4_^$=UO_H#W_P#X"O\ X4?\([K?_0'O_P#P%?\
MPKZLHH ^4_\ A'=;_P"@/?\ _@*_^%'_  CNM_\ 0'O_ /P%?_"OJRB@#Y3_
M .$=UO\ Z ]__P" K_X4?\([K?\ T![_ /\  5_\*^IK/_CQ@_ZYK_*IJ /E
M/_A'=;_Z ]__ . K_P"%'_".ZW_T![__ ,!7_P *^K** /E/_A'=;_Z ]_\
M^ K_ .%'_".ZW_T![_\ \!7_ ,*^K** /E/_ (1W6_\ H#W_ /X"O_A1_P (
M[K?_ $![_P#\!7_PKZLHH ^4_P#A'=;_ .@/?_\ @*_^%'_".ZW_ - >_P#_
M  %?_"OJRB@#Y3_X1W6_^@/?_P#@*_\ A1_PCNM_] >__P# 5_\ "OJRB@#Y
M3_X1W6_^@/?_ /@*_P#A7H'P:TK4;'QC=2WMA=6T9L'4/-"R GS(^,D=>#7M
ME0M_Q_1?]<W_ )K2 FHHHH A7_C^E_ZYI_-JFJ%?^/Z7_KFG\VJ:@ HHHH *
M*PO&WB)/"?@?5]<D(S9VKO&#T:3&$'XL5'XUXM\"O$VAV'C:?P]H^KMJ2:QI
ML5Y-*Z2+B_0'SQ^\ )W [LCCY:2U;7;_ (/^7Y ]%?\ KI_G^9]#45X]\+H9
M+GX ZG;P:DNE3337\<=Z[[! S2, ^[M@D<UB_#P6WPT\07.FZMX5U*UUXZ6\
MY&DWC7T.LJC#,JQLV5DSG X&"W3@4U;KVO\ A<'IMWM^-CWNBO"OB9\3],UC
M1]+T+68M7\*Z=JQDDU#^T[)X[@P1](E1-Q'F/@;NFT'UKK?@%J=IJ/P9T:.S
ME\Q[(/;SC:1LD#%L<CGAE.1QS1'5-]A-V:7<](HHHH&%0M_Q_1?]<W_FM35"
MW_']%_US?^:T 3445RWC[P_>^(='M([""TOA:WB7,VFWSE8+Y%# Q.0&[D,,
MJ1N5<CN$]!K4ZFBO-=*\4WEQ+H>A>#M.M=#6<7T=S;ZE"TOV"6W>/*(D<@5E
MRY  8+@J1C&TR^'/&WB*\;PU=:U'I2VFMRSVC0VJ2!X98DD8R>8S8*L87^3:
M"NY?F;!IBZ'HM5(=6TZX^S^1?VLOVHN+?9,I\XK][;@_-C!SCIBN'T?Q_?7O
MC#3+&26UN['5&G2-K;2[J)(BB%P4NI/W=PI"D915SD$<5D>$O^:>?]=]4_\
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M%-N+%XK=MUO:-+$9!%Q\D)#RE@N%Y;/>O6Z*(^Z[_/\ ])_R_%BDKJW]=?\
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M&]$MM(T6W^S6-JI6&+>S[023U8DGDGJ:L_;+;_GYA_[[%'VRV_Y^8?\ OL4
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M_;+;_GYA_P"^Q1]LMO\ GYA_[[% $U%0_;+;_GYA_P"^Q1]LMO\ GYA_[[%
M$U%0_;+;_GYA_P"^Q1]LMO\ GYA_[[% $U%0_;+;_GYA_P"^Q1]LMO\ GYA_
M[[% $U%0_;+;_GYA_P"^Q1]LMO\ GYA_[[% $U%0_;+;_GYA_P"^Q1]LMO\
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M_G^&O_ _K>>/Q-K5JVG)KV@V]F^H7<=O']GU#SU4.CL<DQJ=R[,$8Q\PPQY
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MOR)GV7*QR;HM@ C+*Z??)/&5P3BZ?&E[;1W?V6PEU*X;Q ^E00RW,<:K^[W
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M^L\__P"%(^&_^?W5/^_L?_QNC_A2/AO_ )_=4_[^Q_\ QNO0/MEM_P _,/\
MWV*/MEM_S\P_]]BCV%/L']K8[_GZSS__ (4CX;_Y_=4_[^Q__&Z/^%(^&_\
MG]U3_O['_P#&Z] ^V6W_ #\P_P#?8H^V6W_/S#_WV*/84^P?VMCO^?K//_\
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M_,/_ 'V*/MEM_P _,/\ WV*/84^P?VMCO^?K//\ _A2/AO\ Y_=4_P"_L?\
M\;H_X4CX;_Y_=4_[^Q__ !NO0/MEM_S\P_\ ?8H^V6W_ #\P_P#?8H]A3[!_
M:V._Y^L\_P#^%(^&_P#G]U3_ +^Q_P#QNC_A2/AO_G]U3_O['_\ &Z] ^V6W
M_/S#_P!]BC[9;?\ /S#_ -]BCV%/L']K8[_GZSS_ /X4CX;_ .?W5/\ O['_
M /&ZC;X*^'1<I']MU3#(S']['V(_Z9^]>B?;+;_GYA_[[%0M=V_VR-O/BP(W
M!.\>JT>PI]@_M;'?\_6<+_PI'PW_ ,_NJ?\ ?V/_ .-T?\*1\-_\_NJ?]_8_
M_C=>@?;+;_GYA_[[%'VRV_Y^8?\ OL4>PI]@_M;'?\_6>?\ _"D?#?\ S^ZI
M_P!_8_\ XW1_PI'PW_S^ZI_W]C_^-UZ!]LMO^?F'_OL4?;+;_GYA_P"^Q1["
MGV#^UL=_S]9Y_P#\*1\-_P#/[JG_ ']C_P#C='_"D?#?_/[JG_?V/_XW7H'V
MRV_Y^8?^^Q1]LMO^?F'_ +[%'L*?8/[6QW_/UGG_ /PI'PW_ ,_NJ?\ ?V/_
M .-T?\*1\-_\_NJ?]_8__C=>@?;+;_GYA_[[%'VRV_Y^8?\ OL4>PI]@_M;'
M?\_6>?\ _"D?#?\ S^ZI_P!_8_\ XW1_PI'PW_S^ZI_W]C_^-UZ!]LMO^?F'
M_OL4?;+;_GYA_P"^Q1["GV#^UL=_S]9YCK?P>T#3?#^H7T%YJ32VMK),@>6,
MJ2JDC.$Z<5QG@#P!<>++P7-V&ATJ%OWDG0RG^XO]3VKWJ^^PZCIUS97%Q'Y-
MS$T4FV4 [6!!P?H:6S.G6%G%:V3V\,$*A4C1P HK-X:#DG;0[:>>8F&'E!R;
MD]F^B_S)K2TM["SBM;.)88(5"I&@P%%%G_QXP?\ 7-?Y4?;+;_GYA_[[%0VE
MW;K9PJT\0(C4$%QQQ74> VV[LN45#]LMO^?F'_OL4?;+;_GYA_[[% B:BH?M
MEM_S\P_]]BC[9;?\_,/_ 'V* )J*A^V6W_/S#_WV*/MEM_S\P_\ ?8H FHJ'
M[9;?\_,/_?8H^V6W_/S#_P!]B@":BH?MEM_S\P_]]BC[9;?\_,/_ 'V* )J*
MA^V6W_/S#_WV*/MEM_S\P_\ ?8H &_X_HO\ KF_\UJ:J;7=O]LC;SXL"-P3O
M'JM3?;+;_GYA_P"^Q0!-14/VRV_Y^8?^^Q1]LMO^?F'_ +[% $U%0_;+;_GY
MA_[[%'VRV_Y^8?\ OL4 345#]LMO^?F'_OL4?;+;_GYA_P"^Q0!-14/VRV_Y
M^8?^^Q1]LMO^?F'_ +[% $U%0_;+;_GYA_[[%'VRV_Y^8?\ OL4 345#]LMO
M^?F'_OL4?;+;_GYA_P"^Q0 6?_'C!_US7^5353M+NW6SA5IX@1&H(+CCBIOM
MEM_S\P_]]B@":BH?MEM_S\P_]]BC[9;?\_,/_?8H FHJ'[9;?\_,/_?8H^V6
MW_/S#_WV* )J*A^V6W_/S#_WV*/MEM_S\P_]]B@":BH?MEM_S\P_]]BC[9;?
M\_,/_?8H FHJ'[9;?\_,/_?8H^V6W_/S#_WV* )JA;_C^B_ZYO\ S6C[9;?\
M_,/_ 'V*8LT4U]'Y4B/B-\[6!QRM %FBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )8 @X# 2(  A$! Q$!_\0
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MPT\ :UX<\>V4?@+QO\.K?7_'O_"<>(M9\%Z]K%A=7^GSGPQ>FZM8_$5UJS1
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MM^/OBS8?!OQKJO@&?5+?3-/\4>&X=#\5MX5U?PDVAW>N)?ZDVH* #_3:\?\
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MU+KG@+P-K \&_#7P'#X=\ VOAK3KN#1[O_A7WAGPI9ZW'9R1O>0:UXAAU'Q
M\!N$FUFZA\B%_P @_P#@E-^SO_P3A_:W^/'_  7?\=?\%-=#^&7Q#^-/@_\
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M^&'A;7]3MKBXLX_$>H> /"_C;6]8\/VO_$QL?"NI:5=7KVJ:Q8SD _K2\?\
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MJ\FL^*=9 /Z$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,9Y6M[*SAA,KO*R&1RQ[BB@"(PPL&#0Q,&(9@8T(9E4(K,".2$ 0$\A0%'
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M&[M9HKBVN(TF@G@ECGAFB<!DDBFA=XI(W4AE>-V5@002*GH _&KP)_P;_?\
M!('X<?&'3OCOX2_89^&NG?$71O$<7BW1;BZ\5_%77?!NB:_;7YU2PO\ 1OA-
MKWCN]^%&DMIFH!+S3;?3O!EI;Z9=0P2V-O$\$+I](?MH_P#!+[]A?_@H5#X1
M'[87[.GA/XS:AX$O;BX\)^(I]7\8> ?&&CV]PQDN-)7QI\,->\'^*[_PW-.%
MNG\+ZEJMUH$UVJWDMK-<A9*_06JYN463RRD@;=M7Y1B3"QLS1Y;+A [%MH+#
MRI..$W@'PQ^SE_P35_8?_9-^-_C_ /:&_9R_9V\(_!GXJ?$KP!X:^%WBW5?
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M=[E(W\LK(7R-H1=^X?N]S?*3L5/,7S&DV! 0S$*\9< ^._&7["'[+OC_ /;
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M3>)=0\,ROX9UE- T_P 2:?JN@ZCX_O\ 1-3\8Z]93^'O[7MKN.\ /Z0/AO\
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MF:6D=N ?W%(<JI&<%01G.>0.N><^N>?6G4@   4 *   ,8 QP!CC&.F.,4M
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MPS\>R^'H(+^ZL]/T822W_B#6-,@O=$T_5].TFPU;SKR3]WZ* /QU_P""?O\
MP2!\'?L7_''XQ?MA_$[X^_$[]KK]M_\ : T&+P?\5OVCOB59Z3X/@O/!-M<^
M$WM/"'A/X8>$''ASPUI-O9^!/!=A"UUJ&O2Z?I_AC2M$\._\(_X82;0)?UY-
M@"KJ7P)$=)?++PF4/$\9#R(Q<D!@L;L7\B-%6&-' D&C10!G)8$,Q=HY<R,\
M>Z"$-"-T4R!7:.7<PNXA=.[*&,[(Z[%MXXR];1T^17B6$J085@ 4LV0S$A]K
M(0<"%D954",-M (O44 4YK02%/F4K'L*(Z!XU=&#)(L9_=K)"RK)"Z(LB2(N
M)%4N&ACL7B4!&C)"*%,@DE=9 H3SI)G8M/.(P(UN-D,Q4+YS3!54:5% %!K(
MM$T&4\DY_=@;5P4/R ,)<)O^01MYEN+3_13;O'G,B6[JR-YC':-IP\@&!MQM
MC+,@ZR#H2-R[&11L%NB@#\<?B+_P2.TSXA?\%C?@'_P5OG^.=[IE_P# GX):
MS\)+/X#I\/+:\M/$-_J_@_XS>##XGE^),GB^*;2;6WL/C%=72Z';>!;F\DOO
M#UJY\2K:ZE<6=O\ L ;1F#JYA=6?<F(E4HO</PWG>8?]<,Q"104)VLPJ]10!
M7AMUA9V"HN\<[4169F=YI&=HXXPQ::663E2?,DEDW9F95)+<2.'W2(PYS'(8
MMW 7$FP R*H&Y0[,-Q(P!BK%% %5K=FWD. [-N!=6E0$8"GRV=5 $9="JX!+
M!P05YC>UE "P3%2'+;YBT[X(?.T,5 <>81$9/.BA$:'R),E5O44 4/L9"[%,
M8 6-1N3>@6( *GEG&(\@L(TD2&,MA8B=SN^.V="Y,@)D/SM&HB+8"JCN0&D>
M98E$(E$J$Q!58$QJU7** *26BIG:J*"-NS@HJ@DA8U$:)&N3N(\ME9OF=6;#
M!S6Q(?!3<V0'D4SNH9F8_,[ X#-^[C79'$.@(&VK=% %,V@)4!F6,/(Y4,<$
MN20NQE,0C7))3RR2^R4.KQ9=(K:6-0IF+X*D$-,C':S'+L\LQD."-X8YD8$,
MZQ^7%'=HH HFUD90KR*P'))#$.<N<,NX2%>(8W\RXF$\"/"ZJ'9C#)IJNI3<
M%1RQF2(R6YE:0*K2EXGS]H^57:X=9)9&4(KP1O('U** (+>'R8]IV%BQ9BBJ
M@8X"AB  2Q55+,Q=BV?FV[0(WM@Y^8*R R,(VRRL9'+'=G(YR!DJYCP#$4&5
M-NB@"@]BCJH*PDQF5H@T,;1QR2N7:41%<%VR5+*Z,%+;6S(Y*/9-(YWNC1Y$
MFUD5W\_<Q\V-W5A"=NU!A)'CC)6*1-JFM"B@"@UFY6-?,'R,I);SG+X"!B6,
MWFDG9L(FEN-T9,<A>%GB9ALG"JL+Q1;$145HVEAC921NC@1[:)"5:3<T:HS&
M11E4BVRZ5% &?]B.4):)@"2Y,*^8?EV+Y<P(>(^7^ZE+B821$QHD"842/:^8
MK)(WRMC<8WEC?Y0%5E8.3$X7H\95U8*\;HZJZW** *0M,$%6V;7)#!B[D,Z2
M,S,PY=F1%(D\T80.2TC;EKIIQ5(TWQQ+&KC%I&;2-F<*F!$C,5MUC55$#R39
M\N'#J(@#JT4 5H8#&[2,59G,AW, TJB1E;RUFVH?)7:%2,H2%5 7(4 $T#3,
M=Q5X2H!A8,%=OW@8R$ET=-K@K'Y*GS$#M(VV,1V:* *GV7Y-CE7^4H  $#(0
M?W;@K(&C.2#&1Y.W 6%0H \Z^+>A?%+6OAMXSTWX+>,O"W@3XL7FCRKX#\6^
M.?"FI^.O!6BZ_%)%+9R^)?!NF^)_"FH:QH\RQR6E_!H_B3P_J AN&N+.]AN(
M8PWJ%% '\YGQ'_X(I_'#]M'7/VL?BY_P4 _:*^$^J_'?XY?L;3?L4?".?]EW
MX6^,_AY\*/A!\/S\0KOXOQ^*O%'AKQU\1/%WC+XJ^(Y/B0GA^Z73K[QMX=TB
MP\,Z1JVAP&XN?$-EJGA7Z'_8K_X)S_M6_#K]HCX1_M#?MK_M$_!GXUZO^S#^
MR[>_LL?LZ:#\$_A'XE^&%K;:3XAN? L'C;XL_$R]\2>-O%;ZU\1O%WA_X:^%
M=&N],\.VVB>#=-C?4'TS2H'\J63]K** "BBB@"&XA2XADA=$=7 ^61$="RL'
M0LLB2*<.JD$H2I 9<, 15:SD8IF=U"HT9$3RQ$@L6+@[V'F/@;WE667+2&*6
M+?)OT** *?V-" 76)W4AT9X_,$;X&YD$K.4Y&X%"A9\O(7=F9FR60DX)&"<N
M"/ED'3:Z)Y<<G&3NE61T<[XC&X5EO44 439AMVYL@MO$;!9$+!I'3<)%92(Y
M'62$;-T+1QJKM&NPPQZ<T<EPXF %R0\[('BFDEC5(HYC+&ZN)&MXK>*8 ^4[
M0&2.*(SR!=2B@#/>S<JH1P-ORJ':1P(F58Y(VW%A*S(N!)(A.% V^9)-,Z_8
M<!1'(8V4/M90% :16WD*@5PK2.93$LJQ;TC.TG)J_10 V-!&B(H 5$5 % 50
M%   50J@ # "JH X  XIU%% !1110 4444 %%%% !1110 4444 %%%% !115
M.6\6*5XW0QJ@C/FRDK&_FNJ(8VC648W>8CB7RG61$PC12K* "Y148E7<B,55
MWSM0MAF*C+;%8*S #DG P.H%,FG\HJH0R,RNP13\Y"% Q&0$VJ'W,6D5L "-
M)7(6@">BHXG\Q-^-OS.NW))&QV3#9"_,-OS 94-D*[J [0"Y9MN(B Q3:Q9B
MDB%3(SPF*.5GPB2,BR)$TA5!\OF @ MT542[WKN,+Q$$[HYF19552REOD:2+
M&]2N3,%&#N92-I<;I,2D-&WE'#!902K8R%F)"I"3QC>_.?;D LT55-T \:"-
MV:3)4*5RJXX>16*,%.&YC60#;U)9 TJR,V[Y"NUBIW97(X(=05R05(SQPP9.
M2N2 2T49&,]L9_"H9)3&I8JH&&P2^%X1FRQVEE7Y?F*JY4'<5*JQ !-14*3!
M\_*0 0NX%64DJK#D$LH.X8WJC8PQ4!ES-0 4444 %%%% !1110 45#+,D1&\
MJJDJNXEA\\CB.),A"NZ21E1 6#.Y"(K,0#(C;E#=,]1SP0<$?,JMD$8(*@@\
M$4 .HHHH **** "BBB@ HHHH **** "BBL\WZH"\T3V\0<QAYB-TL@)"BWCA
M$S2%MDP$;^5/O1%$!$JL #0HJHUVJ;MT;[4E:)B"AP%&XOC>-PVY;RTWSX'$
M1&2(4U%'#X"R&.00N+=Y)]DNZ%'#$0J!'$\Z-))DK%!F:8189% -&BH);A8@
M"1D%MFXLJH#M9CRQ#' 4\(KN?X5/.)(W\Q=V  3QC=RO4'YE1@2#R"O!X!(P
M2 /HHJ&>=+>,R2/&@' :6011YP2-\C A%&"6;!VJ&8*Q&T@$U%1Q.SABT9C(
M8@9R0ZD!D==RHPRK .K(I20.GS!0[24 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?S??\%7?&G[2/C3_@JG_P $
MG_V(O@_^UI\</V5?AI^U%X3_ &R]6^*NN? J\\'Z=XIU/4?A#\(X/B)X)GBG
M\6^&/$]C/<)JGA9M(;[;92VL.G:M>"QBAU!WN3_2#7\W_P#P4 DC7_@XG_X(
M$[I(UV> O^"D6\%U!3S?V8?$21%@3E1*^5C) $C*X3)1]H!Y'^V1KO\ P4P_
MX(L^"M$_;!\-?MA?$C_@H9^R+X9\:>%_#7[3OP;_ &G_  5\/4^(7PV^&?BO
M7-+T;_A;WPV^)GPOT/PAKUUKN@^([JT\*7&BZAHGB3P_8Q^+-(UG4]!U'3++
M6M4\,=Y_P<'?M,?M1^'/@)_P3MM_V"OCUK_PP\7_ +7O[;OP4^#GA[X@_#T:
M'>2>)_#?QD\(>)W\(K:S:EIVHQW^@7VK7OA?Q%#!!)$FHII]BU[A51Z]0_X.
M0/VH/ 7PI_X)J_&/]G]9H?%/QT_:_30_V>/@?\*='U&UN?&'C#Q7XV\3Z9'=
M:G9Z'#/_ &JVF:'H]A>7=Q=0Z>UI>ZY>:+H$%Q_:6JVL4WS+_P %:OA=J'P9
M\!_\&W'P8U+4;?5]4^#O_!5#_@FY\,M5U>-Q%:W]WX \/Z?X5U*]C:1QF*\G
MT6XN%C=C+^^6(*TC)O /U3_X(T?MV:__ ,%"?^"?OP5^/OCK3(-!^+MM#XC^
M&/QQ\/6T(MFT;XL_"[7+[PIXA:72EL[4Z5)XLT^RT?Q_;Z/#$(=(C\3?V"BQ
MG36#?@3_ ,%&_P#@I-^U'XS_ ."A'@;4/V1/VBO$_P /_P!EC]E;_@H+^Q!_
MP3^^+FD>&(-*F\/_ !^^/7QQ\8^.?%WQ]TK4=8N;2>X_L3X.^%OA]X?^&FKZ
M/(%,WB;6=>N-'G?2;?S);_QT_;X\/_\ ! K_ (*,_P#!23PKXC\)W-W^S-^U
MM\#]&_;[_9I\"6LITW1)/VN]0N=,^%OQ.\&Z3J-Q:LHF^,_C;3!XU^(=S#?7
M-]X-T7PYH>LP>'?*F\Z3B_VE/V,U_8S_ ."6_P#P2&T3Q()=1^.OQN_X++?L
M._M-_M/>*[^S:UU[Q1\>OCE/XU\8>.GUJ.6%)H)/"5NNA> ;>-([&.[T[P?9
MZK?67]KSW]PX!^E?_!57]J_]HN#_ (*/_P#!/K_@FS\,?VF)_P!B'X3?M6>%
M_B%XL^(?[0_AK0/"=Y\5/%>O>&['7;'PC\&_AEXB^(6A^)/"'A75]8UBQT+3
MVU&WTP>)KS6?%&@V.DW$UQ<1>'O$?ZD_L;?LN_M!_LPS_$W3OBA^W%\:_P!L
MOPAXKC\'7'P[L/CYX6^&VG>*_A7J.A3^*8_&D7_"=_#K0]"U#Q?:?$"+6/#)
MCL-6\/Q1>$+OP7<O837 \2W%M;Y?[;'['G[ 7_!0=]-_9V_:R\&?"KXG^-_#
MWAZ?QCX/T*[\56_AOX[^ -%\3ZG=Z=%XU\!:AH.K:7\1?"^B:YJ/@W4+:35[
M*2+P]X@OO"YL+A-2&F74=M^.W[!6I?M%?L=?\%2/CA_P2 U3]J;XH?MF_LR^
M(/V0(/V@_@_X[^(WB6Q\6?&#]C6UL?%FK> -/^%GQ(\7+:6<^I7&H:<^EMH5
MC=WFG)86*_#_ %/2/!WAO2=:UB., M? ?XH?\%"/^"U7Q'_:&^*WP?\ VR?$
M?["7_!.OX4_%WQK\'/V9/$_[.G@/PGKGQ5_:U/@K6KO2O%WQ:\0^.OB);^)S
MX;\(VL]E;1^$E\,:3I5G=)K=QI&HZ3<:UX/U+6=9C\0?'[]NS_@CQ^V?^R!\
M)OVHOVM/$'[>?[%/[>?Q+L?@#X4\?_$[P#X)\#?&?]FSXV7=YHT'AA-4\3>"
M=,M[?XD>$O'=QXALX-2N/$=I975GINGZMJ.C6WAR;17D\7=G_P &P7Q*\*^"
M_P!A_P 5_P#!/[Q==Z)X8_:?_80_:!^/_P *?C/\-)"NG^*95UKXN^*_&&B>
M/K/1[I(=9U/P=J1UZ^\,Z7XCFAEW-X3N+6[>WMK/3VG\T_X+YZQI'[37[8?_
M  1S_8C^#=_I'C[XVP?MW^#/CU\1_#WA*]M]8\4_![X.?"N30;CQ9XY\>V^E
M27&H>#?#=QH7B34M4LKG6HK&/6X?#6K1Z5]LN+1D0 _JH /D *23Y6 SHP).
MS +Q@*P)/+( K Y7 /%?S!^ _B9_P4(_X+(?M'?M1W_P!_:U\5?L#_\ !._]
ME_XQ>*_V:_!7B_X,>$/ OB+XZ?M-?&'X;7EM;^/?%3^)O&>FZ[-X/\ Z++=P
MMHB:'#:66NVE]8V&H66H:M#J=YX?_I[.YK<X8AS"<,V,[BG#,8I(USGD^7-&
M,_<D488?S/?\&X/Q'\%_#SP+^VU^POXTU_3/#G[3'P _;Z_:?O\ Q)\,_$$R
M:)XXU_P+XK\1Z3JOA_XG:#X>U!XM1U[P=K;_ &R*#Q%IMN]K]@M]#O[L16&N
M:#=ZB ?J#^QA^S5^V5^S)XE^(6D_'C]NWQ5^VE\'==T+0KCP''\7/AGX,\+?
M%_X:>*--O[U=9C7QQX&BTG2_'/A#7](NK)KO_A*=-M=:TG5M)7^RIA;7-Y]N
M\;\3?\%Y_P#@E=X1U_QCH6J?M9:7JT7P]U]O#?C;Q7X!^#_[07Q.^&7A+4UO
MI-)CL_%OQ@\ ?"3Q!\+/#=S-J:F+S-4\6VFF$(K1:B8F:2O>/^"DWQ<N-$_8
MI_;L\-?!KQ]##^TEX;_8F_:,\>^"/"'@K7+*Z^+^DS:3\.O$-MI?C+PWX0LK
MT^)_M6G:_-I\.AZI;::8W\0/I]G;3M>R0PO\V?\ !([PK^QY9?\ !&[]E;3O
M VF?!Y/@AXJ_9.\"ZE\=DOY/#+>"]5\>:Q\,=-N?VA;KXPMJ,QTZYUA_%DGB
M>+XD?\)'</)8[)A<R6UC$LD(!]Q>.?VZ?V7?AW^RCJ'[<^O_ !F\/7/[*5EX
M1TSQP_Q?\,:;KWCSPS)X8UG6+3PYI.IZ=;>!=(U[Q%JSW/B&_M-(N[/2-*U:
MZT^Z:=[ZWLK>TNY;?Y!U;_@O#_P2GTCQOI_@&\_;#\)1W^K^,5^'NF>+(?A]
M\9;OX3W'CIT5I/"DGQKL_AQ>?!V'6+198C>V4GCM+S3)9%34;>**WNY%_FZT
ME;FW_P"#5O\ X*;VOAN+4$_9UL?VFOVA+']CL7EQJ%W G[+<7[6OP_D\%+HL
M^HD7T^BIXO/CP6CJ(HKB]D>\:6*6XU P_KI_P4I^ ?P9T7_@VV^)?P]T;X6^
M#-'\ _#S]BWX>^.O GAFTTBSL=.\*>-+#3_"OBVW\5:-#!'<2:;XBM_$>IW>
MJOJ,,HO-9U/4-8AU>ZE@U.XOYP#T3_@LG_P6BG_X)L?$#]D7X9>"+70]8\9_
M%W]H+X2:3\:],\9_!'X]^,=+T']FKQK?>*=+\0>*_ACXN\"VFA>#]=^)\%_X
M=FBTKP9:>(/&GC/RXS<#X7:A%-!Y_P!X>*_^"JW[%7@;]EG5?VVO&_Q3\4^!
MOV8=#\:6/P^U'Q_XX^ /[17@S6H?%FI:I8Z19V,WPN\4?";2OBRFG37^HV=I
M'X@@\$7&DRR23W$$\]M;SM;?AK_P7$UJ\UG]G;_@@-XBU[4IK[4;S_@HQ^P;
MKOB'6=3G*W%U>S^!;K4]2U34Y[DQA99';4+F9F((D:>-@LL$L<?T3_P=BM!)
M_P $8?BXKN&\OXM_L_NZ*KS9C_X6+IFX-#&REBVQTC)>)1-MCEFBA>9@ ?J9
M^S?_ ,%3_P!A']KOXE?$_P"$W[.G[2'ACXF>,?@WX?U;Q9\0QIOAGQ[I'AG2
M?"6CZW!X=U7Q/I'C[Q+X.TCP#XNT;1]6F2QU/5O"7B;6M*M+Z257N)(()3#\
MZ?\ $0#_ ,$F(;FZ,O[7^E7>@6/B+_A%;[XAZ5\'/VA-3^"MGKTMU]DM=/NO
MCU:_",_!NU,I19%O+WQM::;,UW"]M>S6LD$A^9/^"[_A.]^ O_!OW^T3X&_9
M@\-S?#G1/!OPG^"O@'3_  _\--.DTY/#OP<U;XP?"KP[\2=$MX-(M;>XM?"E
M_P" [K6[#QQ=&/9/X6N==O\ Q'<21K=W<GUY:^&/V,;3_@C':^'_ !!IOP]B
M_8VF_8-L[W6K:VET>U\(M\/V^#]M<ZC<VUS8[UC\13W9GNK?5+9I=?B\:S*;
M:YDUQ[**< ^??^"_OB.PU_\ 8&^!OBKPUKMMK.C>(/VZOV"]7T/7=&NDN=*U
M70M<^-?A74M.OM)U&U"VVI:5J5C-:WEI=PO/'/!,"+B5&K]_E4(JJHPJ@*!D
MG  P!DDDX'J2:_B?\>S_ !4D_P"#9S_@E0WQG751XV_X:)_8%6U_M@73ZF?A
MW;?M(1Q?!]IA<;[I+=?@_%X&6P2;'E62V]O;AK6*V>3^V $, 0<@\C_/\P>1
MWH 6BBB@ HHHH **** "BBB@ HHHH *_DC_X+.?M=?MU6'[2_P 7G_8!^.6I
M^"/ _P#P2F_9*\)?M;?M:^&_#UK9ZEX;^(_Q$\>_%#POJ_A7]G[XIVSQO=6E
MH_[.?@3Q;\5;J33)OLD'A:^NX;B,7&L6\D?]57COQUX3^&W@_P 8?$#QQKFF
M^'/!_@'PSK?C+Q;XAU>Y2TTOP_X8\-:9<:UK^M:C=.-D-EI.EVD]_?/\S0VR
M"1E DCW?Q9?\$J_'O_!1[5O@K^VC^T/JO_!'SQ[^V7X*_P""KOQN^)WQON?'
MOB3]L']E_P"$,?B7]G7Q?HL_@'P)\++WX>_%CQ7%XRA\*Z)X<F\6:=X;O+_3
MM/TO4?!6O:2-!LY_#<VF7UZ ?UA?!7]I#PY^TQ^QAX$_:J^&ER;/2?BY^SUI
MWQ;\/;)?/O\ 0+W7/!+^('TB\FDC59M1\,ZXL^C:@&A6'^T])O;=X%$<D5?"
M7_!OA\=_C!^U#_P2'_9+^/GQ_P#'WB#XJ_&/QTWQ[7Q=X_\ $T\$GB#Q"/"O
M[3/QF\&>'8]0GM(+2WD72O#&@:-HUHH@5%M;"$R!Y3)*_P"<G_!OM\>_'_AS
M]FS]NO\ X)<?'?X=Z[\)/C/_ ,$\=?\ '5AX<^'_ (E\3^'/&FN:7\"OC79^
M-O&_@#PQ-XJ\+75_I?C/4? 6HR:MIUWXFTJ[N])N_#GB7P FGRK',D"?7G_!
MKS*D?_!"O]B%&;#(?VF'8A6=$$G[7_Q]*%G0A!@,CN#(ACC=))#''(CD XC]
MM+]H7X]_&[_@K1X _P""8.B?MKZS_P $^/AL/V2+#]HG1_&7PUTWX?P_&W]J
M3XF^+/B+?^!;;X5^!?$/Q7L-4T;1K#PQHGAWQ#X@L-/\*:1>^*-5U*P\0S:E
M;W^EZ6B>&OU4_8N_9Q_:*_9KM?B-X=^,G[:_Q,_;,\*^(-6\-7_PQOOC)X(\
M!:+\0?AW;VMMJL7BO3]2\9^!=+\.IX[L?$0?0KZPDU32()M NK2[BLE?3KS<
MWDW[:_["'_!/[_@I9J#_  Q^/^A>#?%GQF^"FG0ZEH/B?P!\0F\+?M'? .X\
M4PVNJ:!KVEZGX6U>R\6>';>[U![+7=&L/&FDZEX1U>_B74;G0IY1)-+^.W_!
M.WXQ?M[_  E_;T_;_P#^"0U[^UY>_MG)\,/V4W^./[-O[6?QQTR\\9^)O@M\
M4?$<?A/P[X-^'_QSU"UU*XU7Q_96^I_$6VUW7M!U37H?$-_9_#_5AI%OI>GZ
M[KVG^'0#^LM"1$I+&0B-27VC=(0H);:H RW7:J@9. !TK^53_@O7^WS^V3I:
M?%3]GO\ X)[?$.;X:_\ #)/P"\0?M6?MT_M!^#SIE]XC^$EB?#>LW/[/W[/M
MK>:C;7=AX<\8_&_4[.Y\6ZE8B >*E^'^GZ5XCT^:'PI+XAL]8^_?A]I7_!97
M]G70_C1\;?VI/B_^S?\ MB>!?AI\ ?B[X^\,?L__ +-OP!\:>"/C+\4/B9X2
M\)3^)?!'@CPEJ@O/$37<_BNZT.3PO:Z1:^%]9UK4]7UG1X]/MKBYC5$_E3U'
M]K#XK? [_@DS^WY\*/C%_P $O/\ @K+;_M0?ML>'/BE\4/VNOVP/BO\ LG^+
M_!GP9B^*'CC(M-0U'Q+XEU&6Y\&?!OX6:(UKX4\++/'86]G:V]UKD6BZ ^J-
MIMN ?WL_LE>)]=\;?LL_LW>,O%&H3:OXG\7? ;X0>*O$NKW(C%UJ_B+Q)\//
M#FN:YJMT(P!]JU/5+^ZOKEBJF6>XDE"A)%KZ$K\D_P#@CM^U5K'[3_[&7POG
MUO\ 9?\ VEOV9H_A+X$^%/PJL[?]I3X>GX=3_%&UT/X4^$+AOB9\,+>XN6E\
M3_#?6(GG33?%!MU%],)([=W>*]6W_6I!A5'(PH&#MSP!UVX7/KM^7/3B@!U%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A
M8 X)_0TFY3W_ $/^%9NK33:<E=.S];V =7Y@?\% _P#@D7^R)_P4L\3_  D\
M9?M(VWQ/A\3?!/3O&VD^ ]<^&'Q)U[X=:I::;\08M&@\365]=Z,S&\M[B'0K
M6*V 2&2WAO=:@>2>'5'CA_3^FEP#CG_/XU7/#^:/WH3=N_R5S\</V-_^""__
M  36_8=^+$?QZ^$OP9U'Q3\;K*VF@T3XI_&CQGXF^+OB?PU<7#QK-K'ABW\8
MZA?>&O#/B9[&VM-)3Q=X=\/Z3XLM='&HZ/9ZY;Z3K.J6%S]L?M+_ +%'P0_:
MWU?]G77/C58Z_JVH?LM_M#> /VG_ (3OH.O7WAU;#XK_  S>ZN/">H:N;)WF
MUG2;*\O);B32;N8PW BMH99&$4C3?6X8$X&1GZ?_ %Z7'N?T_P *.:/246^R
M:N"=^_S5CX,_;,_X)K_LE_M]:O\  +6OVG/ $OCJ]_9N^)/_  L[X<&+5KW2
M$75)SI3ZSX=UT6#QG6/!7BBXT'0KCQ1X:F*6NL/I%EYLD8-U]I]&_:J_8S^"
M?[9>A?"3PY\<;'Q#J>E_!+X_?#7]I7P'%X;\1:AX9DMOBA\)Y=6D\'WVIRV3
M.^I:7!_;5Z+_ $Q_*2]W@F6(J,?5I8 X)_0T!@>A_G4^UIWY>9)WM9]'V8S\
MN/V[_P#@CI^PS_P4;\7^"OB1^TMX#\6W?Q2^'6@IX8\&?$_X=_$CQK\-O&NC
M>'H]=U#Q+;Z,]YX9UFVTO5K'3=<U34]3T(ZWI&I7GA^\U76)M(O+3^U+M7[K
M]@S_ ()=?L?_ /!-WPSXY\.?LM^ +SPW<?%/5;37_BEXN\3>(]?\:>-?B!K>
MGQ74.FW&O:YXAU&]C&FZ8FH:G)IGA^QL+31;*]U75M3ALQJFJZE>7?Z'457/
M#^:/WH#\<OVS_P#@@Y_P3;_;N^+#?'SXT_"'7M$^.EU%IL>L?%GX1_$#Q=\,
M/%7B0Z/#'::7<>)+;P]J:>%];U.RTV&'1X?$%_X=F\3'1K:QTJ36WL-,TRWL
M_6_V$/\ @D3^PM_P3=?QCJ?[*GPHN/"WC+XB6]C9>//B3XK\7>+O'_Q"\4:?
MIUR]]:Z?=>(/%6MZA'I>GM?N;S4=,\-V&B:3K=Q%;3:WI^HSPM+)^F5%'/#^
M:/W@1M&K1-"WSJT9C;S K[E*[3O5@5?</O!E*MD@@@D5^2?[;O\ P1"_X)\_
M\%!/B+I/QI_:#^&OBN/XWZ3HVE^'H_B[\,?B7XX^&_BZ^T717NSI5EJT.AZT
MWAS5IK*&^N;*VU;4="N==MM/>/3+35+?3;/3[.S_ %M+#)^8_D/_ (FC<O\
M>)_#_ "DJE-NRG%OM=!^)^:_[!G_  22_8=_X)MS^.]7_98^&.I^'?&'Q/M]
M,LOB#\0/&/C7Q9\0?&OB>PTJXGO+739M5\5ZMJ%MI&F/>W,M_?:=X=L-'M-5
MOEMKC5HKXV=JL7Q?XL_X-H/^"5/B?Q5XTURU^'GQE\&>%/B3XCD\6?$7X.>
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M !Q2T477=?>@"BBBBZ[K[T 444477=?>@"BBBBZ[K[T 444477=?>@"BBBF
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ML0, \#) ''-63HFAB1(TTJ7+IDEM295# $XS]G'8'!]>,9J,3GS T?S29 C
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M*QA%?6)F "J 03'8#)!./ZU>MM8\->=&FH>%=5,FQ(IW36Q<0QJ9=[-%"]G
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M5R>G4'(/H5<3\/U)\*Z0S')V7QZ ?ZZ_EE(X[*3@>HY-=M7>9!1110 4444
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M>7[<7CFC=TD"';ME@EPYW-MR[;%/1N-N<9KWRP\8QRW%M!;7MQ'&L465,O\
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M=03S[R B((7M(S*PSN:2!MF6P.,B0D<DD ].*]_!3NKQE>UM4WI9)/MJG?\
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MO.R1G*J%&1DMDXVOTP1^9SD<CWPC-^XC#(&^0'.X#((R.",]..>]:ERC);S
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MD1)DJI9L2@#&1DG(&,9ZY%>D1&?-LFK6?1^1V-Q:KLEC8@(3(F6)#%%/R\\
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MRGMVC]Q-;!5*511K4ZE*I+51G"<4[:Z2<>1[+[1Y[%,H:0L7A(&0\88'S-P
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M>:JLMPD]RRQY8&&$.P6/ (' 8 MU.3USCOS!J-YY=G;V5OE59F>=R,AA(X*
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M"Q0F*8F0 QJL$[LP2"9D_*C_ (+5?MU_$C_@G-_P3O\ C%^UC\'O#7@GQ?\
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M R:^#=2US5_!NHW>BZM:207ME-*DMI/'<1,T(PD9GB\PA83$(SYPQ(S?-O\
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MK+H^A_-V=SCBLWQ^,A=4:E5>RBVWRIRF[:O5VMO=]AUP079L[&W,P51P#EB
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MPA@'1BWNN2_!!)!.,YXQ7RCIWC*PO%26RGMIG1!YZB=H[N**4!@1&3L)C7/
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MACA\;79CCA1 K$;2\3!Y',D3%'))9F\._P""J4D\'_!?;_@W]DU];4>%FO\
M]K"/1C.3(C>++SP9HT8 20+Y<\FI7?A)5:)9&:1K-I%M!(BQ^W^)_P#@E!_P
M4@\6_MC?"_\ ;BUK_@JU\&G^.OPE^$?C3X,>#IX?^":]K#X8MO!/C>^:\UV&
M[\+1?ME$:IJ OI6N(=1?5!<64YA@:T:V8V]?8_[=/_!-*S_;P^#GP"TGQS\8
M]=^&W[6'[,OBOPA\4_@S^UY\)O!6DZ3K7@WXQ:)HVF0>+?$-KX U76-7AB\
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MA]\9-'\#VOCK5-"T/Q)HMUX8^(?@>ZT<>(?",VH>'O'7A^]LX]0T^V\3:?\
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M6MZ\$LZJ+Z)=K$G,<L3[8E51DDRQEU'! ) X) K3\0:0+O(6,><@=U9E.YG
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M5%!(/GL" X)'##&."*ZF6<878@58P$5=[*%4<!P1@DCIC/.3QQP-C+  ]2
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M^*K93@W4G)MM7HT&U=MO6^Q_/6?4HT\TS.E2LXPKQOT3:E4M9[/Y6-0*?/#
MKGJ#G'S8X.!D@?0$CTS38]0$\\UPX,9@^3]Z6^<#C SD'GD'T';)JI<R,EP\
MD499A(QR&/4$\K@[0?0D$ XR".#EVUYYXF3>'G95<6[D#)99&=B1M)P$P ".
MI)R*^RGB94XSG)^ZH..CN[OLM'Z^>AXL(N-2-TE=-K70-?\ $LD-_#IZ+'),
MPCQY32; ')QNP%.0.#\O<8[Y[GPW;N&CO[J=+>8+%)%C<3'P"63S(BI;G@MD
M9_[ZKY[U[6_[/\1I-<)Y8%PC8VECY0" ,I+8&6#@ Y''')KK'^("S1>59S,K
ML%4/(Z *#P-J!6)&!QPW7UK\;Q.-3SW&5,1-3=*O*G2A4=G"FU2;Y$[WLY-J
MUM7\SZ:G!O WW3FKVU=K]5;32Y]+1:QX7CN)DO-2GEN9B7DD-QYLA &-@Q\B
MX)X4*H_VO3H=,-KN^UZ9JCDPJ9$BDE190I.Y0'0DL>G4 #@9( -?*NGZK#,L
MCM*B.%/F!H)?FD.2V'\H?,X^YC*[CT/ KO/#7B=+>\CM5C.PQ9)9EWXR&"DN
MJ\A3@@IC(PN%&*]ZGB**?,Y6_=NHK;V32Z/1W=[=>YSRIP2]Q._FK:>OJ?3%
M[X@;4=-1M04W&J6CB(:BQ7S+RR9@/*N BH!(CN'\Q4=BJ;2P!)'F6KF'SO,C
M2+YSEFW2$,5P5P64'*[B#TZ_2K6HWK6]LOD2K([%=F&!# ,-X;G^[N/;G%<C
MK-_*T\2LH6,1AB%<#:SA?N^@.W!R">!ZFOLN&,:Z\*T*G-R2;<7:_N\L;7[-
M:W1YV)3C-7M\"?RN_P#AK&C=-%-"BK@R!7RBY)!=%51^F3TZY&35%KM(;*ZD
M2X"N&,4:QJ,&0,HSN!!V\Y!QDC.1VK)2YDPS[PCC&!\QX P,D-S\H!XZ9]:S
M)YHHA'"^=ID:4Y;DL<X!XQMR!@8S[YYKZ9SIJ#2;<5%I67V=EU[(\YR<9N2^
M)2;735,UH+V6RM)9V8@-&\ADD<IM;.7*D<?-G(!(/'3.:X2VUV[U'5_*MT>>
M,EO-7>0TOS!=RC=DKU!RRG';I6YJMRCZ1?!RK(L#2K$SL 3$CD$!1NR">>>_
M0UYCX1U2TCU6:1G>.5U^1F< 8)&%7@<9X''0#/J?R_C_ !51XW+:#E..'DZ:
MFXIM2BJ7PRLTO.SZGN91"].LW;VLDY.^W*Y='U=WM:Y]1Z1+I^E6T.Z8JDSB
M2:>!C'))P0T+H#@) < -YI+E@64;1756WB;PVP\I5N/D.TS13'.2=V"C'!8;
M@2QYVD>G/SE)X@261HDNX$2-0&7S PCW.BN  ^5E<,&).5RO"\<W;;40H,\4
MR-%'+(NT.@$C  ;V]>-HR" <8QQ@8X#'J*Y,-RPI44DT_=O:W-*W6[U-9PES
M2T]?ZZ_\#T/JVTNWMV2?3[J5U16>"6-M[Q^8N[>K8C"2#.Y3B3:<9#8P:VL3
M_;%281QP37!"WC*C.;B7:Q67<0%C!7=YB*F'<AB<J*\A\'>*KB0M:D,452RN
M7^8[5&U6.2NSC! 4$@C!YXZ^?6+B1T7=@!@V Z\ !NGRGU_SDBOK,JQT*U>%
M-5(R::<DG?=-M+75Z[>3['!CJ,^23LOAONO)]NS*UK!";R7[5.(H(4EW2;64
M@L"(0   3YBD9SQ7(:G(D=U(KL0B@(DH^99BP&#E&R&'WFW[=K9&>*N76HR&
M25E<L-Y$L<A5E8 Y4G:%/REB5YX/)R.*YW4I!<1K(7WLA<[,%0%9LACLV[F7
MCEL@C)*D\C[N%6"A&[E]S['CQ3C*S^U9(LZE>EHK.!YP2O[O*M(7*Y!#RHS;
M')Z8)Q[U4U[7IK.UBCA; "H&RS+&^<](UP0Q/J^/RJM9+!,NYI(Y6B;:6=QO
M9@<_(<[=HZ8(+9[]17*^/;@06]O* JPAEW*+@"7C/(.Q@!C^?2OE^)Z\GE69
MRC=0ITX-RDN5.\->6]^;7=(]+ )_7,/#:2=_+75:[;;]CHO"DLFLW#3W,A6%
M7EVAMV/WFT G8<[ER2,'[X'49-?15K<Z)HEE!!A'@\M7<0M('EE(P[NH)&X_
M+G)4X!QD9Q\O>&=;MM*TUGAVL\31^9YV&W&4'>R;'7Y,?*F5/SXR6 Q7:'6+
M>_C:=9$='2)E1B&=20Y*,&) *\9"JN=P!'''YUP_C*-"A4IN495(6O"Z:=VE
M9/9VU;TTL>]B$JE]'R]=-=U;3ULSW.WUKPW?2H"7M&( RTKQIW (9FQR!SCN
M?K706UVFFS$^9YL%RZ"?SY)$BNHRP#JZ1JT1^4M@F,X;!!4@,/F>VU18I#N(
M4Y'DQG:4 '7*,"O)!8E0,DYZ\U[1H^HF]TBV::83R%0RJQ7?%DG;&3C(=6P7
MX^[T /(^IPV8*I)*,5!JI2O9K6\K:V[?KZGFUZ%/D>CZ[KRZ&OJ-C:/=W&P1
M^2DSM&D8;""1"=@E<@R*NY=N54*-W'05R/B.VTN&R6=&6.[BC.(P5!E5 $8$
M%L[LXQ[<DYS5K5M3E5W9)%C&6)#,"6?: P7:5^5=H/()YY->?:IK$MV8X6"M
MY9D^?:I8B4@L"Q4Y Q@#@@9R3C-?I>&J7HT7*Z;A#IY1M^%CQFHQO%7T;M\]
M?+<_2#X!'=\)?"+=,G6N!TX\1:P.G^>U?.__  4V\5>)/ G_  3F_P""@'CK
MP5X@UGPIXU\$?L0?M7^+/"'BGPYJ5[I'B#PMXGT#X#^/M9\/>(]#U33IH+W2
M=6TC5]-M;ZPU2WEAFL[NV@DAE60!D^@?V>I&D^$/@\D 9_MSIGMXDU@=R:;\
M?/$_P*\,_#+QD?VDM?\ AAX>^"6K:/#X1^(US\:=<\*:#\+M2T+XB7@\#+X8
M\77?CNYL/"=Q8^+[C6!X932]1NG36IM331GM9Y]0L;>Z^_PC3PU%K^1?@>-4
MBU4?E=;^?_#G\KW[!'PL_8._:J^%G[,6F:A_P7U_X*&^*OVGOB;\%_A-XF^(
M/P/TC_@KEXKBU2;XGZY\/-+\2?$+P-9?#NXU.3Q!*-/UN+Q%977A*WFOM6M-
M,LKJ"261;2YND_07_@L/^U+\?--_:"_X)R_\$SOV<OB-XB^"7BC_ (*$?%#Q
MU9_$_P#:#\(R6T_Q2^%?P7^#]IX:U[Q/9?#3^T+>XTVQ\6>.-,U?4K(>++R"
M^?PUI^@7IAL[R[UR+5=-_.G_ (."OV6O^"2GP?\ ^"9/Q1^(/P-^!?[(GPD_
M:-L=;^$MU^S/XE_9D\*?!WX>_%K7/'VH_%+P B'PO=_"V'0_$7BFS?PS/K>J
MZT0^HRVNEZ7?:AIKKJX\-2R7_P!O1_'?P1_;?_X-G?VR?VAY+_1?#WA_PSJ_
MP6_:-^)GBIVT_0O 7Q?^*_P?\%:'9WGQ#UV\@@LO#M[XB\1^*_'&HSW^KRQ:
M=(_A?Q)<3R6)MGDGZ1'M/[9'PY^//_!(GXZ?\$Y?CW\+_P!M[]L/XV_LW_&3
M]L+X3_LC?M8_"[]K?XVZ_P#M#Z+JVC?&6P\0:-H_Q<T74/&@V^ K_2!::KJ&
MOZ3X,L] T.[U6U\,:?X<LO#'AYO$>D^(?ZI4'E0J&=I/+C4-(V"\FQ1EVP "
MS8W'  ))P *_F/\ ^"Z?QC^$_P"T'XR_X)6_L$?#[Q9H7Q ^*G[0?_!1'X!?
M%HV/@/Q#8>)6\(_!'X(:G?:Y\1O'NMPZ#'K4EK9G1O$<#^&CJ*:?::Y8Z=XH
MUC3+N[@\+:O9K_3<PS P=1S"0Z$#'*892 SC'4$!V&.-S#D@'XBW_P#P7M_9
M5N_%7Q_^&?PN^ W[;/[0WQJ_9J^/WQ;^ ?Q0^!_[/WP$T_XE_$;2Y/@WXB;P
MIXA^+#KI_CZU\':-\)?$&O0WFG> K_QAXO\ "_CKQG=:;J5MH_@&6YL9X$^S
M?V;?VZ?@!^WK^R=X@_:?_95\<ZAKW@B;1_&>BO>:EH>I^'?%?@?QYX4T2YGU
MCPOX@\.ZG%%+9>)/#MU=6,TLME-?Z1J<%S9:EH6MZGI$]AJ,OYH_\$#O"GAA
M/$W_  6[\:0>'M%M?%VM?\%V/V^/!NL^*+73;2#Q%J_A;PCJG@/6/#/A_5==
MCB&K:EHF@:QXZ\:ZMHNC7MY/I6CZEXM\37FE65G-KVJM=\O_ ,$4;*VT[X2_
M\%T-)TV*/3M-T7_@M9_P4\T?1[&QA@M[32M+T_PU\*UT_3].MEB\BSL[)9IE
MMK6WCCMXQ-(?++.6H _*K_@VJ_;R_;%M/C'\$?@Q^U[\;/C!\=_A?_P4*_9K
M^*W[0'[/'C7XX^-O%7C_ %CPQ\8OV;?C?\7_ (5?$OX9>!_%_C'4M7U&?2]4
M^&'@&+Q]XC\.WNLO!X?CL?"^K:%IFA:=XCU9+O\ =K_@LI^TOXPM(?V4_P#@
MG;^S_P#$/QC\,_VG?^"COQLTCX4:)\1OAUJVI:-X_P#@A\ /!^JZ;XG_ &C/
MCEX5O](GMKNQ\3^&? >GW6C^%93?Z7-YNNZKK-C>Q/X=NG@_FY^$W@3XF:'_
M ,&N'_!-O]N_]GK1YF_:6_X)Q?&KXQ?M)^ M>TJQU"ZUI/AO)^V9\;_!'QQ\
M)7TUCYEW_P *_P!>\%:W!XE^)NDD_9+_ ,$^"]0N)6M[*P>V?]C/^"4/Q<\*
M?\%??V^?VB?^"L-QX+U?3_A1^S3H/AO]BO\ 8GL/%$"O>:5/=:)?^-_VC?BB
MD<+26,?B/Q7-XX\.>&M$U*VG,]E\.;RXTB_MQK-W<W, !]1?\&X_Q:^+'QN_
MX)0_!3QQ\;/BC\1/C-X\N/B'^T)X?U#X@_%CQCK_ ,0/'FLV'AGXY^/-)T&/
M7/%GB>]U#7-7_L_1[.#3+62_OI7M-/M+&QMDAM+>*WA_=ROYY?\ @UZ.?^"/
MGP2.<Y^,G[49W<C=G]H3XE'?@DD%_O$= 3@ # ']#5 !1110!^*W[709_C]\
M0%C"1NI\*'S)%PLA/@CPZ0H;'S$#(P#D+N]*^/KO5Y03;[PTD8+)M^2 A3@;
M67Y1@CDCZ&OKC]KHPI^T)\0G97:1CX3(Y^3(\"^'5YY&/O#L>_M7Q$TUU;:I
MJ5K=(B_/YD;9!4! 6*H3AMK#'5<ENN!7X%Q#2CB,=FM&:O#Z_C7)+7G7MZEX
M._22NG;6S=M3Z;+IM1I6?*U&%I+>-N6TO5.S[:'S1\;O#FIP7C>*-/B>XM+J
M)I+Z.&".3[+=*Z L\IB8K!+Y@) *Y*.6!R#7QU'XM^Q:C(+B6[<>?,)8E=Y
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MPML;N_$6MWD4<8C>6.S$Q94:8,8PS!%5V!4?-DG+Y)ZUU'B+7%GG$'DVQ2U
M598W8B;YP%.]B5BQU&.0#^-9VKZQ%&B6NG7 @6V(*(L1==Q&<LBS(F2&&2O<
MY/)-<3+(Q60+)*2_W3A"Y9<LJ\G: 2 22PZ=:_K_ ,.N"\-P)P_ALOI1]KBJ
MDZ4\7748IO$.,?;1?)[O)[3FU^+RN?A7$N=3S[&RQM2HU3DI1PU%)6ITI-ND
MKOWKQ@TM;[=3V_PG=FZL;E\DB.\>+@9"L-H6/S1S(1P "25)VCDUL:Q)/!9R
MLC#.$W1R'!(##>H4^HR",=SGI5/P5;7%AX;M5NBCR7'EWL@3#*S.RN<L N&
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MEV1S&"60Q1$A$P6<H,[2QP7>&_V4/%;3(^I:GHJQ1%MTMO<,P==ORK&#;PR
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MY9;Q<FG9:[7TCUL?E,[\UF[VBE=^2T^\\P\>75U;ZC"R"*1UL-YWR[ED6W<
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MN;'4K.QU/3K^RN[+4M-U*QL]1L+VVN[2&5?6:*ZS(_.;]B__ ()0_P#!/O\
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M*3$[A #O(",2&'.TN&(*@YR0GS ' S@5KVT$_E82.1MP #Y$<9Y!P"3OR<9
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MZ\=01FO(=-O4TO1Y[Z\O5AL%W74X,YVK$$Q%$ S;2[$$H.C.50Y!P/P_-O\
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M<<==W'0GI_2NQ_X3#2O&WA2]U/2XY8-UNTDFFS-&]UILY(*6\C EKE=H8I=
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M1<I8>\XK3D34DKVM>]M-&CZ@T"]FU.XBDE>VAMDDW3S-.6 52H<1QO$ZS/\
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M)->6ZYK1U;5'N?/EFA0F.W4/<())$4DNT1 )\Q5X*KM^0Y.2H/[/X:X#'X3
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MPEJ^@W^AZ#H-EIEAINDVFFV6F);Q:9I^G6KP2QVR"'N,S^5/]N2S_9+\6_\
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MZIJUUI/A+PQ8:5H%@^H:IJ-_?WL-O8PPS37$LA5I+B8$ _#W_@U_#K_P1_\
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MJ]J%>0.'B9W4M&#]UU )Q+\Q&>">1VZFMZWU.&[C2VOB9D90NY\OG.%(9'+
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MT5-EZ_H*"3FY=6K>6ZZ?+T+ZP)/+@-)'O8XV .JG!.&YR.!U /3WJXMDB-R
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M"<U?-DLD94@--\V9)%E5% )&99/+VKN[88G'H>G*W7Q6^)MO91BYU:6:S-K
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M\R+RW3RW++^>\,^/?&&"Q^&6?8C"XW U:J56G2BN>$&XIIMPBU97=TV>EF?
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MF8F3YMY!?;NXP.)\)64=_K>KZ_-YCRWLQ=5G5WB2.-WD4VY19&P4 W%@BAL
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M'R].,[>#SQ/C#P-IDWV=XK2.#;#*OF6YCCEF*@>4C/& TKLH;RU+$D$[1UK
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MO"N,M@ J6. 7' ;(R#GTJ#36>;1-&EGMN8+<P;R3OD\@$*9@,@'RPHX+<CG
MZ\QXUNS;:%?D;MX:&"(A5;D^6C_>!&"K$ [203G -?32E)5)-IW4FW'S3;M:
M]OT/-<97<(^[.[26FDMDOZT."UKQ7J=_J<&B:3<R+'=W#07WV:,/)9P,%V,&
MYC82MD&3F2+ $17>P/IOP_\  ALW_M+5+E[MD9F\OYP6*N2C2&1=[?+@9<D
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M#GBOPY>Q366K>"]>\7:=XNL[N"X@ET026UP(O3?VJ/VS?V7_ -B7X=0_%?\
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M#I\F>9=.\$U5G_$5X:T9J[5_/3SL;/PYGMQI!OYV*227,WF),$W1A7**%*J
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MGDN!;S ;0KMM6X0/C)QT#948&!C.[K6'\0I%71 LA$<;WD)WEQV:$\@ ;LX
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M*^#^E:EI&I6[-&_EWNA>(=0LIBNR1$NI1$Z*[;O=O^"*7[0VD?LW>&_VX?\
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M45>.<CH4ZCP=6-:NJ;J*%[VDVU;S^%/4[OP_;2)%F\NLF&!I?-##B)54DE@
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M+9:YI']FW+)'"\<D#QN5. [HSE6V(RNIB7G!'.1CO]'>,X!*8@[-+)!]IPN
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MFW&( [2&.,%BWR+&P8%BQ9]RY+;CT.*]0T\3V<,<=NL<<0ZJHCY()RW"@DG
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MKEG6'Q'\7?B3X.^&F@,8F1)L:SXTU?1=,)B>:W5D6[:9C.NR)L&JWPB_:/\
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MI'Q(Q.QL\'D8 P,9%>\:KHMIX@TN2TN83*TENAC92$7<"Q!1>,X;/S'!XYX
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M@<9KZ$3P)X6A<S#2H9"4"AYIYY]F"QR/,/!^;@=._7IO6FF6L$#PVT,5NC*
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M7-X([]0'9;F"ZM05*@B,>9#G?M*E3T*8(7'-7=-OM%OY8D34H(220YE62/\
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MI? X(R1GK]<\@=KXOE-KHVIWBYD\NSE5@K':?.)@7<J_,3\V<!ADBLZFL_\
M$[+Y)OY:"4DVDKW/D_QGJ_\ :M_=01R'[-:2R6\8.XK+.TK^8\3\O)PH4'8I
M/S= !GIO"O@ ,8K[40PM[B%98XR=[@9 W.GE_+R&XW9X_-_A'P_9WU[+J-VP
MD2V95@MFB'RR>:S*XW _O&<D,2""N, 'YJ](N-:5=1BTVV4>=)))%YD+!@KH
MJ E0!A55RRE.2-OWAR:_->/^/\%P7EE?%RC&KC+-8>G*"DW.*>_OIQ5[6E9W
M6J/K.&>%\3GN.I1A?V$9?[3[UHQA=6<?=:D[7;6EG;4[SPOHEA:FUAMQ';)N
MA)F\D+.R_)E0PE VD#C<$XZA>0/L[X>> X]::0V&I7-B[P1BVGCCDM_+DBA5
M9"TS2-&?,+$#:&W \$'"GXKT+2IKJ5$NKXKN98KB1CMC4& -*%!()926"X?!
MP !T(]-MK'4;*0-8^,+Z2:&.8"T2^N+:UE\AHS$D0BN05"@*[*S."Z9& <'^
M59_2(XXECI8I_4EA5)R^JTX)2JTTVXTVU+1J+A=M.[@]-=/U#$>'60K#JC[6
MI[92?_+I\M[M?%?O?6WF?H7::#K>C 36U]<AH+%BS"\GWO=VHB\O<A:,>6^6
M+!$<D-_%G ^/_CUX_P!>@EN5U6*"YFN7,4+PJ\8E8L1(&D$RF,.K*%<IEF4A
MPO&>H\#_ !R\2^'G6R\3S2:W9O.@8W;3S7%N);987=9S(V]8PBL5"C[N226)
M/D?Q:UBRU:/4KF,QW4-[:+/9((Y,*H>1BZ[F8K)RI+ C) XS7]*^&OC;@^.:
M.'P.,G1P>:2:@J4E&G[2U[QE-U=$N5.-X.[9^4<0\(XO)*U2I!*>&=[.,^9Q
M2=T[*&E[M;]#P*T\;QQ:[IUU<-<#3X+B""\CE5)$C?9Y;!$#LS;2<HY XR21
M7M";9U>>WS(DR"2(' !C8!HSM..61E+#'!)KXQ7495#Q.D8D!=C(RL9OEG4*
M2Q;;G!QG9TQTXKZ_TNX1M+TUB[(T>GV9RAQN)MHCER5;)(Y.,=<CCI^R2E&4
MI<M[)N+=K7<=&UW3>SV:U1\<XN6JLT^^FVGZ'"_$F_73=!C>:)V66;*%1A@R
M6LCKN<$;<LH!P3N!*_Q<_*%GH-_XCOGMK)C)<2,9G<LHVH54F,R-EF !Q& F
M%.\$KD%OI'XUW<KZ7I5K#)'Y4VH7*F)0VUX;>'Y)3@MA23SZN!C R#R_PVTJ
MSLH9->N9HO-<SQPP@@(S%5$@R5##8D8(RW!)/(XKP\ZQ]++<+4QE5J,:5.55
M-K2U-.3OJDF^6R3=V[*^IWX/#5,7B*5*G#G=6<8*-[-MM>3V6M^ECK?"/@.P
MT&.VAN+&"\OY%WLEQY$@5)%\PMODVHLN6.T%L>65YSP/I7PI9PM.FGI*XVR1
M"6* (C,?):-51TC4,1)AF 8CRPV6(.#\X6FL7FKZ@! #':[WCV>8&5T7.R5Y
M2 %4+@$$#Y@1D @5Z_IND6\MI$LGB&;3UC2.2%@=KR3.0&B#'EC"/F ZC!8D
MCK_&'&'TA.)IYEB*&1/#X;#4*]2FJE2G>5?V<^57CSW@H*+LVWS<^EK:_N66
M>'>6T,/3GF4IRJUJ,9*#BYQIWC=J+T6KDD[)6LKW/OOP]\/K'4S9S&6<IY!$
M00*&^TI;'Y'<$NN#@$XQCG)H\4:!K&F:->Q&]-JJ64T:3RLT\#%@3':EGF(Q
M@ ',88$G:.,CXULGDLB]UH/BN]:ZC@VQR07$T,R.05D9'60!7()&['4]^:]4
MT+XJ>)YM-&A>([Z2_M1%Y-I<7$C37<8 *NDDLIFCF+*22[Q&0$\.,5]'P'])
M#-'CZ.7\34:$\-64?]J4+QJ.Z2DXN:4+-VUD_AYEOIX>=>&N&6'G6RNM44HN
M4I4[.$%K*5HRLTTTE=I):O>Q\<>-M2O+&YAANIR+X7UV;F"-I!"5WX0,TASL
M*D?,BEAQR.AU_ >MS2W5SI<ETWV*X5)K6W=GF9;NWQ*6::1<I#*N(F4,S$(N
M5[U4^+D)N#&R1*TD%Y=.MV%P\MJX=@A<8W%"(\GH"HXKC/ .H"+7--MS+\LT
M_EHIC9_,>12I#," N=H 8\#J0:_L/ 9C0S?"4,QP]:%2CB(\U)4FI4W%I-N3
MC)J+2:Y4[MW:OH?D.-P]7"RG1KQY*D))2C>_5[.R^>A]!"",']W&9$)3_6NI
MD*OC:3AB"^#DC.-V>3BOF'XUR#^U8K.$RK*]C:/)$KKS())?-)&\C!^4@_>P
MK9&2 ?J80!/DFV1S$IE(\G9L'13D[B,8!YR1D*.*^0?'936O'T\<T,EKY4MO
M:%E/FEC TV_8H48W;E#1G)P2<X!QO5G&,))W^%RVZ+1G+1_B1\VHKU>QG_#;
MP$NKI;ZG>1*T-M/B$.?W3,^6,C#8=Y  V@C 8#US7U+X;M[3298@6C2U62+>
MK10AD0<EDZ,QD8!E &Q00&9",5R0ELO#FFQ6\$<=O#"D3(L@"&5U!R2@"8+;
MOF&,\#GK3]!AD\17$=U=S?9[8),(B&WL(Q(T<<448W;5F=20TA(9#A<=_P";
M?%GQAJ<)1_LS*(QJ9K-RC3<Z;4:4'%IU'/G^.G*2FJ?*I2M%)IM'ZUPGP?',
MZ4\7C96P]-IM*2D]+.RCRZII/9K<^X?AXVDZ^LL<E_=$RH#;+;6EL4PK8:*Z
ME9E:&*0#874L1R5R:^CX?",D]C%<VTLGV:9I_LUO9K;2O$\!8O [QSM<-"J*
M6)=22F H/ K\Z],TZ*$F"XU2YT^&*!G58&"K(/EP9&650>"3C(.3UK5B36-(
MNC=:)XINFC5LJB7$L;(@41!\1W#8=W4QR-M&Y#C /-?BF6?2)XZP%2&)Q=2&
M/HP:O2="5+DO*-ZJ;G+F<4I1Y=&^:Z>FOTV,X!R+%1DJ;E"44YQ?)RWDKI)O
M_MZ_R/=OC%:ZQ<6 C:&)L(VR=I&E9U*.-WR!2RG)3[ZL,@[3@ _"NJ7%]97<
M<4\'V:'I',SS*SR1!@YC0.[*,RIDA1D8)Z"OKFX\=ZIKVD/H^MK!>[6BECNW
M5C< D>9L*ARBQAERH9#AN23TKY'\6Q31:@]\Y_=,X5Y2FXQ LZA8T7;PX7YR
M0V-N> >?Z_\ #[Q-POB%@:=6$Z5'%QA_M%%VI*\8QG*5W-WF^9JW*G9(_*<^
MX<Q.2UU#DE.A**E"I%\Z5Y2CRMJ-DTHIM7>]STK0M8;6K* R,YN+:**&1G!8
M;8U\M9 XWDIL5>IW@\;.,5'XJE1?#FM%E,J_V?<;HBJ+YJE"&BW @@R*2@((
MP6'(KF/ MY%+%J=NMNJ,LL4J2J['?"(E+ HI!"EMQ<9R6+8QG%=%XI,0\.ZR
MTSI%&MA<,9) 61"J;D+ %20'"YPP/H1UK]$=-.+6C@TU=._NM=/D>)=J])T*
M?.J?-S75[<K;EM?FZV[]3X957F*);V\A;"QV\2D.JL)' MR=Q)6,.-Q()8@'
MYL9KZ-^&/@B*PB&HZG:))-<Q@SI<.TJJNXLGV9&11')G )) &.">E</X*TC2
M=0U-1,RA[21+AMB%(MR2XE9E.XE)5EC9!OR-IRQ[>NZ]XF&D*D&F1QSA0\7[
MQFC"G!"^6 5;.>C$D*<''%?G?'_'.#X#R3%9C7A"M5I0DL'AJD5*-:LZ<I13
MO*-O=7,G:7IK<]WAGAZMQ#CZ.%BOW,I)57S<K24DG=<K]V_5]3Z6\)^*-/TM
M;9YWM;=8V6%B%\XK$K*?F9OFWH0!E4)&X;21FOKWP[<:%JUBEY<W[PV,T@AF
MNIKSR4BPL;JJ# 9&<N,#:1AL$C.!^</@K2WO8EU#5)+F"3:EQ]D^U-+$B*0&
MFW -U<ID<DD@\=#Z#<1Z=-')!J&JW,BML8 S%]VULQHJNKJ&C^]RI &. >3_
M !S1\>>.*V*J8_Z]6H4,14E4I8*-2I[*C2E)^SC%*2BER]$M#]:Q' V14%]5
MG1]K4I)0E*=.SNDM$W>\5K9[-;6/OW6O#>G7-I>SZ')%<LJ Q+]LBF8)(A,X
MD".X+*"?)R>NW>5Y-?FQ\1-$NM"U2\NI+=(?WLB2@&(H)(97R\:H2^PASEBJ
MY(Y .,]O!>:GI4HN-&U6XG@\N,DPW3PD2HBD856V'YE^Z8R&.5P0<#3\?-!K
M^C"]N$8SVUJ!/.3"L5PT\D)E)9_G+J5!]^<^E?NGA/X[9EG^85,HXBIW5:2H
MT:[7M)4V[N,U>47%OV:U6W,_,^)XDX(PV!I?6\NES0C%S<7[MGI>*5GI%R:7
ME%:*]CPO12SW<%PI8.#&"T6 N)B5&_=M.U\%01N/R\XX-=I=0%B8N,^8X,1Q
MM4[B"Q;G)'4KG;R<$X%>9V%TL-PA658T60D%6!1@C%45MC'A NX#((+$]"*]
M$>X$L45T&#F6%"S8)1VVJY(&0V&8'(W$X)&<\U_4CJ0E#1W52"G%I73BWIKM
M?RU?4_-I-0?O:6DXO35-*[T[6ZGRM\:;4+XJB6S/F2RQ6MOMEG9H@'$43R)$
M%PH)X0@DYX*@8--T7PK?WEY!;16ZF"!UAF88C?.,G/R@'&>6R?8D\#?\8V]M
M??$JWBE506MXI8U$+E5?;$=H#,P558[AR2#@DGFO9].MK73]-:\DD0S@^9(5
MVAFC3ABQ4$\+W)Z'VKP<UQU/+<%BL7B:L:>'P=&>(K.Z<U3C=R<87BYRT=HJ
M2;[F^7X6OF&,IX6DHR]JTJ:E)1N^O,VGRZ]7>Z.T\.PZ/X2LWFCS9A%C1Y$:
M-U669U,2&0Q(V2VT-L5A@XSR37NW@WQ[I<=_:VF+^]NG6*=H8+<S23W+';%%
M!MV E@6:%9&5=JREBF &^,QJ$OB:X@33'<VLDA$=M()5MT2W&#<2EHP/-VEN
M3@%MH55Z5]%Z!9:)X3TJX>1XVU6\M85>^BW)=BWW#?%"[M*8MQ<[I%6.0C:$
M90&%?PCQ/X^\99[GDZ618ZME.44?>HT<-.I3<G%.5G2A/W;V2W>Y^]X?@')<
MNP%%8ZA#$XNI=5.:*G%62U<W'INM-6DC]#5\;_#;1(X;'Q-XLT"QU&XCWOI\
M]U-?:A DT*&2*ZCTN"_CAEBD9D>(REH\;2-ZLHY'Q,O@S6;._O\ 1O$&D:C!
M(DTD-G;S223/$J[B[+>V]M-LVJS?NUD;:K94=3\/V</A?4)9C9Z//"#*GGZ@
MLNQP7F=),R*L1^?:6D9AODE9Y'9V9B>OM+8V(46MY)=VI4JT=Q(S/& "$C8A
MY(YEWD<*B^_K7VG GTB>+,/FN#R[.82Q.!JU*6'J8NKSSG!SE"FG:33M+F;D
M^96Y4W='@9KP#E%7#5Z^&?LJ]*,ITH**A%.TF[/_ +=CT^X\VUU FJW\14QQ
MSS7"P$JJ':UU)(I!7+;(TE7:#TRW!&"=358([:TA1KA9YE1$W.#N8;%Y 5-H
MX^4<CIVYJ+Q= 4$$PC+2,UT)95CC4IE8VA4,@Y4;&"[ERH!ZYXPM-O3(C0W4
MZ[C'\IEC9BI9?NHV\ 8/ R#CCGU_MC 9I',,-1QE&<:E.K"C5<J;4E^]5.=E
M9N[7.TU?1II[,_&\3A:N$K2H5&W)2FHRO>ZC*5KNRM9:?<?OY^Q1_P FT_#K
MWG\;_P#JQO%8_I7U8.K?7^@KY2_8G)/[-'PYZ-_I'C@;E!"\?$?Q9ZYY/U[&
MO2?CS\2?&7PG^$7Q%^(?@#X2^)OCEXS\(>%[W6O"_P )?"%_IND>(OB'KD22
M"P\+Z3JVLL-+TR:]E11<:C=K<)I]L6N19WC!8&_9< [X2@U_(?+5OXU;_$[>
MG-*WX'LM%?RX?'[_ (+/?\%0_P!@O0?AM^T)_P %!O\ @F+\,/A?^R-XS\;^
M&O!_CK7?A+^T]HWQ-^+WP1?Q=/<0Z6?%GAZTTW^Q?%6JV\-M<7,EGX8>/1+R
M:&+1Y/$VDZM?6MN?Z>-(U>WUJUM=0L)8;O3;ZRMK^ROH"_EW5M>0Q7%I/&I4
M@175M*ES"&D\P020,RAY'2'L,S7HK\Y_V_/^"B'A']BG3?"?@;PUX \7?M!_
MM:_&W3_$$7[+W[*GP[T?Q%>>,OC9X@\-FR77WF\0Z7X?UO0? '@CP=%JNG:U
MXZ\<>+9;+3M"\._;;NRAUG4X;;2+ODO^"0W[?OB[_@I5^P;\,_VOO&'P^\-?
M#+Q!X^\1?$S1)O!OA?6-2U_1;%/ WQ$U[P78R0:IJD5I=7$M]:Z3%<W:[3B[
M,XLDN(C$@ /U%HK\4OVHOVNO^"P>@?%_XM>%_P!CS_@FE\,OB5\'/A/::3_9
M/Q5^-?[2?AKX?Z[\<]8N?#VB:UK6D_"[X=:3+>7VC1Z/>ZQ-H-CK'C?6M/TK
MQ!?:-J!M[BRFS96_MG_!);_@I/I__!4/]D6Q_:3'PLNO@MXJTCX@>._A3\2_
MAC=^)&\60^$?'/@22PN9H;#Q/-H/A:?5M.UOPYK6@^(8&F\.Z?-I,FHW&B3G
M4&TX:M? 'Z@T5ER:BL$;3W#QP01I))+*ZLL<44!F:XEEE=TA6**&(REO,+LB
M2N(ML9!([]G=8F:!)29$95$LH66*1MZ<!&!$(CD*S+ 0)HW4LI( !J45^"W_
M  6Y_P""MGQQ_P""8=E^ROIOP"_9P\._M'^._P!I;QYX]\):=X8U;Q#KNFWT
M:^"-"\/ZM%9>'M*T&RDO]<\0>()?$4-OI]G#(^)K2.RBM[N[UK35K])?V$/V
MM]%_;B_8\_9W_:R\-Z5:Z+8?''X::+XOU#PW9ZC_ &Q'X2\5 #2O&?@X:H\5
MDVIR>%O&-EKOAF2]:RLGEN=++O:Q[\  ^Q**_F,_X*0?\'!FM?L@?\% /A3^
MQ/\ !'X(^%/C/IT?Q,_9V^%7[2WQ)UWQ%K.CVOPM\??M+:]?7/@3X>:-9Z;"
MZW?BJ/X8^']<\?75W<-J&FRB\TS28XH[O3-;6/\ IOAD$L:N&#$@AMH PZDJ
MZ%0[[61PR.F]BCJRDY!H _F$_P""CAFF_:S^-$$ #2QV_@<HN-V0WPJ\&EAC
MT.1D'KVS7Y1Z5<*EYYUPA+P195]O$1/7&1P#C!'' 'H*_6'_ (*'('_; ^-"
MEVC\R/P!\T1Q(67X5>#"N"> O!W =1C@D5^3UFC07%S'+Y>Y#/$S2-A7$2$%
MF '?.<=<BOYOXO<WB<^2E)/V^:)6=FGS8E*W:SV/O,F?+'"2W2C0>OE[-_/;
MJ0:5JKW>LW$EX4EC$[*WG+RH,LGE,SC[\>%4LI)&%48Q@5ZE#XN;3]T%A?6B
M7,XVRSPQI+R  N-ZG"J,+[;0,\5\QW.K-I6ISK+<$?.1'&C (R*SLI;/S9/F
M YQ]TCKBG6_BVVANY)6&^1R"$7)5. !STY&&)'&2<U_GGG63+,,PQF)J1E5K
M5<17YE)\T4J<^5--WE=Z7NWNS^KX3C/ 8.G"T%1PU!I027,ZD')RE9+5-V5N
MC[GU;I7C#5GN"TM^\P)R[2&-9"!D_*$ RV0!GJIP>U>@:;XC?58HHI&61Q-.
MP?: Y6;8H#'&79O(P[-UVIGH*^1K#Q$&S=%PJ[0PVR!>6C9P,G@EMNP?[3 5
MW_A?Q,+55F<OY&_[++.6^:%FWLVU>W$BX8D9*G!P#7Q6.X=]BG..'5UJMXM2
M_F3C9]MGV,<-4E[1M.SORM[WBK:--.ZW^\^B[[4GDMI[1[A@%0,MNZDQL5.-
M[,PPK #:-N/E _#XK\2(8M3N#YQS(TQVJ9"1F<E2%? ^[T.,[<CIFOI-]96:
M5($F6Z8A7)E=5S;[0<D=<AB5YZX)SSBOG7Q2B'6+@M&HDA.UBA)!4R;3QVYP
M<>^,>G]>_1PQ6(ED6:8+$JKRX:M25)RE4E_$:5FZCDE&-O=<;.VY^.^)U"E2
MS##RITX0E5C&4W&*C>4M9.R26K9[=\$L+HNJR.\^T:E&$8 F,9P#E0<<G@\#
M(X-=WXY+#PKJLD;LCL(4(4X9_P#34 (4'[V#\HXP<5Q'P.6:?1=:&T+:_P!J
MM&&9\,&BVL2JX)9",?,,@'.:]"\468DT75(HXTD<1/-AW.&%HXNI64#KA(V
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MOCG]GAF979&66/XX^ 73+QJ^V5613&Y4JLBHQ*J-P^*/^"GW_!-KX4_L?_\
M!-GQ5_P4G^$_Q*_:.@_X**_L[>#OA1\4M$_;3\1?'/XA^+/BEXJUO6/&/@O0
M_$.@>+-(USQ(_@)OAKKFE>(KVRL_AIHG@NS\(:/ ^FZ4=.O?#]MJFG7O[I?\
M%A?V!?%O_!2[]@GXK?L@>!_'_AWX9>)/B#X@^&NMV/C#Q5INIZOH=B/ WQ!\
M.^,;R"]L=(9;^4WUGHTUG:F$@1W4L$LH\M'!Z?\ X**?L1^*/VU_^"<7QD_8
MB\,>.-!\$>*?B;\-_ G@>P\<:[I^HZAX?TR[\)>*?!GB"YOKS3M/9=1GM[N'
MPO/;P1PL)8Y+J)I,HC@@'X]?\%H=4N/$W[<?_!MKK>HP0&?7OVUI]1U"")6D
MM1/K%M\"[Z2!4E4$P[)YU1)%($)="64DMPW[(G[4VG?\$@_VE?\ @L#^Q%\7
M[1_#7[+G[.7@/Q1_P4E_8D\#QE=+8? OXC7FI:U\2?@_\*(KUI;2X\,Z7\7/
M$&E>#/!6B0I)#IWC1_&L]V9[>^=+7]6?VU/^":/C#]J;XX?\$K/BUH/Q,\->
M$K3_ ()[?&ZS^*GB[2M5TC5;ZZ^(NG6^F^!;632_#TUI(D&F7QN/!4;1SZFK
M0""Z"GYHR&\\_P""L'_!&SP[_P %-_BE^Q]X]U#QKI7@?3?@AX^N--^/&GFU
M\10:K\=?V:-?\0^&/%'C#X(7FJ^'M6TYC8:MJGA.T-A%JR3:?I$NL:]JNG?9
M-2O7>0 _F,_:@^"%_IW[!/\ P31_;J^*6AV]K^U%_P %//\ @MS^R[^U[\;=
M6CMGACL?"OC'3?C?>_ 3X9^&C<J-1C^'OP_^%.KZ7=>%['5)+B_M[WQ=XAGN
M+AUO(HXO]#1?NCZ"OR(_X*A_\$S=9_;O^'O[&7P_^&7C7P9\']*_95_;+^"'
M[2KV5]X=NY=)U'P9\(- \5:#'X#\-Z=H(M[;1[N:UUS3[;2F,$6D:?8:;'9K
M;I'%"#^NX 4 #H!CL/Y8% '\Q7_!0P ?MC?%U@VXE? 9\OCJ/A9X*49XSR"3
MW_ 5^8WB'2H+&[>Y^SGRYQ.V"Q(CD<,K1'@9+C&T]0>@K]-O^"B+QC]L'XO*
M<[A_P@&1NF'_ #2[P5C.V14Z$=!W.<GFO@'6H'OX_*R&C7C!!'?MD!B1C(X;
MGKW-?@F>T:=3,LV52DIP>-QRE'E;YHNM5YDDM[JZ\[GV.7SE"A1:>L:5-Q3=
MDVHII._2Z1\A>-]$E:Y&J0(!%/"IEB ):%H0D2IG! )4 L>"Q.3GI7CU^NH0
M21/$TZ)N)?:N1CV)7TZ_7N!7V-K5@;&2:.\7-K(RM', 0TC*W DXR),L S!?
M+ VY8<XX:[\-64UPL]O"K!I 2DL@\L-)@G!!Q@MDD@[!G[P/%?R]Q9X=X_"9
MA5QF4866*PN*E.I&A2<H*ASOF:?+&?*VXZP;NV[]-/VWA[C;"5<%"AF4YT:]
M&$8.7,HN:@N6.K<;Q2=EITZG@-EJ%X\0A>XD,3;05 +$!,HI 7G<,Y!'1@&/
M ->Y>%;J95CCW32B1&=A*01(Z !6(48!4$@%\<GY<X;&I8>$-.BN'F,:@2G!
MV(J,Q)PH5I 8Q\Q&[.>"<8XQUUA:Z?99F@B<LJ AI60* ?,4?+&H5LLC A\8
M"C& 23\52X XKSFK##QRCZEAW5Y*E6I2G*=]&W[65-6A9JT;I)IOJSW9<7Y#
MA:56NL1*K-0?+2512DY:V<8J3;;>BTUL=!;9MK)KR5=I!&YBRF3&-NS>HV[,
M=  ,'CKDUP<L<VK7Y$<?G7%]*L:0QG=(^XE\* O3*@G'X#TU9Y=0UF>*RBQ,
M5W;+6WC!3&6<F58]Y!^8GAB"",X;BO4_!G@XZ<T>I74$2ZA&N+6"1^8#MVO*
M0"58,I8 !B01DJ.,_P!+<$<'T>$,K6$HMO$5HTIXR:6DZD81YDI6]Y1GS<NV
MA^+\29]7S['_ %JK)1H0]RA2NN:,$VH.I#>,U'EYN;5.]^IZ+X/\-IX;T:UL
M67%R\8O+DE2KK/<+NDC.>P*XQCCGUK>N84EM[@LD;?)(J@L3M&&# (,<MT9?
MX@2#US3X'%PR%W='B"Q)$H4 *G1@3U#DY SD8Y SS)=LQ22/)^XRDG!(RIY^
M7.< _P .[VR>GV;BV[N+;76SN>%S1VO'[U_F?.VJ6L]O>2PL)%MXYV\IBNT*
MC%V*@XR1D^O0<&O%O&?AC]_=:C;QRS_:%;S&B42%2-^55 "P.,,2, [N ,8'
MUE>Z*]Z)XIHB6<.8'8J1P,!\ L1]X<, <'&#7F>L:-?:0(X[FRDDCD#()TBD
MD3[S97,:M@@$$A@, C'6OA^,N#<+Q/@ZD8.5#'8=*I2FTXQ;DFU[-WUGI[UD
MVG:Y]/P[Q+4R+%4ZD7.4)/EJJ+O&4$U:,]TXI7LG:R9\077AS55NEG2SN)(&
M8-M\EE< G=AOE!##NIY##:W2NITVUO"8/-6Z5HX(@=Z8*HP#,,XZ;@H QP#C
M-?2L6@V-S,K)F-U F=9F"( N'+QJ_P WG#DHKIC> &7&:G70])M9A(K,SC+.
M[O:!.>2,&,8Y]MI['IC\"K>'_&U-5,+2RVA.47+V>+J5G4C)<TE&4TZ=I-Q2
M;A?24K;Q/U"EQSDE>,IU*E2D]9./,HW;=VHKF5U=NUNECG_">GWK-$R6LL2@
MJ=S9 :,H,%0% "\,<C()SDFO8TO+?0]-D :-KZ=6"X<M)&7&T,JDCD;L@8P,
M5CVMW:Q!7CP70(JJ&B.< E2/+VJ02&&>O'-:5MH&M>(Y5>WL2(E\LRWEQ"EK
M''%(24=?W8:7 '&TLQXR#FOT#P^\*WE^)CG'$#A5QE&4*E&@DI1A44I-R4/=
MY;:6=CXOB?CJMC,+/ X!)4)N49N;2E.+2MRW3<K:MVU1G>$_#]]XDU5;8LXC
MA+7%U>2Y56BCE5W0X7&Z4?NP20 !@5]2K9QQ!1&J%458TC!R%2-5C1<^RJO.
M,>O)Q6%X7T2V\.6,,,0\^<INN+C/,TI))(5MH$8R< @'(Z8KL83F-"!MWER
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M_"NRI^8,<$$8/J3112I\$9!2;<*6+C=W:6-J6OHMO8]DD-YQCGO.GV_A1_\
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M> _3'XYIB?\ !-'X[*S$^+/A*5/(']N^,<[B<D_\B'C\N?6BBJ_U>RW^2O\
M^%$__D _M+%=Z?\ X+C_ /)$X_X)K?'09_XJOX3<@C_D.^,/_F$JO_P[/^.A
M;+>*_A*5]/[=\89SCW\!XHHJ7PWE;=W#$?\ A3/_ .5D2QV(D[MPO_U[716[
MDA_X)H_'/!V^*OA)G'&==\88_'_BA*A_X=G?'4K\WBSX2;P<KMUWQ@%Y/S;O
M^*"SGA<8]^_-%%5_J[EBVA77IB)__*QK'XE.ZE"_G!/]23_AVA\<Y'WS>+?A
M.6 4+MU[QA@8 !Z^ N,X[?7K37_X)G?'%B2/%7PE!;[Q&N^,!G&/^I#/I_A1
M137#V6II\E>ZV_VB?_RL)9AB9;NGU_Y=KKO]KR*Z_P#!,KX[1R,T7BSX2 'H
M#KWC+(ZYX'@+'Y?3I1_P[/\ C\)'*^+/@[L9XV7.N>,]P5%(.<> L;CN..H^
ME%%:QR3 1ES*-:[_ .G\NGER LPQ*5E*%O\ KVG_ .W'ZM?LX_#+7OA!\&_!
M_P //$MWI%]K7A^3Q(][=:'<7ESI<HUCQ9KFNVWV6>_L-,NW,=IJ<$<_FV4(
M6Y29(S+$J32>X*"!@^O^%%%>G"$:<(PC?EBK*[N[>;ZG')N4I3?Q2=W;17;;
>T73<=1115B"BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &R S0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\?^$'_ "4/XG?]A4?^
MC;B@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;BO8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Y?QUX&TWQYH?]G7S-#+&WF6]S& 6B?&.G<'
MN.^!Z UYIX=_9TMK'6([K6M8%[:0N&6VBAV>;CD!B2<#U _,5[G10 @ 4
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MGP%XM^'@6V\,>$;U"X5F6(6LJ&0@99F9D +8'4FO0:* "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYF!;6H<QR =V<=1Z 'G@^U=S_P *!\#?\\+[_P "C_A0!Z!_;VC_ /06L?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M7K_A[2?$VF-I^M64=W:YW[7R-K8(W CD'!/(]:U*\R^.=Q;6_@BT-\^HBR?4
M8TN%L) CNACDR"2"-O3J#D@?6@#R[Q7_ &9\-KYV\!>/+K[3YGS:6A^T(#G!
MRP^3CIA@6XKVOX8Z_P"(O$?A,WWB6P^QW@G9(QY#1>;$%4A]K>I+#(P.*M>&
M/A]X4\+)'+H^E0";&1=2?O93GN'.<?A@5U- !1110 4444 %%%% !7C_ ,(/
M^2A_$[_L*C_T;<5[!7C_ ,(/^2A_$[_L*C_T;<4 >P4444 %%%% !1110 44
M44 %%%% !1110 5X_P#"C_DIWQ*_[" _]&35[!7C_P */^2G?$K_ +" _P#1
MDU 'L%%%% !1110 4444 >>>!_\ D?\ QC_UW'_H3UZ'7GG@?_D?_&/_ %W'
M_H3UZ'6&&^#YO\V>KG/^]?\ ;L/_ $B(4445N>4%%%% !1110 4444 %%%%
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M !1110 4444 %>/_  @_Y*'\3O\ L*C_ -&W%>P5X_\ "#_DH?Q._P"PJ/\
MT;<4 >P4444 %%%% !1110 4444 %%%% !1110 5X_\ "C_DIWQ*_P"P@/\
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M/_0FZI_X]_\ $4?6:7?\'_D']B8W^5?^!1_^2/0Z*\\_X67J/_0FZI_X]_\
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M<D]/QK3HK.GAZ=-WBCLQN;8O&P4*\KI.^R7Y!1116QYH4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH \_P#C;_R2'7?^W?\ ]*(ZI_ 7_DE=G_U\3?\
MH9JY\;?^20Z[_P!N_P#Z41U3^ O_ "2NS_Z^)O\ T,T >CW-M!>6LMM<Q)-!
M,ACDCD7<KJ1@@@]017BVF_!^ZA\2VVM7>C:3);SWTL=SI!<F"WMND<D9_B<8
M)P1@[\87G'MU%    , 8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \9>++'P5X;GUF
M^5Y$0A(XDX:5ST4>G<Y[ &M^N+^*/A&[\8^#S9Z=(JZA:W"7EJ'. SJ"-I)X
MY#'&>,XS0!S>B_$'QU?Z]J>F7_ABTLKE=#DU.PM"Q:61@X1 YW8 )W C"GCM
M79^!?&%OXW\,1:M#"UO*':&X@8Y,4JXRN?H01[$5Y*WB;XA?\+ _MP?#V]&H
MG2/[+"X<P;_-\SS=^W&.VW=_P*O2_A?X4OO"7A$VVJ2*^I7ES)>7>ULA9'P,
M9'!X49QQG- ':4444 %%%% !1110 5X_\(/^2A_$[_L*C_T;<5[!7C_P@_Y*
M'\3O^PJ/_1MQ0![!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >/
M_M'?\D\T_P#["L?_ **EKV"O'_VCO^2>:?\ ]A6/_P!%2U[!0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'G_QM_Y)#KO_ &[_ /I1'5/X"_\
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M +"H_P#1MQ0![!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >/\
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MS7%ZCK&G2?LZM=)<0) ^AK;J%<$+)Y83R_J&^7'M7>V6B66GZKJ.I6Z2"YU
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MM=>/_"__ )*U\1O^OM?_ $.2O8* "BBB@ HHHH **** "BBB@ HHHH ****
M//\ XV_\DAUW_MW_ /2B.J?P%_Y)79_]?$W_ *&:N?&W_DD.N_\ ;O\ ^E$=
M4_@+_P DKL_^OB;_ -#- 'IE%%% !1110 4444 %%%% !1110 4444 %%%%
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M?:W+_?F@MD1V^K 9-:- 'C__  J#QA_T5G7/RF_^/UR7Q%\+^,/ 'AR+5_\
MA9.N7_F7*V_E>;-%C*L<Y\UO[O3'>OHVO(_VBO\ DG-K_P!A.+_T7)0!ZS"2
M8(R3DE1DGZ4^HX/^/>+_ '!_*I* "BBB@ HHHH **** "BBN:UWQ_P"%O#.H
M"PUG5XK2Z*"01M&Y.TY / ([&@#$^-O_ "2'7?\ MW_]*(ZI_ 7_ ))79_\
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M )(H_P"$A^.?_0F:'_W^7_Y(KV"B@#Q__A(?CG_T)FA_]_E_^2*/^$A^.?\
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M >/_ /"0_'/_ *$S0_\ O\O_ ,D4?\)#\<_^A,T/_O\ +_\ )%>P44 >/_\
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M]_E_^2*/^$A^.?\ T)FA_P#?Y?\ Y(KV"B@#Q_\ X2'XY_\ 0F:'_P!_E_\
MDBKG@'Q]XOUGX@ZCX6\5:9IMC/961N'2U#%@V8]H+>8RD%9,\>U>J5P>E>"M
M2L?C+KGC"6>T.GW]DMO%&KMYH8"$98;<8_=MT)ZC\ #O**** "BBB@ HHHH
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MX1MIH1!=6\:F5U"_)O&\D?*/0'&3AB* /J2BD!# $$$'D$4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROQ!\$V_CSPN^
ME2S&WF203V\V,A) "!D=P0Q!^N>U<CX>^&?BB?Q;IVN^./$%OJ?]E BQA@7C
M/9F)5>0>>Y) R>*]8HH **** "BBB@ HHHH **** "BBB@ HHHH XCXH>&?$
M7B[PPNCZ!>VEHLLH-VUQ(R[XP.$&U6ZG!/3I[FN3\/\ @WXO:''I]C%XFT&+
M2K9D4V\4*C]V#\P!^SYR1GG.23G->QT4 %%%% !1110 4444 %%%% !1110
M4444 8GB7PAH7B^U@MM=L?M<,#F2-?->/:V,9RC#M7FFH? 72I/'6G7=A96D
M7AF.';>6;W4YEDD^?E3R<<Q_Q#H>/7V:B@!J(L:*BC"J  /:G444 %%%% !1
M110 4444 %%%% !1110!B>+?#5KXO\,7NB7CM''<*-LBC)C<'*L!WP0.._2O
M+K+X/^*]0FTK3?%?B6VO/#FDNIMK2%#N=5X"ME1@8 '); R!BO;** "BBB@
MHHHH **** "BBB@ HHHH **** .>\;>%(/&GA2[T2>=K?SMK1S*-WENIR#CN
M.,$>A/3K7F(^$7C76X]/T?Q5XKMKGP[8.K10VZGS&"C !)0<[21DEL9->WT4
M (JA5"J % P .U+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWJ?AO3]1U"W2VN;F!9I(5)(CW#('/< C/OFN?^(7CK_A#O"7]MV$5OJ!^TI
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMXSCSFQ@N[  9 )Q]3P.M>VZ/I5OHFD6NEVAD-M:QB*+S'W,%'09]AQ^%7:
M/&?C$ES:?"SP_P"&TC$NHW<]M:+$ASN9$YQZ_-M'XUZSH^G)I&AV&F1G*6=M
M';J?4(H4?RJIJ'AC3-4\0:;K=Y$\MWIH?[+ESL0MP6V]">G7T%;% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (5 3<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSA@#CGK7G\NOZV?!=YXX74Y4C@GEFCTWRH_):VCE*;"=N_<RKNW;N"1QC(H
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MW6#]:^>/ ?P@O_'F@2:M:ZK;6L:7#0&.6-F)(53GC_>KJ/\ AFO6/^A@L?\
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MW4M3\8P:]J-DMC#96<EM;PF59)'>1E+N2O 4! !SDY.<5XQ_PS7K'_0P6/\
MWY>C_AFO6/\ H8+'_OR] 'MMEIE]9^,?$>K& /!=6EHEN X!D>,2[A[??7D^
MM8WAZSUN/5VUG7M!N;C6)SY?G+<0F&SB)^Y$N_('<G&YC^ KRO\ X9KUC_H8
M+'_OR]'_  S7K'_0P6/_ 'Y>@#T<>$=9@\#3^!(;.$V+N\,6H^> %MFDWDLF
M-WF $C'0D [AFO2$4(BJ"2 ,9)R:^</^&:]8_P"A@L?^_+T?\,UZQ_T,%C_W
MY>@ ^./_ "63P[_UZ6W_ *425](5\=>(? ]SX!\?:-I5U>173RF"Y#Q*5 !E
M*XY_W/UK[%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /'_ (0?\E#^)W_85'_HVXKV"O'_ (0?\E#^)W_85'_HVXKV"@ HHHH
M*XWXKHTGPNU]$4LQMQ@*,D_.M3>+_B+H'@BXM8-9DN$>Y1GC\J(OP" <_G7-
M_P#"_O W_/>^_P# 4_XT 5OV>8I(?AW=++&Z-_:4APRD'_5QUZS7E_\ PO[P
M-_SWOO\ P%/^-'_"_O W_/>^_P# 4_XT >H45R7A'XC^'_&]U<VVC27#R6Z"
M23S82@P3CBNMH **** "BBB@ HHHH **** /G3XVV\\OQA\//'#(Z"UMLLJD
M@?Z1)7T7110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >/_  @_Y*'\3O\ L*C_ -&W%>P5X_\ "#_DH?Q._P"PJ/\ T;<5[!0
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MGIZ$?6O0? _A&W\$^%;;1;>9IRA:269EV^9(QR3CL.@ ] * .CHHHH ****
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ML_X_?\DOG_Z^X?YFM#X)?\DAT+_MX_\ 2B2@#T"BBB@ HHHH **** "BBB@
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M %%%% !1110!8L/^0A;?]=5_F*]WKPBP_P"0A;?]=5_F*]WH **** ,S6?\
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M5?YBO=Z "BBB@#,UG_5Q?4UCUL:S_JXOJ:QZ "BBB@ HHHH **** "MK1_\
MCU?_ '_Z"L6MK1_^/5_]_P#H* -&BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH \?^$'_ "4/XG?]A4?^C;BO8*\?^$'_ "4/XG?]A4?^C;BO8* /
M#-6_Y#-]_P!?$G_H1JG5S5O^0S??]?$G_H1JG0 4444 %%%% !1110!8L/\
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M'/X1@9ZC<V,9KVNO%OB8TWA#XL>'?'LUI/<:3# ;6Y,*Y,;$2+].1)QGJ5-
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MD:1/-# 3'"G9C'[M>H/4_AW?_#./@_\ Z"6N?]_X?_C5 &!16_\ \,X^#_\
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M 'I-%<5_PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5 ':UM:/\
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M110 4444 %%%% !1110 5Q7Q*\2>&/#FBV\OBC2?[3MYY"D4/V=)?GQG/SD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M\&S>(O OB+3_ !1H<&H7.EM?V+EX&N+:5HID5\ .%=2-RY4XR"1S0!V=%%%
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M,_LJ^_Z"L_\ WXC_ /B:/[*OO^@K/_WXC_\ B: -.BLS^RK[_H*S_P#?B/\
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MX^4>U6_[*OO^@K/_ -^(_P#XF@#3HK,_LJ^_Z"L__?B/_P")H_LJ^_Z"L_\
MWXC_ /B: '^)?^0/)_O)_P"ABM"N?\0:7>)I4A.J3,-R\>3'_>'M5W^RK[_H
M*S_]^(__ (F@#3HK,_LJ^_Z"L_\ WXC_ /B:/[*OO^@K/_WXC_\ B: -.J=W
M_P A2S^K_P#H-0?V5??]!6?_ +\1_P#Q-5KO2KW^T;4?VI-DE\'R(^./I0!N
M45F?V5??]!6?_OQ'_P#$T?V5??\ 05G_ ._$?_Q- &G169_95]_T%9_^_$?_
M ,31_95]_P!!6?\ [\1__$T 6H?^0M<?]<H_YO5FL[3+>6WU&X\ZXDN&\N/Y
MF15QR_H!6C0 5\W_ /!4K5OA]HO[*-S-\1M<\4>'])&K68L)]!N9(;J74"Y^
MSQ-ATC>)FSO6=UA*@[F7 (^D*X_XWW<D7PRU2"TDU4:E?6[P:?%I-W:6VI7$
MY4LJ6KW1$ FPI*[_ )>"3P* ///^"<^H?VK^Q]X2N ?";&07)/\ PC>KS:KI
MV?M$GW9Y7D8O_?42.J/O5795!/N=>'_L)S^*[;X6:MI/C33?$^GZUI6NWH!\
M0ZUI^J:E=6TLS30/,UE(\4;>5(J^6 @ 087')]PH :3S7A.J?\%,_@'H6K7E
MA=_%+PO;WFGW$MI<1-,VZ*6)VCD0_+U5U8'W!KW9A@'Z5^;_ ,-KF1?#$X#,
M -9UCC/_ %%;NO'S;,G@Z<9J-[NQQXS%.A'F2N?4G_#TK]GS_HJWA3_O^W_Q
M-'_#TK]GS_HJWA3_ +_O_P#$U\MV/Q:T/4_B3?>#[?6[>?Q1I=A'JEYIT;DS
M6MM(^R.1^P#," ,YXSC%6=&^(.G^(O$VMZ/9:@+C4?#<D$6I0H3FT>:(31JQ
MZ9,9#8[ C/6O"_UJJ?\ /O\ '_@'G_VO+^3\3Z7?_@JC^SO'<1Q-\6O"0DF#
M%%,[9?;C.!M[9'YU)_P])_9[/7XK^%/^_P __P 37R+XRNI#\=OA]^\?_CUU
MKO\ ],;:MKXB?$_1_A+X*U+Q)XEUBWT70='A,][>W4A6*W0=R>OL .23Q3_U
MJGI:GOY^=NP?VM+2T/Q/J ?\%2?V>Q_S5;PI_P!_W_\ B:#_ ,%1_P!GQO\
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MJFG7$=YI^I6\=U:W$1RD\3J&1U/<%2"/K7YX>+KR3_A#]9_>2?\ (/N?XO\
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MN;]E?_DV/X;_ /8KZ9_Z215\.^+;:3_A#]9_=O\ \@^Y_A/_ #Q>ON+]E?\
MY-C^&_\ V*^F?^DD5?(\6;T_G^A]5PSM/Y?J=]1117QY]4%%%% 'S;^T[!Y_
M[0]G[>&__;HUTW[)T7E>(?%"_P#3"R/ZW%8O[0=O]H_:+M_;PT/_ $K-=)^S
M-#Y'BOQ,/^G6Q/ZW%?R'@*G_ !OG$0_Z<+_TB!]9*K_P@QA_>?YGL5%%%?UX
M?)A1110 4444 9OBLD>'[K:%+;> 3@$Y%'G:O_S[:=_X%/\ _&Z=XF_Y %S_
M +H_F*T* ,WSM7_Y]M._\"G_ /C=0WL.H:A;M#/8:7/"_#))<,RM]08ZV**
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M;;3_ /CX;.;E^N!_L5O52T;[UY_U\M_(4 1>=J__ #[:=_X%/_\ &Z/.U?\
MY]M._P# I_\ XW6E10!F^=J__/MIW_@4_P#\;KX__P""XFOZWJ/[)WA?X>^&
M_"L?CGQ!\6/'6B>'X_#K7RV*ZQ;03_VG>6[7# K#');6$T;2,, 2]"2 ?M*H
MGMXW*LR*S1\J2.5.,<>G% '\_P#J7A+7OB;^S-8?"?Q-#XS^'.K? +P[\8S<
M>'?#WB&XA6PN;(:7JNB0R7%N56ZB@2^B\LC"N8%XQN4[7B[Q'\,_A9J?[1,W
MB[2;W6/&/Q,U;X?7>K?VUXLUK1='CL-2T2PFDU34)[,F068U+[0K"(;C(8XO
ME3@?N[80V]_:QW7V>)7NHP[_ "@D[E&03CG@ ?@*=)H]K<!O,M;=]RJC;H@=
MRJ<J#QT!Y [4 ?SW_LY?$2\^.WQ]_8[T/XB^.I-.O=,\,>$M1TZ_\1>(M5L9
M#)!K6LJ;"W@1?)NI-0\BPMV>\>-U%NF!)DBL7P7XS\3^,_A=JB^'_&/Q53Q-
MX@T70$^.\W]IW\5SHWC&;QWI\$:(7.+6Z%LUZ@2W"J($C)7&"?VG^,7_  2_
M^&_QN_:6M_B=K%WXQ@OC-I-UJ>AV6M/!H?B"XTJ=Y]-FO+8#]X]O*Y9<,JDA
M=P;%?0J:9;KYF+>']\XDDP@^=QC#'U/ Y]A0!^%OB+2-1\$Z/XO^&:_%#6?A
M_P""O"%I\4/#FEZQXDU749M/L;*V\6>'?LMO?7$;&X\AUEEMC.&,B17$A#<&
ML74M O/VJ(-%\4VL/Q$^&ECH>B_".R\/Z)HGC758K?28=7\07^F7LL4C'?,)
M;/<(Y9,ND,J'FOWEU>WM[?3YF>UAF63Y70H,.'8!L\<YXSZXJR-/A4?ZF+^'
M^ ?P_=_+MZ4 ?'W_  1<M]:\,?LA:YX7#W5YIG@?XB^+O#.C_P!J:G/<W-OI
MUGK=W#;0F616>0)&H568D[5%?6_G:O\ \^VG?^!3_P#QNKT,*6X(550$EB ,
M9)Y)J2@#-\[5_P#GVT[_ ,"G_P#C=5KJ?5?[0M?]&T_J^/\ 27]/^N=;=4[O
M_D*6?U?_ -!H A\[5_\ GVT[_P "G_\ C='G:O\ \^VG?^!3_P#QNM*B@#-\
M[5_^?;3O_ I__C='G:O_ ,^VG?\ @4__ ,;K2HH S]+DN'U"X^T1PQOY<?$4
MA<8R_<@5H56A_P"0M<?]<H_YO5F@ KQ?]OOP#X;^('[+/B:/Q1=:?I^G:7$N
MH)?7]U<6MI92QGY9)I;=TE2+YB'93\J,S8.*]HKRG]LOXBZ'\.?V>M=FU[Q?
MHO@>VU-!IL6KZH\*06TDF>\R/%OV!RN]&7(&010!3_8:\'P^!_V;]*LK75/#
M&K6KW=[<PGP]J4FIZ9:++=2R"VAN9"9)EBW;-[8.5/RJ %'L5>$_\$YKZYU#
M]D_0IKCQ!IOBE/M=\D&IV4]M/'<Q+=RJI+VT44)?Y>0B#:?E.6#&NJ^*'[2M
MC\,OBQX;\*RZ+K&H-K9A^V7]MY7V?14GN%M;9Y@[J["6Y=8P(U8CEF 49H ]
M);[OM7YS?";]@'X;_$GPM>:YJEOXNDU#4M<U>><V_C+5[6+<=2NL[8HKE8T'
MLJ@>U?<'P]^.>F_$KXG>-O#-A:7RR>!9K6WNKV0*+>[EFC9RL1!R?+VE7) &
M[(&<&O"?V:N?A0G_ &%M6_\ 3E=5_(_TN^(,SRGA_"5LLKSHRE5LW"3BVN5N
MS::NO(]S(Z%*K5DJL5)6ZJYYY_P[*^$O_/GXX_\ "[US_P"3*#_P3+^$H_Y=
M/''_ (7>N?\ R927NF:E#_P4&\11:?K&J))JOPS26""XNY);*SN%OGC26.$G
M8AY&XJ,M@9S@5YG_ ,$E/'-E\2HO&-]I<-QI+:';Z;X?\5:9<W_VJ:7Q-;B<
MZC????,<XD@V3# G$>X?=K^.:F:<81RFMFL<YKM4X4IM<\_^7KM;X]+-/6SO
MUM='O?5<'[14_8QUOT73Y&CXX_X)R_"VS^/7@&S2V\:?9[NUU5I ?&VM%LJD
M&,,;O<O4YP1GOG%=X?\ @F5\)?\ GS\<?^%WKG_R97=?$'_DX_X<?]>FL?\
MH%O5SX__  6T_P"/W@J/PYKUQ<Q>&)KD3:S:PW,EJ=2MU1\0-+&RNB&0QNVU
MAD1E3PQKP?\ B(7$U3ZI"KFM>G&47S-3FW\<];<RN[*R3:OI=I:FO]FX5<UJ
M4?N79>1YU_P[*^$N?^//QQ_X7>N?_)E-7_@F7\)2/^/3QQ_X7>N?_)E>2_"$
MZQ_PS[^R3?77B#Q1<>7XQDL+=[F_D!U?2VL]5^QO=+D"=C;PVSAI,G)W=3FO
MMH')KNX@XHXMRC%TJ+S>O44I27\2:^&I*'\W7EOY7MT(IX+"3BW[*/3HNU^Q
M^:G[.W[&7@C5?@)X.N99?' DFTF!V$7C75XD!*_PJMR%4>P %=G'^P]X%D^[
M)X_/T\<ZS_\ )-=#^S)_R;MX(_[ UO\ ^@UP?[?_ ,*M-\=_ 3Q+K>M:MK&G
MVW@W0;[4])_LV\EM9;;5U53:70,;#>Z.JHB-E29FX.:_W4RF*_LRC4:3?)%_
M@C^>ZTY/$N%VM7^9L_\ #$?@/_GMX^_\+K6?_DFOFK]O'X#Z3\(_B!X)/AW5
M_'FG-J&G:F)W'C'59'<)+9[0&:<D#YCD#@\9Z"ON3PR^H2>%]+;5E5=6:R@-
M^JC %QY:^:!_P/=7R=_P4W_Y*#\._P#L':M_Z,L:^BP&&HRKP4HJS?9'DX[$
M58T).,G>W=GS+_9^H?\ 0X?$7_PK]2_^/4K:9J0Z^+OB-_X5^I?_ !ZH_%FL
M/X>\):MJ$8!DL+&>Z0'H62-F'ZBO/?@QIY\'^+M/T])9I8]>\)VVL79DE9S)
M>K(%EFY/603#./[@KZ^IA<'"K&G[%:];+3MTZL^4HXC%SI2J>U>G2[U[_<CO
M=7T_4/[&O/\ BKOB(?\ 1I>&\7:D0?D/4>=S7]&G[*:[?V7_ (;CT\+Z9_Z2
M15_.OJW_ "!;[_KVE_\ 0&K^BK]E?_DV'X;_ /8K:9_Z215^;>(^%I470]E%
M1OS;)+MV/T'P^Q%6LJWM)-VMN[]SOJ***_,3]("BBB@#P7XUP^=^T?"/^I:'
M_I4U=)^S]#Y/C3Q(O_3G8G_QZYKG_C$<?M)P_P#8M#_TJ:ND^ __ "//B3_K
MRL?_ $*YK^/<OIS_ .(^XB?3V"_](B>[S_\ "5&/]Y_F>I4445_81X04444
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M/_$MU ;;@GD1\_NW_P!O_.* *NH>';KPWJDFI:+\RW#AKRP)VQW/&TR(?X)
M-OJ&$87 )W#6\/:_:^)M.6ZM6;;DHZ,,/"XX9''9E.01V(-)_;DO_0+U+\H_
M_BZY_P 06%XM^VJZ/I]Y!JRIM=',:PWX7E4E(?CN%?!V;V.T]*T4E+26_?\
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MR?\ H8K0H **** "J=W_ ,A2S^K_ /H-7*IW?_(4L_J__H- %RBBB@ HHHH
MK0_\A:X_ZY1_S>K-5H?^0M<?]<H_YO5F@ KRC]L7P;XJ\>_!UM.\):'X7\37
MTE]"9]+\0)&UC<Q?, [>8CK^YE,,^-N6$!4$%@:]7HH \W_99^&FM?!WX06O
MA?6KQM0.BWEU;6-TZ0)-<V8G<P22B!(XA(R$$A$4<\C.:](HHH **** /E?Q
M5H]]X<_;[F\32>%/%UY-;(,ZQ9:?//;2:+)8QP"R61?D9AJ),QA^\H5I2 HW
M5PGP$_9PM_%/B/PJEQX!DL[/2/B7JGB33=2N/#=QI/\ 96GPV\4B1P17!,MM
MYMZ8@P+8N#!<R@;9 !]QT4 %>+_\%!=)CU[]CCQY:R:9X@UB273_ /1K+1;6
MYN;VXG#J80D=L#*X\P*2 ,8!W?+FO:** /F7XM:_I?C+]J?P3J4WAWXC_8?^
M$8\2:5J%S%HFJ)!';NEK(!F-=L<DGER>6P E8H%7G KU#]C^;S/V6/A[']@U
MC2_LF@6=HUGJEG-9W=LT,2Q%)(I@)%(*$?,,D8/.<UZ510 5\LPZ6/#O[9/Q
M8UG_ (1'7IM!UKPY9:9?2VGAF]"WMV&FR7;=MU#,38$D&T0HOE-\SBOJ:B@#
MX4_9-^'.M:-\6_@?*W@_4-+;1+#Q!!=7*>%[[2HHM-EN+MK,^9,Y6WMSF/9I
MDH\^,RPN3B(Y^ZZ** "OSXF^'FJ>(?'>EIH_A'Q[]GL?'VL2Z)<W^C:@O]F7
M\FLZ;=&_>2==RP/9+?JL['RRK21 YD"-^@]% !1110 4444 %%%% '@?QO;_
M (R+C_[%@?\ I6:Z+]G@Y\8>)O\ KTL/YW-<S\=6V_M$Q?\ 8L#_ -*S72?L
MWG/B[Q-_UZ6'\[FOQ[#Y?;Q JXKO32_\EBCIY_\ 9E'S9ZY1117["<P4444
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M(_\ 2RND_9C_ .1G\3?]>UA_.XKF_P!H?_DXB#_L61_Z5UTG[,7_ ",WB?\
MZ][#^=Q7&J?^UN?]U?H8Q=Y6\_T/8J***[#8**** "ODG]OCQZUUX_TSPW-\
M.?B=K%R^GW?]DZSX8O;6%@2D4TSQAV+;X3#$P)7&Y0/FW 'ZVKYD_P""C/A^
M'QM%X'T*R\)>+?%'BS4+R[?2CX?\2)X?N+6)(0;H-=/\NQT*@QD'> >FV@#U
M;X1+ITW[,GA(:3%=QZ2_AZQ^QQW<JRSK"8(]@D=?E9]N-Q'!.<5V!\(:<1_Q
MZQ_F?\:X^+1[SPE^S5I^GZ3HW]@W6G:+;6\.E>>+DZ;LC1?($@R)#&!M##[Q
M7/>NG^'$VJ77@FP?6E*ZDT>9P5 .<\9 Z'&,CUS7C_VLO[2_LWV<K\G/S6]S
M>UK_ ,W6W8Z/J[]C[>ZWM:^NU[V[>9YK\&/VE?AS\>_BKXX\&>'?.FUKP#="
MTU)9(62-FW,C&)L_,%=&4].1QD$$^J'PAIV/^/6/\S_C7*?#3]FOP3\(/'OB
MKQ1X<T&WTS7/&EP+G6+I'=C<R#<<A6)5,LS,0H +,2<FN]Z"N_"JNH?[0TY7
M>VUKZ?A:X8KV#J?[.G:RWM>]E?;I>]O(S?\ A#]-_P"?2/\ ,_XU3U+PKI\5
MW8!;5/GG*GD\CRW/K[5T JCJ_P#Q^Z;_ -?!_P#1;UTG.0_\(?IO_/I'^9_Q
MH_X0_3?^?2/\S_C6I10!E_\ "'Z;_P ^D?YG_&C_ (0_3?\ GTC_ #/^-:E%
M &"/"NG_ -NE?LJ;?(!QD]=WUJU_PA^F_P#/I'^9_P :F'_(R-_U[#_T(U>H
M R_^$/TW_GTC_,_XT?\ "'Z;_P ^D?YG_&M2B@#+/@_3?^?2/\S_ (US-[\-
MH3?7>I:3##%J"RLLD,A80WR@+M1\'AAC"O@[0S<'-=U5'1A\]Y_U\M_(549-
M.Z%9-69B^&H='\203;+/R;BVD\JXMY<B6!\!L,,]U92/9A6I_P (CIO_ #Z1
MY^I_QJMXB\*+JMW#?6D@L=6M@!'<JF69.<Q..-R'<3M/ ;:W4"D\,>*VU=FL
M[V'[#JMNJF:W+95\Y&^)OXXR5;!P#@<J,U4HIKFB)2>S+7_"'Z;_ ,^D?YG_
M !H/A#30I_T1/S/^-:E(QRA^E9E&%H7A/3I=%M&:U0LT*$G)Y.T>]6O^$/TW
M_GTC_,_XU8\._P#(!LO^N"?^@BKE &7_ ,(?IO\ SZ1_F?\ &C_A#]-_Y](_
MS/\ C6I10!S^O^%=/ATF1EM4!RO<_P!X>]7#X/TT_P#+JGYG_&I/$O\ R!Y/
M]Y/_ $,5H4 9?_"'Z;_SZ1_F?\:/^$/TW_GTC_,_XUJ44 9?_"'Z;_SZ1_F?
M\:KW7A/3TU&U M4PQ?/)]/K6Y5.[_P"0I9_5_P#T&@"O_P (?IO_ #Z1_F?\
M:/\ A#]-_P"?2/\ ,_XUJ44 9?\ PA^F_P#/I'^9_P :/^$/TW_GTC_,_P"-
M:E% &=IFG0Z;J%PD$8C7RXS@9]7K1JM#_P A:X_ZY1_S>K- !1110 4444 %
M%%% !1110 45'Y\9BW[EV=FSQZ=:DH **** "BBB@ HIKR+'C<0,G R>IIHN
M$;;M93O&5Y^\/:@"2BBB@ HHHH **** "BBB@#YY_:*;'[0]O_V+ _\ 2RNB
M_9B?=XG\3?\ 7M8?SN*YO]HK_DXFW_[%G_V[KI/V8>?$_BC_ *];#^=S6GL_
M><_)?FCC3_>V\_T/9****S.P**** "ODC_@JU'HVI>%/!]CJ?@S1_%TPNKB\
MB?5?$-SHUIIL:"&*25I(&4D_OT')PJAR>,U];U\N_M\^)?'.E^(=/DT.X^#J
M^"[#2;E/$A\;WOE06WVH^3"95"LPC?#*F!AVWAN * /7O@UJ5MK7[,7@^\L[
M:.SL[GP]82P6\4SS);H8(RJ+(_SN%' 9N3C)ZUZ)7%>"-$O/#_P'T/3M0U"U
MU._L]'M;>XO;*-8X+J18D5I8E4 *C$$J , $5T?_  CO_40U+_O\/\* -*BL
MW_A'#_T$-2_[_#_"C_A'#_T$-2_[_#_"@#2JCJ__ !^Z;_U\'_T6]1_\(X?^
M@AJ7_?X?X53U+02EY8C[=J'S3D<RCC]V_3B@#>HK-_X1P_\ 00U+_O\ #_"C
M_A'#_P!!#4O^_P /\* -*BLW_A'#_P!!#4O^_P /\*/^$</_ $$-2_[_  _P
MH D'_(R-_P!>P_\ 0C5ZL$:"3KI7[=J'_'N#GS1G[WTJY_PCA_Z"&I?]_A_A
M0!I45F_\(X?^@AJ7_?X?X4?\(X?^@AJ7_?X?X4 :54M&^]>?]?+?R%1?\(X?
M^@AJ7_?X?X54TK03(UU_I^H#%PPXE'/ ]J -TUC^)O"\7B.&-MS6][:G?:W4
M8_>V[9!X/=257<O1@,$$5-_PCA_Z"&I?]_A_A1_PCA_Z"&I?]_1_A1%M.Z$U
M=69FZ#XHFM]0&E:Q^YU#YC#*!^YOD!'S(>S89<J<'.[:"HS70GA#]*P=:\ V
M_B"Q-O=76H2)G*D3;7C;!&Y& #*V">5(/)YK&L3>>&+I;'7-3U!H9"%M=2,B
MHDY(QLEPH"29'' 4[D RV16O*I:QW[?Y$7:T>QUWAW_D V7_ %P3_P!!%7*P
M]%\/EM&M2;[45_<I\HE Q\HXZ5:_X1P_]!#4O^_P_P *R-#2HK-_X1P_]!#4
MO^_P_P */^$</_00U+_O\/\ "@!WB7_D#R?[R?\ H8K0K U_0#'I,A^WZ@>5
MX,H_O#VJ[_PCA_Z"&I?]_A_A0!I45F_\(X?^@AJ7_?X?X4?\(X?^@AJ7_?X?
MX4 :54[O_D*6?U?_ -!J'_A'#_T$-2_[_#_"JMSH)74+7_3]1^8O_P M1QQ]
M* -RBLW_ (1P_P#00U+_ +_#_"C_ (1P_P#00U+_ +_#_"@#2HK-_P"$</\
MT$-2_P"_P_PH_P"$</\ T$-2_P"_P_PH LP_\A:X_P"N4?\ -ZLUG:99_8=0
MN%\Z>;]W&<RMN(Y?VK1H **** "BBB@#XP_X+!^,_''@2V^">L> ]4U:SU;P
M[XTN?$=SIUE.\:^([33M$U*]N--E53\Z3PPR*%.?G\LXR!7C<O\ P58U+X"^
M /.\/W6C^+?^$E\3>-O%EH^KOJ%R^JZ/::ULM]/T\6\<C+<3)<*(3(!%&(PI
M!W#;^@/Q"^"^D_$KQUX)U_4FN_M?@/4KC4]/CCD BEDGL;FQ<2J0=R^5=28
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M+Z+)X:\,Z=ITM_?:K)86T5L]Y>,K7-X40*992JJI=L;FVJ!DG  XH TJ***
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MB_\ BJ )!_R,C?\ 7L/_ $(U>K!&IW7]ND_V9<;OLX&WS8^FX_[57/[7O?\
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M+II(HFQT8)!)\O7%:\?[5GP*A\>GQ4F%\3M!]F.KCP;J(OC%C'E^=]EW[/\
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M!<_[H_F*T*S_ !-_R +G_='\Q6A0 4444 %4=7_X_=-_Z^#_ .BWJ]5'5_\
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MF1KFY@CQ$'8;F8C:C&@#TQJ_.#X;7DL?AB<"60 :SK& &/'_ !-;NON7P?\
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M2!)8V*GG#KZUL2ZC;P:A#:O/"MU<(\D4+.!)*J;0S*O4@;ER1TW#UH _+?\
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M* ,_Q)&TFAW(16=MN0JC).#G@4'Q/;?W+W_P$E_^)K0HH S_ /A)[7^Y>?\
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MMH@QMSNS[8QSG'- '6Z/K\-MI%K&\=ZK1PHK#[)+P0!G^&K?_"3VO]R\_P#
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M?V/XG^T?\)-JLNMWYU/Q&EZ3=RX\QTWO\@;"Y4<?*/2OJ=O /P=3]I-? ?\
MPH/X?MI[!K7^W!H&F^7_ &B+47OV3R?+WX^RD/YN=N[Y<=ZX7PE??#GQ;+X?
M>U_9F^%$UMJ'C.;P7J4L/]DW'V*="&,L!2W*W2K%YC2*K*T;6\R'<4S7B_ZJ
MMJSJ_A_P3A_LE[<WX?\ !/#?&'C'16^.?@!AK>B%5M=9W$:A#A<PV^,G=Q79
MCQKHF?\ D/:%_P"#&#_XJOLS_ABCX-_]$E^&?_A+V/\ \:KC_C[^S_\ ![X&
M?!;Q-XOC^!?@+Q$?#>G2Z@=.LO#>FQS7*QJ68!I$5%  )))X . 3@%/A--)>
MTV\O^"+^R/[WX?\ !/COX9>$_!?PH_MB;3M>L+O4O$5Y]OU;4]0UJ*YO=2F"
MA$,DA;[J( B(H"(HPH'.>I7QKH>[_D.Z%_X,H/\ XJOI'Q9\#_A#X9^(7A;0
MX_@+X'U"'Q-9WET+Z'PWIBQV[P1+*L&UD#-)("VW "C8=S#(S-^S[\!_@W\>
M?@KX;\8?\*0^'NA_\)!9)=MIUQX=TZ6:S8Y!B=DC*LRD$$J2..":7^JEY<SJ
M_A_P0>3WU<OP_P""?$'[+?B_1HOV:_ :OK6BQLNA6H96U"$%3L'!&ZJGQZ^!
M?P]_:.O]'N?$'BG4K.?08KB*S?0_&3Z256<*)=Q@D4MN5%'/;([FOT>_X8I^
M#?\ T27X9_\ A+V/_P :KS2R^%'PANOVA/$G@+_A1?PL:71=$CUJVN8=-TJ6
M2Y5FV&.: 1[[;+'$;2<2!)2,;#7ZW3XDM25*5.Z277M\CB_U=:GSQJ6?I_P3
MYG\/ZMX:\+>'[#2['5]"AL=,MHK.VC_M*$^7%&@1!DODX51SWKY1_P""F'B;
M2[OX@?#TQ:KI<P73M5#&.]B?;F2RQG#<?_6K]#?@]JGP>^*OB/X?V,G[/?PI
ML8_'4VK60G@AT>]\FXT]YP[PJD0:ZM&%N?\ 24PJM+$I&7X^A/\ ABCX-X_Y
M)+\,_P#PE['_ .-5VX;C)T:D:BI;>?\ P#EQ'":JTW!U-_+_ ()_/+_;EC_S
M_:?_ .!4?^-4XTT>/Q%)JHO;+[=-:I9LYO$P(E=G  S@?,Q)/?CTK^B;_ABG
MX-_]$E^&?_A+V/\ \:KYUU#Q1\&=.U?3[>;]FWP3;[]?O=*U07&C:4LFE6=O
M?V]@MZ56-A)YDUW;D1*VX(SDG*;3[W_$2V]\/_Y-_P  \2/AW;:O^'_!/QFU
MC6['^QKW_3[#_CVE_P"7J/\ N'WK^C']E1M_[,/PW8'<I\+:801W_P!$BJ@?
MV*?@YGCX2_#+_P )>Q_^-5Z-86,.DV,-M;0QV]O;HL4<4:!$B11@*H'
M%?*<3<3/-W!N'+RWZWO>WDNQ]-P[PXLJ4[3YN:W2UK?-]RS6;XL\367@GPOJ
M6M:E,MMI^D6LM[=3,<+%%&A=V/L%4G\*TJHZYHUGXET:\TW4;6WO]/OX7M[J
MVGC$D-Q$ZE71T.0RLI(((P037RQ],?D%\#/C)XV\ ?#CQHUII?CSX0^*/CEI
M?AGQLNM7\-GYFH:C<^*(;;5+JT"R2JP^Q:IIL>)55L(OR8S7J/@2Z?1/VL/
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M/B#^S[JNDV/@G3?B,+R: 7/AN_:!8=4B$JDH6G98P%8*Y)(.U&V_-M%>L44
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "V F4# 2(  A$! Q$!_\0
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M?6*G<]'_ .%I_P#4,_\ 'Z/^%I_]0S_Q^O.**/J-#^4/K%3N>C_\+3_ZAO\
MX_1_PM/_ *AG_C]>;TM'U&A_*'UBIW/1_P#A:?\ U#/_ !^C_A:?_4,_\?KS
MBBCZC0_E#ZQ4[GH__"T_^H9_X_1_PM/_ *AG_C]><44?4:'\H?6*G<]'_P"%
MI]/^)9_X_1_PM/\ ZAG_ (_7G%%'U&A_*'UBIW/1_P#A:?\ U#/_ !^C_A:?
M_4,_\?KSBBCZC0_E#ZQ4[GH__"T_^H9_X_1_PM/_ *AG_C]><44?4:'\H?6*
MG<]'_P"%I_\ 4,_\?H_X6G_U#?\ Q^O.*3M1]1H?RA]8J=STC_A:?7_B6?\
MC]'_  M/K_Q+/_'Z\XHH^HT/Y0^L5.YZ/_PM/K_Q+/\ Q^C_ (6GU_XEG_C]
M><44?4:'\H?6*G<]'_X6GU_XEG_C]+_PM+K_ ,2S_P ?KS>BCZC0_E#ZQ4[G
MH_\ PM/_ *AG_C]*/BEDC_B6_P#C]>;T+]X?6CZC0_E#ZQ4[GJ.H_$?[!?RV
MW]G[]F/FW]<@'^M5?^%I_P#4,_\ 'ZXSQ%_R'KG_ (#_ .@BKGA?3K#5KS[)
M=03$D%FF5L", =367U3#QI\\H]"O;57+E3.G_P"%I_\ 4,_\?H_X6G_U#/\
MQ^L/^P;*32?,LH#>7 W[RLV"H!X.WO4/_"&7(C+->6RE81,RL>50]S25#"=5
M;[Q^TK=&=%_PM/\ ZAG_ (_1_P +3_ZAG_C]<TO@^[=U*W$#0-%YOG#)&,X_
MG4EAX=6W\3&TO'2:"V3SIRHXV@9Q0Z&$ULOS#VE<Z'_A:?\ U#/_ !^C_A:?
M_4,_\?K)TGPU#=W@N;LPQP7$<DL-N#AMHS@BLV#PK/=6S7$-Q$54C>,'Y03C
MK0J&$O9K\Q^TK=SJ/^%I_P#4,_\ 'ZMV'Q'^VRRH=/*[(FD^_P!<5PNH>&[O
M3;6XN+AD589O) _OGKD>U,T'_CYNO^O63^5-X3#N#<43[:JG9L[+_A:73_B6
M?^/_ /UJ/^%I_P#4,_\ 'Z\XKI=(T_2[S1[V[N;62,6L?^M$I^=ST&,54\)A
MX*[B*->K)V3.B_X6G_U#/_'Z/^%I_P#4,_\ 'ZQ=0\.V[6\)TRV,B/Y8:Y\[
M<%9NH([<U"W@JX1B#?6ORR^2W)X<]!6:HX3JK?>7[2OW.@_X6G_U#/\ Q^C_
M (6G_P!0S_Q^N=@\%WLBN99X8F4N K9.=O4TW3M)B;0)IFA66YNIUM[7=V/<
MBG[#"]%<7M*W5G2?\+3X_P"0;_X_1_PM/K_Q+/\ Q^L>3PQ;6F@SO)+%+=),
M8RZ$X3"DX/XU43P;=S+$\5Q"R2EE4X(^8#..125'"/I^8W.OW.C_ .%I]?\
MB6?^/U;M_B/Y]E>7']GX^SA3C?UR<5Y[J.D3Z9;VTLY4&X4L$[@ XYJ73O\
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M5$G=FAXKUA-:UN2>'_4* D?&.!4.G?\ (&U;_<C_ /0JRJU=._Y VK?[D?\
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M'_H#V_Y4?VA'^5_@'U67<\6I:]H_LS0?^@/!^5']F:#_ - >W_*C^T(_RO\
M /JLNYXO17M']F:#_P! >W_*D.FZ"!DZ1;X^E']H1_E?X!]5EW/&**]G&FZ"
M1D:/;G/M2_V9H/\ T![?\J/[0C_*_P  ^JR[GB]%>T?V9H/_ $![?\J/[,T'
M_H#V_P"5']H1_E?X!]5EW/%Z*]H_LS0?^@/;_E1_9F@_] >W_*C^T(_RO\ ^
MJR[GB]%>T?V9H/\ T![?\J/[,T'_ * ]O^5']H1_E?X!]5EW/%Z3M7M/]F:#
M_P! >W_*C^S-!_Z \'Y4?VA'^5_@'U67<\7HKVC^S-!_Z ]O^5']F:#_ - >
MW_*C^T(_RO\  /JLNYXO17M']F:#_P! >W_*C^S-!_Z ]O\ E1_:$?Y7^ ?5
M9=SQ>BO:/[,T'_H#V_Y4?V9H/_0'M_RH_M"/\K_ /JLNYXO0OWA]:]H_LS0?
M^@/;_E1_9F@Y_P"0/;_E2_M"/\K_  #ZK+N>5^(O^0]<_P# ?_01677MUUI^
MBO<NTVE0/(<98CKQ4/\ 9F@_] >W_*E#'Q44N5_@-X5MWN>8^&M0@L+R=;IB
ML,\#1,0,X)'%7;7QC/97UI+' C1V\/D%"3B0>M>@_P!F:#_T![?\J/[,T'_H
M#V_Y5$L52DVY0>OH4J$TK)GF-]XGO[C4+BY@?[.LS;C&J@@?F*=8^(VL(I&C
M@8W;JP,ID.WGOMZ9KTS^S-!_Z ]O^5']F:#_ - >W_*CZW2MR\C_  #V$[WY
MCS6#Q D%A/:06HB-TH2:1G+#'<@=JB\3:C!J&HH;8[H884B5L8S@<UZ?_9F@
M_P#0'M_RH_LS0?\ H#V_Y4+%TU+F47^ >PFU:YXO6KH/_'S=?]>LG\J]3_LS
M0?\ H#V_Y5-;:?HJNYBTN!"4() ZCTJYX^+BURO\"5A6G>YXC17M']F:#_T!
M[?\ *C^S-!_Z ]O^55_:$?Y7^ OJK[GFFDZG!#H-_8SMM=G2:+CJRGI5R+QM
M<Q75]+]F1H[M-NPG[AQC(KO_ .S-!_Z ]O\ E1_9F@_] >W_ "K%XJE)MN#U
M]/ZZ&BHS25I'DYUN_DB$,LY>'@%-H&1Z9Q5Z?Q$DMG'9"T/V3?OD1Y2Q<_4]
M*]*_LS0?^@/;_E1_9F@_] >W_*J>,IO[#_ E8>:^T>?VVNVMU<6,$T8M;&S(
M=%R6).X$\UAZM>?VAJUU=@8$LA8?2O7/[,T'_H#V_P"5']F:#_T![?\ *B.,
MA%W47^ WAYM6;/%ZU=._Y VK?[D?_H5>I_V9H/\ T![?\JFBT_1A!.J:7 J$
M#>N/O<\54L?%KX7^ EA6GN>(T5[1_9F@_P#0'M_RH_LS0?\ H#V_Y57]H1_E
M?X$_59=SS#PSJ,.G:HS7)VP2Q/$YQTR.M2P^(9-/M[6UM5!6VG,RR?WLCD$5
MZ5_9F@_] >W_ "H_LS0?^@/;_E64L73E*[B_P_KJ6J$TK)GFFI>*K^]U&6Z@
M(MA(!E% (X^HI-/\1M8!I5@9[MMW[TR$+D]]HXKTS^S-!_Z ]O\ E1_9F@_]
M >W_ "H^M4N7EY';Y!["I>_,>:QZ];_V')I;V6?.<2/+YASN]<?C4?B34(+Z
MZMDM6W0V\"Q!L=2.M>G?V9H/_0'M_P J/[,T'_H#V_Y4+%TU+F46'L)M6NCQ
M>CM7M']F:#_T![?\J/[,T'_H#V_Y5K_:$?Y7^!'U67<S/AA_R!;K_KM_2NYJ
MAI5O9V]NPLK9+="V2J=S5^O(Q$_:5'+N=U./+!(****Q+"J][_QZ/5BH+T$V
MC@#)]*<=P9YSXR6Z=M,6TF>.43,XVMC<57.#ZUEZ[KAUJUMVL+AECMVCDG*-
MC#E@-A_6N[ELDGEBDE@WO$<H2.A/%4XO#VG00S11:>B1S.)) %/S,.<UT$'-
MV_B?6)]7D,>GL=.CD:)FV]-HZYSU]JJ7.IZA/<V-Y<2V[126UQ+'%&2"HV]#
MSS]:[ :!8+J!OA9 7)ZN,_RSBHXO#&EPRO)'IRJ[;@QP?XNH]J .:NO%5S8R
M6"PLCQ%8EEC$9.W<.[=JM6NNZJ][#)-]F^QRWC6H10=XQT.:VY?#.F2SI-)I
MZM(@50>> .G&>V*LC2+90@%J $E\Y>#P_K30C!O[C4XO%VV&\C6T6R:0PE>I
M!]:S9_%.LVVGV;M!'-<7PS$(D.(^0,>YYKL+K2+:\N8KBXM=\L0(1N00#U%-
MFT.SGLELY;(- @VJN#\HSVI6=AG*7GB;5K71HI)XUM[[+DQ>47+JO? /%-M=
M7U:?4+F^6YC%L-.6X6W*]&QZ_6NED\+Z9+;0V\E@&BAR4!+<9Z\YYJ0^'[!G
MC<V(W1QF)<9X0]O>@#F/[<\1 '<UCQ9B]R%/ [K_ /7H;Q5K%SJ:)8:>7MT$
M9E^7^\ >N>,9KK?[(M3G-H.8?(Z'_5_W:@?P[ITEQ#<-8CS85"HPR, =.AYH
M$<_!KNL23QR.;<6TUT]JBA3N4]F)JWX6NM0'AR2ZU"Y6Y=2[+M7! !/'O6XN
MD6JA +0 )+YR\'ASW^M+9Z5;V F%M;>6)FWR  D$GO0'4XZ\U74;RYT^Z,L"
MVQOBJ0C(<;0>OK]*NMXFNA86<P$1DFMII6'N@.*W!X<TX7QO18+]H+[]^#PW
MKCH*;'X8TN*5Y(].4.X8$X/0]>_&:-1G-:AXDU73M)M[B6>W:XDA%PT44);Y
M<?7@>]1G4M4DN=8NI+E&M5M8I4M]O3<N>#FNLN_#NGWZPK<V(D$*[(P<C"^G
M!Z4K^'["23S&L06\KRLX/W!V_2@$<_)KVHA)KF VZVMH41X7!WR9 Y![=>*(
M]>U4W@F?[/\ 8C?_ &3RP#OP>C9]JWY/#NG2W<=T]@IF0 *V#VZ9'0U*VD6S
M(5%J #+YXX/#_P![ZTQ$LKLUO(8&4R;3MYSSVS7(#QE<;US$FPP%2?\ IN.W
MTKK+#3%T^W$42.<]6;.6.2?ZU!_PCVGXQ]@3F;S_ +I_UG]Z@#F8O$VN2ZPT
M2:>7M89/*F(7N!DG.?TJNGB'6=4L[YY;(QV,EO*4DQC;@''.>:[!M!L7U$7[
M6?\ I(_C&1D_3.*9'X<TZ.::5+$!IP5DQG# ]>,XI68SF[37-3D\-QW-JL>4
M\N,HR[GC4*,L1GFNKL+@7=A!.)%D\Q0=R\ U7G\-Z=<J5EL000JG&1G'3H:O
MP6HMX4AAA*1H,*H' %,0[\:*=Y;_ -UORH\M_P"XWY4 -HIWEO\ W&_*CRW_
M +C?E0 VBG>6_P#<;\J/+?\ N-^5 #:.].\M_P"XWY4>6^?N-^5 #:*=Y;_W
M&_*CRW_N-^5 #:*=Y;_W&_*CRW_N-^5 #:*=Y;_W&_*CRW_N-^5,!M'>G>6_
M]QORH\M\_<;\J0$EU_Q\O^'\JAJQ=(YN&PK=NWM4/EO_ '&_*A; -J"\B\ZT
MEC\QX]RGYD."*L^6_P#<;\JAN[%+ZUDMKB)GBD&&7D9'X4/8#C$>1-(FM?M,
MOEOJGD/(7^;83Z]J=- 8M+URSAN9UM[4AHB)"2.,E<]<5OVWA/2;2WG@ATX+
M%<?ZQ26.X^O)I\GAC3)M-&GO89M=V[9EN3[G.32MH/J6M.8MIMJ2<DQ+DYZ\
M"K-0V6G1:?:):VL#1PIPJ\G^=6/+?^XWY538AM36WWV_W#4?EO\ W&_*IK='
M#-E6^X>U)[ 5Z*=Y;_W6_*CRW_N-^5,!M8OBJ-FT"Y=9Y(C&-P\ML9YZ5N>6
M_P#<;\JI:GHMKK%N(+^U,T0.=I) S^!J7JAHYK4$%_=2QW,\J);6 FBV2%?G
MQ][WZ5FK+->:7=:I<7$JWUJ8UA D( '';OFNO?POI<D4$3V 9+<8C!+<#TSG
MD?6I9?#]A->QW<EBIGC "M@\8Z<=*.HBY&28T)X) S3J=Y;_ -QORH\M_P"X
MWY50#:FA_P!1-]!4?EO_ '&_*IHD<03?*W0=J3 KT4[RW_N-^5'EO_<;\J &
MTUAN0J&*Y'4'I[U)Y;_W&_*FM"TD;(T;%6!!'/2@#B!)-;Z9J-N+J4H=1$+2
M,_S!#C//:HC$$UTZ$MQ,-,:4$_O3G.W.W=G/6NFMO">DVD<Z0:?M6X&) 2QW
M?F:E_P"$:TW[ ;'[ /L^[?MYSGUSG-*PRKX9=OL%Q"9&>."YDBB9FR2@Z<]Z
MVZCM;&.RMU@MH/+B7[J@&IO+?^XWY4Q#:.].\M_[C?E1Y;Y^XWY4 :FF?\>[
M?[U7:IZ:"+<Y!'S=ZN5SS^)EK8****D84V0XC.*=3)/]6U-;@59)A$A>20*B
M\EF. *59-RAE?*GD$'@UR_C2X:2UMM+2UFN_M<G[V*'[QC')KG=/U[4(=)?3
M[CS].:.Z2)I9 -T<)^7/YKUJR3T>*Y28N(Y0Q1MK8/W3Z&I-[>IKS/3]5GT8
M7NH)?-=V?VV2)W(^^2OR'\^*+O4_$B:E!:_VA%;M''&_[Z4)YI;DC'?'3% '
MIF]O4T;V]37!3W.K20:Q=_VP8/)N3#'&Q"H!QG!/0^A-9U_X@U>==/BL;[[/
M$;<OYUS*$,CAL8)Z'^M ST[>WJ:-S>I_PKE/%&I:G8^&K22VDC2XE:-)9@V%
M0$<G/;ZUE0ZGK>GZ5;:I>7\=Q:V[M]H,3;P4R ,GN>3^5 'H&]O4T;V]37F-
M_K'B)IK9%OXK82Q&X1Y9-@;+<+[@#M[U>N[_ %E9-0O/[2D4630 0(HV-N W
M9]N: ._$F<X?..#STH>78K,S[5 R23TKSB!KJSM=<\K7)$N/MI)2:4#:A_ND
M]"?6MR]U![CX?2743RNS1 %I/O$;L'..O>CH!TXO(2D;>>@$O"$MC=]/6HYM
M3M+:813WL$4K=$>4 G\":X'Q)/-=7<<-EI]S<IIELDD;PXQ')UY_X"/UIOVB
MVU/QBM[+=:?"DEK"X2[C5F)]%)Z'-,70]%BNXYF98YE<J 2%.>O0U)O;U-<W
M9D)XP*0%3$]@C,4^[D-@$?A71T +O;U-&]O4TE%(!=[>IHWMZFDHH 7<WJ?\
M:-[>II/\_6BF N]O4T;V]3244@%WMZFC>WJ:2B@!=[?WJ-[>II/QHH 7>WJ:
M-[>II** %WMZFC>WJ:2B@!=[>IHW-ZFDHI@+O;U-&]O4TE%(!=[>IHWMZFDH
MH 7>WJ:-[>I_.DHH 7>WJ:-[>M)10 ^1B)#@FF[V]32R?ZPTVA +O;U-&]O4
MTE% "[V]31O;U-)10 N]O4T;V]3244 +O;U-.1B2>>U,IT?WC]* $WM_>/YT
M;V]32?C10 N]O4T;V]3244 +O;U-&]O4TE% "[V_O&C>WJ:2B@!=[>IIRL=C
M\]J93E^X_P"% Q-[>IHWMZFDHH$+O;U-&]O4_G244 +O;U-&]O4TE% "[V]3
M1O;U-)10 N]O4T;V]3244 6(22AR<\U)4<'W#]:DJ'N4%%%%( IL@S&13JKW
MO_'I)36X,B,2EPY52X& W&<4R2TAEW>9#$^X8;<H.1Z&LS)]:,GU-;<A%S2%
ME;B+RA;PB/.=NT8S]*66S@G='F@AD=/NLZ@E?I69D^M&3ZT<@7--[2"2-T>"
M)D<Y964$$^_K37L+:1$22V@9$^ZK(I"_2L74-0@TRREN[IRL,8RQ')_"GQW<
M,MNDZRCRY%W*Q.,BCD"YMO DD9CDC1HR,%6P1CTQ35LX4@\A8(EAZ>6%&W\J
MRO,4Y^<<#)YI3( I<N N.6SQBCD"YIRV5O.$$MO#($^X'4';]*<;:,A@8H\-
M][@<_7UK'%S"5#"="/4.*<LJLQ59 2.H#9Q1R!<TWL+64N9+:!R_WMR*=WIG
MUI9K.*>T>U9%$+H4*J0 !6$NIP/J)L5<F41>:2#D;<XZ^M65D5UW(X8>H.:.
M0+FI;6<=K L48& H7)(R<#'/K3'TNRD=6>RMF9?NEHU)'TKGK77[*[U%K%&E
M6=02 Z%=P'4C/6IM3U:UTBT^U7DA2,$+P,DD^U'+UN%S:@TV"WO);J-0))55
M3R, #H .PJUM/M^=8%I>17EG%=PL?*D7>I/'%4HO$6GS:=<W\<S-!;,5D.TY
M!'M0X^87.LVGV_.C:?;\ZYG3-6BU2)I(8[B-5_Y[1E,^XJQ->P6\,DLLZ*D0
MRY+?='O1R!<WMI]OSHVGV_.N;N-4MK?33?\ F;[< ,&0YR#5E9E)4;P&(W!<
M\XHY N;>T^W/O1M/M^=8HFC9]BR*6'50W-07&I6EHB-/<QHKR",$MU8]J.4+
MG0[3[?G1M/M^=8IE4*&,@ /.2W6@S($#F10I_B+<&CD"YM;3[?G1M/M^=8IE
M4%07&6Z GK4<UY%"A8N6PP4A3D@FCD"YO;3ZC\Z-I]OSKF[/4X+[S1&Y!CD:
M,AC@DCK3K+48;[S_ "F(,4K1,#P<KUQ[4<@7.BVGV_.C:?;\ZQ3(NW=O&WUS
MQ2>=&2!YJY;I\W7Z4<@7-O:?;\Z-I]OSKG+34X+R.9T?:L4S0L7./F%/_M"V
M-Z;/[0GV@)O,>[G;1R!<Z#:?;\Z-I'I^=8HE1@Q$BD#@D-TJLNIP/J7V%'W2
M^5YN5.1MSBCD"YT>T^WYT;3[?G7/P:A;7,DT<-PCO"VV0!ONFIEE5DWK("H[
M@Y%')YA<VMI]OSHVGV_.N0C\3:?)#<S*TWE6ZEF<QG##./E/>F0^*M,EM9)_
M,EC\O&8Y(R'YZ8'?-'+YA<[+:?;\Z-I]OS_^O7&OXKTY+..YS.V^0Q"-8R7#
M>A6B[\46-E]F$J77F7";HXUB);'N*.7S"YV6T^WYT;3[?G6';W N+=)E#JKC
M< XP1]14H)SUHY N;,@)D/\ C3=I]OSK-NB?M+\^G\JAR?6A0T"YL;3[?G1M
M/M^=8^3ZU3U+5(-+@$LXE92>!&A8_7BCE\PN=)M/M^=&T^WYUQ[>*--%A%=K
M+)(DK%51$)<D=1M]JEA\06%Q) L4S-YV-K8XR>@/H>M'+YA<ZO:?;\Z-I]OS
MK!M[N.[#F%BRJQ4GL2*FR?6CD"YL;3[?G3T4Y/3IZUB9/K4UL3O;G^ T. 7-
M+:?4?G1M/M^=8^3ZG\Z,GUHY N;&T^WYT;3[?G6/D^M9NHZ]9Z7,D=TTJAL
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M2DD9&=HV9#E21T/M3_L!_P">JT70'FJ:?>V]QI;O:74]PB[=CJ2B+NS][/#
M4U+&\!NXK:SN2AG1S-*I5R=_(Z\C'>O3/L!_YZK1]@/_ #U6BZ#4\MN-,E,]
MTB:7>?;9+UI([A<A=G8YSZX-6;J&^TG3YM16-_M$=](NW.-ZO@9'X\UZ3]@/
M_/9:CETI)@!*T;!2& (Z$470=3DM3TF7_A%;>P19)'#Q^9M/)YRW/YUB:CH$
MP\1@;KV.V!3[+]FBWJH'4%B?EKTS[ ?^>JT?8#_SU6BZO<5CS#5+'45T^> 6
M#R"6\G</Y9<C.-IP".OK2V^CW<4T$\EE-]OETSR5GQG9*">ISQQ7IWV _P#/
M5:/L!_YZK1=#U/*[#1KR+2[SR_[1>0H@GBDB$8?!RP4@\GWK9T"SC7Q,]U::
M7<V5H;38?.&,MN]":[O[ ?\ GJM'V _\]5%":06/.9=)>WFUI;?3I@\MPLK,
M@QYL7=0<]?:M?P];>6]_-#9S6UC)M\JWE!#9 ^8@$\9KK_L!_P">JT?8#_SU
M6A-(-3SB2WO);74;33K>^CLVA8>5<)]R0GC9SR*MSZ'<6-K:Z@\D]_=12Q/*
M-H#;%'10/3-=Y]@/_/5:/L!_YZK1= >>SVJ7*SW]Y8ZDJS7/F0+;C$J87&2
M>,TVXL@]G8RZK:ZK+>1HVR6V/S*,\!L=Z]$^P'_GJM'V _\ /5:+H-3"T-;Q
M-'MUOF8S@<[S\V.V??%:/>KGV _\]5H^P'_GJM/F0K$-U_Q\O^'\JAK0GLB\
MS-YBC/:H_L!_YZK24E8=BG6'XFU"YL[)(K6UN)FN"49X8]YC7NV,UU'V _\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #3 G # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^C'_@I/\
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M3C*/-*49*/WS_P /X/VJ?^B;?!/V_P")?XL_^:'G]*/^'\'[5/\ T3;X*?\
M@O\ %G3_ ,*']?TK\R_V>/V7OC-^U+XHU'PK\'/#*:Q+HMDNI^(M=U>_@T+P
MMX7TQV?RKSQ!KEYFVM6N5CD-K8Q>??3B*21(#&C,/I#6_P#@E_\ M,:-XJ\-
M>&QJGP5U*P\60^('T/QO9?%C0/\ A![F^\+V]I<ZSHEUK,OES6.N107T,]II
M\MA_I<45XZS(MK(1.:<'^ .2X^>59KEG#&!S*EA_K53!5ZM>->G0=*=:$JJ6
M8U*=*=2E3E.E1JU:=>I&THT6GS(PN?>)>.P_US!XW.\1A)5(4J>*I^Q]A6E.
M<::=&<W2]I%5)>SE*,>6,HSBW>.OU)_P_@_:I_Z)M\$^O_0/\6=/_"AZ^_Z4
M?\/X/VJ?^B;?!3_P7^+.G_A0_K^E?.7C3_@E)^U/\/\ POJ/BWQ1J7P2L=*T
M_P .ZCXHC8?%K1%N=4TG2[*2^N)]&M[BWC_M/S(E46R6TLBW$CQQQRAI8]WY
MN6-M=:I<6=CIMI<W]_J,]K:Z;96D$DU[?W5\Z)96=K9Q"2XGO;J5D@AM%1;B
M65R%0LH5NC)> _ WB.AC<1D61</9K1RY1EC)X*K.LJ$92<>>;_M:FH4X<LG4
MJ3<*<%%N4U9HSQ_$GB+E<J4,PS+-\)4K<KHTJ\Z$:E5246G""Y[I\Z5[KWKI
M7M=_MA_P_@_:I_Z)M\$_?_B7^+/_ )H>/UI/^'\'[5/_ $3;X)_^"_Q9^'_,
MP_Y]J_/SXX?L2?M#?LX_"_P)\5_C%X9TSPCHWQ!UG^Q-(T&?6;6Y\7:?>2:;
M=:M!'K^C6V]=,E-G:2B2 W4T]K*-MY'$Y*CY++!02Q  &220 /<D\8_&N[+/
M#+P8SK#RQ>4<.Y#F>%A6K8>>)P52I7P\<3A\34PM;#^VCFRIRJTZ]-Q?LY5(
M.+A.%6=.<)OGQO%WB!EM6E0Q^:9S@ZU>C&O1I5_9QG6HS47"I32C+F4T[QOR
MMVDK)IH_;C_A_!^U3_T3;X)]/^@?XLZ_^%#T]OUH_P"'\'[5/_1-O@GT_P"@
M?XLZ_P#A0]/;]:_$3SHR=JNK/MW"-6!D88R,(,L<]B%(YX%?3_Q3_9DUOX4_
ML^?L]_M":IXMT35=#_:%_P"$E&C>'[*SN;;4/#C>&I/+F_M*_GF:SOENR&,/
MV2*'RS\K;\9JL9X7>#V GEM/%\*Y11GF^.GEN6KEKU(XK'T\-7QE3"PG1S:M
M"%:&'PU6I*%:='2*4>9R0J/&/'5?ZVZ6=YG)8'#1Q>*U2]E0=>AAW-IX>\O9
MU,12]KRQDJ<6Y2>EG^CG_#^#]JG_ *)M\$_;_B7^+/\ YH>?TH_X?P?M4_\
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M*M-JZIT$L.E5FU[W+&7PZWM:_P"W7_#^#]JG_HFWP3_\%_BSK_X4/Z?K2_\
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M2E&FL]S/VKU='_E["#VJ5(?5[PIR=HQFVTY-1W9^W?\ P_@_:I_Z)M\$^O\
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M4P&'GAL'5K5\RQ$J.(EB(8'"9B\5-8C+4X1Y:2DJE/VJ<?U]^#W@OQA\//\
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MC)\(O@:/$EC#J>L>+=(T*UBDM+C5+Z73]0_L_2EM3;6<<M_<HD4(C2MWX[>
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M-^JWB'QW\-?%?_!3SX>?L?Z/^SI\%/"GPN^'?QXUO5[RZL?"5G/X@\::]?\
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M,,\RK'8>BL-&M!9-A<XS?$9C&%&2M[F Q.#IPA;W8RDKZ*WTSXI^'?@[1?\
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MBAXO\3>$+.^UR?0]3ATC17L]&@$4&E6FJW&HZW?ZSJVJW5K<7&MR+#;7JRI
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MF ?^HMS^/; K]!?VAE \8:4!D#^P(> 2!@WEV>@(&1M&#7@X4DX 8GDX!8G
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M3^]1OT3WZ)[JXO\ 5SA=7MPSDJNTW^[K:M;-ZZM=&[M=&CYT_P"'/'_!._\
MZ*%\5O\ PZ&E_P#S+4?\.>/^"=W_ $4'XK>G_)4-+Z>G_(K5]%X'O^9_QHP/
M?\S_ (T+B;CQ)17B-Q<HK:*Q-'E6M](\G*M==(K77?4?^KO#"5EPUDR790KK
M?7I+KU[O>Y\Z?\.>?^"=_P#T4+XK=<_\E0TSJ>"?^16ZD<9H_P"'//\ P3O_
M .BA?%;IC_DJ&E\ = /^*6X [#H*^B\#W_,_XT8'O^9_QI_ZT\?_ /1R.,-G
M'_>Z?PRMS1V^&5E>/PRLN9.RLO\ 5SA>S7^K.2VE\2]G6L_5<UG\TSYT_P"'
M/'_!.[_HH/Q6[?\ -4-+[=/^96H_X<\_\$[_ /HH7Q6_\.AI?_S+5]%X'O\
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MPO\ ]$SDO_@NK_F?.?\ PYW_ ."=W_10?BK_ .'0TO\ ^9:C_ASO_P $[O\
MHH/Q5_\ #H:7_P#,M7T9@>_YG_&C ]_S/^-'^L_'O_1Q^+__  JI?_(A_JYP
MO_T3.2_^"ZO^9\Y_\.=_^"=W_10?BK_X=#2__F6H_P"'._\ P3N_Z*#\5?\
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M9T*\.:I\,9/"UI4GVUKPH0=].2=2WO*+7UA\)KWXRZAX$TNY_:!\,_#/P?\
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MI\\U42@E]MI6>IYQ_P %VKJ2R_X)M?$/4(=-N=9N-/\ C1^S!>VNCV8MUO\
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M !%']L8WO1_\%?\ !#ZM'S^__@'AG_"L?'/_ $+MS_X%Z?\ _)5'_"L?'/\
MT+MS_P"!>G__ "57N>!ZM^:__$48'JWYK_\ $4?VQC>]'_P5_P $/JT?/[_^
M >&?\*Q\<_\ 0NW/_@7I_P#\E4?\*Q\<_P#0NW/_ (%Z?_\ )5>YX'JWYK_\
M11@>K?FO_P 11_:^-[T?_!7_  0^K1\_O_X!X9_PK'QS_P!"[<_^!>G_ /R5
M1_PK'QS_ -"[<_\ @7I__P E5[G@>K?FO_Q%&!ZM^:__ !%']L8WO1_\%?\
M!#ZM'S^__@'AG_"L?'/_ $+MS_X%Z?\ _)5'_"L?'/\ T+MS_P"!>G__ "57
MN>!ZM^:__$48'JWYK_\ $4?VQC>]'_P5_P $/JT?/[_^ >&?\*Q\<_\ 0NW/
M_@7I_P#\E4?\*Q\<_P#0NW/_ (%Z?_\ )5>YX'JWYK_\11@>K?FO_P 11_:^
M-[T?_!7_  0^K1\_O_X!X9_PK'QS_P!"[<_^!>G_ /R51_PK'QS_ -"[<_\
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MO_Q%&!ZM^:__ !%']L8WO1_\%?\ !#ZM'S^__@'AG_"L?'/_ $+MS_X%Z?\
M_)5'_"L?'/\ T+MS_P"!>G__ "57N>!ZM^:__$48'JWYK_\ $4?VOC>]'_P5
M_P $/JT?/[_^ >&?\*Q\<_\ 0NW/_@7I_P#\E4?\*Q\<_P#0NW/_ (%Z?_\
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MWYK_ /$48'JWYK_\13_M?&]Z/_@K_@A]6CY_?_P#PS_A6/CG_H7;G_P+T_\
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M?5H^?W_\ \,_X5CXY_Z%VY_\"]/_ /DJC_A6/CG_ *%VY_\  O3_ /Y*KW/
M]6_-?_B*,#U;\U_^(H_M?&]Z/_@K_@A]6CY_?_P#PS_A6/CG_H7;G_P+T_\
M^2J/^%8^.?\ H7;G_P "]/\ _DJO<\#U;\U_^(HP/5OS7_XBC^V,;WH_^"O^
M"'U:/G]__ /#/^%8^.?^A=N?_ O3_P#Y*KV/X)>#_$?A[Q/J-[K.DS6-K)HS
MP),\UK*&F^UV[B,+#)*V2@9NW3OVT,#U;\U_^(KN/ ./[6N1SS9$Y)])H^
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M.K7:VS1W$T:KN:)_P7>_X)M:XWP^UB7XF_$GPI\*_B;8RCPA^T-XV^!GQ/\
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M +>REF:JTJ3A9<M6<HTN>44C]:/A#_P4A_9Z_:KM_P!H3X=?"2;XP^ ?B_\
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M)6*H134:=1)J*:2:34+<J:4K6C965K*RTLDE[>)) GEAW$>\2^6'<)YB@!9
MN[B154('^\$RN<$TCN\DC2R.SR/CS'=F=G(+$%F8DD[F<\D\NQZFO$/^%J>-
MS_S$K+GKG1=(YQ_VYCGTZT?\+4\;Y/\ Q,K+W_XDND<_C]CP:7]C9@[R]G@-
MU%OZQ-:M^T2^!?:BI?XDG?FM=O%4$I-PJ:>S4GKH^62I)^]TA.2A_*IR6EVC
MVWGVZ>G?\^GM^M'/MT]._P"?3V_6O$O^%J^-_P#H(V?7/_(%T?KZ_P#'G_\
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M_H)6?_@ETCMT_P"7.C_A:GC?_H)677/_ "!=(Z^O_'GUH_LG,?Y,#_X45?\
MY$/K=#^2I^/_ ,F>V<^W3T[_ )]/;]:.?;VX_P#K\_I7B?\ PM3QO_T$K+KG
M_D"Z1U]?^//K1_PM3QO_ -!*RXZ?\272./\ R3H_LC,?Y,#_ .%%7_Y$/K=#
M^2I^/_R9[9S[>W'_ -?G]*.?;KZ=OSZ^_P"E>)_\+4\;_P#02LN.G_$ETCC_
M ,DZ/^%J>-_^@E9=,?\ (%TCIZ?\>?2C^R,Q_DP/_A15_P#D0^MT/Y*GX_\
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MO_T$K+T_Y ND=/3_ (\Z7_A:GC?_ *"5ETQ_R!=(Z>G_ !Y]*/[(S'^3 _\
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M,BFUY5\&OC)X-^.W@ZZ\<^!3JZ:%9^/_ (A?#.7_ (2&PCT:];Q5\,?&FL^
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MGV%G\_SU^T;I?@/]H+XV?\%>/@?K/P$^!?QQ^,7QF_:!7X1_!']H[]H#X^_
M3X2^)OV;;7PYX#\&:19:7:^!OBGXLTWXNV?@7P!K4NJ>(/!^L?"7P_J5E\1K
M^[U&V%O+O:2?#$XVMAJE6@\/3EB,/B<9AZT%7M!?5:>2R4X5.1*:J3SJC%Z)
M0C2G/6]HZ4J$9WE.<H4G1PE6%2,%*ZQ,\;%J2YO=Y/J=UJV^=II<JYO["])U
M#3=:M;'4-+U*QU32]0"2VFI:5>6NI6%W S%3/9WEE-+:W48VN \$[+N1E+AE
M;'P?^R!^V8/CM;_M&O\ %BZ^&OPUNOA3^VA\9OV7_AY9OXFMM$E\;Z-\-FT
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MBM41T445T$A1110 4444 %>\?L]?\CCJG_8!D_\ 2VWKP>O>/V>O^1QU3_L
MR?\ I;;UYF=?\BK'?]>)?G$UH?QJ?^-#OVA\?\)CI1'/_$AB&3[7=Y].G\_:
MOD3Q1\)_AGXV\:?#?XC>,/ GAOQ+X[^#U]K^I_"KQ7K%B;O6/ &J>*=+&B>(
M]2\,SM((]/O]8T8?V7>7(BDE-D6CB:-FW#]#OBAX2\-ZYK5E=ZRFK_:DTY8(
M_P"SKZWMH?)$[N3(DMG.6EWGEP^"H  KS8_#GP+V3Q.,9_YBMD!GMQ_9QX]C
MDUY>6YGAJ. P%.I2KS=*U2,HTU+EJTY<].<;MVE"5G%V5GK;=/KQ&'K2J8BT
MJ352+@U>SE3E%QG%]>5Q]V2OL?&_Q-^$?PO^-.AZ7X:^+G@+PU\1= T/Q7X=
M\=:-I7BJP_M"UTKQIX2O!J'AOQ3IX\R*6SUK1KX&ZL[RWDC99&=9!)$[QMX=
M\?/V"OV+/VIO%6G^._VB?V8OA#\7?'&F6L%A;^,?%GAE)/$LVF6KO);:5J>K
MZ=/I]YK.FV[22"&SU:2]AB21XT58V*U^G'_"N? O]WQ/Z\:K9=?QTX?+[4?\
M*Y\"_P!SQ1[?\36Q_'/_ !+^?;TKKGF.65')SPE>3E5=:3E15W6Y5'G>JUY4
MHVTBH)14%'W3-4L:HJ*JQ4=++F22M[2UM+JWMJMK-?'+RY?ECPSX,\'>"_"F
MD> O!WA+PSX4\"Z!I \/Z'X*\/:'INE>%-)T%8#:C1;'0+2WCTR'3#:L]O+:
M?9FCGBEE^T>:\LCM\J?#_P#X)O\ _!/SX:?%BR^,_@7]CO\ 9_\ "'Q0M-9&
MNV'C/2_ 6G1W6CZS++))-K>A:?<-/HFAZL)I6N$O='TNRN(99/,MI(&1"OZI
M?\*Y\"]E\3^V=6LOQS_Q+>?;K1_PKGP+D?)XG([YU6R./3&=.SGUQU]Z<\TR
MVK-5)X?$RJPIJ%.HZ2YH1@XRC&+NDDN5)65TO=BTM!T:.)HI1YJ:I)?!=<M[
M6CW?X^;ON?QW_&;X.?'J;]GW5/A7>?LI^,]1\17[?\%$?&GPW^(3_!_XK?%7
MQEI'Q.\8?M$^,-5^%WA;P-H?@GQQX+T'X1:_XRT._P!)^(OAWXY^,7OXEL+&
M&VT2XCD-S:3_ &+>_"KQ?K7[6/PFU?7O@]\0OCGJOQ<^#OP@^&'QVM?C%\*/
M'^F:'\"M*MOV>M2TKQ9\1?A%^T+:Z]9> CH^M>(KW_A'OBK\'_$.B3:]XB\;
M:M?ZU:3V]S;LH_I-_P"%>>".P\4@<=-7L\G!!'_,. !7DCT.2#SFC_A77@8C
M!7Q1C/0ZM9$<YX'_ !+N!R<\8Y.,Y.>.CB\'3UK3QLXSEAN:E+#NM%TJ*Q4:
MU*5IQ]VNZ]%RB[-_5XM/0TG3K3E3G3E1BZ=/$136C56K/"RHU5H_>H1P]:,7
MT^L2T?-I_,_^R%^P=X=^)7[*W["_PN\8?#_Q'\#/!W[*WQ5A^*O[17P5\7?#
MCQ'X6UOXV?M)_#/3;K3?AWK$&O:[=K9ZK\.O#>I7;>)+K7O#5K-IOC1].TW3
M[:[@L[:]CD_;OQGX4\,?$7PIXI\"^/-!TSQ=X-\<:)JWAKQCX9URW%[H_B;P
M_KMM-9ZSH^LVK,!>V.I6UQ/#=12-EXY65648 ^HS\.O QQE?%'W0O_(6LN@S
MA1_H P!G@8P.2.IH_P"%<^!?[GBC_P &MC_\K_7],CO751S'+Z6%>%=+%5(U
M(4XXB]))8B<,.L,ZE1.3;<Z2E"W,DHR:M?WB'1Q*K3KPG2C+VE:6&M)7PU*O
MB)XET:>GNQ4YWM9^\M]#XEU?X$?!3Q#X7^&'@?Q!\*_!FM^#/@MK_@?Q1\)O
M"^HZ5]HT?X>>(/AM EIX"U?PI:F7&FZAX2M(TMM#G4R-:1H@ =E#5^+GC+_@
MFW^TO;>+?VMK*T^#O_!.S]J;3OVI_BY\0_B-8?M!_M8Z!XRO_CG\*]+\?:=;
MZ-I?@Z]TNR\,>)/^$ATGX2Z9;0V?@*#PIXK\.V;P6=JU[';3/*P_I]_X5SX%
M_N>*/7_D*V/7_P %_3V[4I^'7@8C&SQ001@AM5LB".X.-.Y![\')QGIFLJ^*
MRK$S56=/'1J*=2<U&-H5E6C0A6]JW)\TJD<-AX2;=W"C35URJY3ABJ5&5%>Q
M4'[*S3]Z*HJK[.,;?9A[>LTM;.I)[O3\_P#]E7X'R?LR_LV_ W]GUO&>L?$*
M;X-_#CPWX#D\<:VLD>I>))]#M1%+J1AEN+J6TL_-9H-*LY;B62RTN&RM9'+P
MFNFT3X%?!GPUX:^)O@WP_P##'P?HWA/XT:_XT\5_%KP[I^EB#2_B+XF^(UFN
MG>/->\66XE)U35/%FGHEEK=U(RM=VRI&P7:I'VU_PKGP+S\OB;/;_B:V6.PY
M']G'WQ_0T'X<^!>R^)^V/^)K9>O/_,.Y_3T]:[)YS@)2DIT,4TZ53#N+IW7L
M<1R3E2=Y-.%25*E-J3DI.G%MZ>]E##XFE[U.<(+G4U)-)\\8U(1D]-)1C5JQ
M6BLJDK)75OR<\#_L5>&_!/[6^B?M&Z=JNB6'@+X3_LLZ!^RS^S9\#M \.2:5
MH7P6\--KYUKQ]K5CJ,FIW<-U<>*[>R\->'=-M[33=/&E:)HS6LMQ=/-)*WU%
MK/PL^&WB+X@^!?BSKO@?PWJWQ.^&.E>)]"^'?CN^L!/XD\&Z-XUMX+7Q?IF@
MWS/BTL_$EM:VT&JPF.1;B*".,;%#!OL#_A7'@4D$IXGSC&?[6LN!Z?\ (-ZX
MYR._;O1_PKGP+_<\4>G_ "%;'I_X+^OO65+-<#2@J:IXN4E5G6E+EO+VE2JZ
M[G=R;4W5<IN2:;D[[623PF(ES2?LK5:*P\W>-JE&/(U3EI9QBX0=K)IQ3YKW
M<OCC1/A%\+?#6N?%+Q/X?\ >&-(\1?&^^L]3^,.M66GB/4/B3J&GZ!'X5L;S
MQ9,SM_:,UKX;ACT2'Y8T6P7RBA/S5RNB?LU?L^^&K'X*Z9X?^#O@/1]._9ON
M-2N_@#96&CB"W^#]UK&F7VC:K<>!4$Q.D2W^DZE?V%RP:4O!=2='VN/O'_A7
M/@7/W/%&.^=6LOPQC3C^/K1_PKGP+_=\3^^-6LOPQ_Q+1CWZ54<VR^/+R8?$
MKE5!1Y:,?=6"JSK4%'LL/5JU*D$FE&<Y2:DY73>&Q-3F;E3G_'Y[M.[Q-.%+
M$.7=U:=.$*C=VXP2NK'SYW)XR3DX"K^B@#\<9/5B6))*^@_^%<^!?[GBC_P:
MV/7_ ,%_3V[T?\*Y\"_W/%'K_P A6QZ_^"_I[5?]M8/_ )]8O16^!;7;_F[M
MOU;)^J8B[=Z5W:[NM;))7^22]$?/E%?0?_"N? O]SQ1_X-;'K_X+^GMVH_X5
MSX%_N>*/;_B:V)^N?^)?S[>E']M8/_GUB_\ P!?YA]4Q'>E]Z/GRBOH/_A7/
M@7^YXH]O^)K8_CG_ (E_/MZ4?\*Y\"_W/%'I_P A6QZ?^"_K[T?VU@_^?6+_
M / %_P#)!]4Q'>E]Z/GRBOH/_A7/@7^YXH]/^0K8]/\ P7]?>C_A7/@7^YXH
M]_\ B:V(^F/^)?Q[^M']M8/_ )]8O_P!?YA]4Q'>E]Z/GRBOH/\ X5SX%_N>
M*/?_ (FMB/IC_B7\>_K1_P *Y\"_W/%'K_R%;'K_ ."_I[4?VU@_^?6+_P#
M%_F'U3$=Z7WH^?**^@_^%<^!?[GBCU_Y"MCU_P#!?T]J/^%<^!?[GBCV_P")
MK8_CG_B7\^WI1_;6#_Y]8O\ \ 7^8?5,1WI?>CY\HKZ#_P"%<^!?[GBCV_XF
MMB?KG_B7\^WI1_PKGP+_ '/%'_@UL>G_ (+^OOVH_MK!_P#/K%_^ +_Y(/JF
M([TOO1\^45]!_P#"N? O]SQ1Z?\ (5L>G_@OZ^]'_"N? O\ <\4?^#6QZ?\
M@OZ^_>C^VL'_ ,^L7_X O_D@^J8CO2^]'SY17T'_ ,*Y\"_W/%'O_P 36Q'T
MQ_Q+^/?UH_X5SX%_N>*/?_B:V/X8_P")?Q[^M']M8/\ Y]8O_P  7^8?5,1W
MI?>CY\HKZ#_X5SX%_N>*/7_D*V/7_P %_3VH_P"%<^!?[GBCU_Y"MCU_\%_3
MVH_MK!_\^L7_ . +_,/JF([TOO1\^45]!_\ "N? O]SQ1[?\36Q/US_Q+^?;
MTH_X5SX%_N>*/;_B:V)^N?\ B7\^WI1_;6#_ .?6+_\  %_F'U3$=Z7WH^?*
M*^@_^%<^!?[GBCT_Y"MCT_\ !?U]Z/\ A7/@7^YXH]/^0K8]/_!?U]Z/[:P?
M_/K%_P#@"_S#ZIB.]+[T?/E%?0?_  KGP+_<\4>__$UL?PQ_Q+^/?UH_X5SX
M%_N>*/?_ (FMB/IC_B7\>_K1_;6#_P"?6+_\ 7_R0?5,1WI?>CY\HKZ#_P"%
M<^!?[GBC_P &MCU_\%_3V[T?\*Y\"_W/%'K_ ,A6QZ_^"_I[4?VU@_\ GUB_
M_ %_F'U3$=Z7WH^?**^@_P#A7/@7^YXH_P#!K8]?_!?T]NU'_"N? O\ <\4>
MW_$UL3]<_P#$OY]O2C^VL'_SZQ?_ ( O\P^J8CO2^]'SY17T'_PKGP+_ '/%
M'M_Q-;'\<_\ $OY]O2C_ (5SX%_N>*/3_D*V/3_P7]?>C^VL'_SZQ?\ X O_
M )(/JF([TOO1\^5V/A#_ %?C/V\!>(O_ $/3Z]2_X5SX%_N>*/3_ )"MCT_\
M%_7WK>T+P+X0LQKIM5\0C[5X;U2RNO/U&S<FTG:V,PM]MBHCN28T\J1LHOS[
ME.1CGQ>;X2>&JPC2Q5Y1BE>&FE2B];/M%FE/#5XSBW*DDGO==FOU/EX'K[EL
M_P#?1/\ /FBOH,?#GP-@C9XFQE@,ZM9$!<]!_P 2L9[YSGKG)['_  KGP+_<
M\4?AJMB.?_!?T]N]=+SC")R<J>*;E-R5H)OEY()7]Y[M:,F6%K\SLZ*5[JS5
MM>Q\^45]!_\ "N? O]SQ1Z_\A6QZ_P#@OZ>U'_"N? W]SQ1_X-;'K_X+^G7C
MMQZ4O[:P?_/K%_\ @"_S)^J8CO2^]'SY17T'_P *Y\"_W/%'M_Q-;$_7/_$O
MY]O2C_A7/@7^YXH_\&MCT_\ !?U]^U']M8/_ )]8O_P!?_)!]4Q'>E]Z/GRB
MOH/_ (5SX%_N>*/3_D*V/3_P7]?>C_A7/@7^YXH_\&MCT_\ !?U]^]']M8/_
M )]8O_P!?YC^JXCO2^]'SY3)(TECEBD4/'-%)#*C %9(9D:.6-P00R21NR,I
MX*L1WKZ&_P"%<^!?[GBCW_XFMB/IC_B7\>_K1_PKGP+_ '?$_O\ \36R[=,#
M^SL?7GFHEF^ DGS4,7).S:<&UH^972GT>JTW''#XJ+4HRI*2O9IQNN9<KMIU
M6C\C\@;#_@E3_P $T-*UFU\1:;^PK^S=8Z_8ZK!KMEK-MX%V:A9ZQ:W<=_;:
MC;W'V\F.Y@O(8[B(@;$F7S F\ECZA\>/V&/V.?VH/%FC>/?VA_V:_A/\8/&G
MA^SBTW3O%'C+PXEWKC:1;S27$&B:C?VT]G+K&BP32R-;Z5JS7EE;[F2"**-G
M1OTN_P"%<^!?[GB?O_S%;+K_ ."X\'TH_P"%<^!O[OBC_P &UEU]0?[.SM]N
MOH/3%YAE+IN+P=?V3E.37L$H\]3D]I*R:UE[.'-WY%?K>U2QK;@JL7[1:QY[
M\\8IKSTBF]FK7=M=3\L?B]^R!H'QB^-?[(WBW7M1T/3/@I^QYJ&N^/\ P#\%
M-#\.06%O?_&5=)@\*_#GQ/)?6KP:?I/@WX5>')-8DT'PEI.FQPWNMWVGW<TY
MM;%+-];XT_L%?L5_M&^/=.^*7QW_ &8/@[\5OB+IUKI]E'XQ\7^%8+[6;ZQT
MMA-I^GZ[/#+;Q>)K#3[C+V=KXBAU..#8D2*L,<<2_IQ_PKCP*.B>)QC.,:K9
M<9Y/_,-&<GUQ@],T?\*Y\#?W?$X],ZM9'ZYQIIS[?RJY9EEKCS5,/B)PE5]M
M>5-2BZSIQI<]K[NE"--JR@X)1E!K1J-'%QDE"I",HP4;1DE+DC5G72\TJTYU
M+N[YI/WK/E/@[XT_LU?L^?M&> ++X5_';X-?#[XI?#K2IK"YT3PAXI\/VL^E
M>'+O2[-=.TV\\,BT%I=>'+JPT]%L+2;1;BQ:&Q M$Q;@1B?X5_LY? +X'?#&
M?X+?"'X-_#KX??":\358]3^'WA[PQI\/AG6UUZW^RZZ?$5C<QW)\12ZU;?N-
M6N-<DO[B_@Q!<RR0!8Q]U?\ "N? O/R^*/\ P:V7(_\ !=U]Z7_A7/@7^[XG
MZX_Y"MET_P#!=U]^M.>:9=.5><\-B92K04<1)T4W.#44E-K5IJ,5I9VC%-V2
M24:&+C&G&,X*-!_NTI)*DXN37+I=6<YVUE\3MN?F7\!OV$?V,OV7?%.L>.?V
M=_V9OA)\(/&>NV5SIFH^*?!_AM;;71I5Y<"[N](TW4;R>\N-#T:YN%22?2=$
M?3]/F"(DMN\:*@^L/\_X#U.!P"<G &2:^A/^%<>!?[OB?'?_ (FMGGVQ_P 2
MW\_6D_X5SX%_N>*/?_B:V(^F/^)?Q[^M7'-\#3C"C&ABH1I.I*%-4E%0E5:=
M625]YM)R;;;LK66A+PN(<G*4J;E*UY.2;=KVU=]%S.R5DKNR5SY\HKZ#_P"%
M<^!?[GBC_P &MCU_\%_3V[T?\*Y\"_W/%'K_ ,A6QZ_^"_I[57]M8/\ Y]8O
M_P  7^8OJF([TOO1\^45]!_\*Y\"_P!SQ1_X-;'K_P""_I[=J/\ A7/@7^YX
MH]O^)K8GZY_XE_/MZ4?VU@_^?6+_ / %_F'U3$=Z7WH^?**^@_\ A7/@7^YX
MH]O^)K8_CG_B7\^WI1_PKGP+_<\4>G_(5L>G_@OZ^]']M8/_ )]8O_P!?_)!
M]4Q'>E]Z/GRO>?V><?\ "8ZIG_H 2X^HO+<U:_X5SX%_N>*/3_D*V/3_ ,%_
M7WKTKX7>%/#>AZY>W.CKK NI=->"0ZA>VT\0@,\3GRUAM(2LGF*F&+],\=<\
M&:9IAJ^ Q-&G3Q*E."2<XI0MS1<E)WV:31OA\-5A6A*?LW%7=HM-WY7:UNSL
MS>^('_(5M/\ KR_]K-7#*K.RHBEG<[43(RY.!P?X0N5R2#DD 5W/Q _Y"MI_
MUY?^UFK\R_\ @J'^U4O[%W[!/[2?Q]LK_3[#QAH_@6?P7\+FU*\@L;2;XL_$
MV:+P)\.Q-=W4D-O;0:?XBUNVUR_N)YH+>STO2KR^EFC%OFOGXUXX;+/;.+G*
M-"2I0C\52O4E&G0IQ=G:52M4I4T^CGS:J+1Z4*+KXVA24HQC*;=24OAC1A[2
MI6F_*%*G4F^ZA9:RC?ZK^%OQJ^#WQQT_Q)JGP8^*?@+XK:?X-\7:GX#\77_@
M#Q-IGBFQ\,^,]%,*ZOX5URXTFXN4L-:L?/@DN+.7]["EQ$K*S$D:W@7XF_#K
MXGKXJ?X;^.?"WCN/P+XRUKX<^,Y/"NLV>LKX6\?^&WBC\0^"]?\ L4DPTOQ+
MH<D\,>J:1<,+NS:6-9D#-BOYE/\ @E--^SE^PA_P4-\%_L;_  '_ &A/@]\:
M?AI^V=^Q9\-?'&N7OPP^*_@_XCQV7[;_ .SA8C2OC'JFM#PQK>MC2]9^+_AC
M5=0\80274MLVI7.F74%G'(EK&J_H%_P16""Q_P""FRIY:X_X*X_M>,X4JN&.
MI^&@3(!RKG.6W@,%&XY4@GK@W-TZ4>6518?&RFW+D_?9=F$<OQ5*TM;QE4A5
MC/13I3@^5-OEYV[QJUK.,/;X"$(M/F]CF> J8["5;=.:%&I3G"UXU8R5[))_
MK3X*^)GPZ^),_B^W^'OCCPOXWE^'_C'5/A[X[A\+ZQ9ZM-X.\=Z'%;3ZYX.\
M1K;2.NE>)='@O+:;4=*NVBDM(YX'G=%F&SP7PM^WO^PUXX^+4GP&\&?MA?LV
M>*_C/%J,VCCX9:#\8?!&I^++G6+8L+O1[#3[/69AJ>KVNQO/TC2I+[5(B&A:
MT\^*:-/YB?BS\4?'/PB_X)S?\%XKSX>>(K[P9JWQ-_X+*>*_@9K'C;1IGM-0
M\)^"?C'XQ^$W@?QSK5CJ,.R73[[_ (135-0TQ;^.2-[7^U%F25)0K#^FKP7^
MP!^Q7X*^$_PK^#F@_LQ?!%O!7P??P3J_P^)^&OAI]=TGQ9X-:VU+0O'5KXE7
M3AXGE\7C6;9M8EUZ35I+_4M0>XFO+B\29K<88;$5<32E73A['FP$8IIJI/Z]
M@88]2Y?L*C2K4%[S;JRG)Q453D57I4Z-:6':J*M"IF%.HV[TXO 8WZB[.RY_
M;58UG:/\*-)<S;J0/K\C!(PPP2,.NUQ@XPRGE3Z@\@]0*2H8;^UU%9KNUO;6
M_B^TS027-I=07D1NXY7BF@::V>6(7*7*FVFA+B2*[/V:14E!0<YK_CKP-X5U
M7PMH/BGQOX.\,:]XXU.71? ^A>(_%&AZ%K7C368426;2?"&DZK?VE_XFU*&*
M1)I;+1+>^N(X6$SQK$"XZ.:/,HRDH\TH1B^C<ZE.FM=$K2JIN^T(SGM%L5.G
M[M[_ &>?;SM;_@_@=314D:JTD:2 [7E$; -M?[X5U5ADJXSP0"5(W#IFOYIK
M?]I#_@J[\=_!'_!37XR?";]J'X"_"#P/^P1^T?\ M,^#_AAX1U+]G?3?'/B+
MXTZ?\$M&LO&'_""_$W7-1U^TM/"/@^S\-F+0K#7/#EGJ7BSQ#K6J76JZM/:6
M^EVD4W-/%0IS<)1FG#"8G&5M'^ZI8:MA*4G/312CB?:)NR7LW'64E;6%"I.$
M*D.5QJ8O"82F^9+GGBJ&)KMQOI>G]6<''>3E=./+9_TJT5_/Y\4_^"C'Q9^*
MM[_P2Y\&^$?C]\*?^"?_ (4_;P_90\0_M-^._P!HSXE^'?"/C"TT;Q+X<\*^
M"=0L_@/\-T^)>O\ AWP/INLZQ<^*+O7+W5O$FH3ZE=>'-*M;72XS>RO%)H_L
M-?\ !0+]H?3/V&?CM^V#^U-XC\;?MKZ'X9_:F\3_  /^#T?[+'[.6BZ5JWCS
MX?\ A7XBQ_#'3/B]\/M"\+ZO<3>.? _C26\3Q5J>KN$MO#5IH]_;Z1=ZS; W
MIU56"K5*,KQE"I7I)I<RE4P^84\MJP;CI"2Q%:A\35XU)26D)2.=RM"A4:M&
MK3P\YM[TWB,#B<>HI-+VG+1PE=.4;+F45HYQ3_8J?]H/X3P?M"V7[*[>))!\
M=+_X1W'QUMO!ITO4O*D^%MKXK3P5<>(VUL6ITE'3Q&WV!-+%R^H2+NNO*2WC
M+'V@>XS@9QN"!CP I8AMN2P((5NA7&2"/YXOVHO"_P"TMX]_X+I_"WPU^R_\
M6/!'P%\4:]_P2UU8^,_BQXV^'*_%#5_!?@+_ (:)O[J\_P"$"^'6H:OI6@:O
MX_U'5!I6F6TWB?5(M%T>QFU:^FBO;RWM(G^N_P#@GY^V/\4-<^"/[:X_;4\7
M^#?$?C;_ ()W_M"_&KX,_%;XS^$_#J>!?#?Q)\$?"OPMIWCRP^(-QX3AO+NQ
M\,ZO=^&M0BM]9L-.F:R.HV\+6X9F_>8T<7!X*=:O)0C2HYYB*DW=R=# 9Q7R
M[VZCRIM4523A!2G*3G""<92C?I=&3Q%*E3]_V\<!2C%^ZH5L=A_K=#F;;MST
MHZO2W,Y-VIRO]J>!_P!J3X:?$?\ :3^//[+7A"V\3ZCX_P#V;/"_PL\2?%?Q
M =+M4\":/??%ZTU#5/"G@BUUX:D\]WXY30M/&O:QH;:= NF:5J%E-)>2S,]N
M/HZOY=_"WQB_:(_9#_X(P_';_@I;X1AT;2OVN?VX?VAO"_[6>IIX]TB/6--L
MO"OQX^,W@[P#\)O .MV%U&K1:7H_P*GT'2;2<+]IT1-5N]3L$>Z95/MWC[XH
M_P#!7WX0?ME_LX_LC:G^U-^S+X]U3]O'X7?%;QC8>/;C]G.3P]I'[&^N?!LZ
M/X@\<CX8^';'Q9+??'6P?PGJRZ)X(M/B;JNBF_\ $2KX@UZ;3K2.33;JZ=64
M5##SIM8A5*.&ES-1<LQQ.!CF2P3NI-.EAG-SK-N'-2G%11E5:TJ)I4ZU+&5\
M)#_GYA\!F#RRI6<MH1JXFW(FG:#A=MRT_<;XX?&KX;_LX?"#XB_'GXQ:Y-X8
M^%GPI\.7'BSQUXB@TR_UB72-!M9[>WN+R+2M+@N=1U&19KJWC2ULH))6+DG
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M65U<SV N;#3[6"\AL4N8[=!*!7RQ\'_V )?A-\&_^"@?PD;XJ)KS?MT_&O\
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M@-V_[3?G1M_VF_.G44>S?=?B'M%V?X#=O^TWYT;?]IOSIU%'LWW7XA[1=G^
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M ,B4Z*N?V=J7_0,U+_P7WG_QBC^SM2_Z!FI?^"^\_P#C%'MJ/_/ZC_X-I?\
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MJ7_@OO/_ (Q1_9VI?] S4O\ P7WG_P 8H]M1_P"?U'_P;2_^6![.I_S[J?\
M@$__ )$IT5<_L[4O^@9J7_@OO/\ XQ1_9VI?] S4O_!?>?\ QBCVU'_G]1_\
M&TO_ )8'LZG_ #[J?^ 3_P#D2G15S^SM2_Z!FI?^"^\_^,4?V=J7_0,U+_P7
MWG_QBCVU'_G]1_\ !M+_ .6![.I_S[J?^ 3_ /D2G3HW\N1) JL4=7"R#<C;
M2#M=<C*-@!E!&1GD9S5K^SM2_P"@9J7_ (+[S_XQ1_9VI?\ 0,U+_P %]Y_\
M8IK$4U:V(A%)W7+7A%I_S1<:EU-*]FFTG9J',E)-4ZMU[E3=?8GW_P )_/=^
MV%_P2&^(;?LX?MVQ?LW?M9?M<>(O%_[2$OQ*^*5_^SK+XA^%$'@'XN_$WQM=
M63OX7\3:OK?AG3];N=%&G6EKHVDB^\663:=I>DZ=I]O=P001QG2^*7[)/[3/
MPJU[_@FW\0M7\!_$W_@HW\,?V7/A[XVL_BO\"O&'C+X7VGQ,T;XM>,=!T>'P
M+\2M!\/>()/"?PM^)"?!E8-0\$>%=.U*XFU/2M(M(]1T^ZU*^G>=?W__ +.U
M($$:;J0(Z$:?> ]0>HAZ9 R.AQS2?V;J. /[+U'Y3D?\2Z[Y[_,?(RP] V0.
MPKRH8/"0C5CA\3#"RE4PU2A)5J=10^J0Q-/#14:DYQBZ$<76E1D_>I3<:D6J
MD(R.N52JW*52C*KS*I&W).*BJLJ<Y^["*3B_913A;E<7*%G&33_(/_@GU\!_
MBSX7_:<_;-_:9U;]GJX_8S^"7[1-K\+K?P1^S%?^)/".K:W>?$'P;;ZG'XX^
M.OB7PU\-]2UCX>> =;\:PWMGI3:/HFHRZCJ4-BM_K2BX05^N-7#INI<$Z;J1
M(& 3I]Z3CKC)ASUZ_0#H!1_9VI?] S4O_!?>?_&*]"E.A2HT:*K4K4:?(OWU
M-[SG4E9NHW9SJ3:5VHJ3C&T4HQXW"<YSJ<M23J24I-TYK50IT_Y%JHTH*4MY
MR3G)N4FW3HJY_9VI?] S4O\ P7WG_P 8H_L[4O\ H&:E_P""^\_^,5I[:C_S
M^H_^#:7_ ,L#V=3_ )]U/_ )_P#R)3HJY_9VI?\ 0,U+_P %]Y_\8H_L[4O^
M@9J7_@OO/_C%'MJ/_/ZC_P"#:7_RP/9U/^?=3_P"?_R)3HJY_9VI?] S4O\
MP7WG_P 8H_L[4O\ H&:E_P""^\_^,4>VH_\ /ZC_ .#:7_RP/9U/^?=3_P
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M0 9/J?S-&3ZG\S111U^:_.(!D^I_,T9/J?S-%%);( R?4_F:,GU/YFBBCO\
MU]E@&3ZG\S1D^I_,T44W^K_, R?4_F::6;*#)Y< \]L'\OJ.:**3Z^GZ@/)(
M)Y/4]S29/J?S-%%/I]WY &3ZG\S1D^I_,T44G_G^0!D^I_,T9/J?S-%%/O\
MU]I@&3ZG\S1D^I_,T44+= &3ZG\S1D^I_,T44NGR7Y1 ,GU/YFC)]3^9HHI@
M&3ZG\S1D^I_,T44/K\__ &\ R?4_F:,GU/YFBB@ R?4_F:,GU/YFBBCK\U^<
M0#)]3^9HR?4_F:**2V0!D^I_,T9/J?S-%%'?^OLL R?4_F:,GU/YFBBF_P!7
@^8!D^I_,THYSDG@9')'(QCH>GJ.A[BBBI?\ 7WL#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ =0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ@/ +'%1_:[?_GXB_P"^Q0!/130P90RD$$9!'>G4 %%%% !14'VNW_Y^(O\
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M9=-U&VOH?]9;RK*H]2ISC\>E?1WBW2?[;\*ZC8*H:22(F(?]-%^9?_'@*^:
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MO"']IZ_/XENDS:Z=^[M\CAIV')_X"IS]64]J^F* /B'QW_R4+Q+_ -A6Z_\
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M0_9IN/,P?%$03/WA8DG\M_\ 6NHT#]G[PQILBS:K<7.JRK_ W[F(^^U3N_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
B0 4444 %%%% !1110 4444 %%%% '__9              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X29H17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(P.C Y.C$P(#$X.C Y.C U   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,R.   DI(  @    ,R.   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,#HP.3HQ," Q.#HP-CHR.0 R,#(P.C Y.C$P(#$X.C V.C(Y      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  %+P         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ 9@"@ P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
M   ! @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!
M!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/D
MY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'
M" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!
M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S
M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HH ** "B@ HH *Y_6[R#3986O);J5)
M%(18[R.WVD?>))DCW9R/7&.V>0#"?6-.:^2X%QJZ1*FTVRZQ:^6QY^8DS[L\
M]F X''6LVXU-VN4,%[JRPQJHQ_;UH/-]2P+'!YS\IQP.G- %J'5H/.\R:YU4
M*5(,:ZY:LH.3_P!-0>A'?MTZDSV>KZ?:B7SKK6+O>Y9?/UBU'EC^Z-DZ\?7)
M]Z .F\/W45]:7$L!F$?GX DNEG8?*O&Y7<#Z9[YQS5)X+Z'5-1:XL=5O(I9U
M>W>VO5C18_*0;=IE7!W!ST[Y[T 4?[.OO+C7R_%N54J7^W6N7)!&3^\QD9!X
MP,@<8R#72SUO,@>Q\28^;8PU6 D\%5SR,9X<]<,2.5 ! )(M-U/YGE7Q<&>+
M:8Q?VI6-N/F4[P2?KQ[5=DAO&LY88=+UY;AE81S2Z@F$8YP3B?H..QX'>@#J
MJ* "B@ HH ** *][?6FFVDEW?W4%K;1XWS3R!$7) &6/ R2!^-<G<>(TOIA+
MX*:UU5U4)=_9%AG\L=8P0US%MSN?&-V<$<8H YS5M<UR:YFAU+P?=7<B*%<G
MPTEPI7:S !A>$,,;NA."<=3@Y2ZCK%[=S7\?A?5(WW+D-X0A0J78DE=]QN.2
M6+')QN).,YH T;6YUR&.!QX4F83.T(W>'+=3E@<EP+P%05^4LV%Q@'K5K2];
M\11W\T.G^$[BUG>-3(X\/1P*ZI\B@N;T*2!P%SG'(&* .W\-7&I7-I=2:K;/
M;W7VC!1H4CXV)CA)I1^.[\!WVJ "B@ HH K6]_:W6G0:A#,IM9XEECE;Y058
M @\XQD$=:A&N:28?.&J61B!QO%PFW.TOC.?[H+?09Z4 .M-8TS4)/+LM1M+E
MRN_;#.KG;G&>#TSQ4ESJ-G921I=7,<!D!93(VT$ @'D\?Q"@"&XUS2K2Q2]N
M]1M;:U=_+6:>58T9LD8!;&3P?RI_]K:=LW_;[;9N9=WFKC<IPPSGJ#P10 V'
M6=+N)?*AU&TDDW^7L2=2=_S';@'K\C\?[)]#4EMJ5E>V\%Q:W,4\$[%8I8FW
M*Y&<X(X_A/Y4 6J@MWN75C<PQQ-N(41R%P5[$DJ,'VY^IH DD=D *QL^3@A2
M./?DBJ#:G;!F:>(1-$Q#&22+*D*#_>X.UB?IGL1D 6WNH1>2PPP%9';S),2)
MD\;2<!L\%0#QU/UJY [R0J\D30L>3&Q!*_7&1GZ&@!(2IEN %P1( QSU.U>?
MRP/PJ:@ HH ** ,BUT<Z;IT-K;ZG?);6T2QQH$B8JBC '^K)/ ]S51K-'G\T
MZMKP;(.!$P7C/\(CQW]/3T% $D<8B)*ZIK1) !W6V[ITZQ?_ *^]2Q210W*W
M,DNIW4BHT:[[0C:#@G[J+UVCUH POM7BBY+3Z-IZ"QDN)559]0$$B$,VXLC6
MK$ N"!AFZ@CCIF7X\;%HKJ72G\YXPJPQ>)%BYX;;M^SJI;KSSPK#.,9 '6MU
MXZDN"\>B\H!&2=?A91DJ>0+<\C=G.,X4X[ [NCOXC>^LWUVSB@B<ML1=069T
M?:W55MT&-N[G>>HX] #I;EKA;=C:Q1R3#&U)9"BGGG+!6(X]C6.3JLDG_$SV
M6J!1Y9T\-<%VYW;MT7RC[N,=<MGH* ,Z6UU@P*(=?D27/S,^AEE(^@QCMWJ*
MX;5EO&2"[U$P[6 <Z3&1NXVG/!P 2"-O..HXR .B36)+LEM3O(K?>K!7T92V
MSG*;AGYON_-MQP>#GB:.VU(>1YFN3MM \[;HN-YSSM^4[>/7=CWH W-+W>7.
M&EGD42_(T\(C;&U>P5<C.><5?H ** "B@ HH *:Y<(?+"ENP8X% &"/%&DVD
M,T-WJ>D6M]&\@:VENTBPVXXSGD9X.<=\XK,D^(>E03B"74=$\PA7S'J#2)MZ
M'YA%C(;HO4CGB@"5?'&E^8RIJ7AX2.=W.J!00  26\OKG  [CGM6M#X@TC4;
MZVM]/U/3[V4N2R0SI(R*$;YL \<X&??WH V*Q;S5=/\ #BQK>WX_?EBINKN-
M"2,9QO9?4<#@>U &6WC#1&EW_P!NQ !LA!?V>!_X_DC&1SGKZ@$1/XSTY9I&
MCUFUD1F5E5]3M%" 'D#!/!''))],'F@!$\9:<UP6DURU2(Q,NQ-0LVPQ(P1D
M]@./=CD' J:#Q?HD3*S:]'-@8/F7]GANO7##U[8^Z/?(!L:=?6FNVMQ-;78D
M@\_:&M[E6QA5RNZ-CCUQG//O68?$=CHNKZK;ZEJEJ6>Y62*-[V%6B0PQC:5=
MP5^8,<8YW9[T *_C?078$:K:I@$86_M>O'/,G;^OTK./BO388?)M]?B9?+V!
MY=4M-Z').X$ELGD#YLCY1QUR 64\7:)Y\4KZ[$=C,YB&HVFPD@C!^?) R<#/
MIZ#$UUXRT>[LYK:UU.S2XFC:.)AJ%O\ *Q& >),]?3F@#J6SM.T@-C@D9J';
M=?\ /:'_ +\G_P"*H -MU_SVA_[\G_XJ@I=D?Z^$>XA/_P 50!AV_A9;A'FU
M2]U22[:60EH-4N8$*[SLPB2A5^7;G '.3@=*HW?@1&.;;6O$0WR$L#KMPOEJ
M0/NYW9P1P#_>.2< 4 36O@6VB"F?6?$<K!RQ#:W<8(P0%RK+QT/KD=2.NC:Z
M!!IM];W%G-J3_,5E%QJ=Q.NTJ?X9)&&<[>0,_K0!M5E")IIFN-)D@MV*B*4S
M6KL&"D[<#<@&,MSSG(]J (;V'4!9R-?ZCI'V51ND,]@VP '.3F;'!KF[BPLI
M[I8'\0^'PB1HBV?]F0E411\J@%BP !8@9XW-CCH 6H;*WLW9Y-<\/R%E3A]/
MC'1<*?ED'\,HQVP_OSNVMMJ<=G"EG?:4MJL:B%8;!@@3'RA<38QC&,4 30NU
MG;W<NH3QSLLH9C!;,NWY5P-N6)/&<CU]JSH[:5;S7'M-1LA;O<!KF*XLF?RF
M^SQ KGS%!&P*>G\6.U &7/HVC261FN#X1>U#E2[Z4K(&/./];C)X^O%4IM(T
MJ^N+66#6?#FVY?R8TM])AD24JN=I)9CQA3U R%'< @&[+9K(\:S7GAUWCMR8
MP^G9*P8VG'[WA,-CTP?>F1V/DZ'?6ME>Z-;Z?&)8[A;+32H0X^?A9<;@/8\T
M =/*C21.BR-&S*0'0#*GU&01GZ@UG?V5>_\ 0P:E_P!^[;_XU0 ?V5>_]#!J
M7_?NV_\ C59VILNFO!#>>)-8#W!/E+%:QR%MN"?N0$]Z .>/BY=,L+C2OLNH
MZEG[1LE FBN)\EGV*$B4A_O*",'*$DCK6S::A/XCD::QC0I V'_TR[A&X@<?
MZM0>,\8."0>.X!F7FLIH]RL5_%<^;-*;2!!>7Z[]Q(PI*$.P!)W+S@?+T%7[
M7QA#?FPN;BUEMHB^]0L%Q(S$JRA1B+:>3V)Z4 =1+>Q0V/VQDN#%M#;4MY&D
MP<8^0 MGGD8R._2L:6]O-;*C27U"R,(S+Y\!MMV[ICS8'W8P<[<8R,YR* *U
MQ9>*(;>26.^NKAU&1%%<VP9_8;K8#\R*S[BS\3R$'S-7<E59A%J-JFTGJI_<
MCD8&>W/!/- #8(/%"21D-JZS/M5HI-1M&,:ECEB/)(P">2,G& ,XQ6O_ &;X
ME_Z"TW_@1!_\B4 266HMI/VBWU-M0N;DR[S)':R7 P57 W10JHZ=,9_,5G6;
M7FKZAJMUHL]]91_:56>.<K"3+Y$7.R2W=@-I0=<$@D>I )?LOBK[0(_M5[LW
M8\W[3:[<8)S_ ,>V<< =,Y8=LD9T]OXJ::5B-9+1$I&$U&T439!R5'E <!0?
MFP1N&.^ "Q"/%TD$4A35(R\JH8VN[+**<9<X@(VC/(!+<< U/<6>O#3;B6_O
M;HVRQN9H3<0;F0 Y'RVPZC_:'7J* .PHH *K26[MJD%R"NR.&2,COEF0C_T$
M_I0 0B\WMY_D%?,;9LSPG;.>I]:L=Z (9[<R.)4DD2149%VN0OS$<E>A(VC!
M(..?4YB6T=Y6>9W495@$G;J".O08^5>,?WO4Y +E4TN'ME_XF-S:HS$E-IV#
M&>GS'D@8Y_04 *VI66/DO;4G(ZS#IGG]*I2^(+2%F$D\&5.!L+.""<#D+Z=?
M3]: (TUR.=@T;V/F!&P))63C=C[Q3_9Y&/0],&M(:E8X&;VVSWQ*O^- $8GD
MN8;EK"2VWB0!)"-RGY5)S@C)[=?2JMEJ$<=_J\=TMK:,EV AX0S+Y,1WDG[Q
MR2N?10.U  VJ3[X0MQI.T?ZUC=')X/W1CCG!Y)[CWJ&77((9;<S/9--Y?S/&
M7<#^\ 0IP,A>IYQTXH E3590L8WZ4H ^91>GCCH/D]?Y>_$EYJ<!TFY(DLY9
M_)?$ D$BNV#A<<%L],8YH U:* "B@ HH ** "N8\2/':RVQNH]4NXV4A%L]0
M2T*$8R6)FBWYR,=<8/3- '.W-Q93V[1QV7BJW<XQ+%XBA+#G/&Z[(YZ=.]94
MINOM)6*'Q28.TC>*;<.>%_A\TCC#=^_Y $D/F,3]H3Q9&.H,?B:V<_=(QS..
M,D-GKD#MD'7^W:?C_D%>)?\ PHX__DV@#HO#;2365P]NMU;P^>=J7UT+N3[J
M_P :S/@9[9]3CFL'47>VUK4TU&'6;HO*AMY;+6$MD6/RHQCRS<I@[PY^[SG-
M &8! ,Y;QD<L&_Y&&UX ZC_CYZ'\_0BJ4RW*73M;_P#"6RPOSME\3VJ>7[*!
M*2?3DGK0!;986$F)/&:%T"C;X@M?D((RPS<]3C'.1SP!5B&2-(IHX8?%$ES*
MQ,$ESX@A*PL1A1A;KE0>>0QY/7@4 >F44 %% !10 44 ,EC6:,HQ8 ]2CE3^
M8YJG865A9W-R;-CYLF&F3SV?G+?-M)(!)SD]3CG.!@ L7GV4VKQWODFWEQ$Z
MS8V/O.T*<\')(&.^<5CO=>%YX?[0-WHSV\KJ@N"T3*[J2P&_."022!U!)- $
MUO>Z/-J,$<&J:?([Q?N[:-XR7VGAEQ\W'S#CCDUJ6TD$MK#):O&]NZ!HFB(*
ME2."".,8Z8H J3VEE.;C[4P>-I%#*[E5!VJ ,9P3T_.J>GVFFPC7HS-'-:R7
M -S'*IV1C[/$"A+<,NP YZ8;':@"S:S:(Z8M)+!E20-B(I@.Q(!X[D[AGOS5
M.27P[<^4XO-*9(U^U+\T9&S:P#]?NA0_/L?0T 2M=Z$TUF+F_L9;EAY,6Z50
M)&95/"YP201COAL#AN5#Z-=>&KQ=,N;-; 0.C26FUTC&ST3T7!QZ8H V:* "
MB@ HH ** (KB=+:!II%D95QD1QM(W7'"J"3^ KF-4NM<UAHQX>^U6AASY_VH
M_9-^X#;M,EK+NQA@<;<=\@@T 9_]G?$'_H(1_P#@TA_^5U8>IQ>/+*2YFN)+
ML1AHU$H\0VT<<F>I4-9K@+WR 3GC=0!8TF+Q]>2W026:%;>0Q[YM<M95DR2V
M1MLG(X(/S!3AAQV&I_9WQ!_Z"$?_ (-(?_E=0!J:)>WVF0W,&N_:I[TS[M\*
M-=+MV+CYX[>,#ITVY[YYXPXG\1ZQJFJW?A\7%A 9XQ/#=W:6[^;]GB)^1K.4
MC"E1PY!*DB@"F\GQ-3S=NG7S[&VKMUBP_>#YN5S9CCY1UP?G7C[V*LK^-TN[
MHRSSHT4DD<A/B*T50!&K;MOV/Y004 R 07!( 8M0!<C/Q,>8QM97L:AMOF-J
M]CM(W!<\69.,$MTS@'C. ;,EKXX^P3RZE,PLT$GGQ'5("SQ*2#C;8C[RC(^9
M3@C.T] #T6B@ HH ** "B@ I&16^\H./44 -\J/_ )YK^55]014TVZ=5"LL+
MD$#!!P: +'E1_P#/-?RH\J/_ )YK^5 $<PEAA8V<$+2D@[7<QJ>V20I[>U8\
M%_B[U=9K>QMITO%6,2L(_.3RHOG+<[CRP!Q_"!V- $HU#]YRVD["J\"[Y#<;
MOX>1C..G3WXJ#Q#"9(P5LA^]\J09D..<9!\O!&0>> 1@Y&1D M)J:O9QR*VE
MM*T8;:]SL&[CCE20,9ZC(Z8HN;^#^R[IB=/DF$+;($D$@=L'"XP"<\#% &W1
M0 44 %% !10 44 %1SQ"XMY86) D0H2.V1B@!9!(4(C95?L67(_+(J'9??\
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M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L
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M^O_:  P# 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$LM'CO8YH?MNGQM>WXDN(PNGQ1.LHBD9)GC21T /TN_X?:_LC_\ 1QGPB_\
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M<<: *B*H 55      HH _12BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ H/(HHH \+^&^N?%WXN:;K&L:
M;XL^&^BZ=#XCUK2+6TN?!M]>S1PV.J75DADF758E=V6W#$K&@RQ &!4?CK]F
MKQU\4;_1[OQ/JWP*\27?AVY^VZ3/JGPMN;R32Y\JWFP-)J[&)\HIW(0<JO/
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M_"XTW_X]0!ZKH'[.7@7P]X)\)^'8?"/AV31? ME!IWAZVGL4N%T>WA2..*.
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MM,J))>W&FPR7#JC*Z R,I8A61& )X**1R!7B_P#P]\_93_Z.3^!?_A<Z;_\
M'J/^'OG[*?\ T<G\"_\ PN=-_P#CU 'MFJ_"OPOKWB"75K[PWH-YJL]LUE)>
MSZ?%)<20,I5HC(REC&5)!4G!!(Q3;WX3>%=2"_:/#/A^XV6:Z<OF:="VVV6.
M6,0#*_ZL1SS($^Z%FD&,,P/BO_#WS]E/_HY/X%_^%SIO_P >H_X>^?LI_P#1
MR?P+_P#"YTW_ ./4 ?0]O;QVD$<44:1Q1J$1$7:J*.  .P'I3Z^=?^'OG[*?
M_1R?P+_\+G3?_CU'_#WS]E/_ *.3^!?_ (7.F_\ QZ@#Z*HKYU_X>^?LI_\
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M6G6.L:/K%K)97]A>VZW%M>P2*4DAEC<%7C=6*LK A@2""#7AY_X)1?LMD?\
M)M?P!]/^2>Z1_P#(]>_44 > _P##J#]EK_HVKX _^&]TC_Y'H_X=0?LM?]&U
M? '_ ,-[I'_R/7OU% '@/_#J#]EK_HVKX _^&]TC_P"1Z/\ AU!^RU_T;5\
M?_#>Z1_\CU[]10!X#_PZ@_9:_P"C:O@#_P"&]TC_ .1Z/^'4'[+7_1M7P!_\
M-[I'_P CU[]10!X#_P .H/V6O^C:O@#_ .&]TC_Y'H_X=0?LM?\ 1M7P!_\
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M7P!_\-[I'_R/7OU% '@/_#J#]EK_ *-J^ /_ (;W2/\ Y'H_X=0?LM?]&U?
M'_PWND?_ "/7OU% '@/_  Z@_9:_Z-J^ /\ X;W2/_D>C_AU!^RU_P!&U? '
M_P -[I'_ ,CU[]10!X#_ ,.H/V6O^C:O@#_X;W2/_D>C_AU!^RU_T;5\ ?\
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MB7\<?COXXUKPCXR\*Z!X8^(WA;P]X?U5KJVNFU:RET;4=3OH9+62)UC"RMJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS_X-(/\ XJC_ (77X-_Z&WPS_P"#2#_XJ@#X<_L7_@J=_P!!C]A3_OQXF_\
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MM]4UK1_^"=6L:G9W#7=O=WNA:_<3P3,D4;2*[Q%E<I! I8')6&,=$4#]#?\
MA=?@W_H;?#/_ (-(/_BJ/^%U^#?^AM\,_P#@T@_^*H _.>#]EC_@HM9^/[3Q
M1:VG[ .GZU9WMQJ@FLK'Q+;+<7T\30O=S+&JB:?R9)HQ)(&95N)@"-Y-=J-$
M_P""IP'_ "&/V%/^_'B;_P")K[C_ .%U^#?^AM\,_P#@T@_^*H_X77X-_P"A
MM\,_^#2#_P"*H ^'/[%_X*G?]!C]A3_OQXF_^)H_L7_@J=_T&/V%/^_'B;_X
MFON/_A=?@W_H;?#/_@T@_P#BJ/\ A=?@W_H;?#/_ (-(/_BJ /AS^Q?^"IW_
M $&/V%/^_'B;_P")H_L7_@J=_P!!C]A3_OQXF_\ B:^X_P#A=?@W_H;?#/\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444&@#RW]C[_DDVK?\
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M.K"_\,Z=JXU:UT;R-"GACA2YRWF?NT0GYY-I)7S)-N]OU:H ^'?^(;?]B/\
MZ()H/_@XU3_Y)H_XAM_V(_\ H@F@_P#@XU3_ .2:^XJ* /AR3_@VX_8E"';\
M ]!W=LZQJG_R37R!\,?V2/\ @G5XM/CR;7_V9;SP[8^%_$$&EZ%)9GQ!KTWC
M2QN[J_L]/U&RALW>62.ZN-*U 1K&L@,<<3[_ -[M7]FM5TV/6=+N+.9KA(;J
M)H7:"=X)55@02DB$.C8/#*0P/(((S7R#XH_X(:?L[IIOANT\&>!;?X;_ -@R
M:6)KCPM<W&EW>KP:?.EQ MQ<0RI*]T)8T<:@S&]1@66<%F) /C[X9?L7_P#!
M,OXI_$/5-!LO@)K%E;Z>?#\,.KZAI7B2UT^_NM9OSIUM:([R!HYTO!Y,J2JA
M1Q*.?L]P8^C^'O\ P3P_X)B_%7XQ^ _ ?A_X36FH^)?B1H \4Z) EIXE6%]-
M/VS;//.SB*WW&PN@JS,CDQ8VY=,_;7_#J3X$)X:CTFS\&ZAHNGPZ/I.B1PZ/
MXGU;2Q'#I=]]OT^=3;W2$7L%T6E6]!^U$R2!IBLCAM[P3_P3N^$?PZ\:?#K7
M]'\.:E;:A\)M-?2?":/XBU.>TTB%XKB%F%M)<-!),8KNX0SRH\VR4KOP   ?
ME#;?L8_LG^#W\[XA?L1>'_#%A:_$Y?AE=_\ "/\ C/7_ !9>R72Z-?:E-+;V
MEK L\VTP6D:JJDO]IE8[!#\_I&L_LB?\$G=%^(OACPNW@?PW<:IXPT2W\0Z8
M;5O$-Q;O:7%E)?V_FS)(8X99;2,RI#*4E960A?G7/Z93_L9_#:YU=;]_#K&[
M7Q;/XZ$@U&[7_B<SZ?+ILMU@2X^:TFDC\O'E#=N"!P&'!I_P2=^ MOK7A^_M
M?!NHZ;/X:\.6OA*T73_%&KV4,^FVUHUE!#=1172QWC);,8A+<K++L"@N=BX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **3>/44;QZB@!:*3>/44;QZB@!:*3>/44;QZB@!:*3>/44;QZB@!:*3
M>/44;QZB@!:*3>/44;QZB@!:*3>/44;QZB@!:*3>/44;QZB@!:*3>/44;QZB
M@!:*3>/44;QZB@!:* P)ZT!LT %%%% !11G%)O7U'YT +12;QZBC>/44 +12
M;QZBC>/44 +12;QZBC>/44 +12;QZBC>/44 +12;QZBC>/44 +12;QZBC>/4
M4 +12;QZBC>/44 +12;QZBC>/44 +12;QZBC>/44 +12;QZBC>/44 +1110
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MA94>( '8_P#$3/\ L._]%XTW_P )O6?_ )#H_P"(F?\ 8=_Z+QIO_A-ZS_\
M(=5/&/\ P5G\ Z!?>(--TGX5Z9XH\1>']3O])FT;3]2T];LW$'CB'PC!&_FA
M%@:XDF2Z3SF1 AVEL?O*[[]AG]MW0OVQ_B=K_A6^^$-OX)O]#TTWZ2R7-EJ,
M-ZT&JW^CWJ*8E#*L5_IMPL;, 98PKE8B?+H XS_B)G_8=_Z+QIO_ (3>L_\
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M26MG.I;[#<)Y@<)#$RONGV@,0#T;_B)G_8=_Z+QIO_A-ZU_\AT?\1,_[#O\
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M5JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF]5D1U([%:^_OBK^S_K'Q \;?L_ZXUUI,UQ\+?%,FN:W/<,WG7L3^&]9TLB
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MVXNY;G2S&X:"UAF.V*[D0JQVDMG&0I'ZQO\ </TK\A_A7\4?#/PB_P"#M/\
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M=M;A99&:3]RA+$J"-VU^%^@6%U<SP:/I4,]Y??VG/(EE$K2W>T*+AB%!:8*
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M5W>459EV9V[6(Q@G/+_\-S_!7_HK_P +?_"LL/\ X[1_PW/\%?\ HK_PM_\
M"LL/_CM 'H?AKPGIO@[34LM)L;'3;.,EEM[2W2")2>I"J ,GZ5HUY7_PW/\
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MUAO+[Q7XNT;PM:0S.\<9-[>QQS2%U5L&.V%Q(JD .\:(63?N'%ZS^V_-\/\
MX>P^/O%FA>'=%^'.K,!HNH'Q3''J5^LCDV[R0W4-O:P"6%'EPUX7^Y&%>1PE
M?)7Q@_;C_:J^->B:39ZI_P $]?'ENVB:[IGB&SN+?XEZ$TT%S8W<5RFTRVSA
M5D$;0R%0',4\H5D9@XY#QG\7_CCX]U&ZNM0_X)K?$8274MW<*EI\<(K*&RFN
MRYNY[:.%T2UFN/-F\Z6 (\PN)P[,)I-P!]U:U_P4<^'ND:S'I<4/B34M:N+Q
M;&WTVTTUFN;AW?24@<!BJK%*VN:5B61E1/M7[UHO+DV66_;^\'VGA#7M8O[#
M6M&A\/RI;3QZK)9Z>))S?RZ:\*S3W"6ZLE]!-;;I)4CE= 87FCDBDD^$])^/
M?[06D_%;6?& _P"";GC";4]8T_0],$;_ !-T58;.'1[A[FR\K; &WB9D=V9F
M+BVMU.5A11JZO^U-^T/K-G>0R?\ !-GQQ;-?3/<O<67Q?L;*ZBE>[GO&DBGA
M"2PN;BYN'W1LK?OG7.T[: /NSX=?ML>#?BOXDT>RT&/6KW3]>D@M[+6#9^7I
M\UQ/I":S# "Q$A9[!_.W",HNTHS*Y56X7XZ?\%#])^$_PXU6]N-'D'B 'Q'!
MI-FUY"L-])I=Q>0#!D>*2;>+0RR1VJ326\9+R!4VR-\I>!?VK_VAOAII.C6.
MA_\ !-/Q9I]KX?N(+O3T7XJ:8_V>6'3%TF-\LA+%;!5@^8G*C)RWS54\<?M,
M?M!?$?1FTW6O^":WC>]TN::ZN;BP_P"%OV,5G>R7,SW$KW$" 1SL)Y'EC,JM
MY,C;XO+;!H ^Y/%W[>?@?P5\5=>\#D:EJGBK0A;+_9>FM;75W=R3W%C;1QB%
M9O,@_>ZE8@R72P1;;@2!S$DDB4/&7[;FF%=+M]#T/6KZ_FU?1].U,31(L.@M
M>:\='DCN&5R3*LT%^JM")(B]KDR!'C=_BV?]I[]H6Z^*<OC2;_@FSXYD\13
M9E;XP61MT;[19W+.EMC[/'(TUA9N[I&&<VZ;B>:;??M,?M ZCXEM]7D_X)K>
M.%O;6\6_ B^+]E%!-<+J$FI)+-"H$4S)>S33H9$;RVE?;M#$$ ^Q?AC^WCI/
MQ9^/'AGPWH.B7]QHGB*#6X&U.26+=87VF_8'\B:.-W\EI(KN4F&<Q7,4ELR2
M0+DE/HB-]Z],5^4OA7]H/]HKP5\8]-\<:?\ \$Z_B+_;&E6.H6,'VSXM:5?[
M1>M9F5Q+<123IM2QBBCCCE6)(WD41_,"/4H_^"I'[7\:!?\ AWEXTX_ZJ?I'
M_P :H _0JBOSW_X>E_M@?](\O&G_ (<_2/\ XU1_P]+_ &P/^D>7C3_PY^D?
M_&J /T(HK\]_^'I?[8'_ $CR\:?^'/TC_P"-4?\ #TO]L#_I'EXT_P##GZ1_
M\:H ]N_X+/\ _*);]H__ +)WK7_I')4/_!%%BW_!(_\ 9RSD_P#% :2.?^O9
M*^2/VU?VPOVPOVN?V1/B7\+X_P!@?QEH4GQ \-WV@IJ+?$?2+A;%KB%HA*8]
MB[PI;.W<N<8R.M?:_P#P2I^%/B+X$_\ !-[X(^"_%VES:'XH\+^#M/TW5+"6
M1)'M+B*%4="4+*2".H)% 'T!39%+H0&V^].HH ^,/^"P'['?AWXL_L??'3QM
MXQU7Q)XLA\,_#C7K[0/#&H7:?\([HM]#I-WMOELXT07-R&(=)+QKCR'17@$#
M#)RO^#;+_E"-\!?^P;?_ /ITO*^A_P#@H%\/]:^+/[!GQM\*^&]/EU;Q%XF\
M Z[I.EV,;HCWEU/IT\4,2LY507D=5!8@ GD@<U^;W_!,[X__ +8O_!/C]AGX
M?_!V?]A/QAXJF\$VMQ;OJL?Q"TFS6[,MW-<9$15RN/-VXW'[N: /U^HK\]_^
M'I?[8'_2/+QI_P"'/TC_ .-4?\/2_P!L#_I'EXT_\.?I'_QJ@#]"**_/?_AZ
M7^V!_P!(\O&G_AS](_\ C5'_  ]+_; _Z1Y>-/\ PY^D?_&J /T(;[IKYPOO
MVJ?$'B#XV^-_!WARQTK[5HOC*P\ V,M_;2B*SNY/#RZ_<7\S1RDW$*VL\,<=
MNJP,TT3*TP699(?!3_P5*_; (_Y1Y>-/_#GZ1_\ &JX*]_:T_:0U;7?%EYJ'
M_!-OQ5JD/C:XL[W5;&]^).B3VDUW:Q+#%=A&@)$_E1VZ;\Y M8=NTJ20#ZRU
M;_@H)H_P=U[Q3X?\::9K%UJGP_TYM2\1:WH]E"NB16L,NG_;+H%[IG@%K;:G
M:W<]O(3*D(D,?VC$9EU-$_X* 6GBJZN%TGX8_$S4K=-<E\/VUR@TB&+4;A0\
MD+PB6_1S#<6ZI<PRLJJT,T1)5F*CX9U#XQ?&Y/"7B'3-!_X)A:KX-N/$7A_4
M/#4FJ:#X\\/6M_:6E\%^TB)S;,H9Y$CE;<K*\D4;.'VUV'@K]M+]H[X<>'M+
MTG0O^"9NM:7INB"U%A;P?$3152T^S6R6EN4_<Y#1V\:1*W4(H7..* /JVZ_X
M*6^"8[2XN;;0?&&HV</A8^*4N;2WM9(I5_LS^U%L"?M \F^>T/F+#<>4""&W
M;&5ST^L_M0->>!+R^@\.ZIH^K:/XPT7PIJFE:N\'GV4E]>Z;&6+VTLT+XMM1
MBF4I(PR0K;6# ?"X_:<^.JZO;W__  ZVF^V6>E/H=O-_PG.@AH+!X8X'M5_<
M?+$T,4494<%(D4Y5% Z:Z_X*!?M1WS7AF_X)N^(YO[1O[?5+K?\ $;1&^TWE
MOY'D7#_N?FEC^RV^QS\R^1'@C:, 'T%X?_X*-:7J?B+Q5//X9U_1])\':29[
MW3M2>P@UN2[:XMXHH!!]M/DO()T"0W*PS2L\9C#AUW=)X1_X*&^&O%CR3OX5
M\<:/H]K?7&E7^JZE;6D,&F7UOIKZC<6TT*W#70DCAC=6*0,N]2 Q&#7QWIO[
M6/Q^T>PO+6T_X)?WUM;Z@GE7,<7CW0D$R;E<*<09VAT1E P%**5P0*L> _VQ
M_P!HCX6:'8:9X9_X)C:EH.GZ5="^LK:P\?:%;Q6MP(/LPE14@ 5_L_[K<.?+
M^7IQ0!]->(/V^[CP#X9\4^)/%WPW\;:)I>C7-E"EC))I$=Y9)<69G,]Y='43
MI\$._P#="1[A%5R QP=Q]1_9%^,&H?'#X/'6-7BLH]6TOQ!K_AF]:R1H[6ZF
MTG6;S2GN(XVDD:))FLC*(FDD:,2;"[E2Q_/[1_VB_C9H'AL:/8_\$KS::3YZ
M7)LXO'&@I"\B0B!&91!AML($0SP(P$^Z !T7PC_;T_:J^"W@6U\/Z/\ \$\?
M'9M89KB[FFG^*6CO/>W5S/)<W5S*PA :6:XFEE<@ %Y&( &  #]+J*_/?_AZ
M7^V!_P!(\O&G_AS](_\ C5'_  ]+_; _Z1Y>-/\ PY^D?_&J /T(HK\]_P#A
MZ7^V!_TCR\:?^'/TC_XU1_P]+_; _P"D>7C3_P .?I'_ ,:H _0=_N'Z5^4G
M[,YQ_P '>7[1'_9&;'_T9H%>IG_@J5^V 1_RCR\:?^'/TC_XU7EO_!-CX-?'
M[XA_\%V_BQ^T=\4O@3K?P9\+^,OAHGA^T@OM>LM6 NX;C256/S(&#$NEK*XS
M&  I&<XR ?JW10#10 4444 %%%% 'EO['YS\)]6_[';Q;_ZD>I5ZE7EO['W_
M "2;5O\ L=_%O_J2:E7J5 !39$\Q=M.H)Q0!\W_&?_@D/^S3^T5\3]6\:>.O
M@SX'\5>+->D234-4U"S,EQ=LD:Q(6.[M&B*/917,?\.'/V//^C>?AK_X+C_\
M57F/Q6_X+)_%RW_;.^+WPA^$O[)^O?&)O@[=:;:ZOJUCXXLM+7-]9K=0DPW$
M.5S^]7Y6?_59)&X"F?\ #TO]L#_I'EXT_P##GZ1_\:H ]1_X<.?L>?\ 1O/P
MU_\ !<?_ (JC_APY^QY_T;S\-?\ P7'_ .*KR[_AZ7^V!_TCR\:?^'/TC_XU
M1_P]+_; _P"D>7C3_P .?I'_ ,:H ]1_X<.?L>?]&\_#7_P7'_XJC_APY^QY
M_P!&\_#7_P %Q_\ BJ\N_P"'I?[8'_2/+QI_X<_2/_C5'_#TO]L#_I'EXT_\
M.?I'_P :H ]1_P"'#G['G_1O/PU_\%Q_^*H_X<.?L>?]&\_#7_P7'_XJO+O^
M'I?[8'_2/+QI_P"'/TC_ .-4?\/2_P!L#_I'EXT_\.?I'_QJ@#U'_APY^QY_
MT;S\-?\ P7'_ .*H_P"'#G['G_1O/PU_\%Q_^*KR[_AZ7^V!_P!(\O&G_AS]
M(_\ C5'_  ]+_; _Z1Y>-/\ PY^D?_&J /4?^'#G['G_ $;S\-?_  7'_P"*
MH_X<.?L>?]&\_#7_ ,%Q_P#BJ\N_X>E_M@?](\O&G_AS](_^-4?\/2_VP/\
MI'EXT_\ #GZ1_P#&J /4?^'#G['G_1O/PU_\%Q_^*H_X<.?L>?\ 1O/PU_\
M!<?_ (JO+O\ AZ7^V!_TCR\:?^'/TC_XU1_P]+_; _Z1Y>-/_#GZ1_\ &J /
M4?\ APY^QY_T;S\-?_!<?_BJ/^'#G['G_1O/PU_\%Q_^*KR[_AZ7^V!_TCR\
M:?\ AS](_P#C5'_#TO\ ; _Z1Y>-/_#GZ1_\:H ]1_X<.?L>?]&\_#7_ ,%Q
M_P#BJ/\ APY^QY_T;S\-?_!<?_BJ\N_X>E_M@?\ 2/+QI_X<_2/_ (U1_P /
M2_VP/^D>7C3_ ,.?I'_QJ@#U'_APY^QY_P!&\_#7_P %Q_\ BJ/^'#G['G_1
MO/PU_P#!<?\ XJO+O^'I?[8'_2/+QI_X<_2/_C5'_#TO]L#_ *1Y>-/_  Y^
MD?\ QJ@#U'_APY^QY_T;S\-?_!<?_BJ/^'#G['G_ $;S\-?_  7'_P"*KR[_
M (>E_M@?](\O&G_AS](_^-4?\/2_VP/^D>7C3_PY^D?_ !J@#U'_ (<.?L>?
M]&\_#7_P7'_XJC_APY^QY_T;S\-?_!<?_BJ\N_X>E_M@?](\O&G_ (<_2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\K_:K_X)G^.OB9\/_P#A#?#OQB^*GB:U\52-I^LR>-=>L+O1M+LS&29WL4L
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MVAD56X^Z2" 0<8()]VKS/X6*#^T)\5./^6VE_P#I&* %_P"&K?#?_0%^)?\
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MO2M@]!^5&P>@_*@#S7_AJWPY_P! 7XE_^&_US_Y$H_X:M\.?] 7XE_\ AO\
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MA"T@*K&;ATWB3Z_0;5I:* $?[A^E?E)^S1_RMY?M$?\ 9&;'_P!&:!7ZMO\
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M\;H_X9.^%?\ T3/X?_\ A.VG_P ;H ^=_P#B(,_8R_Z."\#_ /DS_P#&J/\
MB(,_8R_Z."\#_P#DS_\ &J^B/^&3OA7_ -$S^'__ (3MI_\ &Z/^&3OA7_T3
M/X?_ /A.VG_QN@#YW_XB#/V,O^C@O __ ),__&J/^(@S]C+_ *."\#_^3/\
M\:KZ(_X9.^%?_1,_A_\ ^$[:?_&Z/^&3OA7_ -$S^'__ (3MI_\ &Z /B?\
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MF?P__P#"=M/_ (W0!\[_ /$09^QE_P!'!>!__)G_ .-4?\1!G[&7_1P7@?\
M\F?_ (U7T1_PR=\*_P#HF?P__P#"=M/_ (W1_P ,G?"O_HF?P_\ _"=M/_C=
M 'SO_P 1!G[&7_1P7@?_ ,F?_C5'_$09^QE_T<%X'_\ )G_XU7T1_P ,G?"O
M_HF?P_\ _"=M/_C='_#)WPK_ .B9_#__ ,)VT_\ C= 'SO\ \1!G[&7_ $<%
MX'_\F?\ XU1_Q$&?L9?]'!>!_P#R9_\ C5?1'_#)WPK_ .B9_#__ ,)VT_\
MC='_  R=\*_^B9_#_P#\)VT_^-T ?.__ !$&?L9?]'!>!_\ R9_^-4?\1!G[
M&7_1P7@?_P F?_C5?1'_  R=\*_^B9_#_P#\)VT_^-T?\,G?"O\ Z)G\/_\
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MNWFM[:\U/Q#J9NIQ+<2W!+^6%3(:4@84< 5^L;-M%-W_ .RU 'Y\_P#"S?\
M@IU_T3']D?\ \*#5_P#&C_A9O_!3K_HF/[(__A0:O_C7Z#;_ /9:C?\ [+4
M?GS_ ,+-_P""G7_1,?V1_P#PH-7_ ,:/^%F_\%.O^B8_LC_^%!J_^-?H-O\
M]EJ-_P#LM0!^?/\ PLW_ (*=?]$Q_9'_ /"@U?\ QH/Q-_X*=?\ 1,?V1_\
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M_P!EJ-_^RU 'Y\_\+-_X*=?]$Q_9'_\ "@U?_&C_ (6;_P %.O\ HF/[(_\
MX4&K_P"-?H-O_P!EJ-_^RU 'Y\GXF_\ !3HC_DF/[(__ (4&K_XUR_\ P3H_
M8(_:8T#_ (+#?$;]IKX\:3\+=#C\;^ %\+"S\(ZM<W21W$5QIIC.R9-P4Q6;
MDG>?FP .>/TNW_[+4-*%ZY% #J*** "BBB@ HHHH \M_8^_Y)-JW_8[^+?\
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M'5S/J?AJ]6]T>]N&T";SGM)E9@\'F[]AR3M SSFOTTH _/?_ (6;_P %.O\
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MX;?5;5"MHP,=CHIFND(WF6<+B20#[,P!J?\ "S?^"G7_ $3']D?_ ,*#5_\
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MT\*K9PZ5'XT@M[*R$C0BX,4OAF2ZNI&,GGF2"!1)%*KQ7 !#_P +-_X*=?\
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M%.O^B8_LC_\ A0:O_C1_PLW_ (*=?]$Q_9'_ /"@U?\ QK]"** /SW7XF_\
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M (6;_P %.O\ HF/[(_\ X4&K_P"-?H1393B,T ?GP?B=_P %.@/^28_LC_\
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MC?\ \%+/"6AW6IZI\/?V.]-TVPB:>YNKKQ-JL,%M&HRSN[,%50.220 *M_\
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M9O\ P4Z_Z)C^R/\ ^%!J_P#C1_PLW_@IU_T3']D?_P *#5_\:_0BB@#\]_\
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M_P#A0!^A5!&X5^>O_$2U^S__ -"S\=O_  W5_P#X4?\ $2U^S_\ ]"S\=O\
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MQ\2KKPM>?VLNJ1S0PPQ6FE7&HM.KQQNTH2V21TAC\Z(232A(T,J98;AG\ZO
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M /A0!^A5%?GK_P 1+7[/_P#T+/QV_P##=7_^%'_$2U^S_P#]"S\=O_#=7_\
MA0!^A+=5^M?E-_P:)?\ )BWQJ_[+;KO_ *;])KU ?\'*_P"S^[+_ ,4Y\=5Y
MZ_\ "NK_ /PKSG_@TCT+4M#_ &#?BU+J>DZOHQU7XPZSJ%K#J5G):3202:=I
M11]C@'!P1GID$=C0!]W_ +='A72_&_P%MM'UK3=/UC2=3\8>%+:\L;ZW2XMK
MN)O$>FAHY(W!5U(."""#2#_@GC^S^PS_ ,*,^#O_ (1FF_\ QFM#]L'_ ))-
MI/\ V._A+_U)--KU%/N#Z4 >/?\ #N_]G_\ Z(7\'?\ PC--_P#C-,F_X)W_
M  !V?+\"_@[N_P"Q,TWG_P @U[+10!^=O_!1?_@DS\&= _9:^/WQ'N?!/A>Z
MO=!^'7B&Z\-:5!X?T[3])\-3II-R1=106T"&XNMP#+/<M*T/_+'R<N7]]_X(
MV*%_X).?LWX'_-.-#_\ 2&*NF_X*:6%QJW_!-[]H*TM8)[JZNOAKXCBAAAC,
MDDSMI=R%557EF)(  Y).*_/[_@G5_P %[?@W^S7^P5\&_A]XF\+_ !MC\1>"
M_!VF:+J:6_@"^FA2YM[9(I C@89=RG![C!XZ4 ?KA17YZ_\ $2U^S_\ ]"S\
M=O\ PW5__A1_Q$M?L_\ _0L_';_PW5__ (4 ?H517YZ_\1+7[/\ _P!"S\=O
M_#=7_P#A1_Q$M?L__P#0L_';_P -U?\ ^% 'Z%4$;A7YZ_\ $2U^S_\ ]"S\
M=O\ PW5__A1_Q$M?L_\ _0L_';_PW5__ (4 ?H,;6,_PBC[)'@_(/FX/O7Y\
M_P#$2U^S_P#]"S\=O_#=7_\ A1_Q$M?L_P#_ $+/QV_\-U?_ .% 'Z#B!5;(
M7VK@OVD/C'9?L^?"NZ\375O]J*7=AI5G:^;Y7VR]OKR&QLH"^UO+62ZN8$+[
M2%5RV#C!^-?^(EK]G_\ Z%GX[?\ ANK_ /PK@_VE?^"\W[.W[1?PCO/#,^A_
M'"RG^VZ?J^GW4OPTU*>.TO\ 3[Z#4+.9XT>)I$2ZM8':,2)O52I8!LT ?:7A
M_P#;F^'6O>*SHZ^(M'CU2TU+7+#4[.34K3[3HZ:3-=1W%U<Q+(7B@8VVY7(Z
M2Q[MI-:?AO\ ;@^&7B7Q'-HMMJ^M)K%K?6VFWUE<>&]4M)]+GN-A@6[26W4V
MJR>;$5>?8K>;'@G>N?A35/\ @MY^RCKOAK^QKWP?^T!=:6U[J]\\#^!=3 D?
M5'N6N\LI#8;[7-MP04W#;C:,4O"__!:S]EWP_JFN:E=:/^TEK6L>)[K2[W5]
M2OO 5XMQ?S:;,);-RL*1Q(4VHA$<:ATC7<"VYF /T5^&O[1'A#XW:?JLWA.X
MU#48M)BBFD>32+NQCN8Y8VDADMWGBC2XCD1=RR1%T(*G=A@3YM\-O^"B_P .
M_'OP8@^(UP=<TSP1J,,MUI.I2:9+=MJUE;PQO=ZBD-JLLL5C;RN87NIDCB+H
MKJQAEMY9O@#]AG_@K9^SI^Q1\-M2\(Z?I_QHN/#=S#;0VNGZ?\*=4LXK9HXF
MADN&,US<NTTR&(/L:.(>0I2)"SE]#2O^"JO[(/AG3[FTT;P[^TMHUCJ GAO;
M2T\$7ODW5O=06L-_;[71O*2\^Q6TLS0F.4S+),KI)/.\@!^E$G[9/PY@NM3M
MUUC4GFTNYGLS%#H>H2-?307GV&XCLPL)^VO#=$12"V\TQLRAMN1F'X(_M2>'
M_CO\1=8T/1H;AH;/P]HGBVPNWBDB34M*U87BVL_ER(DD3F73KU3&ZY"+$^?W
MFU/S-_:2_P""I'[)O[07PQ7P])X7^.$;6^H76HP-J/PWU:\M?,NM:M=9N \4
M4T$C*UU:QE=LJ-&!@'UZG]GK_@MW\ /@OXKU37M0L_CCKFL:AH.C^&$EB^%^
MIVJP:?IIO9+>+:\TNXK-J-YMD)WF(PI(TKQM-( ?J^+6,C[HI!91C^&OSZ'_
M  <M?L_@?\BS\=O_  W5_P#X4?\ $2U^S_\ ]"S\=O\ PW5__A0!^@QM(S_"
M.*='&L2[54*/05^>_P#Q$M?L_P#_ $+/QV_\-U?_ .%'_$2U^S__ -"S\=O_
M  W5_P#X4 ?H517YZ_\ $2U^S_\ ]"S\=O\ PW5__A1_Q$M?L_\ _0L_';_P
MW5__ (4 ?H517YZ_\1+7[/\ _P!"S\=O_#=7_P#A1_Q$M?L__P#0L_';_P -
MU?\ ^% 'Z%45^>O_ !$M?L__ /0L_';_ ,-U?_X4?\1+7[/_ /T+/QV_\-U?
M_P"% #_^#?7_ )!7[97_ &=+XV_E845F?\&X/B-O&_P>_::\61Z;KFDZ9XX_
M:'\5>)-*CU?3Y+"ZFLKJ#3I89&BD *Y5AD<X((R<&B@#]&J*** "BBB@!'^X
M?I7Q!^P?_P IDOV\?^OCP#_ZC[U]OO\ </TKX@_8/_Y3)?MX_P#7QX!_]1]Z
M /N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *&7<*** /!?^"H
M%K'!_P $R_VBMJ[?^+8^)>,_]0FY%>*_\&V7_*$;X"_]@V__ /3I>5]1?M;_
M  8N?VC_ -E/XF_#NSOH=+O/'OA35/#D%[-$98[-[RSEMUE9 0653(&(!!(&
M,BOSW_96_P""5G[<W[&7[/\ X;^&/@']JKX7Z;X1\)PR0:=;S_#M+F2-9)I)
MFW2.Q9OGD8\F@#]2J*_/?_ADG_@HM_T=Q\)__#8P_P"-'_#)/_!1;_H[CX3_
M /AL8?\ &@#]"**_/?\ X9)_X*+?]'<?"?\ \-C#_C1_PR3_ ,%%O^CN/A/_
M .&QA_QH _0AONFOD76?B1XOU7XZ?%J'5-0\2Z/X3T/Q_I'AVYNM,6Y>6T\.
MGPO;Z@9XD42>4)=6O)+>:[A176%3F2,VRRQ>8G]DG_@HL?\ F[CX3_\ AL8?
M\:HVW[$G_!0:SUNZU.']JKX-PZE>Q107%VGPJMEGGCB+F)'<?,RH99=H)POF
M/C&XY .XN_VXO''@O5?'-KX1T2_\1>$?!/AF_P#%&G77B#1-0@U/5K339M+E
MN8!<32(LC75O=WT-G-<+$S268E874(:63L/A7^T7\;OB]HMGK5G'X,TO2/$6
MN)!I"W7@_5&G@TJ]MC?V%W<AKR,B6*UEMX;B,*JFY68!XP M>*^*?V'O^"@7
MCGPSJ.BZW^U-\%]8T;6+:6RO["^^%-M<6M]!*A22&6-\J\;HS*RL"&5B""#5
M[_AD7_@HIG/_  UM\)<GO_PK&#_&@#T*Y_;N^+%Q>_9[7P(MO?7O@"37[:PO
M- OM\.IKHT=\,R)*?,MA<R+:>6\<$S2K*J%C$^/3]>\??$*;P/K&GZ@D<NO>
M'/'_ (=T@:CHVDS6MOK&GS7NC3W,\=O(\[)&L%Y<02,)9%'V>1]R<JGS=_PR
M+_P44&?^,MOA+R<G_BV$'^--_P"&0O\ @HIG_D[;X2^G_),(/\: .W\)?M2?
M%VZU'QQKFH:1)<3^'=&:UT^*P\.W4>BM<O=VJ^81-?!IQ"LCF5Y192Q)'+NA
M 4$]3\$_VK?B_P#$W1['7I_"^ER:7/K,^B)I<>@WVGWFIA-%>]BOH[BYF"V\
M,URJQ!986">:%:0NI)\A/[(O_!14_P#-V_PER.__  K&#_&D/[(?_!10Y_XR
MV^$O/_5,(/KZT =7_P -3_%;1/AOXF\4:?>:=XLU";4=-AMF@\#:M%;RH^G>
M9+%8Z;=7L6^<3'#*UY&&9'B'[_,8]X_8)\4:UXL_9\DDURYU"^FTOQ9XJT6Q
MN;YWEN+C3;'Q%J-EI[O+(2\Q:RM[8^<S,TH(D+,7R?EW_AD?_@HMG/\ PUQ\
M)\]/^28P?XU5T#]BG_@H/X4T2STS2_VJO@WINFZ?"MO:VMK\*[:&"VB485$1
M<*J@      4 ?HI17Y[_ /#)/_!1;_H[CX3_ /AL8?\ &C_ADG_@HM_T=Q\)
M_P#PV,/^- 'Z$45^>_\ PR3_ ,%%O^CN/A/_ .&QA_QH_P"&2?\ @HM_T=Q\
M)_\ PV,/^- 'Z#O]P_2ORD_9H_Y6\OVB/^R,V/\ Z,T"O5/^&2?^"BW_ $=Q
M\)__  V,/^--_P""?G_!)[XS?L_?\%+?''[27QC^+GA3XD>)/&W@O_A%)X](
M\.G2=A2>P>*7:&*86.SVD 9)8'/!H _0JB@44 %%%% !1110!Y;^Q]_R2;5O
M^QW\6_\ J2:E7J5>6_L??\DFU;_L=_%O_J2:E71>.OC1H/P[\6^&-#U746MM
M4\8WKV&D6Z6DUPUS(D9D<L8T80Q!0 992L8>2)-V^6-6 .PI&0..:\IU_P#;
M&\"^&-=FT^\U74UDCGEL8KB+0;^:SOKR.5(7LK:Y2 P7-V)69/LT+O-NAG 0
M^1-Y?&'_ (*:?#.;Q\/#-OJ&I3:Y<R&QL+&:T&GW6J:DLZQ/ID-O=O#.UTF]
M'<-&L:QL7,@"/M /HA8P@PN1^-+M]S7Y>7WQ=_;$_:]_X*7_ +3GPW^$OQO\
M$_#;PC\$K_0+>TM-7\%P:K).NHZ;]H.)>&^62*0_-G/F <  5WG_  R5_P %
M%O\ H[CX3_\ AL8?\: /T'V^YHV^YK\^/^&2?^"BW_1W'PG_ /#8P_XT?\,D
M_P#!1;_H[CX3_P#AL8?\: /T'V^YHV^YK\^/^&2?^"BW_1W'PG_\-C#_ (T?
M\,D_\%%O^CN/A/\ ^&QA_P : /T'V^YHV^YK\^/^&2?^"BW_ $=Q\)__  V,
M/^-8WBWX'?M[> ;G1X=>_;4^!^BS>(M032=*2_\ A]:6S:G>NCR):P!W'FS,
MD4C"-,L5C<@84X /T@V^YHV^YK\QO"WA/]M;QS\1KSP?HO[>/[.VL>+M/MYK
MN[T.R\%6%QJ5K##<M:RR26Z2&1$CN%:%F90%D4H<,"*T_AI\&OV]OC'\/])\
M5>%_VS/@]K7AW7K9+O3[^W^&,1BNHF^ZZYP<&@#])MON:-ON:_/8_LG?\%%1
MG_C+CX3\#./^%80_XUEZ+\!/V_/$FNZMI>G?MH?!/4-3\/RQ0:I:6WP[M9I]
M-DDB6:-)T5BT3/$Z2*' )1U89!!H _1W;[FC;[FOST7]E'_@HHZ[A^UU\)B.
MG_),8?\ &G#]DW_@HJW_ #=Q\)^.O_%L8?\ &@#]"=ON:-ON:_/;_AD[_@HI
MG'_#7'PGXZ_\6QAX_6C_ (9-_P""BO\ T=Q\)_\ PV$/^- 'Z$[?<T;?<U^:
M;_"[]N>/Q5H^@M^W%\ UUSQ$U\FE:<? EE]KU-K%@EZL$6_?*;=B%E" F(D!
M]IKHS^R?_P %% #_ ,9<?"?Y>O\ Q;&'C]: /T)V^YHV^YK\UO$/PG_;J\(C
M7O[6_;>^ VE_\(KI:ZYK?VOP%9P_V-I[?:-MY<[G'DVY^R76)9-J'[--S^[;
M&IH'[-W_  4&\5Z'8ZII?[8WP;U+3-2MTO+.\M?AO;S6]W"ZADECD5BKHRD$
M,I((((X- 'Z*[?<T;?<U^:W@OX3_ +=7Q(END\._MO\ P%\0/8W$UI<KIO@*
MSNS;S0S-!-&_EN=KQS(\;*<%74J<$$4[XF?!S]O;X-_#_6?%7BC]LSX/Z+X>
M\/6KWNHWUQ\,8A%9PH,L[8R< <]* /TGV^YHV^YK\^/^&2O^"BW_ $=Q\)__
M  V,/^-'_#)/_!1;_H[CX3_^&QA_QH _0?;[FC;[FOSX_P"&2?\ @HM_T=Q\
M)_\ PV,/^-'_  R3_P %%O\ H[CX3_\ AL8?\: /T'V^YHV^YK\^/^&2?^"B
MW_1W'PG_ /#8P_XT?\,D_P#!1;_H[CX3_P#AL8?\: /T'V^YI%B"L3SD\<FO
MSY7]DO\ X**AQN_:X^$^W//_ !;&'_&K/_!NC^W9\4OV_?V0OB!XD^+FN:=X
M@\2^%OB1J7A:"[LM-BL(S:V]EI\BCRXP!GS)Y3D\X8#/ H ^K?VP?^23:3_V
M._A+_P!233:]13[@^E>7?M@_\DFTG_L=_"7_ *DFFU<U#]J#P;I?B?QCH\VL
MR+J'@&/3WUJ(:=<L(6OBZVD$3B/;<W$S(46"W,DN]XDV!I8PP!Z-17D+?MJ^
M UL))VU/6HFM9GAU""3PSJ:7.A!7"&7483;B33X2")%FNECC>']^K&',@S_V
M=OV]? O[4GB-M+\'W5YJ%Y;VBZC?1$0"32;2:&"XL9[E1*6A6]@N8Y;=7 =@
MDRND;P3)& >VLNX4@3'=OSKRW]N7XJ:Q\$/V)?C%XV\-W$5KX@\'^"-:UO3)
MY8A,D-U;6$\T+LC<,!(BDJ>#C!KX(_9*\&?\%#/VL?V7OA[\3K']J;X6Z/:>
M/_#UEK\-C-\-H))+1;F%91&S# 8KNP2  2.* /U*V^YHV^YK\^/^&2?^"BW_
M $=Q\)__  V,/^--;]DS_@HJB[F_:X^$P ZD_#*#_&@#]"=ON:-ON:_,R]\"
M?MNZ9=Z];W/[=?[/=O/X6N[.PUJ.7P/8H^D7-YY7V2&X!DS#)/Y\/E(^#)YT
M>T-N7-&ST7]M+5?AGH?C33_V[?@#JW@_Q-J-II.DZWIO@&TOM/U*ZNKM;*"*
M*:%F1R]RZQ#!(#G!(P< 'Z@[?<T;?<U^>P_9-_X**MT_:X^$_3/_ "3"'_&H
M[C]EC_@HA:6SS3?M>?"..&-2[2-\,X%15')).<  <YH _0W;[FC;[FOSF\+?
ML]_\% /'7A;3-<T/]LOX+ZUH>M6D5_I^HV'PYMKFTOK:5%>*:*5&*/&Z,K*Z
MDJRD$$CFM ?LG_\ !10_\W<?"?CK_P 6QAX_6@#]"=ON:-ON:_/8?LF?\%%B
M?^3N/A/_ .&QA_QI#^R?_P %%!MS^UQ\)_FX'_%L8>?UH _0K;[FC;[FOSLU
M;]F?_@H3H-BUU??MA?!^QM8RJM-<?#6WBC4LP5069@ 2Q  SR2!6?X/^"O[>
M?Q#GUB/P_P#MK? W79/#NHR:/JR:=\/[2Z;2[Z-4>2UG$;GRIE62-FC?# 2*
M2,$4 ?I'M]S1M]S7YZM^RC_P440K_P 9<?"8[C@?\6QAY_6O-/!6M_M??$/P
M/J7B;2_V^/V>Y/#VCH\U[J$_@&VM8;6%;Z[T\7+M*RA;:2ZL;N.&<_NI_L[M
M$[J-Q /U5V^YHV^YK\]?^&3_ /@HIC_D[CX3\G _XMC#R?SI1^R?_P %%&8K
M_P -<_";<O4?\*QAX_6@#]"=ON:-ON:_-(_##]N8>(_['/[<7P#&L'5!H8L#
MX#L_M7]H&R^WBS\K?O\ M!LO])\K&_R/WF-GS5TG_#)O_!17./\ AKCX3YZX
M_P"%8P_XT ?H3M]S1M]S7YH_%/X7?MY_!3PM;ZUXF_;'^$^FZ7=:KIVBQ7'_
M  JD3*;N_O8;&TC(C#%1)<W$,>\@(I<%F506#]?^%?[='A1_$2ZI^W!\!=,;
MP?IBZUKPN_ =G"=$L&$Y6[NMSCR(&%K<D2R;4(MY2#\C8 /TKV^YHV^YK\[-
M&_9G_P""A/B/2+74-/\ VPO@_?:??0I<6UU;_#6WEAN8G4,CHZL5964@A@2"
M#Q63X'^%'[=7Q.@FE\-?MP? 7Q%';RR02OIG@.SO%BDCF>WD1C&YPR3121,#
MR'C=3AE( !^E.WW-&WW-?FS\2?@S^WM\'_ NJ>)O$W[9GP>T?0=%B\^^O;CX
M91".U3(&6P21]X?G6^/V2O\ @HL?^;N/A/\ ^&QA_P : /T'V^YHV^YK\^/^
M&2?^"BW_ $=Q\)__  V,/^-'_#)/_!1;_H[CX3_^&QA_QH _07R%W9^;/KFB
MOBC_ ((<?M1_%C]IGX1?&RT^,?B;2O%WBSX5_&'7?A\FJ:=I4>FV]U;Z?#9
M.(D QNDDF<;LMAP">** /MJBBB@ HHHH 1_N'Z5\0?L'_P#*9+]O'_KX\ _^
MH^]?;[_</TKX@_8/_P"4R7[>/_7QX!_]1]Z /N"BBB@ HHHH **** "BBB@
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M'Q7I'@+Q?'J>C+9SPG1HUM]5M8X/,D4+<F.2RN(7N(2T$LUO,8F:+8S>3_\
M!O?^Q-\&?BK_ ,$<?@AKWBCX1_#'Q'KFH:=?-=:CJGA:QO+NY*ZG=J"\LD3.
MQ"J ,D\ "@#O/^(G3]AO_HNUG_X2VN?_ "%1_P 1.G[#?_1=K/\ \);7/_D*
MOI#_ (=Q_L]?]$'^#/\ X1.F?_&:/^'<?[/7_1!_@S_X1.F?_&: /F__ (B=
M/V&_^B[6?_A+:Y_\A4?\1.G[#?\ T7:S_P#"6US_ .0J^D/^'<?[/7_1!_@S
M_P"$3IG_ ,9I#_P3D_9Y _Y(1\&?_"*TS_XS0!\X?\1.G[#?_1=K/_PEM<_^
M0J/^(G3]AO\ Z+M9_P#A+:Y_\A57_P""E_\ PS1_P3L^'WAK6KC]G3X#ZY<:
MYJ%SYUK=Z#I6F_9M-LK&XO[^Z1VMG\V5(8 D<"KOEFGA08!+#B_VDOVCOV0/
MV?M'\>30?LK^&?$TW@M=2@@GM/AQI,>FZY?V-DE_/9P715OF%DS7/F,GEF.*
M0!FD"QL =Y_Q$Z?L-_\ 1=K/_P );7/_ )"H_P"(G3]AO_HNUG_X2VN?_(54
M_B'XV_8]^%?Q%C\-ZW^S7X7MKB"&U_MB[7X6Z9)9^'+RZT^;4+?3KR8+M%V\
M$+$I%YJ(9(=[HLBL:_PN^)?['/Q._P"$;B_X9I\+^'K_ ,436D-K8ZU\,=)M
M;J,7>F:KJML\B -L62STBYDY.X>9"&52S! #4_XB=/V&_P#HNUG_ .$MKG_R
M%1_Q$Z?L-_\ 1=K/_P );7/_ )"K!_9O^,/[&/[4/Q \,^'=!_9KT/3;KQ9<
M1VEA=:S\(K*RL7FFT8ZW:QF?RRF^XTZ.>X15W%5@/F"(RP>;SOC;X@? ?0_V
MD9/#=C^S-^S-#X'T[QD_@6\U?6-+BM]4N]3MXK6:[2UM;;2+BW&U+R$1+>7=
MJ\[!MB[-CL >@?\ $3I^PW_T7:S_ /"6US_Y"H_XB=/V&_\ HNUG_P"$MKG_
M ,A5RVF_'3]C>_\ "W@/5I/V7=+L[?QUIMCKVR?X3Z9O\/Z5?7Z:?8:AJ&T,
ML,-S.^8E0R3.B2/Y05&(U'^)W[&LWA^#4+']G'PAJC7UIH5U8V5G\,]*DN[Y
MM9OM4L+&&-" /,:XTBZ#;BJ*K1,6PS; #5_XB=/V&_\ HNUG_P"$MKG_ ,A4
M?\1.G[#?_1=K/_PEM<_^0JL^&M'_ &9/B*WP%O/#?[-WPGGTGXV^(]4\./\
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M47/F+>6<BR?N@$61#DD.J7?B1^V0WPD^)&I:3JGAZ_OM+MM0L;!=1L_+BM[
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MOVC-&\??#_3;'2] ^*-U=0^*?#NHNG_"M_$2;8+76[&YG?+60'RPPR-CJ=N
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M>((O&?C.ZUW5YUM_$%[>:#LU2T1+R*X>^CCMKN>V63_1HVM]A$>Y".Q\?_\
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M>*O 6M>#8_$T$][_ &IHBS>)M1UBS$);=')$]MJ/V67>@>$6ZF(N&VK^B=%
M'Y6:O_P0S^*WB;]G/PMX,U;QYHFN3:1'K<+1Z[K.H7MOI$M[>VMY'>V9M;>S
MB9E:V\HV\MMY4:RET.?,CF_5).E+10 4444 ?GQ_P;Z_\@K]LK_LZ7QM_*PH
MH_X-]?\ D%?ME?\ 9TOC;^5A10!^@]%%% !1110 C_</TK\X?@'XB^*OA_\
MX+)_MO?\*T\&?#WQ;'--X%_M ^)O&MYX=:U8: ?+$2V^E7WFA@7+%C'MVK@-
MDE?T>?[A^E?$'[!__*9+]O'_ *^/ /\ ZC[T >P?\+'_ &IO^B-_L_\ _AY-
M7_\ F8H_X6/^U-_T1O\ 9_\ _#R:O_\ ,Q7T!10!\_\ _"Q_VIO^B-_L_P#_
M (>35_\ YF*/^%C_ +4W_1&_V?\ _P /)J__ ,S%?0%% 'S_ /\ "Q_VIO\
MHC?[/_\ X>35_P#YF*/^%C_M3?\ 1&_V?_\ P\FK_P#S,5] 44 ?/_\ PL?]
MJ;_HC?[/_P#X>35__F8H_P"%C_M3?]$;_9__ /#R:O\ _,Q7T!10!\__ /"Q
M_P!J;_HC?[/_ /X>35__ )F*/^%C_M3?]$;_ &?_ /P\FK__ #,5] 44 ?/_
M /PL?]J;_HC?[/\ _P"'DU?_ .9BC_A8_P"U-_T1O]G_ /\ #R:O_P#,Q7T!
M10!\_P#_  L?]J;_ *(W^S__ .'DU?\ ^9BC_A8_[4W_ $1O]G__ ,/)J_\
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MM$?]D9L?_1F@5^K;?=/TK\I/V:/^5O+]HC_LC-C_ .C- H _5RBBB@ HHHH
M**** /+?V/O^23:M_P!COXM_]234J]2KRW]C[_DDVK?]COXM_P#4DU*O4J "
MF3LRI\J[J?03M% 'Y>W_ ,%OVQOV3/\ @I5^TU\3/@_\'OA[\0/"7QNOM N+
M6XUWQ<FF30+ING?9SB)<M\TDLGWL<1@XYKNO^&H?^"CO_1KWP1_\.)_]:OT(
M#;AD<T4 ?GO_ ,-0_P#!1W_HU_X(_P#AQ/\ ZU'_  U#_P %'?\ HU_X(_\
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M_#B?_6H_X:A_X*._]&O_  1_\.)_]:OT(HH _/?_ (:A_P""CO\ T:_\$?\
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M$CJO_P CT?\ $5M^Q#_T5#6O_"1U7_Y'H YW_B'E^)'_ $?_ /MB?^%A=?\
MQ^C_ (AY?B1_T?\ _MB?^%A=?_'ZZ+_B*V_8A_Z*AK7_ (2.J_\ R/1_Q%;?
ML0_]%0UK_P )'5?_ )'H YW_ (AY?B1_T?\ _MB?^%A=?_'Z/^(>;XDG_F__
M /;$_P#"PNO_ (_71?\ $5M^Q#_T5#6O_"1U7_Y'H_XBMOV(?^BH:U_X2.J_
M_(] '._\0\OQ(_Z/_P#VQ/\ PL+K_P"/T?\ $/+\2/\ H_\ _;$_\+"Z_P#C
M]=%_Q%;?L0_]%0UK_P )'5?_ )'H_P"(K;]B'_HJ&M?^$CJO_P CT <[_P 0
M\OQ(_P"C_P#]L3_PL+K_ ./T'_@WF^))_P";_P#]L3_PL+K_ ./UT7_$5M^Q
M#_T5#6O_  D=5_\ D>C_ (BMOV(?^BH:U_X2.J__ "/0!SO_ !#R_$C_ */_
M /VQ/_"PNO\ X_1_Q#R_$C_H_P#_ &Q/_"PNO_C]=%_Q%;?L0_\ 14-:_P#"
M1U7_ .1Z/^(K;]B'_HJ&M?\ A(ZK_P#(] '._P#$/+\2/^C_ /\ ;$_\+"Z_
M^/T?\0\OQ(_Z/_\ VQ/_  L+K_X_71?\16W[$/\ T5#6O_"1U7_Y'H_XBMOV
M(?\ HJ&M?^$CJO\ \CT <[_Q#R_$C_H__P#;$_\ "PNO_C]'_$/+\2/^C_\
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M+\2/^C__ -L3_P +"Z_^/T?\0\OQ(_Z/_P#VQ/\ PL+K_P"/U^G5% 'YB_\
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M)\2M1\83:QIOB;Q-!XEN=&UJPN-3;/\ ;>GZO=669+S[)]DF>P$'EBS#+$R
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MI?C&QFC\#7EEJCVH\,1BZGN;?1;W1_*@OY9Y;N&Q>&[28VDDLZK<I+*K SL
M >=+_P &\_Q(8?\ )_W[8G_A877_ ,?I?^(>7XD?]'__ +8G_A877_Q^OTZ
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MU [<4V?_ ():VMG\*IO&ES_P4Z_:@L_#MKH$7BFXN+KQU<6\MIIDL4<L=U+
M\XFB0I-$<.BM^\48R0*^_?VZO^"=^F_MQ7]O<WWB:]\.W&F^#]:\.Z=/:6V^
M;3[Z]U#1-0M-21_,7YK6XT2%O)(VS"5E9E4$-\U_%K_@W7T'XP?$E-9U/XG:
MG)IL?P_;P,FG2:*LBVY_X1UM$2ZCS.(<KE;H;X7F$J[1<",(B 'F/A+_ ((T
MZUXU\8:MH-A_P46_;";4M&9%F6?Q/J%M#<AK6"[WVLTDBQ7<:PW,#.]NTB1^
M:JN58XK5'_!#_7FT"35O^'DO[4G]EPVT=Z]Y_P +!D^SI!(S(DI?[3M$;,CJ
M&S@E6 .0:^A/BU_P1HTKXT^ ]5TG5/&S:3>>(/%%OK6IW6@Z''IT<NF/X5L/
M#.J:+%&)6,-G>6MD9 H<K#)]FRLHMEW\WXA_X(86?B+X6_$SPM<?$AKBU\:6
MFGZ?HSS>'PA\/P66OZMK4&XP7,4DTRRZO(HEB>W8&"-QCE" >$^*/^"-NM>$
M?$FGZ1=?\%%/VQ9=0U;P[J'BRRAM/$VH7GVO3+!K-+JXC:*1E?8U_: (I,DG
MG#8KX;'%^!O^"<:_$+XG:WX5L?\ @HK^VA:77AKPUIGBG5KO5O$5_I-MIEMJ
M/S6D4_VJ:.2&X=-KF&1%9 P#A6.T?>_Q0_X)L:MXCT/X5Z;X7^)$7A^S^'_P
M\U#X8:D;WPS#?2:]I%\-)6<H(I;>*UG*Z3'M9(VC7SFQ& H%>;?'#_@@QX0^
M,WA+5+;_ (2^\TC6KRU\*PQ:E:6#6S2-H=A/8K]J-M/#//%-%.'\M9X]DEO;
MMN81[2 ?-OQ)_P""4=Y\*?B%X(\*ZI_P41_;8N-=^(@:30K?2=2UG6%N(5GM
M+=KF66T,L=K;++?6BFXN&CA!G3+XR1M7G_!&;7[/XHZ9X-7_ (*'?MF7GB#5
M%O&6&Q\0ZE>PV(M4A>;[7<0R-!9D+/#M%R\9D+@('.17UEXF_P""4T.O_ ;X
M"_#RU\96FAZ-\$DL/*N;#PZC:B9;.2VDAGTZ[GFEN--D/V<Q.1).)(+B6)PV
M0PY73_\ @B'X?CE\:6]UX[OO[-\7>&?%_A(R:?H=II^KBSU^]T^]:6YOX_WE
MY=026<J>=,#YD4R!E#K++< 'A>B?\$/?$'B2+3WT_P#X*2?M27ZZLVVQ-M\0
M9)1>'][Q'MN3O/[B;[N?]3)_=;!JG_!#SQ!H=IJ5Q>_\%)/VI+.#1ITMM0DG
M^(,D:6,KXVQRDW&(W;<N%;!.1ZUZ+^SE_P &\_@WX$ZI'J]UXFTK6O$=KK>@
M:Y:ZG_PC\SW%G)IFO6VKR>5+>7MW<1M=+:QVTA28*(U4[200T_Q@_P"#?O0?
MBQ\%+GP>WQ$NK;R?%=QX@T^\&B"VDN8)DO%,.JR65Q:W.IW"_;[D+=23HVP1
M@H6:X>X /)_&W_!%?7/A_P"'_%FI:E_P4<_:T2W\"Z?)JNOI!XUN;BXTJV2%
MIVDEACG:0?NT9@-N6 ^4&N#^'G_!-N;Q_P""-)UF3_@H3^VYH,VIZOH_AR;2
M]3US4%OM+U?5--LM2M=.N!'*\:R_9K^V+NCO"C2%3+N5@/L/]GK_ ((OZ#^S
M7X8^.VEZ7XL_T/XU>%AX9%O;:0((]$!@NTEN%\R>5I'=[HD@-&I$2&3S9C).
M\OPO_P""/_AR^UWP[\1O%UCX/M_C!#XG\,^,+O6;#18;J\TMM,T'2],FT:WU
M"0+.]F\MA+*&PG_'RW[K.2P!\^2?\$1-<@AU!Y/^"DW[44:Z3*UO?EOB%(HL
MI%1W9)?])^1E6.1B&P0$8G@'%F]_X(5^*K#Q7:Z#-_P4:_:LCUV^A^TVVFMX
M\F%Y<1?.?,2(W&]EQ'(=P!'R-Z&O5OA1_P $ ? ?@&XTB/6==TSQ=IFA:WIE
MY#97WA#3XX]4L=-AUM;--25!Y=[J'FZY-+-J#HKS-:P$QA]\C\E^R?\ \$EO
MB=^RU_P4:\$>+%;X?>*/A;X'\):7X6M=4U+4[_\ MF!++PQ#I7VRUTY5^R6]
M]-<0!'F9Y#]C>6,."VV@#R;P%_P2?F^)_BB_T?0?^"D7[8&H7VDC4SJ*KXCU
M)(]+&G:C/IET;F5G$=N/MEK=QQ&5E%Q]CN7A\U()63J],_X(<^(M;33VL_\
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M;D_#?P_K_P#P15^ ]U?:%HMY<2:9?[I9[&*21L:I>=692:\%_P""CW[4NO?
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M1+_HT'X7?^'2M_\ "@#]"6ZK]:_*;_@T2_Y,6^-7_9;==_\ 3?I->H#]KO\
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M CX!S:YI7EQZE?:]H/ANUG>,2K9R:MK-EI0N"C?*_DF]$H5N&,>#D$BOE/\
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MP4O^,&I:%;WVJZ=J.I:/;:9J=OHT^EV%Q?WZ71@=FC>&"VD+1X,@8HNW<P%
M'ZYXHQ7Y3Z;^R5XAUC4O#-C;_P#!4SQO)?>--);7M M/M^BK<ZWIRQR2M>6T
M1E#RP+'%*QD0%5$3DD;6PW]F']COX@_MC0^-+SX<_P#!1CXU>*=%\$Z^OAR?
M6M-ATB^TS4K@Z=97[-:W$$LB2QHE]'$Q)4K-%,NW"AF /U:Q1BOSV_X<Z_M
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MYQ_Q$;?#7_HAO[67_AL9_P#X[3?"G'_!TGXH_P"S;+?_ -2)*_0B:40QECG
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MATK3]+C2.&R@@@CC$&FP85(Q@ENM>O44 %%%% !1110 4444 (W5?K7XF?\
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M_P!M3XN:Y\(O!/@V306NK>[\3>//#?AR:Z@$;-9VUWJD$=PVV2*1"&A\R(Y
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MW=/:A_\ @G]^WU(RLW[>GAUBA)4GX):+\I(P<?-Z<5]'?\/8OV6?^CEOV?\
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MG_A[%^RS_P!'+?L__P#AP](_^2*/^'L7[+/_ $<M^S__ .'#TC_Y(H ^=O\
MA@K_ (* ?]'\:%_X971O_BJ/^&"O^"@'_1_&@_\ AE=&_P#BJ^B?^'L7[+/_
M $<M^S__ .'#TC_Y(H_X>Q?LL_\ 1RW[/_\ X</2/_DB@#E_^"3?_!/KQ/\
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MII_T1[]E?_PJ-2_QH_X7!_P4T_Z(]^RO_P"%1J7^- #?^"O?_*1O_@G_ /\
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MFHH?)26(-$I\S8Z.V?H_[,_["?Q:_8,\<_';X??LEVU[H7A/[$M@NL))$OB
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MA4?\0>G[,/\ T.'QX_\ "HM/_D*@#]7,T9K\H_\ B#T_9A_Z'#X\?^%1:?\
MR%1_Q!Z?LP_]#A\>/_"HM/\ Y"H ^Z/^"CNE:QK?[(^O6^CV\=U%)J>BG6H)
M;5+J*XT,:O9G6(WB=6#QMI@O58;22K'&#@UP/C7X>^,_#&K>*]0TGX>^)M8^
M*U[JNHMI?CZ.ZTQH=.TR661K:.,W,SR"W@M62+["MOLEN8WD*HTS7@^5X_\
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M8Y.0  ?1=%%% !39(EE&&_G3J* /!_\ @J!;)'_P30_:(VKS_P *Q\2@#/\
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M:7X?UK?JL%[X*U&[NI[G4B18I80:I*MHME*K7!GLXY6* 1A@#:_XB9/V;_\
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MZOK][>^+=.O+J>:9]7\10Z?I$0A>W:.>Y_LZP@LHVCD,_P!M'S91!. >P_\
M$3)^S>?^8?\ &3_PWNH__$TI_P"#F/\ 9O!_Y!_QE_\ #>ZC_P#$UR7[3?\
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M:=<KJ%S/K-WI+^&=&GEM85>U>&2QDNI)C)>RW899))P3\@R 1?\ $3+^S?\
M] _XR?\ AO=1_P#B:/\ B)E_9O\ ^@?\9/\ PWNH_P#Q-<5I7_!4K]JOQ)\$
MIM<TOX8^&Y=6FDEN$-WX%\1V,6G/!X=U35;O1Y;6>1+F6ZM[JQM;,7BB."=[
M]52-7C,9]D_9V_X*8>*/CK_P4S\1_!^[M?"GAWPIH&G23P>?:W#:CK=VNFZ+
M<O;6MSYXB>2VGOM02YB: /&+2(#<6G\@ Y#_ (B9/V;\_P#(/^,G_AO=1_\
MB:/^(F3]F_\ Z!_QD_\ #>ZC_P#$UP?P,_;S_:(\"?"/XGZGXT\/^,=4\;:!
M=6J>%XKOPM?W>B1^&KC63;3Z]<Q6D*W-Y>6C/.9K*,H_V2RMC",23W4GHWPN
M_P""B/[0FK?$SX?#Q-X!\,V?@>_32U\1Z@N@:K8S3Q7VH>)K>/4X#-*18VPM
M-(TV^>&Z5Y($U$12,K,KJ 5Q_P ',7[.# D:?\9B!U/_  KW4>/_ !RD'_!S
M)^S>?^8?\9?_  WNH_\ Q->=_LU_\%,?B#^W-\-?ACXUU*;1?#'BRU^+?A.P
MT_PCI5O=6.I2V&HZ2QU-;^![B7[3;"WGU2X@9-BE-*2Y=5:)X8O5O!_[5GCS
MQCXBA\%M??$)_$^D?M"7>G:NRZ!=6:6WA@ZCJ<EDHN'M?L\]HT-M!&S1LQ\N
M09D5V5J ,S_B)D_9O/\ S#_C)_X;W4?_ (FE_P"(F3]F_P#Z!_QE_P##>ZC_
M /$UF_L[_P#!0;]J7X@R^!AXW^'_ (1T[3?%FF:?<W[Z/X>UBWNK%]1\):CK
M$85IY72-K2\TX6\NX/O;4H8L0O 'NN*^$?\ P4#_ &HOA!^Q1X\US6/#>L?$
M/QAX?U/PI!I=K>^"KQ;W0])U'0[*YFOKD"2V&J;+EYH9$A>&2*99GD98]D48
M!Z/_ ,1,G[-Y_P"8?\9?_#>ZC_\ $TG_ !$R?LW_ /0/^,G_ (;W4?\ XFN;
M^ '[<O[07[3O[67P!L?%_A]O .@?VM:7^KZ5I/AW7(_[;@G\%ZQ-)>W&H.WV
M&.Q75"+=-/D$EPMQ:12-(=L1?]+ ,CJ?SH _/?\ XB9?V;_^@?\ &3_PWNH_
M_$T?\1,G[-__ $#_ (R_^&]U'_XFOT)V^YHV_6@#P[]@O_@H-\/?^"CWPKUK
MQC\-+C6[C1] UV?PW?#5-,DTZX@O888)I(S')\W"W$?/KN':BOFG_@WW^?2_
MVRRQ+-_PU+XVR2>3Q844 ?H11110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(_P %OV"O 7QIT7Q-
MXFUK4OBU!J6I>-_%7G1Z/\5O%.BV*[/$&H1KY=I9ZA%;Q?*@)\N-=S%F.69B
M>RB_X)?_  QA5@FM_'A0_#!?CEXV&[Z_\3:NT_8^_P"23:M_V._BW_U)-2KU
M*@#YY3_@F%\,HE55USX]*L9W*!\<_&PVGU'_ !-J\]_:%_X),Z'\1?":Z#X5
M\4_%+28=6E>VUN]UOXN>.=6\NP>)Q*MO;'6%BEG=O+4&<F)!EFBG \IOLBFN
M<+^(H _+?_@A%^SCX?\ V0?^"C?[;_PQ\*S:U<>'? __  K[2;"75K][Z]EC
MCT2X&Z25NY.3M0+&@PD:1QJB+^I5?C]\'?\ @IC\#?\ @G?_ ,%JOV[E^,GC
MZS\$MXNU3P:=)6;3[R[-X+?1G\XC[/%)MV^?%][&=W&><?2O_$2_^P__ -%X
MTO\ \)[6/_D2@#[LHKX3_P"(E_\ 8?\ ^B\:7_X3VL?_ ")1_P 1+_[#_P#T
M7C2__">UC_Y$H ^[**^$_P#B)?\ V'_^B\:7_P"$]K'_ ,B4?\1+_P"P_P#]
M%XTO_P )[6/_ )$H ^[*9)")1R6_ U\+?\1+_P"P_P#]%XTO_P )[6/_ )$H
M_P"(E_\ 8?\ ^B\:7_X3VL?_ ")0!]@?%OX$^"_C]X+F\-^.O"GAOQIX?N)4
MGDTS7M+M]2LY)$.4<PSHZ%E/()7(K8\,>"]*\$>'=/T?1=/L]'T?2;:*RL;"
MQ@2WM;*")0L<442 *B(H 55 "@ #%?$__$2_^P__ -%XTO\ \)[6/_D2C_B)
M?_8?_P"B\:7_ .$]K'_R)0!]E?$CQGI?PN\$ZGX@UBXN(-*TN W%RT5M-=S%
M1T$<,*O++(3A5C16=V(506(%8UE\;O#>I_$:3PI;ZG)>:]9N8)Q!;3S6]O<"
M+SC:R7*H;=+H0D2_9VD$WELK[-C!C^>O[;7_  7H_8P_:-_9ZO/#ND_'K1_[
M2M=9T3Q#;0MH>K1"\DTK6++4UM][6FU/.-GY6\\+YF3P#7+?$'_@M3^R?XC\
M%>)?!.E?M1?#^T\#>)-1U#5+B"\^'VMW6HNM[=2WMQ:>:R>2%>YFE_?>072)
MPJ*)46< 'ZR"R63Y6:0<9QNZ^M2M:@MG=)GZU^%&A_M\_L>2Z]K'A_5OVD/"
M,G@V]\%WRJ8?"&LI9Q>*;N'4]+BO[:W9))PMKH=[]@=;B1Q)!'8*C@V[X],\
M=?\ !2;]@'49O%#>%_CQ\/\ PG'XAU)IQ#9_#O4%6/3VL+.WDTPXM,>1)-;2
MSDJHVR7)D51*BRD _8K[,L99M[*!RWS8_$UDV?B&SU36M0TVVNHYKO26C6YA
MC8[[<R)O7=V&5Y'ZX[_D/\,/^"E_["_@Q]%U34/VC/!-YXLT.WT"UL=5MO N
MM))I,.G:[?:I-:VCRQRSQ6\T%Z;,(96(B3YS*&*UT'[0/_!6_P#8A^.7Q'M_
M$$G[1/@H&/5;._C74/ VJZ@UD(4A1]B36SV[LXB(W2PLR;]T;Q.@=@#]5?A]
MXITWXF>!=%\2:3>-?:3X@L(-2LKD1O$+F"9!)$^QP'7*L#M8 C." 1@2^-?$
M^G^ /#%YK.J74EOI^GQ^9<2E'E\M<]=J L>3V!_*OQ@\1?\ !0']C'Q'%9VL
MG[5?@XVZ^ 7\#7-PW@'65N9X#H4NEB,E(U62W,TK7;).)9&9(462-8@6Z'X@
M_P#!2G]A'7?%>H3:#\=_A3INBW=\UUIVG7GPTU:X3PHK1:8';3 D4:6\TLMC
M-)(ZJ SSQ,5)A;S@#];M=^(^D^$_&GAW0-3O&LM2\627$.D))%*([V:")IY(
M5EV^6)1"LDJQLPD>."9E5EAD*=''9@C<S2?-S@MG!K\9=)_X*D_L8>%?VR-#
M^(6G?M!>"8M+3QM-XRU%+?P9J<,W&C^(-/6)KAK9[N>263Q!YNUW:"'[)<&)
M83<F,_6@_P"#E[]A]1_R7C2__">UC_Y$H ^YULU0<-)]=U!L5)^])USC=UKX
M9_XB7_V'_P#HO&E_^$]K'_R)1_Q$O_L/_P#1>-+_ /">UC_Y$H ^[%&T45\)
M_P#$2_\ L/\ _1>-+_\ ">UC_P"1*/\ B)?_ &'_ /HO&E_^$]K'_P B4 ?=
ME%?"?_$2_P#L/_\ 1>-+_P#">UC_ .1*/^(E_P#8?_Z+QI?_ (3VL?\ R)0!
M]V45\)_\1+_[#_\ T7C2_P#PGM8_^1*/^(E_]A__ *+QI?\ X3VL?_(E 'W6
MW5?K7XF?\&Q_[(MC^T#^R!\7]6N?'WQ:\*26GQBUNS%MX5\7W>CVDH%EIC^8
M\41"M(=Y!?J551V%?9'_ !$N?L0NR[?CQI/7G/A_6!_[:5X5_P &?^J6^M_L
M"?&*]LYEN+.\^-.MSP2J"!)&VG:2RL,X/((/(H ^S?\ AV;I7_19OVE/_#F:
MC_\ %4?\.S]+_P"BS?M*="/^2EZA_P#%5]*44 ?-?_#L[2MO_)9OVE/K_P +
M,U'_ .*I1_P3/TL?\UE_:3_\.9J/_P 57TG10!^2O_!47_@CSJ'C7X9_%3XA
MZ]\1?B-#X<^#?@7Q%J?A66?QA>ZOKVNS/H<OVA;BZF"BQL&W36\MG")#=H S
MS(N(:^U?^"-BX_X)._LW_P#9-]"_](8JZ#_@J(?^-:'[1&>A^&7B7/\ X*KF
MOAC_ ()G_P#!P)^Q_P# 3_@G?\#_  3XL^-&F:3XF\*^!](TO5;)M$U65K.Z
MAM(TEB+1VK(Q5@1E6(.."1S0!^KE%?"?_$2_^P__ -%XTO\ \)[6/_D2C_B)
M?_8?_P"B\:7_ .$]K'_R)0!]S2V:S-DLP]0#@'_.:XOQ1^S#\.O&_P 6=)\?
M:UX%\&ZOX[\/Q"'2O$E[H=I<:OIB N0L%T\9FB4&20@(P \QO4U\F_\ $2_^
MP_\ ]%XTO_PGM8_^1*/^(E_]A_\ Z+QI?_A/:Q_\B4 ?<RV:K_%)GUW<T"T5
M3]Z3CISTKX9_XB7_ -A__HO&E_\ A/:Q_P#(E'_$2_\ L/\ _1>-+_\ ">UC
M_P"1* /N86:JQ(>3DY/S=:1+!4_CDW8QG/.*^&O^(E_]A_\ Z+QI?_A/:Q_\
MB4?\1+_[#_\ T7C2_P#PGM8_^1* /N8VBLN"TG/7GK6#\1_&6E_"SP7?Z]K%
MS<0Z;I<7G3/%;37<YYPJQPPJ\LLC,0JQQJS.S!5!8@'XW_XB7_V'_P#HO&E_
M^$]K'_R)7D_[:G_!>O\ 8Q_:(^ <V@:3\>M'.HV.O:#XDMX7T/5HA>/I.M6.
MJBWW-:;5,WV/R@S<*9,G@&@#]&-,^)NBZQ)8I;ZI:S/J%_>Z9:JKDF>YM'F2
MYB7_ &HV@F##UC:NE2V5!N+.ORCG.,"OR.O/^"K?[#,B7LUO^U/=6^H:EJ/B
M6]FE:Q\3SVL2ZO+>NHALW!MX7A%VH,D:*S^6^#'YC8P_AG_P4?\ ^"?_ (+\
M;^(/%$GQG^%-AJ^M:MH>L64.C?#C4[6V\.S:?.AE^QC[,6C^TPPQ*Y4J=VYB
M67"@ _7SQ;H&FZQX:OK#5;:UU#2[VVE@O+6\B6:VN(&0K(DB,"K1LI(8$$$,
M00<XKG_A'\3_  C\2[:^L_!^J:;J5IX;-O87*:>O^CZ>SVL5Q%;\ (K?9YH'
M\L<HDL9( =<_DU_P3-_X++_LF?LK?##Q#HGBCXT>#XM7U&UL+:778?"5W;7N
ML30V[PNTXM89%N$3Y&2YF\NXG::8RQ(55GP?#W[=G["_A?\ 9^TWX5_\-(>
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M$.G2PRA7"NH:-U;#*&&>0#Q10!^D5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y;^Q]_P DFU;_
M +'?Q;_ZDFI5ZE7EO['W_))M6_['?Q;_ .I)J5>I$XH *;(H9>3BG9K/U7Q'
MIMA)<6]SJ-C:S6]O]JE26=5:*')'FL">$R"-QXR#S0!YOX[_ &#O@?\ %7Q?
M?>(?%'P<^%/B;Q!JCK)>ZGJOA+3[R\NV5513)-)$7<A$506)("@= *R/^'9O
M[.'_ $;_ /!'_P (72__ (Q7PQ\;?^"C/[=/Q!_X*&?'CX3_ +-OPS^ OBSP
MQ\%[S2+:XN?$QN[;4,:A8+<IO;^T(4D^=9QE$& J@Y/);_PT'_P5Z_Z(/^RK
M_P"#"Y_^6] 'W3_P[-_9P_Z-_P#@C_X0NE__ !BC_AV;^SA_T;_\$?\ PA=+
M_P#C%?"W_#0?_!7G_H@_[*O_ (,;G_Y;T?\ #0?_  5Y_P"B#_LJ_P#@QN?_
M );T ?=/_#LW]G#_ *-_^"/_ (0NE_\ QBC_ (=F_LX?]&__  1_\(72_P#X
MQ7PM_P -!_\ !7G_ *(/^RK_ .#&Y_\ EO1_PT'_ ,%>?^B#_LJ_^#&Y_P#E
MO0!]T_\ #LW]G#_HW_X(_P#A"Z7_ /&*/^'9O[.'_1O_ ,$?_"%TO_XQ7PM_
MPT'_ ,%>?^B#_LJ_^#&Y_P#EO4=]^TC_ ,%<M,LIKFY^!O[*-O;VZ-++++J=
MPB1(HRS,3J^  !DD]* /NW_AV;^SA_T;_P#!'_PA=+_^,4?\.S?V</\ HW_X
M(_\ A"Z7_P#&*^%(OVB/^"NT\:M'\"?V4W5@&5EU*X((/0C_ (F]10?M,_\
M!6^ZU"XM(O@C^R=)=6@0SPKJL[20AP2NY?[7RNX XSUP: /O#_AV;^SA_P!&
M_P#P1_\ "%TO_P",4?\ #LW]G#_HW_X(_P#A"Z7_ /&*^!O$7[6/_!63P?!;
M2ZM\&_V1=+CO;N&PMFO-9F@6XN9G$<,*%M8&Z21R%5!RS$  GBKE]^TC_P %
M<],LIKFY^!O[*-O;V\9EEEEU.X1(D R68G5\   DD\ 4 ?=O_#LW]G#_ *-_
M^"/_ (0NE_\ QBC_ (=F_LX?]&__  1_\(72_P#XQ7Y\>._VV?\ @JC\+-#U
M+5/$_P +/V-_#>FZ+:?;]0N]4\0O9P6%MN*^=*\FL!8X]P(WL0N1C-;EO^T7
M_P %=KJ%)(O@7^RG)'(H9'34KAE8$9!!_M?D&@#[K_X=F_LX?]&__!'_ ,(7
M2_\ XQ1_P[-_9P_Z-_\ @C_X0NE__&*^"M'_ &J/^"M'B'2_MVG_  7_ &2;
MZR^;_2+?5YI8OEZ_,NKD<=_2IM/_ &E?^"N.K6$-U:_ _P#9/N;6X02Q31:I
M.\<J$9#*PU?!!!'(XYH ^[_^'9O[.'_1O_P1_P#"%TO_ .,4?\.S?V</^C?_
M ((_^$+I?_QBOA;_ (:$_P""O/\ T0?]E7_P8W/_ ,MZ!^T)_P %>2/^2$?L
MJ_\ @QN?_EO0!]T_\.S?V</^C?\ X(_^$+I?_P 8H_X=F_LX?]&__!'_ ,(7
M2_\ XQ7P5?\ [4O_  5JTNWO)KKX*_LDV\.G@-=/+J\R+; C(+DZOA<CGG'%
M7?\ AH/_ (*]?]$'_96_\&%S_P#+>@#[H_X=F_LX?]&__!'_ ,(72_\ XQ1_
MP[-_9P_Z-_\ @C_X0NE__&*^$-/_ &E_^"N&K0M):_ _]D^ZCCD>)FBU2=U5
MT8JZDC5_O*P((Z@@BJOBC]K+_@K)X(TD7^M?!O\ 9%T>Q-Q!:"XO=9FMXC-/
M,D$$>Y]8 WR321QHN<L[JHR2!0!]\_\ #LW]G#_HW_X(_P#A"Z7_ /&*/^'9
MO[.'_1O_ ,$?_"%TO_XQ7PL/VA/^"O7_ $0?]E7_ ,&-S_\ +>C_ (:#_P""
MO/\ T0?]E7_P8W/_ ,MZ /NG_AV;^SA_T;_\$?\ PA=+_P#C%'_#LW]G#_HW
M_P""/_A"Z7_\8KX6_P"&@_\ @KS_ -$'_95_\&-S_P#+>C_AH/\ X*\_]$'_
M &5?_!C<_P#RWH ^Z?\ AV;^SA_T;_\ !'_PA=+_ /C%'_#LW]G#_HW_ ."/
M_A"Z7_\ &*^%O^&@_P#@KS_T0?\ 95_\&-S_ /+>C_AH/_@KS_T0?]E7_P &
M-S_\MZ /NG_AV;^SA_T;_P#!'_PA=+_^,5Z'\(O@7X)^ 7AZ?1_ GA'PMX+T
MBYN&NY;'0=*@TVVDG951I6CA55+E8T4L1DA%&< 8_-0?M!_\%>=P_P"+$?LJ
MC/&3J%S_ /+>O;_^" __  4=^(G_  4[_92\:>-?BAHO@W0O$WA;QY?>$OLW
MAJWN(;,Q6]G8S;F$\\[-)YES("P<*55,*#DD ^Z***,T %%&:I6OB33[Z5(X
M;^RFDDDEB14G5B[Q,5E4 'ED8$,.JD8.* $\2^'-/\8>'K[2=6L;/4M*U2WD
MM+VSNX5FM[R&12DD4D; JZ,I*E6!!!(((->.K_P3,_9P _Y-_P#@CCM_Q0NE
M_P#QBND_;0^+NI?L_P#['WQ6\?:+#87.L^!_!^K^(+"&]1WM9KBTLIKB-)51
MD8QEXU#!64E20&!Y'YD_ O\ ;I_X*M?M$_!?PKX\\*?!#]EJ\\,^,]*MM:TN
M>2[NH7EMIXUDC9D;5@RL5894\@\'F@#]$_\ AV;^SA_T;_\ !'_PA=+_ /C%
M'_#LW]G#_HW_ ."/_A"Z7_\ &*^%O^&@_P#@KS_T0?\ 95_\&-S_ /+>C_AH
M/_@KS_T0?]E7_P &-S_\MZ /NG_AV;^SA_T;_P#!'_PA=+_^,4?\.S?V</\
MHW_X(_\ A"Z7_P#&*^$+G]I;_@KA9W5O!-\#_P!D^*:\8I!&^J3JT[!2Q"@Z
MOEB%4D@= ">U3']H3_@KPJDGX$?LJX')/]HW/'_E7H ^Z?\ AV;^SA_T;_\
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M]'_#0G_!7C'_ "0C]E7_ ,&-S_\ +>@#[I_X=F_LX?\ 1O\ \$?_  A=+_\
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M $;_ /!'_P (72__ (Q1_P .S?V</^C?_@C_ .$+I?\ \8KX6_X:#_X*\_\
M1!_V5?\ P8W/_P MZ/\ AH/_ (*]?]$'_95_\&-S_P#+>@#]*OA)\"/ _P
M?#T^C^!/"/A7P7I-Q<M>2V.@Z5;Z;;23LJ(TK1PHJF0K'&I8C<0BC. ,%?+O
M_!$S]N'XK?MU? _XH7WQFT+P5X;\>?#/XF:M\/KVR\+13+8(UA!9M(<RW$Y=
MO.GF7>K["JI@=2Q0!]H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOG[0C0C4@_;>^'LS:HK7GB*UDT6.5[Z.[\*:O:R6YBB2>2(K):JQF$$B3^2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2?$_5/$=KIEW<P7$GV.>QTU$??"[*1OBE7L<QG@#%?HU0!B@ HHHH ****
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M\.8_LGG_ -J^7]HW@IY6[?N&,9JOXC_X)/:_X.D\2+K'_!6CXPZ2W@R2"+Q
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M:UJNJ7JZEX[@\4QRW/\ 9MG+-I\FNVVD6TL\+O&6$L$6DJD3DDA;F922I H
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MWS2SR"W>W,V%^T#")]O_ /!&T_\ &IS]F_\ [)OH7_I#%0!\=?\ $.W\>/\
MI(W^U'_X-M0_^6-(_P#P;O?'=%S_ ,/&OVI/PU;4/_EC7ZM4V5/,C*^M 'XO
MZQ_P25\:>%]7\=6NM_\ !43]H_P['\-7T^/Q%?:SKM[IUAIQOD5[7=<S:DL1
M\S>BC#'YG5>I J]I/_!'OQEX@UK1]-T[_@JM\<M2U+Q%8C5-)L[3QE+/<ZK:
M&(S"XMXUU4O-$8E9PZ @J"<XYK[E_:(_X)A77Q\\:_%2^@^+WCCP;H_Q<M-*
MCU;2]$@M87BN-.,!@FCN]GVE5=8?+DC610\<L@!5B&')_L]_\$/O _[/NI^
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M[DDNM6BWV\<BM&'@$I8I*P7RX)Y(_P!0M0_X)N+H7[,?P.^'?@7QYJ?@&^^
MLEK/H6OV6CV5U/<RQ:+>Z/))-;S1F!FFAOYY&.S_ %AS7-_&O_@C?X(^/7@E
MM"USQ%XBCMU/C&:">S9+>YM)_$/B>S\2--'(HW*UM=644:;2-\32*WWLT ?
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M\%>/^CC_ -FO_P $[?\ RHH_X9@_X*\?]''_ +-?_@G;_P"5% 'ZM45^4O\
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M//P=\*^ _"?[0?[-NG^&?!NE6VC:7;/IDDS06UO&L4:EWTDLY"J 68DGJ>:
M/V HK\I?^&8/^"O'_1Q_[-?_ ()V_P#E11_PS!_P5X_Z./\ V:__  3M_P#*
MB@#]6J*_*7_AF#_@KQ_T<?\ LU_^"=O_ )44?\,P?\%>/^CC_P!FO_P3M_\
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M$_\ 0X>%O_!K!_\ %T?\+R\$_P#0X>%O_!K!_P#%U\D?\0W?[$O_ $0/P_\
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M^#6#_P"+KY(_XAN_V)?^B!^'_P#P;:G_ /)-'_$-W^Q+_P!$#\/_ /@VU/\
M^2: /K?_ (7EX)_Z'#PM_P"#6#_XNC_A>7@G_H</"W_@U@_^+KY(_P"(;O\
M8E_Z('X?_P#!MJ?_ ,DT?\0W?[$O_1 _#_\ X-M3_P#DF@#ZW_X7EX)_Z'#P
MM_X-8/\ XNC_ (7EX)_Z'#PM_P"#6#_XNODC_B&[_8E_Z('X?_\ !MJ?_P D
MT?\ $-W^Q+_T0/P__P"#;4__ ))H ^M_^%Y>"?\ H</"W_@U@_\ BZ/^%Y>"
M?^AP\+?^#6#_ .+KY(_XAN_V)?\ H@?A_P#\&VI__)-'_$-W^Q+_ -$#\/\
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MVB8S\V_X8>)>".H_LJYKXG_X)D_\$$OV1/CK_P $Z_@;XS\5?!30]6\3>*/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=6U_4M22&1#=,L$,=Q<.D-F#>W1%G$JVP,S?NN!CV_=]?RIDK-E=H/49X[4
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MIO#MCXDMKV#2[?3;:*QLK>+4HFM9XKHN)G?[&KM/&WFCS6;;Y(1$E .XT?\
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M?ME?]G2^-OY6%% 'Z$4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (3.M_\ R'1_Q$V_L._]%VT__P )G6__ )#H \U_XAT/&'_1]?[8G_A9S?\
MQ='_ !#H>,/^CZ_VQ/\ PLYO_BZ]*_XB;?V'?^B[:?\ ^$SK?_R'1_Q$V?L.
M_P#1=M/_ /"9UO\ ^0Z /-?^(=#QA_T?7^V)_P"%G-_\71_Q#H>,/^CZ_P!L
M3_PLYO\ XNO2O^(FW]AW_HNVG_\ A,ZW_P#(='_$3;^P[_T7;3__  F=;_\
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M */K_;$_\+.;_P"+KTK_ (B;?V'?^B[:?_X3.M__ "'0?^#FS]AT?\UVT_\
M\)G6O_D.@#S7_B'0\8?]'U_MB?\ A9S?_%T?\0Z'C#_H^O\ ;$_\+.;_ .+K
MTK_B)M_8=_Z+MI__ (3.M_\ R'1_Q$V_L._]%VT__P )G6__ )#H \U_XAT/
M&'_1]?[8G_A9S?\ Q='_ !#H>,/^CZ_VQ/\ PLYO_BZ]*_XB;?V'?^B[:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX=&3Q;/X=AUI=6TYUN+:W\7CPG-?+!M\T8OYK0K$P!96N26011&Y^X+3X/\
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MIT$*-;!G80$*@'E[I9&V?=S(YQECD ^%[/\ X*C:7IMS\0-1N/"'PS\5^$_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /+?VP?^23:3_V._A+_ -233:]0C^[7E_[8/_))M)_['?PE_P"I
M)IM>H1_=H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A
M7_!44_\ &L[]HK_LF/B7_P!-5S7C7_!)#]L3X1>#_P#@EU^SUI6K?%3X;Z9J
MFG_#W1(+JTNO$UE#/;2+91!D=&E#*RG@J0"""#S7UW\5/ACHGQK^&?B+P=XE
ML_[2\.>+-,N=&U6T\Z2'[5:7,30S1[XV5TW1NR[D96&<@@X-?#__ !"X_L)_
M]$-_\O/Q!_\ )U 'U7_PW1\$O^BQ?"O_ ,*RP_\ CM'_  W1\$O^BQ?"O_PK
M+#_X[7RI_P 0N/["?_1#?_+S\0?_ "=1_P 0N/["?_1#?_+S\0?_ "=0!]5_
M\-T?!$?\UB^%?_A66'_QVC_ANCX)9_Y+%\*__"LL/_CM?&GBW_@V^_X)\^!=
M=\.Z=JWP=M=/NO%FI?V/I$<WC7Q"K7]V+:XNC"G^G8+?9[6XDP<<1'J< \9^
MRE_P;N_L*_%/X)^!9-5^$5I?^+[[P;H>OZS$OC+7HY@;ZW8I.T:WP5%EE@N0
MN !F)@ ,4 ??W_#='P2_Z+%\*_\ PK+#_P".T?\ #='P2_Z+%\*__"LL/_CM
M?#_Q^_X-T_V$?@5\*=6\3R?L_P#]HC3A"B0-X\UZUC,DTT<$;2S/?[88%>0-
M+,P(BC5WPVW!\*?_ ()8?L!0Z5X;O)/V<_#<=OJ6H7&G7]P?C-J8MGDAUW^Q
M"NF2&^ U%VG#2>6/)=4V(P6>18" ?JK_ ,-T?!+_ *+%\*__  K+#_X[1_PW
M1\$O^BQ?"O\ \*RP_P#CM?E7^R[_ ,$H?V%?C]\6Y/!.O?LMQ_#_ ,06<MS;
MW=EK/Q&\46EU).D%G<16UI#=O;27DXANP]P(5*6X$#"2:.ZMY)/JA?\ @US_
M &%&'_)#/_+S\0__ "=0!]6?\-T?!+_HL7PK_P#"LL/_ ([63XW_ &R_@SXD
M\+:E86OQL^%]C<WUI+;Q72>++'=;.Z,JR#$P/RDAN"#D#D=:^:O^(7']A/\
MZ(;_ .7GX@_^3J/^(7']A/\ Z(;_ .7GX@_^3J .9\!Z[H=A^SQ\,],T3XT?
M"3X?^+--^'NC>'/$FIR?$RU^U7D]G8O;FUGM(3-;OAY'9+V&Y69#MP75 K2?
MM&>*?"NFZ59ZAX0^.WPK:ZU#Q%JM_P")$?Q;%JRZM;7.M+=V23P-*[S16UH9
MH!&BDQ%XTB\J(>=#T7_$+C^PG_T0W_R\_$'_ ,G4?\0N/["?_1#?_+S\0?\
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MO^BQ?"O_ ,*RP_\ CM?*G_$+C^PG_P!$-_\ +S\0?_)U'_$+C^PG_P!$-_\
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M\9;*[X5R",@^<_\ !//_ (*)^-OV.OV>-/T7Q!^Q=^V-X@\?:NEK>^+-9L_
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MENM3U37$L]3NV5[N.1;2RL5DN'MPIDB\U7DF"18E +W_  _:\6?]&-_MI?\
MA#)_\>H_X?M>+/\ HQO]M+_PAD_^/547]MG]JSPQ\*_B9>:WX#L[G6-%LX9?
M#<^D_"77IP\J>*;O1IO.L1J+S7:RV5M%J82VE62WM[H.%NU"-+D6?_!0O]K?
M6/A3#JT?P3:Q\1P^!+'6SHMQ\/=<=-6O99KB*^N$G^TJ;0V"QQ3_ -CS1/>W
MJD);R%I5:, Z+_A^UXL_Z,;_ &TO_"&3_P"/4?\ #]KQ9_T8W^VE_P"$,G_Q
MZH/@[_P4(_:.O](\#Q^+OA?,U_XJN=$M5N=.^&/BFQM467QA+8:I+<I<@MIO
MD:#]GNQ]L94\PR.DD\8,:\Y\&/C]^U-X<\(0Z[XGT'Q?XT\8>'/ M[;ZDTG@
M;5M+LH[T^([6">8Z8LZP:I<6FG"6ZB2T9);V.)HH) 9MY .J_P"'[7BS_HQO
M]M+_ ,(9/_CU'_#]KQ9_T8W^VE_X0R?_ !ZO,OBS^V-^U-\5?B%XA^'\/@?Q
MDWA*.PT'4K3Q-H?PJ\1^$[^2X&I^')Y#%-)=W*&WF@NM262U;R[F!;29)U7R
MWW^__MI_&;Q]\/?BE^T-I'AS2?B?JUSJ_P #+>Z^'L6C>'M:OM)D\0VR^*Y;
MF)+RRC,-K>.HTI0K30S2DVJQEG\L4 <;_P /VO%G_1C?[:7_ (0R?_'J/^'[
M7BS_ *,;_;2_\(9/_CU4[C]J7]KCP)XWM[&U\$:/JG@ZQ\0:C90PS> =>O-6
MFT>P\76FA0&6^^W>6]U>:;<R:F+@PE!%9R2B*6.5G@QQ\??VI?A#XE\<ZII/
MAGQ-XHTL:%XWO]!\+:GX4U74%U+5+7Q5JT5DZZAYI>VC.DII\\-HQ5+N,[+0
M*9$,8!TG_#]KQ9_T8W^VE_X0R?\ QZC_ (?M>+/^C&_VTO\ PAD_^/5XS\>O
MVS_VO?C'^Q?JEC_PA^K>%]2\0:%XIM9-6\,_"/QC%J][>0"Q_LNRM;5I8[O1
MYIXI[UA?S?:;8-;H%._='7T'^U-\.OC[X\_X**:AJ7@/6?$F@^ O!GACPSK(
MG&JWHL=0N8]0UN;4-/MM*58[+5+B[@M[.UE-Q>6QM$N()%+.R;0#"_X?M>+/
M^C&_VTO_  AD_P#CU'_#]KQ9_P!&-_MI?^$,G_QZN?\ V3?VQ?VS/VI;?3=.
MU+P;X=^'<ET?$<M[K.N?"77]-!CM-.\/2:?%':WFH1^3/+=ZGJ<7F22/%*-*
MD\M2$<G6_92_:]_:D\0S?!&U\6>%9=5T74M"\,6_C74-0^%VLZ#J\NI7QUV/
M49"9)TBL_L#Z;8"8FU:*8WJ2IY$-Q;J "U_P_:\6?]&-_MI?^$,G_P >H_X?
MM>+/^C&_VTO_  AD_P#CU8OP"_;1_;'^-GC.WT'5/ASX5\!7-]XQTO2+N;5/
MAKXD:W\*V,FG:]=Z@)+A[J&VU+RI]/TVUCO[69;=Y+O)0":WW<#>_M6?MF>/
M3#XXMO!$ECXB^'-GXXD_L:+X=>)[70/$J6VF:1>6=FEM/<PW%W<37#3VMO=R
MQPJ76Y,,$VPJP!ZQ_P /VO%G_1C?[:7_ (0R?_'J3_A^WXL_Z,;_ &T__"%7
M_P"/5Q/Q%_;F_:(^#G[4GC#P+X3\*:AKVI:UXDU/5]'TK4_!VM:Y+J5NNI6.
MG6T$-S]OAATC3Y("\WVV1&LT:.=L!W"/^GL8POXT ?GQ_P /V_%G_1C?[:?_
M (0J_P#QZC_A^WXM/_-C?[:7_A#)_P#'J_0FB@#YV_X)L?\ !1;1?^"E'PJ\
M7>)M(\&^,O 4_@?Q=>^"M6T;Q1;QV^HVE_:0VTLRO'&[[-IN0A5B&#1N"!17
M@/\ P;Z_\@K]LK_LZ7QM_*PHH _0>BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH P/B9\+] ^,7A&30?$^D:?KNC3
M7%O=2V5[")H)9+>>.XA9D/#;)HHW .1E!D$<5R(_8P^$>T9^%_P\/_<O6O\
M\17IM% 'F7_#%_PB_P"B7?#S_P )ZU_^(H_X8O\ A%_T2[X>?^$]:_\ Q%>F
MT4 >9?\ #%_PB_Z)=\//_">M?_B*J:_^PK\'?$FAWFGS?#/P5;PWT30R266E
M1V=PBL,$QS0A)8F]'C96!Y!!KUBB@#YI/_!(GX G_F3]6_\ "OUK_P"2Z/\
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M92-R,RGL30!^MU%? '_$4;^PG_T7+_RS/$'_ ,@T?\11O["?_1<O_+,\0?\
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M0: /O^BO@#_B*-_83_Z+E_Y9GB#_ .0:/^(HW]A/_HN7_EF>(/\ Y!H K_\
M!OK_ ,@K]LK_ +.E\;?RL**P/^#:3XG:'\:/@Y^U/XR\,WW]J>&_%W[2/BW6
MM)O/)DA^UVEQ!ITT,FR15=-T;JVUU5AG! .110!^DU%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <;^T9_R;WX\_P"Q=U#_
M -)I*_(5/N#Z"BB@ HHHH **** "BBB@ HHHH *(_P#7K_GTHHH ).G_  $?
MRII^\?\ =HHH =1110 J_P"?R-,7HOTHHH =1110 4444 %%%% !1110 444
94 ?H3_P24_Y-UUW_ +&6?_TEM**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 51!C0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH :^=CX)!VM@C&0<'!&>,^F>,]:J*+@KD%1P<%AE\\]2H"\
M\<[7P.Q[W:*=]+63UO[ROTMILT^S3T[,F45+=O:VCY>M[\T?>^5TGU/FOXR^
M#_VFO$6HZ:_P/^,?PJ^&ND16TZ:Q;^.O@OK?Q(U.ZN.!!/97ME\5/!%M;!1N
MW)/IUP P#%9@S(/CC]B[X2_\%$/ _P 8_C'K_P"TU\9O"'B/X-:OXW\7:AX,
M\%+IDNL>()EO=6O6T[6]#U5]9OE\%>&6A>%[?P?ON$LXV\AHX&1F'ZMT5Y=7
M*Z=7&X;&O%YC&6&K2K*A#'XF.&J<U)TO9SH*:IRIZ\_+)--Z;-GWN6^(&8Y9
MPOG?"D.'^!<7A,]P&$R[$9IC^"<CQG$6$I83,'F,,3EV>U>;'83,)5;4OKZO
M7A17LX)(_*;]H[Q-X;\(?\%5_P#@GEK'BGQ%H'AK15_8^_X*6Q?;]<O;?3K9
M93X__P""=TQ5M0NGAL[.&.W22X>6>:./RXIRS ;BOQAX\_:>_;M^)?[7O[4O
MA?X'>+-:T33?V8OVC?@%\./!GP_N?&O[*O@[X$>*OA!XI\ _ SXF>._%/QG_
M .%D:7JW[3&JZE\1M/\ B9>>%/A]XD^%,MGHVFS7%E>:*UQK"QM<?N#\6_V=
MOV?_ (]KHT7QQ^!OP=^,Z^'VN?[#B^+'PS\&?$:'14U (FH'3(/%^DZHE@U]
M%"(IGM50R%5,BR(C(:.M_LO_ +-/B3Q-X)\:^)/V>O@?X@\9_#2UTZP^&WB_
M6OA/X U+Q3\/+'2+B*ZT:Q\"^(;OP_)J_A*UT>Y@M[C2H- N]/6PGMX9[41S
M1(X]/MY)*R^%6O\ "G=J][RNVW+6^I\&DEHN[;W;;;;<I-MMRDVK[+1626A^
M,D?[;_Q0NOV^?@+I'PU^,7Q_\5?!'XI?MX_M'?L@^-O"/Q3L/V.+'X,SW/P1
M^$G[0NH^,]+^"/AOX<>&Y?VQ+F[^&'Q4^$NFZ%/XU\=W:>$M2@F6?7=0^P:A
M!(_S'^S+\8?B-\?/VA?^"(?Q\^+O[6]O\4?'/[0WC?\ :N^)>L_LS-'\%H-$
M^!_B"']C?]H"VUS2/ 2>$--M?B"&^$+WT7PM\2#Q#J6L>?-XBN+C4);:\GFM
M5_I'LOV<_P!GS3?B'J7Q<T[X$_!RP^*^L:A%JVK?$ZS^&/@JV^(6IZI!:"PA
MU+4/&<.B)XCO+Z&R M(KNXU*2>.WS"L@C)4PZ#^SM^SSX/\ &>K_ !&\*? _
MX-^$_B%KWB*Z\6:]XZ\._#;P5H'B_7O%M[HVI:-?>(]=\2:5H]GK>LZ]<Z#J
MNIZ?=ZGJ=[<WLVF7UU \Y@FE!!GXR?MY?##QM\8_^"EUE\.? _[.G[/'[1%_
MXL_X)>_$[P[<Z7^T?XGNM"\&^%+3Q!^T7X4T:3Q-'I^G_"_QMJ>O3:<;M)YM
M*TKQ%X2U._@C>VL-:T"[>+64Z'X.>"_VI_A/^T?\(?V,[/\ :L^(=Y\*OV(O
M^"7O[&_Q%\6>"?!7AKX;RZS^T1\9-#\?_'CX9ZY;>)_%_CKX6^._B!IOP[^)
MFC_!>RTJ;3?!VJZ;XFAMH)&TC4[362FH-^WK>$O#'_"5)XW;0-&;QHNBR^&X
M_%C:1IW_  DW_".R:B-6_P"$=CUSR%NQHZWJ-='33,86F NBOV@/,[8?"?AJ
M+Q9>^.8/#^C)XQO]%T_PS?\ BF/3;'_A(;GP_IU_JFH6.@S:N%%T=-T^^U2Y
MOH['>8A/,\A6>1HV0 _GR_9)_:O_ &@?&&O?\$PO'.M?M?7_ ,>KC_@HEX#^
M)'B7]H+]GJZ\-_ VS\+_ +.;:=^S7XO^,U]J'P_'A/P!IGQ T/2/@O\ $W0_
M#W[/>MV/Q+\3:S8^*M:\4V]]XBN;35)%B@^?_A+^UY^V/\2_A%_P3@^$'PT\
M<>,O!&H>/_\ @DW\//VG-0\3_"2Y_9'^'U_XS^+%\=!\%PZ!/H_[1^A2>&I/
M!7PWTMX?%WB[3O *V&HW>A),+-XBUG)'_1%JG[+?PHTJU^*NN_!'PCX _9R^
M+_Q;TF[L?$GQW^%/PH^&NC?$VYO;B-A#K>M:O<>&'?Q3J-A*QN[0^)_[1B2Z
MCADECD6-DDY/P-^PU^S+X=_9L^!'[*OC;X/?#?XW?"_]G;P%X!\ ^ ;#XT?#
MSP/\0A%%X \.Z=X=TWQ1+I7B+P[<Z+IWB*[.F&]N;S1["V N9&FM!#&R0Q '
MYM_"7X[_ +1OQD^/<W@']HS]L*+]D#5OV??V6?V%/BKXG\%_"W4OV;K[PK\;
M?B-\:](\?W/QL\2:QXE^+?PI\7R>)/A9_P )'HNB?#WPW/\ "75]#T:R\0W$
MCV>M3:C]A:\\1^!VB_M/>&/@[_P4>F^ G[6/Q \4?&ZW_P""E/Q'\)Z?X-^(
M'B+]F'P?J$_AZQ^)GPPUWXH:-\&[WQ-\'X_ ^C_%[XE_#+5-=\,_":Z^(4#>
M!=(\<ZMX?O\ Q$D-E:7<R?OEXE_9Z^ ?C'5_ 'B'Q=\#OA!XJ\0?"A;&+X6Z
MYXC^&G@K7-8^&T6FR6[Z?'X!U/5=$NKSP='8-:VSV:^'9M.^RFVA:V$;PQ%<
M+Q?^RQ^S/X\N/B!?^.?V>_@?XRU#XLVF@Z=\5+[Q7\*? 6OW7Q-LO#15?#5K
M\0)]4T*:3Q;;Z%($?2;?6I+R.Q\M$LEA"HB@'FG["_QGT3X\?LQ^"?'WA[Q?
M\6?',)U7XC^!=3\1?&JV^'%K\33XM^%WQ*\6_##QM9^)KKX2Z-HGPOU.31O%
MGA/4]-L=9\'6$FFZK8VT-\@DFEN(H_?/B=I?Q)UOP;JFF_"'Q7X:\!^.)I;&
M32?$_BSPC<>-M!L1#JMO-JD-YX<M==\-75Z+VQCNK=7BU6T8--YT5Q!+Y5S%
MU_A?PMX9\$^'M(\)^#?#NA>$O"V@646G:'X;\,Z38:#H&C6$ /DV6E:/I<%M
MI^GV<63Y=M:P10IDX7DYWJNE4E2JPJQ5.4J<HRC&M3C6HR<7S)5*,[1J1>SC
M)\K5TR*D/:0E3<JD8R33=*I.E45]+QG#5-+9[IGXK_$SX%_\%<+[]HGX'^(/
M"/[4WPA/@+0]-UM?B)JNF?#/5/ W@S4;>75+-X=(UGX<7WC[Q_=Z]K-U:LUO
MH^I0:I;+#*=_FV?EO)'Z-_P65O\ [#^P-XB_X2J\U"#X37GQL_93T3]I_4M(
MAALXH_V6M5_:6^%FD?M/W&JQZHT]E9>$IO@Y<>,H_$4NHSS6$7AN>^>[GDLP
M\S_K%5+4M-T[6=.O](U>PLM5TG5;*ZTW5-+U*U@OM.U+3KZ"2UO;"_LKJ.6V
MO+*\MI9;>ZM;B*2"X@DDAFC>-V4^MF^=XC.88&%?!9-A?J%&="F\KRC!Y9[>
M,ZBJN>+6$M]:K1:Y85:MI0IMPBK29YV6Y51RRIBJE+$YAB?K=6-::Q^.KXUT
MY1@Z:CAY5VW1I-/FE3@N64[3>J1^$'Q5\%_LZ0_\%&_^"=7AS]BJ[^'OPX^(
MGBGX1_M8:-\7?%G[+^G?"Z+6M#_8^O/@/KD7@?Q3KPL]#\0>%M1\)Z%^TY)\
M$M4^'1\4:#XB\-7'CR/3GN-*U6P^W6=Q\(_LT>$?'7C#]E'_ (("Z-X1_:E^
M*]EXL\?_ +27B:>+X@ZEI_P \6^*?@38:?\ \$YOVWD\2^#_  /;?\*B&@6>
MKZQHD-UIV@2^.]"\96&GWEU;7NN:/XCC#V]__3O\+/V>O@'\"5UN/X'?!'X1
M?!H>)KTWWB/_ (55\-O!GP__ +=OF=IGO-:'A30],74[EF+-Y^H+,^YR0ZNP
M)D\,_L^_ CP5J#:MX,^#'PK\(:HWCS6OBDVH^%_ 'A30+QOB7XD\/S^%/$/Q
M >?2M*M7?QGKWANYN-$UGQ(Y;5]4TV:6TOKN>%V4^,_GTW=]NQZC_JY_/O>?
MME_MCRV?[/W[. ^+?Q(\3^)/$'[;G_!0?]F'QQ\<O ?_  RAX*^._C+0_P!D
MWQ)J-]\)M(@@^+/A3PY^SWI'CWQ]X*674->CT7PIH5UJ&EZ UQI9L;RZNYC[
M?\-_''[??Q6^,/["?[//Q,_:3O/A!KWB3]GS]N/XP?';5?A18_ OQ[=?$ZS^
M '[5/[-7@/X+0GQ;:^"M<\(:'J>M> OB-?:=\2K3X>SV-W:7%UK=K97.F:C_
M *98?LOXJ^ /P&\:^#]8^'7C?X,_"CQ=\/?$^OWGBCQ%X%\5_#[P?X@\&^(O
M%5_<?;+OQ!K7AO6=)N]*U;7+F822S:A=VD]U,ID$TCJ$"Z/AKX0?"GP1)X1/
M@KX;^ _!O_""^'M0\%^!8_"OA+PSX>7P;X,U6\TC4]9\)>$[32=*MH-%\-ZG
MJ.BZ?=ZGI&G+;6[SVB7**LD4#( ?E+^W/;_"C6/^"EW_  3D\)_M4Q^%KW]F
M_4?A?^UGJ/@32_B;;>$Y_A9XB_;'TV7X(?\ "LK?Q-!XJC&CW/BVQ^#K?&^]
M\ 02H97U0WL>G1&Y94;S[]K/X\?!_P"$.B^&_A#^PI\5/%?PVU&Z\%_M1_'V
M?1?V+!^Q)!\+K?4/A7K/@.W^(7B[XO\ B/X_R0>'H-)\+^+OB/I%]XE\%_#N
M]M_%^O:?'JNE)'82V6FA_P!J_B1\+/AK\8_#-UX'^+7P]\$?$[P/?303ZCX/
M^(?A/0?&?A?4I[=O,MIKK0_$-GJ&FW#PN67_ $FTE5XY)(BI21\\3JW[,/[-
MFK^&O 'A+5/V?/@5J/A7X1W::G\*/#>K?"/P%J/AKX7ZC#/'=QZCX T*XT+^
MSO!MW%<PQW*W7AN+2ITGBCF64.BL #\%U_:1_;7_ &C?#^E^,_ W[57B_P"
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M-IT6?2;MWN\MC%)=;O\  ;\7.+TN9SRE*]M,KDW?R2QC_%H_K^_X?E?L6?\
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M_P"'^7_SL,?^(N<8?S93_P"&W_[]/Z_O^'Y7[%G_ $#_ (U?^$)I'_S94?\
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M_&K_ ,(32/\ YLJ_D!HI?\2T^&G_ %4W_A_E_P#.P/\ B+G&'\V4_P#AM_\
MOT_K^_X?E?L6?] _XU?^$)I'_P V5'_#\K]BS_H'_&K_ ,(32/\ YLJ_D!HH
M_P"):?#3_JIO_#_+_P"=@?\ $7.,/YLI_P##;_\ ?I_7]_P_*_8L_P"@?\:O
M_"$TC_YLJ/\ A^5^Q9_T#_C5_P"$)I'_ ,V5?R T4?\ $M/AI_U4W_A_E_\
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M (0FD?\ S94?\/ROV+/^@?\ &K_PA-(_^;*OY :*/^):?#3_ *J;_P /\O\
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M]BS_ *!_QJ_\(32/_FRK^0&BC_B6GPT_ZJ;_ ,/\O_G8'_$7.,/YLI_\-O\
M]^G]?W_#\K]BS_H'_&K_ ,(32/\ YLJ/^'Y7[%G_ $#_ (U?^$)I'_S95_(#
M11_Q+3X:?]5-_P"'^7_SL#_B+G&'\V4_^&W_ ._3^O[_ (?E?L6?] _XU?\
MA":1_P#-E1_P_*_8L_Z!_P :O_"$TC_YLJ_D!HH_XEI\-/\ JIO_  _R_P#G
M8'_$7.,/YLI_\-O_ -^G]?W_  _*_8L_Z!_QJ_\ "$TC_P";*C_A^5^Q9_T#
M_C5_X0FD?_-E7\@-%'_$M/AI_P!5-_X?Y?\ SL#_ (BYQA_-E/\ X;?_ +]/
MZ_O^'Y7[%G_0/^-7_A":1_\ -E1_P_*_8L_Z!_QJ_P#"$TC_ .;*OY :*/\
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M&'\V4_\ AM_^_3^O[_A^5^Q9_P! _P"-7_A":1_\V5'_  _*_8L_Z!_QJ_\
M"$TC_P";*OY :*/^):?#3_JIO_#_ "_^=@?\1<XP_FRG_P -O_WZ?U_?\/RO
MV+/^@?\ &K_PA-(_^;*C_A^5^Q9_T#_C5_X0FD?_ #95_(#11_Q+3X:?]5-_
MX?Y?_.P/^(N<8?S93_X;?_OT_K^_X?E?L6?] _XU?^$)I'_S94?\/ROV+/\
MH'_&K_PA-(_^;*OY :*/^):?#3_JIO\ P_R_^=@?\1<XP_FRG_PV_P#WZ?U_
M?\/ROV+/^@?\:O\ PA-(_P#FRH_X?E?L6?\ 0/\ C5_X0FD?_-E7\@-%'_$M
M/AI_U4W_ (?Y?_.P/^(N<8?S93_X;?\ []/Z_O\ A^5^Q9_T#_C5_P"$)I'_
M ,V5'_#\K]BS_H'_ !J_\(32/_FRK^0&BC_B6GPT_P"JF_\ #_+_ .=@?\1<
MXP_FRG_PV_\ WZ?U_?\ #\K]BS_H'_&K_P (32/_ )LJ/^'Y7[%G_0/^-7_A
M":1_\V5?R T4?\2T^&G_ %4W_A_E_P#.P/\ B+G&'\V4_P#AM_\ OT_K^_X?
ME?L6?] _XU?^$)I'_P V5'_#\K]BS_H'_&K_ ,(32/\ YLJ_D!HH_P"):?#3
M_JIO_#_+_P"=@?\ $7.,/YLI_P##;_\ ?I_7]_P_*_8L_P"@?\:O_"$TC_YL
MJ/\ A^5^Q9_T#_C5_P"$)I'_ ,V5?R T4?\ $M/AI_U4W_A_E_\ .P/^(N<8
M?S93_P"&W_[]/Z_O^'Y7[%G_ $#_ (U?^$)I'_S94?\ #\K]BS_H'_&K_P (
M32/_ )LJ_D!HH_XEI\-/^JF_\/\ +_YV!_Q%SC#^;*?_  V__?I_7]_P_*_8
ML_Z!_P :O_"$TC_YLJ/^'Y7[%G_0/^-7_A":1_\ -E7\@-%'_$M/AI_U4W_A
M_E_\[ _XBYQA_-E/_AM_^_3^O[_A^5^Q9_T#_C5_X0FD?_-E1_P_*_8L_P"@
M?\:O_"$TC_YLJ_D!HH_XEI\-/^JF_P##_+_YV!_Q%SC#^;*?_#;_ /?I_7]_
MP_*_8L_Z!_QJ_P#"$TC_ .;*C_A^5^Q9_P! _P"-7_A":1_\V5?R T4?\2T^
M&G_53?\ A_E_\[ _XBYQA_-E/_AM_P#OT_K^_P"'Y7[%G_0/^-7_ (0FD?\
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M_#_+_P"=@?\ $7.,/YLI_P##;_\ ?I_7]_P_*_8L_P"@?\:O_"$TC_YLJ/\
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MA<WS# 8_-\7A\7E66X7#QQ^+HU*V&=5RP4J,H5*J@I<BG4I\S2XZN;Y5#/\
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M:30E^"GQ.\#^(M!T?^P(]22V5+_XBS"2*UD,1-P\-V\*J'^T.1$0E?8GPO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_A=OP8_Z*W\,?\ PN_"=?SMT4?Z_P",_P"A9@__  HQ?_R(?V#1_P"@FO\
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M\+OPG1_PNWX,?]%;^&/_ (7?A.OYVZ*/]?\ &?\ 0LP?_A1B_P#Y$/[!H_\
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MM^#'_16_AC_X7?A.OYVZ*/\ 7_&?]"S!_P#A1B__ )$/[!H_]!-?_P !A_\
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M .%WX3K^=NBC_7_&?]"S!_\ A1B__D0_L&C_ -!-?_P&'_R1_1)_PNWX,?\
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MU)_!1>R;^U?MTMW/Z*Y/C#\)H;:SO;KXI_#B&SU#S#:SMX\\)D3-"?D!]F(
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M .2/Z)/^%V_!C_HK?PQ_\+OPG1_PNWX,?]%;^&/_ (7?A.OYVZ*/]?\ &?\
M0LP?_A1B_P#Y$/[!H_\ 037_ / 8?_)']$G_  NWX,?]%;^&/_A=^$Z1OC;\
M&,'/Q>^&40P<RKX[\)[H^/\ 6#W3[P]Q7\[E/7[X^@_]!JEQ_C;:9=@UJO\
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M@Q_T5OX8_P#A=^$Z/^%V_!C_ **W\,?_  N_"=?SMT4?Z_XS_H68/_PHQ?\
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M@Q_T5OX8_P#A=^$Z/^%V_!C_ **W\,?_  N_"=?SMT4?Z_XS_H68/_PHQ?\
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M6TG%Q>J3V:3M9K6UOR&4C=#]#_*EI&Z'Z'^5:O>/^./YF:VE_@E^1ZA\&/\
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MPYJ/P3?Q$O@6/XFZ1X\TGXAWG@V;1&U*:>RU:[&JVMM#:037$US! K7"(?\
M@DY^W[#\9C\!D_9^D;XA)\(+?]H)7G\?_",?"^#X'WDLEM8?%/4?BA#X]U+X
M;P>&[C489K)1=W\-W'<122-+'M+)2S_)6FUFN72?L?K"4,9AIN=%W<9PC&NY
MM.SNG&+OHDQ/*<P32^IXM1E.5-2GAYP3DI)):WLY)W6KLEJE='YS45^YO[27
M_!(RQ_9M^%.K>(_$<OQWUOQSX6_X)X_LZ_M>>*;'2K#X.:CX9^'?CGXN?&37
M/A5KGA'X@ZA8>/9;OQ/H']F:9-<:#=^"8[S6I;6.5=+$FI1B"/D? W_!&O\
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M%R:IM<SC=1;2E9Z'76R#,Z+A&6&J3G.%6HH4DJK4*-7V,V^1])7LGT3OTO\
MGY17[._L2_\ !&[]HK]HR3PMX^^+/A?7OA1\!?&/P2^+OQE\,_$"Y\4?#U?'
M&M:)X%\$:YXB\+>*;_X5RZ_<?$"P\*^+?$NEP>%;SQ#:VZZI!:S-<63Q3>3<
M5\O?\.QOVXA^SW-^T_'\$'_X5!!\.%^,AO;GQS\(K;QS!\(YKJUTZU^*NH?
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M ,BK'_X,%_ZN<G/2RK_?:7^#%?\ J-,\PHHHKUZGQR_Q5O\ U*Q9YSVCZ/\
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M%B,+7PWL_;T:U)58.=)UJ4Z3J13492A&:C)Q4FHWLM6KI/1%%%%=1SA1110
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MK1Y8=.N/%WB.'QUXB\=2>#-=UR_\3ZCI!\!Z7,\RZI=!9!;7%G'<"+.\:_\
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M.N1]]?MY?\%9O!G[67[,W[/?[._@_P"'/B[X:S7WAGX&S_MS?$F""QB\8_M
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M?LG?LV?LU^!?&WA#]FW]C?P)X]T7P+?_ !8U32-2^*?C'Q?\;O%EKX[^*OQ
M\7-X80>'-.?7O%FG:?IUII]HT@$LQCC=4\N-/SBK[;**F/JY?1GF5*%'%N=9
MRC"'LTZ;JMT9RI>VKJE.5.SG2522IR?+S3LY'S.80P\,2UA6Y4>6-I7NG-*U
M2,)<E/FA"2M&?*G-/FM%6BBBBBO2.$*>OWQ]!_Z#3*>OWQ]!_P"@U:V^<?\
MT_@ROLO_  UO_3=(]-^)OW?A_P#]DO\ "W_HV6O+Z]0^)OW?A_\ ]DO\+?\
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MXG[=+_P1]\-?#OX,_M=? /63X1^+/QXTW]K3_@G#\+/@9\>=)@\6:(DW@/\
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MUN[AHY$3[1N?^"7EY\3M&_X).R_LRZOXM\2Z_P#\%'O"GCV/6KCQ7_9TMEX
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M(TZD*V+IP<XTW[2<73H*5'6H[MN5I.Z/FR;_ ()(_MRR_%#X>?"#0/AOX/\
M''B;XR>$_B3XZ^&.L?#WXS?!7Q=\.?'VG_"G2KV]^(6B^$OB7I7CW4=%MO%O
MA V5Q:>(?!5[J%O;W=]"UC/-'!)YHR-=_P""5'[:OASXA_!SX>S_  ^\(ZH_
MQY\+>,/%_P +_'/AOXU_"'Q'\)]:\-_#>VN;OXF7-Y\8;3Q%?^&O!?\ P@5E
M:7UQXRTO6M0M=-L;:TO)+^XBLX995_=+]D;_ (*0_L[_ !:_:X^"W@31]?\
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M@78_M,:;K^@?'7X)W_PP\0?!4^*D\#1?%/P]\5Y/B$/"$&C6>I27%OXD??\
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M]_P4'\-_%'XT?\%9_#?Q$_;6\9?!+XF_M3R/X,_8]_;'\97GQ3U;3OA;\,/
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M)56%5."E'$+$M1@E&517M)IN6NN]];)-.R:_J6\)?\%W/@A9_ []C_X8>*O
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M5?[[2_P8K_U&F>84445Z]3XY?XJW_J5BSSGM'T?_ *5,****@04444 %%%%
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MPSXITX?M ^-/VCM5\>>&_B_KFC7NI:S8:7J?PO;[->>'=/5_$ZP7-Q R7?\
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M /),/A]_V,_Q)_GX7KS2O2]?_P"28?#[_L9_B3_/PO7FE>9EG\/%?]C#&_\
MIT[\P_B8?_L#PO\ Z;"BBBO2.$1I$B!ED3S(XP9)(P2ID1!N9 5Y&Y05R.1G
M(YK^@-O^")_PMN?%?P5^!>F?\%"_AS:?MA_M ? OX=_&KX4_L_\ B?X!^._"
M^A^*(?'WA#4/%VD^%K;XIV5PWAV76[R]L;?3K>_U/%K!)*);R ['MS_/\&9"
M'78&4AE,DD\,89>1YDUKBZB3(^>2V(G1<M#^\"U_57J_[7?_  2YN/VF?V*_
MV^=7_:J^(^M^-?V0?V9/V<?!47[+/A_]G+QEI>J>+_B=\"? ^J:?HT4WQCUP
M0:';Z!=^([B"UO-7U1FT[3[20WUU.;6.45\KQ-B,UH/!1RQXY<U',YS6"R^E
MF"JXREA:<LIH8JG6I5HQPU7&J:E+EI\DO?\ :KELOH,EHX*M2QGUN.&DU+"0
MA&OB7AYRIU:SA6E2O5A"<J45[7DY93F_<4HQ:YOP[UO]@_XLP>!_V9KCP'X:
M^)_Q%^-/[1/C#X^?#Z+X+Z+\!_B(]QI/B+X"^*_^$:\1V'A+QZQ?0/C$QC9[
MS7]2L<#PMI+R,P!@X\[UC]BC]K[PU\9M!_9SUO\ 9I^.5A\>O%6G'6?#?PHU
M#X4>*/\ A86NZ" 5GUNSLQE;O0+, M,F3&\2^4[+NW#]O?A5_P %1_@6EC_P
M3I\0^(/BO??"GQY\+?'7_!4/Q1^T%;W'P$UWXR^"/#%K^V3XYT?Q'X5\)>,_
M",/D2>,/!&O6%PMKXWLOA[<)XCNM&?48/##6NMW4,K>IZK_P4/\ ^"<ND_&_
M5-$\%>)-1^&.E?&__@G1\<_V.OBC\>/@)\.OC7;? OX+_$'XC^*M#U_PAKGP
M&^ ?Q%UZ[^)&D>!](T_2KI?'NG>$[>%I9)Y;'3H))P'E\=<0\445653(ZE2\
M,16C4C1Q$GAZBQ&74O:3=%04J7^T5I1P]&=63E%TTJ<FD>C4R[)ZK]K''*E1
MDU&G&=6A!R3C4<6U4E4JI/DLN=+W6I1<X/G?\]X_8I_:WN?C6G[-:?LU_&Q_
MCX=/35I/A#)\+_%;>.&T1U#MJESIJC]QH/E/ON)1^[6W+'<1@GGO%W[*/[3O
MP[_X6T?B+\"?B_X$_P"%$KX-/QOG\7> /%6F_P#"J(/'5_#8>!KKQO(R@1VO
MC*ZGBL=(E)PT4H>,L,&OVM^&7[7_ .QE\.M0_:%_9IOOVU/VF/&?@[XW_L,_
M#7]FC2/VZ_'7A'Q7XPC^#OBCX>>/9_&5]\-/A9\)Y77X@Z)^R=XPMI387%I:
M+)K37US?P:?$+J6&:/U*X_X*9?L;3?M(_!7X$?$7QU\0_C;^Q):?\$]'_P""
M?_[3W[0?BGP;XAL?'WQ34:CXN\:^'OBIX:\%ZA;7?CJPM? GQ.GT^?052WOM
M61H@D$%RYCM).G$<1<24ZE14LB]O"EA:M?W*.:X>6(=&E*=Z"KJ+P\JU>%2A
M]7JOF<TL0I3I&$<KRKEBIYC&E*=2G34I5\/6ITW*K.$Y5:<:4)*$**A553EF
MVY*DTDG(_#7P?^P5^VS\0]:B\->!_P!DO]H/Q=XAF^'GACXOVVA:)\+_ !7K
M&J_\*U\:0S'PUXQ>4+N72O$=U 8;!@I8PEG4?NVK,\ ?L1_MA_%#0O%7BOX<
M_LR_'/QOX8\"ZWXJ\/>+?$OA[X9>*KK2?#'B'X?:=/+XKTWQ+.%V:+>Z/9),
M+B\9E>R:-G7+IM']$O@?_@KY^RQ\<-5_;,T/XP^*=%^!UMXT_;$^%'QH_9\\
M3^/OA%\3?BIX.'P)^!_@K3?AE\-OAW=>&_@[XU\"^(?#WQ5\":?IO_"?^$I/
MB%-;^$X]=:W?Q4LUG;K+:?&O[:W_  4K\(_M#_LA_%?X8_#'Q[XIC^+_ ,:/
M^"I/QC_:(UGPKX/\"^+_ (?6WQ!^#GB?X(:-\.O#U_+H.J^*_&LM[!J]WY F
MT>XU0PW?$+0P$R23S2S[BNK7^K2R.AAG5Q=+"T\34^NRIX2$^2I+%UZL9NG-
M1H.HI04H\E6FZ2G*,XS55,KRB%/VE/'5ZTO85*KA2>'E.=>G!RE0ITU[T?>E
M3Y7/E<Z;E5E%*+3_ !QUO]FG]H3PY=?&73]>^"OQ,T>__9^;2O\ A?%GJW@7
MQ-INH?!XW]Y;Z-X8_P"$_>X00>'H-?6_B;2GG/E:@DBN<Q$FO#:_J:_X+!_&
MZ_\ "W["O[/UCXL\%>)OAM^V3_P4>\-_!'XH_MOZ1XBN'L?$NH^'OV,?"!^#
MOPCU2YTX0+'%I7Q:GN+;XG"W$]PR6OAV>%C;^8T2_P LM>[P[FV*SG+WC<5A
MJ.%_VBO0I1HU)U(UH8:I.A/%7G)R4,35I3JT8V7[JSO._,>1F^#HX'$QP]*K
M.JU1I5*G/RWIRJPIU(TWRI6G"$U&HGM.-KZ,****]X\H:_W&_P!UOY&O3?&W
M_(G_  E_[%CQ)_ZL?QM7F3_<;_=;^1KTWQM_R)_PE_[%CQ)_ZL?QM7GXG_D8
M91_V$8C_ -1IG=A_]QS+_KW0_P#3R/->Q^H_DU)2]C]1_)J2N^/PQ_P_K(X?
MYO\ '/\ -"@9('J0/SK5T*UTJ_UO1K+7M7/A[0KO5=.M-:U];(ZB=#TFYO(8
MM1U@:>"/MQTRT>:]%GP;HP^1GYZR:4;,YDC,L8YDB""0R1C[Z",D>877*A/X
MB=O>B49RISC"7))QER3Y8S]G)Q:>(<&M:>$3A7K-2C:FWM:Y5.4(U(.HKQC.
MG+>R5JD>=.^GOPO"[T5[ZZH_9F7_ ((_^,M%_;Z^-O['GBKXQ:1HOPZ^ WP+
M\1?M2^*OVD(_"LESH]Y\ ]!^%L_Q!T?QOIVC6DCS+<:W<:I)X9U&*!VD$D4P
MB+NB@_ C_L6_M:K\$T_:2B_9K^-=W^SX+3[?#\8/^%>^(=%\#7^BQ:E<Z-9^
M(QJUY_H^F:3J<7ER7>L7(-EI\4IN9G\I,M^S/Q5_X*F? WQ7_P $F/#WPTTE
M]7?_ (*)^+?@Y\)?V$?BIXB;05DMKO\ 9.^!GQ-\=^.M U9]S6\2VVO6TLGA
MNY03--*M]<!WMHH_WGMGA/\ ;W_X)V>"/V0?B#\-O _Q0UYO&'Q2_P""3NO?
MLM7>@>.?AO\ M$?$7XT6'[1-WX>N-4CT?4/BIXTUJX^&_ACX)ZKJ=QI]A\./
M#/A")!::G<QO8@O!;VLWY]3SGB?#TG.OE+Q;_M&E@O8+#5(PK4L#*C0S#&1G
MAN6:CF%7&8>MA7)SI^RI3<J<T]/LI9=E%6:C#$4Z=.%*6(G*,X1FE5^L5H48
MN2A)0A'#N'-%KF]IS)1<6G^67QR_X)E7'P0TCXJ7^I?%O7O%+?#W]D3]FG]J
MRV/A']G[XAZYHVI1?M%KI-J?#VM^(/"TDNA_#-;'RC;2ZKJK?8]:A#3WJ0B.
MYCCYWP?_ ,$L?VE)/V=/VD?VE?BYX&^)?P(\-? WX3^$_B[X/C\?_"KQ-':_
M&^P\8_$'2_ 4/_",ZHSH[7!T[58IK- C2E+BVN@@MF::OTW^)O\ P4S_ &3]
M1T']J&;P_P")]3\4W'CC_@G/_P $\_@;X/T#4?"GBFVL/&GQ5_9T\9^ /$'Q
M(\'7MR!BVM;G2P-.N+H,I^SI-(S'<^?6/V@?^"AG_!/OQ?8_\%,_B#8?M5?&
MWXBW'_!0OPS\ -1\._ NX^$WBK0+OX,1_#OX@^%M4\<^&;KQHMQ:1)XBM;32
MKU? %[#=V$-N)8B+B#>TIY%G/%T:+HO*L76J.KAG+$RP-2=6I2IXVM'$4:-/
M#JC&BX4::E[>4JLN6FX-.4E(M9;DDVIRQD(P5*?/#ZU3A*3E0HU8MJI)J[J5
M?8)1C&,>31<]TOPGTS_@F?\ MWR^(_@IX?\ $7[+'QI\#6OQU\:^%/A]\/O$
M_CGX>>+O#GA/5]6\7PP7FFZG/XCM@;C3M":&XBNKO4559+;3DGNH<R0[:[C]
MH'_@F_\ $?\ 9DT+]K%/B]?^,K3QE^R[\8/AY\-9-+L/@9\3KCP9\0+#XCG4
MX]/^)EK\1YC]B\*:/XHBL5N?"=O,6M_%^I6L"$^7< C]R_BW_P %,O\ @G_X
M4^'OQ(\._!3XGW?BFWN?VO/V)OVA?!UG:_"[]H:X^+WB+P)\'O''AV;XF:1\
M8?B?\3-6UC7OB'\;[>TL-8MK^ST2ZM_"D'AB.WLHEGMKBY:W\.^+'_!1+]C+
MP1XG_;F\6^"?BE>?M*P_&C_@H[^R!^VSX!\):GX \8:1IGBKX>_#CXB^(?B'
MX_\ A=J5SK$$.G6XLX+R_P##@EU&&'3A%=,][;>4A1+AGG%5:MIDM946J\XT
M(X'$4957#'3G2G.=9R5']U2I*K&551JU*LI*7-",:BEE>34J"2QD82E*C.55
MXC#U8TH3I-UJ<8QCK.-1QBIWA[LHR]GI9?A3\0OV(_VR_A+HW@'7_B3^RU\<
M? &D_%76-*T7P#J>O_#/Q5HVE^,O$>O"V.@:1X<OU!;6=3\5)=V=OI=DZJ]_
M+>PQQAA*#5/XM?L7?M;? ?P;%\0_C)^S?\:_ACX$G\1WG@^#QQXW^&?B7PWX
M8NM>L+C"V46I7*B$SWD:7%O;3W ^SRRQ2A6?R9BG]!'Q/_X**?L1>$H_VO\
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MQ7[9_P""*>K>"[GQ1_P45\">/?C-\&?@_J/QZ_X)B_M)?!#P7XU^/?Q,\/\
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M6"GKT'^^/Y4RGKT'^^/Y5SXS_=,5_P!@V(_]-FM'^+1_["*'_IR)Z/\ &/\
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MM9+-52VN([A%X6*-1U/[3?\ P5#_ &4/'_CC_@JQXT^'/Q0\>6UW^T]\1_\
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M"Z5OJ^<?^$E#_P";3XU>'6?*_P"]RW5W_P!ZJ?\ S*?EE17ZF_\ #+OP9_Z
M5S_X/]6_PH_X9=^#/_0"N?\ P?ZM_A3_ .(O\+_] ^<?^$E#_P";1_\ $.\^
M_P"?N6_^%53_ .93\LJ*_4W_ (9=^#/_ $ KG_P?ZM_A1_PR[\&?^@%<_P#@
M_P!6_P */^(O\+_] ^<?^$E#_P";0_XAWGW_ #]RW_PJJ?\ S*?EE17ZF_\
M#+OP9_Z 5S_X/]6_PH_X9=^#/_0"N?\ P?ZM_A1_Q%_A?_H'SC_PDH?_ #:'
M_$.\^_Y^Y;_X55/_ )E/RRHK]3?^&7?@S_T KG_P?ZM_A1_PR[\&?^@%<_\
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MO_A54_\ F4_+*BOU-_X9=^#/_0"N?_!_JW^%'_#+OP9_Z 5S_P"#_5O\*/\
MB+_"_P#T#YQ_X24/_FT/^(=Y]_S]RW_PJJ?_ #*?EE17ZF_\,N_!G_H!7/\
MX/\ 5O\ "C_AEWX,_P#0"N?_  ?ZM_A1_P 1?X7_ .@?./\ PDH?_-H?\0[S
M[_G[EO\ X55/_F4_+*BOU-_X9=^#/_0"N?\ P?ZM_A1_PR[\&?\ H!7/_@_U
M;_"C_B+_  O_ - ^<?\ A)0_^;0_XAWGW_/W+?\ PJJ?_,I^65%?J;_PR[\&
M?^@%<_\ @_U;_"C_ (9=^#/_ $ KG_P?ZM_A1_Q%_A?_ *!\X_\ "2A_\VA_
MQ#O/O^?N6_\ A54_^93\LJ*_4W_AEWX,_P#0"N?_  ?ZM_A1_P ,N_!G_H!7
M/_@_U;_"C_B+_"__ $#YQ_X24/\ YM#_ (AWGW_/W+?_  JJ?_,I^65%?J;_
M ,,N_!G_ * 5S_X/]6_PH_X9=^#/_0"N?_!_JW^%'_$7^%_^@?./_"2A_P#-
MH?\ $.\^_P"?N6_^%53_ .93\LJ*_4W_ (9=^#/_ $ KG_P?ZM_A1_PR[\&?
M^@%<_P#@_P!6_P */^(O\+_] ^<?^$E#_P";0_XAWGW_ #]RW_PJJ?\ S*?E
ME17ZF_\ #+OP9_Z 5S_X/]6_PH_X9=^#/_0"N?\ P?ZM_A1_Q%_A?_H'SC_P
MDH?_ #:'_$.\^_Y^Y;_X55/_ )E/RRHK]3?^&7?@S_T KG_P?ZM_A1_PR[\&
M?^@%<_\ @_U;_"C_ (B_PO\ ] ^<?^$E#_YM#_B'>??\_<M_\*JG_P RGY94
M5^IO_#+OP9_Z 5S_ .#_ %;_  H_X9=^#/\ T KG_P '^K?X4?\ $7^%_P#H
M'SC_ ,)*'_S:'_$.\^_Y^Y;_ .%53_YE/RRHK]3?^&7?@S_T KG_ ,'^K?X4
M?\,N_!G_ * 5S_X/]6_PH_XB_P +_P#0/G'_ (24/_FT/^(=Y]_S]RW_ ,*J
MG_S*?EE17ZF_\,N_!G_H!7/_ (/]6_PH_P"&7?@S_P! *Y_\'^K?X4?\1?X7
M_P"@?./_  DH?_-H?\0[S[_G[EO_ (55/_F4_+*BOU-_X9=^#/\ T KG_P '
M^K?X4?\ #+OP9_Z 5S_X/]6_PH_XB_PO_P! ^<?^$E#_ .;0_P"(=Y]_S]RW
M_P *JG_S*?EE17ZF_P##+OP9_P"@%<_^#_5O\*/^&7?@S_T KG_P?ZM_A1_Q
M%_A?_H'SC_PDH?\ S:'_ !#O/O\ G[EO_A54_P#F4_+*BOU-_P"&7?@S_P!
M*Y_\'^K?X4?\,N_!G_H!7/\ X/\ 5O\ "C_B+_"__0/G'_A)0_\ FT/^(=Y]
M_P _<M_\*JG_ ,RGY:)]]?\ >7^8KTWX8?=^('_9*O$O_HC1*^_O^&7?@R.?
M[ N6_P!G^W]6^;VZ=^E;&D_L^?"O1EU+^SM%NX(-6T^[TF]C.O:M\]M?026M
MPI/;,4K#'O7)C_%7AK&8*OAX4<VC*N\/"[PE#W?98S!XSFM]=][F^J>SM=6]
MISZ\O++LP7 6>8>O"K.IE[C&-5:8F;7[RDZ>K]A%IJ_-:SNE:Z/R:HK]3?\
MAEWX,_\ 0"N?_!_JW^%'_#+OP9_Z 5S_ .#_ %;_  KMGXO<,\SYL-FRE>3:
MCA:$K<]6K5LW]<6WM>7;7EOI>RY9>'>>IVC5RYI72E+$5(\VK=TO83[VWW/R
MRHK]3?\ AEWX,_\ 0"N?_!_JW^%'_#+OP9_Z 5S_ .#_ %;_  J?^(O\+_\
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M[\&?^@%<_P#@_P!6_P */^(O\+_] ^<?^$E#_P";0_XAWGW_ #]RW_PJJ?\
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M58TCL-.'+@)",945SE?J;_PR[\&?^@%<_P#@_P!6_P */^&7?@S_ - *Y_\
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M93\LJ*_4W_AEWX,_] *Y_P#!_JW^%'_#+OP9_P"@%<_^#_5O\*/^(O\ "_\
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M ,VA_P 0[S[_ )^Y;_X55/\ YE/S<\"_\COX-_[&KP]_Z=[.F>-O^1P\5?\
M8?U?_P!+HJ_3/3?V;/A%I.HV&J6.B7*7NFWMKJ%F_P#;^K?)=6<\=Q;MT_AE
MC0_A3;[]FWX1:C<W5_=:%=SZC>W/G7,@U_5AM#-EV_ 9)Z_3N>/_ (BKPU+,
M)XSV.:1I++)X5\V%H*7M'C8XB-E]<U3BN7I9N]WL=+X"SM8)T'5R_P!H\7&M
M%1Q,Y<R>&E0:UH0M9RO?6]K'Y4_Q-_P+^1IM?J=_PR]\&O\ H!W7/7_B?ZMS
M^E)_PR[\&?\ H!7/_@_U;_"N^?B_PS?WL+G$964FOJE"WO6:L_KFJMUL<_\
MQ#S/M%[3+TXQC%J6)G'9/MAY;W[JQ^65%?J;_P ,N_!G_H!7/_@_U;_"C_AE
MWX,_] *Y_P#!_JW^%1_Q%_A?_H'SC_PDH?\ S:+_ (AWGW_/W+?_  JJ?_,I
M^67/89/8'H3V!^M>I^,?C5\4O'_P^^%7PI\9>,-4UKX=? C3O%^E?"?PW=?\
M>G@K3/'?B6U\1^([2WP!@:IXBM[9?FR06 ] ?OK_ (9=^#/_ $ KG_P?ZM_A
M1_PR[\&?^@%<_P#@_P!6_P *SJ>+7"E1P<L'FDI0ES1G/ X>4H]U%_75RI];
M;^:T+CX?\0Q4HQKY=&,OB2Q=37S_ -UT?2_;0_+/CWZ?K_ATI*_4W_AEWX,_
M] *Y_P#!_JW^%'_#+OP9_P"@%<_^#_5O\*U?B_PPVW]7SC6UE]4H:65M/]L(
M7AUGRO\ O<N;>K;Q=1_^ZI^65%?J;_PR[\&?^@%<_P#@_P!6_P */^&7?@S_
M - *Y_\ !_JW^%+_ (B_PO\ ] ^<?^$E#_YM#_B'>??\_<M_\*JG_P RGY94
M5^IO_#+OP9_Z 5S_ .#_ %;_  H_X9=^#/\ T KG_P '^K?X4?\ $7^%_P#H
M'SC_ ,)*'_S:'_$.\^_Y^Y;_ .%53_YE/RRHK]3?^&7?@S_T KG_ ,'^K?X4
M?\,N_!G_ * 5S_X/]6_PH_XB_P +_P#0/G'_ (24/_FT/^(=Y]_S]RW_ ,*J
MG_S*?EBW0_0_RKU+X+?\E7\ _P#8SV/_ *6VU??A_9>^# &3H5S@<\:]JV>.
M>.*[/X=_LO?"YOB!X,ATC2[JWOKSQ/X>MK&X?6]4F6WN[C5[.*WF,4G[N00S
M.CE'^1]N&P":X\Q\5^&\5@,;A:6&S93Q.%Q%"$IX;#Q@IUJ4J<>9K%3EIS<V
MBVTW.O!< YYA\30KSJ9?*-*O0J34,3.4N2E5C4;2]A&^W+ZZWZ'^KRW4_4_S
MHIW'0$8''1>QP0,GL<@^^:*_FGV4UHN5J[M>33LVWJK.V_<_8.=?\,I-?)\N
MJ/B3_@I7_P F#_M9_P#9$_&7_I#7^=?7^BA_P4K_ .3!_P!K/_LB?C+_ -(:
M_P Z^NNGL_7]"@HHHJP"D)P"3Y? S^]$K1<?\]%@_?M'_?$/[TKD1_/BEI"R
MJ"S*'51N9&:5%91R59H TRAAP6A!E .8P7 % 'Z%?\$Y?#'[.7B_XL>/=*^/
MK?#9?$P^%OB-OV?M-^./B#6?#_P0U3XQR:GX93P_:?%'Q-X:O]*U1#/IS(D&
MGWNI63O8F9$N(YMAKZ?^%?[)]II/[87[2/B?]H7]D^P\._#[]E[X4-\3/$W[
M-'PTUGQ)XD\'>*?%/B70]*\'_#3PM\/]3OM9\3376D^/-7DC\66X34H&M]IF
MD!2WDB/YF? KXTZ;\%-5\07OB;X(_!#XYZ-K>G65E?\ AGX[>&=5UG3]/:TF
M%Q!<Z7<Z#XFTN\CD11F.35+.:)#AYHF4$5]*>-_^"G'[5/B;3/B=9:5KVE?#
M+7OBIXO\ :[XE\6_">;Q?\./'&G:/\(_#<_A/PK\+=(U&W\0B5O"MF+N)YIX
M@9A"SRJ3)S0!]H#]A#X,?"K]L+]MN^^(7@Z^\9? /]FSX#Z]^U+\,_A='>:[
M:6?Q"T;Q>D=Y\+_"7B&^AN;:_M-&\*)JNJZ/J-Q:SQW]K;K)(&ADB>6+SC]C
M?XE_LP?M'_M;?"SX3>(_V"O@-H&D_%_6=(\(>(DTWQK\9;]-!ET&V\3W']L>
M"6F\?&V\V^TV46FK&2(H70^<)$,@?P+2/^"G/[2>G^+/AGXQO#X"\:Z[X#^"
M&M_LX>,-1\=Z'JWB1?CO\)-;UD:U_P ([\9X]8\4P:IJN]S/I\-SI\]O=7"W
M$TL,BW,S2GS^/]MW7-"_:'^%?[0OPZ^ _P"SQ\']6^#-]<WOA_P+\./!VLZ#
MX)UBYU6:.2ZO_%L<NMZQJ(NWE3-M]CN4N^1]GD6;8P5M_0#TKQ)\2_@7\5[W
MXH_ /PS^S_\ "'X >)_BK\7O@/X!^'GC_2;B75?#'@#2?!WC_P"(NC^-/%VK
M^,OB-K]SXL\/V&MVOC_P-_PD;Z3J%CI]E9K<SI=VZQ"9/(/VT_V6;?\ 9&^)
MD'PVM_%'CO6]3@LM5FU"Y\?_  7UKX3V'VBVUBRMHM1\ ?;==U72_B-X7FGF
M)'B?3;R&>6(&6*6*7:Z_-ECXQGM_'=I\0M0T'PQK5Q%XQ3Q7J/AK5].UV+P3
MK&HR^)D\2WOAJ_L_[3T35KGPMJKAM.U6WT_6=)OYM,N+B.TU.PN&CNXO>OVB
M?VK/%G[16D_"/PG>> _AW\,O /P+T;7= ^&?P^\#6/C&\\.V">*M4BU+Q!>.
MWQ#\:^+_ !!KEM.J2&0V^I0:-I46?-N(X(S(K _1K]JW]FGX:^(O@I\.M>_8
MD^"WP \<_ S6M0^#'A32?CUX:^)_CMOC]X-^)_B9['2=2\)?M&:1K.N2:+H>
MFZYXFU&&RT&YMXYX]+6>W<PF,Q-<<YX__P""-OC#P1?^!]'3XE^(I!J?[0_P
MK_9T\:ZGXO\ @/XJ^'>D66I?%35M#T*P\8?"76[R]M-+^*7A33+H"#7M4TR]
MM&U&&VFCBN[>259$^6/%_P#P4"^(VL_#K4_AK\,_A/\ L_\ [-]IXP\3_#CQ
MI\2/$/P/\#:OH^O>/-?^%VH:?KGPZNM?M]6\3PZ)H]GI&NW5EJ]A':2Q_P!K
M:LNQ)8_-+B;Q=_P4#\2>,/B;X(^.47[//[-GA?XV^&/BCX,^-6L?$OP[HOQ,
MB\1^._%OA&ZT[5=*?Q=+KGQ ?P['HNH-HELGBR3PTLETE@]T]A&9]H9:@>X7
M_P"R-X&\&_"S]N?PS\,?B9\,OVA]>^$+_LU>%O$?B[5/@OXL\->)O"WQ4\7_
M +0?B?P'>>$?A%XF_P"$[O/LV@ZE;Z@EGXKO_LEU]DADGN?LTWE^6W5_%3_@
MCKX[^&EA9R77Q>GTZ\TKXK?!_P"$OCK6OB3\&_$7PS^%MG<_&+6]%T*P\;?"
M[XCR75M'XV\-^$KW6UA\?6\MQ;PW4%E>6D]Q TC%?@G3?VNOB=H^@_M0Z)I-
MCX3T>+]JSQ=X&\8>-]9BT[Q ^H^$M>^'WQ*U'XA^';GPPNH^)X=.:T36;"&X
MM5OY8K)BB"ZD2 R,OH_Q7_;DO_C-KEEXW\:_LR?LTWOQ+O/%7AKQ7XU\=R:'
M\6T\1_$>;PC;6EI:Z3XV=?B;8:&NF:]86:6.KGPC?VFHK9SS'2KFVN_*F# X
M7]L7]FVQ_97^*T7PQM_$7Q!\1WEMIAEN;[X@?"'6/A%=W#_-'<7OA.QU#6=;
MTCQOX-N95D%CXKT^991 //0B1>/E"OIO]I+]J?Q5^TFGPNTK4_!O@CX;^"/@
M]X1?P)\.O ?P]L/%T>B:/I5[.-=NIU?QKXP\:7P6>> +O6]$JQJH612JD?,E
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>WG_ ,17ZIT4<TN[_KY ?E9_PY?_ ."??_1'I?\ P>WG_P 11_PY?_X)]_\
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M>WG_ ,17ZIT4<TN[_KY ?E9_PY?_ ."??_1'I?\ P>WG_P 11_PY?_X)]_\
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M_P#@]O/_ (BOU3HHYI=W_7R _*S_ (<O_P#!/O\ Z(]+_P"#V\_^(H_X<O\
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M#V\_^(K]4Z*.:7=_U\@/RL_X<O\ _!/O_HCTO_@]O/\ XBC_ (<O_P#!/O\
MZ(]+_P"#V\_^(K]4Z*.:7=_U\@/RL_X<O_\ !/O_ *(]+_X/;S_XBC_AR_\
M\$^_^B/2_P#@]O/_ (BOU3HHYI=W_7R _*S_ (<O_P#!/O\ Z(]+_P"#V\_^
M(H_X<O\ _!/O_HCTO_@]O/\ XBOU3HHYI=W_ %\@/RL_X<O_ /!/O_HCTO\
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MXBA.%6E*I0HRE"2?LTMOJ'_AR_\ \$^_^B/2_P#@]O/_ (BC_AR__P $^_\
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M#V\_^(KY>_XB)_V*?^B9?M1?^$#\,?\ Y\E'_$1/^Q3_ -$R_:B_\('X8_\
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M^$>5?_10?7O_  Y?_P""??\ T1Z7_P 'MY_\11_PY?\ ^"??_1'I?_![>?\
MQ%?+W_$1/^Q3_P!$R_:B_P#"!^&/_P ^2C_B(G_8I_Z)E^U%_P"$#\,?_GR4
MO]>^$?\ HHLO_P#!E?\ ^80_XE-^DO\ ]&3XY_\ "/*O_HH/J'_AR_\ \$^_
M^B/2_P#@]O/_ (BC_AR__P $^_\ HCTO_@]O/_B*^7O^(B?]BG_HF7[47_A
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M\1$_[%/_ $3+]J+_ ,('X8__ #Y*/]>^$?\ HHLO_P#!E?\ ^80_XE-^DO\
M]&3XY_\ "/*O_HH/J'_AR_\ \$^_^B/2_P#@]O/_ (BC_AR__P $^_\ HCTO
M_@]O/_B*^7O^(B?]BG_HF7[47_A _#'_ .?)1_Q$3_L4_P#1,OVHO_"!^&/_
M ,^2C_7OA'_HHLO_ /!E?_YA#_B4WZ2__1D^.?\ PCRK_P"B@^H?^'+_ /P3
M[_Z(]+_X/;S_ .(H_P"'+_\ P3[_ .B/2_\ @]O/_B*^7O\ B(G_ &*?^B9?
MM1?^$#\,?_GR4?\ $1/^Q3_T3+]J+_P@?AC_ //DH_U[X1_Z*++_ /P97_\
MF$/^)3?I+_\ 1D^.?_"/*O\ Z*#ZA_X<O_\ !/O_ *(]+_X/;S_XBD/_  1?
M_P""?1!!^#TI!!!!UV\P0>"#\G>OE_\ XB)_V*?^B9?M1?\ A _#'_Y\E(?^
M#B?]B@ D_#/]J$  DD^ OA@  .223\90 !W)( ').*/]>^$?^BBR_P#\&5__
M )A#_B4WZ2__ $9/CG_PCRK_ .B@^@/#O_!'G]@+6CXA:Z^#TCMIWBO7-/B)
MURYRJ1-;L NQ3A?G!4-AQCYATKHO^'+_ /P3[_Z(]+_X/;S_ .(KY!T'_@X/
M_8RTE]?%U\,?VH(S?^*]7N80_@KX52%E>T@N"4"_&?(C\N$A4 +;F  .21N_
M\1$_[%/_ $3+]J+_ ,('X8__ #Y*;X[X1O\ \E%EW_@RO_\ ,(?\2F_27_Z,
MGQS_ .$>5?\ T4'U#_PY?_X)]_\ 1'I?_![>?_$4?\.7_P#@GW_T1Z7_ ,'M
MY_\ $5\O?\1$_P"Q3_T3+]J+_P ('X8__/DH_P"(B?\ 8I_Z)E^U%_X0/PQ_
M^?)2_P!>^$?^BBR__P &5_\ YA#_ (E-^DO_ -&3XY_\(\J_^B@^H?\ AR__
M ,$^_P#HCTO_ (/;S_XBC_AR_P#\$^_^B/2_^#V\_P#B*^7O^(B?]BG_ *)E
M^U%_X0/PQ_\ GR4?\1$_[%/_ $3+]J+_ ,('X8__ #Y*/]>^$?\ HHLO_P#!
ME?\ ^80_XE-^DO\ ]&3XY_\ "/*O_HH/J'_AR_\ \$^_^B/2_P#@]O/_ (BC
M_AR__P $^_\ HCTO_@]O/_B*^7O^(B?]BG_HF7[47_A _#'_ .?)1_Q$3_L4
M_P#1,OVHO_"!^&/_ ,^2C_7OA'_HHLO_ /!E?_YA#_B4WZ2__1D^.?\ PCRK
M_P"B@^H?^'+_ /P3[_Z(]+_X/;S_ .(H_P"'+_\ P3[_ .B/2_\ @]O/_B*^
M7O\ B(G_ &*?^B9?M1?^$#\,?_GR4?\ $1/^Q3_T3+]J+_P@?AC_ //DH_U[
MX1_Z*++_ /P97_\ F$/^)3?I+_\ 1D^.?_"/*O\ Z*#ZA_X<O_\ !/O_ *(]
M+_X/;S_XBC_AR_\ \$^_^B/2_P#@]O/_ (BOE[_B(G_8I_Z)E^U%_P"$#\,?
M_GR4?\1$_P"Q3_T3+]J+_P ('X8__/DH_P!>^$?^BBR__P &5_\ YA#_ (E-
M^DO_ -&3XY_\(\J_^B@^H?\ AR__ ,$^_P#HCTO_ (/;S_XBC_AR_P#\$^_^
MB/2_^#V\_P#B*^7O^(B?]BG_ *)E^U%_X0/PQ_\ GR4?\1$_[%/_ $3+]J+_
M ,('X8__ #Y*/]>^$?\ HHLO_P#!E?\ ^80_XE-^DO\ ]&3XY_\ "/*O_HH/
MJ'_AR_\ \$^_^B/2_P#@]O/_ (BC_AR__P $^_\ HCTO_@]O/_B*^7O^(B?]
MBG_HF7[47_A _#'_ .?)1_Q$3_L4_P#1,OVHO_"!^&/_ ,^2C_7OA'_HHLO_
M /!E?_YA#_B4WZ2__1D^.?\ PCRK_P"B@^HT_P"",7_!/M'1Q\'78HROM?7+
MQD;:0<,-@RIQAAD9&17->$?^"._[ .N>'[+49_@ZZR2R:A &37;@ Q6NI75L
MJJ8E*%"(.<_-RP.!C'@2_P#!Q-^Q06 /PT_:@4$@;G\!?#!47)QN9C\9,*HZ
ML3P ":YSPI_P<'_L7:!H-GI<_P ,?VG8Y+9KN4)%X#^%I4QWNI7-Q$4$?QE(
MP?M ';H3]7_KWPC;_DHLNZ?\O*_G_P!0(?\ $IOTE_\ HR?'/_A'E7_T4'V'
M_P .7_\ @GW_ -$>E_\ ![>?_$4?\.7_ /@GW_T1Z7_P>WG_ ,17R]_Q$3_L
M4_\ 1,OVHO\ P@?AC_\ /DH_XB)_V*?^B9?M1?\ A _#'_Y\E+_7OA'_ **+
M+_\ P97_ /F$/^)3?I+_ /1D^.?_  CRK_Z*#ZA_X<O_ /!/O_HCTO\ X/;S
M_P"(H_X<O_\ !/O_ *(]+_X/;S_XBOE[_B(G_8I_Z)E^U%_X0/PQ_P#GR4?\
M1$_[%/\ T3+]J+_P@?AC_P#/DH_U[X1_Z*++_P#P97_^80_XE-^DO_T9/CG_
M ,(\J_\ HH/J'_AR_P#\$^_^B/2_^#V\_P#B*/\ AR__ ,$^_P#HCTO_ (/;
MS_XBOE[_ (B)_P!BG_HF7[47_A _#'_Y\E'_ !$3_L4_]$R_:B_\('X8_P#S
MY*/]>^$?^BBR_P#\&5__ )A#_B4WZ2__ $9/CG_PCRK_ .B@^H?^'+__  3[
M_P"B/2_^#V\_^(H_X<O_ /!/O_HCTO\ X/;S_P"(KY>_XB)_V*?^B9?M1?\
MA _#'_Y\E'_$1/\ L4_]$R_:B_\ "!^&/_SY*/\ 7OA'_HHLO_\ !E?_ .80
M_P")3?I+_P#1D^.?_"/*O_HH/J'_ (<O_P#!/O\ Z(]+_P"#V\_^(H_X<O\
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M_P 11_PY?_X)]_\ 1'I?_![>?_$5^J=% 'Y6?\.7_P#@GW_T1Z7_ ,'MY_\
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M7>']&M=5CMG/@7[?IT=AX?\ MNS51I%P#=VC:@OV7T[QE_P1O^,MG\4?@_\
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M(K";0["Y71;>&!+>WO+I!+/^@M]\%?A!?>/X?BW<?"SX<R_%RVMOL=A\4Y/
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M&FZ9K-[!.\:2-<^899$>4OYGYB?\$W/^"2'PQ_9 ^%O[(FJ_$A_%OBS]H/\
M9T^$&C>&K*SF^-_QC^('P,^'_P 1]>\))X1^*?C/X.?"_P 5ZQ;>#_"FI^-=
M*O+O3M7UC3?#T,=O%=2BW@B\IKRZ /$OA%_P4"_;6\0?#+]B?]N'Q?J/P%U;
M]E[]N+]H[X._!K1_V?/#_P +/$WAOXK_  E\#_M!^+)_A_\ "[QN?BU<_&+Q
M1I/CGQ5:>)VTG7/B#HI\#:-I=OX;O;X:5;VMU87$EK0'_!47X_?!;X6_MO\
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M/A]XC\2_#Z.\U/Q!?^'[?Q!'X5@NAHUWKTETEY=WELMT8;:*"OU+UC_@E_\
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M26>HV=S8W2)+)"[VUW"]O.B30O'-$S12.%EB=)(R0Z.K $?"OQ _X)I_L?\
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M'_A-Q)_]"Q_.S17]$W_$.;^T9_T7[X*_^ 'Q,_\ B*/^(<W]HS_HOWP5_P#
M#XF?_$4?ZB<7_P#0BQ?_ ('A/_FT/^)Q?HR?]'AX8_\ ";B3_P"A8_G9HK^B
M4_\ !N;^T800/C_\%02" ?[/^)AQ[X*8./0\'H:S+;_@W>_:'OM6UNT'Q_\
M@J#I%U;K'_Q+/B+N*WUFDV)-H9HSY;CU.<XZ9H_U$XO_ .A#B_\ P/"?_-H?
M\3B_1E_Z/#PQI_U#\2?_ $+'\]M%?T3?\0YO[1G_ $7[X*_^ 'Q,_P#B*/\
MB'-_:,_Z+]\%?_ #XF?_ !%'^HG%_P#T(L7_ .!X3_YM#_B<7Z,G_1X>&/\
MPFXD_P#H6/YV:*_HF_XAS?VC/^B_?!7_ , /B9_\11_Q#F_M&?\ 1?O@K_X
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M !%*/^#<S]HHD!_C[\%BA(#@6'Q,R5/W@,IC)&<>]'^HG%__ $(L7_X'A/\
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M?VC/^B_?!7_P ^)G_P 11_Q#F_M&?]%^^"O_ ( ?$S_XBC_43B__ *$6+_\
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M .A8_G9HK^B;_B'-_:,_Z+]\%?\ P ^)G_Q%'_$.;^T9_P!%^^"O_@!\3/\
MXBC_ %$XO_Z$6+_\#PG_ ,VA_P 3B_1D_P"CP\,?^$W$G_T+'\[-%?T3?\0Y
MO[1G_1?O@K_X ?$S_P"(H_XAS?VC/^B_?!7_ , /B9_\11_J)Q?_ -"+%_\
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M6?#G_(O:#_V!M+_](8*K>+_^12\4?]B[K?\ Z;+JK/AS_D7M!_[ VE_^D,%
M&S1110 4444 %%%% !1110 4444 %%%% !1110 5PWQ,_P"1 \6_]@2\_P#0
M*[FN&^)G_(@>+?\ L"7G_H% '<T444 <1\0_^19/_8P^"O\ U-/#]=L>J_7^
MAK@_B9##<>$;B"XC\ZWGUOP?#/#N=/-AD\8:"DL>Z/\ >+O1F7<GSC.5^8"G
MGX:>!SUT" \L3FZU#DLNQL_Z7SE>"#QWZ\T =U17!?\ "L/ ?_0NVW_@3?\
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M#_Z%VV_\";__ .2Z/^%8> _^A=MO_ F__P#DN@#O:*X+_A6'@/\ Z%VV_P#
MF_\ _DNC_A6'@/\ Z%VV_P# F_\ _DN@#O:*X+_A6'@/_H7;;_P)O_\ Y+H_
MX5AX#_Z%VV_\";__ .2Z .]HK@O^%8> _P#H7;;_ ,";_P#^2Z/^%8> _P#H
M7;;_ ,";_P#^2Z .]HK@O^%8> _^A=MO_ F__P#DNC_A6'@/_H7;;_P)O_\
MY+H [VBN"_X5AX#_ .A=MO\ P)O_ /Y+H_X5AX#_ .A=MO\ P)O_ /Y+H [V
MBN"_X5AX#_Z%VV_\";__ .2Z/^%8> _^A=MO_ F__P#DN@#O:*X+_A6'@/\
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M\%V@\+M#H,*?:?&NA03!;O45$B7*3VL@8+<,"&B"J00BG&2ZDDD ]NHK@O\
MA6'@/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\
MH7;;_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P
M)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\ H7;;_P ";_\
M^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P)O\ _P"2Z/\
MA6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\ H7;;_P ";_\ ^2Z/^%8> _\
MH7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P
M)O\ _P"2Z .]HK@O^%8> _\ H7;;_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\
M^2Z .]HK@O\ A6'@/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]
MHK@O^%8> _\ H7;;_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\
MA6'@/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\
MH7;;_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P
M)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\ H7;;_P ";_\
M^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P)O\ _P"2Z/\
MA6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\ H7;;_P ";_\ ^2Z/^%8> _\
MH7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P
M)O\ _P"2Z .]HK@O^%8> _\ H7;;_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\
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M?^!-_P#_ "70!WM%<%_PK#P'_P!"[;?^!-__ /)='_"L/ ?_ $+MM_X$W_\
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M$*Q!Z ]*GT'X:^"+C0]#GG\/V\DSZ-I9=WN=09B391D\M<@]9'YVJ>>0,
M]3HK@O\ A6'@/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]HK@O
M^%8> _\ H7;;_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\ A6'@
M/_H7;;_P)O\ _P"2Z/\ A6'@/_H7;;_P)O\ _P"2Z .]HK@O^%8> _\ H7;;
M_P ";_\ ^2Z/^%8> _\ H7;;_P ";_\ ^2Z .]HK@O\ A6'@/_H7;;_P)O\
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MU/\ M2Z_J>HZC<:47U?4;S3]7UWX9W&KV%SK6HQNM@;O2S)86T4-U'Y_]B5
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M?#SVUY+<^)[CP#X6N?&?B[[/-!;R6MM'HOAZU:^N7O)X-XDB2 2LS!/YC?V
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MT_M?_'/XQ?'[4OV6K+]B+]F3Q+^T7KGP"\<_#'P?\5O GQJ\:^-]'MXOC?\
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M#XS^&W_!+_\ 8^TKXX^.?V=OAQ\9?"'_  4S^+7B7QA\)]=T#PO\2/BKXV^
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MW@S_ .5-'_$3'\+?^C3_ (B?^'.\&?\ RIK^0VBC_B /A=_T(L7_ .'W.?\
MYI#_ (BUQW_T-J'_ (:\N_\ E1_7E_Q$Q_"W_HT_XB?^'.\&?_*FC_B)C^%O
M_1I_Q$_\.=X,_P#E37\AM%'_ ! 'PN_Z$6+_ /#[G/\ \TA_Q%KCO_H;4/\
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MWZ__ %NU2U_)<7>_9-I+32UKZ)*S;=VM?4_H=:*W9O?U_+MW044450PHHHH
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MV756?#G_ "+V@_\ 8&TO_P!(8*K>+_\ D4O%'_8NZW_Z;+JK/AS_ )%[0?\
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M+FG?"7PGI-WI6G>!M4\?Z#K%IJ7B#1;FRO[Z#4/M):]Q?W4=M>V2$0+^G/\
MPL'P'_T.GA3_ ,*'2?\ Y+H_X6#X#_Z'3PI_X4.D_P#R70!\?3?\$U_V1)_!
M?[('P^;X>:DOA3]A;XA^&_BK^SC8KXU\9-=^%O'?A?SY--UW7-6GUN;5/&,L
MM]<2ZEJ$'B.[O[?4+MG6[BEM));63[1\5^&-'\;>%O$O@SQ%!<77A_Q=H&L^
M&-=MK6_O]*NKC1]>TZYTK4X+;5-*N;+5--N)K*[GCAO]-O+2_LY&6XL[F"XC
MCE3/_P"%@^ _^AT\*?\ A0Z3_P#)='_"P? ?_0Z>%/\ PH=)_P#DN@#\O_V5
MO^")W["/[%GQ"\ ?$+]GG2/CMX,N_AI<:_>>$O"=W^T[\>-?^'-K>>*;*ZT[
M7KJY\":WX[OO#M_+J$5_.;J"\LI;.]DE*W5O/'+,C?K?7(?\+!\!_P#0Z>%/
M_"ATG_Y+H_X6#X#_ .AT\*?^%#I/_P ET =?17(?\+!\!_\ 0Z>%/_"ATG_Y
M+H_X6#X#_P"AT\*GV7Q!I3,?90MT6)/8*"2> ,T 4_B?_P D]\8?]@*^_P#1
M==W7COQ#\=>"[GP+XJ@M_%GAB>>71;F%8#K=DQ9KB-DC5DCG:9@^2,!"6.%;
M -=D?B#X%5W1O%_AQ'CE>&17UBQ0I)&JLZONF&T*KJ2QPHR?FX. #L**Y#_A
M8/@/_H=/"G_A0Z3_ /)='_"P? ?_ $.GA3_PH=)_^2Z .+O?V?/@3J7@GQ9\
M,]0^#GPQN_AWX]\3:IXS\<^!9_!'AU_!_C'QAK'B.R\7ZKXH\4^&S8'2->\1
MZCXGL++Q#<ZUJMK=:C+JMI;WSSF>)6'%>*?V-/V0?''Q;T/X]>-?V6_V>/&7
MQR\,3Z)<^'?C'XG^"_PXU[XGZ!<>&F@/AB72?'>I^'+CQ+IL_AOR;1O#\MMJ
M44VDFTMI=.>&:WBD7VG_ (6#X#_Z'3PI_P"%#I/_ ,ET?\+!\!_]#IX4_P#"
MATG_ .2Z /B'X/\ _!-+]F7X=_&#XG_'WQM\+OA)\8?C1XO_ &F/B'^T?X ^
M+/C;X/> [OXE_"&^\?Z;X8LSX8\'>-KG3;_7[2VT"3PXLFEZM:7UE?9F28K%
M/#&Z>Y_$_P#8O_9#^-/CF;XG?&#]EWX!?%3XC77A'4OA_<^.?'_PD\!^+O%D
M_@C6K.?3-5\+SZ]X@T2]U*70KS3;NZL+K3WN6ADL+BXM%C,$SQ/[7_PL'P'_
M -#IX4_\*'2?_DNC_A8/@/\ Z'3PI_X4.D__ "70!3L/AQX$TKQ%XP\9Z%X2
M\-:'XT\?VFD6/C3Q?IN@:)#XB\46_AS3I-'\.V?B+5%LVNM9MO#VGN;/2;/4
M)+BWLK;=;PHL<DJ/\7?L+_\ !-K]FG]ACX;?"'2_"'PP^%&H_''X>?!7P/\
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MZ3_\ET =?17(?\+!\!_]#IX4_P#"ATG_ .2Z/^%@^ _^AT\*?^%#I/\ \ET
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M_P *'2?_ )+H_P"%@^ _^AT\*?\ A0Z3_P#)= '7, RLIS@@@X)4X(P<,I#
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M0Z3_ /)='_"P? ?_ $.GA3_PH=)_^2Z .OHKD/\ A8/@/_H=/"G_ (4.D_\
MR71_PL'P'_T.GA3_ ,*'2?\ Y+H Z^BN0_X6#X#_ .AT\*?^%#I/_P ET?\
M"P? ?_0Z>%/_  H=)_\ DN@#KZ*Y#_A8/@/_ *'3PI_X4.D__)='_"P? ?\
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M>+IQOJ^GI9:'\V'_ !#.?"W_ *.P^(G_ (;'P9_\MJ/^(9SX6_\ 1V'Q$_\
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M_#8^#/\ Y;4?\0SGPM_Z.P^(G_AL?!G_ ,MJ_I/_ .%@^ _^AT\*?^%#I/\
M\ET?\+!\!_\ 0Z>%/_"ATG_Y+H_XC7XH_P#178O_ ,(,F_\ G4'_ !"W@3_H
MGZ'_ (59C_\ -Y_-A_Q#.?"W_H[#XB?^&Q\&?_+:C_B&<^%O_1V'Q$_\-CX,
M_P#EM7])_P#PL'P'_P!#IX4_\*'2?_DNC_A8/@/_ *'3PI_X4.D__)='_$:_
M%'_HKL7_ .$&3?\ SJ#_ (A;P)_T3]#_ ,*LQ_\ F\_FP_XAG/A;_P!'8?$3
M_P -CX,_^6U'_$,Y\+?^CL/B)_X;'P9_\MJ_I/\ ^%@^ _\ H=/"G_A0Z3_\
MET?\+!\!_P#0Z>%/_"ATG_Y+H_XC7XH_]%=B_P#P@R;_ .=0?\0MX$_Z)^A_
MX59C_P#-Y_-A_P 0SGPM_P"CL/B)_P"&Q\&?_+:C_B&<^%O_ $=A\1/_  V/
M@S_Y;5_2?_PL'P'_ -#IX4_\*'2?_DNC_A8/@/\ Z'3PI_X4.D__ "71_P 1
MK\4?^BNQ?_A!DW_SJ#_B%O G_1/T/_"K,?\ YO/YKV_X-G/A=M;;^UA\1 <'
M!_X5CX-X..#QJI/7T&?2L32_^#;3X7WNL^(K!OVI_B!'_8US;QP2+\+O"R,4
MU/3Q,^YYKZ*&7"/C_1Y)E!^\5RN[^FO_ (6#X$[>,_"K'L%U_2F8GL%5;HLQ
M/0*H))X )KB_#OCCP;#XB\>WLGBOP\EK?ZQX?FM9GU2VC1U?PCHD:DM)(J '
MR]V0<*,F3:1BC_B-?BC_ -%=B_\ P@R;\/\ A+_S#_B%O G_ $3]#_PJS'_Y
MO/YY#_P;.?"W!_XRP^(@XZ_\*Q\&#'O_ ,A4]/H?I7P[_P %#?\ @BEX#_8G
M_9E\2_'K1?CYXO\ '>HZ)X@\(>'_ .Q=<\#>'--T][77-7BL97EN;"\N)88H
M]^9YU1?*B+.K;D4'^S!OB#X#VMGQGX488.5&OZ4Q88Z!1=$L3TV@$GH >E>'
M_'_X=?L[_M+^"(?AE\7-8\,>)/"$'C'PEXNO_#J^(])^S:MJ'@W6+7Q!8:3K
MEN)9OM>CWD]G'#J>GN(C>6C-")8RRD>GDOCEXA8;-\LKYMQ)CL;E='&0J8["
MPP.41G7PRC)5:,:E/+(5*7MHI4G.G.$HJ3?,K'!FGA5PC5RW&TLMR;#87'U:
M$J>$Q$\3CG&E6DU:4HSQLX5(QC>7LYIP<K-QZG\H_P#P2!_X)#7O[1-_H7[2
M7[3/A^[LO@3I,\%QX#\!ZXN^_P#C!?6=Y'<0Z[K)Z)X)MIH&M3:OA]4C$ME$
M53[1/;_VB:9IEAHMA9:7I5G:Z=IFG6T%EI]C:11VUI:6EM&L%M:V\,6V**&&
M-5CBBC"HB (JX%<GIGB[X;:/866F:9XJ\&V6F:=:VUCI]E;:UHUM:V%G;1);
M6UK;PI<(D$44<:Q0P@ JN$0!551H_P#"P? ?_0Z>%/\ PH=)_P#DNOD>/^/,
MX\0L[K9IF;=#!4IU*64933G-83+<$IWA3IKW95:E1Q56O5J7=2HWRJ%)1@_H
M>#^$,MX0RNG@\%%5L1.,)XS'5%>KB<0H.$I.TG"$*:;ITH4XP2@ES<TO>.L!
M''(Y/)]2>PZ'OU/3@<]GUR'_  L'P'_T.GA3_P *'2?_ )+H_P"%@^ _^AT\
M*?\ A0Z3_P#)=?#I;^?]:=?O;^6Q]:E9>?5_UL=?17(?\+!\!_\ 0Z>%/_"A
MTG_Y+H_X6#X#_P"AT\*?^%#I/_R73&=?17(?\+!\!_\ 0Z>%/_"ATG_Y+H_X
M6#X#_P"AT\*?^%#I/_R70!U]%<A_PL'P'_T.GA3_ ,*'2?\ Y+H_X6#X#_Z'
M3PI_X4.D_P#R70!U]%<A_P +!\!_]#IX4_\ "ATG_P"2Z/\ A8/@/_H=/"G_
M (4.D_\ R70!U]%<A_PL'P'_ -#IX4_\*'2?_DND/Q"\!@$_\)IX5. 3A=?T
MMV..<*JW19F/95!8G@ D@4 4? /W/&'_ &/WBC_THAKOJ\<\&^-O!MF/%377
MBKP]";OQIKUS&TFJVL2M"[VL43%II$'W44,0=B]<@5VG_"P? ?\ T.GA3_PH
M=)_^2Z .OHKD/^%@^ _^AT\*?^%#I/\ \ET?\+!\!_\ 0Z>%/_"ATG_Y+H Z
M^BN0_P"%@^ _^AT\*?\ A0Z3_P#)='_"P? ?_0Z>%/\ PH=)_P#DN@#KZ*Y#
M_A8/@/\ Z'3PI_X4.D__ "71_P +!\!_]#IX4_\ "ATG_P"2Z .OHKD/^%@^
M _\ H=/"G_A0Z3_\ET?\+!\!_P#0Z>%/_"ATG_Y+H Z^BN0_X6#X#_Z'3PI_
MX4.D_P#R71_PL'P'_P!#IX4_\*'2?_DN@#KZ*Y#_ (6#X#_Z'3PI_P"%#I/_
M ,ET?\+!\!_]#IX4_P#"ATG_ .2Z .OHKD/^%@^ _P#H=/"G_A0Z3_\ )='_
M  L'P'_T.GA3_P *'2?_ )+H Z^N$^&W_(IP_P#8=\8_^IEK]7/^%@>!#P/&
M?A9B> J:_I;NQ[*J)=%G8GA54%F.  20*XKX?>-_!MEX8MK6Y\5>'X9EU+Q-
M*ROJEM&J1S>*=;D1F:61-J[<Y+D 8)SMP2 >R45R'_"P? ?_ $.GA3_PH=)_
M^2Z/^%@^ _\ H=/"G_A0Z3_\ET =?17(?\+!\!_]#IX4_P#"ATG_ .2Z/^%@
M^ _^AT\*?^%#I/\ \ET =?17(?\ "P? ?_0Z>%/_  H=)_\ DNC_ (6#X#_Z
M'3PI_P"%#I/_ ,ET =?17(?\+!\!_P#0Z>%/_"ATG_Y+H_X6#X#_ .AT\*?^
M%#I/_P ET =?17(?\+!\!_\ 0Z>%/_"ATG_Y+H_X6#X#_P"AT\*?^%#I/_R7
M0!U]%<A_PL'P'_T.GA3_ ,*'2?\ Y+H_X6#X#_Z'3PI_X4.D_P#R70!U]%<A
M_P +!\!_]#IX4_\ "ATG_P"2Z/\ A8/@/_H=/"G_ (4.D_\ R70!U]%<A_PL
M'P'_ -#IX4_\*'2?_DNE'C_P*Q"KXS\+,S$*JKK^E,S,3@*JK=%F8G "J"22
M  30!7^&_P#R(7A+_L!V/_HH5VU>._#SQKX.T_P+X3M+WQ;X:BGBT:PC8'5K
M.) &BD>+_72HR@Q1,27"C*'G!7/9_P#"P? ?_0Z>%/\ PH=)_P#DN@#KZ*Y#
M_A8/@/\ Z'3PI_X4.D__ "71_P +!\!_]#IX4_\ "ATG_P"2Z .OHKD/^%@^
M _\ H=/"G_A0Z3_\ET?\+!\!_P#0Z>%/_"ATG_Y+H Z^BN0_X6#X#_Z'3PI_
MX4.D_P#R71_PL'P'_P!#IX4_\*'2?_DN@#KZ*Y#_ (6#X#_Z'3PI_P"%#I/_
M ,ET?\+!\!_]#IX4_P#"ATG_ .2Z .OHKD/^%@^ _P#H=/"G_A0Z3_\ )='_
M  L'P'_T.GA3_P *'2?_ )+H Z^BN0_X6#X#_P"AT\*?^%#I/_R71_PL'P'_
M -#IX4_\*'2?_DN@#KZ*Y#_A8/@/_H=/"G_A0Z3_ /)='_"P? ?_ $.GA3_P
MH=)_^2Z +OB__D4O%'_8NZW_ .FRZJSX<_Y%[0?^P-I?_I#!7&>*/'/@N[\,
M^(K6T\8>&)KJYT+5[>VAAU[3'EEN)M/N(X8XDCNFD>1Y&545%9V8@*"Q J3P
M]X_\#QZ%HL$GBWP]%+#H^EI*D^KV<3QL+*,8D\Z5""#&^2P&-N3C(R >D45R
M'_"P? ?_ $.GA3_PH=)_^2Z/^%@^ _\ H=/"G_A0Z3_\ET =?17(?\+!\!_]
M#IX4_P#"ATG_ .2Z/^%@^ _^AT\*?^%#I/\ \ET =?17(?\ "P? ?_0Z>%/_
M  H=)_\ DNC_ (6#X#_Z'3PI_P"%#I/_ ,ET =?17(?\+!\!_P#0Z>%/_"AT
MG_Y+H_X6#X#_ .AT\*?^%#I/_P ET =?17(?\+!\!_\ 0Z>%/_"ATG_Y+H_X
M6#X#_P"AT\*?^%#I/_R70!U]%<A_PL'P'_T.GA3_ ,*'2?\ Y+H_X6#X#_Z'
M3PI_X4.D_P#R70!U]%<A_P +!\!_]#IX4_\ "ATG_P"2Z/\ A8/@/_H=/"G_
M (4.D_\ R70!U]<-\3/^1 \6_P#8$O/_ $"K7_"P? ?_ $.GA4^R^(-*9C[*
M%NBQ)[!023P!FN/\?^./!UYX)\3VMGXI\.W5W/I$UO#:PZS92SRRW2F*&**&
M.=II)96.V- G[Q]J-@-0!Z_1110!PWQ&1)/"SQR(DD;Z_P"#$>.1=Z.C>,M
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MW_\ C=']E:7_ - VP_\  .W_ /C=7Z* *']E:7_T#;#_ , [?_XW1_96E_\
M0-L/_ .W_P#C=7Z* *']E:7_ - VP_\  .W_ /C=']E:7_T#;#_P#M__ (W5
M^B@"A_96E_\ 0-L/_ .W_P#C=']E:7_T#;#_ , [?_XW5^B@"A_96F?] VP_
M\ [?_P"-UP_CG3]/0>$6%A8 MXZ\.JQ>SA;(D:>)P-J#YFC 0,V5  !& ,>C
MUP'CW_6>!_\ L?\ 0O\ TFU.@#L/[*TO_H&V'_@';_\ QNC^RM+_ .@;8?\
M@';_ /QNK]!X!P,G' ]?;GCGWH H?V5I?_0-L/\ P#M__C=']E:7_P! VP_\
M [?_ .-UQ_Q'\:VWP^\">*/&][X>\6>+(?#&@7^N2^&_ ?A/4?&WC+6(K.TF
MN)-+\->%=)5]2\2ZWJ"Q-::9H6F+_:&K7LD%A:(T]S$M?$O[/?\ P4T^"G[2
M7Q7UGX.?#WX2_M<6'B3PEXRU7P!X_P!8\<?LP_%/PCX+^&_C/3?#B^*VT#Q]
MXNU?2_[)\-7M]I\]M'IT5W.T9NKNT@G>UAE24 'Z%?V5I?\ T#;#_P  [?\
M^-T?V5I?_0-L/_ .W_\ C=7F)"L0I<@$A%V[F(&=HW%5RW0;F5<GD@9-?/K?
MM#^$H/VIK']DO^S-:;QU>? #4_VAX]96"!?#D7A#2_B+I7PU;2S,)!-_;+ZO
MJT5PL*PB(6,32;]S;4 /=/[*TO\ Z!MA_P" =O\ _&Z/[*TO_H&V'_@';_\
MQNK]'^?3^5 %#^RM+_Z!MA_X!V__ ,;H_LK2_P#H&V'_ (!V_P#\;KY^^)/[
M2W@[X9?'OX#_ +/NN:1XGO?%/[0?A'XZ^+?!]]HNGQW]A9V_P%T?P-K?B>QU
M*"*4ZF^HZE8^-K4:%#IUM=275W;RVA@9G66+TOX3^/H/BK\//!_Q'A\(^-_
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M^"/B5H5CJHMDU2TT3QWX=T[Q+H\.HQV5U>VL=VMEJ4,<Z07=Q")ED1)I I-
M'=_V5I?_ $#;#_P#M_\ XW1_96E_] VP_P# .W_^-U?HH H?V5I?_0-L/_ .
MW_\ C=']E:7_ - VP_\  .W_ /C=7Z* *']E:7_T#;#_ , [?_XW1_96E_\
M0-L/_ .W_P#C=7Z* *']E:7_ - VP_\  .W_ /C=']E:7_T#;#_P#M__ (W5
M^B@"A_96E_\ 0-L/_ .W_P#C=']E:7_T#;#_ , [?_XW5^B@"A_96E_] VP_
M\ [?_P"-T?V5I?\ T#;#_P  [?\ ^-U?HH H?V5I?_0-L/\ P#M__C=']E:7
M_P! VP_\ [?_ .-U?HH H?V5I?\ T#;#_P  [?\ ^-T?V5I?_0-L/_ .W_\
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M_P#T5WP7_P"&<^%W_P >H_XEJ\0/^@WA?_PYXS_YUA_Q&[A#_H%S[_PAPO\
M\\3^]?\ LK2_^@;8?^ =O_\ &Z/[*TO_ *!MA_X!V_\ \;K^"C_A_#_P4G_Z
M*[X+_P##.?"[_P"/4?\ #^'_ (*3_P#17?!?_AG/A=_\>H_XEJ\0/^@WA?\
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M_P"-T?V5I?\ T#;#_P  [?\ ^-U?HH H?V5I?_0-L/\ P#M__C=']E:7_P!
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MW1_96E_] VP_\ [?_P"-U?HH H?V5I?_ $#;#_P#M_\ XW1_96E_] VP_P#
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M_ .W_P#C=']E:7_T#;#_ , [?_XW5^B@"A_96E_] VP_\ [?_P"-T?V5I?\
MT#;#_P  [?\ ^-U?HH Y'Q7IFF)X6\2N-/T]2F@:RP8V<!"E=.N2"0L8) QD
MX(/H<U8\/Z;IS^']!+6%B^-&TL _9(,8^Q18VAD)5?F8@9X#'N3F3Q?_ ,BE
MXH_[%W6__39=59\.?\B]H/\ V!M+_P#2&"@"U_96E_\ 0-L/_ .W_P#C=']E
M:7_T#;#_ , [?_XW5^B@"A_96E_] VP_\ [?_P"-T?V5I?\ T#;#_P  [?\
M^-U?HH H?V5I?_0-L/\ P#M__C=']E:7_P! VP_\ [?_ .-U?HH H?V5I?\
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M_7;'JOU_H:XGXA_\BR?^QA\%?^IIX?KMCU7Z_P!#0 M%%%  2 "20 !DD\
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MKXT_!_\ 9T\,WW["G['NF?L0?$;]ICPI\:KZ^\!^([OX&^+;/XI^-/V5]8\
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M4C&O-SY9^SP[BI1T3UUW5EO_ )V5%?Z)O_#H7_@F]_T:GX"_\&?C;_YJJ/\
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M% !1110 4444 %%%% !1110 4444 %<)\-O^13A_[#OC'_U,M?KNZX3X;?\
M(IP_]AWQC_ZF6OT =W1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<3\-_P#D0O"7_8#L?_10KMJXGX;_ /(A>$O^P'8_^BA7;4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '.^+_P#D4O%'_8NZW_Z;+JK/AS_D7M!_[ VE
M_P#I#!5;Q?\ \BEXH_[%W6__ $V756?#G_(O:#_V!M+_ /2&"@#9HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X;XF?\B!XM_P"P)>?^@5W-<-\3/^1
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M .$/XC_^0*[VB@#@O^%@V'_0M^/?_"'\1_\ R!1_PL&P_P"A;\>_^$/XC_\
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MB/\ ^0*/^%@V'_0M^/?_  A_$?\ \@5WM% '!?\ "P;#_H6_'O\ X0_B/_Y
MH_X6#8?]"WX]_P#"'\1__(%=[10!P7_"P;#_ *%OQ[_X0_B/_P"0*/\ A8-A
M_P!"WX]_\(?Q'_\ (%=[10!P7_"P;#_H6_'O_A#^(_\ Y H_X6#8?]"WX]_\
M(?Q'_P#(%=[10!P7_"P;#_H6_'O_ (0_B/\ ^0*/^%@V'_0M^/?_  A_$?\
M\@5WM% '!?\ "P;#_H6_'O\ X0_B/_Y H_X6#8?]"WX]_P#"'\1__(%=[10!
MP7_"P;#_ *%OQ[_X0_B/_P"0*/\ A8-A_P!"WX]_\(?Q'_\ (%=[10!P7_"P
M;#_H6_'O_A#^(_\ Y H_X6#8?]"WX]_\(?Q'_P#(%=[10!P7_"P;#_H6_'O_
M (0_B/\ ^0*/^%@V'_0M^/?_  A_$?\ \@5WM% '!?\ "P;#_H6_'O\ X0_B
M/_Y H_X6#8?]"WX]_P#"'\1__(%=[10!P7_"P;#_ *%OQ[_X0_B/_P"0*/\
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M(:TOFQVJSW+);+]G5I)9%!BA559FF5D"$@9]MK@/'O\ K/ __8_Z%_Z3:G0
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M@U.RO?#^E^%/%V@:U\3VMC9ZI'X:U?4=.L[JVF@GDN@#],O^%@V'_0M^/?\
MPA_$?_R!1_PL&P_Z%OQ[_P"$/XC_ /D"OS<U_P#X*?7FE^+_ -MZT\/_ +*?
MQ4\1_"/]@73/BW<_&OXW1^*/ NE^%]3\0?#/X Z7\?E\*> O#]Q?OXH\4ZUX
M@T[6['0+F2VTZ.S\/ZE<Q76H33I/Y">X>,/V\? ?@KQ;\#O#^K>!_&<\7QO_
M &0OCW^UYI]]H]OIM_>Z3X2^ &E?!36M=\)_8I;NT_M'Q1J=E\;+"+2H%FM[
M-[^R\AYUCO7FM@#ZS_X6#8?]"WX]_P#"'\1__(%'_"P;#_H6_'O_ (0_B/\
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M(?Q'_P#(%'_"P;#_ *%OQ[_X0_B/_P"0*[VB@#@O^%@V'_0M^/?_  A_$?\
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MFOA)_P#/HH_XA#XG?]$1GO\ X*P?_P \P_XB-P/_ -%/E7_@S%?_ #O/W?\
M^%@V'_0M^/?_  A_$?\ \@4?\+!L/^A;\>_^$/XC_P#D"OP@_P"(D;]BK_HD
MG[4'_A-?"3_Y]%'_ !$C?L5?]$D_:@_\)KX2?_/HH_XA#XG?]$1GO_@K!_\
MSS#_ (B-P/\ ]%/E7_@S%?\ SO/W?_X6#8?]"WX]_P#"'\1__(%'_"P;#_H6
M_'O_ (0_B/\ ^0*_"#_B)&_8J_Z))^U!_P"$U\)/_GT4?\1(W[%7_1)/VH/_
M  FOA)_\^BC_ (A#XG?]$1GO_@K!_P#SS#_B(W __13Y5_X,Q7_SO/W?_P"%
M@V'_ $+?CW_PA_$?_P @4?\ "P;#_H6_'O\ X0_B/_Y K\(/^(D;]BK_ *))
M^U!_X37PD_\ GT4?\1(W[%7_ $23]J#_ ,)KX2?_ #Z*/^(0^)W_ $1&>_\
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MT+?CW_PA_$?_ ,@5WM% '!?\+!L/^A;\>_\ A#^(_P#Y H_X6#8?]"WX]_\
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M/^A;\>_^$/XC_P#D"C_A8-A_T+?CW_PA_$?_ ,@5WM% '!?\+!L/^A;\>_\
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MX"\9VFF>"/"=F?#?CR41:+IZ%X_!NM2@;H78LWEP2':NSD@L<218!+X'7_\
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MW8W/AOQ!;_\ "/\ CB+S]$U6'S9_!/B)((_-L+A/,F=K)52)-VZ1V955 Q+
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M .$/XC_^0*[VB@#@O^%@V'_0M^/?_"'\1_\ R!1_PL&P_P"A;\>_^$/XC_\
MD"N]HH X+_A8-A_T+?CW_P (?Q'_ /(%'_"P;#_H6_'O_A#^(_\ Y KO:* .
M"_X6#8?]"WX]_P#"'\1__(%'_"P;#_H6_'O_ (0_B/\ ^0*[VB@#@C\0;'!_
MXIOQZ?8>!_$>3[<V('YD#WKEO'7C.SOO!7B2W70_&%N]QI4T*O>^$-?MH(VG
M&P23SR6D<-O#"?GGGEE6*W0>;+NC5@?9JX;XF?\ (@>+?^P)>?\ H% '<T44
M4 <1\0_^19/_ &,/@K_U-/#]=L>W..3R,9'RGD9!'Y@CVKB/B+_R*[?]C!X+
M_P#4ST"NS90R%3G# J=KO&V#'CY7C(=#SPZ$.IY4@@4 >8_&'XP_#/\ 9]^%
MOC[XT_%_Q3IW@3X6?"WPGJWC;QOXKU!;V6PT'PQH5E<:AJ%]]@TVVN]1OYXX
M+64PZ?IMA=ZC>RF.TL;:ZNI8H'^8/V-O^"B/P/\ VYF\5P?"+PE^T%X,G\->
M'O#7B^TD^//[/OQ-^#%IXN\&^,DNV\->-/ UWXXT;2K'Q=X9U(6C20W>F7PE
MDADAE6(0NTT>Y_P4-T_]G[5?V)_VCM _:QTSQEK/[._B?X>:KX9^+A^'F@>(
M->\8Z3X,\07T&FW'B;1+'PK8:MK<=SX&6\A\4MJ=MIE__9RZ*VIO87PA>PN?
MY$/A!^W_ /'[]GG]EG_@I#\)/V8/V@?C?^WU^Q?\/_V>?AC\&_V"?VA/&OP<
M\8^!?B;X/_:'^/\ J.E?!GPC\!]#\5^,_#^@2^-YO@YX;UV#Q1:F3PQ<W4<V
MCZ=:PZ;#;WBZ*X!_6!^P]_P4O_9#_P""A.J?&S1OV7/'.J>+M1^ /BJU\*_$
MJ+6/#6I^'I+/4-7NO$"6$NERWX3^TM,GN]#U9(+R E$\C88T:56'SC-_P79_
MX)]WWQBU3X->$_%?QD\>/HWQ(T;X*ZI\6_AU^SK\8_B%\#;#XS>(M=M/#>B_
M"27XA^$O#EY93>/-6UZ\M=#T^RM8I;)]1N(BNH& EF_!']D/X'_M@_\ !-/_
M (*"?L2>"/BG^SIX(_9F^&G[5?[$NI_\$X+WQ+\(_C(WQL\->./V@_A%H.I^
M._A_^T/\1]G@?PS=^!?%GC[Q3KEKX=CL[59[7?-J7V>9H8YHYOI;_@A)^WM^
MSU^Q?^S!\ /^"4?[0G@OXS_"K]NKP3\9/&GPG\9?!-O@;\6O$FI>+?%'Q1^-
MNMZOH_Q=M_&6E>';GPC8_#*+0_%6FW_B3Q;K6K:?I^E:)82:PLITRS6>] /T
MZ\ _\%[_ -AOXD?&+3O@#X;\*?M=#XJ7^L^&M)O?"FK_ +)?QBTN?P]!XR\2
M6?AK1_$GBJ^OM#33_#W@]K^_CN+OQ'J5S%I5GIJ75Y+-'#I]XL/Z:_M.?M-_
M W]CWX*>-?V@_P!H[XA:3\,/A+X#L4N?$/BK58=2O2DUY.EGI6E:3H^BVM]K
MNOZ_K-_-#IVBZ#H5E>:QJVH30VEA:RS2 +^.O[/VE:S%_P '%?\ P4BU98I+
M>RN?V!_V5+;3;Z:WFN[3[6FKW//V6WGMI[D1RQ.SP07%O-,(Y(XYHG973XP_
MX*_?"[_@IQKW[(_PB^)'[5/A3]F_]H3PO^RY_P %"_V4?VF_$?PE_8O\"_'5
M->\2_L]?#'2OB-%\71\2+7QAXZU*\U&XDOM2LIO(\+V$\3(;IX)K>YMTH _7
MKX3_ /!9W]AGXI?#7XW_ !7U;Q+\4O@9X+_9\\$>&_B7\1;[]HOX+?$;X.WB
M?#_Q@UVGA'Q=X8TSQ'HL=]XQTSQ--:"VT*U\.17^KZM=7EA966FS75Y'"<G]
MF[_@MA^P[^T[\9/!7P#\/W7QM^&'Q#^+.A:KXF^"EA^T#\"/B%\&M)^.GAG2
M1(USK7PEUGQAI5KI_B^RN88I9=/BBEM[S4D7RK.TFN'2!_R/_P""KO[9WP6_
MX*U_\$W?C)8_L$Z7\6?VBH_V=?BI^SA\</B_X8TGX,_$SPW%XQ^'_A/QO=:S
MXT\#6!\2:)H.H>(O$&A:3HNL2:QX?TU)99KK3&CTZ6[XGBI?M%_M>?!;_@L%
M^VK_ ,$BO G[ D/C/XCR?LK?M@^$OVJ/V@_B%_PK;QKX.\,?LY_#/X>Z?H[^
M(/A1XLO];TG1;6/Q;XWO+%_#PTV"*]L[>>W@M8;F6*0>6 ?O1\/_ /@IK^R+
M\2OV*OB5^WOH?C;5;;]GCX26/Q4N/B#J^N>'+RQ\2Z/>?!Z;4K'QCHLGA9&D
MN]1UUY]-\C1=)L6GFUN6^TVWLU$]RL4?$M_P5W_8<M?CW^S-^R[)\4-3F^/O
M[5OAWP?XL^'_ ,+[3PAX@O/$GA/1/'_@:V^('A2Z^*OEQ/;>"#X@T:Y1--34
M'$D=RR13V\-D%O'_ )G_ -J'X0_$GPO_ ,%!OVG/^"(OA[P1XKF_9U_X*G_M
MS?LQ?MR0ZWID\T>DZ%\!+_[9\2?VZK5)) \=K-JOC;X#1:?I\:3I!Y"M'<6T
MIN$CN/M7_@LC^V!^RI\)?^"G'_!*JRUKQ F@ZI^RM^T?XM^*?[2TVF?"OXEW
M:>#O!WCGX*1^'_ VMZCK7A3P??P:Y(NG0PSVNFZ9+JLDUA;6T:QB&&>R8 _6
M/]HC_@M-^PA^R]\:?%?P/^*/C3X@R:Q\+KGP)IOQU\>^!_A)\0/'GP:_9UU3
MXFWEI:> M+^.GQ3T#1;CPS\/[_Q4;ZSEL(]4G=;6"4RZFUB$G5?U<M;BWO;:
M"[M9H;FUNHHKFUN+>19K>XMYD66WN(9DRDL4T3))'(A9&5@49EPQ_A'_ ."N
M?P_\#W/Q3_X*$_L\?L2?MJ_$?Q%\>/\ @I1J/P"U#XF?\$Z+3]BGQ7\0];\6
M^.M3'@A]!^)VF_M#:_I^CP_"SX<VWA>6UUSQC*L-['X6TE;Z[_X^;*VMX_[>
M?@_X;U'P5\)?A;X.UJ3S-7\*_#OP5X:U.0LA\W4M#\-:=IM]M*X#?O[.9@0#
ME!N);#-0!<^)_P#R3WQA_P!@*^_]%UW=<)\3_P#DGOC#_L!7W_HNN[H *1@2
MK 8!*D L"R@D8&Y05+#U 921QD=:6D8A59B<!0222   ,DDL0HP.Y( [G% '
MXEZ=_P %:?B3:>+O$/B#Q?\ LC6FG_LO:1_P4#UO_@GA#\;?"O[0-IXN\>+\
M4[+]H&7]G#1_%6M? ^]^#W@]])\':IX\ET[[9-IWQ)\3:CI6F7)EBM=4>-#=
M_I%JW[8O[*>A_&NT_9LUG]HGX/:1\?M2GL++3OA!J/C_ ,-V/Q!O;[5K1;S2
MK&T\-WE_'?3W^IP21-IUFL+7%[++#!;Q2S2QQ-^!-A_P32^*/PWU;QG^V[X7
M^"^M>(/VG?A=_P %@OC[^TGX8^%.N^)]1\7>&/B]^S!\5/VCO$NA^(=2\+>!
M/$WB&7P1X1^)UM\%_'.O_%?X;>*]+LK74M#\9>'M+OK87EQ-;VEMN:)^Q1\9
M++X\?M ?"7XT^#/^"@/BOX6?%C_@H_>_M:>#M;^ ]]^PS:_LT:AX3UKXQ?#/
MXN^!=9^*J_$9$^,EK>?!WQ7X5M]1\0CPA;2^-KW3M&9_"5K?:TVG(X!^W&L_
MMW_L6>&OBCI'P/U[]JKX!Z/\8-=\66W@32?AOJGQ1\'V/C74O&-[-#:V/AJS
M\/RZE'?W&MWM[<VUE9Z<D"SW5W.EK;K)<LL+>DZY^T3\!O#.A_&GQ1XC^+/@
M+1?#O[.-Q]A^.FKZGX@TVTT_X2W*^$M \?M%XVNI95BT/_BD?$OAW7@URRQ?
M9+V':YGCGBA_F.UKP9\:/V@O W_!7/\ 8I^#W[(WBOQ-XA_:,_X*?>*K&V_:
MIT2X^#47PR^'9\+W/[,'B2^^)WQ6U35O&WAKQ9'XR^$,.FW/BWP7X>T3PKK^
MN7NHZ18VFBV;ZF%M[[VS]N_X(?ME+X9_X+5_L^_"?]D+Q[\:H?\ @H5;>'/B
M-\%_B3X8U_X;V_PXTN*']E3X+? +QKX>\<3>+/%^C>(M-\7Z7J/P?U#7?#VB
M:7H6IW6MRZAIT>D@M):B\ /WB\7?M?\ [+/@3XLZ)\!/&?[0OPC\*_&OQ/JE
MGH?A_P"%FM^.O#VG>/M4U34]'@U_3K:R\,7=XNJ2F]TBZM[^SF:T^S7$<T:1
MR/(XC/+?"3]NW]BSXZ?$*P^%GP;_ &GO@7\1OBCJ_@NR\=:?X \&?$CPMKWB
M^Z\&26%IJL.K)H6FZC/>&WM;/5HKBZACC>>PCDE:[BA\BX$/B?P0^ GB+PC_
M ,%"_P#@HI\??$G@%-,T7XQ?#[]D/P[\._B) +:74?$^E?#OP#\1+#QAH=H8
MV-U%)H/B&^MI#"Z@R/<VLHP@A+?BM_P3 \ _&OX__LU_\$,/"?A_]D?Q3\"O
M 7[(=MI7[2?BS]H_5;KX9V7@WQAX9U_]F3XM_#M_#WPC3PGJDOC&^'[0_BOX
MW6'Q(\;17FGZ*L$6EZC_ &G+?RM:7%B ?T4^&OVWOV/?&?QKU+]F[PG^TW\$
M/$GQ[TF\U+3=2^$.B?$CPQJ/Q L]0T>T^W:O83>&[349-26]TRTS/?VRPF>T
M57$Z1LC*NIX$_; _98^)GC#X@?#[P!^T+\(/&/C;X3V6MZC\3O#GA[QYX?U+
M4? EAX:OAIGB*_\ $\4%\RZ-8:)?D6VIW=ZT-O9.0UQ)&IW5^!GP%_9I_:DC
M^"__  3R_85\3?LC^-OA[XK_ &)?VQOA=\:?B)^U-?R_"Q/@[XB\'?!OQMXJ
M\87_ (O^&6HZ#\1M2\=ZIXM_:#\.ZA+\-]9TO6M#MI])3Q%J@UI)K!FFAJ7_
M .R5^V5\1?@K^V[^Q_\ L\?#K]HOX)?LI?$?]D7]HC1_A[\-OVIKW]G6TU'P
ME^TM\0/&T>KV'PJ^ ?C;X<ZYXCUL_ #XE^')O$-EXHT_XJSZWX>LK379UU&5
M6U/4+.@#]]_A'^V1^RK\?]+\<:O\$/VA_@[\4=.^&]E+?^.K_P )?$#0-3TW
MPA916]U<27WB74+2ZEBT738(;*YEO-1N@+:RBAEEG=0@!^6O@[_P4I^!7[2G
M[:7A#]G/]FGXG?!_X[?#;5_V6OCE\:?%?Q"^''CG2O&4VB^,OA;\8/@%\.;'
MP=>C2[FZ@6WN-.^+^I7TAFF#^;:I$64*HD_,3QA^Q+\:/VHO@?\ MC76F^ /
MV\_#?[3GC7]@7XB?LH> IOVS=5_8FTGX1-I?B#5O#_C&7X(>!H/V<+G0O$=S
MH/B'7]#71],\7>.Q#H=IH.J7,FJWP29[0?8/[.FA?&#XP_\ !2OX9_M5:S^Q
M!\1OV6OA?X1_X)T_&/\ 9TU;7OBGJ'PI3QC>^/;[]H3]G+Q9X9^'<GA[P'XL
M\5ZK<>&=)\+>#/$FL^%/$5T]O87D#7T$=O8SN+24 ^A_CE^V?^T-X._:ZU7]
MDW]G;]E#PK^T/XB\-?LV^"_VE_%6L^)?VC[/X(7=EX<\<_$[XI?#G3O#/A_3
MM0^#OC?2-=UV>\^&-VVF'5/%'A?399+FWM]7U+2[6&?61TGPG_X*8?LK^-_V
M>[#]H#XJ>-M&_9ATZS^)'Q)^"?Q!\'?M!ZUH/@3Q#\,?CQ\'=+\6:O\ %;X3
M^(+J]U Z->^(O"^C>"?%?B*.XTF^G@UGPQ91ZK:('N6LX_G+XV7O[0OP)_X*
M;^,OVE/!'['_ ,>OVE_A[XV_8!^$WP&T?4_@YJ'P/L--L_BQX*_:"^./CN?3
M?%,_Q,^-/@/5=#T-M'\?:5+J6M:;X7\1R:?"9I+6SU6:+[#)\U^#OV"_V@(;
MK]DCQ-\7/A=X3U7Q+X^_X+0?%;_@HS\>_ FEWWA?7]#^#^G>)/V:_CSX,^''
MV[5Y=MIKNN>"M1B\ 7#ZOH:W2W/B,!;6XFNULV< _;#P=^T]^SO\0_#NN^)O
M!OQF^'/B3P[X;^%7@;XV^)-:T_Q+IMUI>@_"+XG^'=9\5_#[XA:]=&6*#3?#
M/BWPKX?UCQ!I=_>O!%/I%A/>Y6U\N:3S?XK_ /!0/]B'X$:?X2U#XS?M7? K
MX;6/CKP?I7C[P==^,OB1X;T/_A*?!&M7 L=)\6Z*MQ=PF_T34[XBUM=1M$^R
MRW&^.)PZ-&OYR?M8>!?VG_AQ^TO_ ,%"_$WPK_92^)'[0N@_MR?L,? _X*_#
MOQ5\-M>^&6DZ/X&^)OPIM_VJO#>H:=\5IOB1\0O#UWI.@/:?'31?$-OJ_A7P
MKXJN);&UNK&UT+6]45K-?R$^)7@+XQZ+??M+_"+Q/X*^)$W[/WPD_P""77_!
M-+X/_P#!172O@XOP#U_Q[X:\-_#3X/?%;QSXUT>&Y^-WQ*\':E'=1>#+K7+*
MRU#X0>#]>\=)<2VNH^%=%U'Q4=,MI0#^J#]K3]K7PW^S3^QA\8_VRM!T6/XO
M^%OAI\(;[XL^']#\-Z]:Z=#X_P!-%A!>Z+;Z3XD:VU*TM;;6TO+1[?4A9W:)
M!+YRPRDJM>-Z'_P46\$WO_!.S4/V];[P+JNE3:+X5\2V>J_!"X\06#^*;?\
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MGA#3O"7PGU_P[\0/^$DN= ^/U]X1M?'.JZ_XPA\*Z/X>NVM%\57%Y<60U.8
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M?P>MOBM\2I?BOK]GXQL/@WIWB*ZO-"M](\(Z3+K\FDZ=+J%E-<P6]LGK5O\
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M .%E>,?B(/';YUG1I]=TB\?Q4NA^(? IU/2;?Q#HUO<6;:WIKW0NHOM[Q/\
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MI?\ :?V5[*#Q'I#W;7MK]#T4 ?B/\&O^"5?Q=\&_LN_&[]CCXT_M'_!?XM?
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M'0/"6N_%+XS^)]:\1>,/%^DZ+=ZQXIUCQG]KCM;!=.:V%FP-O^A%% !1110
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M_P!'8^$/_#3-_P#+"C_B&6^(/_1V/A#_ ,-,W_RPH_XC?X6?]%;A?_"#.?\
MYUA_Q"WCO_H05O\ PKR[_P";C^7ZBOZ@?^(9;X@_]'8^$/\ PTS?_+"C_B&6
M^(/_ $=CX0_\-,W_ ,L*/^(W^%G_ $5N%_\ "#.?_G6'_$+>._\ H05O_"O+
MO_FX_E^HK^H _P#!LK\02"/^&LO"*Y!&5^$[!AGC*G^T.".H/K67:?\ !M;X
M_OM4U?3!^U?X31?#]S"MN_\ PJBXWR)J=B)B)=]XD3?NGPPAEF ;@D @D_XC
M?X6?]%;AO_"#.?\ YUA_Q"WCO_H05O\ PKR[_P";C^9.BOZ@3_P;+_$)02/V
MLO!^0,C=\)F*Y'(W#^T1D9ZC(X[U\??MU?\ !%'Q=^Q1^SSKWQVU+X\^'?B%
M::)K7A;PZ?#%MX#N=%\T:_JD5COANH[F=+61GD"BZD BMBZ2L3@UV9=XP>&^
M:X_"Y9@.)\/B,;CJL,/@\/' YO&>(Q-27+"C"53+J=*#EK)SJU(0BDVVDCEQ
MOAUQEEV%KXW&Y)5H83#4Y5<37>*P$E0HP5Y5JD(8J<W37POV:E/F:2@[W/P^
M*>8#'Y23[QL\B1MD<V[Y?*D?^%),[&;LI)[5_;+_ ,$!?C%^U;\3/@)K6C_&
M#2KG7/@?X+CM=)^"OQ6\17H?Q-XEC1A%?>'XK9>9M T&-#!:73#="5B@W%9%
M5?Q'_P""4G_!*/Q+^VAXEL_B[\7[*Z\/_LO>'M9A5[A[.33M4^-6IVL\32Z1
MX8CC1Q!X.C$4NF^(M68H\L+7"VS&17>/^YKPGX4\.>!/#NB>#_"6BZ?X=\+>
M'-,M-&T'1-+@6UT[3=/LHDBM;*UM8OD5(HDW-(!YC9,DC2,TLA_%OI$^(/#]
M?!RX&P6&P>;YM0Q5.MC<R_=U:.0U$HJ5/"XB,TJF-JTGR552;C1BY0J*4Y*"
M_2O!OA'.:>)7%&(KXG+LNJ49T\/A(OV<\UI-NU2M2E:HL-&=N2-2G&525IP?
M+J='\H(XZE.??(^G3IW_ ,)ZA#J2,$<$*3@#))& !V]<\#/IQ4U?R!&+C[MK
M)6C&.ONQBK+?K+63]5UN?T?WO\6\K[J^L4^R479;Z7"BBBJ&%%%% !1110 4
M444 %%%% ' ^ ?N>,/\ L?O%'_I1#7?5P/@'[GC#_L?O%'_I1#7?4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7"?#;_D4X?\ L.^,?_4RU^N[KA/A
MM_R*</\ V'?&/_J9:_0!W=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Q/PW_P"1"\)?]@.Q_P#10KMJXGX;_P#(A>$O^P'8_P#HH5VU !1110 4
M444 %%%% !1110 4444 %%%% !1110!SOB__ )%+Q1_V+NM_^FRZJSX<_P"1
M>T'_ + VE_\ I#!5;Q?_ ,BEXH_[%W6__39=59\.?\B]H/\ V!M+_P#2&"@#
M9HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;XF?\B!XM_[ EY_Z!7<U
MPWQ,_P"1 \6_]@2\_P#0* .YHHHH XCXA_\ (LG_ +&'P5_ZFGA^NV/5?K_0
MURGC2PO=1\/SP:=9B^O$U'0+V.R-PMK]L32O$.FZG);?:6REOY\-I)'YS?+#
MO+D87%9HU_QPJX'P\^Z% '_"6Z1R. >3!_".>>6QZF@#OJ*X'_A(?'/_ $3S
M_P NW1__ (Q1_P )#XY_Z)Y_Y=NC_P#QB@#OJ*X'_A(?'/\ T3S_ ,NW1_\
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MZ)Y_Y=NC_P#QB@#OJ*X'_A(?'/\ T3S_ ,NW1_\ XQ1_PD/CG_HGG_EVZ/\
M_&* .^HK@?\ A(?'/_1//_+MT?\ ^,4?\)#XY_Z)Y_Y=NC__ !B@#OJ^9_BO
M^QQ^R5\</'&A_$KXQ_LN_ #XM_$?PXEM%X?\??$CX/\ P]\;^+?#R6DT4UH^
MD>(?$FCWFM:7<63Q)+IMWI]U'<Z=/%%/:-&\2"O6O^$A\<_]$\_\NW1__C%'
M_"0^.?\ HGG_ )=NC_\ QB@#L+>*.T1(;<(D"F&"**)"(+=8D6!;6VM8 ([6
M"**/"K]R+J^X D7JX'_A(?'/_1//_+MT?_XQ1_PD/CG_ *)Y_P"7;H__ ,8H
M [ZBN!_X2'QS_P!$\_\ +MT?_P",4?\ "0^.?^B>?^7;H_\ \8H [ZBN!_X2
M'QS_ -$\_P#+MT?_ .,4?\)#XY_Z)Y_Y=NC_ /QB@#OJ*X'_ (2'QS_T3S_R
M[='_ /C%'_"0^.?^B>?^7;H__P 8H [ZBN!_X2'QS_T3S_R[='_^,4?\)#XY
M_P"B>?\ EVZ/_P#&* .^HK@?^$A\<_\ 1//_ "[='_\ C%'_  D/CG_HGG_E
MVZ/_ /&* .^HK@?^$A\<_P#1//\ R[='_P#C%'_"0^.?^B>?^7;H_P#\8H [
MZBN!_P"$A\<_]$\_\NW1_P#XQ1_PD/CG_HGG_EVZ/_\ &* .^HK@?^$A\<_]
M$\_\NW1__C%'_"0^.?\ HGG_ )=NC_\ QB@#OJ*X'_A(?'/_ $3S_P NW1__
M (Q1_P )#XY_Z)Y_Y=NC_P#QB@#OJ*X'_A(?'/\ T3S_ ,NW1_\ XQ1_PD/C
MG_HGG_EVZ/\ _&* .^HK@?\ A(?'/_1//_+MT?\ ^,4?\)#XY_Z)Y_Y=NC__
M !B@#OJX#Q[_ *SP/_V/^A?^DVITO_"0^.>_P\_\NW1__C(KG_$-SX]UC^QD
MB\ ^6FF^(=)UB1SXOTI#)'I_F7#1 )"2V^4K"5;Y6SO(V990#UZBN!_X2'QS
M_P!$\_\ +MT?_P",4?\ "0^.?^B>?^7;H_\ \8H X+]JK6?&'AS]E_\ :0\0
M_#U[F+Q]H/P$^,.L^!Y;/_C[C\8:7\/?$5]X9>U_Z>4UJ"R:#_IJ%K^?*"Y^
M#OP[TW_@V-\8>.M2T'0?V2_#GP*N;+2O$GC&YTO2_AMI7QS\2?L6_#./]E_5
M_$.H:@([:R\7ZK8I\0H_"5_?S+%!J=S=7,<D,@>8_P!(ESKOC>6WN(G^&L=T
MDD,L;6TWBW13#<*Z,K02A[9T,<P)CD#HZ[6.Y6&0?E+X'_LK:!\'/V7_  [^
MQ]K?PTLOC9\$_!EAKGA7P_X<^+$_@OQ+I5Y\.+CQCK>K>#_ WB30=3T_4-)U
MBP\$^%IM%\,V9O;:Z@O+2P@BF@:-&8 'Y_?\%.OB]^S9XG\3?L+^+YO'OPD\
M9? ;X9?\%-/@8?VQM:T#7? ^NZ+X/U-/@_\ %B#X!:I\;-2L[J9-,\/:)\7K
MWX<WAN]?D32K&&.S^UF.UM]J=/\ 'K6/A!\=/^"P?[ &B_"'5/!OQ,\4>%/V
M<OVT_P#AJ>[\%:OHGB"+2?V:/B+X)\&:#X T3Q_J6BW<[0Z;XF^+[Z%-X5TV
M69;B4QW^HQHMO-#<2?IMX;^%G@OP?\.=2^#_ (3_ &5?A7X5^$VIVFH:=J/P
MN\-Z5\-]%^&^JZ=J\)M=6LK_ ,%:;H5GX<NK/4K8F#4;2YTB2&]@)AN$E0[:
M9\)?A+X&^ .AZCH/P(_93^$WP5T;5K]M2U3P_P#"?2?AS\.='U/4G+DZCJ-E
MX.T#2+.[N_WD@-S/:SW 5V"MC*D _GU_9+_X2'X@?&3]D?\ X)'>)IWO9?\
M@EE^TK\9OBU\9)+V%;._U?X%?LQG1YO^";L\A,LD<\_C+1_V@_@3\4[B" RB
M"3X:7"+)\LK)S^F:]I'A[3_@CK.N:E9>'](T[_@ZH_:]GU'5=3NH+'3K6TM[
M7]MJ>[O;^^NI([:SLHH8Y9KJ[N)8X+:WBDFF=(T9A_2=9>&ET?Q=XG^(6A?
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MCG_HGG_EVZ/_ /&*/^$A\<_]$\_\NW1__C% '?45P/\ PD/CG_HGG_EVZ/\
M_&*/^$A\<_\ 1//_ "[='_\ C% '?45P/_"0^.?^B>?^7;H__P 8H_X2'QS_
M -$\_P#+MT?_ .,4 =]17 _\)#XY_P"B>?\ EVZ/_P#&*/\ A(?'/_1//_+M
MT?\ ^,4 =]17 _\ "0^.?^B>?^7;H_\ \8H_X2'QS_T3S_R[='_^,4 =]17
M_P#"0^.?^B>?^7;H_P#\8H_X2'QS_P!$\_\ +MT?_P",4 =]7$>&_P#D:?B'
M_P!AG0O_ %$]%J >(?'.>?AY@=S_ ,);HYQ_Y!KG],N/'FG:SXFU+_A7XD37
M[W3;Q4_X3#2OW)LM$TO3&0HT&U2SVTO*8#>3N/\ K$) /73T/T-?,W[5?[+G
MP^_:]^%3?!OXHM>MX(O/&/@SQ3X@TZP(3_A(K'PIKUGK4_AR]D#QNFG:[%:-
MIU[-$PFBMYF>,,R!3ZY_PD/CG_HGG_EVZ/\ _&*/^$A\<_\ 1//_ "[='_\
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M (Q0!WU%<#_PD/CG_HGG_EVZ/_\ &*0^(O'0!(^'6X@$A?\ A+M'&2!P,F'
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MS_R[='_^,4?\)#XY_P"B>?\ EVZ/_P#&* .^HK@?^$A\<_\ 1//_ "[='_\
MC%'_  D/CG_HGG_EVZ/_ /&* .^HK@?^$A\<_P#1//\ R[='_P#C%'_"0^.?
M^B>?^7;H_P#\8H [ZBN!_P"$A\<_]$\_\NW1_P#XQ1_PD/CG_HGG_EVZ/_\
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MUO1AX#2R?4]/FLDN'\5Z9,L372F(R^5%"KS>3N$@A#*T^/*7YF (!Z[1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"$V\;_ /0X^*/_  ?:O1_PFWC?_H<?%'_@^U>N7HH^K87_ *!L-_X3X?\
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MJ]'_  FWC?\ Z''Q1_X/M7KEZ*/JV%_Z!L-_X3X?_P"4![6M_P _ZW_@R?\
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MAQ\4?^#[5ZY>BCZMA?\ H&PW_A/A_P#Y0'M:W_/^M_X,G_\ +#J/^$V\;_\
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MMXW_ .AQ\4?^#[5ZY>BCZMA?^@;#?^$^'_\ E >UK?\ /^M_X,G_ /+#J/\
MA-O&_P#T./BC_P 'VKT?\)MXW_Z''Q1_X/M7KEZ*/JV%_P"@;#?^$^'_ /E
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M>N7HH^K87_H&PW_A/A__ )0'M:W_ #_K?^#)_P#RPZC_ (3;QO\ ]#CXH_\
M!]J]'_";>-_^AQ\4?^#[5ZY>BCZMA?\ H&PW_A/A_P#Y0'M:W_/^M_X,G_\
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M<?%'_@^U>N7HH^K87_H&PW_A/A__ )0'M:W_ #_K?^#)_P#RPZC_ (3;QO\
M]#CXH_\ !]J]'_";>-_^AQ\4?^#[5ZY>BCZMA?\ H&PW_A/A_P#Y0'M:W_/^
MM_X,G_\ +#J/^$V\;_\ 0X^*/_!]J]'_  FWC?\ Z''Q1_X/M7KEZ*/JV%_Z
M!L-_X3X?_P"4![6M_P _ZW_@R?\ \L.H_P"$V\;_ /0X^*/_  ?:O1_PFWC?
M_H<?%'_@^U>N7HH^K87_ *!L-_X3X?\ ^4![6M_S_K?^#)__ "PZC_A-O&__
M $./BC_P?:O1_P )MXW_ .AQ\4?^#[5ZY>BCZMA?^@;#?^$^'_\ E >UK?\
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M/JV%_P"@;#?^$^'_ /E >UK?\_ZW_@R?_P L.H_X3;QO_P!#CXH_\'VKT?\
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MC_A-O&__ $./BC_P?:O1_P )MXW_ .AQ\4?^#[5ZY>BCZMA?^@;#?^$^'_\
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M?^#)_P#RPZC_ (3;QO\ ]#CXH_\ !]J]'_";>-_^AQ\4?^#[5ZY>BCZMA?\
MH&PW_A/A_P#Y0'M:W_/^M_X,G_\ +#J/^$V\;_\ 0X^*/_!]J]'_  FWC?\
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M-<FTY?R?S/O3;_%^K/[BI_PZ>LOX<.K_ )(^9\=?\%",?\,3?M.;L ?\*?\
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M%"]N+&*WO!XJ\8:=;:GJD6A+K$D\1@OM0"+9DI<-: "63PWPU\/?&^H_ /\
M8FT&;P-XO^V^&?VG;R]\3Z?/X:U>:^LM*F\76,LU_K!>+$%A%;"5Y_.C2.*
M,92B*S#]SJ*^8QWA+#,<;F6,Q?$^95GCZ>+I157"4JU6E#$YSD^<TXU:]7,)
MJNL/5RB-&FJ>$P4>2O)NFY0YI^MAN.983"X3#X?)\)1^K2HSFJ5>I3HU*E+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5V/P[_ .2@>!?^QQ\,?^GNQKCJ['X=_P#)0/ O_8X^&/\
MT]V-<.:?\BO,O^Q;F?\ Z@5C;"?[]@_^PO _^IE,_P!%R/\ U<?^XO\ Z"**
M(_\ 5Q_[B_\ H(HK_("I_$J?XY_^E2/[GI_PZ?\ U[A_Z1$_.3_@KUJVI^'_
M /@F3^W!KVBW3V.L:3^SQX^U#3KZ+_6VEY9:?]HMKB/_ *:02J)$_P!H"O\
M*6_X:C^/_P#T4S7?S/\ C7^JK_P66_Y18_MW_P#9M_Q#_P#3:*_R,:_I_P #
ML7BL-DN>1P^)Q-",\TPDI*AB*U%2:RV44Y*E4@I-+1-IM+1.VA^.>)5*E4S+
M+G4I4ZC6"K).<(3:3Q46TG).R;ULNI[S_P -1_'_ /Z*9KOYG_&C_AJ/X_\
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M?\:\&HKTO[4S'_H88_\ \+L7_P#-!R?5L-_T#4/_  32_P#D3WG_ (:C^/\
M_P!%,UW\S_C1_P -1_'_ /Z*9KOYG_&O!J*/[4S'_H88_P#\+L7_ /- ?5L-
M_P! U#_P32_^1/>?^&H_C_\ ]%,UW\S_ (T?\-1_'_\ Z*9KOYG_ !KP:BC^
MU,Q_Z&&/_P#"[%__ #0'U;#?] U#_P $TO\ Y$]Y_P"&H_C_ /\ 13-=_,_X
MT?\ #4?Q_P#^BF:[^9_QKP:BC^U,Q_Z&&/\ _"[%_P#S0'U;#?\ 0-0_\$TO
M_D3WG_AJ/X__ /13-=_,_P"-'_#4?Q__ .BF:[^9_P :\&HH_M3,?^AAC_\
MPNQ?_P T!]6PW_0-0_\ !-+_ .1/>?\ AJ/X_P#_ $4S7?S/^-'_  U'\?\
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M .BF:[^9_P :\&HH_M3,?^AAC_\ PNQ?_P T!]6PW_0-0_\ !-+_ .1/>?\
MAJ/X_P#_ $4S7?S/^-'_  U'\?\ _HIFN_F?\:\&HH_M3,?^AAC_ /PNQ?\
M\T!]6PW_ $#4/_!-+_Y$]Y_X:C^/_P#T4S7?S/\ C1_PU'\?_P#HIFN_F?\
M&O!J*/[4S'_H88__ ,+L7_\ - ?5L-_T#4/_  32_P#D3WG_ (:C^/\ _P!%
M,UW\S_C1_P -1_'_ /Z*9KOYG_&O!J*/[4S'_H88_P#\+L7_ /- ?5L-_P!
MU#_P32_^1/>?^&H_C_\ ]%,UW\S_ (T?\-1_'_\ Z*9KOYG_ !KP:BC^U,Q_
MZ&&/_P#"[%__ #0'U;#?] U#_P $TO\ Y$]Y_P"&H_C_ /\ 13-=_,_XT?\
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M2=I1<5WSX:FDITL-AL13E3I555H4J3IN-957"SG&$KM4G=<JDFU&UTS\O?\
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MYG_&OU8G_P""%_Q1TW1/&LFL?M??L@>&O$7PY^ OPY_:D^(?@O6?$/Q=?7O
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M4Z<817LH<[3JRI2HQD[-)3J4[VNDUJ?@S_PU'\?_ /HIFN_F?\:/^&H_C_\
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M_P -1_'_ /Z*9KOYG_&C_AJ/X_\ _13-=_,_XUX-11_:F8_]##'_ /A=B_\
MYH#ZMAO^@:A_X)I?_(GO/_#4?Q__ .BF:[^9_P :/^&H_C__ -%,UW\S_C7@
MU%']J9C_ -##'_\ A=B__F@/JV&_Z!J'_@FE_P#(GO/_  U'\?\ _HIFN_F?
M\:/^&H_C_P#]%,UW\S_C7@U%']J9C_T,,?\ ^%V+_P#F@/JV&_Z!J'_@FE_\
MB>\_\-1_'_\ Z*9KOYG_ !H_X:C^/_\ T4S7?S/^->#44?VIF/\ T,,?_P"%
MV+_^: ^K8;_H&H?^":7_ ,B>\_\ #4?Q_P#^BF:[^9_QH_X:C^/_ /T4S7?S
M/^->#44?VIF/_0PQ_P#X78O_ .: ^K8;_H&H?^":7_R)[S_PU'\?_P#HIFN_
MF?\ &C_AJ/X__P#13-=_,_XUX-11_:F8_P#0PQ__ (78O_YH#ZMAO^@:A_X)
MI?\ R)[S_P -1_'_ /Z*9KOYG_&C_AJ/X_\ _13-=_,_XUX-11_:F8_]##'_
M /A=B_\ YH#ZMAO^@:A_X)I?_(GO/_#4?Q__ .BF:[^9_P :/^&H_C__ -%,
MUW\S_C7@U%']J9C_ -##'_\ A=B__F@/JV&_Z!J'_@FE_P#(GO/_  U'\?\
M_HIFN_F?\:/^&H_C_P#]%,UW\S_C7@U%']J9C_T,,?\ ^%V+_P#F@/JV&_Z!
MJ'_@FE_\B>\_\-1_'_\ Z*9KOYG_ !H_X:C^/_\ T4S7?S/^->#44?VIF/\
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M;_E%C^W?_P!FW_$/_P!-HK_(QK^C/!7_ )$V=?\ 8SPO_JND?COB/_R,LO\
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M+X]_9;^!HUKXO?#'X9+I'Q%^/4<,GCQO':+K#S1?#,*ENWACP?XAA5[<_*K
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M?^$&:?\ SI#^R\;_ ,^Z?_A5@O\ YO/EJBOJ7_AG7P3_ -':_LU?^!_QL_\
MG,4?\,Z^"?\ H[7]FK_P/^-G_P YBC^V\M_Y_5O_  @S3_YTA_9>-_Y]T_\
MPJP7_P WGRU17U+_ ,,Z^"?^CM?V:O\ P/\ C9_\YBC_ (9U\$_]':_LU?\
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MGS2C%)3G+DC>,7RV2]*IB,\JPJTI5(JE6^.E"MEM&DGRQC[M&&+C1IV4(/\
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M\?\ ["6B_P#!/G0/@#I'Q)\;^'+OP'\ O">J:3XB\)SI\8M41Y?$FLR:M<7
M6Y=5-R\QWX5V\[\U_P#AG7P3_P!':_LU?^!_QL_^<Q1_PSKX)_Z.U_9J_P#
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MVU;X9?"KPMX'L=*MY]5U'P[>P_\ ":+9&XMKF/;"B_S*?\,Z^"?^CM?V:O\
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M;/\ YS%'_#.O@G_H[7]FK_P/^-G_ ,YBC^V\M_Y_5O\ P@S3_P"=(?V7C?\
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M+4Z,+EF,6(PZ]E&4IXK#12CB,'*RA6A4O[N.D_LVLHO>^NQ_L&Q_='T7_P!
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MU71OL?4/[%W_ "=C^S__ -E*\,_^E-E7RW']W_@1_P#1;U]2?L7?\G8_L_\
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MGHL:7%_=QBTMC))Y_P# ;_@EM^TG\3?A/\:_C=\2_!/Q*^ 7PI^%G[)GQ/\
MVH_ OQ#\;?"OQ1>^%/BDGP\C\$V$O@_PQJ64:TU#Q#8!H;*XP9+6*=+TH;>/
M-?JS\>_^"C?['>L^!?B9X*\+?&[QQ\09S_P1)^%_["&@^-O$GPN\=>'-4\:_
M'SX:?'C7=<U6QN8I8P-)T'5=)G@-UJ$@"65J0SS-';-&W=?%7_@I#^P?XXN/
MV]?V@-'_ &DOBO#XJ_;5_P"";*_LX>%?V3M:^$GC.Q\/_ ;XDZ)\+_AAX+M]
M @\<7-W;^&YGU?6=&?5=-U74;NPTL+J4\VKZ@EBSA.2&>\74\')?V97>(24J
M.+G@<0JJP^&JTYU8T<+3M*E.K@Z])N>,56C"$GS0<VIJXY;DSK2E3Q=*--QE
M!TJ>*HIRER8>:E.4[IRE[9I6BDN5[S:3_G_A_P""=_[<,WAKX<>,9_V2?COI
MOA'XP^)? W@_P!XIU;X>^*M,\,>)_%'Q,UVR\.>"=*TS4D/F ^*]2U&SM+*1
M\-)Y^^(G;7KGQG_X)/\ [</PH_:?\>?LGZ)\!/B7\9OB=X \*Z)XSO)OA)\/
MO'/B/1M3\+ZY:(__  F^F7!3R6\)3WS2^#[3S&0'Q/!);NJ,"A_9KX[?\%#?
M^">.F?LM_MB_"G]G_P"+NIWVH_&_P5^Q->_">S\8_#O]HS6/CE:^(OV<?BGX
M2\9?$.R_:#^/'QCU37M%U7Q@]UI=U'\,;7P3<1^#-"@&GD^99JVWUOQ]_P %
M-?\ @G[XZ^+/[=FC']H.!?"G[7?Q)_9M_:(\$?%7XF_LV_M!>(M!^']]\-M-
MU?PYXA^ 7C'P1X)\:^"_'$OC[P'>Z-/XS^'=Y'J&F?#G6=6N+>+5+Y--*WT.
ME7B3BQ5ZZI\.U8TJ<<0Z2G@<="W+B(JEB_:TZLYQ2HQK*K"G6G3=17I^S2]F
MR&4Y(H+GS**]JY.*^LX>IR146G9)2O=Q33YHVOK%[O\ D2'@3QB?&J_#.;P[
MK.G^/AXHMO!K>#]=TZ_TC5--\3W.H1Z6N@:EH.HR0RQ7LU_*EHT/FPLTC; Z
M$Y7[]\,_\$]X?&O_  4XF_X)Q>$_C/'?7<'QW\3_  ''QMF\&&VMSKW@N'Q'
M8>*]5ET >(&:_32O$&BQ:(]P)"TBVQ8<8#>OWG[8'P)^*?\ P6;M_P!MKXK^
M(+>/X*:1\>]/^.3:W8_#?Q1X,L_%;?!S0M,U[X9Z!#X43Q3\1M?T=O&_B3PK
M8::6\4ZK!IUN;\OJ5S!:+,T?B'_!.K]J#P9\&O\ @I+\!OVK/VA]?DT_PGX:
M^,OB'XB_$SQ+'I$UV^F_V]9:M;ZY>)9VR27%R\UY/IEDL$*--*<QQJ7< _28
MC$9O5PM:M3H5:-2/#D\332H>W4,YKQE.E[)XF,*E1JE'V37-[-RG%\Z:Y3R*
M6'P=.M1I5)JK2JYE1@YQG%QGA8+WXOV:DE>I?>+G'5<D]&??WPN_X(!_$;XB
M?M.?MO\ [.EQ\=M%\,Z+^QIX5\%^)-.^(K?#O5C9_%>/XH> ]7^*G@33M-99
MD,32?#7P_P"(([J:*226VP\D43O&(7_(#1_V-OVL=>^#.J?M&Z'^SI\;/$/P
M T!-2O[[XQ67PK\5W?@%;/PW?WNC:WKE]JP&;#1M/MK:2ZU+4<;;&V1YW*;
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ML=%SA"4IU:E>BO:W5*K"<H6C.F^6<H2IMK6G*4+QNE^:WQ>_X)3>*OAAI?Q
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MWY9_OM+_ *]8K_U'F?,%%%%>M/XE_@7_ *?QAYT?Z^^04445)04444 %%%%
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MG!\LZ7U>UG!*RDJTO=DKQ=-]&%%%%>\>2%%%% !1110 4444 %%%% !1110
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M_P#HJBA?X?\ KC'_ .BJ*VP_^[8/_L P7_IEF=?_ 'C$?]?9!1116QF%%%%
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M "BBB@ HHHH **** "OI[XB?\FG_ +-'_94/VF/_ $1\#J^8:^GOB)_R:?\
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M +*5X9_]*;*OEN/[O_ C_P"BWKZD_8N_Y.Q_9_\ ^RE>&?\ TILJ^6X_N_\
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M'4;[3=3\3^+KK2/!FI?"XZGHPTZ\OM<T33_&M_K,^EVTD%M(UPZ&OOCXS_\
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MJ_CCPM\)+B#P;X7OXM5TZ37O&GQ'U/2?#GA:SOIK_P 0W%OI]H;F3XC^!_\
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MSXU_\%J?&_QW_9MOOA)XE^%7B2/XI^(?@7X2_9ZU_P"*NE?M6?M#:!\*-5\
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M('_!+?\ :O\ %G[4/[*_[)WA_P#:O^&W[0WP#^&OQ:\=_"WXK?%3QSX)\:>
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M-4J^R?LI8A8B6&P<HX&=.I5KU\/-TYT_:4[0JJ#BZ%6DU3NJ:E*4%[_\9O\
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MS_\ ]E*\,_\ I395\MQ_=_X$?_1;UP4_^1QB?^Q;_P"[L3O_ .9;0_[#8_\
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MW%W=6R-(8_ /A5_P4$U?X8? []DOX(P?"_2]5M/V4/VVHOVR;3Q%)XG^Q?\
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M6MZYIL5IX;^'>J^)]+U[Q3)J&F6,FIV$5]]L@V-1_P""-?[0FF?LW7/QTO\
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M[%W_ "=C^S__ -E*\,_^E-E7RW']W_@1_P#1;UP4_P#D<8G_ +%O_N[$[_\
MF6T/^PV/_IECJ***]%?"O\=7_P!+1PRW?^*7YA1112)"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $;H?H?Y5]0?LR_=_:)_[-<^)W_I;H-?+[=#]#_*OJ
M#]F7[O[1/_9KGQ._]+=!KR\Z_P"19B_\%#_U992=^6?[[2_Z]8K_ -1YGS!1
M117K3^)?X%_Z?QAYT?Z^^04445)04444 %%%% !1110 4444 %%%% !1110
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M)^=-RC*UG.#<U"371R46[7=MCZ9_8Z_Y.G^!/_90M _]&VM?,J_P_P#7&/\
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MO[XG+=F;UZ?T+?LGZIHWQV_8TL_V8/V?/%_@GX4?M0^'/"/QW\0_$[P1X_\
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MZ)UX#_\ "3TG_&C_ (5C\,?^B=> _P#PD])_QKNJ*/[4S7_H:YG_ .'',O\
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M_GF'U' ?] & _P#"+"__ #,<+_PK'X8_]$Z\!_\ A)Z3_C1_PK'X8_\ 1.O
M?_A)Z3_C7=44?VIFO_0US/\ \..9?_/,/J. _P"@# ?^$6%_^9CA?^%8_#'_
M *)UX#_\)/2?\:/^%8_#'_HG7@/_ ,)/2?\ &NZHH_M3-?\ H:YG_P"'',O_
M )YA]1P'_0!@/_"+"_\ S,<+_P *Q^&/_1.O ?\ X2>D_P"-'_"L?AC_ -$Z
M\!_^$GI/^-=U11_:F:_]#7,__#CF7_SS#ZC@/^@# ?\ A%A?_F8X7_A6/PQ_
MZ)UX#_\ "3TG_&C_ (5C\,?^B=> _P#PD])_QKNJ*/[4S7_H:YG_ .'',O\
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M_GF'U' ?] & _P#"+"__ #,<+_PK'X8_]$Z\!_\ A)Z3_C1_PK'X8_\ 1.O
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M5C\,?^B=> __  D])_QKNJ*/[4S7_H:YG_X<<R_^>8?4<!_T 8#_ ,(L+_\
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MC_T3KP'_ .$GI/\ C7=44?VIFO\ T-<S_P##CF7_ ,\P^HX#_H P'_A%A?\
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M *&N9_\ AQS+_P">8?4<!_T 8#_PBPO_ ,S'"_\ "L?AC_T3KP'_ .$GI/\
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M?AC_ -$Z\!_^$GI/^-'_  K'X8_]$Z\!_P#A)Z3_ (UW5%']J9K_ -#7,_\
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MH_M3-?\ H:YG_P"'',O_ )YB^HX#_H P'_A%A?\ YF.%_P"%8_#'_HG7@/\
M\)/2?\:/^%8_#'_HG7@/_P )/2?\:[JBC^U,U_Z&N9_^'',O_GF'U' ?] &
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M3S+,9PG%Q<)X_'3B[]6JF.JI^EAK!8*+YHX/"0DMG#"82+7S^K<WW-'^G?\
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MO]*W_AE/]G7_ *)+X4_[\77_ ,ET?\,I_LZ_]$E\*?\ ?BZ_^2Z/:>7X_P#
M _SD?"GQ:\?^ O!_Q&\"^$?%%SI'A7XNZ1I&D?$#1]/%B9/$WAWP]X@A\0^&
MH[K['F\$8U& P3&TQ=&.1UA_>%:]"\#_ +5W[0WPQT?X<:%X!^*?B#PGI?PB
M\7>(/B!\-;;3XM,-SX7\7>,+-]-\3ZGI6MM%++>Z9K=A--9ZAH?B&*;3+F.>
M>WOHFMIIT;_0L_X93_9U_P"B2^%/^_%U_P#)='_#*?[.O_1)?"G_ 'XNO_DN
MCVGE^/\ P /X$V_;W_:Y?QAXT^(,7Q@U0:]\0_!=M\./$L<NA^&QINI>!M,\
MV:QT*ZT>ZT&&QL[A;R6:=];T>:&ZM!*UQ:RI(BL,WPQ^W%^U;X'\5Z=XU\*?
M&CQ!9:]I'PNT'X*QWC:'HPAOOA1X1>XA\%>%=9\,R_N]8CTTW]W<6<C_ "7"
ME4?(?G^_[_AE/]G7_HDOA3_OQ=?_ "71_P ,I_LZ_P#1)?"G_?BZ_P#DNCVG
ME^/_   /X(_!_P#P40_;1^'-MXEM?"WQ]\7:+:^)OB#>?%?6&@M?"-U<7GQ$
MU>^M)]1UM-28;5L+ZPMELG\('Y;Z/-@PQ+7F>C?M6?M%>'?^$1?PY\4]?T>Y
M^'?Q.\4?%SPE<Z"^A+/H_P 4/&43#Q/XLM;@6M[I;1:W!(T6H:+J%G>6$X>6
MWN;6>"26*3_0H_X93_9U_P"B2^%/^_%U_P#)='_#*?[.O_1)?"G_ 'XNO_DN
MCG\OQ_X '^=U\:/VA_B[^T-?:)>_%WQ/;>+)O#L=T-$CTWPMH'@^&V^V[CJ=
MS##X:T+2K;4KB[#.VHW[6DRY9W,,@'EGH_'?[5W[0/Q&^&>C_!CQ;\2)M8^&
MVB2: UIX<M?#_A?PU;ZO-X1L7T'PE=>)M8T3P[_;VLW&B:/<S/9P7'[RY,0C
M'S.M?Z$7_#*?[.O_ $27PI_WXNO_ )+H_P"&4OV=?^B2^%/^_%W_ /)='M/+
M\?\ @ ?Y_/A[]MO]J;PI\'H_@7X:^+WB'2/A6-#U+PPWA]-/\+RZLGA+Q-%/
M-J&@S>)=-T*W\5MX=UI'GLKS3A/#>2V<\D<,L4S(XJQ_MF?M,#X0VOP2F^+&
MJZG\.[#PO=>"[+3M;\/^"/$/B+3O">I/,+OP_8?$*[\.7_B:TTK5A<369T*X
MU*TEDCF,(NH&(E3^^CQU^S/\ M)\'>)M2L?A5X6BO+/1[BXMY!#>H4GM$,EL
MY:.>1_W4H5LA"3C!XY'4G]E3]G<LSGX3>%"[[]SF"[+-YC*\F6-WD[F52>>W
MH2">T\OQ_P" !_GI1_M2_M VOQ.T'XS6?Q)U-OB9X5\$0_#G0/%PTK3)C8^!
M+#P5J/PYM?#HA@Q++)+X:U>]A"PE9GD8>6PD(-;?AW]LK]I'PE\*S\#=(^*M
MQ%\)DT_Q-H6GZ3K/A[P=XAN=&T3Q<MT_BNU\-^)M:\,:IJ?A2WUPWUW%>SV=
MW#=Z<)FN;>:.:%'7_01_X93_ &=?^B2^%/\ OQ=?_)='_#*?[.O_ $27PI_W
MXNO_ )+H]IY?C_P /\]?XD?M7?M!?%WP#HGPL^('C^YU3P-X>O\ 3M2M?#5E
MX;\+>%8=1U?2=*DTJ/4O$<_AO08=1\075C:NDEC=ZC-%%,R*9I$4LX^>J_TK
M?^&4_P!G7_HDOA3_ +\77_R71_PRG^SK_P!$E\*?]^+K_P"2Z/:>7X_\ #_-
M2HK_ $K?^&4_V=?^B2^%/^_%U_\ )='_  RG^SK_ -$E\*?]^+K_ .2Z/:>7
MX_\   _S4J*_TK?^&4_V=?\ HDOA3_OQ=?\ R71_PRG^SK_T27PI_P!^+K_Y
M+H]IY?C_ , #_-2HK_2M_P"&4_V=?^B2^%/^_%U_\ET?\,I_LZ_]$E\*?]^+
MK_Y+H]IY?C_P /\ -2HK_2M_X93_ &=?^B2^%/\ OQ=?_)='_#*?[.O_ $27
MPI_WXNO_ )+H]IY?C_P /\U*BO\ 2M_X93_9U_Z)+X4_[\77_P ET?\ #*?[
M.O\ T27PI_WXNO\ Y+H]IY?C_P  #_-2HK_2M_X93_9U_P"B2^%/^_%U_P#)
M='_#*?[.O_1)?"G_ 'XNO_DNCVGE^/\ P /\U*BO]*W_ (93_9U_Z)+X4_[\
M77_R71_PRG^SK_T27PI_WXNO_DNCVGE^/_  _P U*BO]*W_AE/\ 9U_Z)+X4
M_P"_%U_\ET?\,I_LZ_\ 1)?"G_?BZ_\ DNCVGE^/_  _S4J*_P!*W_AE/]G7
M_HDOA3_OQ=?_ "71_P ,I_LZ_P#1)?"G_?BZ_P#DNCVGE^/_   /\U*BO]*W
M_AE/]G7_ *)+X4_[\77_ ,ET?\,I_LZ_]$E\*?\ ?BZ_^2Z/:>7X_P#  _S4
MJ*_TK?\ AE/]G7_HDOA3_OQ=?_)='_#*?[.O_1)?"G_?BZ_^2Z/:>7X_\ #_
M #4J*_TK?^&4_P!G7_HDOA3_ +\77_R71_PRG^SK_P!$E\*?]^+K_P"2Z/:>
M7X_\ #_-2HK_ $K?^&4_V=?^B2^%/^_%U_\ )='_  RG^SK_ -$E\*?]^+K_
M .2Z/:>7X_\   _S4J*_TK?^&4_V=?\ HDOA3_OQ=?\ R71_PRG^SK_T27PI
M_P!^+K_Y+H]IY?C_ , #_-2HK_2M_P"&4_V=?^B2^%/^_%U_\ET?\,I_LZ_]
M$E\*?]^+K_Y+H]IY?C_P /\ -2HK_2M_X93_ &=?^B2^%/\ OQ=?_)='_#*?
M[.O_ $27PI_WXNO_ )+H]IY?C_P /\U*BO\ 2M_X93_9U_Z)+X4_[\77_P E
MT?\ #*?[.O\ T27PI_WXNO\ Y+H]IY?C_P  #_-2HK_2M_X93_9U_P"B2^%/
M^_%U_P#)='_#*?[.O_1)?"G_ 'XNO_DNCVGE^/\ P /\U*BO]*X?LI_L[ @C
MX2^$\@@C-O=$9'/(-T01[$$'N*Y3Q9^S-\ =.7PZ+3X5>$X6OO%NB64X6WEC
M,MK<"6VN(SF=BP-OE2J[6/&'!/)[3R_'_@ ?YOE%?Z5O_#*?[.O_ $27PI_W
MXNO_ )+H_P"&4_V=AR/A-X5!'(*PWBL#V*LMV"I'4$$$'D$&CVGE^/\ P /\
MU*BO]''XC? []FKX8^#?$/CB^^ >H>++'PUIMS?R>&OAQX*\7_$'QAJ2["9K
M/PSX'\-K?ZAK%]<1;_\ 1=,M6N+EAY(2261$?Y9_9F^)'["W[5GBWQ1X4^%G
M[.'QTM&\&ZWXT\)^)?$_Q/\ V=_CM\./ ^B>,/A]J\&B^*/ <WBSQ]I>EZ-;
M^(K"]N 1X=@F F2&=DC,T1C)[3R_'_@ ?P:45_I6_P##*?[.O_1)?"G_ 'XN
MO_DND/[*7[.I!!^$GA0@@@CR+OH>O_+W1[3R_'_@ ?YJ=%?Z.'A;X2?L>^,O
M%OQ+\ ^&?!/@C5/%?P?UKPUX<^(F@V\=X;OPKJOB/P?8>//#EO=H;D"+^U/"
MOC&VU&!HF*RP7DD3C,14=[_PRG^SK_T27PI_WXNO_DNCVGE^/_  _P U*BO]
M*W_AE/\ 9U_Z)+X4_P"_%U_\ET?\,I_L[?\ 1)?"G_@/=?\ R71[3R_'_@ ?
MYJ5%?Z-_@SX2?L>?$+6_B7X>\(>!_ 6NZY\'O'$?PV^(]E91W,L_A;QK=^ _
M 7Q!'A^]8W"LMPW@OQGX)U0JG[ORKV",XFAF1.]/[*7[.V#CX3>%U.#AHXKZ
M.13_ 'HY([Q9$<=5>-E=6 92& -'M/+\?^ !_FIT5_H%?"VV_9:^+_QU^.7P
M9\&?LM^*+C2?V>_$5M\.O'GQHN1X%B^#\GQ)7P=X!^(-Y\,-(M(/BK<_$R[\
M1:3X7^)'A74M0DO_ (6Z?X7#2W4$>O3RV]L+OK_@#X1_9&_:'\/>/O$7@WX.
MVEM:?#[XY?&[X":VOB2UNUN9?%_[/OQ+\1_"3Q9<Z1(=7O&DT";7/#%V=-F1
M[<3VI19K9609/:>7X_\   _SQJ*_TK?^&4_V=AR/A+X4![$078(]P1=Y!]Q7
M"_$CX._L=_!_P?K/Q&^)/@?P%X1\':%_9%OK'B'58+U=.T\:OK-AH&DI+Y<T
MI4W6L:I8V47E1%S-<Q[N#FCVGE^/_  _SC**_P!*L?LI?LZ'K\)/"IVD;=\-
MXVT@<&/==D*"#@E",CY6S@@9/B']FS]G+PYH&N>(9?@GI>L1:#H^IZS)I'A_
M0]1US7M5CTNRGOGTW1-$MKA[G6-7OE@-KINEVZ//J%Y+#:1*TDR@GM/+\?\
M@ ?YM5%?Z0O@K]G/]F[QAX3\,>,+;X*Z=I$/BCPYI.MQZ/XAT;6-$U?38M8T
M_3[W[!J_A^_N8Y=+U2U$=O!>VD\"SVUS;NA=CN=_-OA'X,_9,^,?C#]HKP=X
M=^#=C:ZE^SC\9X_@3XYDUO3YH+?4?$][\(_A!\=DDT,?;I?/T2+P[\9O"+6<
MH$7EW\4K0I&T:8/:>7X_\ #_ #PZ*_T=_AS\"OV;OB1X-T3QM;_L^W/@^'7(
M[J4>&/B/X-UCP=XNTTV>H7>G2+KOA35;C[3I\UX;-KB+[0C'4=+N+6X9Y;:Z
M4'Q3XN:=^S+\*OCC\ /@%:?LN>)_BG\0?V@4\>>*-,@\"KX7DTGX=_#_ .&G
MB'X4^%OBC\5O'^H>/_B9X/DB\)>$;KXS^ 4FT_P=IOBKQ=>VMU/::#X:U&Z2
MRTZ<]IY?C_P /\_.BO\ 2L;]E3]G;Y@?A+X7/F,I8""]QD$ -\MWA-O7(V].
MO&:X7XB?"+]CKX3Z)I>O_$/P5X$\*Z+X@\:_#OX::3=:A#?K#J?C?XG>-=#^
M'GP[\,VD$$TKSZGXE\9^)-$T'3(DB)DO+^+S&6,/(I[3R_'_ ( '^<;17^C?
MHWP2_9IUSQSXT\ )\ KNPN_ EKX5O[GQ#K?A#7M/\(^(X_%\6J26Z^#O$EQ<
M-:^)Y]%ET:2W\0I;D+HT\UHK.ZNS1]]_PRG^SK_T27PI_P!^+K_Y+H]IY?C_
M , #_-2HK_2M_P"&4_V=?^B2^%/^_%U_\ET?\,I_LZ_]$E\*?]^+K_Y+H]IY
M?C_P /\ -2HK_2M_X93_ &=?^B2^%/\ OQ=?_)='_#*?[.O_ $27PI_WXNO_
M )+H]IY?C_P /\U*BO\ 2M_X93_9U_Z)+X4_[\77_P ET?\ #*?[.P_YI+X4
M_P"_%U_\ET>T\OQ_X '^:E17^AU\2O!_[(WPK^*/[.WPBU[X.6LGB+]IKQMX
MU\!> Y=*@9=%M]:\ ?"CQM\:=9?Q \NO6<L8?PK\/M:-@]I8ZC<37,(BD$,*
MEF6/PC^R&_[2DW[+R_!^P/Q!A^!\'Q_-Q]BG;PL?!=YX[U/X=QQ+-_:Y(UH:
MVU[(D']GB-;-S<1W*21QQ@]IY?C_ , #_/$HK_2M_P"&4_V=?^B2^%/^_%U_
M\ET?\,I_LZ_]$E\*?]^+K_Y+H]IY?C_P /\ -2HK_2M_X93_ &=?^B2^%/\
MOQ=?_)='_#*?[.P_YI+X4_[\77_R71[3R_'_ ( '^:E17^D+IW[,?P N?%OB
M:PE^%?A9[;3=-\+FTA,5\1";H>(&EPK7 1=V]L!&?@G.PX%=1_PRG^SK_P!$
ME\*?]^+K_P"2Z/:>7X_\ #_-2HK_ $K?^&4_V=?^B2^%/^_%U_\ )='_  RG
M^SK_ -$E\*?]^+K_ .2Z/:>7X_\   _S4J*_TK?^&4_V=?\ HDOA3_OQ=?\
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MO; 1GX)SL.!1[3R_'_@ ?YO5%?Z5O_#*?[.O_1)?"G_?BZ_^2Z/^&4_V=?\
MHDOA3_OQ=?\ R71[3R_'_@ ?YJ5%?Z5O_#*?[.O_ $27PI_WXNO_ )+H_P"&
M4_V=?^B2^%/^_%U_\ET>T\OQ_P" !_FI45_I6_\ #*?[.O\ T27PI_WXNO\
MY+H_X93_ &=?^B2^%/\ OQ=?_)='M/+\?^ !_FI45_I6_P##*?[.O_1)?"G_
M 'XNO_DNC_AE/]G7_HDOA3_OQ=?_ "71[3R_'_@ ?YJ5%?Z5O_#*?[.O_1)?
M"G_?BZ_^2Z/^&4_V=?\ HDOA3_OQ=?\ R71[3R_'_@ ?YJ5%?Z5O_#*?[.O_
M $27PI_WXNO_ )+H_P"&4_V=?^B2^%/^_%U_\ET>T\OQ_P" !_FI45_I6_\
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MO_1)?"G_ 'XNO_DNCVGE^/\ P /\U*BO]*M_V4_V=@K$?";PFI"L0QM[HA<
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M *)+X4_[\77_ ,ET>T\OQ_X '^:E17^E;_PRG^SK_P!$E\*?]^+K_P"2Z/\
MAE+]G7_HDOA3_OQ=_P#R71[3R_'_ ( '^:E17^D+XZ_9G^ 6D^#O$VI6/PJ\
M+17EGH]Q<6\@AO4*3VB&2V<M'/(_[J4*V0A)Q@\<CJ3^RI^SN69S\)O"A=]^
MYS!=EF\QE>3+&[R=S*I//;T)!/:>7X_\ #_-1HK_ $K?^&4_V=?^B2^%/^_%
MU_\ )='_  RG^SK_ -$E\*?]^+K_ .2Z/:>7X_\   _S4J*_TK?^&4_V=?\
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MRU\2>!_B!X.T#Q5X5UNS;?%?Z+K-C#/:SJ>H.=T<P PDT3H<[,UZ=0 4444
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M8H^$?@O]D"XM/^"77[6?[2>N?LZ?$6\\9?&BP^*E_P##GX=?"8_#7QC^Q_\
MM!6NFW'PAO\ PAXN\>>'+[3]3O;+2+J\TRZ;2[C3;OZTB_9$F\7?M3_MM?%S
MXL?#_P"(/Q5\<?#G]B/]F+0?V:OBIXH\.^.K1-:^(\WP7_:&\._%CQA\+_#,
MYN[+2OB?KM]=>&K#7K:PL+[Q]X>O9-/L[-X;UXC+^^5% '\;O[2?@#XYZM\!
M/@9X4T7]D34;']H7X-_L&?\ !.ZY^!OQ9F_8=_:$^._QJ\0?$+0[#2]5^)WA
MGX8_M">#?$?ASX2?L4ZA\%;[PQ:S^.?!WCG2]1U+X@V^H7WVS3+ZWFM;"/\
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MZ;=SK/X,TWQ0^]+6+R20WC*-46.,D(NW#OEC\Y_\1'_Q7_Z-F^'G_A=Z]_\
M(-?G%_P6)_Y22?M*_P#7]\./_5-?#&OS/K^:L^XYXIP&>9O@\+F]>GA\-C\1
M1I4_8X22C"$[))RPLW;7;FZ==S_=_P &?HE?1VXG\)O#?B+/?#'*\QSK/."N
M'\US7'ULUXEA4Q>.QN"]KB*\J=#/Z-&#G-7Y:5*$5=VBM$?TF_\ $1_\5_\
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MJ*/^(B\8_P#0ZK_^",#_ /,0?\26_1A_Z-+D_P#X=^*O_HD/Z3?^(C_XK_\
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M_P#X=^*O_HD/Z3?^(C_XK_\ 1LWP\_\ "[U[_P"0:/\ B(_^*_\ T;-\//\
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MI<G_ /#OQ5_]$A_2;_Q$?_%?_HV;X>?^%WKW_P @T?\ $1_\5_\ HV;X>?\
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MZCI9_9A\ +]NM;FRR_CKQ"%4W,$D ?\ =6L3_+YF?O@<?C7\Y=%'_$1.,?\
MH=5__!&!_P#F(/\ B2WZ,/\ T:;)_P#P[\5?_1(?TH?\1'OQ6'F+_P ,R> 5
M"/Y4<K>.M=*2-%$'F_Y<MW+9"$L2!C=O()IG_$1_\5_^C9OAY_X7>O?_ "#7
M\V5%'_$1>,?^AU7_ /!&!_\ F(/^)+?HP_\ 1I<G_P##OQ5_]$A_2;_Q$?\
MQ7_Z-F^'G_A=Z]_\@T?\1'_Q7_Z-F^'G_A=Z]_\ (-?S944?\1%XQ_Z'5?\
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MO;M=7/A2/4M7O;H:++(UC-=SRR/!(YW->_X6#X#_ .AT\*?^%#I/_P ET?\
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M6UB[#Z!KD/\ A8/@/_H=/"G_ (4.D_\ R71_PL'P'_T.GA3_ ,*'2?\ Y+H
MZ^BN0_X6#X#_ .AT\*?^%#I/_P ET?\ "P? ?_0Z>%/_  H=)_\ DN@#KZ*Y
M#_A8/@/_ *'3PI_X4.D__)='_"P? ?\ T.GA3_PH=)_^2Z .OHKD/^%@^ _^
MAT\*?^%#I/\ \ET?\+!\!_\ 0Z>%/_"ATG_Y+H Z^BN0_P"%@^ _^AT\*?\
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MAP7_ (%B_P#YN#_B<+Z3'_1X.)__  3P]_\ 0P?@)_Q#E?LY_P#1>?C9_P"
MO@W_ .4U'_$.5^SG_P!%Y^-G_@+X-_\ E-7[]_\ "P? ?_0Z>%/_  H=)_\
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M ,+!\!_]#IX4_P#"ATG_ .2Z/^%@^ _^AT\*?^%#I/\ \ET?ZB<(?]"'!?\
M@6+_ /FX/^)POI,?]'@XG_\ !/#W_P!#!^ G_$.5^SG_ -%Y^-G_ ("^#?\
MY34?\0Y7[.?_ $7GXV?^ O@W_P"4U?OW_P +!\!_]#IX4_\ "ATG_P"2Z/\
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M71_J)PA_T(<%_P"!8O\ ^;@_XG"^DQ_T>#B?_P $\/?_ $,'X"?\0Y7[.?\
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MUHMOF!MTX"[-R[B< #))X.'?\+!\!_\ 0Z>%/_"ATG_Y+H_U$X0_Z$."_P#
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M$R:BY1<Z'#CCSJ[A9SX9BE+FC&,;2BVZFC5M?X!;_P#85\>^//VX?B5^R%\
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MD_\ R71_PL'P'_T.GA3_ ,*'2?\ Y+H&=?17(?\ "P? ?_0Z>%/_  H=)_\
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M8L4*21JK.K[IAM"JZDL<*,GYN#@ ["BN0_X6#X#_ .AT\*?^%#I/_P ET?\
M"P? ?_0Z>%/_  H=)_\ DN@#KZ*Y#_A8/@/_ *'3PI_X4.D__)='_"P? ?\
MT.GA3_PH=)_^2Z .OHKD/^%@^ _^AT\*?^%#I/\ \ET?\+!\!_\ 0Z>%/_"A
MTG_Y+H Z^BN0_P"%@^ _^AT\*?\ A0Z3_P#)='_"P? ?_0Z>%/\ PH=)_P#D
MN@#KZ*Y#_A8/@/\ Z'3PI_X4.D__ "71_P +!\!_]#IX4_\ "ATG_P"2Z .O
MHKD/^%@^ _\ H=/"G_A0Z3_\ET?\+!\!_P#0Z>%/_"ATG_Y+H Z^N$T;_DH'
MCG_L#>"?Y^)JN?\ "P/ 9X_X3/PH<\8'B#2B3GL +LDD], $GI7%:/XX\&CQ
MOXRO&\5>'$M+C1_!*V]PVKZ;''+A?%$APYF4D*H)R[$* <%1Q0![)17(?\+!
M\!_]#IX4_P#"ATG_ .2Z/^%@^ _^AT\*?^%#I/\ \ET =?17(?\ "P? ?_0Z
M>%/_  H=)_\ DNC_ (6#X#_Z'3PI_P"%#I/_ ,ET =?17(?\+!\!_P#0Z>%/
M_"ATG_Y+H_X6#X#_ .AT\*?^%#I/_P ET =?17(?\+!\!_\ 0Z>%/_"ATG_Y
M+H_X6#X#_P"AT\*?^%#I/_R70!U]%<A_PL'P'_T.GA3_ ,*'2?\ Y+H_X6#X
M#_Z'3PI_X4.D_P#R70!U]%<A_P +!\!_]#IX4_\ "ATG_P"2Z/\ A8/@/_H=
M/"G_ (4.D_\ R70!U]<-\3/^1 \6_P#8$O/_ $"K7_"P? ?_ $.GA4^R^(-*
M9C[*%NBQ)[!023P!FN/\?^./!UYX)\3VMGXI\.W5W/I$UO#:PZS92SRRW2F*
M&**&.=II)96.V- G[Q]J-@-0!Z_1110!PWQ&1)/"SQR(DD;Z_P"#$>.1=Z.C
M>,M 5D=/XD9259?X@2.]=7_9FF_] ^QZ8_X]+?IC;C_5]-ORX]..E<M\0_\
MD63_ -C#X*_]33P_7;'JOU_H: */]E:7_P! VP_\ [?_ .-T?V5I?_0-L/\
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M*TO_ *!MA_X!V_\ \;H_LK2_^@;8?^ =O_\ &ZOT4 4/[*TO_H&V'_@';_\
MQN@:7I@.1IU@".019V^0?7_5U?HH \Z^)>FZ;_P@/BPFPL/ET6[8,]G"P4I&
M2C$*@8[.2,'CGMD'N&TW36SOL+)MS!FW6L!W-A5#',?+855SR< +T %<C\3_
M /DGOC#_ + 5]_Z+KNZ *']E:7_T#;#_ , [?_XW1_96E_\ 0-L/_ .W_P#C
M=7Z1L[6VXW8.W)(&<<9(R0,]2 2!TH H_P!E:7_T#;#_ , [?_XW1_96E_\
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M&V'_ (!V_P#\;H_LK2_^@;8?^ =O_P#&ZNL2JLP5G*J2$4J&<@$A5+LB!F/
M+NJY/S,HR1X!HG[0?A35OVH/B#^RG#I6NQ^./AW\"OA+\?=2UR:"W7P_?>%/
MB_X\^,GP^T2PM9T=)?[3LM6^"NNO<(82DEO<0X:-K<FX /<O[*TO_H&V'_@'
M;_\ QNC^RM+_ .@;8?\ @';_ /QNK]% %#^RM+_Z!MA_X!V__P ;H_LK2_\
MH&V'_@';_P#QNK]% %#^RM+_ .@;8?\ @';_ /QNC^RM+_Z!MA_X!V__ ,;J
M_10!0_LK2_\ H&V'_@';_P#QNC^RM+_Z!MA_X!V__P ;J_10!0_LK2_^@;8?
M^ =O_P#&Z/[*TO\ Z!MA_P" =O\ _&ZOT4 4/[*TO_H&V'_@';__ !NC^RM+
M_P"@;8?^ =O_ /&ZOT4 4/[*TO\ Z!MA_P" =O\ _&Z/[*TO_H&V'_@';_\
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M]BK_ (*4_&*P^->N_'/PMXRG\?\ C'_@C+^VS^QW,_Q#^(/[-D>AZO\ M/\
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M9!_;-_9>^'_@C35_96T+]I>]^('_  21_89_8;\5>'[_ .*?PTT2V^"GQ'^
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M"G]E:7_T#;#_ , [?_XW1_96E_\ 0-L/_ .W_P#C=?Y]?_#[+_@IW_T=!/\
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M!]?]77^?7_P^R_X*=_\ 1T$__AJO@7_\[BE'_!;'_@IV2 /VH)R20 /^%5?
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M<;,,Q55!8YZ#.<4G]E:7_P! VP_\ [?_ .-U?HH H?V5I?\ T#;#_P  [?\
M^-T?V5I?_0-L/_ .W_\ C=7Z* *']E:7_P! VP_\ [?_ .-T?V5I?_0-L/\
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M_ .W_P#C=']E:7_T#;#_ , [?_XW5^B@"A_96E_] VP_\ [?_P"-T?V5I?\
MT#;#_P  [?\ ^-U?HH H?V5I?_0-L/\ P#M__C=']E:7_P! VP_\ [?_ .-U
M?HH H?V5I?\ T#;#_P  [?\ ^-T?V5I?_0-L/_ .W_\ C=7Z* *']E:7_P!
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MM+_Z!MA_X!V__P ;J_10!0_LK2_^@;8?^ =O_P#&Z/[*TO\ Z!MA_P" =O\
M_&ZOT4 4/[*TO_H&V'_@';__ !NC^RM+_P"@;8?^ =O_ /&ZOT4 4/[*TO\
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M^)+.\O'B7P=X9\'_  <^#L?AI+JRBAL5TFTF,R"9'FQ?V%OBSX9^(G_!1O\
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M)XSN?AKJVO7-M::7J(U2XM5>Z5BOU%J.G?"GP'?_ /!.;P)_P4,^/5[^T/\
ML"V_[,/[3<7A'XSW=E\5-!^#7CO]H>Z^,7@O4O@#9>.+>'7=9UJ\U;PM^S9)
MXST/X,WVKW37,TFG7-WI<CWUQ8-7]8U% '\P/Q)_:%^$?[-7Q,_;MT.ZU_Q_
MX<^'W[2?_!*O]CW2/V%]/U+3/B9JVN?$N[\(> /VS?#VIZ!X9E\30W$H^*.E
M6_B[X>7OB"WFE@U >'I='U+5B9K>[E3YX^)D'[04?P9^-&M?!^U\>6_Q9/\
MP05_X(RVVJ:AX?TKQA<^/;?P3_PTA^T--^TY'INE^#[W3/&%]XI@^"A\87!T
M_P *:EI_B>6\@-IH=]::L5N(_P"P6B@#\%O^"0?@[P'9_%;]H'QC\$_VD_V<
M/'_PDU+P+\---U3X"_LLZ!\4[/X6> OB9'XA\?7%[\3KC4?B?XV\6W]O\0O'
M>CE]*\>Z4GEZFVI:)!+K<POH)3=?O3110 4444 %%%% !1110 4444 %%%%
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MN[J>1DCAMK:".2:>61U2.)&=F502'6-[:ZC:07UC<VUY9W4:S6MW9SI<VUQ
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M_P @?YO5%?Z+OCG_ ()J?L 6?@[Q)<1?LB_ X/%IEQ-&?^$+M$"S)&5ADW1
M.#&Q#*%X)4;N,UU+?\$S/^"?I<2/^R/\$G<G!9O!=HQ):+R/FSG(,8VG=D8Y
M//-'_$T'"W_1,\0_^%&3_P#RT?\ Q O/O^AWD_\ X)S'_P"0/\WFBO\ 2%_X
M=D?\$^_^C0_@=_X1%A_\31_P[(_X)]_]&A_ [_PB+#_XFC_B:#A;_HF>(O\
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M[(_X)]_]&A_ [_PB+#_XFC_AV1_P3[_Z-#^!W_A$6'_Q-'_$T'"W_1,\1?\
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M444 %%%% !1110 4444 %%%% !1110!PGQ/_ .2>^,/^P%??^BZ[NN$^)_\
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M[VB@#@O^%@V/_0M>/?\ PB/$/_R%1_PL&Q_Z%KQ[_P"$1XA_^0J[VB@#@O\
MA8-C_P!"UX]_\(CQ#_\ (5'_  L&Q_Z%KQ[_ .$1XA_^0J[VB@#@O^%@V/\
MT+7CW_PB/$/_ ,A4?\+!L?\ H6O'O_A$>(?_ )"KO:* ."_X6#8_]"UX]_\
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M]=1"Y6XH _12Z\)_!/4OAMHWPAOO@>=0^%?AD>#(O#?PVO\ X-SR^#/#?_"
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MX.?#>VBM!&=*\&S_ +&W[(OQ?$-V4E1[R2;Q=\7/%%TS%HF82E%D[J ?3?\
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M^)J[N@#@O^%@V/\ T+7CW_PB/$/_ ,A4?\+!L?\ H6O'O_A$>(?_ )"KO:*
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M  L&Q_Z%KQ[_ .$1XA_^0J[VB@#@O^%@V/\ T+7CW_PB/$/_ ,A4?\+!L?\
MH6O'O_A$>(?_ )"KO:* ."_X6#8_]"UX]_\ "(\0_P#R%1_PL&Q_Z%KQ[_X1
M'B'_ .0J[VB@#@O^%@V/_0M>/?\ PB/$/_R%1_PL&Q_Z%KQ[_P"$1XA_^0J[
MVB@#@O\ A8-C_P!"UX]_\(CQ#_\ (5'_  L&Q_Z%KQ[_ .$1XA_^0J[VB@#@
MO^%@V7;PSX])[#_A"=?&3V&6LU49]68*.I('-<GIOC6TA\9^+;K_ (1KQP?M
M.D>$ 53P7K/FCRY/$<>YB(2T@ .>%!0 JH<FO::X31O^2@>.?^P-X)_GXFH
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M^D44 <%_PL&Q_P"A:\>_^$1XA_\ D*C_ (6#8_\ 0M>/?_"(\0__ "%7>T4
M<"?B#98./#7C[.#C'@G7\YQQC=9A<^FXA<]>*Y+QUXUMKCP1XE@7PWX\C,ND
MSQ;G\&ZO)(3,FTML,2AF7^/+#:2" <8KVNN&^)G_ "('BW_L"7G_ *!0 UO'
MMJIP?#/CO&6^9?!VLL/DVD\+;LV&W87Y<L58+R!EO_"P;'_H6O'O_A$>(?\
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M\+?B%K>O?##Q-;>'-"TKQKJ<S>>]Q<R7K7@:RBT_YU_X+2?MRZ;\6?%_P?\
M^"0/[8OCW1_@7\/-5\,?!KXL?\%*/VB?AS\%_COXE\!^(HM$UCP?\3=*^!O[
M-'ACP?I?Q3\<VB>(/$&CV,]SXS\:7K6^AZ?'87-TDDL6H6;@']D6B:SI?B/1
MM(\0Z'>PZEHNO:98:SH^HVQ8V^H:7JEK%?:?>P%E5C#=6D\,\1958I(I*@\5
MIUY5\%-=^'GB+X-_";7?A)/-<?"W7/AQX$U3X9S7&F:KHDUSX!O_  WIUSX1
MF.DZ_9Z1K=@9O#@M+DV>JZ?::C A(NK..16@'JM !1110!PGQ/\ ^2>^,/\
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MIT,EYE4\Q8$+O&HQFU\+_P!MK]D+XV_$K7/@Y\'OVEO@I\3OBIX;M]4N];\
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M_7?B]HUNVE:1;_'G2==DUGX;Z)XD-YI]EJ.FZ%IFOZEY$*?/GQ9_X)Z?M?\
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MS0ZC\9]0M/%0NK_P1HFE>(/#/@Z#PZNI:=-=7,.JQ7LTL<O[$T4 ?BO\<_\
M@F'XW^-OQP'[2?BS3/V%?BK\2/'OP0^'GP5^,OA/]I+]ECQ#\:OAC&_PNU_X
MH:]X=\<?";2]6^*]M?>&9M1D^(S:?X@\*:NVH6.L:98;+S53+<,D?UGX;_8P
MG\-_$#]K_P 5V7B[0='T?]I[]G_X$_ [0?#_ (7\'C1M'^&*_!SP#\5O! O-
M"T)M2O;"#P],OQ#M[W0O#27/V?2H--_LI[J<,MU/]ZT4 ?SP?&'_ ((J?$[X
MJ_#[PU\,;[XZ_!_5/#>D?LK?LG? +2=1^)'P<\7^/_$OP6\3_LSZ*UGJ_B_]
MG6X_X6OX>\.> 6^,=]%IW_"3WMWX7U2[TQ;.WNCINO/$]G/^O7[/G[/UY\$_
MB1^V)XUN/$D&MVO[3G[26E_'73M-M]/6S'A.UT_]FK]G;X#_ -@3NDC"YGDN
M/@L^L"<!%>'4HVV+(TH7ZEHH _+K]E7_ ()[:U^S9XR_9'\2S_%&Q\0P?LU_
MLM?M0_LYW=A#H*V1\6W7[0_QS^!_QH37(96D5[6W\/CX-1:<UJH669IA,HV3
M7)BS_P!G7_@F]=?!%OV/+35_B5'XHT7]F7]C;]IO]DW7[&QT9M)N/'&F?M"?
M$']G[QH=2MK^&ZAN=(30X/@G'91/"T5P)KF*>/:UQ.\'Z,>&?B3X0\8^*_B'
MX,\/:LUYXA^%.M:-X>\=:<VGZA;-I&J^(?#.C^,=&A2[NK>&SO8[OP_K5E=E
M[&2Z5//"2/ ZJ)>]_P ^G\J /P6^"/\ P1:\._#_ ."OC3]FOQEX<_8HOO N
MJ?LM?%C]E/1?CY\-OV1H/A_^UUJW@_XI> [WX;2:QXO^)\?Q O535-)\+W\]
MEJQTHRGQ?!&BW-QICW$LJ_1/C3]CW]M+XO\ [-5Q\'/B[^T+\ M2\>^ O'7[
M)WQ)^!7COPM\%?']CI-KXT_90^-W@SXXZ7JWQ:T75_C)J-UXBC^(VH?#_0_"
M?BJ#PQ>Z&EAI-YJ6H:=%+>M$J?H5<?&CX?V_QPTG]G>75G'Q3UGX4^(/C39:
M%]FEV-X \,^+_#/@?4]6:[($ >/Q'XLTBS2V#&4B224A452WJCJK*RN 592K
M \ J0003Q@$$T ?D+\6?^"<'Q.^*WC[XI?&FX^./@WPU\;/%VO?L'?%SP+J&
MG?#G6-0\!>%_C+^Q'J'Q,UA5U;POJ?CU]<U7X;_$:[^(*^']?LM(\2Z%XCM?
M"T^H6UOJJZG<)?T)_P $XOBQXR\3:S\7?C%\:_ &K_&GQO\ M6_L8_'SQA-\
M/?AKK7A;X>:/X _8P\4R:YX-^%O@G1O$?C3QGKMO-KUO<ZD^J>)-1U<RKJ&K
MW;+:-'#%(_W?XQ_:H^"'P]\<_$GX>^+?%-YI/B7X4_#WX2?%+QO;R:)KU[::
M;X1^.OC[Q_\ #/X;7L5Y:6=U!,^N>,_AEXJT@VT6U;(V\5Q,T=L]Q)!]"^9N
MVE=Y)95V&/R2?GCWN%G"NRHC9;;G@,JGS-H !^5'Q<_X)^^-O'%Q^V0;"\_9
MQ^(&A?M;_M,?#CXXZOX'_:(^$/B'Q[H'AW1OA_\ LL? OX!6$6B:CX<\;>&M
M2T'X@:'XG^#-CXZ\%^,=+4WWAB_-K=Z?<17B$Q]EXO\ V%/'?BG]A'X+?LO7
M'QVO]9^-_P"SUK/[.WQ+\!?'WQKHM_XEL]9^,O[-OQ$\)?%7P5KOC'PS>>)[
MKQ%J_@C5/$7A2#PYXAT-/&.G^(;CPI->65AXBLKG[/?#]+",@@ '((P>AXZ'
MV]?:O$_&G[1_P*^'GQ@^$WP \;_%#PAX:^,_QUM_%EW\(?ASJ^J1VOB7Q[;^
M!M,_M;Q5-H-FRGSX](T\^=.7>-I23%:K/,K1@ ^!/V@OV*OVM?VEM"^"ES\5
M?CG^SAX@U[X<>.?B#K'C#X8W'P*^)L_[.'Q#\/\ B[PG>^'?""^)/ASJ'Q_O
MKOQ%XF^%6J30^,_#5[K^H7=E?:F;BPFMK*W NY_+?A5_P3!_: _9TT#]E;_A
MGW]H+X/^%O&WP/\ V6_B1^R3XZUCQ1\#_$>N^%-;\!?$3XG^'OB;9^)/AWX,
MLOBMIMIX<USX?:GI<X\.:3XANM<TC5FCM[#5C'HTTUJOZI>)/VB/@AX.^-?P
MV_9Q\3?$OPQH_P <_B_H7BOQ1\-/AA>7S#Q7XP\/>";.?4?%>LZ18K&XDT_1
M+2WN)KN:66)0L,JPB0PR*GD7PC_X* _L;?';XB6_PG^%'Q_\#^+OB-J$GBN/
M1_"5M+J6GZMXA'@5Y(_&$WAN'5]/T]?$%MX<DBG35;C2'O(;802RES GFD ^
M!++_ ()6?%+3_AU_P3_^%5E\4_@5I,7[$_PO_9D\#67Q]\._!WQOH'[5=H_P
M,UKP/=?$'0?AC\3M-^+,6F>'/AK\=?#OA6]\&^-?!FN>&]7T-M#U^]AU/2=<
MML6:]/\  K_@E38_ OX[3^.;3PG^Q+XZ\%Q?'KXJ?'G1?'WC7]DY-2_; \/W
M_P 3?'/BKXC2^'-'^.UG\0=)LH6T'Q)XKOFT/Q'<^&YIK(I%>KI1FC@BM_O;
MX,?MJ?LN_M#^-]=^'GP7^,7ACXA>*_#VGZSK%U8Z"-1EM+[1_#OB%/"/B#6-
M!UF:RAT;Q'I>C>*9!X>U&]T._OX+;4U,3.4:.5N]^#O[0_P2_:!/Q*7X+_$O
MPK\1V^#WQ.\3?!GXF#PQJ*7Y\'?$[P>+,^)/"&L!0OE:GI8O[7S3'YEK+YA^
MSW$WER[ #\N/V:_^"9G[0?P6\7?L+Z-XH_:7^'_BOX ?\$]M9^(\'P0\'^'?
MA)KOA_QYXN\%>-/@%X\^"/AZS^)7B[4?B+KNDSZMX-LO'-S<V+Z/H M;Z*UB
M>[=IV.SZ"_:,_96_:EU[]J,?M2?LO_'SX2?##Q->?LR7/[--SX8^*GPB\0?$
M.QV7/Q"OO'T'CK2+W2/B5X3M+;7= EN?.TVQU/P]X@TVX>Q\O5;'4=/EN+%_
MTKHH _GC^*7_  3 ;PK\:?\ @D)\$?A>WC_5O@U\!?A?%\'_ -I/QB?#:76C
M^./@W^R[K'PD^/GP(\,?$+Q*WFIHMOJG[0OPUT>?1O"MG=W'VNRU?7K(JNG6
M9FN?Z$HXT@\N*,(D<>Q8XH\0PV\ C\F**.)0%*C:%10H .0NP*BU:HH 0]#]
M#TZU%@$,&^?/'..0<Y&.AXXQSGMP:FIC?</U/_H514ERPGHG[CNFMTVDT^MF
MF[I.SZH.R[RCTU33NFGO=>31_%%_P5._;_\ VQO@3_P4#_:(^'7PC^/7BOP'
MX0TJZ^&DEAH6@6]N]I ]U\)_!^I2DK,IB5II9I'F<@!V=V<X)Q\"_P##V?\
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M9N)/^B@SO_P[9C_\UGZ+?\/9_P#@HW_T=;\1/_ /0_\ XFC_ (>S_P#!1O\
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MFXD_Z*#._P#P[9C_ /-9^BW_  ]G_P""C?\ T=;\1/\ P#T/_P")H_X>S_\
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M ,31_P /9_\ @HW_ -'6_$3_ , ]#_\ B:_.FBC_ %,X/_Z)3AK_ ,,.3_\
MSN#_ %FXD_Z*#.__  [9C_\ -9^BW_#V?_@HW_T=;\1/_ /0_P#XFC_A[/\
M\%&_^CK?B)_X!Z'_ /$U^=-%'^IG!_\ T2G#7_AAR?\ ^=P?ZS<2?]%!G?\
MX=LQ_P#FL_1;_A[/_P %&_\ HZWXB?\ @'H?_P 31_P]G_X*-_\ 1UOQ$_\
M /0__B:_.FBC_4S@_P#Z)3AK_P ,.3__ #N#_6;B3_HH,[_\.V8__-9^BI_X
M*S_\%',''[5WQ"!P<%K/0]H/8M\OW0>3[55B_P""K_\ P40BN;N[@_:M^("S
MZ@8?-8Q:,Z,+<;<1QL"JL%RB8 P#A<*2*_/2BC_4S@__ *)3AK_PPY/_ /.X
M/]9N)/\ HH,[_P##MF/_ ,UGZ*G_ (*R_P#!1MP4_P"&L/B$F\%=[V6B,J;N
M-S*J%BJYR0H+$ @ G%?"VO?$#QCXI\<ZW\4=7\2:Q=_$3Q/XJO?'^I>-(_\
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M &_XX_Z)\O\ X5NE?_(U']O^./\ HGR_^%;I7_R-0!WE%<'_ &_XX_Z)\O\
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M .%;I7_R-1_;_CC_ *)\O_A6Z5_\C4 ?S1?%;XF>-+OXO?M!1S?&O]HW1_\
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MJ_\ G8>#?\,&?L.?]&9_LH?^(\?!_P#^9"C_ (8,_8<_Z,S_ &4/_$>/@_\
M_,A7O/\ ;_CC_HGR_P#A6Z5_\C4?V_XX_P"B?+_X5NE?_(U']O\ $'_0_P ]
M_P##[GO_ ,_0_L7*/^A5E?\ X:LJ_P#G8>#?\,&?L.?]&9_LH?\ B/'P?_\
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M .1J/[?\<?\ 1/E_\*W2O_D:C^W^(/\ H?Y[_P"'W/?_ )^A_8N4?]"K*_\
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M(/\ H?Y[_P"'W/?_ )^A_8N4?]"K*_\ PU95_P#.P\&_X8,_8<_Z,S_90_\
M$>/@_P#_ #(4?\,&?L.?]&9_LH?^(\?!_P#^9"O>?[?\<?\ 1/E_\*W2O_D:
MC^W_ !Q_T3Y?_"MTK_Y&H_M_B#_H?Y[_ .'W/?\ Y^A_8N4?]"K*_P#PU95_
M\[#P<?L&_L.@@C]C/]E$$$$$?L\?" $$<@@CPAD$'D$=*Y/3/V'?V)IO&OC&
MU;]CS]E1HX=&\' Q_P##/GPDYW'Q-M$@/AV96"H2L>+2S"H67_2 3(/J3^W_
M !QW^'PQ[>+-))_ &W SZ9('N*Y/3=:\6KXR\631^!]]S+H_A$3V_P#PE6D_
MN=LGB01Y/ED+N4[C\HW<E=V*/[?X@_Z'^?:_]3W/?_GZ']BY1_T*LK_\-65?
M_.P\Q;]@W]A[:VS]C3]E)7VG:R_L]?")&5L?*5=/"*NK X(9&5E."I! -?S"
M_LY?\$AKG]JC]NG]J'QQXZ\-1?#G]D/P#^U;\>="T?1M%TO2O#T7Q L_#7Q@
M\>6$7@#P?9Z= HTSP;;RF[@\2W,$-O')$\T%KY4LD87^O4:_XW)&?A^H&1D_
M\)9I1P.YQ]F&<>F1FD77/&:)B/X>A &;Y!XIT=02S%BPV0E<,Q+.20V2QPQZ
M_4<-^)/%7#%#/XX',\=6Q>>990RN&-QV8YCC:F5TH8WZW7Q& I8W'XVE2QE>
MGS86.(BH3HTYRE'G?*EX.=<#Y%G>(R>IB<)A:6&RO%XC&5,)AL#@L/',)5<*
ML/2HXF=#"X=O#T:B5>5/EFZDHQCS4U=O1\*^&?#W@?P]H7@[PEHFG^'?"OAK
M3K'1M T32[>.WL-,TZT1(+2RM;6$D!88D#R2G)R6FD:1C+(.KK@_[?\ ''_1
M/E_\*W2O_D:C^W_''_1/E_\ "MTK_P"1J^"E*<YSJ5)RG.I*4YRE*4I2E*4Y
MRG*4Y2E*I.4Y2J3<GS2;=EL?7PC&$8PA&,(0C"$(07+"$80C!1C&]HQ2C%**
MLDE;4[RBN#_M_P <?]$^7_PK=*_^1J/[?\<?]$^7_P *W2O_ )&I%'>45P?]
MO^./^B?+_P"%;I7_ ,C4?V_XX_Z)\O\ X5NE?_(U '>45P?]O^./^B?+_P"%
M;I7_ ,C4?V_XX_Z)\O\ X5NE?_(U '>45P?]O^./^B?+_P"%;I7_ ,C4?V_X
MX_Z)\O\ X5NE?_(U '>5PWQ,_P"1 \6_]@2\_P#0*:-?\<9&?A^H&1D_\)9I
M1P.YQ]FYQZ5R'CS7/&4O@GQ0MSX%2TC;2IT:0^*]*?;'(I620 0H&,8P5A+#
MSR1$.6P0#VJBN%;7_&H\S9X +;9-L>[Q5I"&6/*?O>(GV8W.=C'=\G^T*;_;
M_CC_ *)\O_A6Z5_\C4 =Y17!_P!O^./^B?+_ .%;I7_R-1_;_CC_ *)\O_A6
MZ5_\C4 =Y17!_P!O^./^B?+_ .%;I7_R-1_;_CC_ *)\O_A6Z5_\C4 =Y17!
M_P!O^./^B?+_ .%;I7_R-1_;_CC_ *)\O_A6Z5_\C4 =Y17!_P!O^./^B?+_
M .%;I7_R-1_;_CC_ *)\O_A6Z5_\C4 =Y17!_P!O^./^B?+_ .%;I7_R-1_;
M_CC_ *)\O_A6Z5_\C4 =Y17!_P!O^./^B?+_ .%;I7_R-2C7_'&1GX?J!GD_
M\)9I1P/7'V:@ T;_ )*!XY_[ W@G^?B:N[KQ/2M;\7#QQXP>/P1&]P^B>#S<
M0#Q7I9: J_B;R0V(6P9E^92508&3G&:[#^W_ !Q_T3Y?_"MTK_Y&H [RBN#_
M +?\<?\ 1/E_\*W2O_D:C^W_ !Q_T3Y?_"MTK_Y&H [RBN#_ +?\<?\ 1/E_
M\*W2O_D:C^W_ !Q_T3Y?_"MTK_Y&H [RBN#_ +?\<?\ 1/E_\*W2O_D:C^W_
M !Q_T3Y?_"MTK_Y&H [RBN#_ +?\<?\ 1/E_\*W2O_D:C^W_ !Q_T3Y?_"MT
MK_Y&H [RBN#_ +?\<?\ 1/E_\*W2O_D:C^W_ !Q_T3Y?_"MTK_Y&H [RBN#_
M +?\<?\ 1/E_\*W2O_D:E&O^.,C/P_4#(R?^$LTHX'<X^S<X]* #XG_\D]\8
M?]@*^_\ 1==W7B7C_7/&4W@;Q6ESX%2TC?1[F-I#XMTKY8Y$99) P@4 Q@@K
M&S#SB0@ZD'M)->\:@R>7X!#A)%6,MXJTJ,RH2FZ0 0/LVAG.QCN/EX'WA0!W
M-%<'_;_CC_HGR_\ A6Z5_P#(U']O^./^B?+_ .%;I7_R-0!WE%<'_;_CC_HG
MR_\ A6Z5_P#(U']O^./^B?+_ .%;I7_R-0!WE%<'_;_CC_HGR_\ A6Z5_P#(
MU']O^./^B?+_ .%;I7_R-0!WE%<'_;_CC_HGR_\ A6Z5_P#(U']O^./^B?+_
M .%;I7_R-0!WE%<'_;_CC_HGR_\ A6Z5_P#(U']O^./^B?+_ .%;I7_R-0!W
ME%<'_;_CC_HGR_\ A6Z5_P#(U']O^./^B?+_ .%;I7_R-0!WE<)HW_)0/'/_
M &!O!/\ /Q-0-?\ '&1GX?J!GD_\)9I1P/7'V:N.TK6_%P\<>,'C\$1O</HG
M@\W$ \5Z66@*OXF\D-B%L&9?F4E4&!DYQF@#VRBN#_M_QQ_T3Y?_  K=*_\
MD:C^W_''_1/E_P#"MTK_ .1J .\HK@_[?\<?]$^7_P *W2O_ )&H_M_QQ_T3
MY?\ PK=*_P#D:@#O**X/^W_''_1/E_\ "MTK_P"1J/[?\<?]$^7_ ,*W2O\
MY&H [RBN#_M_QQ_T3Y?_  K=*_\ D:C^W_''_1/E_P#"MTK_ .1J .\HK@_[
M?\<?]$^7_P *W2O_ )&H_M_QQ_T3Y?\ PK=*_P#D:@#O**X/^W_''_1/E_\
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MSSWS:9J;6)@G /VXHKXR_8V^.?[3GQO\&^)-9_:=_9'LOV4-:L=4TT^"]/\
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M\,^(-<T;XN_'#3_A)\)O!L6K?8;C7KKQS\;=>\'7:>'?#'A/3KB\OM=\21^
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M\:/^%G?$C_HHGCS_ ,*[5O\ &C_B5K%?]%KAO_#!B_\ YXA_Q'G#?]$U6_\
M#M0_^8C_ %-J*_RR?^%G?$C_ **)X\_\*[5O\:/^%G?$C_HHGCS_ ,*[5O\
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M/4]?7MCCD8_EZBI*_$D[WT:LVM>MNJ_NOH^JULC]1_X 4444P"BBB@ HHHH
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M0/#_ ,//V<_@S\0_#7QU^%W[,7@']DC7?'^F?%CXA_"?X'^$?#GQ&O\ X?\
M[2FE:O\ "CQ]?: / OC;P;XQUVPCN_'D.D>)[BY\/W]RKKY(!^^7B/XN?"GP
M=%X1G\6_$WX?>%[?Q_?V&E^!9_$7C+P[HL'C34]5-NNE:=X4FU+4;:/Q#?:F
MUW:)I]II+7<]Z]U;);)*T\0?S:R_:8^'VG6GQ(U3XKZEX:^"/A[P)\6+CX3Z
M=XD^)7Q$^'>F:%XVOSH/AS6],U#1-0A\33V]I-K2^(H[.R\,ZN]GXF\^U=9=
M+5Y5B7\+?&W[(/Q+^#OPZ_8YE_9&^ O[67C3XW?"?X5^(O!7@6S_ &D/"'['
M?BGX4ZMX%^)'QH\._%'Q1\)OVN+'1/&/A;3/AM#H=S9P7?A[Q%\&-)?7_"6C
MJ]KH%KK&MZ5'I;R?'/\ 98^/^E:S^T7\1/"/P+^./BCXWQ?MO_M3?&?]EC5/
M!O@W]FSXB_"O7=(^)G[.?P"^'$/AWX\>&OC?XGM[K3OAE\3-=\)ZOX=O->\*
MQ67B30=!LM1U6"[L;@V>P _<+PU^U[^SEXR^/'Q-_9LT+XK>#[OXQ?"#P_X0
M\3>-?"?]OZ5%?V6E>,M-UW7=.:T#7JO>FSTCPW=ZGKB0*RZ98M%+>%8UG:'T
MCPQ\;_@OXW\/Z]XL\%_%WX8>+O"OA6^N-+\3^)O"_C[PIK_A_P .:G:-LNM.
MU[6-*U:[T_2+^W8[9[2_N+>>)N)(U) /XW#X,_M!> OVA?VYOB/H_P"Q=X-^
M)'Q(_:+_ &!O@M:?"[Q#=>&OA!<_ M?V@_A?\(OV@M&\;_ 7XD76H_$"U\5V
M7A?Q[XUU[PIX9O[:PM;OPA?Z!J_EZGK*1?;]4F^&[S]C?]L/XE?#'_@IV-0^
M /Q(TV7]HG]@O]F#X2>'?#GCWP1^R[\,_P#A-OC'\/OB)\=;WQOX?\)_#;X!
M:QJVAMX,T/1/&-C#H&M^/I1XBO=-NQ:BYNH'BNI #^G[0OBY\)_%.A>*?$WA
MCXF> ->\.>"+C4[#QGXBT/Q?X<U/1/"=UHEF;_5[;Q%J]K?S:;HTFCV3&\U!
M-2GMQ8P!YKH11+(1E2_'GX&P_#F3XPM\8_A9_P *I V?\+*/Q!\+'X?F19#;
MK;KXM757T#SWN#]F%O%>-.]R1 (GG*QG\-OVN_\ @G_X_'Q@_:7O/V>?V>=%
MN_@5J_PT_P""2GBS6_@SX.@\'>%?#?[2%K^R3^V5\??B1^T)\&CI6K3:3X9U
M?Q;K7P$'@;PYHNG^++_2?#FMS:GI.F:WJ<4%Y<SG5_:?^ WQ-^+<_P"R%\:/
MA)^R%\<OV?O 'PI^-GQZ\1?$[X(?#[X??L':K\<-6U+XF?!BR\'^$?CP?AEX
M]UGXC_LZ:Q-I&H1WOA#69[O6KOXJ0^'-0EGTY5=H@H!^_P!I&J:9K>FV>KZ+
MJ5CK.D:E;PWNF:KIEY::AIFH65P@D@N=/OK%Y;:[M)(R&AGB=XY5(9)'4AJT
MJ^*_^">_P8T[X ?LI^ /ACI-C\<-(T^PUKXE>)K70_VBQ\)X?BWHJ^/_ (G^
M,/'4^G>(K#X(6MG\,=*MHKWQ#=OHND^%[:.TTW2)+2S=5G@E1?M2@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /0
M_2HS@$;@>%.[//MT&2<\C'/4<5)12>J:6C::[K6VZZ[;":O;R:?GI?9]-S^
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M'_"L?B1_T3SQX/?_ (1'5N/?IVK_ %-J*/\ B:7%?]$5AO\ P_XO_P"=P?\
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M:7%?]$5AO_#_ (O_ .=P?\0&PW_12UO_  TT/_FT_P LG_A6/Q(_Z)WX\_\
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M-5U62VNM?\4:E&)M"\'Z+->P6MUK^JVY(%U8:3%,;VYM%R]U%";>-6>55/\
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M110 5PWQ,_Y$#Q;_ -@2\_\ 0*[FN&^)G_(@>+?^P)>?^@4 =S1110 4444
M%%%% !1110 4444 %%%% !1110!PFC?\E \<_P#8&\$_S\35W=<)HW_)0/'/
M_8&\$_S\35W= !1110 4444 %%%% !1110 4444 %%%% '"?$_\ Y)[XP_[
M5]_Z+KNZX3XG_P#)/?&'_8"OO_1==W0 4444 %%%% !1110 4444 %%%% !1
M110 5PFC?\E \<_]@;P3_/Q-7=UPFC?\E \<_P#8&\$_S\34 =W1110 4444
M %%%% !1110 4444 %%%% !7#?$S_D0/%O\ V!+S_P! KN:X;XF?\B!XM_[
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M^+O_ ,^>C_B(K_;8_P"B7?LK_P#A&_%W_P"?/7X%T @$$[  <DR?ZL ==_\
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M'?VT-:TB_P!+;X4_LOE=0LKFRG_XHOXM<)<PR0.8\_&8;'"NVUR3M;!K1?\
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MW[*__A&_%W_Y\]'_ !$5_ML?]$N_97_\(WXN_P#SYZ_ NBCECV7]?,#]]/\
MB(K_ &V/^B7?LK_^$;\7?_GST?\ $17^VQ_T2[]E?_PC?B[_ //GK\"Z*.6/
M9?U\P/WT_P"(BO\ ;8_Z)=^RO_X1OQ=_^?/1_P 1%?[;'_1+OV5__"-^+O\
M\^>OP+HHY8]E_7S _?3_ (B*_P!MC_HEW[*__A&_%W_Y\]'_ !$5_ML?]$N_
M97_\(WXN_P#SYZ_ NBCECV7]?,#]]/\ B(K_ &V/^B7?LK_^$;\7?_GST?\
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M$!O"?Q8<"6QN$G0J%^,BG!* XR22!SWK\(:*.5=D!^^G_$17^VQ_T2[]E?\
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M^(BO]MC_ *)=^RO_ .$;\7?_ )\]?@711RQ[+^OF!^^G_$17^VQ_T2[]E?\
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M^(BO]MC_ *)=^RO_ .$;\7?_ )\]?@711RQ[+^OF!^^G_$17^VQ_T2[]E?\
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M^(BO]MC_ *)=^RO_ .$;\7?_ )\]?@711RQ[+^OF!^^G_$17^VQ_T2[]E?\
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M/^(BO]MC_HEW[*__ (1OQ=_^?/7X%T4<L>R_KY@?OI_Q$5_ML?\ 1+OV5_\
MPC?B[_\ /GH_XB*_VV/^B7?LK_\ A&_%W_Y\]?@711RQ[+^OF!^^G_$17^VQ
M_P!$N_97_P#"-^+O_P ^>C_B(K_;8_Z)=^RO_P"$;\7?_GSU^!=%'+'LOZ^8
M'[Z?\1%?[;'_ $2[]E?_ ,(WXN__ #YZ/^(BO]MC_HEW[*__ (1OQ=_^?/7X
M%T4<L>R_KY@?OI_Q$5_ML?\ 1+OV5_\ PC?B[_\ /GH_XB*_VV/^B7?LK_\
MA&_%W_Y\]?@711RQ[+^OF!^^G_$17^VQ_P!$N_97_P#"-^+O_P ^>FO_ ,'%
M?[;&UO\ BUO[*[?*WR_\(9\7#G@\8/QGP<],'KTK\#:*.6/9?U\P/WDU;_@X
M<_;/UO2+_2I/A3^R^4U&RN;&XSX+^+7RQW4,EO(8\_&8;'"NVUR3M.#6H/\
M@XL_;2<OL^%O[+,:EY8X1/X5^*XD<P0^9(=J_&/YB6!"*"">!N)YK\!Z*.6/
M9?U\P/WT_P"(BO\ ;8_Z)=^RO_X1OQ=_^?/1_P 1%?[;'_1+OV5__"-^+O\
M\^>OP+HHY8]E_7S _?3_ (B*_P!MC_HEW[*__A&_%W_Y\]'_ !$5_ML?]$N_
M97_\(WXN_P#SYZ_ NBCECV7]?,#]]/\ B(K_ &V/^B7?LK_^$;\7?_GST?\
M$17^VQ_T2[]E?_PC?B[_ //GK\"Z*.6/9?U\P/WT_P"(BO\ ;8_Z)=^RO_X1
MOQ=_^?/1_P 1%?[;'_1+OV5__"-^+O\ \^>OP+HHY8]E_7S _?3_ (B*_P!M
MC_HEW[*__A&_%W_Y\]'_ !$5_ML?]$N_97_\(WXN_P#SYZ_ NBCECV7]?,#]
M]/\ B(K_ &V/^B7?LK_^$;\7?_GST?\ $17^VQ_T2[]E?_PC?B[_ //GK\"Z
M*.6/9?U\P/WU'_!Q7^VOD9^%O[*Y&1D#P=\7 2/0$_&8@?4C ZFLNU_X.&_V
MS+;4]7UA/A9^RUG6+?2DC_XI3XKEM]F9+=?, ^,GS@+,_P J!3D+\PP0?P>H
MHY5V7]?,#]]/^(BO]MC_ *)=^RO_ .$;\7?_ )\]'_$17^VQ_P!$N_97_P#"
M-^+O_P ^>OP+HHY8]E_7S _?3_B(K_;8_P"B7?LK_P#A&_%W_P"?/1_Q$5_M
ML?\ 1+OV5_\ PC?B[_\ /GK\"Z*.6/9?U\P/WT_XB*_VV/\ HEW[*_\ X1OQ
M=_\ GST?\1%?[;'_ $2[]E?_ ,(WXN__ #YZ_ NBCECV7]?,#]]/^(BO]MC_
M *)=^RO_ .$;\7?_ )\]'_$17^VQ_P!$N_97_P#"-^+O_P ^>OP+HHY8]E_7
MS _?3_B(K_;8_P"B7?LK_P#A&_%W_P"?/1_Q$5_ML?\ 1+OV5_\ PC?B[_\
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M/^B7?LK_ /A&_%W_ .?/7X%T4<L>R_KY@?OI_P 1%?[;'_1+OV5__"-^+O\
M\^>C_B(K_;8_Z)=^RO\ ^$;\7?\ Y\]?@711RQ[+^OF!^^G_ !$5_ML?]$N_
M97_\(WXN_P#SYZ/^(BO]MC_HEW[*_P#X1OQ=_P#GSU^!=%'+'LOZ^8'[Z?\
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MZ^8'[Z?\1%?[;'_1+OV5_P#PC?B[_P#/GH_XB*_VV/\ HEW[*_\ X1OQ=_\
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M_P"(BO\ ;8_Z)=^RO_X1OQ=_^?/7X%T4<L>R_KY@?OI_Q$5_ML?]$N_97_\
M"-^+O_SYZ/\ B(K_ &V/^B7?LK_^$;\7?_GSU^!=%'+'LOZ^8'[Z?\1%?[;'
M_1+OV5__  C?B[_\^>C_ (B*_P!MC_HEW[*__A&_%W_Y\]?@711RQ[+^OF!^
M^G_$17^VQ_T2[]E?_P (WXN__/GH_P"(BO\ ;8_Z)=^RO_X1OQ=_^?/7X%T4
M<L>R_KY@?OD__!Q7^VQM;_BUO[*[?*WR_P#"&?%PYX/&#\9\'/3!Z]*N6/\
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M:\*>"_$/BKQS!I$4>IV4_B/PCX:DT"WFM3+J,!NY7M9#*L*C]]_^' G['?\
MSTUS_P #?%G_ ,W5'_#@3]CO_GIKG_@;XL_^;JCFCW_!@?SH>-?V\O"'C7XD
M>!/'5W\)_C5#;^$-;\5:]):R_ML?&?4O$.E^*?$UL^[5OAAXJNO]%\ QV-XX
MNM&\.W/[BUN(K:.;]VC5\Q_M9?M'ZM^U=\<_$?QQU3PSI'A2[\3Z3X6TLZ-8
M3:AKUS;V?@_PSH.B6NHZSXIU']]XHU^X3;)J5\GS3S%V7YB*_K+_ .' G['?
M_/37/_ WQ9_\W5'_  X$_8[_ .>FN?\ @;XL_P#FZHYX]_P8'\SG[*/[:'@'
M]E.#PSXT\-?LTZ!XA_:+\!6GBK3O"OQLN/BUX_\ #]F]IXJLYK-9/%GPRL/^
M)'K!TZ65)8H=0:.QO(HS;W$D44K2)W2?\%(-:U7X#>$?A#XX\'^.[[Q%X#^'
MGB;X9^%/'?P__:"^(WP@\-7.A:P-4O;/5?'_ ,+?#0&@^,I?"^K:A#/HVGZL
M6T[5H+&#3;T_9)6 _HI_X<"?L=_\]-<_\#?%G_S=4J_\$!?V.@P)DUW ()VW
MWBL-C/.TMXX=0<="R. >2K#@G-'O^# _FHTK]O;6M$^/G['7QV7X8V:WO[('
MP4\"_!C2_"B^)=22S\6)X%7Q?)/JFK:G.KPV$EU_PE1,][*C16JNT\BLD9%=
MKHW_  4BUP? SPI\%O%O@+QW?:A\-M.\=>&OAYXO^&_[0_Q,^"MM%IGC+6+[
MQ#%;_$7P3X=_T3XA2>'KZ\1M(DE_=ZFENEN_R3&OZ"O$O_!!G]C/1-!U34Q-
MXEC%C9W5V1)J?B5ED,%O),(\1^)V;YO+VCY2.>2*W9/^"!/[&=ROF*?$L9D:
M.<8U/Q)L+^4JG<O_  E4;E'/S%0T;@'&5;D'-'>_ELP/YC-=_;9L+O\ 8[N?
MV3?"'PPU+PYHGB:Z^&^J^(M6USXM>-OB7H%GK/@6>?4I-:^%O@36OE^#X\32
MC[%XJ:7$7B#?*T@VL37PA7]KG_#@3]CO_GIKG_@;XL_^;JC_ (<"?L=_\]-<
M_P# WQ9_\W5'/'O^#_R _BCHK^US_AP)^QW_ ,]-<_\  WQ9_P#-U1_PX$_8
M[_YZ:Y_X&^+/_FZHYX]_P8'\4=%?VN?\.!/V._\ GIKG_@;XL_\ FZH_X<"?
ML=_\]-<_\#?%G_S=4<\>_P"# _BCHK^US_AP)^QW_P ]-<_\#?%G_P W5'_#
M@3]CO_GIKG_@;XL_^;JCGCW_  8'\4=%?VN?\.!/V._^>FN?^!OBS_YNJ/\
MAP)^QW_STUS_ ,#?%G_S=4<\>_X,#^*.BO[7/^' G['?_/37/_ WQ9_\W5'_
M  X$_8[_ .>FN?\ @;XL_P#FZHYX]_P8'\4=%?VN?\.!/V._^>FN?^!OBS_Y
MNJ/^' G['?\ STUS_P #?%G_ ,W5'/'O^# _BCHK^US_ (<"?L=_\]-<_P#
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MY_X&^+/_ )NJ/^' G['?_/37/_ WQ9_\W5'/'O\ @P/XHZ*_M<_X<"?L=_\
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M$P%A:W-Z4;4_$K><;>%YA"!'XG9MTGE[%^4C)Y(HYHO2_P"# _BXHK^U\?\
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MC^&DWQ,\977B/1?@)X[_ &!/CE\05\4^!/#4,@#>$/"7B?\ 9<MH/BLMLJK
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M4/B%X/\ "6L67COPA>>";VRU^Q:&XBN[:YM)[:&P6UE@?]/J "BBB@ HHHH
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MP^)NJ:39^ GNK:W>"PNMFH)J%QB47M<_X*]?$V;X.?LB?$>V^'7PB^ FF?M
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M9=AGE/U;!9AB<-1]KEWM*G)2J.*<Y_6H<S>CV^;Z?W1_\1"O_!/?_GI\<_\
MPULG_P OZ/\ B(5_X)[_ //3XY_^&MD_^7]?PN45]#_Q+=X;=N(__#Y_^##R
MO^(T\:]\F_\ #7_]^']T?_$0K_P3W_YZ?'/_ ,-;)_\ +^C_ (B%?^">_P#S
MT^.?_AK9/_E_7\+E%'_$MWAMVXC_ /#Y_P#@P/\ B-/&O?)O_#7_ /?A_='_
M ,1"O_!/?_GI\<__  ULG_R_H_XB%?\ @GO_ ,]/CG_X:V3_ .7]?PN44?\
M$MWAMVXC_P##Y_\ @P/^(T\:]\F_\-?_ -^']T?_ !$*_P#!/?\ YZ?'/_PU
MLG_R_H_XB%?^">__ #T^.?\ X:V3_P"7]?PN44?\2W>&W;B/_P /G_X,#_B-
M/&O?)O\ PU__ 'X?W1_\1"O_  3W_P">GQS_ /#6R?\ R_H_XB%?^">__/3X
MY_\ AK9/_E_7\+E%'_$MWAMVXC_\/G_X,#_B-/&O?)O_  U__?A_='_Q$*_\
M$]_^>GQS_P##6R?_ "_I#_P<+?\ !/@ GS/CGP">?A;(!^?]O\?6OX7:*/\
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M_P"[I_='_P 1"O\ P3W_ .>GQS_\-;)_\OZ/^(A7_@GO_P ]/CG_ .&MD_\
ME_7\+E%'_$MWAMVXC_\ #Y_^# _XC3QKWR;_ ,-?_P!^']T?_$0K_P $]_\
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M^(T\:]\F_P##7_\ ?A_=&/\ @X5_X)[Y_P!9\<A[GX6R #W)_M_IZUS6G?\
M!P'^P%;^)?$NIRM\<TM+^TT18'/PRC9)6M5G@ 1(]52XW,9\_OKJ9?O!0@VJ
MO\0-%'_$M_AMKIQ'K_U/-O3_ (3 _P"(T\:=?['_ /#9;_W=/[H_^(A7_@GO
M_P ]/CG_ .&MD_\ E_1_Q$*_\$]_^>GQS_\ #6R?_+^OX7**/^);O#;MQ'_X
M?/\ \&!_Q&GC3I_8_P#X;+_^[I_='_Q$*_\ !/?_ )Z?'/\ \-9(?T_X2 9I
M%_X.$O\ @GR[(HD^..68*/\ BU4@SN8#G&O$_@ 3Z"OX7:*7_$MWAO>33XDB
MW%*+6>;-3YFW_P )FJ<;QMI9^]?2P?\ $:>,VFFLE=[.+>6:QDG=-?[;9^GX
MG]67_!2O_@L5^QS^U;^Q3\9O@3\,+?XJZAXS\<#X>'1[#7? $NEZ7/'X?^*7
MP^\73MJ=X]_=+;V$MMIC6][)M_<P2R3!@4Q7G7_!'G_@L*W@27PU^RQ^U3XN
MFOO TYL])^$_QH\0-#:Q>&+JYNHK&Q\">-[Z5HXK2W,\\-IHUY,VRWA5!*Z0
M;F3^9*@*SD(J2RLQVK%#_KI&;@)%_P!-7)VQ_P"T17T5+P5X&I<*9EPC&AC?
MJ.,Q4LSPV,Q6)^N8[ 9M[!86ABL+5>&I--4U&-6DH*$X<\ISU<3Q9>)G$\L^
MPW$DJN&6+PU!86I0H4/J^%Q>%=55:M#%1]K6O&33=.:=XSY8I-VD?ZL,,UM>
M)!<6TL4\4JP30W,$N8IK>5%FBFMYH2RSPS#RV&'\J1&R2ZE0U^OYP_\ @W__
M &E_VF_BS\-?%'PV^)^@ZCXH^#7PUM[&Q^&GQEU*2"WDD<.D$G@<QLHFOCIR
M.!"RL6MHT*YV/MK^CROX-XNX8Q7!W$69\.XS$X/%ULOJQ7UC!5Z->G5I58N=
M&514FW1KNFH^VHU;3C.]KQM)_P!:<-YY0XCR;!9QAL/B,)3Q=/F=#$TW"K3J
M1M&JE?XZ7M.9T9I13IVT70HHHKYL]P**** "N&^)G_(@>+?^P)>?^@5W-<-\
M3/\ D0/%O_8$O/\ T"@#N:*** "BBB@ HHHH **** "BBB@ HHHH **** .$
MT;_DH'CG_L#>"?Y^)J[NN$T;_DH'CG_L#>"?Y^)J[N@ HHHH **** "BBB@
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
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M&OAT^'K?X!V7P8LO".L>$=:O[273M'^&&GZA;":=['4(W8I+^C-% 'Y9R_\
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M[@/_ *%^._\ #OCC^-W_ (AI_P!H7_HXOX,_^"+XC4?\0T_[0O\ T<7\&?\
MP1?$:O[(J*/^)@?%+_H<Y;_XC^6__+ _X@]P'_T+\=_X=\<?QN_\0T_[0O\
MT<7\&?\ P1?$:C_B&G_:%_Z.+^#/_@B^(U?V144?\3 ^*7_0YRW_ ,1_+?\
MY8'_ !![@/\ Z%^._P##OCC^-W_B&G_:%_Z.+^#/_@B^(U'_ !#3_M"_]'%_
M!G_P1?$:O[(J*/\ B8'Q2_Z'.6_^(_EO_P L#_B#W ?_ $+\=_X=\<?QN_\
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MZ%OVC/@R%W+N*:)\0]^,C.S=N7=C[NX%<XR",BO['ST.>F#FF$[CMZ @$G\
M?;''?FA?2"\4E))9QEK;3YO^$#+?@_\ !FW,T4O"#@:*ERY?C;2C:=\VQS]V
M^OHC^$O]KK_@AW\8?V/?V=?'O[0OBKXV?"_Q=H_P\'AD77A[0]'\86FH7Y\7
M^,_!7@$?9I;^*. W'E:L IF B$CJSYC#D>-?\$Q_^"9GCO\ ;Q\>QZ_KRW7A
M3]G7PCJ-G'XY\<AT67Q3>PWEO)-X,\%ACF.6\LR]IJ%V59+03"5@[&..7^X'
M]K[]FKP_^US\ ?%_[/WBG5[W0_#7CO6/AU+XBU#3"$U)]#\'_$WP?X[U/3K&
M8@BVNM8LO#-QH]O=X8V<M^MV$8Q;6]/^%WPJ\"?!+P%X5^%_PU\/6/A;P1X/
MTVWTO0M'TZ-8(+:.,%))[F1-K75W>/(TMQ-*C2W5U)+-(S%QY?T=/Z1'%7^I
M^.P.(JX?$\78W&3HT,RI8##8+#Y;E,L*HSKNGAZC5?'.O*:H<W*X4HW;<4HR
M\)^#N2?ZR4,51IU:.0X;#1J5,'+%UZ];'8V-52ITO:57>GAE2BG4A%24Y]GJ
MI?A;\-/ ?P7\"^%OA;\,_#NG^%O!?@_3+?2="T+3(4C@L;*!3F64@ O/<S;Y
M9YW)EN+F5Y'R2[+Z140&#G R2 P].00?J3SQ_P#6$M?SM.I6KU:U?$5:M?$5
MZLZU>O7J.I6K5:DG.I5G)MOWY2E**;ORO5M[?LU&G3HTJ=*C&%.E3A&G2I4X
M\D*5."48TXP5[<J23UU:O9!1114FH4444 %<-\3/^1 \6_\ 8$O/_0*[FN&^
M)G_(@>+?^P)>?^@4 =S1110 4444 %%%% !1110 4444 %%%% !1110!PFC?
M\E \<_\ 8&\$_P _$U=W7":-_P E \<_]@;P3_/Q-7=T %%%% !1110 4444
M %%%% !1110 4444 <)\3_\ DGOC#_L!7W_HNN[KA/B?_P D]\8?]@*^_P#1
M==W0 4444 %%%% !1110 4444 %%%% !1110 5PFC?\ )0/'/_8&\$_S\35W
M=<)HW_)0/'/_ &!O!/\ /Q-0!W=%%% !1110 4444 %%%% !1110 4444 %<
M-\3/^1 \6_\ 8$O/_0*[FN&^)G_(@>+?^P)>?^@4 =S1110!P7Q,C2;PA<12
M//''+K?A".22UN'M+I$?QAH*L]M=1_O+:=5),-PGSPR!9%^912-\/-,*@?V]
MXV0>9YGR^,M>'S,OED<WAX;TZY/![5/\0_\ D63_ -C#X*_]33P_7;'JOU_H
M:"91YK:VL<!_PKK3?^A@\<?^%EKO_P ET?\ "NM-_P"A@\<?^%EKO_R77H%%
M!/L_/\/^">?_ /"NM-_Z&#QQ_P"%EKO_ ,ET?\*ZTW_H8/''_A9:[_\ )=>@
M44![/S_#_@GG_P#PKK3?^A@\<?\ A9:[_P#)='_"NM-_Z&#QQ_X66N__ "77
MH%% >S\_P_X)Y_\ \*ZTW_H8/''_ (66N_\ R71_PKK3?^A@\<?^%EKO_P E
MUZ!10'L_/\/^">?_ /"NM-_Z&#QQ_P"%EKO_ ,ET?\*ZTW_H8/''_A9:[_\
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MI:IHUW=Z%J-EJUC!JFCWJVE]IUY=VAE%OJ=A/N2:Q9UDCDW;LKL<]*RJRE6
M96!5E8 JRD8((/!!'!!X(X- >S\_P_X)P'_"NM-_Z&#QQ_X66N__ "71_P *
MZTW_ *&#QQ_X66N__)=6O"?Q$\#^.-1\:Z5X/\5^'_$]_P##CQ=/X \>VN@Z
MO9:J_@[QO;:%X=\42^$_$7V61VTSQ)'X=\7>&]6N=*N/](MK35+0S+&\@#=M
M0'L_/\/^">?_ /"NM-_Z&#QQ_P"%EKO_ ,ET?\*ZTW_H8/''_A9:[_\ )=>@
M4A( ))V@ DMP-H Y.3P,=>>/6@/9^?X?\$X#_A76F_\ 0P>./_"RUW_Y+H_X
M5UIO_0P>./\ PLM=_P#DNK?@?Q]X(^)NACQ5X \5>'?&OAS^W/$OAH:_X3U>
MSUS2#KW@GQ%JWA/Q7I7]IV#O UWX=\5Z'KGA[4X$D?R-0L;JVE ?S(U[6@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$\__P"%=:;_ -#!XX_\++7?_DNC_A76F_\ 0P>./_"RUW_Y+KT"B@/9
M^?X?\$X ?#O300?[?\;G!!P?&6O$'!S@@78X/0\CCO7'>+_ VG6?_"+[=7\6
M7!NO&&AV>;KQ5K4YMXY([A#);.T[O#-&L0>&0,I24!@XPH'N%<!X]_UG@?\
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M6Q\;W/@==9L/^$KC\&ZCJ=WHMGXI.AB47CZ)/JVGW=@-12 6RW,+Q!UD>))
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MUZ!10'L_/\/^">?_ /"NM-_Z&#QQ_P"%EKO_ ,ET?\*ZTW_H8/''_A9:[_\
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M\EB>.>#L'7JX7%<1Y;0Q-&<J=:C4G6C.E.+:<9)X/?1[-KS9^Z?_  KK3?\
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MOA-_\^^C_B)#_8=_Z)9^U?\ ^$-\)O\ Y]]'_$(O$W_HB<^_\)\+_P#/8/\
MB(7 _P#T5&5?^#:O_P QG[I_\*ZTW_H8/''_ (66N_\ R71_PKK3?^A@\<?^
M%EKO_P EU^%G_$2'^P[_ -$L_:O_ /"&^$W_ ,^^C_B)#_8=_P"B6?M7_P#A
M#?";_P"??1_Q"+Q-_P"B)S[_ ,)\+_\ /8/^(A<#_P#1495_X-J__,9^Z?\
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M /A76F_]#!XX_P#"RUW_ .2Z/^%=:;_T,'CC_P ++7?_ )+KT"B@/9^?X?\
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M?X?\$\__ .%=:;_T,'CC_P ++7?_ )+H_P"%=:;_ -#!XX_\++7?_DNO0**
M]GY_A_P3S_\ X5UIO_0P>./_  LM=_\ DNC_ (5UIO\ T,'CC_PLM=_^2Z]
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MG[V.3QSP?\*ZTW_H8/''_A9:[_\ )=>@44![/S_#_@GG_P#PKK3?^A@\<?\
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MXA_\BR?^QA\%?^IIX?KMCU7Z_P!#7$_$/_D63_V,/@K_ -33P_7;'JOU_H:
M%HHHH /U_P ^]?DM_P %R_VKOB9^Q'_P2P_:R_:-^#-Q_97Q0\*^%/"/A+P;
MXBC\LS^#M4^+/Q*\%?"C_A,K".2*:.74_"</C*37])C>)D.IZ=9LZ,@='_6@
MC((.<$$<$J>1V(((/H000>00:\3_ &B_V>_A3^U7\$OB5^SU\</#4/C#X4_%
MGPIJ7A#QAH#SS6<]Q8:BH$-]I>IVSQ76DZUIERL.HZ1J=HZW-AJEO9W<$@>
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MNSU!8;ZUU>*YM+*:V ,?]@+Q[^U)XR^$7C5/VL_"?BG0O&OA/XS^._!_P_\
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MQ)\7[SX>7GCWX#:)>WWP[^&?AWX(>%H= \7_ !#\"6J_!3PU=B?3?A-XAM/
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M&M@\-1H5<;BI.=>O.$$I.4VDY0B[QI)W<:<8Q<FU<****\8]4**** "BBB@
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M/_\  VV_^.4?VMI7_03T_P#\#;;_ ..5A_\ "!>!?^A+\)_^$YH__P AT?\
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M^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\
M^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@G
MI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_
M /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"
M7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_
M ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\
M0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <
MK#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O
M^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\
M^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@G
MI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_
M /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"
M7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_
M ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\
M0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <
MK#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O
M^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\
M^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@G
MI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_
M /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"
M7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_
M ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\
M0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <
MK#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O
M^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\
M^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@G
MI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_
M /D.@#<_M;2O^@GI_P#X&VW_ ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"
M7X3_ /"<T?\ ^0Z/^$"\"_\ 0E^$_P#PG-'_ /D.@#<_M;2O^@GI_P#X&VW_
M ,<H_M;2O^@GI_\ X&VW_P <K#_X0+P+_P!"7X3_ /"<T?\ ^0Z/^$"\"_\
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M/3__  -MO_CE8?\ P@7@7_H2_"?_ (3FC_\ R'1_P@7@7_H2_"?_ (3FC_\
MR'0!N?VMI7_03T__ ,#;;_XY1_:VE?\ 03T__P #;;_XY6'_ ,(%X%_Z$OPG
M_P"$YH__ ,AT?\(%X%_Z$OPG_P"$YH__ ,AT ;G]K:5_T$]/_P# VV_^.4?V
MMI7_ $$]/_\  VV_^.5A_P#"!>!?^A+\)_\ A.:/_P#(='_"!>!?^A+\)_\
MA.:/_P#(= &Y_:VE?]!/3_\ P-MO_CE']K:5_P!!/3__  -MO_CE8?\ P@7@
M7_H2_"?_ (3FC_\ R'1_P@7@7_H2_"?_ (3FC_\ R'0!N?VMI7_03T__ ,#;
M;_XY1_:VE?\ 03T__P #;;_XY6'_ ,(%X%_Z$OPG_P"$YH__ ,AT?\(%X%_Z
M$OPG_P"$YH__ ,AT ;G]K:5_T$]/_P# VV_^.4?VMI7_ $$]/_\  VV_^.5A
M_P#"!>!?^A+\)_\ A.:/_P#(='_"!>!?^A+\)_\ A.:/_P#(= &Y_:VE?]!/
M3_\ P-MO_CE']K:5_P!!/3__  -MO_CE8?\ P@7@7_H2_"?_ (3FC_\ R'1_
MP@7@7_H2_"?_ (3FC_\ R'0!N?VMI7_03T__ ,#;;_XY1_:VE?\ 03T__P #
M;;_XY6'_ ,(%X%_Z$OPG_P"$YH__ ,AT?\(%X%_Z$OPG_P"$YH__ ,AT ;G]
MK:5_T$]/_P# VV_^.4?VMI7_ $$]/_\  VV_^.5A_P#"!>!?^A+\)_\ A.:/
M_P#(='_"!>!?^A+\)_\ A.:/_P#(= &Y_:VE?]!/3_\ P-MO_CE']K:5_P!!
M/3__  -MO_CE8?\ P@7@7_H2_"?_ (3FC_\ R'1_P@7@7_H2_"?_ (3FC_\
MR'0!N?VMI7_03T__ ,#;;_XY1_:VE?\ 03T__P #;;_XY6'_ ,(%X%_Z$OPG
M_P"$YH__ ,AT?\(%X%_Z$OPG_P"$YH__ ,AT ;G]K:5_T$]/_P# VV_^.4?V
MMI7_ $$]/_\  VV_^.5A_P#"!>!?^A+\)_\ A.:/_P#(='_"!>!?^A+\)_\
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M_P#CE']K:5_T$]/_ / VV_\ CE8?_"!>!?\ H2_"?_A.:/\ _(='_"!>!?\
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M1Z9_:VEX'_$ST_KS_IEO^6/,X'N>F!3O[6TK_H)Z?_X&VW_QRN?/@/P*"/\
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M]Q-H)4;E)H ],_M;2O\ H)Z?_P"!MM_\<H_M;2O^@GI__@;;?_'*P_\ A O
MO_0E^$__  G-'_\ D.C_ (0+P+_T)?A/_P )S1__ )#H W/[6TK_ *">G_\
M@;;?_'*/[6TK_H)Z?_X&VW_QRL/_ (0+P+_T)?A/_P )S1__ )#H_P"$"\"_
M]"7X3_\ "<T?_P"0Z -S^UM*_P"@GI__ (&VW_QRC^UM*_Z">G_^!MM_\<K#
M_P"$"\"_]"7X3_\ "<T?_P"0Z/\ A O O_0E^$__  G-'_\ D.@#<_M;2O\
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M_D.N1^('@SP;:>"?$\]OX0\*QS1:1<R1NOAO2'*21KF*0(+:/<T3'?'\XVL
M1GH0#TIM4TI7*OJ.GK(@P0UW;!U#;3@@R!E#90X.,Y7U%']K:5_T$]/_ / V
MV_\ CE8K^!O!#%FD\'^%27;+L_A_2"7=BHRQ:T^9F(49.22%') IO_"!>!?^
MA+\)_P#A.:/_ /(= &Y_:VE?]!/3_P#P-MO_ (Y1_:VE?]!/3_\ P-MO_CE8
M?_"!>!?^A+\)_P#A.:/_ /(='_"!>!?^A+\)_P#A.:/_ /(= &Y_:VE?]!/3
M_P#P-MO_ (Y1_:VE?]!/3_\ P-MO_CE8?_"!>!?^A+\)_P#A.:/_ /(='_"!
M>!?^A+\)_P#A.:/_ /(= &Y_:VE?]!/3_P#P-MO_ (Y1_:VE?]!/3_\ P-MO
M_CE8?_"!>!?^A+\)_P#A.:/_ /(='_"!>!?^A+\)_P#A.:/_ /(= &Y_:VE?
M]!/3_P#P-MO_ (Y1_:VE?]!/3_\ P-MO_CE8?_"!>!?^A+\)_P#A.:/_ /(=
M'_"!>!?^A+\)_P#A.:/_ /(= &Y_:VE?]!/3_P#P-MO_ (Y1_:VE?]!/3_\
MP-MO_CE8?_"!>!?^A+\)_P#A.:/_ /(='_"!>!?^A+\)_P#A.:/_ /(= &Y_
M:VE?]!/3_P#P-MO_ (Y1_:VE?]!/3_\ P-MO_CM8?_"!>!?^A+\)_P#A.:/_
M /(=*/ ?@8$$>#/"8(.01X=T<$$="#]CX(H P-'U/3%\?^.'.HZ<%?1O!&UO
MMMIEN/$Y&=KAN5&5WD[ER4PH-=U_:VE?]!/3_P#P-MO_ (Y7F6E>#_"DWCGQ
ME:S>%/#3VMMHO@L6L3Z!I)BC#?\ "3JXC4VS#&,KC8@5257*DUV/_"!>!?\
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ME<;$"J2JY4F@#TW^UM*_Z">G_P#@;;?_ !RC^UM*_P"@GI__ (&VW_QRL/\
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MVL:?^T?\<+R^FG\>>"_$_A6\UOQ5X+TM'\1>%O"=Q>SQZAJGV0"PU%97L;@
M_I.I& 92K $$$$$;@01@@CN".".XXK^-J'XX_M+^/_!G_!,SPA^UW\3O#'A'
MX=>._P#@GYXH^*%SK7[1G[9OQO\ V!?#OQ*^.Z?%#P]8:)KWBKXO_"W3==U?
MQSX\TCX!/;^._"7P^\1O*FC:U>#Q[<RFX8>7^UC>*OVF?AS_ ,$5/'_C#PC\
M:?"G[2?[4W@G]BOXT>(/ ?QO^#GB+5/B_H/Q#\>>'/!'C*]\$>)_!/BG5'M]
M;^)&IPFUT:WM-;NHWU#Q+XBM/M<UG=2W;6\H!][>.OVC?AO\.?C7\/\ X%>)
M?^$@D\=_$?X4?&[XU^&X-"\-:[XE!\%_ *]^%^F^.?,@T.RU#5+W5FNOC!H$
M?A_0M*L-0U+5Y3/8Z=8R7K6<%QZ=\-_B!X=^*O@'P=\2O"3:LWA?QWX:T/Q;
MX>?7-!UKPQJLNC>(=,M=6TR6\T+Q%8:9K.G32V5W#(]O?64$T;,RLH*X'\L_
M[/\ =_LMVG[;O[-FM?L=?M1>-_VDYI/^"67[<GB_QUKFI_M&^-_V@W\)^,=0
ME_8VO?#/C.UU+7O$&N6WPH^+WC*X&NP^*_".F#3&L;#2K&*?1-(E^SVTG*:Y
M\>&\!_ G_@EA\>OBK\=XOB_I^G_\$UOV!=1\7_LI:9^VG\0?V?\ ]J>X^(WQ
M)B\,P:5^UO\ !KPOX.O[8?M3>-_%6IRR>![OX:^*[BTTCQ/<Z=]AU*]:VU;4
M+=0#^OFO$_V>/C]\/OVG?A'X7^-?PNN=0NO!'B^\\7VFB3:M9_V=J,S>"O&G
MB#P'K#S61EF,2KKGAO4%BQ(X:$PN2#( /Q3_ &>/'OP&\:?MQ?M-)^UO^U/X
ML\%_M??#K]OO5?AS^SM\"9_VH_B=\*(%^!XT'P1J'[/F@^"?V:]'^(VG^&/B
M-X'^+'AC4;[5_'&LZEX.U;2_%7B$:S]LAM[+S5?X<^"'CKP:GPA_X)<?"C]I
M/XS>(?@=^Q;X]T7_ (*8ZUXK\0VWQP\5?LX>#OB+\??!_P"UI;S_  <^'7C_
M .,?@/Q1X3U70=.E\!:I\6O&/A;PRNNZ._B76-&BM_/O;O3X[4 ']?=%?QY>
M+?C)K?\ PRWX,^(/C']K+1?'?[//P5_:5_X*%:M\)/A)\<_VZ?B%^S5X_P#V
M\OV-?AEXHTS2/A[XH\&?'_0?$>H>+?BQXL^"WBBY@/PP/B>6RM?$%[#X?M=0
MU728I+*ZCV/VF?C#\1/CA^T5\3M&\0_';P!^RSX<@_8N_9:^(G[%VM?M-_\
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M]\.]/UW4V%S%,CL[374SJ&)0$A5 50*^,O\ B(+_ ."A'_/W\'?_  V5]_\
M)->$?\%J_P#E)S^U#_U]_"O_ -4E\+*_+2O]#>!_#C@/'\'<+XW&<(Y!B<3B
MLBRVO7KU\!&K5JU:F'3J3J3=>/-*4M7:*6NQ_''$_&?%F$XBSO"X7B/-\/A\
M/FF-I4J-+%\M.G"-9I**]B[+LKNQ^X7_ !$%_P#!0C_G[^#O_ALK[_Y)H_XB
M"_\ @H1_S]_!W_PV5]_\DU^'M%?5?\0M\.O^B*X;_P##9#_YI/"_UZXS_P"B
MISO_ ,+?_N!^X7_$07_P4(_Y^_@[_P"&ROO_ ))H_P"(@O\ X*$?\_?P=_\
M#97W_P DU^'M%'_$+?#K_HBN&_\ PV0_^:0_UZXS_P"BISO_ ,+?_N!^X7_$
M07_P4(_Y^_@[_P"&ROO_ ))H_P"(@O\ X*$?\_?P=_\ #97W_P DU^'M%'_$
M+?#K_HBN&_\ PV0_^:0_UZXS_P"BISO_ ,+?_N!^X7_$07_P4(_Y^_@[_P"&
MROO_ ))H_P"(@O\ X*$?\_?P=_\ #97W_P DU^'M%'_$+?#K_HBN&_\ PV0_
M^:0_UZXS_P"BISO_ ,+?_N!^X7_$07_P4(_Y^_@[_P"&ROO_ ))H_P"(@O\
MX*$?\_?P=_\ #97W_P DU^'M%'_$+?#K_HBN&_\ PV0_^:0_UZXS_P"BISO_
M ,+?_N!^X7_$07_P4(_Y^_@[_P"&ROO_ ))H_P"(@O\ X*$=KOX.$]@?AG?*
M">P+&YP![G@=:_#VBC_B%OAU_P!$5PW_ .&R'_S2'^O7&?\ T5.=_P#A;_\
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M^_\ 1==W7"?$_P#Y)[XP_P"P%??^BZ[N@ HHHH **** "BBB@ HHHH ****
M"BBB@ KA-&_Y*!XY_P"P-X)_GXFKNZX31O\ DH'CG_L#>"?Y^)J .[HHHH *
M*** "BBB@ HHHH **** "BBB@ KAOB9_R('BW_L"7G_H%=S7#?$S_D0/%O\
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MFU.OAL_\%>/^"<1!!_:@\+ '@EO"GQ*50#P2S-X*"JH'5F( &22 ,UR_BO\
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M.BOS<_X>\_\ !./_ *.?\,?^$E\2_P#YB:/^'O/_  3C_P"CG_#'_A)?$O\
M^8F@#](Z*_-S_A[S_P $X_\ HY_PQ_X27Q+_ /F)H_X>\_\ !./_ *.?\,?^
M$E\2_P#YB: /TCHK\W/^'O/_  3C_P"CG_#'_A)?$O\ ^8FC_A[S_P $X_\
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M.BOS<_X>\_\ !./_ *.?\,?^$E\2_P#YB:/^'O/_  3C_P"CG_#'_A)?$O\
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M%O:YX-7A7ABO5G7K\/9+6K59<U2K5RO!5*E23WE.<Z$I2;N]6^K.!_X<A_\
M!,#_ *-C3_P\WQ__ /GK4?\ #D/_ ()@?]&QI_X>;X__ /SUJ[[_ (>\_P#!
M./\ Z.?\,?\ A)?$O_YB:/\ A[S_ ,$X_P#HY_PQ_P"$E\2__F)K;_7WC[_H
MN>+/_#_FG_S29_ZG\)_]$UD/_AHP'_S.<#_PY#_X)@?]&QI_X>;X_P#_ ,]:
MC_AR'_P3 _Z-C3_P\WQ__P#GK5WW_#WG_@G'_P!'/^&/_"2^)?\ \Q-'_#WG
M_@G'_P!'/^&/_"2^)?\ \Q-'^OO'W_1<\6?^'_-/_FD/]3^$_P#HFLA_\-&
M_P#F<X'_ (<A_P#!,#_HV-/_  \WQ_\ _GK4?\.0_P#@F!_T;&G_ (>;X_\
M_P ]:N^_X>\_\$X_^CG_  Q_X27Q+_\ F)H_X>\_\$X_^CG_  Q_X27Q+_\
MF)H_U]X^_P"BYXL_\/\ FG_S2'^I_"?_ $360_\ AHP'_P SG _\.0_^"8'_
M $;&G_AYOC__ //6H_X<A_\ !,#_ *-C3_P\WQ__ /GK5WW_  ]Y_P""<?\
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MC_PDOB7_ /,31_P]Y_X)Q_\ 1S_AC_PDOB7_ /,30!^D=%?FY_P]Y_X)Q_\
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ME\2__F)H_P"'O/\ P3C_ .CG_#'_ (27Q+_^8F@#](Z*_-S_ (>\_P#!./\
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M_AC_ ,)+XE__ #$TA_X*]?\ !.)06;]J#PN%4$DGPE\2P  ,DD_\(5P .2:
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M7YN?\/>?^"<?_1S_ (8_\)+XE_\ S$T?\/>?^"<?_1S_ (8_\)+XE_\ S$T
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M&^)G_(@>+?\ L"7G_H%?"A_X*]?\$XE!9OVH/"X5022?"7Q+   R23_PA7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_CE?WO44>T?9?B!_!#_ ,.9/V__ /HD5G_X$0__ !RC_AS)^W__ -$BL_\
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M*S_\"(?_ (Y1_P .9/V__P#HD5G_ .!$/_QRO[WJ*/:/LOQ _@A_X<R?M_\
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M6?\ X$0__'*_O>HH]H^R_$#^"'_AS)^W_P#]$BL__ B'_P".4?\ #F3]O_\
MZ)%9_P#@1#_\<K^]ZBCVC[+\0/X(#_P1D_X* 8./A'; X.#'>0Q2 XX,<N_]
MV_\ =D_@;#=J@G_X(U?M\V0@-Q\)+:'[3-';1/-X@BN))9IF"11&-6PS2,0H
MC8C=]W@$U_?-7 >/?]9X'_['_0O_ $FU.CVC[+[V!_#!_P .9/V__P#HD5G_
M .!$/_QRC_AS)^W_ /\ 1(K/_P "(?\ XY7][U%'M'V7X@?P0_\ #F3]O_\
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MS_\  B'_ ..5_>]11[1]E^('\$/_  YD_;__ .B16?\ X$0__'*/^',G[?\
M_P!$BL__  (A_P#CE?WO44>T?9?B!_!#_P .9/V__P#HD5G_ .!$/_QRC_AS
M)^W_ /\ 1(K/_P "(?\ XY7][U%'M'V7X@?P0_\ #F3]O_\ Z)%9_P#@1#_\
M<H_X<R?M_P#_ $2*S_\  B'_ ..5_>]11[1]E^('\$/_  YD_;__ .B16?\
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M.?\ L#>"?Y^)J[NCVC[+[V!_!#_PYD_;_P#^B16?_@1#_P#'*/\ AS)^W_\
M]$BL_P#P(A_^.5_>]11[1]E^('\$/_#F3]O_ /Z)%9_^!$/_ ,<H_P"',G[?
M_P#T2*S_ / B'_XY7][U%'M'V7X@?P0_\.9/V_\ _HD5G_X$0_\ QRC_ (<R
M?M__ /1(K/\ \"(?_CE?WO44>T?9?B!_!#_PYD_;_P#^B16?_@1#_P#'*/\
MAS)^W_\ ]$BL_P#P(A_^.5_>]11[1]E^('\$/_#F3]O_ /Z)%9_^!$/_ ,<H
M_P"',G[?_P#T2*S_ / B'_XY7][U%'M'V7X@?P0_\.9/V_\ _HD5G_X$0_\
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M /Z)%9_^!$/_ ,<K^Z/1O^2@>.?^P-X)_GXFKNZ/:/LOO8'\$/\ PYD_;_\
M^B16?_@1#_\ '*/^',G[?_\ T2*S_P# B'_XY7][U%'M'V7X@?P0_P##F3]O
M_P#Z)%9_^!$/_P <H_X<R?M__P#1(K/_ ,"(?_CE?WO44>T?9?B!_!#_ ,.9
M/V__ /HD5G_X$0__ !RC_AS)^W__ -$BL_\ P(A_^.5_>]11[1]E^('\$/\
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M^_\ 1==W1[1]E][ _@A_X<R?M_\ _1(K/_P(A_\ CE'_  YD_;__ .B16?\
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M\0_^19/_ &,/@K_U-/#]=L>J_7^AKB?B'_R+)_[&'P5_ZFGA^NV/5?K_ $-
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M+N#>>.M8^-OQ5U[Q%X$MA=L61KSPYJ>DRW;2>7:^5>/;7+K'.ZN ?8'PZ_;
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MQ1+:&YT/P!I'E:E! WB7Q5>+!IV@65S/"MY<N,.4MI?*]%O/^"C'[!VF>"/
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M;\/^%/$+6VG^ =>UZYB\5WND/<KJOVPQQ7*@'ZJT444 %%%% !1110 4444
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MXR_^',^(?^%>+44?V9EO_0MR[_PW9;_\[0^OX_\ Z&&/_P#"W%__ #4>T_\
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M $7?XR_^',^(?^%'_#2'[17?X[_&7'?_ (N9\0^G?M7BU%']F9;_ -"W+O\
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M (;LM_\ G:'U_'_]##'_ /A;B_\ YJ/:1^TC^T4""?CO\9<#K_Q<SX@=._\
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MHHH **** "N$T;_DH'CG_L#>"?Y^)J[NN$T;_DH'CG_L#>"?Y^)J .[HHHH
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ME?##_HU?XA?^'*\&_P#RLHY)=OQ0']+E%?S1_P#$25\,/^C5_B%_X<KP;_\
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MZ?=Q7 :+RK&%"XV-M\\31 GYHV!.3DEV_(#^GNBOYH_^(DKX8?\ 1J_Q"_\
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MRC_B)*^&'_1J_P 0O_#E>#?_ )64<DNWXH#^ERBOYH_^(DKX8?\ 1J_Q"_\
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MQ"@GXE>#B 2< X&F9/T')[4<DNWXH#^B#1O^2@>.?^P-X)_GXFKNZ_F%L/\
M@XS^&%KK>MZV/V8?'<D6M6VDB*-/B/X9\W.G":WQ)YEDUNF%G<[HH8LD#>6.
M2=[_ (B2OAA_T:O\0O\ PY7@W_Y64<DNWY ?TN45_-'_ ,1)7PP_Z-7^(7_A
MRO!O_P K*/\ B)*^&'_1J_Q"_P##E>#?_E91R2[?B@/Z7**_FC_XB2OAA_T:
MO\0O_#E>#?\ Y64?\1)7PP_Z-7^(7_ARO!O_ ,K*.27;\4!_2Y17\T?_ !$E
M?##_ *-7^(7_ (<KP;_\K*/^(DKX8?\ 1J_Q"_\ #E>#?_E91R2[?B@/Z7**
M_FC_ .(DKX8?]&K_ !"_\.5X-_\ E91_Q$E?##_HU?XA?^'*\&__ "LHY)=O
MQ0']+E%?S1_\1)7PP_Z-7^(7_ARO!O\ \K*/^(DKX8?]&K_$+_PY7@W_ .5E
M')+M^* _I<HK^:/_ (B2OAA_T:O\0O\ PY7@W_Y64H_X.2?A@2 /V5_B%R0/
M^2E>#N__ '#*.27;\4!_1!\3_P#DGOC#_L!7W_HNN[K^83Q+_P '&_PSU_P[
MJ^DQ_LL?$!#J5E=Z:SO\3O"J)$+R"2V,KFVL()61/,W%%D ;;@Y[;J_\')7P
MPP%7]EOX@.$;RC*/B-X3V2211!Y0F[3"1SE5+NQ'5R31R2_JP']+U%?S1_\
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MQ"_\.5X-_P#E90!_2Y17\T?_ !$E?##_ *-7^(7_ (<KP;_\K*/^(DKX8?\
M1J_Q"_\ #E>#?_E90!_2Y17\T?\ Q$E?##_HU?XA?^'*\&__ "LH_P"(DKX8
M?]&K_$+_ ,.5X-_^5E ']+E%?S1_\1)7PP_Z-7^(7_ARO!O_ ,K*/^(DKX8?
M]&K_ !"_\.5X-_\ E90!_2Y17\T?_$25\,/^C5_B%_X<KP;_ /*RC_B)*^&'
M_1J_Q"_\.5X-_P#E90!_2Y17\T?_ !$E?##_ *-7^(7_ (<KP;_\K*/^(DKX
M8?\ 1J_Q"_\ #E>#?_E90!_2Y7#?$S_D0/%O_8$O/_0*_G='_!R3\,"0!^RO
M\0N2!_R4KP=W_P"X95&[_P"#B+X>>/+5O!VG?LN>.K>]\5S)X8MKB[^(_AB:
MTMKG7&&EP7%U;V5A!<W5M#+=+)-:Q2!IXT:-2688 /Z::*** /A__@I7_P F
M#_M9_P#9$_&7_I#7^=?7^BA_P4K_ .3!_P!K/_LB?C+_ -(:_P Z^M:>S]?T
M ****L HX_B3S!WC\SR?,'=/-_Y9;A\OF?P9W=J*0@$$%0P(P5;.U@>JMB*<
MX(X.()C@\12'Y& /M?\ 8B_9(M?VL/%OQ3LM?\2^*]'\/_!7X->)?B[KNC_#
M_P (0>/_ (J>-8="U#P[H?\ 8GP[\&75W86VIWEW$YL;5KB^LH;F]G@BEN[=
M',T>1I'['WCCXU_$_P"*/AK]DW1/&?Q2\"?#JWT>[U3Q7\0])\(?"C4_#TFO
MSKIMKX4\96_B7Q[J6GOXJ;47^R:7HNGW-O-<WABMHI87<,N)^R9XX^$OPY^(
MDWBWXG_$O]I+X.ZAHL"-X&^(O[,\'A^Z\3:+K(99=0TW5;;5Y=+^T:;<PJ!<
MP26<ZS1;XVAE#&-OT4^*_P#P4,_9=_:0U']JCP3\9? _QK\"_#;XTZ]\!?%6
MB^,_AQ:_#V_^*VM>)O@;X3?PSJ%S\0]*E/V:V;Q;$(X[CS4*VL$\D2%(FD#
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M_P %MW_\:H_XAP$_Z.)G_P#!;=__ !JOZE:*?/+R^X#^6K_B' 3_ *.)G_\
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M_P#P6W?_ ,:H_P"(<!/^CB9__!;=_P#QJOZE:*.>7E]P'\M7_$. G_1Q,_\
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M *.)G_\ !;=__&J_J5HHYY>7W ?RU?\ $. G_1Q,_P#X+;O_ .-4?\0X"?\
M1Q,__@MN_P#XU7]2M%'/+R^X#^6K_B' 3_HXF?\ \%MW_P#&J/\ B' 3_HXF
M?_P6W?\ \:K^I6BCGEY?<!_+5_Q#@)_T<3/_ ."V[_\ C5'_ !#@)_T<3/\
M^"V[_P#C5?U*T4<\O+[@/Y:O^(<!/^CB9_\ P6W?_P :H_XAP$_Z.)G_ /!;
M=_\ QJOZE:*.>7E]P'\M7_$. G_1Q,__ (+;O_XU1_Q#@)_T<3/_ ."V[_\
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M G_1Q,__ (+;O_XU1_Q#@)_T<3/_ ."V[_\ C5?U*T4<\O+[@/Y:O^(<!/\
MHXF?_P %MW_\:H_XAP$_Z.)G_P#!;=__ !JOZE:*.>7E]P'\M7_$. G_ $<3
M/_X+;O\ ^-4?\0X"?]'$S_\ @MN__C5?U*T4<\O+[@/Y:O\ B' 3_HXF?_P6
MW?\ \:H_XAP$_P"CB9__  6W?_QJOZE:*.>7E]P'\M7_ !#@)_T<3/\ ^"V[
M_P#C5'_$. G_ $<3/_X+;O\ ^-5_4K11SR\ON _EJ_XAP$_Z.)G_ /!;=_\
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M (+;O_XU7]2M%'/+R^X#^6K_ (AP$_Z.)G_\%MW_ /&J/^(<!/\ HXF<>_\
M9ET<?@8L'Z'@U_4H<8.>!@Y/M41*XZ\>O!/3USCCT''K2=22MUOHMEKVNVE?
MR2;\A-VVLW:]KI.W?5K1=6]%W/Y6;7_@W2L[G5=6T5/VBY\Z/;:5)&!I4F_=
M>-)<#S$ +HK)$X# 'DK@8.:U_P#B' 3_ *.)G_\ !;=__&J_:GQE^W/^Q]\%
MOC'\2O _Q4_:#^''@3Q?I5KX'&J:)XDUN.QNK?[7IE_<V8; D0N\,Z%HSAHV
M.UANW!:__#T#_@GO_P!'<?!/_P *N+_XQ7MT>'.*,12IUZ'#>?UZ%6*G1K4,
MDS:O1JP:34Z=6GELJ<XNZ:<)SBTTU)W5_*J9[DM&<J5;.,HHU8/EJ4JN:8"G
M4A+M*$\7&2?DU=;'XO?\0X"?]'$S_P#@MN__ (U1_P 0X"?]'$S_ /@MN_\
MXU7[0_\ #T#_ ()[_P#1W'P3_P#"KB_^,4?\/0/^">__ $=Q\$__  JXO_C%
M:_ZK<6_]$MQ+_P"(_G/_ ,["/]8<A_Z'F2?^'?+O_FT_%[_B' 3_ *.)G_\
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M_P#P6W?_ ,:H_P"(<!/^CB9__!;=_P#QJOZE:*.>7E]P'\M7_$. G_1Q,_\
MX+;O_P"-4?\ $. G_1Q,X]_[,NCC\#%@_0\&OZE:*.>7E]P'\J=K_P &Z5G<
MZKJVBI^T7/G1[;2I(P-*DW[KQI+@>8@!=%9(G 8 \E<#!S6O_P 0X"?]'$S_
M /@MN_\ XU7]+6C?\E \<_\ 8&\$_P _$U=W1SOR^X#^6K_B' 3_ *.)G_\
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M_P#P6W?_ ,:H_P"(<!/^CB9__!;=_P#QJOZE:*.>7E]P'\M7_$. G_1Q,_\
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M &YOVOOV_?V:OC[:?\$\O@[^P[\1_@K^U!X$^)OQ!_;^^'W[67A?Q#KGQ4^
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M=_ WX-?MW^./ G[1?Q@^&NN?#+4?BE\3OAW\:[#P+\!_#GC/P-X0^+.B^.O
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M_&-YX@7PPVGZ0TD%C!X-GU2]N[9-9&Z.X^@OC[^P;+\=OB7^VWXHU;XD#0=
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MZ\!>,_!.I_#;[58Z-XH\6>,M2@\0?\(SJ3W&H79U9++^TW<VUM!:PK))\P_
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M#I'C;X=?&K]EB\\<_LL:_+\5/$'A/5M(\:>$?@WJ/Q8U+4SX[^"5KX8C\/\
M@_6/%OB.];5HM1DN[Z33+G=O]$_9(_X)JZS^S%>_\$_YKCXKZ+XH@_8I_9@_
M:>_9]U"#1_ B^%K+QQ<_M#_$'X&>.(M5T;33K.K+X2T/PJ/@^NGV&B175Z8K
M:XMK>*X,#R+;@%[3_P#@J9\/_%WPK_9;\8_!KX$?&WXK?$W]KN^^+^F?#7]G
MK1W^'/AGQ]H=[^SAK5[X0^/,?C77/&WC[1OAKX7TSX:>+M-3PIJM['XJEMK_
M %/4+"33#<17,]U;+\2_^"GEMX!OK_PW;?LJ_'WQ=X]\!_ [PO\ M$?M%?#G
M2M9^!.E>*/V=?AMXGN_$FGZ78^+U\1?%^UTCQMXUUB_\%^+(]%\(_#6\\1ZO
MXDM[6SMM$2ZU*[MH#X]I'_!,CXX?"K0_V9/%?P"^//PRTCX_?LN?%C]O;Q/H
MNL?$OX9ZWXJ^%_CSX=_MY?M$Z_\ 'OQAX \4Z!X:\:^$_$NG:GX:?_A"19:Y
MI&I0R?;=%GFM@D=[)<#)^+'_  2L^)WQ$^.LO[3>N7G[!/QZ^+GQ ^#WPQ^%
M_P :]/\ VKOV)IOB=\.I?$7PLE\;MX=^)WP5TD_%^;Q'\.+Z72/B%JWA?Q#X
M6O==U6R\1Z?I]K//J-C,T+VP!]-Z=_P4J\-^.OC]\'_@'\#OV?\ XV_&Z^^+
M7P%_9R_:HD^(?A<_##P]\-?A_P#L[?M$^,_&GA/3OB%XTUSQG\1-%U*:Y\)V
MW@O5-<O_  AX2T;Q'XDU^&VN+'PW:ZAJ*QV<WZ85\3?"']DS4?AC^U'XG_:&
M?Q-X6.E^(/V-_P!F;]EF#P%X3\'?\(IH6A7'[/WCCXZ>,#K/AFQ75-1B\/\
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MFI1[-.SW6A^4M%?JU_PY$_X*@?\ 1L4?_AYO@#_\^*C_ (<B?\%0/^C8H_\
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MAD=E(!YSS6BW_!=#_@HRC%8_B?X.E/G-"%/PA^'NZ..*'<\S$<L007.>#C&
M.*.1]U^(']V-%?PF_P##]#_@HU_T5+P;_P"&?^'G^%'_  _0_P""C7_14O!O
M_AG_ (>?X4<C[K\?\@/[LJ*_A-_X?H?\%&O^BI>#?_#/_#S_  H_X?H?\%&O
M^BI>#?\ PS_P\_PHY'W7X_Y ?W945_";_P /T/\ @HU_T5+P;_X9_P"'G^%'
M_#]#_@HU_P!%2\&_^&?^'G^%'(^Z_'_(#^[*BOX3?^'Z'_!1K_HJ7@W_ ,,_
M\//\*/\ A^A_P4:_Z*EX-_\ #/\ P\_PHY'W7X_Y ?W945_";_P_0_X*-?\
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M ) ?W945_";_ ,/T/^"C7_14O!O_ (9_X>?X4?\ #]#_ (*-?]%2\&_^&?\
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M";_P_0_X*-?]%2\&_P#AG_AY_A1_P_0_X*-?]%2\&_\ AG_AY_A1R/NOQ_R
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M^'Z'_!1K_HJ7@W_PS_P\_P *.1]U^/\ D!_=E17\)O\ P_0_X*-?]%2\&_\
MAG_AY_A1_P /T/\ @HU_T5+P;_X9_P"'G^%'(^Z_'_(#^[*BOX3?^'Z'_!1K
M_HJ7@W_PS_P\_P */^'Z'_!1K_HJ7@W_ ,,_\//\*.1]U^/^0']V5<-\3/\
MD0/%O_8$O/\ T"OXAQ_P7/\ ^"C1( ^*/@TDD #_ (4_\/.I/TJGJ/\ P7#_
M ."BFH:?=6D_Q5\'I%/'+;W"K\(?AV/,@E1HY8R< A7C+ANG!Y.*.1]U^(']
MWM%?PG?\/SO^"C2NR1_%/P1,&D=8XQ\(OAYNBAA@W/(3U8@@O\Q.>F .*3_A
M^A_P4:_Z*EX-_P##/_#S_"CD?=?U\@/[LJ*_A-_X?H?\%&O^BI>#?_#/_#S_
M  H_X?H?\%&O^BI>#?\ PS_P\_PHY'W7X_Y ?W945_";_P /T/\ @HU_T5+P
M;_X9_P"'G^%'_#]#_@HU_P!%2\&_^&?^'G^%'(^Z_'_(#^[*BOX3?^'Z'_!1
MK_HJ7@W_ ,,_\//\*/\ A^A_P4:_Z*EX-_\ #/\ P\_PHY'W7X_Y ?W945_"
M;_P_0_X*-?\ 14O!O_AG_AY_A1_P_0_X*-?]%2\&_P#AG_AY_A1R/NOQ_P @
M/[LJ*_A-_P"'Z'_!1K_HJ7@W_P ,_P##S_"C_A^A_P %&O\ HJ7@W_PS_P /
M/\*.1]U^/^0']V5%?PF_\/T/^"C7_14O!O\ X9_X>?X4C?\ !<[_ (*.NK+'
M\4_!@D8%8R?@_P##P@.PPI((P0&(X/%'(^Z_'_(#^WC1O^2@>.?^P-X)_GXF
MKNZ_@\A_X+??\%#8-1U#5[7XG^$5N-76SCFW_"+X>F/&G(8OE4]PA=03R-QX
M)Y&C_P /T/\ @HU_T5+P;_X9_P"'G^%'(^Z _NRHK^$W_A^A_P %&O\ HJ7@
MW_PS_P //\*/^'Z'_!1K_HJ7@W_PS_P\_P *.1]U^/\ D!_=E17\)O\ P_0_
MX*-?]%2\&_\ AG_AY_A1_P /T/\ @HU_T5+P;_X9_P"'G^%'(^Z_'_(#^[*B
MOX3?^'Z'_!1K_HJ7@W_PS_P\_P */^'Z'_!1K_HJ7@W_ ,,_\//\*.1]U^/^
M0']V5%?PF_\ #]#_ (*-?]%2\&_^&?\ AY_A1_P_0_X*-?\ 14O!O_AG_AY_
MA1R/NOQ_R _NRHK^$W_A^A_P4:_Z*EX-_P##/_#S_"C_ (?H?\%&O^BI>#?_
M  S_ ,//\*.1]U^/^0']V5%?PF_\/T/^"C7_ $5+P;_X9_X>?X4H_P""Y_\
MP4:) 'Q2\&Y)P/\ BS_P\ZFCD?=?C_D!_;M\3_\ DGOC#_L!7W_HNN[K^#W4
M/^"X/_!1?5K"YT^;XJ^$$CNXY;2X6/X1?#M6DAN$:&1,XSAD=E(!YSS6BW_!
M=#_@HRC%8_B?X.E/G-"%/PA^'NZ..*'<\S$<L007.>#C& .*.1]U^(']V-%?
MPF_\/T/^"C7_ $5+P;_X9_X>?X4?\/T/^"C7_14O!O\ X9_X>?X4<C[K\?\
M(#^[*BOX3?\ A^A_P4:_Z*EX-_\ #/\ P\_PH_X?H?\ !1K_ **EX-_\,_\
M#S_"CD?=?C_D!_=E17\)O_#]#_@HU_T5+P;_ .&?^'G^%'_#]#_@HU_T5+P;
M_P"&?^'G^%'(^Z_'_(#^[*BOX3?^'Z'_  4:_P"BI>#?_#/_  \_PH_X?H?\
M%&O^BI>#?_#/_#S_  HY'W7X_P"0']V5%?PF_P##]#_@HU_T5+P;_P"&?^'G
M^%'_  _0_P""C7_14O!O_AG_ (>?X4<C[K\?\@/[LJ*_A-_X?H?\%&O^BI>#
M?_#/_#S_  H_X?H?\%&O^BI>#?\ PS_P\_PHY'W7X_Y ?W95PFC?\E \<_\
M8&\$_P _$U?Q#M_P7._X*.NK+'\4_!@D8%8R?@_\/" [#"D@C! 8C@\5GP_\
M%OO^"AL&HZAJ]K\3_"*W&KK9QS;_ (1?#TQXTY#%\JGN$+J">1N/!/(.1]T!
M_>'17\)O_#]#_@HU_P!%2\&_^&?^'G^%'_#]#_@HU_T5+P;_ .&?^'G^%'(^
MZ_'_ " _NRHK^$W_ (?H?\%&O^BI>#?_  S_ ,//\*/^'Z'_  4:_P"BI>#?
M_#/_  \_PHY'W7X_Y ?W945_";_P_0_X*-?]%2\&_P#AG_AY_A1_P_0_X*-?
M]%2\&_\ AG_AY_A1R/NOQ_R _NRHK^$W_A^A_P %&O\ HJ7@W_PS_P //\*/
M^'Z'_!1K_HJ7@W_PS_P\_P *.1]U^/\ D!_=E17\)O\ P_0_X*-?]%2\&_\
MAG_AY_A1_P /T/\ @HU_T5+P;_X9_P"'G^%'(^Z_'_(#^[*BOX3?^'Z'_!1K
M_HJ7@W_PS_P\_P */^'Z'_!1K_HJ7@W_ ,,_\//\*.1]U^/^0']V5<-\3/\
MD0/%O_8$O/\ T"OXAQ_P7/\ ^"C1( ^*/@TDD #_ (4_\/.I/TK1T?\ X+2?
M\%"/'>K:/X,UGXJ^%(])\5ZSIOAG5Q;?"KP)93OI>NWL.E7Z17EF!>6CM:74
MP2YM?](A8B6']XJU+BX[@?W04444@/A__@I7_P F#_M9_P#9$_&7_I#7^=?7
M^BA_P4K_ .3!_P!K/_LB?C+_ -(:_P Z^M:>S]?T ****L H&[(V\-GY3ASA
MNW$?[P\XX3YST7YL44%@H+,AD5?F9%^\X')0>[#@>YH ^^_V!OA7\-OC]?\
M[1'P%\2^&]/U/XH>-OV?O%WB;]G77/M&K?;M ^,/P[AO?&I\/VMD5E6:76]!
MTY8C&UM>"6-I(1:S-(H'V/\ ";]FWX9Z+HO[)_PS/P^^&^H_&GXD_LJ?M/\
M[5'Q2U3XF^&?%GQ M]/\(ZSX<\0WOP-\/>'-.MO%/AJST3Q#8^"=#UN]TRZG
MT/4H+2]$,LFFWJH;67\DO@E\8O&/[//Q>\ ?&?P)-:?\)=\-O$ECXCT^UUR&
M[GT35KC2[RVCU+0]8@L9[6^GTO4+-6L]0BL[JVNY+2:9+>>&8I(OT=J?[?\
M\:-6_:>\9_M1ZAH'P^G\;>,/ &O_  NU#PY'IGBRV\%:)X:U;X80?"E+30[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[KX7?\ )3/AW_V/7A'_
M -2#3ZX6NZ^%W_)3/AW_ -CUX1_]2#3Z /\ 3VHHHKG \@^/?@WP]\1?A+XN
M^'_BZS.H>%/'$>C>$?$]@LGE-?>'O$?B'2='UJT67_ED;G3;RYA$G\!?=VKX
M5/\ P1K_ & "6)^#I.X1!@=:NB#Y6-N04P<X^8'(.3P*_1+XA_\ (LG_ +&'
MP5_ZFGA^NV/5?K_0T ?EQ_PYK_X)_?\ 1&8__!K/_P#&J/\ AS7_ ,$_O^B,
MQ_\ @UG_ /C5?J110!^6_P#PYK_X)_?]$9C_ /!K/_\ &J/^'-?_  3^_P"B
M,Q_^#6?_ .-5^I%% 'Y;_P##FO\ X)_?]$9C_P#!K/\ _&J/^'-?_!/[_HC,
M?_@UG_\ C5?J110!^6__  YK_P""?W_1&8__  :S_P#QJC_AS7_P3^_Z(S'_
M .#6?_XU7ZD44 ?EO_PYK_X)_?\ 1&8__!K/_P#&J/\ AS7_ ,$_O^B,Q_\
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M-5^I%%'-+N_Z^0'Y;_\ #FO_ ()_?]$9C_\ !K/_ /&J/^'-?_!/[_HC,?\
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M ,&L_P#\:H_X<U_\$_O^B,Q_^#6?_P"-5^@GQ/\ !ES\0? WB'P=IOC?QO\
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MU[XN\,?LSNGQS^$8UGQ+X[\"Z=XS\1ZY:^.],N1]M\">!%\.>"M3U;4_%_\
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MW.:7=_U\@-G_ (<U_P#!/[_HC,?_ (-9_P#XU1_PYK_X)_?]$9C_ /!K/_\
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MZ/XDO/$WPR+:]\./B%\-_B#K>BWVIIH@U'4]+BGM-2T:_EN[6W68YI=W_7R
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M&L__ ,:H_P"'-?\ P3^_Z(S'_P"#6?\ ^-5^>W_$2U^SM_T;O\9__!UX&_\
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M_P#P=>!O_EC1_P 1+7[.W_1N_P 9_P#P=>!O_EC1_P 0:\5/^B-S/_P=EO\
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MO_EC1_Q$M?L[?]&[_&?_ ,'7@;_Y8T?\0:\5/^B-S/\ \'9;_P#/0/\ B)?
MG_12X'_P7C?_ )@/T)_X<U_\$_O^B,Q_^#6?_P"-4?\ #FO_ ()_?]$9C_\
M!K/_ /&J_/;_ (B6OV=O^C=_C/\ ^#KP-_\ +&C_ (B6OV=O^C=_C/\ ^#KP
M-_\ +&C_ (@UXJ?]$;F?_@[+?_GH'_$2^!/^BEP/_@O&_P#S ?H3_P .:_\
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M&L__ ,:H_P"'-?\ P3^_Z(S'_P"#6?\ ^-5^I%% 'Y;_ /#FO_@G]_T1F/\
M\&L__P :H_X<U_\ !/[_ *(S'_X-9_\ XU7ZD44 ?EO_ ,.:_P#@G]_T1F/_
M ,&L_P#\:H_X<U_\$_O^B,Q_^#6?_P"-5^I%% 'Y;_\ #FO_ ()_?]$9C_\
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M /QJC_AS7_P3^_Z(S'_X-9__ (U7ZD44 ?EO_P .:_\ @G]_T1F/_P &L_\
M\:H_X<U_\$_O^B,Q_P#@UG_^-5^I%% 'Y;_\.:_^"?W_ $1F/_P:S_\ QJC_
M (<U_P#!/[_HC,?_ (-9_P#XU7ZD44 ?EO\ \.:_^"?W_1&8_P#P:S__ !JC
M_AS7_P $_O\ HC,?_@UG_P#C5?J110!^6_\ PYK_ ."?W_1&8_\ P:S_ /QJ
MC_AS7_P3^_Z(S'_X-9__ (U7ZD44 ?EO_P .:_\ @G]_T1F/_P &L_\ \:H_
MX<U_\$_N_P &8\?]A:X'ZB,$?4$$=B*_4BB@#\D_%O\ P1\_8#T7PSX@U:W^
M#A2:QTVZOD*ZS<$"2VA>2,E9%"LH9064G+ 8!YKI&_X(U_\ !/YGGD/P9BW7
M%P+J7&J2C=-Y0AW?ZG(RHW$9^_R,#Y:_0WXG_P#)/?&'_8"OO_1==W0!^6__
M  YK_P""?W_1&8__  :S_P#QJC_AS7_P3^_Z(S'_ .#6?_XU7ZD44 ?EO_PY
MK_X)_?\ 1&8__!K/_P#&J/\ AS7_ ,$_O^B,Q_\ @UG_ /C5?J110!^6_P#P
MYK_X)_?]$9C_ /!K/_\ &J/^'-?_  3^_P"B,Q_^#6?_ .-5^I%% 'Y;_P##
MFO\ X)_?]$9C_P#!K/\ _&J/^'-?_!/[_HC,?_@UG_\ C5?J110!^6__  YK
M_P""?W_1&8__  :S_P#QJC_AS7_P3^_Z(S'_ .#6?_XU7ZD44 ?EO_PYK_X)
M_?\ 1&8__!K/_P#&J/\ AS7_ ,$_O^B,Q_\ @UG_ /C5?J110!^6Y_X(U_\
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M-6T@B^TV7RY%"R+'>00NT9.7"[0>:_6"N&^)G_(@>+?^P)>?^@4 =R  , 8
MX '0#THHHH XCXA_\BR?^QA\%?\ J:>'Z[8]5^O]#7$_$/\ Y%D_]C#X*_\
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M?CM8OX2FTSQK:S:7XW\-^(K32[V]GG\)7HMO%VGSZ9;:O=/!H\S)IEWM^Q3
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MXJV1U#3-5BU3Q/X*%QX4G\617^F23V\R>-;;2;3Q81'(GE/J@A6)%1C+]<T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7 >/?]9X'_ .Q_T+_TFU.N_K@/'O\ K/ _
M_8_Z%_Z3:G0!W]%%% !7Y]Z;^PCIUG\&?^"AWP=_X6/JAM?V^_B!^T%XZU'Q
M ^C6]Y/\-V^/?P5\)?!Z[L],TV2Y@@UB/PQ%X975[.&ZO+9-1:3R)FM0TKK]
MV^(=?TCPKH&N>*/$%['IN@^&]'U/7];U&5)I8K#2-'LI]1U*]DCMXYKB2.UL
MK>:=T@BEF=8RL4;N54_!WP2_X*B?L.?M$>+OAYX(^&?QJN#XK^+VE'7?A'HO
MQ"^%OQF^#O\ PM73(]-76I;WX::C\7?A_P"#-&\?0P:=:W-Q)_PB%QK$BB*1
MHRIS)* 9GQX_X)^P?%?PC^R/_P (E\3K'P9\6?V,[1K+X8^._%7PK\*_%/PC
MK]AJOPHG^$7C'1_&_P -/$5W8Q7>C^,/#=P\6HIX?\4^']:LH9+B#3-=M)Y8
M;ZT\P^+7_!.CXF?%G1?V8-6\1_'CX77/QB_9E\>_$WQQI?B:7]DSPW=_!3QG
M<_%71+KPQ>/JOP NOBAJ6G:7XM\*6%X;SPEXWC\27TND:@AOKBRNA+<QG](/
MA[\5O"OQ/E\<1>%HO$J'X>?$#7?AIXC/B+PAXH\)J_B;P[%92ZD=#;Q)I&FK
MXCT()?PFT\1Z&U[HM^RM]COIHPSCTJ@#\=/#/_!*S7?AS^SY^R/\+_A+^TQ>
M>%?BI^QW^TS\??VE?A_\8=6^$'A[6M*U?4?VD]8_:4N?B!X3USX51^)-*T:W
ML(?#O[3/B;0](N;/5K=[+^Q].NX;2W:[FBM?3/BE_P $V]+^*GP]_P""C?P_
MUSXKW^F1?\%#?'?@+QQK>J:7X/L)O^%;WW@CX'_ GX."#2M-OM6N/[<CU7_A
M2=MKKB^NH39+JTT"S/):_:IOT_HH _-;]J3_ ()Q> /VK?'?[1_B;QUXX\0Z
M9I_[0_['/@/]DVYTG1--LVN/!E[\-/BU\1?C/X/^*6DZI+)M;7]#\7^.]+U'
M3M$OD%C=RZ#;FYD:*5XDX;Q'_P $ZOBQ\3_V=?VAOV>?C'^TA\/M;TCXV>']
M$\.Z5K_PL_9<\+_!C6?#4?A[Q?IWB:WUC7[G2/'WB#_A--<U>WTJVL-4N)4T
M:R@FDDO;2P.PV\WZQ44 ?#7Q;_8@\+_&'XT?';XK^(/&&KV-G\=OV'+W]B'7
M/#6G6< 33?#.K^+/B9XFU7QE9W[3+)_;)C^(L]C;6IC$(^QB=Y@[!3W/[/G[
M//BGX:?LP:+^S7\;?BE:?'VVTCP')\+9?%,'@"R^%SZI\-XO"]KX0L- OM"T
MGQ#X@MY;ZTT..2SN]?@O[:74&G6:2TMKA'>7ZLHH _'OX'?\$T?B#\-M?_94
M\,_%;]K+Q+\=O@'^PYJVE:M^S#\(-0^%GAKP9J6DZSX<^'/B;X/^!=7^*'Q&
MTO4+FZ\>WOPO^'_C/5(/"<$5AH)O[R*#4KZ*Z>%[>?[D_8\_9OT[]DOX >&O
M@1IGB:\\96'A[Q;\7_%,/B#4+:&UN;X_%KXR_$#XO7%L]O'))&B:9-XZFTV,
M+)(&@LT=6;=@?4%% 'X<WW_!![]BGQ1^SC\2?A?\2? ?PP\=?M3?%B'XV^)?
M$'[=.I_!?P##^T5#\9/C%XP\5^.YOC3INMPQPZE_;O@'Q5XOTNY\,Q6^L00V
M[>'])66:!YI'C]-^._\ P2]\4_&?0?VJK2/]J"]\+^(/VO-$_9.\._%;4+OX
M3Z=XH\.^(/#_ .S7INJZ-XE\(>(O"C>-]!?Q#X+^/>FZQ<:'\2M"77=(>3PW
M>ZIH5C>I#J!FB_7FB@#X(T[]D3XBZY\2/V/?BW\9OC;X>^('CO\ 9)UKXUWU
MC=>#/@^_PJ\/>,=/^,/PTU#X:V^GMX<7XB>.X]"'A/3;N%K>6'4+X7ZP[IH[
M-E+S_.'B?_@E+8:D]MXM\$_'&'PW\8O"_P"V/^T]^UM\/O&7C#X.^&?B+X6T
ME?VKH=2TGXD_"_QC\,-=UG2K;QAX;N=!N)M&@URSUWPIK4MK:B?3[C39F-RG
M[#44 ?GWIO[%WBF^\6?L8^/_ (G?%WP]XK\;?LD?%OXL_%);SP%\'=)^$WAC
MQU-\5?@-\3/@3)II\&V'B?Q>/#RZ!I_Q)FU&.[M]8O&NDM8X;F2)8P]<1\)_
M^";ND?"WP7_P3<\&V_Q/U?6(O^">7B_QUXLTNZN-&M;;_A8DGCCX+_&'X0FW
MU!%FE73VT:T^*MQ<VKPO*TL-@/-$4DD8'Z=T4 ?D+XU_X)0Z3KL.I>)/"7QE
M3PO\7]-_;@^,O[;7PW\>Z_\ "G0_'OAWPQK_ ,</ ;_#KQY\-O$WP[U'Q#H]
MEXT\$^(/#-S?Z5KSPZ]X;U;4["\G2SOM)N)3=+[9)^QAXTU^+]DJY^)WQG\,
M>(O%/[+W[4-_^TT-2\ ?!7P_\*/#?C%I?@)\9?@9%X2B\$CQ1XU30;>QL_C#
M/J1UFVUU[A?L=LA82QP2Q?H=10!Y#\;O!GQ$\>?#/Q'X6^$_Q$T;X5^.-4BM
M8=*\9>)/AWI?Q1\.V\<6I03:MI?B'P%JVJ:!;>(=#\2V"76C:O:V^LZ+?26-
M[--IVK6-XMK=1>#?L3_L;:5^QU\)O'_PWC\3Z3XTG^)OQ?\ B9\9O%#>%_ =
MC\)_ MAKGQ1OH+[7-"\!_#;2=>\1:=X+\-0R0O+;:9:ZW=F2\NKNYEN4,RK#
M]KT4 ?SB>-/^#?[_ (65\'_AA^S7XV_;"\32? S]G/2O$.D?L[3>&_@EX"T7
MXU>%-'\0^'_$>ES> _'_ ,5+J^U*+XG_  >NIO$30>,_AE>^&=-TSXA^&(;C
MPMK]_##=?:;;]E?BK\ ?$?QN_8V^+/[+?Q%^)!U+Q1\8?V=?B'\"?&7Q9T?P
MGI_A]YM3^(_P[UKP%JOC/3_"%G(^D63VHUE]1BTFSN5LHY(!;(;6,!8OJ:B@
M#Y8^*G[,.C_%;]C3QM^QQK'C/7M*T;QW^SMKG[/5SX\T2*&Q\26.G:S\/9_A
M^_BJRL1<K:G4+.VN!JIT]K@VLLT9MVD".''P!\._^"1M]X<M?VBI?&7Q]\-7
MNK_'C]AG7?V$M+L/A5^SIX'^#'@?P)X*U-?%WV;QX/"^C>(M;N_&7CQ6\2FZ
MU2YUS6H;2]-H;.UCL-/,,%K^TU% 'YV?'+_@G-\*?VAO"_['GP\^*5ZGBWX9
M?LMZ=X[\.:[X#U?1+:71/BWX:\??LF?%#]E'4[#68%FWZ)/:Z)\2[OQ%IUUI
M[R2V%[;;;6:*58+N+B_A]_P3P\1^'=7_ &>M5\=?M(^,_BAJW[.?[/7[6O[.
M7A7Q7XI\,6B^+?$O@;]I[6_@YJ.AZKXPU?[68K_Q9\+-.^#^F>&-,DA2WBUK
M2KA;F^M;2_DNI;K]1Z* /S9\#_\ !/VS\ ^&?^"9^AZ9\3M2AU#_ ()R?!74
MOA)X:NH]#M;M?'4FH?LRV7[-]OXEO;>>5%M9=(CM(/$<5F5DMYGF>UO9H8@)
M'^=M8_X)!3?$I/VHM?\ CI^T);:_\5?VF?A]\*O!-W\1_@E\#/"7P&;0?$_P
M-^+"_&_X3?&[7_#FF^*/%4'CKXM>$_B1I_AO4D\0:CJ%I#)8Z)%ID5G:VMR'
ML/VOHH _&?XB_P#!*KQW^T'X1_:@N/VF_P!JZ^^*7QH_:"_9/\5_L;>'?'_A
MGX.>'OAIX1^$WPC\8ZZGBW7ETCX>6?B3Q!;^)?$^N^);32-1UCQ+J6MVTK1:
M=#IMC9VEG!#!%]\7G[.EE)^V5H7[7'_"47K:KIG[,_B/]FY/!)T>#^SY+#Q!
M\5/"GQ.G\6-XA5C/#>02>%QIG]CM;I;7$<B7"SB95CKZ@HH _-3]I#]@_P 9
M_M,?M#_!OXF^-_C=X9'PM^!?QG^#_P =O /@&V^ 'A@_%7PQXP^$_B;1O$\6
MC>'?VA)/%4&KV'@/QU?Z4\/Q \/?\(E=7>I:-/<:3%J(BN(Q'^E=%% !3&^X
M?J?_ $*G$X!/H":B8ANHY'(]0,9!QSGOSC&/3-14CS1:ZRBTOE:3^Y+_ "#9
MQ?2_=*[5VEJTM>]_D?Y\'_!:O_E)S^U#_P!??PK_ /5)?"RORTK^T']L/_@A
M[%^V)^UK\:/C7)^TF_PY;QG;?#C5SH"?":/QIY4-IX:'@Y@=0E^)'AL*TB>"
MHV4BQ0*2?E^4%OGW_B&0T[_H\VY_\1XL_P#Y]%?W?P=XT^&N4<)\-Y7CN(:E
M/&8#),NPN*I0R?.JJIUZ.'C&I#VE/ 2I3Y977-3G.+L_>/Y-XB\,^,\?GN;X
M["90JN&QF88K$T9_7LNA>%6JVO=J8J$M--;:WU2>A_*!17]7_P#Q#(:=_P!'
MFW/_ (CQ9_\ SZ*/^(9#3O\ H\VY_P#$>+/_ .?17TG_ !'KPK_Z*.M_X8\]
M_P#G>>-_Q"GCO_H2_P#F0RK_ .;3^4"BOZO_ /B&0T[_ */-N?\ Q'BS_P#G
MT4?\0R&G?]'FW/\ XCQ9_P#SZ*/^(]>%?_11UO\ PQY[_P#.\/\ B%/'?_0E
M_P#,AE7_ ,VG\H%%?U?_ /$,AIW_ $>;<_\ B/%G_P#/HH_XAD-._P"CS;G_
M ,1XL_\ Y]%'_$>O"O\ Z*.M_P"&//?_ )WA_P 0IX[_ .A+_P"9#*O_ )M/
MY0**_J__ .(9#3O^CS;G_P 1XL__ )]%'_$,AIW_ $>;<_\ B/%G_P#/HH_X
MCUX5_P#11UO_  QY[_\ .\/^(4\=_P#0E_\ ,AE7_P VG\H%%?U?_P#$,AIW
M_1YMS_XCQ9__ #Z*/^(9#3O^CS;G_P 1XL__ )]%'_$>O"O_ **.M_X8\]_^
M=X?\0IX[_P"A+_YD,J_^;3^4"BOZO_\ B&0T[_H\VY_\1XL__GT4C?\ !L?I
MS*5/[9MSA@0<?L\V@.",'!'QIR/J.11_Q'KPK_Z*.M_X8\]_^=X?\0IX[_Z$
MO_F0RK_YM/Y0:*_JGU__ (-H]-T+1-7UA/VSKI&L+.6]);]GN%@?LJ&14VI\
M:2VYV4*I ."1D8Y&[)_P;)Z:Q)3]LV_C!=I"H^ %LREY(_+DRI^-&"K\DJ>@
M)7)Y)/\ B/7A7_T4E;_PQY[_ /.\/^(4<=_]"7_S(95_\VG\G=%?U?\ _$,A
MIW_1YMS_ .(\6?\ \^BC_B&0T[_H\VY_\1XL_P#Y]%'_ !'KPK_Z*.M_X8\]
M_P#G>'_$*>._^A+_ .9#*O\ YM/Y0**_J_\ ^(9#3O\ H\VY_P#$>+/_ .?1
M1_Q#(:=_T>;<_P#B/%G_ //HH_XCUX5_]%'6_P##'GO_ ,[P_P"(4\=_]"7_
M ,R&5?\ S:?R@45_5_\ \0R&G?\ 1YMS_P"(\6?_ ,^BC_B&0T[_ */-N?\
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MAM%^$^G:I T=[X8\&VTBAM/O[ZTE2+Q+=1\W%VDT,;>2LAE_8W1O^2@>.?\
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MD_\ 8P^"O_4T\/UVQZK]?Z&N'^(SI'X6>21TCC37_!CO)(VQ$1?&6@,SN_\
M"BJ"S-_" 3VKJ_[3TW_H(6/3/_'W;],;L_ZSIM^;/ISTH O450_M72_^@E8?
M^!EO_P#'*/[5TO\ Z"5A_P"!EO\ _'* +]%4/[5TO_H)6'_@9;__ !RC^U=+
M_P"@E8?^!EO_ /'* +]%4/[5TO\ Z"5A_P"!EO\ _'*/[5TO_H)6'_@9;_\
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M_P"@E8?^!EO_ /'* +]%4/[5TO\ Z"5A_P"!EO\ _'*/[5TO_H)6'_@9;_\
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M_@9;_P#QRC^U=+_Z"5A_X&6__P <H OT50_M72_^@E8?^!EO_P#'*/[5TO\
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MJA_:NE_]!*P_\#+?_P".4?VKI?\ T$K#_P #+?\ ^.4 7Z*H?VKI?_02L/\
MP,M__CE']JZ7_P!!*P_\#+?_ ..4 7Z*H?VKI?\ T$K#_P #+?\ ^.4?VKI?
M_02L/_ RW_\ CE %^BJ']JZ7_P!!*P_\#+?_ ..4?VKI?_02L/\ P,M__CE
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M_M72_P#H)6'_ (&6_P#\<H&J:83@:C8$G@ 7EODGT_UE ')_$_\ Y)[XP_[
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M"O\ X3VD?_(==537W;6V %]IV@MM!;!V@MM?:"<9;8^!SM;H0#E_^$%\$?\
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MXAT/4-(MLI=W#)9WERT4=I;&6X^KZ .5_P"$%\$?]"=X5_\ ">TC_P"0Z/\
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MW6[K-U;SQ,2LEPQ4,S1Q\*@" "OC/_B(7_X*!_\ 5#__  A-2_\ DZOVO*/
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MQD\$^"Y&9F\(^%I'+ NTF@:2[$DIDL3:%BS*!@D]0I.0!7\/&K?\' 7_  4
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M^0Z/^$%\$?\ 0G>%?_">TC_Y#KJJ* .5_P"$%\$?]"=X5_\ ">TC_P"0Z/\
MA!?!'_0G>%?_  GM(_\ D.NJHH Y8>!?!(((\'>%00<@CP]I ((Z$'['P17&
MZ5X1\*R^./&5K+X5\//:VVC^"Q:Q2:#I1@CW#Q,'\E?L[#@$J?D3:"47*DUZ
MW7":-_R4#QS_ -@;P3_/Q-0!H_\ ""^"/^A.\*_^$]I'_P AT?\ ""^"/^A.
M\*_^$]I'_P AUU5% '*_\(+X(_Z$[PK_ .$]I'_R'1_P@O@C_H3O"O\ X3VD
M?_(==510!RO_  @O@C_H3O"O_A/:1_\ (='_  @O@C_H3O"O_A/:1_\ (==5
M10!RO_""^"/^A.\*_P#A/:1_\AT?\(+X(_Z$[PK_ .$]I'_R'7544 <K_P (
M+X(_Z$[PK_X3VD?_ "'1_P (+X(_Z$[PK_X3VD?_ "'7544 <K_P@O@C_H3O
M"O\ X3VD?_(='_""^"/^A.\*_P#A/:1_\AUU5% '*_\ ""^"/^A-\*_^$]I'
M_P AUQ_Q \&>#;3P3XGN+?PAX5CEBTBYDC<>'=(^22-<Q2 "VC^:)COC;<-C
M ,,XP?6JX;XF?\B!XM_[ EY_Z!0!H2>"?!<C,S>$?"TCE@7:30-)=B24R6)M
M"Q9E P2>H4G( I/^$%\$?]"=X5_\)[2/_D.NJHH Y7_A!?!'_0G>%?\ PGM(
M_P#D.C_A!?!'_0G>%?\ PGM(_P#D.NJHH Y7_A!?!'_0G>%?_">TC_Y#H_X0
M7P1_T)WA7_PGM(_^0ZZJB@#E?^$%\$?]"=X5_P#">TC_ .0Z/^$%\$?]"=X5
M_P#">TC_ .0ZZJB@#E?^$%\$?]"=X5_\)[2/_D.C_A!?!'_0G>%?_">TC_Y#
MKJJ* .5_X07P1_T)WA7_ ,)[2/\ Y#H_X07P1_T)WA7_ ,)[2/\ Y#KJJ* .
M5_X07P1_T)WA7_PGM(_^0Z4>!O!(((\'>%@0001X>TD$$<@@BTR"#T-=310!
MY#I/A#PC+XX\9V<OA/PX]K:Z1X*DMX9- TDV\1?_ (28$P*;=@"-I!.Q-I8A
M<@DUVG_""^"/^A.\*_\ A/:1_P#(=9VC?\E \<_]@;P3_/Q-7=T <K_P@O@C
M_H3O"O\ X3VD?_(='_""^"/^A.\*_P#A/:1_\AUU5% '*_\ ""^"/^A.\*_^
M$]I'_P AT?\ ""^"/^A.\*_^$]I'_P AUU5% '*_\(+X(_Z$[PK_ .$]I'_R
M'1_P@O@C_H3O"O\ X3VD?_(==510!RO_  @O@C_H3O"O_A/:1_\ (='_  @O
M@C_H3O"O_A/:1_\ (==510!RO_""^"/^A.\*_P#A/:1_\AT?\(+X(_Z$[PK_
M .$]I'_R'7544 <K_P (+X(_Z$[PK_X3VD?_ "'1_P (+X(_Z$WPK_X3VD?_
M "'7544 >1?$3P;X.L_ OBJXMO"'A6.>'1;N2)U\.Z22DL<9,,@ MH_FB?#Q
MMO&Q@&&<8/;2>"?!DS%Y?"/AB5F<R%I- TIV+L &<LUH278*H+$Y(4 G@5E_
M$_\ Y)[XP_[ 5]_Z+KNZ .5_X07P1_T)WA7_ ,)[2/\ Y#H_X07P1_T)WA7_
M ,)[2/\ Y#KJJ* .5_X07P1_T)WA7_PGM(_^0Z/^$%\$?]"=X5_\)[2/_D.N
MJHH Y7_A!?!'_0G>%?\ PGM(_P#D.C_A!?!'_0G>%?\ PGM(_P#D.NJHH Y7
M_A!?!'_0G>%?_">TC_Y#H_X07P1_T)WA7_PGM(_^0ZZJB@#E?^$%\$?]"=X5
M_P#">TC_ .0Z/^$%\$?]"=X5_P#">TC_ .0ZZJB@#E?^$%\$?]"=X5_\)[2/
M_D.C_A!?!'_0G>%?_">TC_Y#KJJ* .6'@;P2""/!WA8$$$$>'M)!!'(((M,@
M@]#7%:3X0\(R^./&=G+X3\./:VND>"I+>&30-)-O$7_X28$P*;=@"-I!.Q-I
M8A<@DUZ]7":-_P E \<_]@;P3_/Q-0!H_P#""^"/^A.\*_\ A/:1_P#(='_"
M"^"/^A.\*_\ A/:1_P#(==510!RO_""^"/\ H3O"O_A/:1_\AT?\(+X(_P"A
M.\*_^$]I'_R'7544 <K_ ,(+X(_Z$[PK_P"$]I'_ ,AT?\(+X(_Z$[PK_P"$
M]I'_ ,AUU5% '*_\(+X(_P"A.\*_^$]I'_R'1_P@O@C_ *$[PK_X3VD?_(==
M510!RO\ P@O@C_H3O"O_ (3VD?\ R'1_P@O@C_H3O"O_ (3VD?\ R'7544 <
MK_P@O@C_ *$[PK_X3VD?_(='_""^"/\ H3O"O_A/:1_\AUU5% '*_P#""^"/
M^A-\*_\ A/:1_P#(=<=\0/!W@^R\$>)[FT\)^&;>X@TBYF@G@T'2XIH)HDW0
M3PR16T;Q36[XE@E1P\,BK(F2N#ZW7#?$S_D0/%O_ &!+S_T"@#N:*** .(^(
M?_(LG_L8?!7_ *FGA^NV/5?K_0UQ/Q#_ .19/_8P^"O_ %-/#]=L>J_7^AH
M6BBB@ .<''7MD9&?<9&?ID?6OR9_X+?_ ++5]^UG_P $R?VF_ WA6(?\+*\
M>$X/C_\ ".:)5,__  LKX#WUO\3?#VGVX(VM+XDB\.7GA10S*F-;#.P5!C]9
MJ:Z)*CQR(LD<BLDD;J'1T<%71U8%65E)5E8$,"000: /XL-&_:'TS_@L'\7/
M$?[6FGO#K7PV_P""?O\ P1"^)_B#5(+>TBM+7P]^W-^W)\%O&$7Q9T6**,H!
M'IWPN\'&PQ&FR.YB#J%2X"CZR^$/[(WCW]N;_@UW_9A_9;^&7Q*\/_#CQ_\
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M<-K%YKN6(CC 9F.<EJUZ "BBB@ HHHH **** "BBB@ HHHH *X#Q[_K/ _\
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M'?\ 9V\8_!?XL?$#PU8_&#XJ> /V@[VS\5>*_P!E:R?P)J5_JWQMN/A]H_\
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M/R%9&$6W"8!((!_*9\2OVG9_C5IO_!,P2RQ?!']B[XN?LS?'KQ5HO@W]I/\
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M';^/'_ST:/\ ARC_ ,$QO^C8K;_P[?QX_P#GHT?\3.<$?]"3BW_PDRC_ .?
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M\%6M?_*ZC_A:7@7_ *#;?^"K6O\ Y75Z!10!Y_\ \+2\"_\ 0;;_ ,%6M?\
MRNH_X6EX%_Z#;?\ @JUK_P"5U>@44 >?_P#"TO O_0;;_P %6M?_ "NH_P"%
MI>!?^@VW_@JUK_Y75Z!10!Y__P +2\"_]!MO_!5K7_RNH_X6EX%_Z#;?^"K6
MO_E=7H%% 'G_ /PM+P+_ -!MO_!5K7_RNH_X6EX%_P"@VW_@JUK_ .5U>@44
M >?_ /"TO O_ $&V_P#!5K7_ ,KJ/^%I>!?^@VW_ (*M:_\ E=7H%% 'G_\
MPM+P+_T&V_\ !5K7_P KJ/\ A:7@7_H-M_X*M:_^5U>@44 >?_\ "TO O_0;
M;_P5:U_\KJ/^%I>!?^@VW_@JUK_Y75Z!10!Y_P#\+2\"_P#0;;_P5:U_\KJ/
M^%I>!?\ H-M_X*M:_P#E=7H%% 'G_P#PM+P+_P!!MO\ P5:U_P#*ZC_A:7@7
M_H-M_P""K6O_ )75Z!10!Y__ ,+2\"_]!MO_  5:U_\ *ZC_ (6EX%_Z#;?^
M"K6O_E=7H%% 'G__  M+P+_T&V_\%6M?_*ZC_A:7@7_H-M_X*M:_^5U>@44
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M:U_\KJ] HH \_P#^%I>!?^@VW_@JUK_Y74?\+2\"_P#0;;_P5:U_\KJ] HH
M\_\ ^%I>!?\ H-M_X*M:_P#E=1_PM+P+_P!!MO\ P5:U_P#*ZO0** //_P#A
M:7@7_H-M_P""K6O_ )74?\+2\"_]!MO_  5:U_\ *ZO0** //_\ A:7@7_H-
MM_X*M:_^5U'_  M+P+_T&V_\%6M?_*ZO0** //\ _A:7@7_H-M_X*M:_^5U'
M_"TO O\ T&V_\%6M?_*ZO0** //_ /A:7@7_ *#;?^"K6O\ Y74?\+2\"_\
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M7[!JA<^6ZHX""Q+95V52,9R>!P<=[10!Y_\ \+2\"?\ 0<(]SI>LJ![ECIP
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MKJ] HH \_P#^%I>!?^@VW_@JUK_Y74?\+2\"_P#0;;_P5:U_\KJ] HH \_\
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MG_\ PM+P+_T&V_\ !5K7_P KJ/\ A:7@7_H-M_X*M:_^5U>@44 >?_\ "TO
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M%% 'G_\ PM+P+_T&V_\ !5K7_P KJ/\ A:7@7_H-M_X*M:_^5U>@44 >?_\
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M_"*A_P#-I_:'17\7G_#Y?]O?_HIOA3_PU/@/_P".T?\ #Y?]O?\ Z*;X4_\
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M_P##4^ __CM'_#Y?]O?_ **;X4_\-3X#_P#CM'_$L7B'_P!!W"O_ (<\=_\
M.D/^(Q<+?] V=?\ A%0_^;3^T.BOXO/^'R_[>_\ T4WPI_X:GP'_ /':/^'R
M_P"WO_T4WPI_X:GP'_\ ':/^)8O$/_H.X5_\.>._^=(?\1BX6_Z!LZ_\(J'_
M ,VG]H=%?Q>?\/E_V]_^BF^%/_#4^ __ ([1_P /E_V]_P#HIOA3_P -3X#_
M /CM'_$L7B'_ -!W"O\ X<\=_P#.D/\ B,7"W_0-G7_A%0_^;3^T.BOXO/\
MA\O^WO\ ]%-\*?\ AJ? ?_QVC_A\O^WO_P!%-\*?^&I\!_\ QVC_ (EB\0_^
M@[A7_P .>._^=(?\1BX6_P"@;.O_  BH?_-I_:'17\7G_#Y?]O?_ **;X4_\
M-3X#_P#CM'_#Y?\ ;W_Z*;X4_P##4^ __CM'_$L7B'_T'<*_^'/'?_.D/^(Q
M<+?] V=?^$5#_P";3^T.BOXO/^'R_P"WO_T4WPI_X:GP'_\ ':/^'R_[>_\
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M !+%XA_]!W"O_ASQW_SI#_B,7"W_ $#9U_X14/\ YM/[0Z*_B\_X?+_M[_\
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M]O?_ **;X4_\-3X#_P#CM'_$L7B'_P!!W"O_ (<\=_\ .D/^(Q<+?] V=?\
MA%0_^;3^T.BOXO/^'R_[>_\ T4WPI_X:GP'_ /':/^'R_P"WO_T4WPI_X:GP
M'_\ ':/^)8O$/_H.X5_\.>._^=(?\1BX6_Z!LZ_\(J'_ ,VG]H=%?Q>?\/E_
MV]_^BF^%/_#4^ __ ([1_P /E_V]_P#HIOA3_P -3X#_ /CM'_$L7B'_ -!W
M"O\ X<\=_P#.D/\ B,7"W_0-G7_A%0_^;3^T.BOXO/\ A\O^WO\ ]%-\*?\
MAJ? ?_QVC_A\O^WO_P!%-\*?^&I\!_\ QVC_ (EB\0_^@[A7_P .>._^=(?\
M1BX6_P"@;.O_  BH?_-I_:'17\7G_#Y?]O?_ **;X4_\-3X#_P#CM'_#Y?\
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MX6_Z!LZ_\(J'_P VG]H=%?Q>?\/E_P!O?_HIOA3_ ,-3X#_^.T?\/E_V]_\
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M0_\ H.X5_P##GCO_ )TA_P 1BX6_Z!LZ_P#"*A_\VG]H=%?Q>?\ #Y?]O?\
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MU/@/_P".T?\ #Y?]O?\ Z*;X4_\ #4^ _P#X[1_Q+%XA_P#0=PK_ .'/'?\
MSI#_ (C%PM_T#9U_X14/_FT_M#HK^+S_ (?+_M[_ /13?"G_ (:GP'_\=H_X
M?+_M[_\ 13?"G_AJ? ?_ ,=H_P")8O$/_H.X5_\ #GCO_G2'_$8N%O\ H&SK
M_P (J'_S:?VAT5_%Y_P^7_;W_P"BF^%/_#4^ _\ X[1_P^7_ &]_^BF^%/\
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M ([1_P /E_V]_P#HIOA3_P -3X#_ /CM'_$L7B'_ -!W"O\ X<\=_P#.D/\
MB,7"W_0-G7_A%0_^;3^T.BOXO/\ A\O^WO\ ]%-\*?\ AJ? ?_QVC_A\O^WO
M_P!%-\*?^&I\!_\ QVC_ (EB\0_^@[A7_P .>._^=(?\1BX6_P"@;.O_  BH
M?_-I_:'17\7G_#Y?]O?_ **;X4_\-3X#_P#CM'_#Y?\ ;W_Z*;X4_P##4^ _
M_CM'_$L7B'_T'<*_^'/'?_.D/^(Q<+?] V=?^$5#_P";3^T.BOXO/^'R_P"W
MO_T4WPI_X:GP'_\ ':/^'R_[>_\ T4WPI_X:GP'_ /':/^)8O$/_ *#N%?\
MPYX[_P"=(?\ $8N%O^@;.O\ PBH?_-I_:'17\7G_  ^7_;W_ .BF^%/_  U/
M@/\ ^.T?\/E_V]_^BF^%/_#4^ __ ([1_P 2Q>(?_0=PK_X<\=_\Z0_XC%PM
M_P! V=?^$5#_ .;3^T.BOXO/^'R_[>__ $4WPI_X:GP'_P#':/\ A\O^WO\
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M;3^T.BOXO/\ A\O^WO\ ]%-\*?\ AJ? ?_QVC_A\O^WO_P!%-\*?^&I\!_\
MQVC_ (EB\0_^@[A7_P .>._^=(?\1BX6_P"@;.O_  BH?_-I_:'17\7G_#Y?
M]O?_ **;X4_\-3X#_P#CM'_#Y?\ ;W_Z*;X4_P##4^ __CM'_$L7B'_T'<*_
M^'/'?_.D/^(Q<+?] V=?^$5#_P";3^T.BOXO/^'R_P"WO_T4WPI_X:GP'_\
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M?_HIOA3_ ,-3X#_^.T?\/E_V]_\ HIOA3_PU/@/_ ..T?\2Q>(?_ $'<*_\
MASQW_P Z0_XC%PM_T#9U_P"$5#_YM/[0Z*_B\_X?+_M[_P#13?"G_AJ? ?\
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M6D7S,U_I&?\ !08$_L4?M-@=3\(?%H'U-EQ^M?YA7[=GAK1?&GQC_8N\):_
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MK/\ "T69\=:YJGC73_#<$=]J+*EC9:39*%$TLLQ>WM8X7>9[F/RQ'DHQ]=^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NQ^'?_ "4#P+_V./AC
M_P!/=C7'5V/P[_Y*!X%_[''PQ_Z>[&N'-/\ D5YE_P!BW,__ % K&V$_W[!_
M]A>!_P#4RF?Z+D?^KC_W%_\ 0111'_JX_P#<7_T$45_D!4_B5/\ '/\ ]*D?
MW/3_ (=/_KW#_P!(B?'7_!0DD?L3?M.%6*D?!_Q<0P."I%CPP/8@\@]B,U_
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MI]@+2!;:T.GNQ"EU5!Y8<A&. _!-?GO_ ,/#?^J=C_P/?_XFC_AX;_U3L?\
M@>__ ,35_P"NG"'LJU!\.9FZ.(PU#"UJ'^JV CAZE'"5)U,-&>&AF$:$XTG4
MFN2<)0DI-.*6\2R3.95(U99S@I582YXU99[BW6C/?VD*RPRJ0GHM82BM$VFT
MFOM_2/@/\&O#T5Z^B_"KP%I<FI^%KGP-J8TO0],M;?5_#&H126FIZ+J=O'EY
M+/4=/GFL[I(QYCP2NJ_-C'>>'O#.A>"]'T_PUX9T73]$T#2%>STC2=*M!9VE
MLBYGG^R1<[W49\M>[!1T-?G)_P /#?\ JG8_\#W_ /B:/^'AO_5.Q_X'O_\
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M>'O$YLD&N:5I7V1K*#3;'S#Y?]EQH?+#2 JL1;) 9J_.'_AXGK7_ $2W2O\
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M-M^RII.VBJTDEITLTW??6[/U-HK\LO\ AXGK7_1+=*_\*X__ !-'_#Q/6O\
MHENE?^%<?_B:/]<>'O\ H,K?^$6)%_8>8_\ /NG_ .#J?_R1^IM%?EE_P\3U
MK_HENE?^%<?_ (FC_AXGK7_1+=*_\*X__$T?ZX\/?]!E;_PBQ(?V'F/_ #[I
M_P#@ZG_\D?J;17Y9?\/$]:_Z);I7_A7'_P")H_X>)ZU_T2W2O_"N/_Q-'^N/
M#W_096_\(L2']AYC_P ^Z?\ X.I__)'ZFT5^67_#Q/6O^B6Z5_X5Q_\ B:/^
M'B>M?]$MTK_PKC_\31_KCP]_T&5O_"+$A_8>8_\ /NG_ .#J?_R1^IM%?EE_
MP\3UK_HENE?^%<?_ (FC_AXGK7_1+=*_\*X__$T?ZX\/?]!E;_PBQ(?V'F/_
M #[I_P#@ZG_\D?J;17Y9?\/$]:_Z);I7_A7'_P")H_X>)ZU_T2W2O_"N/_Q-
M'^N/#W_096_\(L2']AYC_P ^Z?\ X.I__)'ZFT5^67_#Q/6O^B6Z5_X5Q_\
MB:/^'B>M?]$MTK_PKC_\31_KCP]_T&5O_"+$A_8>8_\ /NG_ .#J?_R1^IM%
M?EE_P\3UK_HENE?^%<?_ (FC_AXGK7_1+=*_\*X__$T?ZX\/?]!E;_PBQ(?V
M'F/_ #[I_P#@ZG_\D?J;17Y9?\/$]:_Z);I7_A7'_P")H_X>)ZU_T2W2O_"N
M/_Q-'^N/#W_096_\(L2']AYC_P ^Z?\ X.I__)'ZFT5^67_#Q/6O^B6Z5_X5
MQ_\ B:/^'B>M?]$MTK_PKC_\31_KCP]_T&5O_"+$A_8>8_\ /NG_ .#J?_R1
M^IM%?EE_P\3UK_HENE?^%<?_ (FC_AXGK7_1+=*_\*X__$T?ZX\/?]!E;_PB
MQ(?V'F/_ #[I_P#@ZG_\D?J;17Y9?\/$]:_Z);I7_A7'_P")H_X>)ZU_T2W2
MO_"N/_Q-'^N/#W_096_\(L2']AYC_P ^Z?\ X.I__)'ZFT5^67_#Q/6O^B6Z
M5_X5Q_\ B:/^'B>M?]$MTK_PKC_\31_KCP]_T&5O_"+$A_8>8_\ /NG_ .#J
M?_R1^IM%?EE_P\3UK_HENE?^%<?_ (FC_AXGK7_1+=*_\*X__$T?ZX\/?]!E
M;_PBQ(?V'F/_ #[I_P#@ZG_\D?J;17Y9?\/$]:_Z);I7_A7'_P")H_X>)ZU_
MT2W2O_"N/_Q-'^N/#W_096_\(L2']AYC_P ^Z?\ X.I__)'ZFT5^6B?\%$M9
M+H#\+]*4%E!;_A+"^T$CYMNWYL==O?&.]=-X:_;PUGQ FO\ _%N-+M3H?AB\
MUG'_  D!C^U_V=#-=B'<0-OG>3LW <9S65?C?ANA2J5IXVLH4O9NH_J.*]V%
M2JJ7-HGM)K32^Q=+(,RJUJ=&-*#E451W]M3=E3IN>W-K>W+Y;GZ2T5^67_#Q
M+6C_ ,TMTKU_Y&UO_B:/^'B>M?\ 1+=*_P#"N/\ \36BXSX==_\ ;*VCT_V'
M%:Q:3A+6UN:+O;6W=F:R/,;*]*FG:[7MJ;L]=+\VNWXGZFT5^67_  \3UK_H
MENE?^%<?_B:/^'B>M?\ 1+=*_P#"N/\ \33_ -<>'O\ H,K?^$6)'_8>8_\
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M);I7_A7'_P")H_X>)ZU_T2W2O_"N/_Q-'^N/#W_096_\(L2']AYC_P ^Z?\
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M5^;5]^WIK%GX3\->(/\ A7.E3?VU>>(]/%N?$&SRO[!'ANVSN&=N/,'S=L9
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M'^N/#W_096_\(L2']AYC_P ^Z?\ X.I__)'ZFT5^67_#Q/6O^B6Z5_X5Q_\
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M#L+_ .J^H?DOB3_OF6?]@6(_]3(#:***_:H?"OG^9^81WE_B"BBBJ+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!R??7_>7^8KTWX8?=^('_ &2KQ+_Z(T2O,D^^O^\O\Q7IOPP^[\0/
M^R5>)?\ T1HE>7G?_(JQ_P#@P7_JYR<]+*O]]I?X,5_ZC3/,****]>I\<O\
M%6_]2L6><]H^C_\ 2IA1114""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I)/NM_N?\
MLE+22?=;_<_]DIKXH?\ 7VE_Z6A+XX^D_P#TEGIFO_\ ),/A]_V,_P 2?Y^%
MZ\TKTO7_ /DF'P^_[&?XD_S\+UYI7F99_#Q7_8PQO_IT[\P_B8?_ + \+_Z;
M"BBBO2.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!5ZCZC^=>G_&+_ )'VZ_[%GP%_ZKOP/7F"]1]1_.O3_C%_R/MU
M_P!BSX"_]5WX'KS:_P#R-LK],5_Z;D=M+_D79C_W+?\ IZ)Y?1117I](?]>X
M?E(XGO+_ !R_-!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O3O@G_R6;X1_P#93O 7_J5:37F->G?!/_DLWPC_ .RG
M> O_ %*M)K'%_P"XXS_L$QW_ *AU#IPG^\4?^PC"?^I5(_VKX_NCZ+_Z M%$
M?W1]%_\ 0%HK^%GN_5_FS^G8_#'_  Q_])B?D?\ \%X/^43'[8O_ &*WP\_]
M71\-J_R=&ZG_ +;?^E#5_K%_\%X/^43'[8O_ &*WP\_]71\-J_R=&ZG_ +;?
M^E#5_0?@I_N6>_\ 8=A?_5?4/RGQ&_WS+/\ L#K_ /J7$;02  3N(4$D)]_
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MD%Y)%WQQH#EG=?XD5<LR_P 2@CO7]^7@[X#?"G]JW]F?_@D5X:\4:'X4TO\
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M56*7):SNFY7]T_I*_P""C?P%_9C_ &@?CI^UQ_P4*_:5T7XC:]\+/@=^R?\
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M*** ')]]?]Y?YBO3?AA]WX@?]DJ\2_\ HC1*\R3[Z_[R_P Q7IOPP^[\0/\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@!T8+.BJI=F=0J"=+8N20 HN9
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MKU\KS#ZC#'**E[7$T(T83C.=+V:C4523=2G4IS?,HN'(G'=R<GI$_>?X#_\
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M]I+X6?LV?M*^#OVT++Q1\-?%WCKX>7_Q=\$?$+]E?P%XA\31:YX.\50?#/\
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M/A'PP0L:AC8/HQM'8?,S.S,Q9CEGB[]N?]JSQS=_&W4?%'Q@UK6=0_:,\ ^
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M?^C+OVL?_$>/BS_\SE'_  P%^W3_ -&7?M8_^(\?%G_YG*/[6RG_ *&F6_\
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ML_\ S.4?\,!?MT_]&7?M8_\ B/'Q9_\ F<H_M;*?^AIEO_AQR[_YY!]1Q_\
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M (CQ\6?_ )G*/[6RG_H:9;_X<<N_^>0?4<?_ - .+_\ ";$__,Q\D45];_\
M# 7[=/\ T9=^UC_XCQ\6?_F<H_X8"_;I_P"C+OVL?_$>/BS_ /,Y1_:V4_\
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MW3_T9=^UC_XCQ\6?_F<H_P"& OVZ?^C+OVL?_$>/BS_\SE']K93_ -#3+?\
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M+XN^+WA/PFMUI\;M$TM[=E&0HS ']"']GV/_ #Z6_P#WZ3_"C^S['_GTM_\
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MM:/[.L/^?2#_ +]K5VB@"E_9UA_SZ0?]^UH_LZP_Y](/^_:U=H.,'/3'/TH
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M ,X2C_B)/!O_ $-__++,?_F0/^)'?I0_]&R_\V_@?_Z(C^IFBOY9O^(E5_\
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MXD=^E#_T;+_S;^!__HB/ZF:*_EF_XB57_P"C+Q_XD;)_\X2C_B)5?_HR\?\
MB1LG_P X2C_B)/!O_0W_ /++,?\ YD#_ (D=^E#_ -&R_P#-OX'_ /HB/ZF:
M*_EF_P"(E5_^C+Q_XD;)_P#.$H_XB57_ .C+Q_XD;)_\X2C_ (B3P;_T-_\
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MXD=^E#_T;+_S;^!__HB/ZF:*_EF_XB57_P"C+Q_XD;)_\X2C_B)5?_HR\?\
MB1LG_P X2C_B)/!O_0W_ /++,?\ YD#_ (D=^E#_ -&R_P#-OX'_ /HB/ZF:
M*_EF_P"(E5_^C+Q_XD;)_P#.$H_XB57_ .C+Q_XD;)_\X2C_ (B3P;_T-_\
MRRS'_P"9 _XD=^E#_P!&R_\ -OX'_P#HB/ZF:*_EF_XB57_Z,O'_ (D;)_\
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M<?LUQ?\ !,.X^%G[46A:?KG_  3TL/VA/ _BV\U+X"I<Z'\?/A-^TI\1]/\
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MU:_\=_%74-2@BOKRUDO=/FL?"7@KP_I&L>+O%VM6@NKG2] TBYN(;2ZG41R
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M1FK:)^S7\3_%GQ4^ 'PE\1?%0W_PF^$^M^.?#GCKPMXIT[PYX930(9/['O\
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MBBB@ HHHH **** "BBB@ K@/'O\ K/ __8_Z%_Z3:G7?UP'CW_6>!_\ L?\
M0O\ TFU.@#OZ*** /.?C#\.[7XO?"3XI?":]U74=!LOBA\.?&_P[N]<T>9K?
M5]&M?&OAG4_#5QJNESJ5:'4=.BU-[RQF5E:.YAB<$%<U_)%\2OVR?VE_B'\
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ME\+ZBVEV\5X]Q+#8V.G6!=[2SC1O5_V;OV!_#/[+MWX7TKX?_M#?M3:M\(O
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MZ\;:;JWA:?Q';SW>JI8:19SVZ^C^*/\ @E'_ ,+A_:R_;+\<>/?B5\;/A/\
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M#GB%["&._P!/6 HP /SU\.?\%=_B]XX^.ZV7@/X=^'/$_P &I?VU[S]D7_A
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M<?"WQ7#\.?\ A/\ 6OA@VJ7'A_4XK[3?$NEZB-*BTVZTNZ/V^QNI]0$UK#/
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M"QM(:6,R7AS"T:U2GQ!4KU8X2->C"%*E?VLZ\*4(RJ4X\JA)2?-3<7-;NUG
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M=!_X1?@+TSCGM0!W-%<%_;7Q#_Z$71/_  N&_P#F6H_MKXA_]"+HG_A<-_\
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M7Q#_ .A%T3_PN&_^9:@#O:*X+^VOB'_T(NB?^%PW_P RU']M?$/_ *$71/\
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MM?$/_H1=$_\ "X;_ .9:CZE@_P#H$PG_ (287_YF#_6CBG_HJ>*/_$FXD_\
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M?_AF/]G+_H@'P4_\-7X#_P#E#1_PS'^SE_T0#X*?^&K\!_\ RAKN/[:^(?\
MT(NB?^%PW_S+4?VU\0_^A%T3_P +AO\ YEJ/J6#_ .@3"?\ A)A?_F8/]:.*
M?^BIXH_\2;B3_P"B$X?_ (9C_9R_Z(!\%/\ PU?@/_Y0T?\ #,?[.7_1 /@I
M_P"&K\!__*&NX_MKXA_]"+HG_A<-_P#,M1_;7Q#_ .A%T3_PN&_^9:CZE@_^
M@3"?^$F%_P#F8/\ 6CBG_HJ>*/\ Q)N)/_HA.'_X9C_9R_Z(!\%/_#5^ _\
MY0T?\,Q_LY?]$ ^"G_AJ_ ?_ ,H:[C^VOB'_ -"+HG_A<-_\RU']M?$/_H1=
M$_\ "X;_ .9:CZE@_P#H$PG_ (287_YF#_6CBG_HJ>*/_$FXD_\ HA.'_P"&
M8_V<O^B ?!3_ ,-7X#_^4-'_  S'^SE_T0#X*?\ AJ_ ?_RAKN/[:^(?_0BZ
M)_X7#?\ S+4?VU\0_P#H1=$_\+AO_F6H^I8/_H$PG_A)A?\ YF#_ %HXI_Z*
MGBC_ ,2;B3_Z(3A_^&8_V<O^B ?!3_PU?@/_ .4-'_#,?[.7_1 /@I_X:OP'
M_P#*&NX_MKXA_P#0BZ)_X7#?_,M1_;7Q#_Z$71/_  N&_P#F6H^I8/\ Z!,)
M_P"$F%_^9@_UHXI_Z*GBC_Q)N)/_ *(3A_\ AF/]G+_H@'P4_P##5^ __E#1
M_P ,Q_LY?]$ ^"G_ (:OP'_\H:[C^VOB'_T(NB?^%PW_ ,RU']M?$/\ Z$71
M/_"X;_YEJ/J6#_Z!,)_X287_ .9@_P!:.*?^BIXH_P#$FXD_^B$X?_AF/]G+
M_H@'P4_\-7X#_P#E#1_PS'^SE_T0#X*?^&K\!_\ RAKN/[:^(?\ T(NB?^%P
MW_S+4?VU\0_^A%T3_P +AO\ YEJ/J6#_ .@3"?\ A)A?_F8/]:.*?^BIXH_\
M2;B3_P"B$X?_ (9C_9R_Z(!\%/\ PU?@/_Y0T?\ #,?[.7_1 /@I_P"&K\!_
M_*&NX_MKXA_]"+HG_A<-_P#,M1_;7Q#_ .A%T3_PN&_^9:CZE@_^@3"?^$F%
M_P#F8/\ 6CBG_HJ>*/\ Q)N)/_HA.'_X9C_9R_Z(!\%/_#5^ _\ Y0T?\,Q_
MLY?]$ ^"G_AJ_ ?_ ,H:[C^VOB'_ -"+HG_A<-_\RU']M?$/_H1=$_\ "X;_
M .9:CZE@_P#H$PG_ (287_YF#_6CBG_HJ>*/_$FXD_\ HA.'_P"&8_V<O^B
M?!3_ ,-7X#_^4-'_  S'^SE_T0#X*?\ AJ_ ?_RAKN/[:^(?_0BZ)_X7#?\
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MXA_]"+HG_A<-_P#,M1_;7Q#_ .A%T3_PN&_^9:CZE@_^@3"?^$F%_P#F8/\
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MX:+-LCN8?F52 )%3[T;@/ZE@_P#H$PG_ (287_YF#_6CBG_HJ>*/_$FXD_\
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M*?\ AJ_ ?_RAH_X9C_9R_P"B ?!3_P -7X#_ /E#7<?VU\0_^A%T3_PN&_\
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M<2?_ $0G#_\ #,?[.7_1 /@I_P"&K\!__*&C_AF/]G+_ *(!\%/_  U?@/\
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M&_\ F6H_MKXA_P#0BZ)_X7#?_,M1]2P?_0)A/_"3"_\ S,'^M'%/_14\4?\
MB3<2?_1"</\ \,Q_LY?]$ ^"G_AJ_ ?_ ,H:/^&8_P!G+_H@'P4_\-7X#_\
ME#7<?VU\0_\ H1=$_P#"X;_YEJ/[:^(?_0BZ)_X7#?\ S+4?4L'_ - F$_\
M"3"__,P?ZT<4_P#14\4?^)-Q)_\ 1"</_P ,Q_LY?]$ ^"G_ (:OP'_\H:/^
M&8_V<O\ H@'P4_\ #5^ _P#Y0UW']M?$/_H1=$_\+AO_ )EJ/[:^(?\ T(NB
M?^%PW_S+4?4L'_T"83_PDPO_ ,S!_K1Q3_T5/%'_ (DW$G_T0G#_ /#,?[.7
M_1 /@I_X:OP'_P#*&C_AF/\ 9R_Z(!\%/_#5^ __ )0UW']M?$/_ *$71/\
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M "2_\!E_D!;HJI]OLO\ GZ@_[^+_ (T?;[+_ )^H/^_B_P"-')/^27_@,O\
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M?^ R_P @+=%5/M]E_P _4'_?Q?\ &C[?9?\ /U!_W\7_ !HY)_R2_P# 9?Y
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MS3O&,DXN\7&:4H--.2DG%I\T9SA+>$FCP]>JLTW&47HXRBVFGJ]4T^P4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=C\._\ DH'@7_L<
M?#'_ *>[&N.KL?AW_P E \"_]CCX8_\ 3W8UPYI_R*\R_P"Q;F?_ *@5C;"?
M[]@_^PO _P#J93/]%R/_ %<?^XO_ *"**(_]7'_N+_Z"**_R J?Q*G^.?_I4
MC^YZ?\.G_P!>X?\ I$3X[_X*$;?^&)OVG-Y 7_A4'B[<2P0!?L7)+GA0!G+'
MA>IZ5_FB_M7>"/$_BGX[_L;7.E>$]6U[P]H?C#QS/XJU'3M!UG4-%T"PU)O"
M,<P\1:C8@V]KH[P!I-3NG*QVUD)YG)1"*_TNO^"A'_)DW[3G_9(/%W_I%7\&
MU?V3]'WA[#<4^'_%^2XRM4HX:MQ1DE>JZ=*C4<XX3!87&.E)56G:H\)"":=H
M2:J6DX\K_"_$[-:F2\3Y)CZ-&G7J1R;,Z"A5G5C3MB<4J3DXTVN9PYN9)[VY
M=F?@5X4_9P^,5CH?[4-AK?@CQQ+%\,?AIXD^%OP@L;WPUKH/B/3]<^*.K^(;
MI_#0$!.IJKBZNXH8!<_;#J"P( Y>(^Q_$7X3>/\ 0+G]C'XN/H7QL@\/^"?V
M??"/PY^(4'PBMA%\8/!6JVVA:K;0G^Q;^VNVBMF^UB5TN+.>*2&&1#&\IBBD
M_9*BOV'#^#.3X;"XS#TLXS%U,1B5CJ6(J8?"3G3Q\>*:W$]/$5XQQ&&>+A2J
M5*>#IX>6(PL53I*JZ]VJ2^)K^(F/Q.)P]>MEV"E&C&I"=/VE=^TA7R9Y-B8Q
ME.G55+VU)^U<U3J3C)N*C)-M_B[=?LZ^,OB)^SY^TAJGA#P'\;M%\3>-_%GA
M+6;*Q^,/B+3KWQE\1['P/JFNSF:+PS#H?A^XM-3W,8(T$3DS[886>#RRV_\
M$'Q7\0/CUXY_8ZU+1/V>_C'X.T7X5_%7P$?&6M^*O!%WIPTJYCUSP\][>0Q6
MR&6/P^L-E-J,^L3+$+6"U,\NQT"U^P=%=$O"7!1HPH87/<;@Z5?"Y;2S>G0R
MO)W3S/$93Q#A>(L%BJ7M)5*N5-8K#U*5:G@<14G7IUVYXEN+Y\?]?,3.I[2O
ME>'K2HU<=/ .6/S"+P5/,<JJ91B:-X0@L5&>'E3DG7IP=-TW"G'DFVOR&G^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P -*_'?_HJ?C+_P/_\ L:\1HH^N8S_H,QG_ (5XO_YJ#V5'_GQ1_P#!</\
MY6>W?\-*_'?_ **GXR_\#_\ [&C_ (:5^.__ $5/QE_X'_\ V->(T4?7,9_T
M&8S_ ,*\7_\ -0>RH_\ /BC_ ."X?_*SV[_AI7X[_P#14_&7_@?_ /8T?\-*
M_'?_ **GXR_\#_\ [&O$:*/KF,_Z#,9_X5XO_P":@]E1_P"?%'_P7#_Y6>W?
M\-*_'?\ Z*GXR_\  _\ ^QH_X:5^._\ T5/QE_X'_P#V->(T4?7,9_T&8S_P
MKQ?_ ,U![*C_ ,^*/_@N'_RL]N_X:5^._P#T5/QE_P"!_P#]C1_PTK\=_P#H
MJ?C+_P #_P#[&O$:*/KF,_Z#,9_X5XO_ .:@]E1_Y\4?_!</_E9[=_PTK\=_
M^BI^,O\ P/\ _L:/^&E?CO\ ]%3\9?\ @?\ _8UXC11]<QG_ $&8S_PKQ?\
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M3T6'FVES4FU?NNFC1QW_  TK\=_^BI^,O_ __P"M1_PTK\=_^BI^,O\ P/\
M_L:\1HKU98S&\S<L;C92E&+;EC,6]8NK2_Z"M+^PYO\ MZW2[X51H?9P]%72
M_P"75+HY?RTH_B>W?\-*_'?_ **GXR_\#_\ [&C_ (:5^.__ $5/QE_X'_\
MV->(T4OKF,_Z#,9_X5XO_P":A^RH_P#/BC_X+A_\K/;O^&E?CO\ ]%3\9?\
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MPTK\=_\ HJ?C+_P/_P#L:/\ AI7X[_\ 14_&7_@?_P#8UXC11]<QG_09C/\
MPKQ?_P U![*C_P ^*/\ X+A_\K/;O^&E?CO_ -%3\9?^!_\ ]C1_PTK\=_\
MHJ?C+_P/_P#L:\1HH^N8S_H,QG_A7B__ )J#V5'_ )\4?_!</_E9[=_PTK\=
M_P#HJ?C+_P #_P#[&C_AI7X[_P#14_&7_@?_ /8UXC11]<QG_09C/_"O%_\
MS4'LJ/\ SXH_^"X?_*SV[_AI7X[_ /14_&7_ ('_ /V-'_#2OQW_ .BI^,O_
M  /_ /L:\1HH^N8S_H,QG_A7B_\ YJ#V5'_GQ1_\%P_^5GMW_#2OQW_Z*GXR
M_P# _P#^QH_X:5^._P#T5/QE_P"!_P#]C7B-%'US&?\ 09C/_"O%_P#S4'LJ
M/_/BC_X+A_\ *SV[_AI7X[_]%3\9?^!__P!C1_PTK\=_^BI^,O\ P/\ _L:\
M1HH^N8S_ *#,9_X5XO\ ^:@]E1_Y\4?_  7#_P"5GMW_  TK\=_^BI^,O_ _
M_P"QH_X:5^.__14_&7_@?_\ 8UXC11]<QG_09C/_  KQ?_S4'LJ/_/BC_P""
MX?\ RL]N_P"&E?CO_P!%3\9?^!__ -C1_P -*_'?_HJ?C+_P/_\ L:\1HH^N
M8S_H,QG_ (5XO_YJ#V5'_GQ1_P#!</\ Y6>W?\-*_'?_ **GXR_\#_\ [&C_
M (:5^.__ $5/QE_X'_\ V->(T4?7,9_T&8S_ ,*\7_\ -0>RH_\ /BC_ ."X
M?_*SV[_AI7X[_P#14_&7_@?_ /8T?\-*_'?_ **GXR_\#_\ [&O$:*/KF,_Z
M#,9_X5XO_P":@]E1_P"?%'_P7#_Y6>W?\-*_'?\ Z*GXR_\  _\ ^QH_X:5^
M._\ T5/QE_X'_P#V->(T4?7,9_T&8S_PKQ?_ ,U![*C_ ,^*/_@N'_RL]N_X
M:5^._P#T5/QE_P"!_P#]C0W[2OQVP<_%/QDPQR/MYY]5^[SGI7B-._B7_@/\
MA0L9C+JV-QR<ITHIQQN+5OWB=VOK6OX L/AY27-0HNT:O_+JD_\ EV_YJ+_
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MH_X:5^.__14_&7_@?_\ 8UXC11]<QG_09C/_  KQ?_S4'LJ/_/BC_P""X?\
MRL]N_P"&E?CO_P!%3\9?^!__ -C1_P -*_'?_HJ?C+_P/_\ L:\1HH^N8S_H
M,QG_ (5XO_YJ#V5'_GQ1_P#!</\ Y6>W?\-*_'?_ **GXR_\#_\ [&C_ (:5
M^.__ $5/QE_X'_\ V->(T4?7,9_T&8S_ ,*\7_\ -0>RH_\ /BC_ ."X?_*S
MV[_AI7X[_P#14_&7_@?_ /8T?\-*_'?_ **GXR_\#_\ [&O$:*/KF,_Z#,9_
MX5XO_P":@]E1_P"?%'_P7#_Y6>W?\-*_'?\ Z*GXR_\  _\ ^QH_X:5^._\
MT5/QE_X'_P#V->(T4?7,9_T&8S_PKQ?_ ,U![*C_ ,^*/_@N'_RL]N_X:5^.
M_P#T5/QE_P"!_P#]C1_PTK\=_P#HJ?C+_P #_P#[&O$:*/KF,_Z#,9_X5XO_
M .:@]E1_Y\4?_!</_E9[=_PTK\=_^BI^,O\ P/\ _L:/^&E?CO\ ]%3\9?\
M@?\ _8UXC11]<QG_ $&8S_PKQ?\ \U![*C_SXH_^"X?_ "L]N_X:5^.__14_
M&7_@?_\ 8T?\-*_'?_HJ?C+_ ,#_ /[&O$:*/KF,_P"@S&?^%>+_ /FH/94?
M^?%'_P %P_\ E9[=_P -*_'?_HJ?C+_P/_\ L:/^&E?CO_T5/QE_X'__ &->
M(T4?7,9_T&8S_P *\7_\U![*C_SXH_\ @N'_ ,K/;O\ AI7X[_\ 14_&7_@?
M_P#8T?\ #2OQW_Z*GXR_\#__ +&O$:*/KF,_Z#,9_P"%>+_^:@]E1_Y\4?\
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M /[&C_AI7X[_ /14_&7_ ('_ /V-?LUJ/_!#KPIX>T?Q]'XD_;U^%WACQ?\
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MIP<W"I6=-T82<4W%3G!R2NHV:M_.M_PTK\=_^BI^,O\ P/\ _L:/^&E?CO\
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M_P -*_'?_HJ?C+_P/_\ L:\1HH^N8S_H,QG_ (5XO_YJ#V5'_GQ1_P#!</\
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M^BI^,O\ P/\ _L:/^&E?CO\ ]%3\9?\ @?\ _8UXC11]<QG_ $&8S_PKQ?\
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ML[/0^8**^G_^%/? ?_H[[P%_X:7XV_\ SNZ/^%/? ?\ Z.^\!?\ AI?C;_\
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M9A9JZ?\ 9&;-/TM@'^(O[-Q/?#?^%V7K\\8CY@HKZ?\ ^%/? ?\ Z.^\!?\
MAI?C;_\ .[H_X4]\!_\ H[[P%_X:7XV__.[I?VQ@_P"3'_\ AHSC_P"=X?V;
MB?\ J'_\+\N_^;3Y@HKZ?_X4]\!_^COO 7_AI?C;_P#.[H_X4]\!_P#H[[P%
M_P"&E^-O_P [NC^V,'_)C_\ PT9Q_P#.\/[-Q/\ U#_^%^7?_-I\P45]/_\
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M -'?> O_  TOQM_^=W1_;&#_ ),?_P"&C./_ )WA_9N)_P"H?_POR[_YM/F
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M34;7S;&TE>TOHT2,1?S=_P#"GO@/_P!'?> O_#2_&W_YW='_  I[X#_]'?>
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M]?R]77_;V,1\P45]/_\ "GO@/_T=]X"_\-+\;?\ YW='_"GO@/\ ]'?> O\
MPTOQM_\ G=T?VQ@_Y,?_ .&C./\ YWC_ +-Q/_4/_P"%^7?_ #:?,%%?3_\
MPI[X#_\ 1WW@+_PTOQM_^=W1_P *>^ __1WW@+_PTOQM_P#G=T?VQ@_Y,?\
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M3]B[_D[']G__ +*5X9_]*;*OEN/[O_ C_P"BWKBI_P#(XQ/_ &+?_=V)W_\
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M:@.1L_0#XU_\%,O^"=;_ ++W[5WP8_9M\+>-_"-G^T'\/?V2#X ^']]^S?\
M"'P?+X)U[X!?$/X>^,?&^A_%3]IMOB5_PL[X[:CXIU+2+F3PQKVJQRZ3\/XK
MN2=U6U$Q'KOC'_@K+_P3T\??$K]N'3K[4OBIHOPP_;,^(WP _:67QCX[_9+^
M$OQMN_AU\1_AKH2^#/&7PAUSX3?$OQG-X<OM0ET305U+P1\0DL;RST2^N1<R
M)J%O;>9<:U,^XU=:I*.2U/J\*<W2I3P-:*Y7BG3P]>7+B_:0J4L/2K0G",W&
MO-\W/%Q]XAEV0.DE/'1C*;A&#>)IRY%&G)*+BZ,7-2:3IVE%P5XM:L_EYO\
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MX@_M3?MR?!+7_P!H?7]!^&?[+OA+X:^*?A?\2K7P-HME+\<I_BG\)?$7QP\
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M)^TY^R?I=I_P41B^)_@_0/ >@_LY:KX(^&2ZGX%UNSU>SUB\O/$EY?\ BWX
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M,GQ)_9VUBZTFWU"]L+"Z^(NE:/XEO)M$L;VZM+2[UN*QCNKJV@$D@[#X&?\
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MQ+\1>([T::)$^'VM1/=:=XS81%I3X<TVWADU2^* ,MC;2D8QE?@*OZ*?%/\
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MVHU;1C)J7))J+M+=WUCJOP$HK]P?$_\ P1YL/@7:?M+^(_VO/VJ?#/P7\#_
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M(UJF)IS<GI3A2J7Y5*TY.3GHXQ<965*:?-;F5CX(HK^LF#_@D[\/F_X)/R>
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ME[HI^'<_Q,FCCN-.T_4I-:1':S=%]J^-G_!(CP1^V9^TU^U#X]^#VM6_P3^
M_P (/VM-3_88\)>'_P!F_P#8>\:_$2[M?BEX/O;"X\3ZY\7/"VA^-I;B[\%^
M&&UF(^+_ (T:I8W.FV.E;M;NK QQBWG\Y\;Y%&OR2K5%AU2<YXUTYPH4ZT<9
M6P,\+-3ASNO&M0J*T'*#MI-W1U_ZLYC:5O92J*5-*E&I!SE&>&6*<HKF7P4>
M:33ZQ2NKV/Y.**_I>B_X)!?LM^'?V7?A;X*^-'Q\O_A-^U;XM_X*<>,?V+_$
M_CVU^&7B7QUX5BU?1%M/"VA?#VT%SXKT;2M"T+2=*U_2_&>H_%"2.6WURUDN
MO#-RK0)&[^ _ S_@DE<>"OB[^S))^TCXOT^WD\6_\%"_BU\#/$WP2O?!9*>*
M?V=/V,)+?Q#^U%\:'UC^W;@6_AN![+^Q=1TP6\I2PU+I,L@AK:/&.2U*52=.
MM6=2-3%4J%&IAJ]*>)J86-"<XT7*,HR4HXFA:47\52,;7<>;">08^$TI1AR6
MHN=13C*-..(7-3<U&[BW&\K24;*+Z:K\'Z*_;+_@D/\ #[X*_M5_\%2+K2?B
M)\*/A9JWPF\5^'_VI?'NG_#7XAQSZ3\/=.N+'X=^+?&'P]M=8FM[NPGL]#\/
MS>&[+Q!J-[#>VC6-D)KH3)Y)8?3?Q _8MO?VZ?VA_A+^SEX*\.?\$M/A'::-
MX(^,OQO^(?Q'_P""8S_$#]H/Q':>!O!T-\B^&?%/PS\/^/-;U_QI\4)K&S-K
MHW@[1YUU;Q1KL]OH]C/;W%W"BUB>*<)@\=/!XG#U:-.A@,-F&,Q=2K25+#TL
M33=2,>2-*I.HXVLW[6BW=?NWJU=+(:];#JM3K0G.>)JX6A0IPE.=6K2>W.JB
MC#F2=DZ51WM[R31_-E17[W>*/^")M[X%_:2^%OPH\5?%WXV6'PV^-O[/^M_'
MKX=SZ)^P]\;==_:;U*3PGKR^$M4^&7B+]D_3;B36/"7CZ"*[34[GQKXQU_2]
M'T;1KB'4M5U*QM(KBXB]/T+_ (-]]5NOCG^T-\)M0_:8U[5](^"WPB^ 7Q=T
MIOA;^SM-X\^/_P 0O#W[05C?2VVIZ7^S5<_&RU\1Z+%\/M0LVD\8?V3>1:M)
M]FGATMX[YH'$U.-.&Z5-U)9C%Q>'EB:?)1KS52C3J1A4DI*"C%Q4DTG?FE[J
MENTH<.9I-R2H6<)TZ<XN<.:,YS<&FDTTXM-VDDVKO1:O^<*BOW[^"'["OA/P
MQX3_ &E]%\5V'PV^)VE_!G_@HI^PU\%=8U/QG\%?C'\._BMK/A[XD>/M<L-6
M\.>'+CQKXK\.W7@:'4["]ET_QCH?BCX5^*9XX;F\;0/'1$$=_%ZW^U3_ ,$N
M/@9J/[1_[7OQ'_9<^-7@3Q#9?LO_ +;GPB\&_&C]E_Q'\$-<TCX=_#3X??M!
M_&ZR\"> ;;POXDM=9TE_B+HMGXFUIH/'NAZ=K6D/K.FPW]E#JUGYT=U&I\7Y
M72Q57#U56C3I4Z\WBXQ=3#1E1<80AB)TZ+>&5:M5H4XSJ^ZG54F]$I.'#^+G
M2512IJI>*="4Z:JWE2JUGR153FFHQIVYE%1YGRMIV/YJ:*_KDU/]@7X-C5_#
MGA.'X1_L\M\1KO\ X.(/&O[*-QKUW\-?%9^'6H_!RU^"6C>)])\ ZWX'NO'^
MNW5[X9DU6XBDU#3+?Q)IDVHV,][91:CI\I6]7P"/_@EM^QO\4O@;^RY8W?QY
M_P"%0?'+]IG_ (* ?'W]G&7QOIOP=\::[X"U?Q=H.OWFB>%?A]X=\'ZW\5+F
MW\'>&8]1.AV,&LW(U&)(KZZ-QIZQZ;B^PAQKE<I+GI8FG2=>=#VG(ZUE3I0J
M5*[]A3G%45SKD?-SR@G*4(R3IJWPYB_>4*E.4X1I.4)?NGSU8<_LH\\O>J**
M;5ERRZN.K/YFJECZQ_\ 75?YBOOC]I']A+Q/^RY^SI\-/BY\7/&S:5\4OBK\
M>_CY\*-&^"PT$R7(\+_LWZZ? GQ%^*5]XG:1GTZWU_XB7.A1V6@M#&LL5S&B
M22G>(O@>/K'_ -=5_F*]Z..PN8Y;B\1A*CJT5#%T5/DG",G##X>;<>>,&[>W
MY9632</B?,K>95PE;!8FA1KQY*OMZ+E!VO&U5);-W4MXOJNS32^DOVRO^3JO
MV@?^RI^+/_2^UKYHKZ7_ &RO^3JOV@?^RI^+/_2^UKYG;H?H?Y5TX#_<<#_V
M"4/_ $F1EC/]ZQ/_ &$5_P#TX+17UM^P#X(\)_$S]N_]B[X;^/= L/%?@;X@
M?M7?L[>"/&GA;58VETSQ)X3\5_&#P?H/B/0-2B5XVEL-8T>_O-.O(UDC9[>Y
MD4.I(8?T7?\ !2/]GC]DCP!^S=^W#)\7O@-^P+^SO\6? 7QI\+^'/V&;G]E#
MXM2^)_CS\2M%3XO7>D^.H_BO\+(_C':W6GVT'AXP)XBLQ/HMS8I>:E:F.VDL
M[*6X\7..)</DV.PN!JX3$XF>)P[Q+EAY4W*%+ZTL&G&@X3K5K5FIU73452H)
MU&VURGH9=DU3,<-7Q,<31H0H5E1DJL:C3D\.ZZ:G%J*6G*TTW:\E=*S_ )&Z
M*_I!_;'_ .".NM>./VDOCU9_L]:_\-G\6^#/VWOV</V6/&7P,^$OP8U+P'\/
M?A-X6_:'^&G@_4? 'QIL;;6/BIXKN)O $_BG7[;PQXENYK^UDAURYOW>>#:S
M)XW9?\$BO@'I-U)?_%S]OFV^&OPX^(O[5'Q#_9'_ &4?&=M^SOXA\?W7QS\8
M?"OQ!IGA/Q5\0?$]OIWCNYLO@]\,+#Q1J$OA?[=F\>]AB%_<VYAG@6Y5/BW)
M:E)5(5ZCE^[4J4:&(J3YI5*E.?+[*@[P2HU:E*34'7ITY5(PC!/EK^P,Q3;]
MG'V=DXU74IJ$FZ;J))RE'2RM?772RT;_  BHK^B3XI_\$L/V>?@]^PUX1F^)
MWQ;N?!'[8Q_X*2>)OV2?'6N6/PO^(?Q$\,75CX?U;3-#N/"VE:=X?>+6O%$'
M@;P5KEM\2[+Q%H1CU7XANDOP]TQUO9K9D^I/V:O^")WPV^"W[:G_  3PUWXA
M^(_&/Q^^!WQ_^,?QH^%?C;X8_M$_LW^*/V=?%UMK_P ./@'X@\7:%KK?#_QK
MX@D\3ZKX7N[BU$VB:U<QM)%;""<HSMSRRXVR2.&J8AU*]_;8VCAJ4L/B*<L5
M+!4J.(J>SJ5*2I1OAJ]*HE*:UG&.SN:KAS'NK[.]%N,:$JKA4C/V2KQYES*+
M:5EJE)J3L[I6N_Y-Z*_4;_@DM^S%\)OVH/VQ8_#WQIT'5/$?P;^%?PO^,'QY
M\7_#'1-2O=)O?'6E_!OPCXAU/0?AY!JFG7>G:G8Z+K-GHL>C3W>G:CIVHQ6U
MP39W]G<F*ZB]3U+]I;]E7]KN?X&>$+S_ ()P_!?X"_$.W_:R^$7A_2OB#^SK
M_P )EX.^&/BKX+>*-:M['6?AE\8/!OB+6O$=QXI\<ZCH<%Q#J'BR/7=.8R2R
M727VG_-.O?6SY4\14H4LOQ.)6'P=/&8RM3KX*E#"QK86OC*$91Q%:G4K>TH4
M)3YJ$9Q@FE)<]HO"&4Q=.%2MC:6']MB:F'P\)TJLZE?V>)I85SC[/W(KGJIM
M.>T=').Z_&:BOZF/VAO^":_P[^*WCOQ;\+?AKI'PH^"OA[QS_P %V/B=^QAX
M6\6:;\&M7UGX@^!M#N/@_H6NO':7<OQ&LDU;X3:=<W;W-II)GLR^LF%'GM1=
MJ\?-?LH_\$>OA9/\<?V=/&OPX_:.^%W[5?A1OVTOBU^Q'\:_"/Q9_9O\4Z=\
M,-(^-7@K]G_XD?&L1V<,?QC,_CCP,+'P]%'HUI']F-MXBE1(Y9&$D*\:XSR7
MZNL1.K.$9.<5%TZTK/V&%G2=2M"A+#4HU*^)EAI<]52BZ,JD(54^2.KX=Q_,
MU",9J,%*5I04[RJ8N$5&DY.I)26%;4HQ<5*I&$G#EE,_F,HK];- _P""=7P;
MT[]G7X+?&C]I+]M?0/V;OB+^TYX0^+GQ#_9]^'<_P7^('C+PKK?AWX9ZOXET
M?2KWX@?$[3?%.MZE\,4\=:A8VGA;P):W?AW7AI#7,$DNE:I+:2V,WJ'P;_X(
M]V?QM_8F\<?M6>#/C]X[7Q!X*_9P^)O[2%_X7;]C_P",^A_L\S:5\,K77M1\
M0_#7P[^TWXHU#P9HFL>.+31]"F\1:=I-MX>U2T:\>,SVEU;+,K];XIR6%"GB
M:V(JTL/.O3PZK2PN*5*56I4HT^6C5GAZ=&NH3J5(SG2J2A&=)P;4F^7..0X^
MI5=&G&G.JH.HXJK3NJ<79RE!3=2.UTI0BW'6W0_$.BOU0_X*W_![X8_!7X[?
M O0/A+X&T+P'H/B+]B/]D3Q]KEAHJE8]0\:^-OA:-0\0:K>!F8F\OX[)I&8'
M:[DR*%5@J_E?7J9=C89C@L-CJ490IXF%2<%)IOEABL9AD]/YEA/:6:37M%'7
MEYGYN*P\L+7G0FU*5.R;2DM6DVM4MGI=-IM/:QZI\"O^2W?!S_LJGP]_]2[2
M*J?&C_DL7Q6_[*?X[_\ 3]JU6_@5_P EN^#G_95/A[_ZEVD54^-'_)8OBM_V
M4_QW_P"G[5JYY?\ (ZE_V(JG_JVIFO\ S+?^ZBO_ %7U#SC^)O\ @7\C3:=_
M$W_ OY&FU[$]_F_S1Q=(?]>X?E(**49R,%5.1AG^X#GJ^8+D;1U;_1KCC/[B
M7_5M_3=_P2Q_9O\ "?CC_@FQ\5?C1X9_96_8K_:%^.FD_MO:5\-;;4_VW/%W
M_"OOAWI_P<'P3T'7+EM+\1O\1O!$5KK4%RTRZ:HTNXEECN=0NXM%U=]/86?B
M9WG-'(\''&5Z4ZT)8BAAE3IU*=.2E7G**J3G6BZ4*4>6W-)\TIM04>IZ&6Y?
M/,J[H4ZL*4E2K5FYQE)<M*$9/2+B[/FM?F2C:[35VOYD**_I7_:-_P""<'[
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MT5_D8U_KG?\ !9;_ )18_MW_ /9M_P 0_P#TVBO\C&OZ(\%?^1-G7_8SPO\
MZKI'X]XC_P#(RR__ + ZW_J5$****_9S\Z"BBB@ HHHH **** "BBB@ I5ZC
MZC^=)2KU'U'\Z3WC_CC^8UM+_!+\CZA_8N_Y.Q_9_P#^RE>&?_2FRKY;C^[_
M ,"/_HMZ^I/V+O\ D[']G_\ [*5X9_\ 2FRKY;C^[_P(_P#HMZX*?_(XQ/\
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M./@]J6G_  F^$GQOT/3XO#NG^//A'X/\$>)M-U#PE+I5BMF^H:9XNL+W3/&
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MJOB#4],TX/*LE[>6L"S3Q>6_ 7]B6VTC_@JG\*OV ?VBDMM8L;/]J70/@/\
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $;H?H?Y5]0?LR_=_:)_[-<^
M)W_I;H-?+[=#]#_*OJ#]F7[O[1/_ &:Y\3O_ $MT&O+SK_D68O\ P4/_ %99
M2=^6?[[2_P"O6*_]1YGS!1117K3^)?X%_P"G\8>='^OOD%%%%24%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !3OXE_X#_(4VG?Q+_P !_D*:^*'_ %]I?^EH<=U_AJ_^
MFV?2WC[_ )-8_9Q_[*%^T=_[PZOF>OICQ]_R:Q^SC_V4+]H[_P!X=7S/7F99
M\&+_ .QAC/\ TZSKQW\2C_V"8;_TV%%%%>D<84444 &,\9VYXW;/,VY[[,C?
MCKLR-W3(SFOM?]F_]KZ/]G[]G7]M;X%/\.&\9/\ MA?#+X?_  W3Q,/%G]DK
M\/'\ _$&+QTK-H1\.WYU9;I(Y'.FC4+'[652 74/F-)'\445RXK!T,;35'$P
M]I24Z=50YI1_>T:D:M*=XR5^2<(RL]VEK:Z>^'Q%3#5(U:3M.*FHNR=O:0=.
M>Z>KA)QT>S>Y]Z_$#]M5?'/[-W_!/[]GQOATMDO[#GC#X]>+G\62>./M<?Q6
M7XZ_%G0?BH]K+IIL=07P^FF_V%Y#WC66H"T7,YLYS&T,GZP^'?\ @X)T;0O'
MOQ6^)*?LF^,_#^K^/OVUM!_;"MA\+OVK=4^$.J^)6T/PMX?\,P?!KX^ZW8?!
MR&Q^.7PXM/["&L:-HEP(;:P%TUDQA@#L_P#-317DXCA?)<5'DK81SCS5)I>W
MQ$;3JXBMBZC?)5BFI8FO5JV:;5U%-15CT*&=X_#S<J551O&E'X*;M&C%P@DY
M0E;W&TVK;MK9'Z6_M7?\%!K#]I?X&ZW\&;/X,R?#[^VOVY_VCOVTH]?_ .%@
M_P#"5QZ/)^T&L<ES\+EL#X#LO/\ [,=)M0?5?MMLS!(7\RV*M(GYI445ZN!P
M&%R[#_5L'2]E3=25::YZD^>M.GAJ4JG[R<W%NGA,/%I.S<+VNSAQ6+K8RI[6
MLU*=FKJ,8Z-W^S&*LME>[2ZN["BBBNLY@HHHH 5>H^H_G7TO\9/^2)?LA_\
M9)_B3_ZT7\3*^:%ZCZC^=?2_QD_Y(E^R'_V2?XD_^M%_$RO/Q/\ O^4_]?\
M$?\ J-([,/\ [KC_ /KWA_\ U(1\ST445WQ^&/\ A_61R/\ ]OG^<0HHHIB"
MBBB@ HHHH **** "BBB@ HHHH *<W3_MF?\ T%J;3FZ?]LS_ .@M5K;YQ_\
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M=NK3=FOV=_:=_P""M\/[1^C?\%$=(_X4(_@4_M[_ /##0-[_ ,+:AU7_ (5
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MW8Z;_P %Q_AGJ_Q*^%WQB^-'[#*?$SXD_LX_M8?M&_M#_LY:WIW[0&J>!/\
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M<?& 27FB>$/ ?CKX-?$G7?V>!?I\,Y7MH?%7Q"^#MC='4H($,$6O74CVD^R
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M!8N-KW2Y<%53:73F;NUW.'!JU>BNV(PGXXND?[5\?W1]%_\ 0%HHC^Z/HO\
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MFXWL)<1R,)%RK"OFRG]<Q?\ T%XO_P *\7_\U!]7PW_0-AO_  FH?_*CF_\
MA"/!?_0F^%__  1:3_\ %4?\(1X+_P"A-\+_ /@BTG_XJNDHH^N8O_H+Q?\
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MP7_T)OA?_P $6D__ !5=)11]<Q?_ $%XO_PKQ?\ \U!]7PW_ $#8;_PFH?\
MRHYO_A"/!?\ T)OA?_P1:3_\51_PA'@O_H3?"_\ X(M)_P#BJZ2BCZYB_P#H
M+Q?_ (5XO_YJ#ZOAO^@;#?\ A-0_^5'-_P#"$>"_^A-\+_\ @BTG_P"*H_X0
MCP7_ -";X7_\$6D__%5TE%'US%_]!>+_ /"O%_\ S4'U?#?] V&_\)J'_P J
M.;_X0CP7_P!";X7_ /!%I/\ \51_PA'@O_H3?"__ ((M)_\ BJZ2BCZYB_\
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M;X7_ /!%I/\ \57244?7,7_T%XO_ ,*\7_\ -0?5\-_T#8;_ ,)J'_RHYO\
MX0CP7_T)OA?_ ,$6D_\ Q5'_  A'@O\ Z$WPO_X(M)_^*KI**/KF+_Z"\7_X
M5XO_ .:@^KX;_H&PW_A-0_\ E1S?_"$>"_\ H3?"_P#X(M)_^*H_X0CP7_T)
MOA?_ ,$6D_\ Q5=)11]<Q?\ T%XO_P *\7_\U!]7PW_0-AO_  FH?_*CF_\
MA"/!?_0F^%__  1:3_\ %4?\(1X+_P"A-\+_ /@BTG_XJNDHH^N8O_H+Q?\
MX5XO_P":@^KX;_H&PW_A-0_^5'-_\(1X+_Z$WPO_ ."+2?\ XJC_ (0CP7_T
M)OA?_P $6D__ !5=)11]<Q?_ $%XO_PKQ?\ \U!]7PW_ $#8;_PFH?\ RHYO
M_A"/!?\ T)OA?_P1:3_\51_PA'@O_H3?"_\ X(M)_P#BJZ2BCZYB_P#H+Q?_
M (5XO_YJ#ZOAO^@;#?\ A-0_^5'--X)\%!6)\&^&. 3\NA:3NX'\//7T]ZL2
M^%/"LT5E9S>'- G@L(Y1';-H.D[8S."!N] ,Y(XXYSGINT4?7,7_ -!>+_\
M"O%__-0?5\-_T#8;_P )J'_RHYO_ (0CP7_T)OA?_P $6D__ !5'_"$>"_\
MH3?"_P#X(M)_^*KI**/KF+_Z"\7_ .%>+_\ FH/J^&_Z!L-_X34/_E1S?_"$
M>"_^A-\+_P#@BTG_ .*H_P"$(\%_]";X7_\ !%I/_P 57244?7,7_P!!>+_\
M*\7_ /-0?5\-_P! V&_\)J'_ ,J.;_X0CP7_ -";X7_\$6D__%4?\(1X+_Z$
MWPO_ ."+2?\ XJNDHH^N8O\ Z"\7_P"%>+_^:@^KX;_H&PW_ (34/_E1S?\
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MP7_T)OA?_P $6D__ !5=)11]<Q?_ $%XO_PKQ?\ \U!]7PW_ $#8;_PFH?\
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M_BJZ2BCZYB_^@O%_^%>+_P#FH/J^&_Z!L-_X34/_ )4<W_PA'@O_ *$WPO\
M^"+2?_BJ/^$(\%_]";X7_P#!%I/_ ,57244?7,7_ -!>+_\ "O%__-0?5\-_
MT#8;_P )J'_RHYO_ (0CP7_T)OA?_P $6D__ !5'_"$>"_\ H3?"_P#X(M)_
M^*KI**/KF+_Z"\7_ .%>+_\ FH/J^&_Z!L-_X34/_E1S?_"$>"_^A-\+_P#@
MBTG_ .*H_P"$(\%_]";X7_\ !%I/_P 57244?7,7_P!!>+_\*\7_ /-0?5\-
M_P! V&_\)J'_ ,J.;_X0CP7_ -";X7_\$6D__%4?\(1X+_Z$WPO_ ."+2?\
MXJNDHH^N8O\ Z"\7_P"%>+_^:@^KX;_H&PW_ (34/_E1S?\ PA'@O_H3?"__
M ((M)_\ BJ0^"?!8!(\(^&X2 2)8M"TGS8B!Q)'\W^L3[R?[0%=+11]<Q?\
MT%XO_P *\7_\U!]7PW_0-AO_  FH?_*C"N?"GA749KBYN_#'AZZDN;LWMVUW
MH.D^9O6 06N/?<%QSU%0?\(1X+_Z$WPO_P""+2?_ (JNDHH^N8O_ *"\7_X5
MXO\ ^:@^KX;_ *!L-_X34/\ Y4<W_P (1X+_ .A-\+_^"+2?_BJ/^$(\%_\
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M?_BJZ2BCZYB_^@O%_P#A7B__ )J#ZOAO^@;#?^$U#_Y4<W_PA'@O_H3?"_\
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M$==J?.W1?F(K_3T_X5?\/?\ H4-#_P# -*/^%7_#W_H4-#_\ TH]IY?C_P
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MFW&&&T<$U_HH?\*O^'O_ $*&A_\ @&E'_"K_ (>_]"AH?_@&E'/Y?C_P /\
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M$FNZKJ>MZEKDCP^5"\\\GR*;8X+/)\BXRWR@BN8K_3T_X5?\/?\ H4-#_P#
M-*/^%7_#W_H4-#_\ TH]IY?C_P  #_,+HK_3T_X5?\/?^A0T/_P#2C_A5_P]
M_P"A0T/_ , TH]IY?C_P /\ ,+HK_3T_X5?\/?\ H4-#_P# -*/^%7_#W_H4
M-#_\ TH]IY?C_P  #_,+HK_3T_X5?\/?^A0T/_P#2C_A5_P]_P"A0T/_ , T
MH]IY?C_P /\ ,+HK_3T_X5?\/?\ H4-#_P# -*/^%7_#W_H4-#_\ TH]IY?C
M_P  #_,+HK_3T_X5?\/?^A0T/_P#2C_A5_P]_P"A0T/_ , TH]IY?C_P /\
M,+HK_3T_X5?\/?\ H4-#_P# -*/^%7_#W_H4-#_\ TH]IY?C_P  #_,+HK_3
MT_X5?\/?^A0T/_P#2C_A5_P]_P"A0T/_ , TH]IY?C_P /\ ,+HK_3T_X5?\
M/?\ H4-#_P# -*/^%7_#W_H4-#_\ TH]IY?C_P  #_,+HK_3T_X5?\/?^A0T
M/_P#2C_A5_P]_P"A0T/_ , TH]IY?C_P /\ ,+HK_3T_X5?\/?\ H4-#_P#
M-*/^%7_#W_H4-#_\ TH]IY?C_P  #_,+HK_3T_X5?\/?^A0T/_P#2C_A5_P]
M_P"A0T/_ , TH]IY?C_P /\ ,+HK_3T_X5?\/?\ H4-#_P# -*/^%7_#W_H4
M-#_\ TH]IY?C_P  #_,+HK_3T_X5?\/?^A0T/_P#2C_A5_P]_P"A0T/_ , T
MH]IY?C_P /\ ,+HK_3T_X5?\/?\ H4-#_P# -*/^%7_#W_H4-#_\ TH]IY?C
M_P  #_,+HK_3T_X5?\/?^A0T/_P#2C_A5_P]_P"A0T/_ , TH]IY?C_P /\
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M / -*/:>7X_\ #_,+HK_ $]/^%7_  ]_Z%#0_P#P#2C_ (5?\/?^A0T/_P
MTH]IY?C_ , #_,+HK_3T_P"%7_#W_H4-#_\  -*/^%7_  ]_Z%#0_P#P#2CV
MGE^/_  _S"Z*_P!/3_A5_P /?^A0T/\ \ TH_P"%7_#W_H4-#_\  -*/:>7X
M_P#  _S"Z*_T]/\ A5_P]_Z%#0__  #2C_A5_P /?^A0T/\ \ TH]IY?C_P
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MJ*_T]/\ A5_P]_Z%#0__  #2C_A5_P /?^A0T/\ \ TH]IY?C_P /\PNBO\
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M:'_X!I1_PJ_X>_\ 0H:'_P" :4>T\OQ_X '^8717^GI_PJ_X>_\ 0H:'_P"
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M-#_\ TH_X5?\/?\ H4-#_P# -*/:>7X_\ #_ #"Z*_T]/^%7_#W_ *%#0_\
MP#2C_A5_P]_Z%#0__ -*/:>7X_\   _S"Z*_T]/^%7_#W_H4-#_\ TH_X5?\
M/?\ H4-#_P# -*/:>7X_\ #_ #"Z*_T]/^%7_#W_ *%#0_\ P#2C_A5_P]_Z
M%#0__ -*/:>7X_\   _S"Z*_TV_$?PY\"V/A[7KVS\(Z&MW9Z-JEU:M]D1=M
MQ;V,\L#;ARN)44[ATZ]JET'X:^ 9]#T>>7PCH32SZ3IDDK&SC?<YLXVR'/)P
M9'PW!.<]A@]IY?C_ , #_,?HK_3T_P"%7_#W_H4-#_\  -*/^%7_  ]_Z%#0
M_P#P#2CVGE^/_  _S"Z*_P!/3_A5_P /?^A0T/\ \ TH_P"%7_#W_H4-#_\
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M.?$"YU;PQ<V^A>!8M+U*YO[J\@B.KVD5G/<2_1/QM_:S\1^,?^"5OCW]MO\
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MO /B/7((=,GU=]9DO-"MYUU+4=.6&2QLY0#]2J*_$'XE_P#!3']I/Q7\(O\
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M?#WQK\6>'?A5X)OM#U"^^*NN> /A'XGTS7]3TN.^\+/=:H\'AA+I=0FBO;@
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MWQY\?OC%I/PJG\2_#*UTQO%^D^$O%&OVFF>!M-\53ZDZZ)9G3[R_M1;);K,
M?T<T5^7OP<_X*3>&/B]X=_8;M- ^%'B?3?B/^UYXX^.?P^\4_#*[UJQM=6^
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MWT?4+-?#FB7EE?\ B&WMKNUU#1YO$4-[;3JV8R]O-(T:A#@G<>01G>_X;?\
MV1?^CA?A;_X4]C_A7T,>$^*9PA4I\,\0U*=6$*M*K#(\WE3JTZD5*$Z52.6R
MA4BTT^:$I1U2O<^+J>)/AW1JU:-;C_@:E6HU)T:U*IQCPM3J4JU.3C4I5:=7
MB&E5IU:4DX5(3IQE&::MI<^K**^4_P#AM_\ 9%_Z.%^%O_A3V/\ A1_PV_\
MLB_]'"_"W_PI['_"G_JEQ9_T2_$?_ABSC_YV$?\ $3?#?_HX7 ?_ (FG"?\
M]$I]645\I_\ #;_[(O\ T<+\+?\ PI['_"C_ (;?_9%_Z.%^%O\ X4]C_A1_
MJEQ9_P!$OQ'_ .&+./\ YV!_Q$WPW_Z.%P'_ .)IPG_]$I]645\I_P##;_[(
MO_1POPM_\*>Q_P */^&W_P!D7_HX7X6_^%/8_P"%'^J7%G_1+\1_^&+./_G8
M'_$3?#?_ *.%P'_XFG"?_P!$I]645\I_\-O_ +(O_1POPM_\*>Q_PH_X;?\
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MXZ FOQ!^#/\ P4"E_9Z_:D^.%EJ%^?&7[._C?XY_%'6)/[-DCO9?#[:SX_\
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M*** "BBB@#@? /W/&'_8_>*/_2B&N^K@? /W/&'_ &/WBC_THAKOJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KA/AM_R*</\ V'?&/_J9:_7=UPGP
MV_Y%.'_L.^,?_4RU^@#NZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#B?AO_ ,B%X2_[ =C_ .BA7;5Q/PW_ .1"\)?]@.Q_]%"NVH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .=\7_P#(I>*/^Q=UO_TV756?#G_(O:#_
M -@;2_\ TA@JMXO_ .12\4?]B[K?_ILNJL^'/^1>T'_L#:7_ .D,% &S1110
M 4444 %%%% !1110 4444 %%%% !1110 5PWQ,_Y$#Q;_P!@2\_] KN:X;XF
M?\B!XM_[ EY_Z!0!W-%%% '$?$/_ )%D_P#8P^"O_4T\/UVQZK]?Z&N)^(?_
M "+)_P"QA\%?^IIX?KMCU7Z_T- "T444 (<X.#@X.#C.#ZX/!QUQ7BO[0WQ_
M^&7[+?P2^*/[0OQFUQ_#GPO^$'@_6O''C35([66_OH-(T6!I?(TO3H )=1U+
M49(Q::98QL)+N_N+:!602ET]K_SZ?RKY$_;Q3X53_LA?'K3?CK\'/B%\?_@W
MKO@6_P##OQ-^$WPH\)ZOXT^('BGP5XAN[72=>?PSX;T"YM]>OM1\/Z9=S^(A
M)HUS;ZK:KI+WVF21WUO;A0#XETG_ (+1?""Y_9E_:$_:L\?_ +*?[;OP4^$G
MP"^'O@OXH3WWQO\ @=9>!Y/BGX&^(>I?V9X3USX7;_%VIVOB&WU"8Q3.M[/I
M;P6T\<I20D(/I7]J?_@HM\#/V0O@G\%OC#XX\/\ Q<\>W7[1OB7P%X(^!GPI
M^%_@B'Q7\9/BEX]^)>EQ:GX2\':)X8DU+1-'@U[4%N+/3G&J:[IFF6FHW5K:
M37L43&9/X_E\%?M3^(_V!_\ @KE^SG^SS!_P4!^-_P#P3GL_V8OA?%^RO8_M
M>?"7QOI/QMT/XMV?Q9\*:AXP^%'PAT_Q1HVD>*?%_@OPKX>6Z1=#LM/\Z;R-
M.T[28FG@6XOOT]_:4_:0_8=_;<_8.^#WPJ_:,_9@_P""J7@JT^!5W\(+>P^*
M7PO_ &/_ (V>%/B5\ /C5X7^'=O%X<\<^%]63P_K-X)="U+[->6KQ:3KMI=7
MD>EB\LKD".-P#^CK]F+]H.+]I_X36OQ._P"%+_'WX!33ZUK7A^]^&?[2G@&#
MX9_%;2+[0IXX)KG4?#MAKWB6R73[QG6;2=5T[6[RWO(PTD,B/&R+\FG_ (*M
M_LQ1_P#!03P)_P $W+#_ (6+XB^/GCE_B!93:YI/@>2V^$WAK7_AK\-]3^*7
MB/0-2\6WUY#=2:ZWAG3YA]GL;34[1+S[+#+>6S7<8E_-;_@FSHG_  66^.'[
M#^DQZA^U9=? 7Q7X4_:-^,5A\-?'G[7?[+$_Q(^-OQP_92M+#1?^%0:]XX\/
M:UXW^&]QX/\ $-QJ-[=K/J<FBWEZ;..%KN&^,$=M?>:?\% OVFXM"_X+;?\
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M#'B.TL]1LDU'31<26[&2SUBQT[5=.N(+J.:WNM,U2RL[^SNH9[>XM8YH944
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M\0:??>'+K1=.^)U[<7WAZ71=4T[5KG3('DN8?M;FW\8^-/\ P2-^'GQET/\
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MK:YKFJ-"]PNFZ/I-A<7^IW[6\=O=R3K9V5O/<&%+2Z>41[%MYF81M\#>#/\
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MFJ_M5_%;]IN;P1J$"S+%::=)>?%:Y\,W-]"\TIM;$3I$QF8)^G->*_&OX]>
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M'$^&'_S>T?\ #K?]M_\ Z(U:_P#AQ/AA_P#-[7J?\1(\/O\ HN.$O_$ARO\
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M\_:"54%G$K(.66#_ %S*.6$/_34C(C_V\5^@+?\ !+?]MT*Q;X.6:* 2S/\
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M "*</_8=\8_^IEK]=W7"?#;_ )%.'_L.^,?_ %,M?H [NBBB@ HHHH ****
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M<(\.>";V];2]0^S3_P!3>O\ AGP]XJMHK+Q)H6D:_9V]Q%=PVNL:=;W\,5W
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MC;6^G6MI86D,<-K:V\=M!!;@>7%' 4A55'&%4,"V>1AB2QZ@%^BBB@ HHHH
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M2K62^L[HN;VTO?)LT%Q:W(9EFAF:595>42?>- '\F?QL\=?$/Q1\8-"^#/Q
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M_P#:-_:M^*'['OAGXS_LM:OX*U?P7\"O@'X4^.O@G6M*\0?#.7PC\&XOA/\
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MR^<$<-YB(1KI8V*7SZA':VZZA+%%97%ZL 65[>!C-%;LYYV OE/F8 [1DE4
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M_P#Z'WQM_P!__#7_ ,S- ';45Q/_  A]_P#]#[XV_P"__AK_ .9FC_A#[_\
MZ'WQM_W_ /#7_P S- ';45Q/_"'W_P#T/OC;_O\ ^&O_ )F:/^$/O_\ H??&
MW_?_ ,-?_,S0!VU%<3_PA]__ -#[XV_[_P#AK_YF:/\ A#[_ /Z'WQM_W_\
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M '_\-?\ S,T =M17$_\ "'W_ /T/OC;_ +_^&O\ YF:/^$/O_P#H??&W_?\
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MX0^__P"A]\;?]_\ PU_\S- ';45Q/_"'W_\ T/OC;_O_ .&O_F9H_P"$/O\
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M&O\ YF:/^$/O_P#H??&W_?\ \-?_ #,T =M17$_\(??_ /0^^-O^_P#X:_\
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M  U_\S-'_"'W_P#T/OC;_O\ ^&O_ )F: .VHKB?^$/O_ /H??&W_ '_\-?\
MS,T?\(??_P#0^^-O^_\ X:_^9F@#MJ*XG_A#[_\ Z'WQM_W_ /#7_P S-'_"
M'W__ $/OC;_O_P"&O_F9H [:BN)_X0^__P"A]\;?]_\ PU_\S-'_  A]_P#]
M#[XV_P"__AK_ .9F@#MJ*XG_ (0^_P#^A]\;?]__  U_\S-'_"'W_P#T/OC;
M_O\ ^&O_ )F: .VHKB?^$/O_ /H??&W_ '_\-?\ S,T?\(??_P#0^^-O^_\
MX:_^9F@#MJXCPW_R-/Q#_P"PSH7_ *B>BTO_  A]_P#]#[XV_P"__AK^OADC
M\P15.W\ S6MS?7</CKQP)]0:)KEFNO#K F$%4V(WAHJF%)7(&0I(4J* /0J*
MXG_A#[__ *'WQM_W_P##7_S,T?\ "'W_ /T/OC;_ +_^&O\ YF: .VHKB?\
MA#[_ /Z'WQM_W_\ #7_S,T?\(??_ /0^^-O^_P#X:_\ F9H [:BN)_X0^_\
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M&O\ YF: .VHKB?\ A#[_ /Z'WQM_W_\ #7_S,T?\(??_ /0^^-O^_P#X:_\
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MG>'W)?>V"XP=AV'Y#MJ]_P (??\ _0^^-O\ O_X:_P#F9H [:BN)_P"$/O\
M_H??&W_?_P -?_,S1_PA]_\ ]#[XV_[_ /AK_P"9F@#MJ*XG_A#[_P#Z'WQM
M_P!__#7_ ,S-'_"'W_\ T/OC;_O_ .&O_F9H [:BN)_X0^__ .A]\;?]_P#P
MU_\ ,S1_PA]__P!#[XV_[_\ AK_YF: .VHKB?^$/O_\ H??&W_?_ ,-?_,S1
M_P (??\ _0^^-O\ O_X:_P#F9H [:BN)_P"$/O\ _H??&W_?_P -?_,S1_PA
M]_\ ]#[XV_[_ /AK_P"9F@#MJ*XG_A#[_P#Z'WQM_P!__#7_ ,S-'_"'W_\
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M[_\ Z'WQM_W_ /#7_P S- ';45Q/_"'W_P#T/OC;_O\ ^&O_ )F:/^$/O_\
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 &5F:6QE+F5D
M9V%R   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ_\  $0@!106X P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT?\ "^_'_P#T%(/_  #B_P#B:\WHH]A2_E#VL^YZ1_POOQ__ -!2#_P#B_\
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M , XO_B:/^%]^/\ _H*0?^ <7_Q->;T4>PI?RA[6?<](_P"%]^/_ /H*0?\
M@'%_\31_POOQ_P#]!2#_ , XO_B:\WHH]A2_E#VL^YZ1_P +[\?_ /04@_\
M .+_ .)J6Z^.WCZ"\FB3582L<C*";.+. <?W:\RJQJ'_ "$KK_KL_P#,U/L*
M?-L/VL[;GH'_  OOQ_\ ]!2#_P  XO\ XFC_ (7WX_\ ^@I!_P" <7_Q->;U
MH:;H&LZS'(^CZ3?7Z1?ZQK6V>4)]=H.*KV%)=!>UJ=SN/^%]^/\ _H*0?^ <
M7_Q-'_"^_'__ $%(/_ .+_XFO.&4HQ5@58'!!'(-)1["EV#VL^YZ1_POOQ__
M -!2#_P#B_\ B:/^%]^/_P#H*0?^ <7_ ,37F]%'L*7\H>UGW/2/^%]^/_\
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MYKMH-%TIR_CPV'[ZPBD"VY S$H92 OL.G;!I15*35H_T^7_,;YTG=[?IS?\
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M !-'_"^_'_\ T%(/_ .+_P")KS>BJ]A2_E%[6?<](_X7WX__ .@I!_X!Q?\
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M ,37F]%'L*7\H>UGW/2/^%]^/_\ H*0?^ <7_P 31_POOQ__ -!2#_P#B_\
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M'%_\37F]%'L*7\H>UGW/2/\ A??C_P#Z"D'_ (!Q?_$T?\+[\?\ _04@_P#
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M=+9PS6E[#<1F9B $9XW95)R/O$4W1HIV:0O:5'U.F_X7WX__ .@I!_X!Q?\
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M+:>&-9)872-RRHY4[6*]0#T.,BHJ?L*78'4J+1L](_X7WX__ .@I!_X!Q?\
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M]JZ6VH2Z4M^MS-J=JD1D9=PA%N2)2". X.,]J;K13U_K?_(E4VTFNO\ P/\
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MNDWR7$L:I9PD1\!&'.$R#^>>*\ETN\M=#^)=K=Z<[&SL]55H68\F)9>,_P#
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M32'<\DC%F8^I)ZU<*<HM7?\ 5O\ /7\-B93B[Z?U_6A'1116YD%%%% %A/\
MD&S?]=H_Y/5>K"?\@V;_ *[1_P GJO4QW8WLAR(TCJD:EF8X55&23Z5HWGAK
M7=.EMXM0T74+62Z8+ D]JZ&8^B@CYCR.E=)\(_)_X6);;_\ CY^SW'V+./\
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MOZW*IRYJD?Z[GTO1117D'>?-'[3'_([:3_V#O_:CUXO7M'[3'_([:3_V#O\
MVH]>+U[6%_@K^NIYM?\ B,*L6-[<:;J-O?64GE7-M*LT3[0=KJ<@X/!Y'>J]
M%=!B6+Z^N-2U&XOKV3S;FYE:65]H&YV.2<#@<GM6N?&_B$^)+C7CJ).HW,?E
M3R>4FV5-H78T>W8RX4<$8.*P**7*K6L/F=[G=:+X_P#*;5[_ %^XNKN_N-)E
MTNSMX;:-((D<8_A90@'/RJASGM6*/'/B)=(&FC4/W"VQM _D1^<(#UB$VWS
MG;;NQCCI7/T5/LXWV_K^FRN>5K7_ *T_R1OMXV\0MHG]DMJ&;4VXM2?)C\TP
M@Y$7F[=^P'^'=CVJY_PLSQ7]J>Y.HPM-(8V=VL;<EG0823E/]8!P'^]C'/%<
MI13Y(O="YGW'RRR3S/-.[222,6=V.2Q/))/K3***HG<*L)_R#9O^NT?\GJO5
MA/\ D&S?]=H_Y/4RV''<KT4450@HHHH **** "BBB@ HHHH W-)\8:WHMFEI
M8W,1@BE\^*.XM8K@0R?WX_,5MC>ZX/ JS8_$+Q1IZ2+!JA<O<F[WW$$<[K,1
M@R*SJ2C8[J17-45+C%ZM#NT;\WC?Q#/N\V_!W:E_:IQ!&,W73S.%]NG3VJ6U
M^('B:SN+J>'45,EU>?;I#);12 7'_/5 RD(W/5<<<5S=%')'M_7])?</FD^O
M]?TW]YNS^,_$%Q',DFHN!/J']IN4C1&^T_\ /0, "#ST&![5:NOB-XINTC63
M4EC$=Z+]?(M88<7 S^\^1!EN3GU[YKF**.2/;^OZ2#FD^O\ 7]-G3WGQ%\47
MT,<4^H1K''=K?(L-G#$!.I)$GR(/FR22>_?-$7Q$\2PW%Q,EY;YN)Q=2(=/M
MS'YPZ2JA3:K^K* 3W-<Q12]G#L'-+N:-MKVIVFO?VU#=O_:7F-+]ID =B[9R
MWS \\GG\:KZ?J%UI6IV^H6$OE75M*LL4FT-M<'(.#D'GUJM15));";;W.EC^
M(/BB'[.(]58"VOGU"(>3'A;A\EGQMY^\>#P,\"FV?C_Q-I]MY%KJ>U5>22)F
M@C=X&DR7,3LI:/.3G817.45/LX6M8?-+N=)H_C_Q+H-O;0Z7J(C6T=WMVDMH
MI6A+_?"LZEE#=P#@^E2:7\1O%.C6UK#IVI+&MGO^S.]K#(\(8Y95=D+!2>JY
MP?2N7HIN$7N@YI=S?L_&_B'3VTPV>H"+^RI)9;+$$9\II?OGE><^ASCMBK6@
M^+I8KO1[;7KN;^R=+NQ=Q"VLXI)T;?O*H[;64,W7YL=\'&*Y:BCECV$Y-Z-F
MWXP\0OXK\8:EK;HT8O)BZ1L<E$'"C\ !6)111&*C%170<I.4G)]0HHHJB0HH
MHH **** "BBB@ JQJ'_(2NO^NS_S-5ZL:A_R$KK_ *[/_,U/VD/H5Z***H04
M444 %%%% !1110 4444 %%%% !6]8>-?$&F+I0L;_P H:1YWV']S&?)\W/F=
M5^;.3][..V*P:*32:LQIM;&Y:>,=?L8]+2TU%H5TB226RVQH/*:0Y?G'S ]P
MV1CCI5O_ (6)XG%UIEPFH1Q/I32/9"*SA1(#(,/A%0+@^F,#M7,44G"+W0^:
M7<W['QQXBTW3!86>H>7 HD$9,$;20B3_ %@CD*EHPW<*1FK,?Q'\51V/V1=2
M3RS:?8F9K2$R/!@CRVD*;F4 G )..U<O10X1>Z#GDM;G0IX[\1);QPK?1@1V
M#:<K_98=_P!F88,9?9N(P.,G([8I%\=>(UT<:8-2/V<6_P!E#&&,RB'_ )Y"
M7;O"?[.['M7/T4<D7T%S/O\ U_2-X>-O$"NKC4/F33?[*4^3'Q:XQY?W?_'O
MO>]8-%%-)+5!=M6"BBBF(**** "BBB@ HHHH **** "BBB@ JQJ'_(2NO^NS
M_P S5>K&H?\ (2NO^NS_ ,S4_:0^A7HHHJA!7JJ>(M:T+P/\.ET6_N8%FENA
M);Q2-Y=Q_I.-KH.'')&#ZUY5716'CK7]-TZRLK6XM?)T\L;0RV%O+);EFW$I
M(R%E.[G(/IZ5,U>VE[._X/\ S&MFNYZ7X@\-:2L&KZ?)JTFEZ&?&*021HD8A
MA#0DELE=P(R5^]M YQQ61J_PNTG3+Z\NV.HG1[/2WOLK=02&[(D" 0S*N-OS
M*23'D=,'(-<):>,?$%C;B&UU.6-?MXU'=A2YN ,>86(W$X)R,X.>15AO'WB1
MM0CN_MZ*T<#VZQ):Q+!Y3G+H80OED,>3E>3R:YXTJD59/^N5+\SHE4IR=VOZ
MYF_R->S\.>%;G1-9\2H^L2:38-;PQV9>)+AI9,[@9,,NQ<'#; 6SC Q6V_PD
ML[RXN+'1+J[FO?\ 0;RW60KS9W!VMN4#[\;$$L#C'85QJ^/_ !*+^XNVU$2-
M=1)#-#);1/ R)]Q?)*F,!>P"\=JBM_&_B.U\17&NP:K*NIW,30RW&U22A &T
M C & ,8 Q@8QBKY:E[I_UV^_KO8R3CU_KS^[\=3M[?X<^&6M;K4WOKB33&U=
M]/MB^IVMJR1H!NF9I0 Y[A% ..]9LO@WPQH_A:^U;4[R\U5;?7&TR*73;J)(
MI(O+#B4$H^3UX!]LCK7+Z-XPUO0+5K;3;M%@:9;CRI[:*=5E'211(K!6Z?,,
M'@>E17'B75K[3)=-O[^26SGO3?3!D5F:8C:9"Q^8G';.*%"HGOV_2_Z_?]SY
MH=N_ZV_3[OOZWQK\/=-\):)?7PO+B8RZDL&D_,I6:W,0E,C8'S<.HR,#.>*\
M\KK_ !SXNMO$-GH.F:6;MK'1;!;9)+M0CRO_ !-M5F"CA0!D\#K7(55)2M[W
M]=/QW^8IVNK?UU_#;Y!1116IF6++_CX;_KC+_P"BVJO5BR_X^&_ZXR_^BVJO
M4_:970****HD['X5ZM'I7Q%TY;HC['?DV-RK=&CE&SGVR0?PKK-0\.3^&/!L
M/A 13_;_ !'K[QL(E!E>V@?8N 2!RQW#) /J!7DBLR.&0E64Y!!Y!K?U?QWX
MEUW7;+6=4U1Y=0L0HMIUC2,Q[6W#A0 >3W%93@Y237S^6J_$N,N6+7W?=9_A
M^1W9\"Z)I%QHFMZ)>RN\/B2#3YH'NTN.<AL[DC0!ACE07'/WJT=7\.S>)#K6
MGIJ4MO%>^.FMC$50QJ65LR?=WE@. -P!],\UYS>?$7Q/?0QQ3W\0CCO%OD2*
MR@C43J21)A4'S9)R>_?-59_&?B"XCF2347 GU#^TW*1HC?:?^>@8 $'GH,#V
MK-4ZFCD_ZO%_HS5U()-17]6DOU7XGHEQHVFW7PUFT3P]!J7E-XOCM-LS1RS.
M?+9=R\(O(YVG&#U;O2V_PX\+PWNC7T$LUW;MX@32KJS:^2;=E=P)=(U (_B5
M2XP<!\UPEU\1O%-VD:R:DL8CO1?KY%K##BX&?WGR(,MR<^O?-%Y\1?%%]#'%
M/J$:QQW:WR+#9PQ 3J21)\B#YLDDGOWS1&G477U_!?HQ2G!JUNC_ %_S1WDO
MA>#7-)O](TBYN-.L9_&8LEM',3QQG8P,@(16R,'"YQC Y/S5D6_@#P]K,DC:
M/-J<$5CKEOIEX+N2-FF2639YD>$&QL@_*P;KU/2N3N_''B"]CD22^6-9+U=0
M;[/;10'[0HP) 448;Z=3R>>:?=^/_$M]-;2SZBH:VNEO4\NVBC#3KTE<*H$C
M>[9/7UHC3J1MKV_3_)_>*<XRV\__ &[_ #7W&YXM\%Z+I?AK4=2T9[]7TW7'
MTJ1;N5'$H"E@XVHNT\8QD^OM7 5KWOBG6-0T^[L;R\\RVO+TW\Z>4@WSD$%\
M@9'!/ X]JR*UIQE%>\_ZLOUN34<6_=7]7?Z6"BBBM#,L)_R#9O\ KM'_ ">J
M]6$_Y!LW_7:/^3U7J8[L;V0Y':-U>-BK*<JRG!!]:T;WQ+KNI36\NHZUJ-W)
M;-O@>>[=S$WJI)^4\#D5F455D(T/[>U@EB=5OLM<B\)^TOS..DO7[_\ M=?>
MD_MS5B&!U2]PUS]K8?:'YG_YZ]?O_P"UU]ZH44K(=V:=MXEUVRGNIK/6M1MY
M;QBUS)%=NK3D]2Y!^8\GKZTZR\4>(-.LUM-/US4K2V5]ZPP7<B(&SG(4'&<\
MYKHM+M=&T_X6KKU[H5KJEX^M&S)N9IT B\D/@".11G.>3GK5O7?AQ'+XNEMM
M!NH;2RFLX+Z"*[=Y)0LR@B-4C5Y),'/(4X&,GN<W*/-9K^K7+2DU>_\ 5['#
M3ZC>W5K%;7-Y<36\#,T44DK,D98Y8J"< D\G'6K&F>(=:T6.2/1]7O\ 3TE.
M9%M;EX@Y]PI&:ZZ?X82:5HOBB;7=3@M+[0G@180'9)?,Y4[@A^\.%Z<_>VBJ
M%]\.-7TWPU/KZ75C>6MGY33_ &<NX3>>,.4$<F#@'8S8SS1[2FUY?YV_S0<D
M[^9CPZQXDT* Q6^HZIIL5ZHG*)/)"MPIX#X!&X'!YYZ55N-:U2\BDBN]2O)X
MY9_M,B2SLP>7&/,()Y;'&[K6UXY\01>([G1KI+G[3/#I4,%RWEE-LH9R5Q@#
M R.G'I7+U45?5HE^3-*^\1ZYJ;V[:EK.H7;6S;H#<73R&(^JY/RG@=/2MNU\
M>W<'AO7+.X%W>ZIK:1PW.I7=X9"(4.=@4KG)Z9+'CH!7)44W"+5F@4FG<***
M*HDL7/\ Q[VG_7$_^C'JO5BY_P"/>T_ZXG_T8]5ZF.Q4MPHHHJB3V;PYHJ^/
M_"O@JYG42'1=1>POV/:V4><I;T 52H^M4K;1M+^(GB*]\1>();N"+5=9%G:.
M+J.!-O 4*"DCR. 5&T*JCN_/' Z)XPUWPYI^H6.BZ@UM;:E'Y=U&(T;S%P1U
M8$KPQY&#4FC>-O$&@:>MEI5\L5ND_P!HC62WBE,4N,;T+J2C8XRI%8.G+F;7
MR^;3E^6AJIKE2?\ 5KV_/\#T6PT?^R/"<FC0W;G[)X\AMDN4"[OE4J& ((SQ
MGD$4/X7T[3_&9U[6KF_O;JY\7-8VQB>--I20$RR@)AB21\J[.Y]J\ZD\;^(9
M3(7U 'S=1&J/B",9N1TDX7].GM4MK\0/$UG<74\.HJ9+J\^W2&2VBD N/^>J
M!E(1N>JXXXJ8TZB=V]?_ -G_ "94IP:<4M/_ -K_ #7XG?7'@G2=>\=:Y=Z]
M)=6\=WXDEL8)%N8X$8E^=H*2/(_S#Y=JJ.[^C8?"NBZ)HEG%%#,VJP^,1IR:
MG%*@8!&&&VLC#&/X?[W))'RUP]O\1O%-J\[Q:DI:>[:^9I+6%RD[?>D3<A\M
MC_LXJ'_A//$6;@M>QN;B^&HN7M(6Q<@@^8N4^0\#[N,]*(TZBLKZ*WX6_P""
M.=2$FW;=O\;_ .:.R\0^$M&MM0U36O$]UJE\;SQ%/I\0M7BC<;6RTLAV%23G
M[@51[BGM\,-#T@RQ:W<:A=2KXD71E:SE2)3&Z*RR$,C?,-W(Z'IQUKC+;Q_X
MEM+B[FBU%6:\NC>3+-;12IYY_P"6JJRE4;W4 U67QAKRVXA.HNZC41J>9$5V
M-ST\PL023QT)Q[4XTZB23?;]/\G]Y,IQ;;MW_7_-?<5_$FE+H7BC4])20RK9
M7<D"N1@L%8@']*S*LZCJ%SJVIW.H:A+YMU=2M+-)M"[G8Y)P  .3VJM6T$U%
M*6YG-IR;CL%%%%426-0_Y"5U_P!=G_F:KU8U#_D)77_79_YFJ]3#X4.6[.M^
M&&GRW_Q%TLQ1VSQVDGVNX^U<QB*,;G)&"2<#CCKBNS^-E@][8:/X@T\K<Z*T
M8CM]2GN-]Q=F4M)A@0#A,%0#R*\KTK5K[0]3BU#2KE[:ZA)*2+@XR,$$'@@@
MX(/!K6U;QWXBUO15TC4;V-M.0J8[6*TABCC*YQM"(-O4],9[UG4A*4XR73^G
M^&Q<)**DGU_I?B;OPNUW1],_MC3M5U2YT*XU.*..UUFV4EK1E8D@XY"MP#C'
M YQU%_Q/X(N0OC+5?$FH+>:GIXLYX+BR6-(;E9V(WLJJ.< =,<Y)SUKA]'\3
MZKH-M=6VG3QBVN]OGV]Q;QSQ2%3E24D5ER/7&:M)XZ\1+?ZA>/J FEU-52[$
M]O'*DH7&T;&4J-N!C &.V*)0DY\R_K;[NWZ#C-*-F>E2>'M'\(Z%\0]*;[=<
MZ=#%I<A E19G+_/C?LP/F;KM/'8UD:E\._#FCZ;K>JW,^J7-G9Q6%Q:PQRQ1
MR,ES_"[;&&X>H'X<URA^(WBE[S4;F744EDU18EO?-M(76<1C"!E9"N .V.>^
M:J7WC/7]2BU..^U!IDU5XGO 8D'F&/[F,#Y0.P7 J53J7NWVO\K7_)E.<+6L
M=KXI^'7A_2;?Q5'I<^IFZ\/+;2^9<2QLDRS,/EVA 05!'S;N3G@5OZGX#TCQ
M)\0-;@UG6;Z^U.&.T$%JL]O!<3JT"DLN4".5X 4;>.K<UY9>^-O$&HMJK7FH
M>8=86);[]S&/.$>-G1?EQ@?=QGO5I?B/XJ74+B].IJ\]PT3N9+6%P'C7;&ZJ
M4(5E' 90#[TO9U+:O7_AO\F-3A?8Z*;X=:2/AW<:O8W-]>ZI9JYO(HI(1]C9
M9"I66 _.HVC[P9N?X<<UK>-O"E@-;\2:]XDOM2U&#35L85CA:&*:9Y85QN81
M[550/[G/UYKSZ3QOXBET=],EU)GMY(VB9FB0RM&S[RGF[=^TMSMW8]JE_P"$
M_P#$IU2\OY-166:^CCCNEEMHGBF5  FZ)E*'  P<9I\E2][_ -77Z"YZ?1'6
M7OPYT'2+'7M2O9]1NK2RM;"]LXH98XI'2Y)&R0E& 88Z@8[XYP.3\?>&[;PG
MXTO-(L9I9K:)8WB:;&_:\:N <  D;L< 56N?&.O7D>J)=:B\RZN8C>[T4^;Y
M9R@!Q\H'8+@8XZ53UK6]0\0ZI)J.L7'VB[D55:38J9"J%7A0!T '2JC&:E=O
M3_AO^"2Y0M:Q0JQ9?\?#?]<9?_1;57JQ9?\ 'PW_ %QE_P#1;5I+X61'=%>B
MBBJ)"O<DL=-L;SPC_:-KX7M_#T^A03:G]LCM$GD8HVYU_P"6Y8\8*]_QKPVM
M?7O$=WXB&FB]CAC_ +.L8[&+R5(W1IG!;)/S<\XP/:LZD7))+^M&7!I-W[?J
MCJ++X=V5^=)\W6C87'B&23^RK4VIE&P.50RON&S<>!@-ZFI+#X76TUKH2ZEK
MS65_K=Q<6L%LMEYJQRQ2%,,X<?*2 ,@'&>A'-9&D_$35-)T_3K<66GW<NE%S
MIUU<PLTMIN.3MPP5N>1O#8/2MX_$:'3?!OA46"6>H:YI[WDLLEY#(SVLLDI9
M9%.0K,02>=PR 2,BLY*HM%W_  UM^E[]2TXO5_U_73R*NF_"R2^O/#-M/JOV
M>779KN%P+;=]F-NQ4_Q#?G;_ +./>K3^%+75O!?@:TMHH[:ZO[N_CGNX;-I9
M9 CC&0@+/@ X'09Y(&363HGQ/U?1(=, LM.O9M*FFEM+B[21GC,O^L'RNH()
M)/()&>#4.F?$C6-)@TB&WM[%X])-SY:RQ,PF6X_UBO\ -R/3&#[T-5?Z^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O2/@A_R.UY_P!@Y_\ T9'7F]>D?!#_ )':\_[!
MS_\ HR.@#W:BBBD!6:&*:^D\V-'Q&F-R@XY:G_8[;_GVA_[]BA?^/Z7_ *YI
M_-JFH A^QVW_ #[0_P#?L4?8[;_GVA_[]BIJ* (?L=M_S[0_]^Q1]CMO^?:'
M_OV*FHH A^QVW_/M#_W[%'V.V_Y]H?\ OV*FHH A^QVW_/M#_P!^Q1]CMO\
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M6:7?\SK_ +"S#_GW^,?\SUC[';?\^T/_ '[%'V.V_P"?:'_OV*\G_P"%[_\
M4N?^3W_VNC_A>_\ U+G_ )/?_:Z/K-+O^8?V%F'_ #[_ !C_ )GK'V.V_P"?
M:'_OV*/L=M_S[0_]^Q7D_P#PO?\ ZES_ ,GO_M='_"]_^I<_\GO_ +71]9I=
M_P P_L+,/^??XQ_S/6/L=M_S[0_]^Q1]CMO^?:'_ +]BO)_^%[_]2Y_Y/?\
MVNC_ (7O_P!2Y_Y/?_:Z/K-+O^8?V%F'_/O\8_YGK'V.V_Y]H?\ OV*/L=M_
MS[0_]^Q7D_\ PO?_ *ES_P GO_M='_"]_P#J7/\ R>_^UT?6:7?\P_L+,/\
MGW^,?\SUC[';?\^T/_?L4?8[;_GVA_[]BO)_^%[_ /4N?^3W_P!KH_X7O_U+
MG_D]_P#:Z/K-+O\ F']A9A_S[_&/^9ZQ]CMO^?:'_OV*/L=M_P ^T/\ W[%>
M3_\ "]_^I<_\GO\ [71_PO?_ *ES_P GO_M='UFEW_,/["S#_GW^,?\ ,]2N
M;2W6)2L$0/F(.$']X5-]CMO^?:'_ +]BO))?CGYJ!?\ A'<896_X_O0@_P#/
M/VI__"]_^I<_\GO_ +71]9I=_P P_L+,/^??XQ_S/6/L=M_S[0_]^Q1]CMO^
M?:'_ +]BO)_^%[_]2Y_Y/?\ VNC_ (7O_P!2Y_Y/?_:Z/K-+O^8?V%F'_/O\
M8_YGK'V.V_Y]H?\ OV*/L=M_S[0_]^Q7D_\ PO?_ *ES_P GO_M='_"]_P#J
M7/\ R>_^UT?6:7?\P_L+,/\ GW^,?\SUC[';?\^T/_?L4?8[;_GVA_[]BO)_
M^%[_ /4N?^3W_P!KH_X7O_U+G_D]_P#:Z/K-+O\ F']A9A_S[_&/^9ZQ]CMO
M^?:'_OV*/L=M_P ^T/\ W[%>3_\ "]_^I<_\GO\ [71_PO?_ *ES_P GO_M=
M'UFEW_,/["S#_GW^,?\ ,]8^QVW_ #[0_P#?L4?8[;_GVA_[]BO)_P#A>_\
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M_,/["S#_ )]_C'_,]8^QVW_/M#_W[%'V.V_Y]H?^_8KR?_A>_P#U+G_D]_\
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M_8H^QVW_ #[0_P#?L5-10!#]CMO^?:'_ +]BC[';?\^T/_?L5-10!#]CMO\
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M #_ 2ORJ^XT^(M5L381:YHT%M/>:@MFIMK[SH]K1L^\,8U8D;2"I5?8FN?\
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M#L,8%5-*^'-GI-SI<D6LZM-#H^\:?;2O#Y=NKHR%1MC!? ;@N6(P.>6RNO\
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M^V4?5JO8/[<R_P#Y^?A+_(\BHKUW_A1'_4Q_^2/_ -LH_P"%$?\ 4Q_^2/\
M]LH^K5>P?VYE_P#S\_"7^1Y%17KO_"B/^IC_ /)'_P"V4?\ "B/^IC_\D?\
M[91]6J]@_MS+_P#GY^$O\CR*BO7?^%$?]3'_ .2/_P!LH_X41_U,?_DC_P#;
M*/JU7L']N9?_ ,_/PE_D>145ZTGP,WO(O_"18\MMO_'CUX!_YZ>]/_X41_U,
M?_DC_P#;*/JU7L']N9?_ ,_/PE_D>145Z[_PHC_J8_\ R1_^V4?\*(_ZF/\
M\D?_ +91]6J]@_MS+_\ GY^$O\CR*BO7?^%$?]3'_P"2/_VRC_A1'_4Q_P#D
MC_\ ;*/JU7L']N9?_P _/PE_D>145Z[_ ,*(_P"IC_\ )'_[91_PHC_J8_\
MR1_^V4?5JO8/[<R__GY^$O\ (\BHKUW_ (41_P!3'_Y(_P#VRC_A1'_4Q_\
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M_8H^QVW_ #[0_P#?L4 345#]CMO^?:'_ +]BC[';?\^T/_?L4 345#]CMO\
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M#]CMO^?:'_OV*/L=M_S[0_\ ?L4 345#]CMO^?:'_OV*/L=M_P ^T/\ W[%
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M_OV* )J*A^QVW_/M#_W[%'V.V_Y]H?\ OV* )J*A^QVW_/M#_P!^Q1]CMO\
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MU%_U*'_E3_\ M5'U6MV_(/;T^Y[_ $5X!_PU%_U*'_E3_P#M5'_#47_4H?\
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M4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\
M#47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y
M4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51
M]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;
MT^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17
M@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\
M4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\
M[51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_
M %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U58U#]I?[!J=U:?\
M(GYGV>9XM_\ :6-VUB,X\KCI2^K5;VM^0>VI]SW>BO /^&HO^I0_\J?_ -JH
M_P"&HO\ J4/_ "I__:J?U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_
M %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\
M[51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=
MOR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[
M_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#
M47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^
M5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_
MPU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'
M_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]
M5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V
M]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@
M'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4
MH?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\
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M7_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\
ME3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?
M\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_
M )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5
M'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]
M/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%
M> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H
M?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^
MU4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?
M]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4_
M_M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6M
MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_
MT5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\
M-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/
M_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U4?\
M-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!_P -1?\ 4H?^5/\ ^U4?\-1?]2A_
MY4__ +51]5K=OR#V]/N>_P!%> ?\-1?]2A_Y4_\ [51_PU%_U*'_ )4__M5'
MU6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U4?\ #47_ %*'_E3_ /M5'U6MV_(/
M;T^Y[_17@'_#47_4H?\ E3_^U4?\-1?]2A_Y4_\ [51]5K=OR#V]/N>_T5X!
M_P -1?\ 4H?^5/\ ^U4?\-1?]2A_Y4__ +51]5K=OR#V]/N>_P!%> ?\-1?]
M2A_Y4_\ [51_PU%_U*'_ )4__M5'U6MV_(/;T^Y[_17@'_#47_4H?^5/_P"U
M4?\ #47_ %*'_E3_ /M5'U6MV_(/;T^Y[_17@'_#47_4H?\ E3_^U5V'PT^,
MO_"Q/$EQI/\ 87]G>3:-<^;]L\W.'1=N-B_W\YSVJ98>K%7:&JT&[)GI]%%%
M8&I\P?M*_P#)2=/_ .P3'_Z.FKQ^O8/VE?\ DI.G_P#8)C_]'35X_7N4/X43
MS*OQL****V,@HHHH **** "BBB@ HHHH *T8?^19O?\ K\M__0)JSJT8?^19
MO?\ K\M__0)JF6PX[F=1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *T?$'
M_(S:I_U^2_\ H9K.K1\0?\C-JG_7Y+_Z&:G[2'T,ZBBBJ$%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6CX@_P"1FU3_ *_)?_0S6=6CX@_Y&;5/^OR7_P!#-3]I#Z&=
M1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -KPWX:G\37%ZD%Y:V<=
MC9O>3S71?:L:$ \(K,3\PXQ2Z[X6NM#L;&_%U:ZAI^H!OL]Y9LYC9E.&4AU5
ME8<<$#K6U\-I8%D\2V\]W:VTEYH-Q;P&ZN4@5Y&9,+N<A<G![]J['PCJWA[P
MW;>%]#\0WEA<3QWEW>2R13QS0VCO'LAW2KN3.1G(R%X)Z5C4G*+T[;=]_P"O
M^'-(Q36O_#;'C-%>T7/C&RL-?\.C5I(+GS#<6FHW!UF/4)WM)OD*RR1Q*A4$
M[U&YB .0.*GL=?\ #>G^+Y]$M-1ADATC0C8Z5?I=) CW)(>5TF8,L;,2P#GC
MCWJ?;2M\/?\ "_\ P/O\A^S7?^G_ $W\O,\G\/\ AR[\237T=C)!&;&REO9/
M.8C*1C+ 8!^;GCH/>LBO:?\ A(-+;Q'J+W5S807)\)W-M-<?VHETUS,1\BO*
ML:(\N,#Y=V<#DD5+#KVDBWM7_M?3QX07P_Y$^C^>@D:Z\L@@P?>:3S,'S,>^
MZDZTEK;^O>_.RMZC]FM%?K_\C^5W]QXC17OMUJ?]G:=H;:OJMJF@-X.1+C3I
M+A ]Q*T9$>(3R[;MN& .W:>1W@3QK!;SM!!KUJMM%X)C$48N$V"]3&T8S@RC
M' ^\*;K-7LMO^#_E^*"--.VN]OQY?\_P/":*]TLO$FA3:QIUY>ZG!+K$WA)(
MDO?MT<<B7>XY#3L&$<NW@,XR.G>J\?B?3X?$&J7+7=C:WZ^$YH&NAJD=T]Q/
ME2@>41HCS8&/DW9P.210ZTDW[O?\+_Y?B"II]>WXV_S_  /'K#2K[4Q<FPMG
MG%I UQ.5'$<:]6)]*G\/Z%>^)M>M=(TP(;FY8A/,;:J@ DDGT !/X5[';>+(
M9) UMXBACU._\%K$]R=16(M>JQVB20L )0.[$&O*/!\]]9^,K.XTW5K/2KV*
M0M'=WLF(0V#D,P!&&Y&3QSR1UJXS;;7;_-K]"9122=_ZLG^H^?P=>-?65IHM
M[8:[+>JYC73I69EV9W!T=59.!G+  CD&N>KWRP\2Z!;^-?#NKW3Z1HVNW:7<
M>J'2KY&M2IC/EM(RL44L^#]XGH2>F'>!=5LM-M]'BUCQ#IUS'.]V=9-WK,2J
MLK%E :-"/M&[(/F.9% SC&!67MI16JO_ $_\OQ\S1TXWW_K3^OQV/ :*]]^&
M]_')>>"K30=4L[:U@>[75+ 7*"2:<[MKF/.9,KMVL 0H'453\-^(=%M/">B1
MV<]HL=N;D:O9W6KQ6D4S$MS-"T3O."N NP$C@8XXJ59IM)?UK_E^*)]EY_U_
MG_P3PZBI+AHWN96A39&7)1<YVC/ SWJ.NA;&35G8****!!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>P?LU?\E)U#_L$R?^CH:\?KV#]FK_DI.H?]@F3_ -'0
MUC7_ (4C2E\:/I^BBBO#/4/F#]I7_DI.G_\ 8)C_ /1TU>/U[!^TK_R4G3_^
MP3'_ .CIJ\?KW*'\*)YE7XV%%%%;&04444 %%%% !1110 4444 %:,/_ "+-
M[_U^6_\ Z!-6=6C#_P BS>_]?EO_ .@35,MAQW,ZBBBJ$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5H^(/^1FU3_K\E_]#-9U:/B#_D9M4_Z_)?\ T,U/VD/H
M9U%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#I2;O>W]/_-/Y ZD4K)?U>__  !GC+PW:^%VTBS22=M0FT^.YOTD(Q#(^2$
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MC)@C:2$2?ZP1R%2T8;N%(S5F/XC^*H['[(NI)Y9M/L3,UI"9'@P1Y;2%-S*
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M^9--_LI3Y,?%KC'E_=_\>^][U@UK&,E)MO\ J[_2Q$G%Q26__ 7ZW"BBBM"
MHHHH **** "BBB@ HHHH **** "M'Q!_R,VJ?]?DO_H9K.K5UF":Z\77]O;1
M/--+?2)''&I9G8R$  #DDGM4_:0^AE45.;*Z6_\ L+6TPN_,\K[.8SYF_.-N
MWKG/&.M-N+:>SN9+:[AD@GB8I)%*I5D8<$$'D$>E5=!9D5=Q\,?^/CQ/_P!B
MY>?R6N'I\,,MQ/'#;QO++(P1(T4LS,3@  =2:F4>:+CW'&7+)2[.YZU\*] M
M[CP_;7\^E6^J)<:PEM<!;**9K>(*"S2O+N$<>"3\J!CC[XX%&O:=IGA_P=KP
MM],LX<>+9M/\^:SCFEAMO+SM1G!(P.01R.H(->;0>&=>N6N5MM$U&9K63RK@
M1VDC&%\XVM@?*<]C5">">RNY(+J%X)X7*R12H59&!Y!4]#[&L^3FGS7_ *T_
MR_$M2<86M_6O^?X'N/B/P]8P:+XT\[0=/M-'M%L1I-]#9QAS"SH&=),;I,@\
ML23DD9[4SQII6A:18:I-:Z+MT^U-M)I-]'IEM%"IR"")S*6N@PSN!1L=<"O-
M=1\=W5]H][IUKI&DZ5'J'E?;'TZW:(SB/[H*[BBC/)V*N3UKG;*QN]2O([33
MK6:[N9#A(8(R[OQGA1R>!6<*4E9M[?\  _R_$IU(VV_KMZ?\ [KXVFZ?XH7\
MMQ;B."1(VM91;K&)H]B_,& 'F<Y&XYZ8SQ@>?4I!!((P1U!I*WIPY(*/8SG)
MRDVPHI\44D\R10HTDDC!41!DL3T '<U8U+2=1T>Z%MJ]A=6$Y4,(KJ%HF(]<
M, <59!-#_P BS>_]?EO_ .@35G5HP_\ (LWO_7Y;_P#H$U5K6PN[[SOL5K/<
M^1$9I?)C+^7&.KMCHHR,D\5*W93Z%>BBBJ)"BBK%U87=DL#7MK/;BXC$T)EC
M*>:AZ,N>JG!Y'% %>BM<^$_$8TS^T3H&J"Q\OS?M7V*3RMF,[M^,8QSG.*H2
MV%W!907DUK/':W!80SO&0DI4X8*W0X[XZ4KH=F5Z***8@HHHH **** -'Q!_
MR,VJ?]?DO_H9K.K1\0?\C-JG_7Y+_P"AFLZIC\*'+=A1115"%ZU>UK1=0\/:
MM-IFL6_V>\AV^9'O5]N0&'*DCH1WJBOWA]:]1^+GAG5Y_B;J>IR:1J7]D?N&
MEOH[1VB5!$@9M^-O'/?M4N5I17>_Z?YE)7BWV/+:*]O\=Z#H-IH^LQVVC^7I
MZ+;_ -DZA'I]O;PH6QR+GSM]R&&=PVL1UP,9JWXF\):7;>#?$<5YHD=N--^Q
MFUOX+&*!9%+J)'A(S)(FUAEGD?)(Z$5BL1%I:;_\#_,T]DSQ2RT34-0TO4-2
ML[?S+3351KJ3>H\L.VU>"<G)XX!JA7O/B33VT[PC\08+/2K2RT58+$:9/;0*
M@N(MZG=Y@&9<]2Q+<DC->#5=.I[2[_K:Y,X<J7S"BBBM3,*T8?\ D6;W_K\M
M_P#T":LZM&'_ )%F]_Z_+?\ ] FJ9;#CN9U%%7[?0M7N_LGV32KV?[;O^R^5
M;NWVC9][9@?-C'.,XJKV$4**N0:1J5U LUMI]U-$\XMEDC@9E:8](P0/O'^[
MUJ?4_#6NZ+ LVLZ+J.GQ.VU9+JT>)6/H"P'-*Z'9F916CI?A_6=<$AT72;[4
M1%CS#:6SR[,],[0<9P?RJOJ&FWVDWC6FJ6=Q97*@%H;F)HW /(RK &BZO8+.
MURM115B&PN[BSN+N"UGEMK;;Y\R1DI%N.%W,.%R>!GK3$5Z*L0V%Y<VMQ<V]
MK/+;VH4SRQQEDB#' W$<+D\#-%[8W>FW36VHVLUI<* 6BGC*. 1D'!YY!!HN
M%F5Z*** "M'Q!_R,VJ?]?DO_ *&:SJT?$'_(S:I_U^2_^AFI^TA]#.HHHJA!
M15BQL+S4[R.TTVUGO+F3.R&WC,CM@9.%')X!-7;SPOK^G36\.H:'J5K+=/Y<
M"3VDB-*W3:H(^8\C@4KI.P[,RJ*DG@FM;B2WN8GAFB8I)'(I5D8<$$'D$>E1
MTQ!1110 45.+*Z:P:^%M,;19!$UP(SY8<C(4MTS@9QUJ"@ HHHH T8?^19O?
M^ORW_P#0)JSJT8?^19O?^ORW_P#0)JSJE;L;V044450@HK7L?"7B/4[%+S3?
M#^J7=J^=L]O922(V#@X8#!P015%M.O4L6O7L[A;59O(:<Q,$$F,[-V,;L<XZ
MTKJ]AV96HHHIB"BBK>G:7J&KW7V;2;&YOKC:6\JVA:1\#J<*"<4 5**EN;:>
MSN9+>\AD@GB;;)%*A5D/H0>0:BHW#8**** -'Q!_R,VJ?]?DO_H9K.K1\0?\
MC-JG_7Y+_P"AFLZIC\*'+=A115BQL+S4[R.TTVUGO+F3.R&WC,CM@9.%')X!
M-4(KT5JWGA?7].FMX=0T/4K66Z?RX$GM)$:5NFU01\QY' K.G@FM;B2WN8GA
MFB8I)'(I5D8<$$'D$>E)-/8=FMR.BBBF(***O3:)JMMI<6I7&F7D5A,<1W3V
M[K$Y]G(P>GK1=("C1110 5[C^S'_ ,C%KO\ UZ1_^AFO#J]Q_9C_ .1BUW_K
MTC_]#-<^*_@O^NIM0_B(^CJ***\4](^8/VE?^2DZ?_V"8_\ T=-7C]>P?M*_
M\E)T_P#[!,?_ *.FKQ^O<H?PHGF5?C84445L9!1110 4444 %%%% !1110 5
MHP_\BS>_]?EO_P"@35G5HP_\BS>_]?EO_P"@35,MAQW,ZBBBJ$%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5H^(/\ D9M4_P"OR7_T,UG5H^(/^1FU3_K\E_\
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M2-)$#U"L3D9]JC7Q+KJ:LVJ)K6H+J#KL:\%TXF9?0OG../6IE"<G=.VG^?\
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ML?V?>?\ /I/_ -^C_A1_9]Y_SZ3_ /?H_P"%'-'N'*^Q7HJQ_9]Y_P ^D_\
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M\*OZY9W,WB+49(K>5XWNI65E0D,"YP0>XJ>:/-N/E=MC(HJQ_9]Y_P ^D_\
MWZ/^%']GWG_/I/\ ]^C_ (57-'N+E?8]:\ :A!KO@RQ\->'_ !!_PC_B*!Y_
M]'GB#VNJB3/#@@J2!A1N!QC@'MGZ=\,=(31-)F\1ZF+*YU43%KAM2M8(K+8Q
M49CD(:;D<[",9KE]/\6>+]+T^VL[*258[0.+5WL8Y);</][RY&0NF<_PD4W3
M?%7B_2-/BL["6=(H&=H&>S222W+_ 'C'(REH\Y/W2.IKGDGS-Q:U_P"#_P /
MU-4URI26W]?,[S3_  DGBKP=X$T6>[6*!9M4>6:)E^98V!.TGCG'!/ SGM61
M#\.-"U'5=,%AJPBAFCN)+VR74K:]N(5A0N"KPG:=X&!E1M.>M<K;>(?%=E#I
M<=K-=1+I,DDEGL@ ,32'+\[<L#W#9&..E32^*O%\NH6-XLLT$NGLS6JVMFD$
M<1;[Y$:*%^;/.1SWS1:2>DEU^_7_ ( [QLKK^OZZG1>$-.\$ZE%X@N(=-U2X
M6TT*:X:"\N(\PR*P!,<BIAB01@E!M(/#9!&CJ7A.WU6STF]UG4;Z:PTWPE%?
MM"GE"7&]E6%"$ "Y/WF#$=\UR'_"8>,!=K<!B-EJ]FL TZ(0"%SED\G9Y>">
M3\O-11^*?%\5Y:W,<UPLEI9_8(@+1=GV?)/E,FW:Z\]&!HDFW=-??_B_S0)I
M*S7]>[_DSJ+/X<Z#=Q+JOGZDNEW&@7&JPP>;'Y\<D+A&1GV;64YX(4'VXYY?
MQOX=L- ET:;26N/LVJZ9%?+'<R*[Q%R05W*JAAE>N!1)XH\72W=Q<M+.'N+%
MM/=5M$5%MSUC5 NU!Q_"!6?J=WKNLQV2:DD\RV%LMK;#[/MV1*20O &>IY.3
M5*_,FY:>OK_P/N)TY;6U_P"&_P"#]YCT58_L^\_Y])_^_1_PH_L^\_Y])_\
MOT?\*VYH]S/E?8LP_P#(LWO_ %^6_P#Z!-6=6O#9W(\.W<9MY1(UU RKL.2
MDN3CT&1^8JA_9]Y_SZ3_ /?H_P"%2I1N]1N+LM"O15C^S[S_ )])_P#OT?\
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MO#"S@'S).,@=>17G_P#PCNM_] >__P# 5_\ "OJ9?^/Z7_KFG\VJ:F!\I_\
M".ZW_P! >_\ _ 5_\*/^$=UO_H#W_P#X"O\ X5]644 ?*?\ PCNM_P#0'O\
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M ?*?_".ZW_T![_\ \!7_ ,*/^$=UO_H#W_\ X"O_ (5]644 ?*?_  CNM_\
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M ,*/^$=UO_H#W_\ X"O_ (5]644 ?*?_  CNM_\ 0'O_ /P%?_"C_A'=;_Z
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M7_PH_P"$=UO_ * ]_P#^ K_X5]644 ?*?_".ZW_T![__ ,!7_P */^$=UO\
MZ ]__P" K_X5]650M]7@N->O=)1)!/9PQ32,0-I$A<+@YSG]V<\>E 'S%_PC
MNM_] >__ / 5_P#"C_A'=;_Z ]__ . K_P"%?3VE:O!K$5S);)(HMKJ6U?S
M!EXVVDC!/&1Q5ZE?2X'RG_PCNM_] >__ / 5_P#"C_A'=;_Z ]__ . K_P"%
M?5E0V?\ QXP?]<U_E3 ^6?\ A'=;_P"@/?\ _@*_^%'_  CNM_\ 0'O_ /P%
M?_"OJRB@#Y3_ .$=UO\ Z ]__P" K_X4?\([K?\ T![_ /\  5_\*^K** /E
M/_A'=;_Z ]__ . K_P"%'_".ZW_T![__ ,!7_P *^K** /E/_A'=;_Z ]_\
M^ K_ .%'_".ZW_T![_\ \!7_ ,*^K** /E/_ (1W6_\ H#W_ /X"O_A1_P (
M[K?_ $![_P#\!7_PKZLHH ^4_P#A'=;_ .@/?_\ @*_^%'_".ZW_ - >_P#_
M  %?_"OJRB@#Y3_X1W6_^@/?_P#@*_\ A1_PCNM_] >__P# 5_\ "OJ9O^/Z
M+_KF_P#-:FH ^4_^$=UO_H#W_P#X"O\ X4?\([K?_0'O_P#P%?\ PKZLHH ^
M4_\ A'=;_P"@/?\ _@*_^%'_  CNM_\ 0'O_ /P%?_"OJRB@#Y3_ .$=UO\
MZ ]__P" K_X4?\([K?\ T![_ /\  5_\*^K** /E/_A'=;_Z ]__ . K_P"%
M'_".ZW_T![__ ,!7_P *^K** /E/_A'=;_Z ]_\ ^ K_ .%'_".ZW_T![_\
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MO_H#W_\ X"O_ (4?\([K?_0'O_\ P%?_  KZLHH ^4_^$=UO_H#W_P#X"O\
MX4?\([K?_0'O_P#P%?\ PKZLHH ^4_\ A'=;_P"@/?\ _@*_^%'_  CNM_\
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M?_0'O_\ P%?_  KZLHH ^4_^$=UO_H#W_P#X"O\ X4?\([K?_0'O_P#P%?\
MPKZLHH ^4_\ A'=;_P"@/?\ _@*_^%'_  CNM_\ 0'O_ /P%?_"OJRB@#Y3_
M .$=UO\ Z ]__P" K_X4?\([K?\ T![_ /\  5_\*^IK/_CQ@_ZYK_*IJ /E
M/_A'=;_Z ]__ . K_P"%'_".ZW_T![__ ,!7_P *^K** /E/_A'=;_Z ]_\
M^ K_ .%'_".ZW_T![_\ \!7_ ,*^K** /E/_ (1W6_\ H#W_ /X"O_A1_P (
M[K?_ $![_P#\!7_PKZLHH ^4_P#A'=;_ .@/?_\ @*_^%'_".ZW_ - >_P#_
M  %?_"OJRB@#Y3_X1W6_^@/?_P#@*_\ A1_PCNM_] >__P# 5_\ "OJRB@#Y
M3_X1W6_^@/?_ /@*_P#A7H'P:TK4;'QC=2WMA=6T9L'4/-"R GS(^,D=>#7M
ME0M_Q_1?]<W_ )K2 FHHHH A7_C^E_ZYI_-JFJ%?^/Z7_KFG\VJ:@ HHHH *
M*PO&WB)/"?@?5]<D(S9VKO&#T:3&$'XL5'XUXM\"O$VAV'C:?P]H^KMJ2:QI
ML5Y-*Z2+B_0'SQ^\ )W [LCCY:2U;7;_ (/^7Y ]%?\ KI_G^9]#45X]\+H9
M+GX ZG;P:DNE3337\<=Z[[! S2, ^[M@D<UB_#P6WPT\07.FZMX5U*UUXZ6\
MY&DWC7T.LJC#,JQLV5DSG X&"W3@4U;KVO\ A<'IMWM^-CWNBO"OB9\3],UC
M1]+T+68M7\*Z=JQDDU#^T[)X[@P1](E1-Q'F/@;NFT'UKK?@%J=IJ/P9T:.S
ME\Q[(/;SC:1LD#%L<CGAE.1QS1'5-]A-V:7<](HHHH&%0M_Q_1?]<W_FM35"
MW_']%_US?^:T 3445RWC[P_>^(='M([""TOA:WB7,VFWSE8+Y%# Q.0&[D,,
MJ1N5<CN$]!K4ZFBO-=*\4WEQ+H>A>#M.M=#6<7T=S;ZE"TOV"6W>/*(D<@5E
MRY  8+@J1C&TR^'/&WB*\;PU=:U'I2VFMRSVC0VJ2!X98DD8R>8S8*L87^3:
M"NY?F;!IBZ'HM5(=6TZX^S^1?VLOVHN+?9,I\XK][;@_-C!SCIBN'T?Q_?7O
MC#3+&26UN['5&G2-K;2[J)(BB%P4NI/W=PI"D915SD$<5D>$O^:>?]=]4_\
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M%-N+%XK=MUO:-+$9!%Q\D)#RE@N%Y;/>O6Z*(^Z[_/\ ])_R_%BDKJW]=?\
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M&]$MM(T6W^S6-JI6&+>S[023U8DGDGJ:L_;+;_GYA_[[%'VRV_Y^8?\ OL4
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M_;+;_GYA_P"^Q1]LMO\ GYA_[[% $U%0_;+;_GYA_P"^Q1]LMO\ GYA_[[%
M$U%0_;+;_GYA_P"^Q1]LMO\ GYA_[[% $U%0_;+;_GYA_P"^Q1]LMO\ GYA_
M[[% $U%0_;+;_GYA_P"^Q1]LMO\ GYA_[[% $U%0_;+;_GYA_P"^Q1]LMO\
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M_G^&O_ _K>>/Q-K5JVG)KV@V]F^H7<=O']GU#SU4.CL<DQJ=R[,$8Q\PPQY
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MOR)GV7*QR;HM@ C+*Z??)/&5P3BZ?&E[;1W?V6PEU*X;Q ^E00RW,<:K^[W
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M^L\__P"%(^&_^?W5/^_L?_QNC_A2/AO_ )_=4_[^Q_\ QNO0/MEM_P _,/\
MWV*/MEM_S\P_]]BCV%/L']K8[_GZSS__ (4CX;_Y_=4_[^Q__&Z/^%(^&_\
MG]U3_O['_P#&Z] ^V6W_ #\P_P#?8H^V6W_/S#_WV*/84^P?VMCO^?K//_\
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M_,/_ 'V*/MEM_P _,/\ WV*/84^P?VMCO^?K//\ _A2/AO\ Y_=4_P"_L?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
